APPLICATION_ID,ACTIVITY,ADMINISTERING_IC,APPLICATION_TYPE,ARRA_FUNDED,AWARD_NOTICE_DATE,BUDGET_START,BUDGET_END,CFDA_CODE,CORE_PROJECT_NUM,ED_INST_TYPE,OPPORTUNITY NUMBER,FULL_PROJECT_NUM,FUNDING_ICs,FUNDING_MECHANISM,FY,IC_NAME,NIH_SPENDING_CATS,ORG_CITY,ORG_COUNTRY,ORG_DEPT,ORG_DISTRICT,ORG_DUNS,ORG_FIPS,ORG_IPF_CODE,ORG_NAME,ORG_STATE,ORG_ZIPCODE,PHR,PI_IDS,PI_NAMEs,PROGRAM_OFFICER_NAME,PROJECT_START,PROJECT_END,PROJECT_TERMS,PROJECT_TITLE,SERIAL_NUMBER,STUDY_SECTION,STUDY_SECTION_NAME,SUBPROJECT_ID,SUFFIX,SUPPORT_YEAR,DIRECT_COST_AMT,INDIRECT_COST_AMT,TOTAL_COST,TOTAL_COST_SUB_PROJECT
11194727,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002803,NA,NA,1ZIAMH002803-22,NIMH:1634577\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,9416741 (contact),"SHEN, JUN  (contact)",NA,NA,NA,Address;Amino Acids;Autopsy;Biological;Blood flow;Brain;Brain Diseases;brain metabolism;Carbon;cell type;Cells;Cerebral cortex;Chemicals;Choline;Clinical;clinical application;cognitive function;Coupling;Creatine;Custom;Data Set;Dimensions;Emotions;Environment;enzyme activity;Enzymes;frontal lobe;Functional disorder;gamma-Aminobutyric Acid;Glutamates;Glutamine;Glutathione;Goals;Human;imaging study;Imaging Techniques;in vivo;in vivo magnetic resonance spectroscopy;Individual;innovation;insight;Label;Link;magnetic field;Magnetic Resonance Imaging;Magnetic Resonance Spectroscopy;Maps;Measurement;Measures;Medial;Mental Depression;Mental disorders;Metabolic;metabolic abnormality assessment;Methods;Molecular;Monitor;myoinositol;N-acetylaspartate;neurochemistry;Neuroglia;Neurons;neuropsychiatric disorder;neurotransmission;Neurotransmitters;Non-Invasive Detection;novel;Pathology;Pattern;Personality;Pharmaceutical Preparations;Phosphocreatine;Phosphorus;Play;Prefrontal Cortex;Protocols documentation;Protons;radio frequency;Relaxation;Research;Resolution;Role;Schizophrenia;Signal Transduction;Social Interaction;Synapses;Techniques;Technology;Time;Tissue Sample,Magnetic Resonance Spectroscopy and Imaging Studies of Brain Functions,2803,NA,NA,NA,NA,22,NA,NA,1634577,NA
11194728,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002804,NA,NA,1ZIAMH002804-22,NIMH:2994514\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,8174758 (contact),"MERIKANGAS, KATHLEEN R (contact)",NA,NA,NA,17 year old;Accelerometer;actigraphy;Address;Adult;Affect;Affective;Age;Algorithms;Anxiety;Anxiety Disorders;anxiety spectrum disorders;anxious;Assessment tool;Biological;Biological Factors;Bioperiodicity;Bipolar Disorder;Bipolar I;Bipolar II;Breeding;Cardiovascular Diseases;Cardiovascular Physiology;Cardiovascular system;Child;Circadian Rhythms;Clinical;clinical center;clinical phenotype;Cognitive;cognitive testing;cohort;Collaborations;Communities;community setting;comorbidity;comparison control;computer program;computerized;dashboard;Data;data acquisition;Data Analyses;Data Collection;data management;Data Science;Depressed mood;Development;Diagnostic;diagnostic criteria;diaries;Dimensions;Disease;Disease susceptibility;disorder subtype;DSM-V;Dual-Energy X-Ray Absorptiometry;Early Intervention;Ecological momentary assessment;Electronics;endophenotype;Enrollment;Etiology;Evaluation;Event;Evolution;Exercise;Exercise Test;Exhibits;Family;family structure;Family Study;First Degree Relative;follow-up;Future;Genetic;genetic epidemiology;Goals;Headache;Health;heuristics;high risk;Homeostasis;immune function;implementation measures;improved;Individual;Inpatients;instrument;Intervention;Interview;Investigation;Laboratories;Lead;Life;life span;Light;Link;longitudinal design;Magnetic Resonance Imaging;Major Depressive Disorder;Measures;Medical;Medical History;Mental disorders;Mental Health;Metabolic;method development;Methodology;Methods;Migraine;Modeling;Mood Disorders;Moods;Motor Activity;National Institute of Mental Health;Natural History;Neurologic Examination;Neuropsychology;Nomenclature;novel;novel strategies;Operations Research;Outpatients;Pain;Participant;Pathology;Patient Recruitments;Patient Self-Report;Pattern;Personality;Persons;Phase;phenomenological models;Phenotype;physical conditioning;Physical Examination;Physiological;Prevention;proband;Procedures;Process;prognostic;prospective;Protocols documentation;Psyche structure;Psychiatry;Psychology;Psychopathology;Psychophysiology;psychosocial;Public Health;Recontacts;Recording of previous events;recruit;Reporting;Research;Research Personnel;Resolution;Risk;Role;Saliva;Sampling;Series;Sleep;Sleep Disorders;sleep pattern;sleep quality;smartphone based assessment;Specificity;Spouses;stability testing;Stress;Structure;Subgroup;Substance Use Disorder;Suicide;Surveys;symptom cluster;Symptoms;Syndrome;System;Testing;Time;tool;transmission process;United States National Institutes of Health;Update;user-friendly;Visualization;Work,Family Study of Affective and Anxiety Spectrum Disorders,2804,NA,NA,NA,NA,22,NA,NA,2994514,NA
11194729,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002810,NA,NA,1ZIAMH002810-22,NIMH:2388476\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,1893483 (contact),"MCMAHON, FRANCIS J (contact)",NA,NA,NA,16p11.2;Address;Affect;age group;Agreement;Alternative Splicing;Anterior;Antipsychotic Agents;Astrocytes;atypical antipsychotic;Autopsy;Biological Models;Biology;Bipolar Depression;Bipolar Disorder;Brain;brain cell;brain shape;brain tissue;case control;Catalogs;causal variant;Cause of Death;Cell Differentiation process;cell growth;Cell Line;Cell model;cell motility;Cell Nucleus;Cell Reprogramming;cell type;Cells;Cellular Stress;Cessation of life;Chromosomes;Chronic;cingulate cortex;Collection;Copy Number Polymorphism;Data;deep sequencing;Defect;Development;Diagnosis;differential expression;disability;Disease;DNA;DNA Sequence Alteration;Drug Exposure;Drug usage;Electrophysiology (science);Energy Metabolism;Energy Metabolism Pathway;Exhibits;Exposure to;Family;functional genomics;Gene Expression;Gene Expression Profile;Gene Expression Profiling;Gene Expression Regulation;gene network;Genes;Genetic;Genetic Markers;Genetic Risk;genetic risk factor;genetic variant;Genome;genome editing;genome wide association study;Genomics;Goals;Harvest;Heritability;high risk;Human;Impairment;improved;In Vitro;Individual;induced pluripotent stem cell;Induced pluripotent stem cell derived human neuron;Induced pluripotent stem cell derived neurons;Inherited;Interneurons;Life;Link;Lithium;Macaca;Maintenance;Major Depressive Disorder;Major Mental Illness;Measures;Medicine;Mental disorders;Methods;microscopic imaging;Modeling;Molecular;Mood stabilizers;Morphology;Neurobiology;Neuroglia;Neuronal Dysfunction;neuronal growth;Neurons;neuropsychiatry;notch protein;novel therapeutics;Occupational;Participant;Pathway Analysis;Pathway interactions;Patients;Pattern;Persons;Pharmaceutical Preparations;Play;Prefrontal Cortex;Proliferating;Public Health;Recreation;Resolution;Resources;Risk;Risk Factors;risk variant;RNA;Role;Sampling;Schizophrenia;schizophrenia risk;screening;severe mental illness;Signal Transduction;social;Source;Stress;Structure;Suicide;Synapses;synaptic function;Techniques;Testing;Therapeutic Agents;Time;Tissue-Specific Gene Expression;Tissues;tool;Transcript;transcriptome;transcriptome sequencing;transcriptomics;Valproic Acid;Variant,Functional Genomics of Bipolar Disorder,2810,NA,NA,NA,NA,22,NA,NA,2388476,NA
11194730,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002838,NA,NA,1ZIAMH002838-21,NIMH:1234762\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,77874251 (contact),"LEOPOLD, DAVID A (contact)",NA,NA,NA,3-Dimensional;Affect;Animals;Area;Behavior;Brain;brain pathway;Characteristics;Cognition;Complex;Development;Dimensions;Disease;Electrophysiology (science);Environment;Evaluation;Event;experience;experimental study;Eye;Face;Failure;Familiarity;Feeling;Functional Magnetic Resonance Imaging;gene therapy;Geometry;Hand;Human;Image;Individual;Injury;insight;Investigation;Laboratories;Learning;Leber&apos;s amaurosis;Life Experience;Methods;movie;Nature;Neurologic;neuromechanism;Neurons;operation;Pathway interactions;Patients;Pattern;phenomenological models;Process;programs;Psychologist;Publishing;rehabilitation strategy;remote monitoring;Research;Research Personnel;Residual state;response;Retina;Retinal Degeneration;Retinal gene therapy;retinotectal;Shapes;Signal Transduction;social;Social Interaction;Stimulus;stimulus processing;Structure;Temporal Lobe;Time;tool;Veins;virtual reality environment;Vision;Visual;visual cognition;Visual Pathways;Visual Perception;visual stimulus;Work,Neural Mechanisms of Natural Visual Perception,2838,NA,NA,NA,NA,21,NA,NA,1234762,NA
11194731,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002843,NA,NA,1ZIAMH002843-21,NIMH:2123089\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,1893483 (contact),"MCMAHON, FRANCIS J (contact)",NA,NA,NA,Address;age group;Amish;anti-epileptic agents;Antipsychotic Agents;Anxiety;Anxiety Disorders;Attention deficit hyperactivity disorder;autism spectrum disorder;Biology;Bipolar Disorder;Blood Cells;Blood specimen;Brain;Brazil;Calcium Channel Blockers;Calcium ion;Canada;Catalogs;Cause of Death;cell repository;Cessation of life;Clinical;clinical diagnosis;Cognition;Cognitive deficits;cognitive testing;Cohort Studies;Collaborations;Collection;Communities;comorbidity;Copy Number Polymorphism;Data;de novo mutation;depressive symptoms;Diagnosis;Diagnostic;Dimensions;disability;Disease;DNA;DNA Repository;Enrollment;exome;exome sequencing;Family;follow-up;Functional disorder;functional genomics;Future;gene function;gene interaction;Genes;Genetic;genetic association;Genetic Counseling;Genetic Determinism;genetic disorder diagnosis;genetic information;Genetic Risk;genetic risk factor;genetic testing;genetic variant;Genetic Variation;genome sequencing;genome wide association study;genome-wide;Hearing;Heritability;high risk;Immunity;immunoregulation;Impairment;improved outcome;Individual;Individual Differences;induced pluripotent stem cell;Inherited;Ion Transport;Lead;Learning;Life;Lithium;Major Depressive Disorder;Measures;Mennonite;Mental Depression;Mental disorders;Methods;Modeling;Mood Disorders;mood symptom;Moods;Mutation;National Institute of Allergy and Infectious Disease;nervous system development;neurodevelopment;neurogenesis;neuropsychiatry;Neurotic Disorders;novel;novel therapeutics;Occupational;offspring;Parents;Participant;Pathway Analysis;Patients;Persons;Phenotype;Play;polygenic risk score;Population;postsynaptic;Prevention;Process;psychiatric genomics;Publishing;Questionnaires;rare variant;Recording of previous events;Recurrence;Resources;response;Risk;Risk Factors;Risk Taking;risk variant;Role;Sampling;Schizophrenia;schizophrenia risk;severe mental illness;Skin;Sleeplessness;Smoking;SNP array;social;social stigma;Source;Special Population;suicidal risk;Suicide;Suicide attempt;Testing;treatment response,Identification of Genes Involved in Major Mood Disorders,2843,NA,NA,NA,NA,21,NA,NA,2123089,NA
11194732,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002844,NA,NA,1ZIAMH002844-21,NIMH:796158\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,1893483 (contact),"MCMAHON, FRANCIS J (contact)",NA,NA,NA,"Adverse effects;Adverse event;Aftercare;Alleles;anti-depressive agents;antidepressant effect;Anxiety;Attention;Biological;Biological Assay;Biological Factors;Brain;Candidate Disease Gene;career;cell growth;cell growth regulation;cellular development;Cellular Morphology;clinical center;Code;Collaborations;confocal imaging;cost;Data;database of Genotypes and Phenotypes;Dendritic Spines;Disease remission;Dose;effective therapy;Electrodes;Electrophysiology (science);exome;exome sequencing;experimental study;Family Study;Funding;Future;GABA Receptor;Gene Expression;Genes;Genetic;Genetic Determinism;Genetic Markers;genetic testing;genetic variant;Genome;genome wide association study;genome-wide;Genomics;Glutamate Receptor;Goals;Heritability;High-Throughput Nucleotide Sequencing;Human;human induced pluripotent stem cells;improved;In Vitro;individual variation;Induced pluripotent stem cell derived human neuron;insight;Ketamine;Learning;Length;Lithium;Major Depressive Disorder;Measures;Mental Depression;Meta-Analysis;Methods;Morbidity - disease rate;Morphology;mortality;Mus;National Heart, Lung, and Blood Institute;Neurites;Neurons;novel;Outcome;Outcome Study;Pathway interactions;Patients;personalized approach;Persons;Pharmaceutical Preparations;programs;psilocin;Psilocybin;Recovery;Resistance;response;Risk;Sampling;Series;side effect;Signal Pathway;Signal Transduction;social factors;stem cells;Symptoms;Synapses;synaptogenesis;Testing;therapy resistant;Time;Treatment outcome;treatment response;treatment-resistant depression;Twin Studies;United States National Institutes of Health;Variant;Withdrawal;Work",Genetic Determinants of Antidepressant Response,2844,NA,NA,NA,NA,21,NA,NA,796158,NA
11194733,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002852,NA,NA,1ZIAMH002852-20,NIMH:3362515\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,8469041 (contact),"INNIS, ROBERT  (contact)",NA,NA,NA,ABCG2 gene;Age;alertness;Amyloid;Amyloid Proteins;Animals;Annual Reports;anti-depressive agents;Astrocytes;Binding;Binding Sites;Biological Markers;Blood specimen;Brain;Brain region;Cells;Characteristics;Chemicals;Chemistry;Chronic;Clinical Research;cognitive performance;Collaborations;Cyclic AMP;cyclooxygenase 1;cyclooxygenase 2;density;Development;Diagnostic;Disease;Dose;Electroencephalography;Enrollment;Exhibits;experience;Female;first-in-human;Functional disorder;Future;General Population;Glycoproteins;Goals;healthy volunteer;Hippocampus;Hour;Human;Human Volunteers;Image;In Vitro;in vivo imaging;indexing;Individual;Inflammation;Inflammatory;inhibitor;intravenous injection;Ketoprofen;Knockout Mice;Label;Laboratories;Literature;Magnetic Resonance Imaging;male;Measures;Microglia;Military Personnel;Mitochondrial Proteins;Modeling;Monkeys;neuroimaging;neuroinflammation;neuropsychiatric disorder;nonhuman primate;novel;Occipital lobe;Oral Administration;overexpression;Parents;Participant;Patients;Pattern;PDE4B;Peripheral;Permeability;Phagocytosis;Pharmaceutical Preparations;phosphodiesterase IV;Physiological Processes;Positron-Emission Tomography;Process;Prostaglandin-Endoperoxide Synthase;Protein Isoforms;Proteins;Protocols documentation;Radioactivity;Radiolabeled;radioligand;radiotracer;Rattus;receptor;Recovery;research clinical testing;Research Institute;Rolipram;Scanning;Second Messenger Systems;Selective Serotonin Reuptake Inhibitor;single episode major depressive disorder;Site;Sleep;Sleep Deprivation;Sum;Synapses;Synaptic Vesicles;System;Techniques;Testing;Thalamic structure;Time;Tissues;tool;Travel;uptake;virtual;volunteer;Work,Clinical Evaluation of PET Radiotracers,2852,NA,NA,NA,NA,20,NA,NA,3362515,NA
11194734,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002857,NA,NA,1ZIAMH002857-20,NIMH:3366147\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,9694517 (contact),"ZARATE, CARLOS  (contact)",NA,NA,NA,Acute;Affect;Age;AMPA Receptors;Amygdaloid structure;Anhedonia;Anterior;anti-depressive agents;antidepressant effect;Architecture;Arousal;Biochemical;Biological Markers;biomarker identification;Bipolar Depression;Bipolar Disorder;blood-brain barrier crossing;Brain-Derived Neurotrophic Factor;Cell Adhesion;Cell Adhesion Molecules;cellular targeting;Cerebrospinal Fluid;Cessation of life;Chronic;cingulate cortex;Clinical;Corpus striatum structure;Cross-Over Trials;Data;Depressed mood;depressive symptoms;Diagnostic;Disabling;Dorsal;Double-Blind Method;Drug Kinetics;Electroencephalography;Electrophysiology (science);Fatigue;Feeling suicidal;Female;Functional disorder;Functional Magnetic Resonance Imaging;Genetic;Glutamates;Growth Factor;healthy volunteer;Hippocampus;Homeostasis;Hour;Image;Impairment;improved;Individual;Infusion procedures;Insula of Reil;Insulin;interest;Ketamine;Laboratories;Left;Magnetic Resonance Imaging;Magnetoencephalography;Major Depressive Disorder;male;Measures;Mediation;Medical;Mental Depression;metabolomics;MicroRNAs;Molecular Target;Montgomery and Asberg depression rating scale;Mood Disorders;neural correlate;neural network;neurogenesis;Neuronal Plasticity;Neuropsychology;neurotransmission;NMDA receptor antagonist;non rapid eye movement;norketamine;Outcome Measure;Participant;Pathway interactions;Patients;Pattern;Placebo Control;Placebos;Plasma;pleasure;Polysomnography;Prefrontal Cortex;primary outcome;Protein Tyrosine Kinase;Proteins;Proteomics;Protocols documentation;Public Health;Randomized;rapid eye movement;Recurrence;Relapse;Research;response;Rest;Saline;Scanning;secondary analysis;severe mental illness;sex;Sex Differences;Sleep;Sleep disturbances;sleep onset;Slow-Wave Sleep;Spectrum Analysis;standard care;suicidal;suicidal behavior;Symptoms;Synaptic plasticity;synaptogenesis;System;Time;treatment-resistant depression;Work,Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect,2857,NA,NA,NA,NA,20,NA,NA,3366147,NA
11194735,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002863,NA,NA,1ZIAMH002863-20,NIMH:1843873\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,8469065 (contact),"BERMAN, KAREN FAITH (contact)",NA,NA,NA,7q11.23;Absence of pain sensation;Adult;Affect;Age;Age at Menarche;Amygdaloid structure;Anterior;Anxiety;Aorta;Aortic Valve Stenosis;Area;autism spectrum disorder;Behavior;Behavioral;Behavioral Mechanisms;behavioral phenotyping;Bilateral;boys;Brain;Brain region;brain size;Cell Line;Cell Physiology;Cells;Cellular Morphology;Cerebellum;Characteristics;Child;Childhood;Chromosome 7;Clinical;clinical predictors;clinically relevant;Cognition;cognitive function;cohort;Complex;connectome;Copy Number Polymorphism;Data;Data Collection;data resource;Dedications;design;Development;Diffusion Magnetic Resonance Imaging;Disease;DNA;DNA Sequence;dorsal visual stream;Dose;Elastin;emerging adult;Emotional;Equation;experience;experimental study;Face;Face Processing;Fiber;Fright;Functional Magnetic Resonance Imaging;Gene Dosage;Gene Duplication;Gene Mutation;General Population;Genes;Genetic;Genetic Determinism;genome wide association study;genome-wide;Genomic Segment;Genotype;girls;Goals;gray matter;Growth;Handedness;Haploidy;Haplotypes;Heterogeneity;human model;in vivo;indexing;Individual;induced pluripotent stem cell;Insula of Reil;intraparietal sulcus;Judgment;Knowledge;Lead;Life;LIMK1 gene;Link;Literature;Magnetic Resonance Imaging;Measurement;Measures;Methodology;Methods;microdeletion;Modeling;Molecular Abnormality;morphometry;Multimodal Imaging;multimodal neuroimaging;myelination;Nature;neural;neural circuit;Neurobiology;neurodevelopment;neurogenetics;neuroimaging;neuromechanism;Neurons;neuropsychiatric disorder;novel;Pain management;pain sensitivity;Participant;Pathology;Pattern;Personality;Persons;Phenotype;Pituitary Gland;Play;Population Characteristics;Positron-Emission Tomography;pubertal timing;Puberty;rare genetic disorder;Regression Analysis;Regulation;response;Rest;Role;Route;Sampling;Seminal;Series;sex;Shapes;Siblings;Single Nucleotide Polymorphism;SNP array;SNP genotyping;social;Social Behavior;social cognition;social influence;Stimulus;Structure;success;Surface;Syndrome;System;Techniques;Testing;Tissues;transcriptome sequencing;Translating;Variant;Veins;ventral visual stream;Visual;Visuospatial;Williams Syndrome;Work,Multimodal Neuroimaging of Gene-Brain Relationships in Williams Syndrome,2863,NA,NA,NA,NA,20,NA,NA,1843873,NA
11194736,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002865,NA,NA,1ZIAMH002865-19,NIMH:647708\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,9416711 (contact),"SCHMIDT, PETER  (contact)",NA,NA,NA,Accounting;Address;Affective;Affective Symptoms;Allopregnanolone;Amygdaloid structure;Anxiety;Appearance;Behavior;Behavioral;behavioral health;behavioral phenotyping;behavioral response;Biological;Body mass index;Brain;Brain region;Breast;burden of illness;cell injury;Cell Line;Cell model;cell type;Cellular Stress;Central Nervous System;Characteristics;Child;Childbirth;Chronic Disease;Classification;Clinical;clinical diagnosis;Clinical Management;Clinical Protocols;Clinical Research;Clinical Trials;cognitive function;Collaborations;comorbidity;comparison control;Data;Data Analyses;Data Set;Depressed mood;depressive symptoms;desensitization;Development;Diagnostic;differential expression;Direct Costs;Disease;Disparity;DNA;DNA Methylation;Down-Regulation;Endocrine;Epidemiology;epidemiology study;Estradiol;Event;Exposure to;Facilities and Administrative Costs;food craving;Free Radicals;Frequencies;Functional disorder;Future;Gene Expression;Genes;Genetic;Genetic Transcription;genomic data;Genomics;Genotype;Glucocorticoids;Glutathione S-Transferase;GSTT1 gene;Health;Heavy Metals;High Risk Woman;Hormonal;Hormone imbalance;Hormone secretion;hormone therapy;Hormone use;Hormones;human induced pluripotent stem cells;Hypothyroidism;In Vitro;in vivo;Infant;Infanticide;innovation;interest;Intervention;Laboratories;life span;lymphoblastoid cell line;Machine Learning;Major Depressive Disorder;Medial;Mediator;member;Menstrual cycle;Menstruation Disturbances;Mental Depression;Mental disorders;metabolome;metabolomics;Methods;Modeling;Molecular;Molecular Target;Mood Disorders;Moods;Morbidity - disease rate;mortality;Mothers;mouse model;multimodal neuroimaging;multiple datasets;National Institute on Alcohol Abuse and Alcoholism;Nature;neural;Neurons;neuroregulation;neurosteroids;novel;novel therapeutics;Ovarian;Pain;Patients;Pattern;Perimenopause;Phenotype;physical symptom;Physiological;polygenic risk score;Postpartum Depression;Postpartum Period;Predisposition;Prefrontal Cortex;Pregnancy;premenstrual dysphoric disorder;Premenstrual syndrome;prevent;Procedures;Process;Progesterone;Proteins;Psychoses;Rare Diseases;Reactive Oxygen Species;Recurrence;Reduced Glutathione;Reporting;reproductive;reproductive hormone;Reproductive Periods;reproductive system disorder;Research;response;Risk;Risk Factors;risk variant;RNA;Role;Sampling;Sex Differences;Signal Transduction;single nucleus RNA-sequencing;Sleep;Source;Specificity;steroid hormone;Steroid Receptors;Steroids;Stimulus;Suicide;Symptoms;System;Techniques;Testing;Transcript;transcriptomics;Transgenic Mice;Variant;Woman;Women&apos;s study;Work,Reproductive Endocrine Related Mood Disorders-Differential Sensitivity,2865,NA,NA,NA,NA,19,NA,NA,647708,NA
11194737,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002874,NA,NA,1ZIAMH002874-18,NIMH:323854\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,9416711 (contact),"SCHMIDT, PETER  (contact)",NA,NA,NA,Acute;Affect;Affective;Agonist;Allopregnanolone;Amygdaloid structure;Animals;Back;Behavior;behavioral response;Biological;Brain;Brain region;Brain-Derived Neurotrophic Factor;C57BL/6 Mouse;Cell Line;cell type;Cells;Central Nervous System;Cerebrovascular Circulation;Child;Cholinergic Receptors;cingulate cortex;Clinical Protocols;Clinical Research;Cognitive;cognitive performance;Collaborations;Companions;Data;density;dentate gyrus;Development;differential expression;differentiation protocol;Dopamine;Dopamine D2 Receptor;Dopamine Receptor;Dose;Electrophysiology (science);Estradiol;Estrus;Evaluation;experience;Exposure to;extracellular vesicles;Functional disorder;Functional Magnetic Resonance Imaging;functional MRI scan;GABA transporter;Gene Expression;Genes;Genetic;genetic variant;Genetic Variation;genomic variation;Genotype;Glutamate Receptor;Goals;Gonadal Steroid Hormones;Gonadotropin Hormone Releasing Hormone;Hippocampus;Hormonal;Hormone Antagonists;hormone sensitivity;Hormones;Human;Hypogonadism;hypothalamic-pituitary-adrenal axis;immunocytochemistry;Individual;induced pluripotent stem cell;Longitudinal Studies;Mass Spectrum Analysis;Measures;Menopause;Menstrual cycle;Mental Depression;methylome;Mood Disorders;Mus;nerve stem cell;Nervous System Physiology;neural;neural circuit;neuroimaging;Neurons;neurophysiology;neuropsychiatry;neurosteroids;Nucleus Accumbens;older women;Oral;Ovarian;Ovarian Ablation;Ovarian hormone;Ovariectomy;Oxygen;Oxytocin Receptor;Patients;Perimenopause;phenomenological models;Physiological;pleiotropism;Positron-Emission Tomography;Prefrontal Cortex;premenstrual dysphoric disorder;Procedures;Process;Progesterone;Protocols documentation;Puberty;Regimen;Regulation;Reporting;response;Rewards;Role;serotonin receptor;Signal Repression;Signal Transduction;Sorting;Steroid Receptors;Steroids;Stress;Symptoms;System;Techniques;Testing;Time;Tissues;trafficking;transcriptome sequencing;Variant;Water;Wisconsin;Withdrawal;Woman;Work;young woman,The Neuroregulatory Effects of Gonadal Steroids in Humans,2874,NA,NA,NA,NA,18,NA,NA,323854,NA
11194738,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002881,NA,NA,1ZIAMH002881-18,NIMH:1874458\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,9416721 (contact),"LI, ZHENG  (contact)",NA,NA,NA,3-Dimensional;Address;Adolescent;Adult;Adverse event;Affect;Aggressive behavior;aging brain;Anxiety;Anxiety Disorders;Apical;Attention deficit hyperactivity disorder;autism spectrum disorder;Autophagocytosis;Autophagosome;Behavior;Behavioral;Behavioral Paradigm;Bipolar Disorder;Brain;brain circuitry;Brain region;CASP3 gene;Chemosensitization;Classification;Cognitive;Complement;Computer software;Consumption;Dendrites;Dendritic Spines;density;design;Development;Distal;Dyes;Electrophysiology (science);Emotional;Emotions;Excitatory Synapse;Extinction;FDA approved;Fiji;Filopodia;Foundations;Frustration;Genetic;Goals;Golgi method;Growth;Heterogeneity;Hippocampus;Human;human study;Impaired cognition;Impairment;in vivo;Individual;insight;interest;Intermittent Explosive Disorders;Investigation;Knockout Mice;Label;learned behavior;Learning;life span;Locomotion;Long-Term Depression;Magnetoencephalography;Major Depressive Disorder;Manuals;Maps;Measures;Mediating;Mediator;Memory;Mental Depression;Mental disorders;Methodology;Methods;Microglia;Modeling;Molecular;Morphology;Motivation;Mus;Neck;Nervous System Disorder;neural;neural circuit;neuromechanism;Neurons;novel;Oppositional Defiant Disorder;optogenetics;Output;Participant;Pathology;Physiology;Plug-in;Positioning Attribute;postsynaptic;postsynaptic neurons;presynaptic;Preventive;Process;Property;protein degradation;Proteins;Protocols documentation;Public Health;reconstruction;Regulation;Reproducibility;Research;Research Personnel;Resistance;response;Rewards;Role;Schizophrenia;severe mood dysregulation;Site;Social Behavior;Stains;stem;Structure;Symptoms;Synapses;synaptic function;Synaptic plasticity;Techniques;Technology;Therapeutic;Thinness;Three-dimensional analysis;Time;tool;transmission process;Vertebral column;Visualization;Work;Workload;Youth,Molecular Mechanisms of Synapse Development and Plasticity,2881,NA,NA,NA,NA,18,NA,NA,1874458,NA
11194739,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002886,NA,NA,1ZIAMH002886-18,NIMH:756169\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,1905955 (contact),"MURRAY, ELISABETH A (contact)",NA,NA,NA,Achievement;Affect;Amygdaloid structure;Animal Testing;Animals;Anterior;Anxiety Disorders;Arousal;Behavior Control;Behavioral;Bilateral;Brain;cingulate cortex;Control Animal;Data;Decision Making;Diameter;Emotional;Emotions;Event;expectation;Feedback;frontal lobe;Functional disorder;Future;Goals;Heart Rate;improved;Laboratories;Lesion;Major Depressive Disorder;Measures;Medial;Mental Depression;Mental disorders;Methods;Mood Disorders;neuromechanism;Neurons;neurophysiology;Neuropsychology;neurotoxic;Obsessive-Compulsive Disorder;Outcome;Panic Attack;Persons;Play;Process;Property;Pupil;Reaction;Regulation;response;reward anticipation;reward expectancy;reward processing;Rewards;Role;Sensory;Signal Transduction;social cognition;Stimulus;Syndrome;theories;Time,Neural mechanisms of reward processing and emotion,2886,NA,NA,NA,NA,18,NA,NA,756169,NA
11194740,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002887,NA,NA,1ZIAMH002887-18,NIMH:2268506\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,1905955 (contact),"MURRAY, ELISABETH A (contact)",NA,NA,NA,Acetylcholine;Address;Affect;Amines;Amygdaloid structure;Anatomic Border;anatomical tracer;Anatomy;Animal Model;Animals;Anterior;Anxiety;Area;Arousal;aspirate;Attention;autism spectrum disorder;Basal Ganglia;Behavior;behavioral impairment;Bilateral;Bipolar Disorder;Brain;calbindin;Cell Nucleus;Cells;Cercopithecidae;Cerebrovascular Circulation;Choice Behavior;Cholera Toxin Protomer B;cholinergic;Cholinergic Fibers;cingulate cortex;Clinical Research;Cognitive;cognitive testing;Comparative Study;Complex;Corpus striatum structure;Decision Making;Deep Brain Stimulation;density;Dextrans;Disease;Disparity;Dorsal;Electrophysiology (science);emotion regulation;Emotions;esterase;Evolution;Excision;Excitotoxic lesion;Exhibits;Fiber;flexibility;Foundations;frontal lobe;Functional disorder;Genetic;Glutamate Transporter;Goals;Health;Impairment;improved;Inferior;information processing;Injections;Interneurons;Interruption;Intervention;Knowledge;Label;Lateral;Learning;Lesion;Limbic System;Link;Macaca;magnocellular;Major Depressive Disorder;Measures;Medial;Mediating;Mental disorders;Methodology;Methods;Modeling;Molecular;Monkeys;Mood Disorders;Nature;Negative Valence;nerve supply;neural;neuroimaging;Neurons;neurophysiology;Nucleus Basalis Magnocellularis;Obsessive-Compulsive Disorder;Panic Attack;Parvalbumins;parvocellular;Pathway interactions;Patients;Pattern;Phobias;Phylogenetic Analysis;Positioning Attribute;Positive Valence;Prefrontal Cortex;Primates;Process;Pulvinar structure;Quality of life;Rattus;reduce symptoms;Reporting;Research;response;reward processing;Rodent;Role;Schizophrenia;social cognition;Source;Stains;Stimulus;Structure;Structure-Activity Relationship;superior colliculus Corpora quadrigemina;Tarsiidae;Temporal Lobe;Time;Tissue Stains;Tissues;Tracer;Translating;Tupaiidae;Visual;visual information;Visual Pathways;Visual System;Visualization;Work,Neural Substrates of Reward Processing and Emotion,2887,NA,NA,NA,NA,18,NA,NA,2268506,NA
11194741,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002893,NA,NA,1ZIAMH002893-18,NIMH:353303\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,79363713 (contact),"BAKER, CHRIS  (contact)",NA,NA,NA,Adult;Age;Amputation;Amputees;Area;arm;behavior measurement;Behavioral;Biomimetics;Bionics;Blindness;Body part;Brain;brain computer interface;Brain imaging;Cognitive;Critical Thinking;Data;design;Development;Devices;Digit structure;Electromyography;experience;Feedback;flexibility;foot;Forearm;Functional disorder;Functional Magnetic Resonance Imaging;Goals;gray matter;Hand;Hand functions;Human;Human body;improved;Injury;insight;Intuition;Learning;life span;Limb Prosthesis;Limb structure;Lip structure;Magnetic Resonance Imaging;Maps;Measures;Motor;Movement;Nature;Nervous System;neural;neuromechanism;novel;Participant;Patients;Performance;Population;preservation;Prosthesis;prosthetic hand;Regimen;Rehabilitation therapy;Research;Robotics;Scanning;Shapes;skills;Source;Stroke;Structure;System;Task Performances;Time;tool;Training;training opportunity;Upper Extremity;Visual;visual tracking;white matter;Work,Learning and plasticity in the human brain,2893,NA,NA,NA,NA,18,NA,NA,353303,NA
11194742,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002896,NA,NA,1ZIAMH002896-18,NIMH:1198444\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,77874251 (contact),"LEOPOLD, DAVID A (contact)",NA,NA,NA,Affect;Anatomy;Area;Arousal;Atlases;basal forebrain;Blood flow;Brain;Brain Mapping;Cells;cholinergic;cognitive task;Complex;Databases;Disease;Electrophysiology (science);experimental study;follow-up;Follow-Up Studies;Frustration;Functional Magnetic Resonance Imaging;functional MRI scan;Health;hemodynamics;Hippocampus;Human;insight;Laboratories;Light;Link;Location;Magnetic Resonance Imaging;Maps;Measures;Mental disorders;Methods;Mus;Nature;neural;neuroimaging;Neurons;neuroregulation;Neurosciences;neurotransmission;neurovascular coupling;operation;optogenetics;Patients;Pattern;Periodicals;Physiology;Population;Positioning Attribute;programs;Prosencephalon;Reporting;Research;Research Personnel;response;Rest;Sensory;Shapes;Signal Transduction;Sleep;Structure;Technology;Thinking;Wakefulness;Work,The Neural Underpinnings of Functional MRI Networks,2896,NA,NA,NA,NA,18,NA,NA,1198444,NA
11194743,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002898,NA,NA,1ZIAMH002898-18,NIMH:1198444\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,77874251 (contact),"LEOPOLD, DAVID A (contact)",NA,NA,NA,absorption;Adult;Animals;Area;Behavior;Biology;Brain;Brain Diseases;Brain Injuries;Brain Mapping;Businesses;cell cortex;Cells;Cerebral cortex;Characteristics;Childhood;clinical application;combinatorial;Dedications;Development;Electrophysiology (science);experience;Exposure to;extrastriate visual cortex;Face;Facial Expression Recognition;Familiarity;Fluorescence;Functional Imaging;Functional Magnetic Resonance Imaging;Future;gene therapy;Genetic;Goals;Human;imaging modality;Impairment;Individual;Learning;Life;Light;Link;Memory;Mental disorders;Methods;Microelectrodes;Modification;Monitor;Nature;Nervous System Disorder;neural circuit;neurodevelopment;Neuronal Plasticity;Neurons;Neurosciences;novel;operation;Opsin;optical imaging;Physiology;Play;Population;pre-clinical research;preference;Pregnancy;Process;Research;Research Personnel;response;Signal Transduction;skills;social;Social Interaction;Social Perception;Sports;Spouses;Stimulus;System;Temporal Lobe;Time;tool;Traction;transgene expression;Translating;Viral;Vision;Visual;visual information;visual learning;visual processing;Voice;Work,Neurodevelopment and Plasticity in Social Neural Circuits,2898,NA,NA,NA,NA,18,NA,NA,1198444,NA
11194744,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002909,NA,NA,1ZIAMH002909-17,NIMH:3179727\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,79363713 (contact),"BAKER, CHRIS  (contact)",NA,NA,NA,Affect;American;Apple;Area;autism spectrum disorder;Behavior;Behavioral;behavioral response;Body part;Brain;Brain imaging;Brain region;Categories;Cephalic;cognitive process;Complex;Computer Models;computer science;crowdsourcing;Data;Databases;Dimensions;Electric Stimulation;Elements;English Language;Episodic memory;experience;experimental study;Eye;Eye Movements;Face;Face Processing;falls;Food;foot;Functional Magnetic Resonance Imaging;Goals;Grain;grasp;Hand;Human;Image;Individual;insight;interest;Knowledge;large-scale database;Learning;Leg;Light;Link;Magnetic Resonance Imaging;Magnetoencephalography;Measures;Medial;Memory;Mental Health;mental representation;Modeling;Nature;Nervous System Disorder;neural;Neurosciences;novel;object recognition;Parietal;Participant;Perception;Persons;Psychology;Research;Resources;response;Retina;Role;Running;Sampling;Shapes;skills;Social Behavior;Stimulus;Stroke;Tennis;Testing;tool;Transcranial magnetic stimulation;Visual;Visual Cortex;Visual Perception;Work,"Object, face,  body and scene representations in the human brain",2909,NA,NA,NA,NA,17,NA,NA,3179727,NA
11194745,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002920,NA,NA,1ZIAMH002920-16,NIMH:447563\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,6482398 (contact),"MARTIN, ALEX  (contact)",NA,NA,NA,Affect;autism spectrum disorder;autism symptoms;Autobiography;base;Behavior;Behavioral;Brain imaging;Cerebral hemisphere;Characteristics;Clinical;Cognition;cognitive neuroscience;Communication;Communication difficulty;developmental disease;Event;Exhibits;experience;flexibility;Functional Magnetic Resonance Imaging;Goals;imaging study;Individual;individuals with autism spectrum disorder;instrument;interest;Intuition;Journals;Left;Life;Literature;Magnetic Resonance Imaging;Magnetoencephalography;Measures;Memory;Memory impairment;neural;neural circuit;neural correlate;neuroimaging;Neuropsychological Tests;Neuropsychology;Neurosciences;Participant;Pervasive Development Disorder;Play;Process;Protocols documentation;Publishing;Questionnaires;Reporting;Research;Role;skills;social;social cognition;social communication;Speech;Technology;visual tracking;way finding;Work,The Cognitive Neuroscience of Autism Spectrum Disorders,2920,NA,NA,NA,NA,16,NA,NA,447563,NA
11194746,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002922,NA,NA,1ZIAMH002922-16,NIMH:1130023\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,10422620 (contact),"PAO, MARYLAND  (contact)",NA,NA,NA,Address;Adult;Age;Alaska Native;Allergic Reaction;Ambulatory Care Facilities;American Indians;Anxiety;Area;Argentina;Argentine;Arterial Disorder;Attention;Autoimmune;autosome;Awareness;Behavioral;behavioral phenotyping;Black race;Brain Diseases;Brain Neoplasms;Catatonia;Cerebrum;Childhood;Chronic;Chronic Fatigue Syndrome;Clinical;clinical care;clinical center;Clinical Pathways;Clinical Research;clinical training;Clinical Trials;Clinics and Hospitals;Cognitive;cognitive function;Collaborations;Communicable Diseases;Communities;Consult;Consultations;Convalescence;coping;COVID-19;COVID-19 pandemic;COVID-19 pandemic effects;COVID-19 sequelae;COVID-19 survivors;COVID-19 vaccine;Data Analyses;Data Set;data submission;Delirium;design;Disease;Disparity;Distress;Documentation;Dose;Educational workshop;Electronics;Emotional;emotional functioning;Encephalitis;Enrollment;Environmental Impact;environmental stressor;Epilepsy;Ethiopia;Evaluation;experience;Extramural Activities;Faculty;Family;Fatigue;Follow-Up Studies;Gender;Genetic;Health;Health Status;healthy volunteer;high risk;HIV;HIV/AIDS;Hypersensitivity;Immune System Diseases;Inflammatory;interdisciplinary approach;International;Intramural Research Program;irradiation;Knowledge;Language;Lead;life span;Longitudinal Studies;Measurement;Measures;Medical;Mental disorders;Mental Health;Mission;Monitor;multidisciplinary;N-Methyl-D-Aspartate Receptors;National Institute of Allergy and Infectious Disease;National Institute of Child Health and Human Development;National Institute of Drug Abuse;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;native youth;Natural History;Neonatal;Nepal;neuroAIDS;neurocognitive disorder;neurodevelopment;Neurodevelopmental Disorder;neuropsychiatry;Neuropsychology;Nevada;NIH Office of AIDS Research;opioid use disorder;outreach;Parkinson Disease;Participant;Pathway interactions;Patient Self-Report;Patients;Pediatric Oncology;pediatric patients;Persian Gulf Syndrome;Persons;Phenotype;physical conditioning;Play;Population;Population Heterogeneity;Portugal;Post-Acute Sequelae of SARS-CoV-2 Infection;Prevention Research;programs;Protocols documentation;Psyche structure;psychiatric comorbidity;Psychiatrist;Psychiatry;psychologic;Psychologist;Psychoses;psychosocial;Public Health;public repository;Publishing;Questionnaires;Race;Rare Diseases;Reaction;recruit;Research;research clinical testing;Research Personnel;research study;Research Subjects;Research Support;Resource-limited setting;Resources;response;Role;safety assessment;SARS-CoV-2 immunity;SARS-CoV-2 infection;screening;Screening procedure;screening program;Services;Site;Sleep;sleep difficulty;social;Social Workers;Spanish;Spirituality;Standardization;Study Subject;Subcortical Infarctions;Subcortical Leukoencephalopathy;Substance abuse problem;suicidal behavior;suicidal risk;Suicide;Suicide prevention;suicide rate;Symptoms;Syndrome;telehealth;Time;tool;tool development;Training;Translating;United States Indian Health Service;United States National Institutes of Health;Vaccines;validation studies;Visit;volunteer;web site;Work;Youth,Clinical Research in the NIMH Office of the Clinical Director,2922,NA,NA,NA,NA,16,NA,NA,1130023,NA
11194747,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002927,NA,NA,1ZIAMH002927-15,NIMH:3366147\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,9694517 (contact),"ZARATE, CARLOS  (contact)",NA,NA,NA,Adult;Affect;Age;AMPA Receptors;antagonist;Anterior;anti-depressive agents;antidepressant effect;Behavioral;Biological Markers;biomarker identification;Bipolar Disorder;Body mass index;Brain imaging;Cessation of life;cingulate cortex;Clinical;Clinical Trials;Cognitive;collected works;comorbidity;computerized;Controlled Clinical Trials;Data;depressive symptoms;design;Diagnosis;Dimensions;Disease;Dissociation;Dorsal;Double-Blind Method;efficacy evaluation;Electrophysiology (science);Enrollment;experience;Feeling hopeless;Feeling suicidal;Female;follow up assessment;Frequencies;Functional disorder;Future;Genes;Genetic;Hallucinations;healthy volunteer;high body mass index;High Prevalence;high risk;high risk population;hospitalization rates;improved;indexing;Individual;inpatient psychiatric treatment;Insula of Reil;Intervention;Intrinsic drive;Investigation;Investigational Therapies;Ketamine;Lassitude;Left;Life;Link;Literature;Longterm Follow-up;Magnetoencephalography;Major Depressive Disorder;male;Measures;Mediating;Medical;Mental Depression;metabotropic glutamate receptor 2;minimal risk;Montgomery and Asberg depression rating scale;Mood Disorders;mood symptom;National Institute of Mental Health;neural correlate;Neurobiology;Neuropsychological Tests;new therapeutic target;novel;novel therapeutics;Obesity;open label;optimism;Oral;Outcome;Outcome Measure;Outpatients;Overweight;Participant;Patient Self-Report;Patients;peripheral blood;Pharmacotherapy;phenomenological models;Phenotype;Pilot Projects;Placebos;Prefrontal Cortex;Prevalence;Protocols documentation;Proxy;Psyche structure;psychiatric comorbidity;Pyramidal Cells;Questionnaires;receptor;Receptor Activation;Recording of previous events;recruit;Reporting;Research;Research Domain Criteria;Rest;Risk;Risk Factors;Sampling;Scanning;Severities;Severity of illness;single episode major depressive disorder;stellate cell;Stratum Granulosum;suicidal;suicidal behavior;suicidal risk;Suicide;Suicide attempt;suicide attempter;suicide rate;symptomatology;Symptoms;Syndrome;System;Therapeutic Agents;Time;transgender;treatment effect;treatment response;treatment-resistant depression;Validation;women patients,Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders,2927,NA,NA,NA,NA,15,NA,NA,3366147,NA
11194748,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002928,NA,NA,1ZIAMH002928-15,NIMH:2713014\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,10687538 (contact),"AVERBECK, BRUNO  (contact)",NA,NA,NA,addiction;Adolescence;Amygdaloid structure;Animal Model;Animals;Anxiety;Anxiety Disorders;Area;Basal Ganglia;base;Behavior;Behavioral;Brain;Clinical;Code;Cognitive;Computer Models;Conceptions;Corpus striatum structure;cost;Development;Disease;Dopamine;dopamine system;dopaminergic neuron;Dorsal;experience;experimental study;Feeling;Food;Globus Pallidus;Goals;Human;Image;Lead;Learning;Life;Limbic System;Liquid substance;Mental Depression;Mental disorders;Modeling;motivational processes;neural;neurophysiology;Outcome;Pathologic;Pathology;Patients;Pharmacology;Phylogenetic Analysis;Play;Population;Prefrontal Cortex;Prevalence;Primates;Process;programs;Public Health;Punishment;reinforcer;Research;Rewards;Role;Signal Transduction;Societies;Structure;Students;Support System;System;teacher;Thalamic structure;Trauma;Ventral Striatum;Vertebrates;Work,Frontal Striatal Systems and Dopamine in Normal and Pathological Behavior,2928,NA,NA,NA,NA,15,NA,NA,2713014,NA
11194749,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002933,NA,NA,1ZIAMH002933-13,NIMH:971563\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,9416711 (contact),"SCHMIDT, PETER  (contact)",NA,NA,NA,7q11.23;Adolescence;Adolescent;adolescent health;Adrenal Glands;Adrenal hormone preparation;Age;Age at Menarche;age related;Androgens;Anxiety Disorders;Attention;Autopsy;Basic Science;Behavior;behavior measurement;Behavioral;Bilateral;Biochemical;Blood specimen;Body Composition;Body mass index;bone age;Bone Development;boys;Brain;Breast;burden of illness;Cell Line;Cerebellum;Characteristics;Child;Childhood;Clinical Protocols;cohort;Companions;contextual factors;Data;Dehydroepiandrosterone Sulfate;Delayed Puberty;Depressive disorder;Development;developmental disease;disability;Disease;Dorsal;Dose;Dual-Energy X-Ray Absorptiometry;early life stress;Early-life trauma;Elements;Emotional;Emotions;Endocrine;Entire hair of pubis;Environmental Risk Factor;Estradiol;Evaluation;Event;Exhibits;experience;Exposure to;Family;Family history of;Female Adolescents;First Degree Relative;Functional disorder;functional genomics;Functional Magnetic Resonance Imaging;Future;genome wide association study;Genotype;girls;Gonadal Hormones;Gonadal Steroid Hormones;gray matter;Growth;Growth Factor;Gynecology;Hemorrhage;Hippocampus;Hormones;Human;hypothalamic pituitary gonadal axis;Incidence;indexing;Individual;Interview;Left;Link;Lymphocyte;Magnetic Resonance Imaging;Manuscripts;Maps;Measures;Medical;Menarche;Mental Depression;Mental disorders;Metabolic;methylome;Modeling;Mood Disorders;Moods;Morphology;multimodal neuroimaging;neural;neural network;Neurobiology;neurodevelopment;Neuronal Plasticity;neuroprotection;neuropsychiatric disorder;Neurotransmitters;Outcome Measure;Ovarian;Participant;Pathology;Pattern;peer;Peripheral;Physiological;Pituitary Gland;pituitary gland development;Plasma;Play;Polycystic Ovary Syndrome;Precocious Puberty;Prefrontal Cortex;prepuberty;Prevalence;primary ovarian insufficiency;Process;Production;pubertal timing;Puberty;puberty transition;Radiology Specialty;Reporting;reproductive;Rest;Retinal blind spot;reward anticipation;reward processing;Rewards;Risk;Role;Sampling;Selection Criteria;Serum;Services;Sex Differences;sexual dimorphism;Short-Term Memory;Signal Transduction;Sleep;social;Steroids;Stress;Structure;Structure of supramarginal gyrus;Sulfate;Syndrome;System;Techniques;telomere;Testis;Testosterone;TFF1 gene;Tissues;transcriptome;transcriptome sequencing;United States National Institutes of Health;Variant;virtual;Visceral fat;Visit;white matter;Williams Syndrome;Work,Endocrine and Neurobiologic Events Accompanying Puberty,2933,NA,NA,NA,NA,13,NA,NA,971563,NA
11194750,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002949,NA,NA,1ZIAMH002949-09,NIMH:4357172\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,14761200 (contact),"RAZNAHAN, ARMIN  (contact)",NA,NA,NA,Address;Affect;Aneuploidy;Area;Atlases;autism spectrum disorder;Autopsy;Behavior;Behavioral;Biological;Biological Psychiatry;Biology;Brain;Brain imaging;Brain region;Brain scan;Cerebral cortex;Childhood;Chromosome Mapping;Clinical assessments;clinical care;clinical center;Clinical Protocols;Cognition;Cognitive;Collaborations;Complex;computerized tools;Copy Number Polymorphism;cortex mapping;Data;Data Set;Dedications;Detection;Development;Disease;dosage;Ethics;Event;experimental study;falls;Family member;Female;Fingerprint;flexibility;follow-up;Gene Abnormality;Gene Cluster;Gene Dosage;Gene Expression;Gene Expression Profile;General Population;Genes;Genetic Diseases;genetic variant;Genome;Genomics;Goals;Grain;Health;Human;Human Genome;improved;Individual;individuals with autism spectrum disorder;insight;Logistics;male;Maps;Measures;Medical;Mental disorders;Mental Health;Methodology;Methods;Micro Array Data;Modeling;Molecular;mouse model;multi-scale modeling;Mus;Neurobiology;Neurodevelopmental Disorder;neurogenomics;neuroimaging;neuropsychiatric disorder;Outcome;Participant;Pathway interactions;Phenotype;Phenotypic Sex;Population;Prevalence;Property;Protocols documentation;Psychiatry;Publishing;rare genetic disorder;Research;Research Personnel;resilience;Resources;Risk;risk variant;Sampling;sex;Sex Bias;sex chromosome aneuploidy;Sex Chromosomes;Sex Differences;Structure;Syndrome;System;Testing;Thick;tool;Transgenic Mice;translational study;United States National Institutes of Health;Universities;Variant;Vertebral column;Work;X Chromosome;Y Chromosome,Section on Developmental Neurogenomics,2949,NA,NA,NA,NA,9,NA,NA,4357172,NA
11194751,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002950,NA,NA,1ZIAMH002950-09,NIMH:2374928\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,14761202 (contact),"PENZO, MARIO  (contact)",NA,NA,NA,Adaptive Behaviors;Address;Animals;Behavior;Behavioral;Biology;Brain;Calcium;Cells;Complex;Decision Making;Disease;Dorsal;Electrophysiology (science);Emotional;experience;follow-up;Future;goal oriented behavior;Goals;Hunger;Hypothalamic structure;Image;insight;Memory;Mental disorders;Molecular;Monitor;motivated behavior;Motivation;mouse genetics;Mus;Nature;neural circuit;neuromechanism;neuronal circuitry;Neurons;Pathway interactions;Population;Prefrontal Cortex;Process;Publishing;PubMed;Research;Role;sensory integration;Shapes;Signal Transduction;Stress;Structure of paraventricular nucleus of thalamus;System;Techniques;Text;Thalamic structure;Therapeutic Intervention;therapeutic target;Ventral Striatum;Work,Dissecting the stress circuits of the paraventricular nucleus of the thalamus,2950,NA,NA,NA,NA,9,NA,NA,2374928,NA
11194752,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002951,NA,NA,1ZIAMH002951-09,NIMH:2600456\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,14761204 (contact),"CHUDASAMA, YOGITA  (contact)",NA,NA,NA,Acute;acute symptom;Address;Adrenergic Agents;Affect;Agonist;Amygdaloid structure;anatomical tracer;Anxiety;Area;Attention;Attention deficit hyperactivity disorder;Basic Science;Behavior;Behavior Control;behavior test;Behavioral;Brain;brain circuitry;Calcium Signaling;Categories;cell type;Cells;Clinical;Cognition;Cognitive;cognitive control;cognitive function;Collection;Complex;Decision Making;Detection;Disinhibition;Dopamine D1 Receptor;Dorsal;emotion regulation;emotional behavior;Emotions;executive function;Fiber;Fluorescent in Situ Hybridization;frontal lobe;Galanin;galanin receptor;GALR1 Galanin Receptor;Glutamates;Goals;Hippocampus;Human;improved;Impulsivity;inattention;Lesion;Mediating;Medicine;Memory impairment;Methods;Minor;Nature;Nervous System Disorder;neural circuit;Neuroanatomy;Neurobehavioral Manifestations;Neurons;Neuropeptides;Neuropharmacology;neuropsychiatric disorder;neurotransmission;Neurotransmitters;noradrenergic;Norepinephrine;optogenetics;Pathway interactions;Patients;Pattern;Performance;pharmacologic;Pharmacology;Photometry;Play;Population;Prefrontal Cortex;premature;programs;promoter;Prosencephalon;psychosocial;Quality of life;Rattus;receptor;Recombinants;reduce symptoms;Research;response;Rewards;Risk;Risk Behaviors;Risk Taking;Role;selective attention;Shapes;Signal Transduction;Site;skills;social;Social Behavior;spatial memory;Stimulant;Stimulus;Stress;Structure;Synapses;Temporal Lobe;Thalamic Nuclei;Thalamic structure;Time;Ventral Striatum;Virus;Work,Neural Circuits Underlying the Control of Executive and Emotional Behavior,2951,NA,NA,NA,NA,9,NA,NA,2600456,NA
11194753,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002953,NA,NA,1ZIAMH002953-09,NIMH:579583\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,8174758 (contact),"MERIKANGAS, KATHLEEN R (contact)",NA,NA,NA,addiction;Adolescent;Adult;adverse outcome;Age;age group;Alaska Native;Alcohols;American Indians;Anxiety;Asian population;Attention;Australia;Bayesian Network;Behavior;Behavioral;Benefits and Risks;Biochemical;Black race;Brain;Brazil;burden of illness;California;Canada;Cardiovascular Diseases;cardiovascular risk factor;Child;child depression;Childhood;climate change;Clinical;Code;Cohort Studies;Collaborations;Communication;Community Health;comorbidity;compare effectiveness;Complement;Consult;convict;COVID-19 pandemic;COVID-19 pandemic effects;cyberbullying;Data;Data Analyses;data resource;Data Sources;design;Development;developmental genetics;Diagnostic;disability burden;Disease;disease classification;early onset;Electronic cigarette;Emotional;epidemiologic data;Epidemiology;epidemiology study;Ethnic Origin;Etiology;evidence base;Exposure to;Family;Family Study;Feeling suicidal;follow-up;Future;Genetic;genetic epidemiology;Goals;Health;health assessment;Health behavior;Health Surveys;high risk;Hispanic Populations;Impairment;improved;Incidence;Individual;Internet;Intervention;Interview;Investigation;Life;Longitudinal Studies;Manic;Maps;Mental Depression;Mental disorders;Mental Health;Mental Health Services;Methods;Mind;Monitor;Mood Disorders;Moods;Music;musician;National Institute of Mental Health;Native-Born;New York;non-affective psychoses;novel;Occupational;Outcome;Parents;Participant;Pattern;pediatric department;Pennsylvania;Perception;Persons;Philadelphia;Physical activity;physical conditioning;Physiological;Population Assessment of Tobacco and Health;population based;Population Heterogeneity;Population Research;Population Study;Predisposition;Prevalence;Prevention;Primary Care;programs;prospective;Prospective Studies;Psyche structure;psychiatric comorbidity;Psychotic Disorders;Public Health;Publications;Publishing;Race;Research;Research Personnel;research study;Resources;Retrospective cohort study;Risk;Risk Factors;Sampling;School Drop-Outs;Self-Injurious Behavior;Sleep;social;Source;Structure;Student Dropouts;Substance Addiction;substance use;Substance Use Disorder;suicidal;Suicide;Surveys;Switzerland;Symptoms;System;systematic review;Thinking;Time;Tobacco use;Universities;Work;years lived with disability;young adult;Youth,Population-Based Epidemiologic Research,2953,NA,NA,NA,NA,9,NA,NA,579583,NA
11194754,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002954,NA,NA,1ZIAMH002954-09,NIMH:1255764\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,8174758 (contact),"MERIKANGAS, KATHLEEN R (contact)",NA,NA,NA,Academic Medical Centers;Accelerometer;actigraphy;Address;Adolescent;Adult;Affect;Affective;analytical method;Anxiety;Anxiety Disorders;anxiety spectrum disorders;Applet;assessment application;Attention deficit hyperactivity disorder;Australia;Behavior;Biological;Biometry;Bipolar Disorder;Bipolar I;Brain;brain health;Callithrix;Cardiovascular Diseases;Child;Chinese;circadian;circadian biology;Circadian Dysregulation;Circadian Rhythms;Classification;climate change;climate impact;Clinic;Clinical;cognitive function;cognitive testing;cohort;Cohort Studies;Collaborations;comorbid depression;Data;Data Analyses;Data Collection;data management;data modalities;Databases;Depressive disorder;depressive symptoms;design;Development;Devices;diaries;Disease;Doctor of Philosophy;Eating;Ecological momentary assessment;Electronics;Emotions;executive function;Exercise;Exposure to;Family;Family Study;Future;Genetic;genetic association;genetic risk factor;Genetic study;Goals;Health;health data;Heritability;high risk;Hong Kong;Human;Image;indexing;Individual;individual variation;interest;Intervention Studies;Investigation;Joints;Learning;Light;Machine Learning;Major Depressive Disorder;Measures;Memory;Mental Depression;Mental disorders;Mental Health;Methodology;Methods;mHealth;Mind;mobile application;Modeling;Monitor;Monkeys;Mood Disorders;Moods;Motor;Motor Activity;multimodal data;multimodal neuroimaging;multimodality;National Institute of Mental Health;Netherlands;nonhuman primate;novel;offspring;online intervention;Paper;Parents;Participant;Perception;Periodicity;Phase;Phenotype;Philadelphia;Physical activity;physical conditioning;physical inactivity;Population;Population Research;Prevention;Procedures;Process;programs;Protocols documentation;Public Health;Public Health Schools;Publishing;Queensland;Recording of previous events;Reporting;Research;Research Activity;Research Institute;Research Personnel;Role;Sample Size;Sampling;sedentary lifestyle;Site;Sleep;sleep pattern;smartphone based assessment;social deficits;Standardization;Statistical Methods;Structure;Subgroup;substance use;Switzerland;Symptoms;System;Technology;Temperature;Testing;Time;trait;translational study;Twin Multiple Birth;Twin Studies;United States National Institutes of Health;Universities;Work;Wrist;Youth,Motor Activity Research Consortium for Health (mMarch),2954,NA,NA,NA,NA,9,NA,NA,1255764,NA
11194755,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002955,NA,NA,1ZIAMH002955-09,NIMH:6395511\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,14771945 (contact),"LISANBY, SARAH  (contact)",NA,NA,NA,15 year old;Acute;Address;adolescent with autism spectrum disorder;Affect;Age;anti-depressive agents;Anxiety;auditory processing;autism spectrum disorder;Automobile Driving;Award;Behavior;Behavioral;Biological Markers;biomarker discovery;blood-based biomarker;Brain;brain behavior;brain control;Brain region;Cephalic;Cessation of life;Clinical;clinical heterogeneity;Clinical Protocols;Cognitive;cognitive enhancement;Cognitive Therapy;Collaborations;Compulsive Behavior;Data;Development;Devices;diagnostic strategy;Dimensions;disability;Dose;Double-Blind Method;effective intervention;effective therapy;electric field;Electric Stimulation Therapy;Electroconvulsive Therapy;Electroencephalography;endophenotype;Feasibility Studies;Fellowship;Functional disorder;Functional Magnetic Resonance Imaging;General Population;Goals;healthy volunteer;image guided;Impairment;improved;Impulsivity;Individual;inter-individual variation;Intramural Research Program;Ketamine;Learning;Link;Magnetoencephalography;Measures;Memory Loss;Mental Depression;Mentors;Migraine;millisecond;Modeling;Motor Cortex;neurochemistry;Neurocognitive;neurofeedback;neuroimaging;Neuronal Plasticity;neuroregulation;noninvasive brain stimulation;novel;Obsessive-Compulsive Disorder;Outcome;patient stratification;Patients;Performance;personalized approach;personalized intervention;Phase;Population;Protocols documentation;Public Health;Randomized;Research;response;Role;Safety;Sampling;secondary outcome;Seizures;Selection for Treatments;side effect;signal processing;single episode major depressive disorder;smoking addiction;Source;suicidal;Symptoms;Task Performances;Techniques;Testing;Therapeutic;Time;Transcranial magnetic stimulation;transmission process;Treatment Efficacy;treatment-resistant depression;United States National Institutes of Health;Universities;Work;Youth,Non-invasive Neuromodulation Unit (NNU),2955,NA,NA,NA,NA,9,NA,NA,6395511,NA
11194756,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002956,NA,NA,1ZIAMH002956-09,NIMH:1493438\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,14761208 (contact),"HISTED, MARK  (contact)",NA,NA,NA,Adult;Animals;Area;area striata;Artificial Intelligence;Back;Behavior;Behavioral;Behavioral Assay;behavioral response;Biological;Biological Assay;Brain;calcium indicator;Cells;Cerebral cortex;Code;Cognition;Complex;Data;Decision Making;Dependovirus;design;Detection;Development;Dimensions;Esthesia;experience;Fire - disasters;Genes;Genetic;Hearing;Holography;Image;improved;in vivo;insight;Learning;learning network;Life;Link;Machine Learning;Measures;Methods;Modeling;movie;multi-photon;Mus;neural;neural circuit;neural patterning;neuronal cell body;neuronal patterning;Neurons;novel;operation;Opsin;Optics;optogenetics;Organism;Output;Pattern;Performance;Photic Stimulation;Play;Population;Process;programs;Property;Psychophysics;Recurrence;recurrent neural network;Resolution;response;Role;Sensory;sensory cortex;sensory stimulus;Shapes;speech processing;statistics;Structure;Synapses;System;Time;tool;Training;two-photon;Virus;Vision;Visual;Visual Cortex;Weight;Work,Patterns of neuronal activity underlying behavioral decisions,2956,NA,NA,NA,NA,9,NA,NA,1493438,NA
11194757,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002958,NA,NA,1ZIAMH002958-08,NIMH:2165258\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,15226858 (contact),"AFRAZ, ARASH  (contact)",NA,NA,NA,Area;Artificial Intelligence;Behavior;Brain;Communication;electrical microstimulation;Event;extrastriate visual cortex;Eye Movements;Face;Goals;Inferior;Link;Measures;Microinjections;Nature;neural;Neurons;novel strategies;object recognition;optogenetics;Paper;Pharmaceutical Preparations;Primates;Psychophysics;Publishing;Stream;Technology;Temporal Lobe;United States National Academy of Sciences;Visual;Visual Perception;visual processing,"Unit on Neurons, Circuits and Behavior",2958,NA,NA,NA,NA,8,NA,NA,2165258,NA
11194758,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002959,NA,NA,1ZIAMH002959-08,NIMH:1892552\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,15226860 (contact),"LEE, SOOHYUN  (contact)",NA,NA,NA,Address;Adult;Anatomy;Area;autism spectrum disorder;Behavioral;Brain;cell type;Cells;Characteristics;Communication;Dendrites;Development;Developmental Process;Disinhibition;Elements;excitatory neuron;Feedback;gamma-Aminobutyric Acid;Glutamates;Goals;Heterogeneity;high risk;hippocampal pyramidal neuron;Impairment;in vivo calcium imaging;Individual;Intellectual functioning disability;Interneurons;Lead;Link;Maps;Mediating;Motor Cortex;Movement;Mutation;Neocortex;neural;neural circuit;Neurons;Neuropharmacology;neuroregulation;optogenetics;Pattern;Perception;pharmacologic;Population;postsynaptic;presynaptic;Process;programs;Proteins;recruit;Research;risk variant;Role;scaffold;Schizophrenia;selective attention;Sensory;sensory cortex;sensory feedback;Somatosensory Cortex;Somatostatin;Specificity;Synapses;Synaptic Transmission;SYNGAP1;Thalamic Nuclei;Thalamic structure;Time;tool;Transgenic Mice;transmission process;Vasoactive Intestinal Peptide;Work,Circuit mechanisms underlying cortical communications,2959,NA,NA,NA,NA,8,NA,NA,1892552,NA
11194759,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002962,NA,NA,1ZIAMH002962-08,NIMH:2739460\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,15226871 (contact),"BUCKLEY, ASHURA  (contact)",NA,NA,NA,"Adult;Apnea;Archives;arm;autism spectrum disorder;autistic children;Behavior assessment;Behavioral;behavioral health;behavioral phenotyping;Biological Markers;biomarker discovery;Biomedical Engineering;Brain;brain based;Child;Childhood;Chronic;Chronic Disease;Clinical assessments;clinical center;clinical diagnosis;cohort;Collaborations;Collection;Consensus;Consultations;Data;Data Collection;Deposition;Development;Developmental Delay Disorders;Devices;Diagnosis;Discipline;Disease;Educational workshop;Electrophysiology (science);Enrollment;Evaluation;Event;Goals;Home;Hospitals;Individual;Joints;Knowledge;Link;Mediating;Medical;medical specialties;meetings;Mental disorders;Mission;National Heart, Lung, and Blood Institute;National Institute of Biomedical Imaging and Bioengineering;National Institute of Child Health and Human Development;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;neurodevelopment;Neurodevelopmental Disorder;Neurologist;neurophysiology;neuropsychiatric disorder;neuropsychiatry;novel therapeutic intervention;Obstructive Sleep Apnea;Patients;Pattern;Pediatric cohort;pediatric patients;Persons;Phenotype;Physiological;point-of-care diagnostics;Polysomnography;post SARS-CoV-2 infection;predictive marker;Predisposition;prospective;Protocols documentation;Psychiatrist;Psychologist;public database;Publishing;Pulmonology;recruit;repository;Research;Research Personnel;response biomarker;Risk;Scientist;Services;Signal Transduction;Sleep;Sleep Disorders;sleep pattern;Specialist;Standardization;Therapeutic Intervention;therapeutic target;Translating;Translations;treatment strategy;United States National Institutes of Health;Validation;Woman;Work",Sleep and Neurodevelopment Service,2962,NA,NA,NA,NA,8,NA,NA,2739460,NA
11194760,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002964,NA,NA,1ZIAMH002964-08,NIMH:2733192\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,15265879 (contact),"HATTAR, SAMER  (contact)",NA,NA,NA,Affect;Animals;Area;Behavior;Behavioral Assay;Biological Clocks;Brain;Brain region;Cell Physiology;Cells;circadian;circadian pacemaker;Circadian Rhythms;Collaborations;Data;Development;Electrophysiology (science);Environment;Future;ganglion cell;Gene Modified;Genetic;Genetic Techniques;Growth;Health;Human;Image;improved;in vivo;Individual;interest;Label;Learning;Life;Light;light effects;Major Depressive Disorder;Manuscripts;Measures;Mediating;medical schools;Memory;Metabolism;Modernization;Molecular;mood regulation;Moods;Morphology;mouse model;Mus;Nature;neural circuit;Neurosciences;novel;Pathway interactions;Personal Satisfaction;Photoreceptors;Phototherapy;Placebo Effect;Population;Primates;Process;Publications;Publishing;Pupil light reflex;receptor;Regulation;Research;Research Project Grants;Rest;Retina;Retinal Ganglion Cells;Role;Signal Transduction;Sleep;Specific qualifier value;Stimulus;Stress;Structure of paraventricular nucleus of thalamus;suprachiasmatic nucleus;System;Thalamic structure;Therapeutic;transcriptome;Universities;Vertebrate Photoreceptors;Virus;Vision;Visual;Work,Section on Light and Circadian Rhythms,2964,NA,NA,NA,NA,8,NA,NA,2733192,NA
11194761,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002966,NA,NA,1ZIAMH002966-08,NIMH:1896432\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,15265881 (contact),"MERRIAM, ELISHA  (contact)",NA,NA,NA,area striata;Arousal;Attention;Attention deficit hyperactivity disorder;Auditory;autism spectrum disorder;Brain;Bypass;cerebral hemodynamics;Clinical Protocols;Cognitive;cognitive function;Compensation;Computer Analysis;computer framework;Computer Models;Computer Simulation;computer studies;Confusion;Disease;Emotional;Exhibits;extrastriate visual cortex;Feedback;Frequencies;Functional Magnetic Resonance Imaging;Goals;Health;heart rate variability;Human;imaging study;insight;Laboratories;Lesion;Link;Measurement;Measures;Mental disorders;Modeling;Motion;Motor;multimodality;Mus;Nervous System Disorder;neural;neuromechanism;neuropsychiatric disorder;orientation selectivity;Patients;Perception;Performance;Periodicals;Physiological;Population;Primates;Process;Psychophysics;Publishing;Pupil;receptive field;Research;response;retinotopic;Rewards;Rodent;Role;Schizophrenia;Sensory;Signal Transduction;Stimulus;Stroke;Structure;superior colliculus Corpora quadrigemina;Surface;Testing;Thalamic structure;two-photon;V1 neuron;Visual;Visual Cortex;Visual Perception;visual processing;visual stimulus;Visual System;Work,Multiple Scales of Stimulus Representation in the Human Brain,2966,NA,NA,NA,NA,8,NA,NA,1896432,NA
11194762,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002967,NA,NA,1ZIAMH002967-08,NIMH:995625\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,14761208 (contact),"HISTED, MARK  (contact)",NA,NA,NA,Affect;Anesthesia procedures;Animals;Area;Artificial Intelligence;Attenuated;attenuation;awake;Behavior;Behavioral;behavioral response;Brain;Brain region;Cells;Cerebral cortex;Cognition;Complex;Data;Expert Systems;Fire - disasters;In Vitro;in vivo;Joints;Machine Learning;Measures;Mus;network models;neural;Neurons;Neurosciences;Optics;optogenetics;Output;Pattern;Process;Property;Recurrence;response;Rest;Sensory;sensory cortex;sensory stimulus;Shapes;Sorting;Sum;Synapses;System;Testing;Theoretical model;Visual;Visual Cortex;Weight;Work,Computation by recurrent circuits of the cerebral cortex,2967,NA,NA,NA,NA,8,NA,NA,995625,NA
11194763,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002969,NA,NA,1ZIAMH002969-06,NIMH:2331021\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,16155929 (contact),"BROTMAN, MELISSA  (contact)",NA,NA,NA,"Address;Affect;Aftercare;Age;Anxiety;Anxiety Disorders;Articulation;associated symptom;Attention;Award;Behavior Therapy;Behavioral;Behavioral Mechanisms;bench to bedside;Benchmarking;Brain;brain based;Child;Childhood;Clinic;Clinical;clinical phenotype;Clinical Trials;Cognitive;cognitive enhancement;Cognitive Therapy;Complex;Coupled;Data;Data Analyses;Development;Diagnosis;digital;Ecological momentary assessment;Event;Exhibits;Extinction;Foundations;Frustration;Functional Magnetic Resonance Imaging;Future;Goals;Human;Impairment;Intervention;Learning;Manuscripts;Mental disorders;Metabolic;mobile application;mobile computing;negative affect;neural;neuromechanism;Neurosciences;nonhuman primate;novel;novel therapeutics;Outcome;overtreatment;Paper;Pathologic;Patients;Pharmaceutical Preparations;Phenotype;Process;programs;Protocols documentation;psychologic;Public Health;Publications;Publishing;Randomized;Randomized, Controlled Trials;response;Sampling;Scanning;side effect;smartphone based assessment;Social Environment;Standardization;Symptoms;Taxonomy;Technology;Testing;Time;Translating;translational neuroscience;Treatment Efficacy;treatment response;visual tracking;Work;Writing;Youth",Unit on Neuroscience and Novel Therapeutics,2969,NA,NA,NA,NA,6,NA,NA,2331021,NA
11194764,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002970,NA,NA,1ZIAMH002970-06,NIMH:1659554\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,16151864 (contact),"TEJEDA, HUGO  (contact)",NA,NA,NA,Ablation;Adaptive Behaviors;addiction;Adult;Affect;Affective;Agreement;antagonist;Arousal;Automobile Driving;Behavior;Behavioral;behavioral response;Bipolar Disorder;Calcium;cell assembly;cell cortex;Cell Physiology;cell type;Cells;Charge;Chronic stress;Classification;clinically relevant;Cognition;Cognitive;coping;Corpus striatum structure;Cues;delta opioid receptor;Desire for food;Discrimination;Disease;Disinhibition;Dopamine;Dopamine D1 Receptor;dopamine D3 receptor;Dopamine Receptor;Dynorphins;Electrophysiology (science);emotion regulation;Emotional;emotional behavior;Emotions;endogenous opioids;Enkephalins;Etiology;experience;Foundations;Fright;Gene Expression;Genetic;Goals;hedonic;Human;Image;imaging approach;Impairment;in vivo imaging;interest;Interneurons;kappa opioid receptors;knock-down;Knock-out;Knowledge;Laboratories;Learning;Life Experience;Ligands;maladaptive behavior;Mediating;Memory;Mental Depression;Mental disorders;Mission;Modeling;monoamine;Mood Disorders;motivated behavior;Motivation;mu opioid receptors;Mus;negative affect;Neuromodulator;Neurons;Neuropeptides;neuropsychiatric disorder;neuroregulation;novel;novel strategies;Nucleus Accumbens;Opioid Peptide;Outcome;Pathway interactions;Peptides;Physiological;Population;Prefrontal Cortex;presynaptic;Presynaptic Terminals;Procedures;psychologic;Psychological reinforcement;Psychotic Disorders;receptor;Receptor Activation;Receptor Signaling;recruit;Reporting;response;Retrieval;reward processing;Rewards;Role;Schizophrenia;sensor;Shapes;Signal Transduction;Site;Somatostatin;Somatostatin Receptor;Stress;stress reactivity;Substance Use Disorder;Synapses;Synaptic Transmission;System;Therapeutic Effect;transmission process;Ventral Striatum;Viral;Work,Unit of Neuromodulation and Synaptic Integration,2970,NA,NA,NA,NA,6,NA,NA,1659554,NA
11194766,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002977,NA,NA,1ZIAMH002977-04,NIMH:774600\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,8469041 (contact),"INNIS, ROBERT  (contact)",NA,NA,NA,3-Dimensional;Address;Adopted;Adoption;analysis pipeline;Archives;Articulation;Atlases;Automation;Autopsy;Award;Brain;Brain imaging;BRAIN initiative;Bypass;cohesion;Collaborations;Communities;Computer software;Consumption;Data;data acquisition;Data Analyses;data analysis pipeline;data archive;data curation;data format;data repository;Data Science;Data Set;data sharing;data standards;data structure;Deposition;Documentation;Ensure;expiration;Feedback;Functional Magnetic Resonance Imaging;Funding;Future;General Hospitals;Genes;Goals;Grant;Guidelines;Human;Image;imaging facilities;imaging modality;improved;Individual;Institution;interest;International;Intramural Research Program;invention;Journals;Lateral;Literature;Magnetic Resonance Imaging;Manuals;Maps;Massachusetts;molecular imaging;Molecular Target;Motion;National Institute of Mental Health;neuroimaging;Online Systems;Paper;Persons;pharmacokinetic model;Plasma;Positron-Emission Tomography;Preparation;prevent;Process;publication formats;Publishing;Quality Control;radioligand;Recommendation;Regulation;Reporting;repository;Reproducibility;Research Personnel;Running;Sampling;Security;Sensory Receptors;shared repository;software systems;Source;Specific qualifier value;Standardization;symposium;targeted imaging;Testing;Time;tool;Transcript;United States National Institutes of Health;Universities;University Hospitals;user-friendly;Work,BRAIN project: OpenNeuroPET: An Archive for PET data,2977,NA,NA,NA,NA,4,NA,NA,774600,NA
11194767,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002981,NA,NA,1ZIAMH002981-03,NIMH:642399\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,78860843 (contact),"LOPEZ-GUZMAN, SILVIA  (contact)",NA,NA,NA,Acute;acute stress;Affect;Affective;Aggressive behavior;Anger;Anxiety Disorders;Area;Back;Behavior;Behavioral;Brain;Choice Behavior;Clinic;Computer Models;coping;Decision Making;Development;Disease;Drug usage;Emotional;emotional distress;Emotional Intelligence;Emotions;Exhibits;experience;Goals;improved;Impulsivity;Individual;Individual Differences;insight;inter-individual variation;interest;Interoception;Intervention;Laboratories;Literature;Major Depressive Disorder;Measures;Mental disorders;Mental Health;metacognition;Monitor;Moods;Motivation;multimodality;multiple data sources;Negative Valence;neuroimaging;Neurosciences;Outcome;Pain;Participant;Patient Recruitments;Patients;Personal Satisfaction;Personality Traits;Persons;Physiological;preference;Protocols documentation;Psychiatry;Punishment;recruit;Relapse;repaired;Reporting;Research;resilience;response;Rewards;Risk;Stress;stressor;Substance Use Disorder;Suicide;Techniques;Therapeutic;Time;tool;trait;Visit,"State-dependent interoception, value-based decision-making, and introspection",2981,NA,NA,NA,NA,3,NA,NA,642399,NA
11194768,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002982,NA,NA,1ZIAMH002982-02,NIMH:2064341\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,79363742 (contact),"BARTLEY, CHRISTOPHER  (contact)",NA,NA,NA,Affect;Age of Onset;Antibodies;antibody diagnostic;Antibody Repertoire;Antipsychotic Agents;Area;Auditory Hallucination;Autoantibodies;Autoimmune;Autoimmune encephalitis;Autoimmunity;Autopsy;Award;Bacteria;Bacteriophage T7;Basic Science;Behavior;bench to bedside;Benchmarking;biobank;Biological Markers;Blinded;Blood;Blood specimen;Brain;Brain Diseases;Carrier Proteins;Catalogs;Catatonia;Cell Line;Cerebrospinal Fluid;Child;Clinical;clinical diagnostics;clinical phenotype;Clinical Research;Collaborations;Collection;college;Data Set;Delusions;Dendrites;Diagnosis;differential expression;Disease;Down&apos;s Syndrome;Dyskinetic syndrome;Encephalitis;Engineering;Epitopes;Evaluation;Focal Neurologic Deficits;Funding;fungus;Generations;Glial Fibrillary Acidic Protein;Health;Hippocampus;Human;Immune;Immunoglobulin A;Immunoglobulin G;Immunologic Factors;Immunological Models;Immunophenotyping;Immunoprecipitation;Impaired cognition;indexing;Individual;Infection;Interview;lead candidate;Letters;Libraries;Los Angeles;Lyme Disease;Magnetic Resonance Imaging;Major Depressive Disorder;Malignant Neoplasms;Manic;Maps;Measures;Mediating;Medicine;Memory impairment;Mental Depression;Mental disorders;Methods;Microbe;model organism;Modeling;Molecular Conformation;Monoclonal Antibodies;Movement Disorders;multiple omics;N-Methyl-D-Aspartate Receptors;nanoluciferase;National Human Genome Research Institute;National Institute of Allergy and Infectious Disease;National Institute of Mental Health;neural;neuroimaging;neuroimmunology;neuroinflammation;Neurology;Neurons;neuropsychiatric disorder;neuropsychiatry;next generation;novel;Nucleotides;Obsessive-Compulsive Disorder;Oligonucleotides;Parasites;Pathogenicity;patient derived induced pluripotent stem cells;Patients;Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections;Pediatric Hospitals;Penetration;Peptides;Performance;Pharmaceutical Preparations;Phase;Phenotype;Plasma;programs;prospective;Protein Array;Protein Isoforms;Protein Secretion;Proteins;Protocols documentation;Psychiatric Diagnosis;psychiatric symptom;Psychoses;psychotic;Recording of previous events;Research;Research Activity;research and development;response;Rheumatism;Sampling;Schizoaffective Disorders;Schizophrenia;schizophrenia spectrum disorder;Seizures;seropositive;Serum;Signal Transduction;Site;Specificity;Standardization;Streptococcus;suicide victim;Symptoms;System;Technology;technology platform;Testing;translational research program;United States National Institutes of Health;Validation;Virus;Visual Hallucination;Woman;Work,Translational Immunopsychiatry Unit,2982,NA,NA,NA,NA,2,NA,NA,2064341,NA
11194769,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002983,NA,NA,1ZIAMH002983-02,NIMH:1017759\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,79363744 (contact),"LANGDON, ANGELA  (contact)",NA,NA,NA,Adaptive Behaviors;addiction;analog;Animals;Anxiety;Back;Behavior;Behavioral;Brain;Brain region;clinically relevant;Cognitive Science;cohort;Collaborations;Complex;Compulsive Behavior;Computer Models;Corpus striatum structure;data acquisition;Decision Making;Dopamine;E-learning;Educational process of instructing;Electrophysiology (science);Environment;Equilibrium;Event;flexibility;Future;Goals;graduate student;Human;human subject;Individual Differences;insight;International;Intramural Research Program;Learning;learning algorithm;Maps;Measures;meetings;member;Mental disorders;Modeling;motivated behavior;National Institute of Mental Health;neural;neural circuit;neural correlate;neuromechanism;Neuromodulator;novel;Outcome;Participant;Patient Self-Report;Persons;phenomenological models;Play;Postbaccalaureate;preference;Prefrontal Cortex;Process;programs;Psychological reinforcement;Publishing;Rattus;recruit;Reporting;Research;Rewards;Rodent;Series;Shapes;Signal Transduction;Statistical Models;Structure;symposium;Symptoms;Testing;theories;translational model;United States National Institutes of Health;Universities;Update;Work,Unit on Neural Computations in Learning,2983,NA,NA,NA,NA,2,NA,NA,1017759,NA
11194770,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002984,NA,NA,1ZIAMH002984-02,NIMH:2999963\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,79363746 (contact),"BOURNE, JAMES  (contact)",NA,NA,NA,Acute;Adult;Anatomy;Area;area striata;Attention;Behavior;Behavioral;Birth;Brain;Brain region;burden of illness;Cell Nucleus;Cells;Clinical;Coffee;Cognitive;cognitive function;Collection;Complex;Conscious;Cortical Blindness;Data;Development;Disease;Engineering;experimental study;extrastriate visual cortex;Eye;Functional disorder;Genetic;grasp;hazard;Health;Hearing;Human;Inferior;insight;Laboratories;Lateral;Lesion;Life;life span;Link;Magnetic Resonance Imaging;Maps;Medial;Mental disorders;Mental Health;millisecond;Modeling;Molecular;Monitor;Motor;Neocortex;neocortical;Nervous System Disorder;neural;neurodevelopment;Neurodevelopmental Disorder;Neuronal Plasticity;Neurons;new technology;news;Pathogenicity;Pathology;Patients;Persons;Physiological;Physiology;Play;postnatal development;preservation;Process;programs;Psychologist;Pulvinar structure;Reaction;Reading;repaired;Research;Residual state;Retina;Role;Route;Schizophrenia;Seminal;Shapes;skills;Speed;Stream;Symptoms;System;Technology;Telephone;Textbooks;Texture;Thalamic Nuclei;Thalamic structure;theories;Therapeutic;tool;Touch sensation;Tracer;Unconscious State;United States National Institutes of Health;Vision;vision development;Visual Cortex;visual information;visual motor;Visual Perception;visual processing;Visual System;Visually Impaired Persons;Work,Section on Cellular and Cognitive Neurodevelopment,2984,NA,NA,NA,NA,2,NA,NA,2999963,NA
11194771,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002985,NA,NA,1ZIAMH002985-02,NIMH:844848\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,79347530 (contact),"MERSON, TOBIAS  (contact)",NA,NA,NA,Ablation;Action Potentials;Adult;AMPA Receptors;Anterior;Area;Astrocytes;autism spectrum disorder;Axon;Binding;Biochemical;Brain;burden of illness;cell regeneration;Cells;Central Nervous System;Communication;Complex;Corpus Callosum;CSPG4 gene;Cuprizone;cytokine;Data;Demyelinations;depressive symptoms;Development;Disease;Dorsal;Electrophysiology (science);Exhibits;experience;functional outcomes;Genetic;Glutamates;Goals;Health;Impairment;Individual;Injury;Interest Group;Intervention;Knowledge;Learning;LIF gene;Ligands;Link;Major Depressive Disorder;Mediating;Mental Health;Methods;migration;Molecular;Morphology;Multiple Sclerosis;Mus;Myelin;Myelin Sheath;myelination;National Institute of Mental Health;Nerve Degeneration;Nerve Regeneration;nerve stem cell;Nervous System Disorder;neural network;Neuroglia;Neurologic;Neuronal Plasticity;Neurons;neurotransmitter release;novel;oligodendrocyte progenitor;Oligodendroglia;Pathologic;Pattern;PDGFRA gene;Pharmacogenetics;Play;Population;postsynaptic;Prevention strategy;Process;programs;Proliferating;Property;Prosencephalon;psychologic;Purinoceptor;receptor;recombinase;regenerative;remyelination;repaired;Research;response;Rodent;Role;Schizophrenia;Signal Transduction;Speed;stem cell differentiation;stem cell population;stem cell proliferation;stem cell self renewal;stem cells;Structure;subventricular zone;Synapses;System;Testing;Thinness;tool;Transgenic Organisms;Ventricular;vesicular release;Viral;white matter;working group,Oligodendroglial Interactions Group,2985,NA,NA,NA,NA,2,NA,NA,844848,NA
11194772,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002986,NA,NA,1ZIAMH002986-02,NIMH:2106102\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,79363748 (contact),"WHITE, TONYA  (contact)",NA,NA,NA,Adolescent;adolescent with autism spectrum disorder;Affect;Amygdaloid structure;Anorexia Nervosa;Anterior;Anxiety;associated symptom;Attention;Autism Diagnosis;autism spectrum disorder;autism symptoms;autistic;autistic children;Behavior;Behavioral;Brain;Brain Mapping;brain overgrowth;Brain region;Centers for Disease Control and Prevention (U.S.);Cerebellum;Characteristics;Chemicals;Child;Child Rearing;Childhood;cingulate cortex;Clinical;Cognition;Cognitive;cognitive development;cognitive testing;cohort;Collaborations;Communities;comorbidity;conduct problem;connectome;Corpus Callosum;COVID-19 pandemic effects;Data;Data Set;design;Development;Diffusion Magnetic Resonance Imaging;Disease;dual diagnosis;Education;Electroencephalography;Electrophysiology (science);Environment;Etiology;Family;Female Adolescents;Fingerprint;Functional Magnetic Resonance Imaging;functional near infrared spectroscopy;gender diverse;General Population;Generations;Genetic;girls;Goals;Heritability;Heterogeneity;Human;Hyperactivity;infection risk;Infrastructure;Insula of Reil;International;Interview;large datasets;life span;longitudinal analysis;longitudinal dataset;Longitudinal Studies;Magnetic Resonance Imaging;Magnetic Resonance Spectroscopy;Magnetoencephalography;Manuscripts;Measures;meetings;Mental Depression;Mental Health;Methods;Modality;Modeling;Monozygotic twins;Nature;Neurobiology;neurochemistry;Neurodevelopmental Disorder;neuroimaging;Neuropsychology;Neurosciences;non-genetic;open data;pandemic disease;Paper;Parents;Pattern;Plasticizers;Population;Prefrontal Cortex;pressure;Printing;Protocols documentation;Psychopathology;Publications;Publishing;Questionnaires;recruit;Registries;Reporting;Research;Review Committee;Review Literature;Role;Sampling;Severities;sexual dimorphism;Site;Sleep;social;Statistical Models;Stochastic Processes;Structure;Subgroup;symposium;symptomatology;Symptoms;System;Techniques;Testing;Thalamic structure;Twin Multiple Birth;United States;United States National Institutes of Health;Universities;Virginia;Virus Diseases;visual tracking;Work;Writing;young adult;young woman;Youth,Research within the Section on Social and Cognitive Developmental Neuroscience,2986,NA,NA,NA,NA,2,NA,NA,2106102,NA
11194773,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002987,NA,NA,1ZIAMH002987-02,NIMH:2116403\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,79363750 (contact),"ALVAREZ, VERONICA  (contact)",NA,NA,NA,Absence of pain sensation;Affect;Agonist;Attenuated;Basal Ganglia;Behavior;behavior influence;Behavioral Assay;Brain;cell type;Chemosensitization;cholinergic;Cocaine;cocaine self-administration;Compulsive Behavior;Consumption;Corpus striatum structure;Cre-LoxP;Dopamine;Dopamine D1 Receptor;Dopamine D2 Receptor;dopamine D3 receptor;dopaminergic neuron;drug of abuse;Environment;experimental study;Exploratory Behavior;GABA-B Receptor;gamma-Aminobutyric Acid;Goals;Hyperactivity;improved;In Situ Hybridization;Locomotion;Macaca;Mediating;mesolimbic system;Microdialysis;Midbrain structure;Mission;Motivation;Mus;neural circuit;Neurobiology;Neuromodulator;neuronal excitability;Neurons;Nicotinic Receptors;nonhuman primate;novel;Nucleus Accumbens;Opioid;optogenetics;Oxycodone;oxycodone self-administration;Periodicity;Pharmaceutical Preparations;pharmacologic;Photometry;Physiologic pulse;Play;Population;postsynaptic;Predisposing Factor;presynaptic;Presynaptic Receptors;Property;receptor;receptor expression;Research;response;Reverse Transcriptase Polymerase Chain Reaction;Rewards;Rodent;Role;Scanning;sensor;Shapes;Signal Transduction;Slice;Substance of Abuse;Substance Use Disorder;substance use prevention;Synapses;synaptic function;Synaptic plasticity;Techniques,Section on Neurobiology of Compulsive Behaviors,2987,NA,NA,NA,NA,2,NA,NA,2116403,NA
11194774,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002988,NA,NA,1ZIAMH002988-02,NIMH:275314\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,78860843 (contact),"LOPEZ-GUZMAN, SILVIA  (contact)",NA,NA,NA,Adult;Anxiety;Behavior;Clinical;clinically relevant;Cognition;Cognitive;Collaborations;comorbidity;comparison control;computational neuroscience;Computer Models;computerized;Computing Methodologies;Data;Data Set;Decision Making;diagnostic tool;Dimensions;discounting;Discrimination;Disease;Evaluation;experimental study;financial incentive;Goals;Home;Human;Incentives;Individual;Individual Differences;Internet;Intervention;Joints;Judgment;Learning;Major Depressive Disorder;Measures;Mental Depression;Mental disorders;Mental Health;metacognition;Modeling;Neurosciences;novel;Obsessive-Compulsive Disorder;Participant;Patient Self-Report;Patients;Performance;posters;preference;Process;Protocols documentation;Psychiatry;Psychological reinforcement;Reporting;Research Design;Risk;Running;Sampling;social;Societies;Substance Use Disorder;symposium;Testing;Training;trait;Uncertainty;United States National Institutes of Health;Visual;Withdrawal;Work,Introspection and decision-making: value-based decision-making and confidence computations,2988,NA,NA,NA,NA,2,NA,NA,275314,NA
11194775,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002989,NA,NA,1ZIAMH002989-01,NIMH:100000\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,16151864 (contact),"TEJEDA, HUGO  (contact)",NA,NA,NA,Acute;Affinity;Agonist;Amphibia;Behavior;Behavioral;Biological Assay;Bradykinin;Bradykinin B2 Receptor;Brain;candidate validation;cell type;Cells;cellular imaging;Chimera organism;Communities;Electrophysiology (science);endogenous opioids;Engineering;Esthesia;experimental study;Exposure to;Extracellular Space;G-Protein-Coupled Receptors;Go Alpha Subunit;Human;in vivo;information processing;Knowledge;Learning;Ligands;Light;Memory;Methods;Modification;mu opioid receptors;Mus;neural circuit;Neurons;Neuropeptides;Neurosciences;Opioid Peptide;Opioid Receptor;Optics;optogenetics;Perception;Play;postsynaptic;presynaptic;Procedures;receptor;Receptor Signaling;Research;Role;Second Messenger Systems;Signal Transduction;Slice;Source;Synapses;Synaptic Transmission;System;Testing;tool;tool development;trafficking;Validation;Viral;viral gene delivery;Viral Vector,Trans-synaptic optogenetic control of user-defined pre- and post-synaptic partners,2989,NA,NA,NA,NA,1,NA,NA,100000,NA
11194776,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002204,NA,NA,1ZIANS002204-49,NINDS:442523\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416904 (contact),"JACOBSON, STEVEN  (contact)",NA,NA,NA,Acceleration;aged;Alzheimer&apos;s Disease;Alzheimer&apos;s disease pathology;Alzheimer&apos;s disease therapeutic;Alzheimer’s disease biomarker;Amyloid beta-Protein;Anatomy;Animal Model;Animals;Anti-viral Agents;Antibody Formation;Antibody Response;Antigens;Autoimmune;Autoimmune Diseases of the Nervous System;Autoimmunity;Automobile Driving;autoreactivity;B lymphoid malignancy;B-Cell Lymphomas;Binding;Biological Assay;Biological Markers;Biological Specimen Banks;Biology;Blood Banks;Brain;brain tissue;Callithrix;Callithrix jacchus jacchus;CD8-Positive T-Lymphocytes;Central Nervous System;Central Nervous System Diseases;chemokine;Chronic;chronic infection;Circulation;Clinical;Clinical Trials;Collaborations;comparative;comparison control;Control Animal;cytokine;Data;demographics;Demyelinations;Development;digital;Disease;Disease Progression;DNA Polymerase Inhibitor;Drug usage;Early Diagnosis;early onset;Encephalitis;Epilepsy;Exhibits;experimental analysis;Experimental Autoimmune Encephalomyelitis;Experimental Models;exposed human population;exposure route;Exposure to;Future;gammaherpesvirus;Generations;Genetic;Herpesviridae;Herpesviridae Infections;HHV-6A;HHV-6B;Human;Human Herpesvirus 6;Immune;Immunize;immunogenic;Immunologics;Infection;Inflammatory;interest;Intravenous;Investigation;Lesion;Liquid substance;Lymphocryptovirus;Lymphoma;Lymphoproliferative Disorders;Magnetic Resonance Imaging;Malignant neoplasm of brain;Mediating;Methods;Microbe;Modality;Modeling;Monitor;Mucous body substance;Mucous Membrane;Multiple Sclerosis;multiple sclerosis patient;multiple sclerosis treatment;Myelin;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;Nerve Degeneration;Nervous System Disorder;Neurodegenerative Disorders;Neurofibrillary Tangles;neuroinflammation;nonhuman primate;Nose;novel therapeutics;Oncogenic Viruses;Onset of illness;Pathogenesis;Pathogenicity;Pathologic;Pathology;Peptides;Peripheral;Peripheral Blood Mononuclear Cell;PET/CT scan;Phenotype;Physiological;Plasma;pre-clinical;preclinical study;Predisposition;Prevalence;Preventive measure;Property;Proteins;Radiology Specialty;Relapse;Reporting;Rodent;Role;Route;Saliva;Senile Plaques;small molecule inhibitor;Symptoms;System;T-Lymphocyte Subsets;tau Proteins;Testing;Therapeutic;Time;United States National Institutes of Health;Universities;Viral;Viral Antigens;viral DNA;Viral Load result;Viral reservoir;Virus;Virus Diseases;Virus Receptors;white matter;X-Ray Computed Tomography,Immunologic Mechanisms In Experimental Autoimmune Diseases Of The Nervous System,2204,NA,NA,NA,NA,49,NA,NA,442523,NA
11194777,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002263,NA,NA,1ZIANS002263-48,NINDS:2008564\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416880 (contact),"SIBLEY, DAVID  (contact)",NA,NA,NA,Affinity;Agonist;Allosteric Site;Amphetamines;analog;Animal Model;antagonist;Antipsychotic Agents;Attention deficit hyperactivity disorder;Attenuated;behavior test;beta-arrestin;Binding;Binding Sites;Biochemical;Biological Assay;Biological Availability;Brain;Catalepsy;Chemicals;Clinic;design;Development;Diabetes Mellitus;disability;Docking;Dopamine;Dopamine Agonists;Dopamine Antagonists;Dopamine D1 Receptor;Dopamine D2 Receptor;Dopamine Receptor;Dose;DRD4 gene;drug candidate;drug craving;Drug Kinetics;Drug Receptors;effective therapy;Exhibits;FDA approved;functional loss;G-Protein-Coupled Receptors;Goals;GTP-Binding Proteins;Half-Life;high throughput screening;Illness impact;Impaired cognition;in vivo;Investigation;Lead;Ligands;Link;Locomotion;Mediating;Membrane;Mental disorders;Metabolism;Minor;Modeling;Molecular;Molecular Bank;Motivation;Motor;Movement;Mus;Mutagenesis;mutant;Mutate;Mutation;Nervous System Disorder;Neurons;neuropsychiatry;Neurotransmitters;novel;novel therapeutics;Oral;Output;Parents;Parkinson Disease;Patients;Penetrance;Penetration;Pharmaceutical Chemistry;Pharmaceutical Preparations;pharmacologic;Pharmacology Study;Plasma;Point Mutation;Population;positive allosteric modulator;pre-clinical;prepulse inhibition;programs;protein activation;radioligand;receptor;receptor binding;receptor expression;Receptor Signaling;recruit;Regulation;Research;Rewards;scaffold;Schizophrenia;Sedation procedure;Sequence Homology;side effect;Signal Transduction;simulation;Site;Site-Directed Mutagenesis;small molecule;small molecule libraries;Structure;Substance Use Disorder;Symptoms;System;Testing;Therapeutic;trafficking;United States National Institutes of Health;Validation;Weight Gain;Work,Molecular And Pharmacological Studies Of Dopamine Receptors,2263,NA,NA,NA,NA,48,NA,NA,2008564,NA
11194778,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002817,NA,NA,1ZIANS002817-35,NINDS:783838\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416904 (contact),"JACOBSON, STEVEN  (contact)",NA,NA,NA,Adult;Alzheimer&apos;s Disease;Amyloid beta-Protein;analysis pipeline;anti-microbial peptide;Anti-Retroviral Agents;Antibodies;Antibody Response;Antibody Specificity;Antigens;Anxiety;Area;Atlases;Atrophic;Autopsy;B-Cell Antigen Receptor;Bioinformatics;Blood;Bone Marrow Transplantation;Brain;brain control;brain fog;cadmium ion;CD28 Antigens;CD44 gene;CD8-Positive T-Lymphocytes;CD8B1 gene;Cell Separation;Cells;Central Nervous System Diseases;cerebral atrophy;Cerebrospinal Fluid;Chronic;chronic neurologic disease;Classification;Clinical;Clonal Expansion;cohort;Color;comparison control;Coupled;COVID-19 patient;cytokine;cytotoxic;cytotoxic CD8 T cells;Data;Defect;Dementia;Development;Disease;DNA;Encephalitis;Epilepsy;Etiology;Exhibits;exosome;experience;extracellular;extracellular vesicles;Flow Cytometry;Frequencies;Frontotemporal Dementia;Genomics;Headache;healthy volunteer;Herpesviridae;Heterogeneity;HIV;HLA-A2 Antigen;Human;Human Herpesvirus 4;Human Herpesvirus 6;Human T-lymphotropic virus 1;IL2RA gene;Imaging Techniques;Immune;Immune response;Immunologics;Immunophenotyping;immunoregulation;In Vitro;Individual;infected B cell;Infection;Inflammatory;inflammatory milieu;interest;JC Virus;Length;machine learning method;Magnetic Resonance Imaging;Mediating;Mental Depression;Methods;Microbe;Microfluidics;Molecular;multimodality;Multiple Sclerosis;multiple sclerosis patient;nanoparticle;Nervous System Disorder;neuroinflammation;Neurologic;neurologic sequelae of COVID-19;Neurologic Symptoms;novel;particle;pathogen;Pathogenesis;Pathogenicity;Pathologic;Pathology;Patients;Pattern;Peptides;peripheral blood;Peripheral Blood Mononuclear Cell;Persons;Pharmaceutical Preparations;Physiologic pulse;Post-Acute Sequelae of SARS-CoV-2 Infection;post-COVID-19;potential biomarker;Process;Progressive Multifocal Leukoencephalopathy;Regulatory T-Lymphocyte;Relapsing-Remitting Multiple Sclerosis;Reporting;Reproducibility;response;RNA;Role;Sampling;SARS-CoV-2 infection;Senile Plaques;Serum;single cell genomics;single-cell RNA sequencing;Sleep Disorders;Specificity;Spinal Cord;Spinal Cord Diseases;Surface;Symptoms;T-cell receptor repertoire;T-Lymphocyte;Technology;TNFRSF5 gene;training data;transcriptome;transcriptomic profiling;Tropical Spastic Paraparesis;Vesicle;Viral;Viral Antibodies;viral detection;Viral Proteins;viral RNA;Virus;Virus Diseases;Work,Involvement Of Human Viruses Associated With Chronic Neurologic Disease,2817,NA,NA,NA,NA,35,NA,NA,783838,NA
11194779,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002824,NA,NA,1ZIANS002824-34,NINDS:2511726\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,2076500 (contact),"WRAY, SUSAN  (contact)",NA,NA,NA,"Address;Adenylate Cyclase;animal facility;Animals;Award;Axon;Biochemical;Biological Assay;Biological Models;Brain;Calcium;Cell Line;cell motility;Cells;Cellular Neurobiology;chemokine;Chronic;circadian;Collaborations;Coupled;craniofacial development;Cues;Cyclic AMP-Dependent Protein Kinases;Destinations;Development;developmental neurobiology;differential expression;Electrophysiology (science);Event;Female;Fertility;Floods;food restriction;Functional disorder;Future;G-Protein-Coupled Receptors;Gene Expression;Genes;Genetic;Genetic study;Goals;Gonadotropin Hormone Releasing Hormone;graduate student;Hormones;Human;Human Genetics;hypothalamic pituitary gonadal axis;Idiopathic Hypogonadotropic Hypogonadism;Image;In Vitro;in vitro Model;infertility treatment;Knockout Mice;Leadership;Libraries;Link;Location;male;Maryland;Measures;medical schools;member;migration;molecular array;Monitor;Morphology;mouse model;Movement;Mus;Mutate;Mutation;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;Nervous System;Neurobiology;Neuronal Differentiation;Neurons;Neurosciences;Neurosecretory Systems;new therapeutic target;Nose;Occupations;Outcome;Paper;patient screening;Patients;Pattern;Peptide Synthesis;Peptides;Phenotype;Phosphatidylinositol 4,5-Diphosphate;Phosphatidylinositols;Phospholipase C;pituitary gonadal axis;Population;Positioning Attribute;Postbaccalaureate;Postdoctoral Fellow;Process;progenitor;programs;Property;Prosencephalon;Proteins;Puberty;Publishing;receptor;Regulation;Reproduction;reproductive;reproductive function;Research;Review Committee;Route;Science;screening;Series;Services;shift work;Signal Pathway;suprachiasmatic nucleus;symposium;Synapses;Syndrome;System;tool;Training;Transgenic Animals;Universities;Vasoactive Intestinal Peptide;Vasoactive Intestinal Peptide Receptors;Vertebrates;Work",Development And Regulation Of The Gonadotropin Releasing Hormone System,2824,NA,NA,NA,NA,34,NA,NA,2511726,NA
11194780,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002945,NA,NA,1ZIANS002945-28,NINDS:2866061\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416860 (contact),"SWARTZ, KENTON  (contact)",NA,NA,NA,"Acceleration;Adopted;Afferent Neurons;Agonist;Amino Acid Sequence;base;Binding;Binding Sites;Biological;Borates;Calcium Channel;Cannabidiol;Cannabinoids;Cardiac;Cations;Cell Physiology;Cells;Central Nervous System;Characteristics;Chemicals;clinically relevant;Collaborations;Coupled;Coupling;Cryoelectron Microscopy;disease-causing mutation;Electrophysiology (science);Elements;Environment;epileptic encephalopathies;Esthesia;Family;Foundations;Goals;Hydrophobicity;icilin;Immune;Immunosuppression;inhibitor;Ion Channel;Ion Channel Protein;Ions;Kv2.1 channel;Ligands;Lipids;mechanical force;Mechanics;member;Membrane Lipids;Molecular;Molecular Conformation;Movement;mutant;Mutation;Nervous System;neuronal excitability;Neurons;new therapeutic target;Nociception;Nociceptors;Pain;Patch-Clamp Techniques;Pathway interactions;Perception;Permeability;Pharmaceutical Preparations;Pharmacology;Phosphatidylinositol 4,5-Diphosphate;Play;Positioning Attribute;Potassium;Potassium Channel;Process;Property;Rationalization;Rattus;Regulation;Reporting;Residual state;resilience;Resolution;response;Role;Schwann Cells;sensor;Sensory;Series;Short-Term Memory;Signal Transduction;simulation;Site;Skin;small molecule;Sodium Channel;Solid;Specificity;Stimulus;Structure;sulfated glycoprotein 2;T-Lymphocyte;Temperature;Temperature Sense;temporal measurement;Therapeutic;Therapeutic Uses;tool;Transmembrane Domain;TRP channel;TRPM5 gene;TRPV1 gene;Vanilloid;voltage;Voltage-Gated Potassium Channel",Gating mechanisms and pharmacology of voltage-activated ion channels,2945,NA,NA,NA,NA,28,NA,NA,2866061,NA
11194781,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002946,NA,NA,1ZIANS002946-28,NINDS:1404493\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9811937 (contact),"SHENG, ZU-HANG  (contact)",NA,NA,NA,Address;Age Months;Aging;alpha synuclein;autism onset;autism spectrum disorder;Automobile Driving;Autophagocytosis;Autophagosome;Axon;axonal degeneration;Axonal Transport;axonopathy;Behavioral;Binding;Biological;Biological Models;Cells;Cellular biology;Cholesterol;Chronic;Communication;Complex;Defect;Degradation Pathway;density;Development;Disease;disease phenotype;Disease Progression;Distal;Distant;dopaminergic neuron;Dynein ATPase;Elderly;Event;Exhibits;exome sequencing;experimental study;Face;familial amyotrophic lateral sclerosis;Foundations;Functional disorder;Gene Mutation;Genes;Genetic;Guidelines;Health;Homeostasis;Human;human induced pluripotent stem cells;Hybrids;Image;Impairment;In Vitro;in vivo;in vivo Model;Individual;insight;Intervention;Investigation;Journals;Kinesin;Knock-out;Knockout Mice;Label;late endosome;Lead;Learning;Link;Lipids;LRRK2 gene;lysosome membrane;Lysosomes;Maintenance;Mediating;Membrane;Membrane Lipids;Memory;Modeling;Molecular;Monomeric GTP-Binding Proteins;Motor;motor impairment;Motor Neurons;mouse model;Movement;Mus;Muscle Rigidity;Nature;Neimann-Pick&apos;s Disease Type C;Nerve Degeneration;Nervous System;Neurodegenerative Disorders;Neurodevelopmental Disorder;neuron loss;neuronal cell body;Neurons;Neurosciences;Onset of illness;Organelles;Parkinson Disease;Pathogenesis;Pathogenicity;Pathologic;Pathway interactions;Patients;pharmacologic;Phenotype;Play;polarized cell;Positioning Attribute;postsynaptic;Predisposition;Preparation;presynaptic;Presynaptic Terminals;protein aggregation;protein function;Proteins;Psychiatry;recruit;Reporting;Research;response;Rest Tremor;retrograde transport;Role;Scaffolding Protein;Shuffling Gaits;Signal Transduction;SNAPIN gene;social;Solid;Stereotyped Behavior;Stress;Susceptibility Gene;Swelling;Symptoms;Synapses;synaptic function;Synaptic plasticity;Synaptic Transmission;Synaptic Vesicles;synaptogenesis;trafficking;trait;translational applications;ultra high resolution;Variant;Walking,Axonal transport of endolysosomal organelles and presynaptic cargos for the maintenance of axon cellular homeostasis and presynaptic function,2946,NA,NA,NA,NA,28,NA,NA,1404493,NA
11194782,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002972,NA,NA,1ZIANS002972-27,NINDS:1895091\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,6482573 (contact),"REESE, THOMAS S (contact)",NA,NA,NA,3-Dimensional;Acceleration;Affect;Algorithm Design;Algorithms;Architecture;automated segmentation;Automation;Binding;Bioinformatics;Brain;calmodulin-dependent protein kinase II;Classification;classification algorithm;Clustered Regularly Interspaced Short Palindromic Repeats;Collaborations;Complex;Computer software;computerized data processing;computing resources;Cryo-electron tomography;Cryoelectron Microscopy;Darkness;Data;data acquisition;data pipeline;Data Set;Dendritic Spines;density;design;Development;Devices;DLG4 gene;Electron Microscopy;electron optics;electron tomography;Electrons;Elements;Environment;Enzymes;Event;Excitatory Synapse;Exocytosis;Filament;Freezing;Future;Genetic;Glutamate Receptor;Goals;Gold;Hand;Hippocampus;Hour;Image;Image Analysis;image processing;Imaging Techniques;improved;Individual;innovation;insight;Internet;Investigation;Ions;Knock-in;Label;Laboratories;laptop;light microscopy;Link;Machine Learning;Manuals;Maps;Membrane;Memory;Methods;Microscope;Molecular;Molecular Probes;Molecular Structure;Morphology;Motion;nano;nanobodies;nanoGold;nanoscale;Nature;Neurobiology;Neurons;Noise;Organelles;overexpression;particle;postsynaptic;Postsynaptic Membrane;Preparation;presynaptic;Presynaptic Terminals;Process;Progress Reports;Proteins;Publications;Publishing;Rattus;reconstruction;Research;Resolution;response;Rodent;Role;Scanning;Series;Shapes;Sonication;Specificity;Structural Models;Structure;Subcellular structure;supercomputer;Synapses;Synaptic Cleft;synaptic function;Synaptic Membranes;Synaptic plasticity;Synaptic Transmission;Synaptosomes;Tablets;Techniques;Technology;Testing;Thinness;Time;Tomogram;tomography;tool;trafficking;United States National Institutes of Health;usability;Vertebral column;Vesicle;Visualization;Work,Macromolecular Architecture  Of The Synapse,2972,NA,NA,NA,NA,27,NA,NA,1895091,NA
11194783,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002977,NA,NA,1ZIANS002977-26,NINDS:534537\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,7019916 (contact),"WASSERMANN, ERIC M (contact)",NA,NA,NA,Acute Pain;Affect;Anatomy;Anisotropy;Anterior;Area;Athletic Injuries;Back;Basal Ganglia;Behavior;Behavioral;Belief;Biological Markers;Brain;brain based;Brain region;Cell Nucleus;central sensitization;Cephalic;Chronic Fatigue Syndrome;chronic pain;cingulate cortex;Clinical;Clinical effectiveness;clinically relevant;Cognitive;cognitive skill;cohort;cost;Dental Care;Dependence;Dimensions;Disease;Dopamine;Dose;drug development;Economics;Electrodes;Electroencephalography;Electrophysiology (science);Emotional;Episodic memory;Event;experience;experimental study;Fatigue;Functional Imaging;Functional Magnetic Resonance Imaging;Goals;grasp;Habits;Hippocampus;Home;Human;Impairment;improved;Individual;Individual Differences;Inferior;interest;Intervention;Intervention Trial;Investigation;Knowledge;Lateral;Learning;Maps;Measures;Medial;medial temporal lobe;member;Memory;memory encoding;Midbrain structure;Motivation;Motor Skills;neural;neurobehavioral disorder;neuroregulation;noninvasive brain stimulation;Outcome;Pain;Pain intensity;pain perception;Parietal Lobe;Parkinson Disease;Pathway interactions;Performance;Physical Efforts;Physiological;pre-clinical;Predisposition;Prefrontal Cortex;Production;Punishment;Reaction;Records;Refractory;response;Rest;Retrieval;Rewards;Risk;Route;segregation;Sensory;sensory system;Site;Somatosensory Cortex;Source;Stimulus;Structure;Surrogate Endpoint;synchronous delivery;System;Techniques;Thalamic structure;Time;Training;Transcranial magnetic stimulation;Uncertainty;Update;Ventral Striatum;visual learning;white matter;willingness;Work,Electrophysiological Probes And Treatments In Neurobehavioral Disorders,2977,NA,NA,NA,NA,26,NA,NA,534537,NA
11194784,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002989,NA,NA,1ZIANS002989-25,NINDS:2424801\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416918 (contact),"KORETSKY, ALAN  (contact)",NA,NA,NA,1 year old;Adult;Affect;Age;age effect;anatomic imaging;Anatomy;animal old age;Animals;Area;Back;barrel cortex;Behavioral;Behavioral Paradigm;Blood Vessels;Brain;Brain Diseases;Brain imaging;Brain region;brain tissue;Cells;cellular imaging;Chemosensitization;Contralateral;Cortical Column;Coupling;critical period;Data;Denervation;Detection;Development;developmental plasticity;discrimination task;Down-Regulation;Electrophysiology (science);Embryo;Endothelial Cells;Excision;Functional Imaging;Functional Magnetic Resonance Imaging;Gene Expression;Goals;gray matter;Growth;Human;Image;Imaging Device;Imaging Techniques;Implant;improved;in vivo;Injury;interest;Ipsilateral;Knowledge;Learning;Limb structure;Magnetic Resonance Imaging;Manganese;Manuscripts;Maps;Measures;migration;Molecular;molecular imaging;Monitor;Motor Cortex;Motor Pathways;Myelin;Nerve;nerve injury;nerve stem cell;nerve supply;neural;Neurons;Neurosciences;Nose;novel;Odors;olfactory bulb;Oligodendroglia;optical imaging;Pathway interactions;Peripheral;Physiology;Population;precursor cell;Process;Professional counselor;recruit;Regulation;repaired;Reporter;Resolution;response;response to injury;Rodent;Rodent Model;Site;Slice;somatosensory;Somatosensory Cortex;stellate cell;stem cells;Stroke;structural determinants;subventricular zone;Synapses;Synaptic plasticity;System;Techniques;Testing;Textbooks;Thalamic structure;Tissues;tool;Translating;Transplantation;Vibrissae;Visualization;white matter;Work,Functional Imaging of The Brain,2989,NA,NA,NA,NA,25,NA,NA,2424801,NA
11194785,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002990,NA,NA,1ZIANS002990-25,NINDS:1379555\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,79334152 (contact),"DUYN, JEFF  (contact)",NA,NA,NA,Anatomy;Animals;Area;biophysical model;Biophysics;Blood;Brain;brain health;brain iron;brain tissue;Cardiac;Classification;Clinical;Communication;Computer software;contrast enhanced;cryostat;Detection;detector;Development;Devices;Diffusion;Electromagnetic Energy;Enhancement Technology;Equipment;experimental study;flexibility;Generations;Goals;Head;Heating;Helium;Histology;Human;Image;Image Analysis;image reconstruction;improved;in vivo;Iron;Legal patent;Lesion;Liquid substance;magnetic field;Magnetic Resonance;Magnetic Resonance Imaging;Measurement;Medicine;Methodology;Methods;Motion;Multiple Sclerosis;Myelin;National Institute of Neurological Disorders and Stroke;Nerve Degeneration;Nervous System Disorder;neuroimaging;new technology;novel;Pathologic;Patients;Perfusion;Peripheral;Physiologic pulse;Play;Publishing;radio frequency;Ramp;Resolution;response;risk minimization;Role;Sampling;Scanning;Signal Transduction;simulation;Structure;System;Techniques;Technology;technology development;Time;Tissues;transmission process;United States National Institutes of Health;Visualization;water diffusion;Work,Magnetic Resonance Imaging Technology Development,2990,NA,NA,NA,NA,25,NA,NA,1379555,NA
11194786,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002993,NA,NA,1ZIANS002993-23,NINDS:1709028\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,2276433 (contact),"HOLMGREN, MIGUEL  (contact)",NA,NA,NA,Action Potentials;Affinity;alternating hemiplegia;Amino Acids;Animals;Arrhythmia;ATP1A1 gene;ATP1A3 gene;Behavioral;Binding;Binding Sites;Biology;Biophysics;Birth;Calcium;Calcium ion;Cardiac;Catalytic Domain;Cations;Cell Death;Cell membrane;Cell Physiology;Cells;Cerebellar Ataxia;Childhood;Cryoelectron Microscopy;Disabling;Disease;Dystonia;Dystonia 12;Electronics;Electrophysiology (science);Encephalopathies;Environment;Enzymes;Epilepsy;experimental study;extracellular;Eye Movements;falls;Fever;Genes;Goals;Heart;Homologous Gene;Human;Hydrolysis;Impaired cognition;Impairment;Integral Membrane Protein;Intellectual functioning disability;Ion Channel;Ion Transport;Ions;K ATPase;Knock-in Mouse;large-conductance calcium-activated potassium channels;Mammalian Cell;Membrane;Membrane Potentials;Membrane Proteins;Membrane Structure and Function;Mitochondria;Molecular;Molecular Conformation;Monitor;Movement;Movement Disorders;Muscle hypotonia;Mutation;Nervous System Disorder;neural;Neurologic;Neurological outcome;Neurotransmitters;Nonstructural Protein;Nutrient;Open Reading Frames;Optic Atrophy;Organelles;Paralysed;particle;Pathogenesis;Pathogenicity;Pathway interactions;Patients;Phenotype;Phosphorylation;Potassium;Probability;Property;Protein Conformation;Protein Dephosphorylation;Protein Dynamics;Protein Isoforms;Proteins;Proteomics;Pump;recruit;Recurrence;Resistance;SARS coronavirus;SARS-CoV-2 genome;sensor;Sensorineural Hearing Loss;Series;Side;Signal Transduction;Site;Site-Directed Mutagenesis;Sodium;spasticity;Structural Protein;Structure;Symptoms;Syndrome;Talipes cavus;Techniques;Tissues;Transmembrane Domain;Transport Process;Variant;Virus Replication;voltage;Work,Structure and Function of Membrane Proteins,2993,NA,NA,NA,NA,23,NA,NA,1709028,NA
11194787,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002994,NA,NA,1ZIANS002994-23,NINDS:1904293\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416896 (contact),"ROCHE, KATHERINE  (contact)",NA,NA,NA,Affect;Amino Acids;AMPA Receptors;autism spectrum disorder;bench to bedside;Binding;Biochemical;Biological;Brain;C-terminal;Central Nervous System;Clinical;Clustered Regularly Interspaced Short Palindromic Repeats;Collaborations;Communication;comorbidity;Complex;Data;de novo mutation;deep sequencing;Defect;density;Development;Diagnosis;Disease;Epilepsy;Event;excitatory neuron;Excitatory Synapse;exome;experience;experimental study;Family;Frameshift Mutation;Functional disorder;G-Protein-Coupled Receptors;Genes;genome sequencing;Genotype;Glutamate Receptor;Glutamates;Goals;Heterozygote;Hippocampus;Human Genetics;Individual;induced pluripotent stem cell;insight;Intellectual functioning disability;interest;Kainic Acid Receptors;Knock-out;Laboratory Study;Mental disorders;Metabotropic Glutamate Receptors;Methods;Missense Mutation;Molecular;Mus;Mutation;N-Methyl-D-Aspartate Receptors;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;Nervous System Disorder;Neurodevelopmental Disorder;Neurons;neuropathology;Neurotransmitter Receptor;Neurotransmitters;NMDA receptor A1;Paper;Pathogenicity;Patients;Persons;Phosphorylation;Play;Post-Translational Protein Processing;programs;protein protein interaction;Proteins;Protocols documentation;public database;Publishing;rare variant;receptor;receptor function;Regulation;Reporting;Research;response;Role;Scaffolding Protein;Site;Stimulus;Stretching;Structure;Surface;Synapses;synaptic function;System;Techniques;Testing;Therapeutic;trafficking;Variant;Vertebral column;whole genome;Work,Subunit-Specific Regulation Of Glutamate Receptors,2994,NA,NA,NA,NA,23,NA,NA,1904293,NA
11194788,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003000,NA,NA,1ZIANS003000-22,NINDS:1164258\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,7877320 (contact),"MINDELL, JOSEPH A (contact)",NA,NA,NA,antiport;antiporter;Area;Biochemical;Biological Assay;Biological Process;Carrier Proteins;Cell surface;Chlorides;CLC Gene;Collaborations;Defect;dicarboxylate-binding protein;Disease;Electrophysiology (science);Family;Family member;Goals;Homologous Gene;Individual;inhibitor;insight;interest;Ion Channel;Liposomes;Mammalian Cell;Mediating;member;Membrane Potentials;Methods;Molecular Conformation;Movement;mutant;Mutation;Neurons;Patients;pH Homeostasis;pharmacologic;Physiological;Property;protein function;Proteins;proteoliposomes;Protons;Reproducibility;Rest;single molecule;Skeletal Muscle;Structure;Subgroup;Transport Process;Work;Xenopus oocyte,Conformational changes in CIC chloride transporters,3000,NA,NA,NA,NA,22,NA,NA,1164258,NA
11194789,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003009,NA,NA,1ZIANS003009-21,NINDS:2180015\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416849 (contact),"WU, LING GANG  (contact)",NA,NA,NA,Actins;base;Biological;Biology;Biophysical Process;Brain;Calcium;Capsid Proteins;Cell membrane;Cells;Chromaffin Cells;Clathrin;constriction;Cytoskeleton;Distal;Dynamin;Electrophysiology (science);Endocytosis;Event;Exocytosis;Floods;Goals;Hormones;Image;Individual;Kinetics;Mediating;Membrane;Membrane Fusion;Microscope;Modeling;Molecular;nanometer;Nerve;Nervous System Physiology;Neurosecretory Systems;Neurotransmitters;Osmotic Pressure;Physiological;polymerization;Polymers;predictive modeling;Probability;Process;Proteins;Recycling;Regulation;Research;Retrieval;Role;Route;Running;Shapes;Signal Transduction;SNAP receptor;Speed;Structure;Synapses;Synaptic Transmission;Synaptic Vesicles;Techniques;Time;trafficking;Vesicle;vesicular release;Visualization;Work,Synaptic Vesicle Exocytosis,3009,NA,NA,NA,NA,21,NA,NA,2180015,NA
11194790,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003013,NA,NA,1ZIANS003013-20,NINDS:857385\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,8480539 (contact),"GINIGER, EDWARD  (contact)",NA,NA,NA,Actins;Animals;Axon;axon growth;axon guidance;Biophysics;Cell Physiology;Cell surface;Cell Surface Receptors;Cellular biology;Collaborations;Computer Models;Computer Simulation;Computing Methodologies;Cytoskeletal Modeling;Cytoskeleton;Development;Drosophila genus;experimental study;genetic manipulation;Growth;Growth Cones;high resolution imaging;Image;in silico;in vivo;Laboratories;Libraries;Ligands;Link;Modeling;Molecular;Motility;Nerve;neuron development;Neurons;notch protein;Proto-Oncogene Proteins c-abl;Reagent;receptor;Regulation;Signal Pathway;Signal Transduction;Signaling Molecule;Signaling Protein;simulation;Structure;Surface;System;Testing;Transgenes;Vertebrates;Wing;Zebrafish,Mechanisms of axon guidance during development,3013,NA,NA,NA,NA,20,NA,NA,857385,NA
11194791,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003015,NA,NA,1ZIANS003015-19,NINDS:860818\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,7877320 (contact),"MINDELL, JOSEPH A (contact)",NA,NA,NA,Acids;Albers-Schonberg disease;Anions;antiporter;ATP phosphohydrolase;Carrier Proteins;Cells;Chlorides;CLC Gene;Collaborations;COVID-19 pandemic;Cytoplasm;Defect;Disease;Endosomes;Functional disorder;Genes;Genome;Goals;human disease;Ion Transport;Ions;Knock-out;Lysosomes;Measures;Membrane;Metabolism;Methods;Molecular;mutant;Mutation;novel;Optical Methods;Organelles;Pathway interactions;Patients;Pattern;Permeability;Play;Process;programs;Property;Proton Pump;Publishing;Pump;Regulation;Role;Shunt Device;shunt pathway;Stimulus;Syndrome;Tissues;voltage;Work,Chloride fluxes in organellar membranes,3015,NA,NA,NA,NA,19,NA,NA,860818,NA
11194792,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003018,NA,NA,1ZIANS003018-18,NINDS:624508\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416860 (contact),"SWARTZ, KENTON  (contact)",NA,NA,NA,Afferent Neurons;Anions;aqueous;ATP Receptors;Binding;Binding Sites;Cations;Cellular Membrane;Complex;Cytoplasm;Detergents;Diffuse;Disease;Exhibits;extracellular;Extracellular Domain;Future;Goals;Human;Ion Channel;ion dynamics;Ions;Lateral;Lipids;Mammals;Membrane;Membrane Lipids;nanobodies;nanodisk;Neuroglia;Neurons;non-Native;P2X-receptor;Pathway interactions;Permeability;Pharmacology;Play;Property;receptor;Reporting;response;Role;Shapes;Side;Structure;Sulfhydryl Compounds;therapeutic target;Therapeutic Uses;tool;TRP channel;voltage,Gating mechanisms and pharmacology of P2X receptor channels,3018,NA,NA,NA,NA,18,NA,NA,624508,NA
11194793,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003027,NA,NA,1ZIANS003027-18,NINDS:1873818\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,79334152 (contact),"DUYN, JEFF  (contact)",NA,NA,NA,Affect;Anatomy;Area;Arousal;Behavioral;Brain;Brain region;brain tissue;Classification;Collaborations;Communication;Data;Data Analyses;Data Set;data sharing;Electroencephalography;Electrophysiology (science);Epilepsy;Event;Exhibits;experience;experimental study;Functional Magnetic Resonance Imaging;functional magnetic resonance imaging/electroencephalography;Goals;Heart Rate;Hippocampus;Hour;human imaging;improved;in vivo;Individual;insight;Iron;Joints;Learning;Link;magnetic field;Magnetic Resonance Imaging;Magnetism;markov model;Measurement;meetings;memory consolidation;Methods;Modeling;movie;Multiple Sclerosis;Mus;Myelin;neural;neural patterning;Neurodegenerative Disorders;Neurologic;Neurons;non rapid eye movement;Operative Surgical Procedures;Parkinson Disease;Participant;Pathology;Pathway interactions;Patients;Pattern;Periodicals;Physiological;Physiology;Pilot Projects;Population;Predisposition;Primary Lateral Sclerosis;Probability;Procedures;Prosencephalon;Publishing;rapid eye movement;Recurrence;Reproducibility;Respiration;response;Rest;Role;Series;Services;Signal Transduction;Sleep;Sleep Stages;Source;Specificity;Structure;success;Techniques;Time;Training;United States National Institutes of Health;Universities;unsupervised learning;Work,Magnetic Resonance Imaging of Human Brain Anatomy and Function,3027,NA,NA,NA,NA,18,NA,NA,1873818,NA
11194794,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003029,NA,NA,1ZIANS003029-18,NINDS:2312606\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9811937 (contact),"SHENG, ZU-HANG  (contact)",NA,NA,NA,A kinase anchoring protein;Acceleration;Acute;Address;Adult;adult neurogenesis;Affect;age related;aged;Aging;Alzheimer&apos;s Disease;Area;Attenuated;Axon;axon injury;axon regeneration;axonal degeneration;Behavior;Behavioral;Bioenergetics;Biology;Bipolar Disorder;Bipolar Neuron;Brain;Brain Injuries;Brain Ischemia;Brain region;Cell Death;cell regeneration;Cells;Cellular Metabolic Process;Chronic;clinically relevant;Collaborations;Communication;Corticospinal Tracts;Creatine;Deacetylase;Deacetylation;deprivation;disease model;Disease Progression;Distal;Energy consumption;Energy Metabolism;Energy Supply;Ensure;Exhibits;exosome;F-Actin;Face;Failure;Foundations;frontier;Functional disorder;Generations;Genes;Glucose;Growth;healthy aging;Hippocampus;Human;human induced pluripotent stem cells;Impairment;Indiana;induced pluripotent stem cell;Induced pluripotent stem cell derived human neuron;Injections;Injury;Investigation;Ischemia;ischemic injury;knock-down;Knockout Mice;Knowledge;Lead;Lesion;Lithium;Lysosomes;Maintenance;Manic;Mediating;Metabolic;Metabolism;Mitochondria;mitochondrial dysfunction;Mitochondrial Proteins;Modeling;Molecular Motors;Moods;Motility;Motor Cortex;Mus;myosin VI;Natural regeneration;Nature;Nerve Degeneration;Nervous System Disorder;Neurobiology;Neurodegenerative Disorders;Neuroglia;neuron regeneration;neuronal cell body;neuronal growth;neuronal survival;Neurons;Neurosciences;newborn neuron;novel;Oligodendroglia;Organoids;Oxidation-Reduction;Oxygen;PAK6 gene;Pathologic;Pathology;Pathway interactions;Patients;Pharmaceutical Preparations;Phenotype;Phosphorylation;Phosphotransferases;Physiologic pulse;Physiological;Play;Positioning Attribute;Preparation;presynaptic;Presynaptic Terminals;Proteins;Proto-Oncogene Proteins c-akt;Recovery;recruit;Regulation;repaired;Reporting;Research;response;response to injury;restraint;risk variant;Role;Signal Pathway;Signal Transduction;Sirtuins;SLC25A4 gene;SLC25A5 gene;Solid;spatiotemporal;Spinal Cord;Spinal cord injury;Stress;Structure;Synapses;synaptic depression;Synaptic plasticity;Synaptic Transmission;syntaphilin;Testing;Therapeutic;therapeutic target;trafficking;trait;Universities;Variant;Vesicle,Mitochondrial transport and energy metabolism in synaptic transmission and neuronal degeneration and regeneration,3029,NA,NA,NA,NA,18,NA,NA,2312606,NA
11194795,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003034,NA,NA,1ZIANS003034-18,NINDS:1706465\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416892 (contact),"GOLDSTEIN, DAVID  (contact)",NA,NA,NA,"Acute;alpha synuclein;Area;Area Under Curve;Autonomic nervous system;Autopsy;Back;Baroreflex;Behavior;Biochemical;Biological Assay;Biological Markers;biomarker identification;Blood Pressure;Blood specimen;Brain;brain fog;Cardiac;Cardiovascular system;Catecholamines;Catechols;Cellular Assay;Cerebrospinal Fluid;Clinical;clinical center;clinical diagnosis;clinical investigation;Clinical Protocols;Cognitive;cognitive testing;cohort;Collaborations;comparison control;COVID-19;Cutaneous;Data;Dementia with Lewy Bodies;Deposition;Development;Diagnosis;disability;Disease;Disease Progression;Dopamine;Doppler Ultrasound;Dreams;Eligibility Determination;Evaluation;Evolution;experience;Failure;falls;Fatigue;Fiber;follow up assessment;follow-up;Frequencies;Functional disorder;Genetic;Genetic Processes;Head;Heart Rate;heart rate variability;Hypotension;Immune;Immunologics;immunoreactivity;in vivo;indexing;Individual;Inflammatory;Inflammatory Response;Inpatients;interest;Journals;Karnofsky Performance Status;Laboratories;Lewy Body Disease;Long COVID;longitudinal, prospective study;Longterm Follow-up;Magnetic Resonance Imaging;Measurement;Measures;Modification;multimodality;Multiple System Atrophy;Myocardial;National Institute of Allergy and Infectious Disease;National Institute of Neurological Disorders and Stroke;Nerve;Nerve Degeneration;Neurodegenerative Disorders;Neurologic Symptoms;Neurology;Neuropsychology;Neurosecretory Systems;Neurotransmitters;noradrenergic;Norepinephrine;Olfactory dysfunction;Oligoclonal Bands;Orthostatic Hypotension;orthostatic intolerance;Parkinson Disease;Participant;Patient Self-Report;Patients;Pattern;Pennsylvania;Personal Satisfaction;Persons;Phase;Phenotype;Physiological;Plasma;Positron-Emission Tomography;pre-clinical;pressure;prevent;Probability;Process;prospective;Protocols documentation;Publishing;Pure Autonomic Failures;Radioactivity;Rare Diseases;Recovery;Reporting;Research Personnel;response;Risk;Risk Factors;Sampling;Serum;Signal Transduction;Skin;skin biopsy;Smell Perception;Spinal Puncture;Symptoms;synuclein;synucleinopathy;System;Test Result;Testing;Tilt-Table Test;Time;Tissues;Toxic effect;Tyrosine 3-Monooxygenase;United States National Institutes of Health;Universities;Valsalva Maneuver;Visit;web site",Biomarkers of Catecholaminergic Neurodegeneration,3034,NA,NA,NA,NA,18,NA,NA,1706465,NA
11194796,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003040,NA,NA,1ZIANS003040-18,NINDS:405720\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416904 (contact),"JACOBSON, STEVEN  (contact)",NA,NA,NA,Activated Lymphocyte;Africa;Anti-Retroviral Agents;Antibodies;antigen-specific T cells;Antigens;Area;Atrophic;B cell therapy;B-Lymphocyte Subsets;B-Lymphocytes;Bar Codes;Bladder;Blood;brain volume;Carbon Nanotubes;Caribbean region;Catalogs;CD4 Positive T Lymphocytes;CD8-Positive T-Lymphocytes;Cell Culture Techniques;Cell Differentiation process;Cells;cerebral atrophy;Cerebrospinal Fluid;Chronic;chronic neurologic disease;Cladribine;Classification;Clinical;clinical outcome measures;Clinical Treatment;Clinical Trials;Clonal Expansion;cohort;Collection;Color;complementarity-determining region 3;convolutional neural network;Coupled;Cytostatics;cytotoxic;Data;deep learning;Diagnosis;Differential Diagnosis;Dihydroorotate Dehydrogenase Inhibitor;disability;Disease;Disease Progression;DNA Binding;Drops;Epidemiology;Epstein-Barr Virus Nuclear Antigens;experience;Fingerprint;Flow Cytometry;forest;Frequencies;Functional disorder;Genomics;healthy volunteer;HIV;HIV-1;HTLV-1 Infection;Human;Human Herpesvirus 4;Human Herpesvirus 6;Human T-lymphotropic virus 1;Immune;immune activation;Immunologics;Immunophenotyping;Immunotherapeutic agent;In Vitro;India;Individual;Inflammatory;inhibitor;Integrase Inhibitors;interest;Intestines;Japan;JC Virus;Laboratories;learning strategy;Life Cycle Stages;Long COVID;lymphoblastoid cell line;Machine Learning;Measurement;Measures;Metabolic;Molecular;Molecular Genetics;MRI Scans;Multiple Sclerosis;multiple sclerosis patient;Nerve Degeneration;Nervous System Disorder;Neurologic;novel;Nucleic Acids;nucleoside analog;Pathogenesis;Pathogenicity;Pathology;Patients;peripheral blood;Peripheral Blood Mononuclear Cell;Pharmaceutical Preparations;Phylogenetic Analysis;Privatization;Process;Progressive Multifocal Leukoencephalopathy;Proliferating;Raman Spectrum Analysis;Retroviridae;Role;Safety;Sampling;single-cell RNA sequencing;Site;small molecule inhibitor;Spastic Paraparesis;Spinal Cord;Spinal Cord Diseases;T cell infiltration;T-Cell Receptor;T-cell receptor repertoire;T-Lymphocyte;Taxes;Techniques;Technology;Time;translational study;Translations;treatment strategy;Trees;Tropical Spastic Paraparesis;Viral;Viral load measurement;Virus;virus identification,Translational studies of human viruses and chronic neurologic disease,3040,NA,NA,NA,NA,18,NA,NA,405720,NA
11194797,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003043,NA,NA,1ZIANS003043-18,NINDS:1189241\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,12000928 (contact),"LATOUR, LAWRENCE  (contact)",NA,NA,NA,Accident and Emergency department;Acute;acute stroke;Address;Aftercare;Biological;biological systems;Biology;biomarker identification;Blood flow;blood-brain barrier disruption;Brain;Categories;Cerebral Ischemia;Cerebrovascular Disorders;Classification;Clinical;clinical center;Coagulation Process;Collaborations;Communities;Complex;complex biological systems;Data;Data Analyses;Diagnosis;Diffusion Magnetic Resonance Imaging;Disease Marker;drug development;Edema;effective therapy;Embolectomy;Enrollment;Excision;experience;Functional disorder;Future;health care availability;health care disparity;Hemorrhage;Hospitals;Human;Image;imaging biomarker;improved;Injury;insight;interest;Interruption;Intervention;Intravenous;Investigation;Learning;Lesion;Magnetic Resonance Imaging;Mechanics;MicroRNAs;Minor;Modality;Modeling;Motion;National Institute of Neurological Disorders and Stroke;Natural History;neuroimaging;next generation sequencing;novel;Observational Study;Outcome;Participant;participant enrollment;patient population;patient registry;Patient Selection;patient stratification;Patients;peripheral blood;Phenotype;Population;prospective;Prospective Studies;Protocols documentation;Publishing;Reperfusion Therapy;responders and non-responders;response;social health determinants;Speed;standard of care;Stroke;stroke outcome;stroke symptom;stroke therapy;Symptoms;therapy development;Thrombolytic Therapy;Time;Tissue-Specific Gene Expression;Transient Ischemic Attack;treatment responders;treatment response;United States National Institutes of Health;Validation;Withholding Treatment,Novel Insights Into Cerebral Ischemic Pathophysiology In Humans,3043,NA,NA,NA,NA,18,NA,NA,1189241,NA
11194798,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003047,NA,NA,1ZIANS003047-18,NINDS:1743043\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416918 (contact),"KORETSKY, ALAN  (contact)",NA,NA,NA,Adult;Affect;Anatomy;Animal Model;Animals;Antibodies;antibody detection;Area;arterial spin labeling;Astrocytes;Back;Behavior;blood-brain barrier disruption;Brain;Brain imaging;Brain region;Calcium;cell motility;Cell Physiology;Cells;cellular imaging;Chemicals;Clinical;Collaborations;Complex;contrast imaging;Contrast Media;Coupling;Cues;Data;Dependence;Detection;Development;disease model;Early Diagnosis;Encephalitis;Engineering;Environment;Enzymes;experimental study;Fc Receptor;Functional Imaging;Functional Magnetic Resonance Imaging;Gene Expression;Goals;High Fat Diet;Human;Image;imaging approach;Imaging Techniques;Immunoglobulin G;in vivo;Individual;Inflammation;Injections;interest;Ions;Iron;iron oxide;Label;Lead;light microscopy;magnetic field;Magnetic Resonance Imaging;Magnetism;Manganese;manufacture;Manuscripts;Measurement;Measures;migration;Modeling;Molecular;molecular imaging;Monitor;mouse model;Mus;Nerve Degeneration;nerve stem cell;neural;neuroinflammation;Neurons;New Agents;Nose;novel;novel strategies;olfactory bulb;Paper;particle;Pathway interactions;pre-clinical;preclinical imaging;Process;Property;Publishing;radiological imaging;Rattus;receptor;Recording of previous events;Recovery;Regional Blood Flow;Reporter;Reporting;Research;Resolution;Rodent;Site;Specificity;Stream;subventricular zone;Temperature;Testing;TFRC gene;Time;Toxic effect;Tracer;translational potential;uptake;Vascular Cell Adhesion Molecule-1;Virus;Work,MRI contrast for molecular and cellular imaging of the brain,3047,NA,NA,NA,NA,18,NA,NA,1743043,NA
11194799,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003050,NA,NA,1ZIANS003050-17,NINDS:1183526\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,11599386 (contact),"HEISS, JOHN  (contact)",NA,NA,NA,"Adhesions;Adhesives;Adopted;Adult;Affect;Appearance;Arachnoiditis;Auditory;Automobile Driving;Brain;Brain imaging;Brain Stem;Candidate Disease Gene;Caring;Cerebellar tonsil;Cerebellum;Cerebrospinal Fluid;cerebrospinal fluid flow;Cerebrospinal Fluid Pressure;Characteristics;Child;Childhood;Chromosomes;Chronic;Cicatrix;Clinical;Clinical Research;cohort;Collaborations;Communication;Complex;Congenital Disorders;cranium;Cyst;Data;data cleaning;Data Set;Development;Disease;Dissection;Dizziness;DNA;Doctor of Medicine;Doctor of Philosophy;Dorsal;Dura Mater;Dyes;Edema;Effectiveness;Endoscopes;Endoscopy;Enrollment;Equilibrium;Etiology;Excision;exome;exome sequencing;Extended Family;Family;Family member;Family Study;flexibility;follow-up;foramen magnum;Functional disorder;Funding;Future;Genetic;genetic linkage analysis;genetic variant;genome sequencing;genome-wide;genomic locus;Genotype;Headache;Hearing;improved;Incidence;Individual;Infection;Laminectomy;Link;Liquid substance;longitudinal, prospective study;Magnetic Resonance Imaging;malformation;Maps;Measures;member;Membrane;Methods;morphological criteria;Morphology;Myelography;National Human Genome Research Institute;Natural History;Neck Pain;neural;Neuroendoscopy;Neurologic Dysfunctions;Neurologic Examination;Obstruction;Operative Surgical Procedures;Outcome;Outcome Measure;pain scale;Paralysed;Pathway interactions;Patient Monitoring;patient population;Patient-Focused Outcomes;Patients;pediatric patients;Phenotype;Population;Posterior Fossa;Postoperative Period;Posture;Procedures;Process;Prognosis;programs;Publishing;Reporting;Research Personnel;Sampling;scoliosis;Sensory;Shapes;Signal Transduction;Signs and Symptoms;somatosensory;Specialist;Specimen;Spinal;Spinal Cord;Structure;Subarachnoid Space;Subgroup;Symptoms;Syringes;Syringomyelia;technique development;Testing;Tonsil;trait;transmission process;Trauma;tumor;United States;Variant;Vertebral column;Vestibular Diseases;vestibular system;Visual;whole genome;women patients",Pathophysiology and Treatment of Syringomyelia,3050,NA,NA,NA,NA,17,NA,NA,1183526,NA
11194800,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003051,NA,NA,1ZIANS003051-17,NINDS:197254\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,11599386 (contact),"HEISS, JOHN  (contact)",NA,NA,NA,adenovirus mediated delivery;Adverse effects;Affect;afferent nerve;Agonist;Anatomy;Animal Experimentation;Animal Model;Animals;Area;Autopsy;Autoradiography;Behavioral;bench to bedside;Bilateral;Binding;Biopsy;Blood;blood-brain barrier crossing;Botulinum Toxins;Brain;Brain Injuries;Brain Neoplasms;Brain Stem;Brain Stem Glioma;Case Study;Catechols;Catheters;cell type;Central Nervous System;Central Nervous System Agents;Cervical;Cessation of life;Characteristics;Chemicals;Childhood Brain Neoplasm;Chronic;Clinical;clinical candidate;Clinical Protocols;Clinical Research;Clinical Trials;clinically relevant;Collaborations;Consent;Convection;Corpus striatum structure;Deep Brain Stimulation;Degenerative Disorder;design;Development;Diffuse;Diffuse intrinsic pontine glioma;diffuse midline glioma;Disease;Dopamine;dopaminergic neuron;Dose;Drug Delivery Systems;drug development;drug distribution;Drug Monitoring;effectiveness evaluation;Electrodes;Enrollment;Epilepsy;Extracellular Space;Family;Gadolinium DTPA;gamma-Aminobutyric Acid;Gene Expression;gene therapy;Genes;giant axonal neuropathy;glial cell-line derived neurotrophic factor;Glioblastoma;Glioma;Grant;Hippocampus;Histopathology;Human;Image;Immunologics;immunoreactivity;improved;Infusion procedures;Injections;Institution;Interleukin-13;Intractable Epilepsy;Laboratories;Laboratory Animals;Magnetic Resonance Imaging;Malignant Neoplasms;Manuscripts;Measures;Methods;Microdialysis;Modeling;Monitor;Motor;Movement Disorder Society Unified Parkinson&apos;s Disease Rating Scale;Muscimol;National Institute of Neurological Disorders and Stroke;Nervous System;Neural Inhibition;neuro-oncology;Neurodegenerative Disorders;Neurologic;Neurons;neuropathology;neurosurgery;Neurotransmitters;neurotrophic factor;non-invasive imaging;non-invasive monitor;nonhuman primate;Oncolytic;Operative Surgical Procedures;palliative;Parkinson Disease;Parkinsonian Disorders;Pathologic;Patients;pediatric patients;Perfusion;Peripheral Nerves;Pharmaceutical Preparations;Pontine structure;Positron-Emission Tomography;Postoperative Period;preclinical study;presynaptic;prevent;Primates;Property;Pseudomonas;Publishing;Pump;Radiation therapy;radiological imaging;real-time images;recruit;regeneration potential;Reporting;Research Personnel;Rodent;Seizures;Signal Transduction;Spondylosis;Structure;Structure of subthalamic nucleus;Study Subject;Synapses;Techniques;Technology;Therapeutic;Therapeutic Agents;Time;time use;Toxic effect;Toxin;Tracer;treatment site;Tumor Tissue;Tyrosine 3-Monooxygenase;Unresectable;uptake;Viral Vector;Virotherapy;Work;Writing;X-Ray Computed Tomography,Central Nervous System Drug Delivery Techniques,3051,NA,NA,NA,NA,17,NA,NA,197254,NA
11194801,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003052,NA,NA,1ZIANS003052-17,NINDS:1040298\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,11599386 (contact),"HEISS, JOHN  (contact)",NA,NA,NA,adaptive immune response;AKT inhibition;Animal Model;Anti-Retroviral Agents;antitumor effect;Apoptosis;Arginine;Astrocytes;Autophagocytosis;Basic Science;Brain;Brain Neoplasms;CASP3 gene;Cell Aggregation;Cell Communication;cell growth;Cell Physiology;Cell Proliferation;Cell Survival;Cells;chemosensitizing agent;Chemotherapy and/or radiation;Clinical;Clinical Research;Clinical Trials;Collaborations;cytotoxicity;Defect;Development;diagnostic technologies;diagnostic tool;drug repurposing;Endogenous Retroviruses;Endothelial Cells;Epigenetic Process;epitranscriptome;ERBB3 gene;Etiology;experimental study;Genetic;Genetic Heterogeneity;Glioblastoma;Glioma;Glomerular basement membrane antibody;Head;Heterogeneity;Human;Immune;Immune checkpoint inhibitor;Immunologic Surveillance;Immunology;Immunophilins;Immunotherapy;improved;in vivo;Induction of Apoptosis;Inherited;inhibitor;insight;Investigation;JUN gene;kinase inhibitor;knock-down;Laboratories;Literature;Malignant Neoplasms;Manuscripts;MAPK8 gene;Mediating;Medical;Medical Genetics;medical schools;Melanoma;Modeling;Molecular;molecular diagnostics;Morphology;Mus;Mutation;National Institute of Neurological Disorders and Stroke;Natural Immunity;neoplasm surgery;Neoplasms;neoplastic cell;nervous system infection;neuro-oncology;Neurology;Neurosphere;neurosurgery;new technology;novel;oncolytic herpes simplex virus;Operative Surgical Procedures;overexpression;Pathogenesis;Pathologic;Pathology;Pathway interactions;Patients;PD-1 blockade;pharmacologic;Phase I Clinical Trials;Phosphoric Monoester Hydrolases;professor;programmed cell death protein 1;Protein Inhibition;Protein phosphatase;Protein-Arginine N-Methyltransferase;Proto-Oncogene Proteins c-akt;PTEN gene;Publications;Publishing;Radiation-Sensitizing Agents;Regulation;Reporting;Research;Research Personnel;Resistance;Role;self-renewal;senescence;Signal Transduction;Site;small molecule inhibitor;Spinal;Spinal Neoplasms;stem;stem cell niche;summer student;Tacrolimus Binding Proteins;Techniques;Tertiary Protein Structure;Testing;Therapeutic;therapeutic target;therapy resistant;Time;Tissues;Translating;Translational Research;tumor;Tumor Biology;tumor heterogeneity;tumorigenesis;United States National Institutes of Health;Universities;vaccine trial;vasculogenesis;Virus;Work;Xenograft Model;Xenograft procedure,Molecular Pathogenesis of Neoplasia,3052,NA,NA,NA,NA,17,NA,NA,1040298,NA
11194802,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003053,NA,NA,1ZIANS003053-17,NINDS:551013\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,14285237 (contact),"CHITTIBOINA, PRASHANT  (contact)",NA,NA,NA,Acceleration;Adolescent;Adrenal Glands;Affect;associated symptom;Axonal Neuropathy;bilateral vestibular Schwannoma;Biochemical;Body System;Cataract;Cells;Central Nervous System;Central Nervous System Neoplasms;Chromosomes;Clinical;cohort;Cranial Nerves;Cutaneous T-cell lymphoma;Cyst;Data;Development;Ear;endolymphatic sac;Enrollment;Ependymoma;Evolution;Excision;Extravasation;Fascicle;Future;Gene Mutation;Genetic;Germ Lines;Germ-Line Mutation;Glioma;Growth;Hamartoma;HDAC4 gene;hearing impairment;hemangioblastoma;Histone Deacetylase Inhibitor;Immunohistochemistry;inclusion criteria;Inherited;insight;Kidney;Knowledge;Laboratories;Lesion;longitudinal analysis;Magnetic Resonance Imaging;Mediating;meetings;meningioma;Molecular;Morbidity - disease rate;mutant;Mutate;Natural History;Nature;Neoplasms;Nerve;Nervous System;Nervous System Neoplasms;Neurilemmoma;neuro-oncology;Neurofibromatosis 2;Neurologic Deficit;Neuropathy;novel therapeutics;Operative Surgical Procedures;Oral;Organ;Pancreas;Patient Monitoring;Patients;Pattern;Peripheral;Peripheral Nerves;Peripheral Nervous System Diseases;Peripheral Nervous System Neoplasms;Permeability;Plasma;predictive marker;Predisposition;Prevalence;prospective;Proteins;Refractory;reproductive;Resolution;Retina;Role;Signal Transduction;Spinal nerve structure;Stuttering;symptom treatment;Symptoms;Syndrome;Syringes;Testing;Time;treatment duration;treatment risk;tumor;Tumor Biology;tumor growth;tumor progression;Tumor Suppressor Genes;Tumor Suppressor Proteins;Tumor Volume;Vestibular Nerve;VHL mutation;VHL protein;Visceral;Von Hippel-Lindau Syndrome;Vorinostat;Western Blotting,Neuro-oncology of Familial Neoplasia Syndromes,3053,NA,NA,NA,NA,17,NA,NA,551013,NA
11194803,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003105,NA,NA,1ZIANS003105-16,NINDS:2410033\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416849 (contact),"WU, LING GANG  (contact)",NA,NA,NA,Actins;Address;base;Biological;Biophysics;Calcineurin;Calcium;Calmodulin;Capsid Proteins;Cell membrane;Chromaffin Cells;Classification;Clathrin;Coated vesicle;Communication;constriction;Coupling;Cytoskeleton;Dynamin;Electron Microscopy;Electrophysiology (science);Endocytosis;Exocytosis;Floods;Goals;Hippocampus;Homeostasis;improved;Individual;Kinetics;Maintenance;mathematical model;mechanical force;Mediating;Membrane;Membrane Fusion;Microscope;Modeling;Molecular;nanometer;Nerve;Nervous System;Nervous System Physiology;Neuroendocrine Cell;Neurons;Neurosecretory Systems;Neurotransmitters;Osmotic Pressure;Pathology;Phosphorylation;Physiology;polymerization;Polymers;Probability;Process;Protein Dephosphorylation;Protein Kinase C;Proteins;Recycling;Reporting;Research;Retrieval;Role;Running;Shapes;Signal Pathway;Signal Transduction;Signaling Protein;SNAP receptor;Speed;superresolution imaging;Synapses;Synaptic Transmission;Synaptic Vesicles;Techniques;Time;trafficking;Vesicle;Virus Diseases;Visualization;Work,Synaptic Vesicle Endocytosis,3105,NA,NA,NA,NA,16,NA,NA,2410033,NA
11194804,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003106,NA,NA,1ZIANS003106-16,NINDS:1585714\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,8480539 (contact),"GINIGER, EDWARD  (contact)",NA,NA,NA,Adult;age acceleration;age related changes;Aging;aging process;Animals;antioxidant therapy;Autophagocytosis;Axon;Back;Cell Culture Techniques;Cell Physiology;clinical application;Cytoskeletal Modeling;Disease Progression;DNA Sequence;Drosophila genus;electrical property;Event;Exclusion;experimental study;extend lifespan;fly;Future;Genetic;genetic manipulation;Health;Housekeeping;Human;improved;In Vitro;in vivo;in vivo evaluation;insight;Invaded;Mitochondria;Modeling;Molecular;mortality;mutant;Nerve Degeneration;Neurodegenerative Disorders;neurodevelopment;neuron loss;Neurons;Orthologous Gene;Oxidation-Reduction;Oxidative Stress;Pathogenicity;pharmacologic;Play;Population;Process;response;Role;tau-protein kinase;Testing;translational study;Vertebrates,Roles of Cdk5 in neurodevelopment and neurodegeneration,3106,NA,NA,NA,NA,16,NA,NA,1585714,NA
11194805,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003111,NA,NA,1ZIANS003111-16,NINDS:1461102\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,10274198 (contact),"MCGAVERN, DORIAN  (contact)",NA,NA,NA,adaptive immune response;Adaptive Immune System;Adoptive Immunotherapy;Aging;Autoimmunity;Brain;Cells;Central Nervous System;Central Nervous System Infections;Cephalic;Chronic;chronic infection;Data;Dendritic Cells;design;Deterioration;Disease;Engraftment;Equilibrium;exhaustion;Failure;Fostering;Future;Glioblastoma;Health;HIV;HIV-1;Homeostasis;human pathogen;Humoral Immunities;Immune;Immune response;Immune system;Immunologics;immunopathology;immunoreaction;immunoregulation;Impairment;imprint;In Situ;Infection;Infectious Diseases Research;Infiltration;Innate Immune System;Intention;interest;Laboratories;Laboratory Study;Lymphocytic choriomeningitis virus;Lytic;Macrophage;Maintenance;Meningeal;Meninges;Modeling;monocyte;Mus;neoplastic cell;Nerve Degeneration;Nervous System Physiology;pathogen;Peripheral;preservation;prevent;programs;Property;purge;Resolution;response;response to brain injury;sensor;Sinus;Structure;T-Lymphocyte;Therapeutic;Tissues;tumor;Tumor Immunity;tumor immunology;Tumor Promotion;Viral;Virus;Virus Diseases;wound healing,Mechanisms Underlying Clearance of Persistent Infections and Tumors,3111,NA,NA,NA,NA,16,NA,NA,1461102,NA
11194806,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003112,NA,NA,1ZIANS003112-16,NINDS:1691119\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,10274198 (contact),"MCGAVERN, DORIAN  (contact)",NA,NA,NA,Acute;acute infection;Antibody Response;Area;B-Lymphocytes;Biological;Blood;blood damage;Blood Vessels;bone;Brain;Brain Injuries;brain parenchyma;Candida albicans;CD4 Positive T Lymphocytes;CD8-Positive T-Lymphocytes;Cell Death;Cell Maturation;Cells;Central Nervous System;Central Nervous System Infections;central nervous system injury;Cerebral hemisphere hemorrhage;Cerebral Malaria;cerebrovascular;Cerebrovascular system;Compensation;Complex;Cortical vasculature;cranium;cytokine;Degenerative Disorder;Dendritic Cells;Disease;Drainage procedure;Dura Mater;efficacy evaluation;Encephalitis;Endowment;Fibrosis;Film;Generations;genetic signature;Genomics;Goals;healing;Health;Human;human disease;imaging approach;Immune;Immune response;Immune system;Immunologics;Immunology;improved;Infection;Inflammatory;Injury;insight;interest;Interferons;Interleukin-6;intravital imaging;Invaded;Laboratories;Laser Scanning Microscopy;Lead;Lesion;Liquid substance;Location;Lymphocytic choriomeningitis virus;Lymphoid Cell;Macrophage;Mediating;Meninges;Meningitis;Microbe;Microglia;Molecular;monocyte;Myeloid Cells;Nerve Degeneration;Nervous System Disorder;Nervous System Physiology;neural;Neurons;neutrophil;pathogen;Pathogenesis;Peripheral;Plasmodium berghei;preservation;Process;Property;Reaction;Recovery;Recovery of Function;repaired;Research;response;Risk;Rodent;Sampling;seal;Signal Induction;Signal Pathway;Signal Transduction;Site;Stroke;Structure;Structure of germinal center of lymph node;System;Therapeutic;therapeutic evaluation;Therapeutic Intervention;Tight Junctions;Time;Tissues;TNF gene;Toxin;transcriptomics;Traumatic Brain Injury;two-photon;vaccine development;VEGFA gene;venous sinus;Vesicular stomatitis Indiana virus;Viral;Visualization,Pathogenesis of Acute CNS infection and injury,3112,NA,NA,NA,NA,16,NA,NA,1691119,NA
11194807,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003113,NA,NA,1ZIANS003113-15,NINDS:1259560\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,6482573 (contact),"REESE, THOMAS S (contact)",NA,NA,NA,3-Dimensional;A kinase anchoring protein;Affect;Affinity;AMPA Receptors;analog;Antibodies;Architecture;beta-Hydroxybutyrate;Binding;Binding Sites;biological adaptation to stress;Calcium;Calmodulin;calmodulin-dependent protein kinase II;Clustered Regularly Interspaced Short Palindromic Repeats;Collaborations;Color;Complement;Complex;CRISPR/Cas technology;Cryo-electron tomography;Cryoelectron Microscopy;Cyclic AMP-Dependent Protein Kinases;Darkness;Data;density;DLG4 gene;electron tomography;Elements;Environment;Event;Evolution;Exocytosis;Filament;Fluorescence;Freeze Substitution;Genetic;Glutamate Receptor;Glutamates;Goals;Gold;Hippocampus;Holoenzymes;Image;Immunoelectron Microscopy;Individual;information processing;Inhibitory Synapse;insight;Knock-in;Knock-out;knowledge integration;Label;Learning;Length;Link;Location;Maps;Mediating;Membrane;Memory;Methods;Microtomy;Molecular;Molecular Conformation;molecular dynamics;Molecular Machines;mutant;N-Methyl-D-Aspartate Receptors;N-Methylaspartate;nano;nanobodies;nanoGold;Nervous System;Neurons;Neuroprotective Agents;Neurotransmitters;NMDA receptor A1;novel;NR2B NMDA receptor;particle;Peroxides;Phosphoric Monoester Hydrolases;Phosphotransferases;Phylogenetic Analysis;Physical condensation;Plastic Embedding;Positioning Attribute;postsynaptic;postsynaptic density protein;Potassium;presynaptic;Presynaptic Terminals;Property;protein complex;Protein Isoforms;Proteins;Publications;Reaction;reconstruction;Research;Rest;Rodent;Role;Sampling;Scaffolding Protein;Scanning;Sensory;Signal Transduction;Site;Stains;Structural Models;Structure;Subcellular structure;supercomputer;symposium;Synapses;synaptic function;Synaptic plasticity;Synaptic Transmission;Synaptic Vesicles;Techniques;Time;Tomogram;tomography;trafficking;United States National Institutes of Health;Validation;Vertebral column;Vesicle;Visualization;Work,Dynamic Structural Properties of Synapses,3113,NA,NA,NA,NA,15,NA,NA,1259560,NA
11194808,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003119,NA,NA,1ZIANS003119-15,NINDS:5074716\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,10673201 (contact),"REICH, DANIEL  (contact)",NA,NA,NA,accurate diagnosis;Affect;Age;Animal Model;Animals;Atlases;Autopsy;Axon;biobank;Biology;Blood Vessels;Brain;brain cell;Callithrix;Callithrix jacchus jacchus;Categories;Cell Aging;Cells;Central Nervous System;Central Vein;Cerebral cortex;Cerebral hemisphere;Cerebrospinal Fluid;Cerebrum;Chemicals;Chronic;Clinical;Clinical Trials;CNS degeneration;Collaborations;Communities;complement system;Conduct Clinical Trials;Consensus;Data;Demyelinations;design;Detection;Development;Diagnostic;diagnostic algorithm;disability;Disease;Dura Mater;Evaluation;experimental study;Extramural Activities;Functional disorder;Gene Expression Profile;Goals;Human;Image;imaging biomarker;improved;Industry;Inflammation;Inflammatory;International;Investigation;Lesion;Lipids;Lipofuscin;Liquid substance;Location;Longitudinal Studies;Magnetic Resonance Imaging;Meninges;Methodology;Methods;Microscopy;Modeling;Molecular;multimodality;Multiple Sclerosis;Multiple Sclerosis Lesions;multiple sclerosis patient;Myelin;National Institute of Neurological Disorders and Stroke;Natural History;Nerve Degeneration;Neuroanatomy;neuroimaging;neuroinflammation;nonhuman primate;novel therapeutics;Onset of illness;Organoids;Outcome;Paper;Pathologic;Pathology;Pathway interactions;Patients;Persons;Phase;Phenotype;Physiologic pulse;Pigments;Play;portability;Positioning Attribute;prevent;Primates;Prognosis;prognostic significance;programs;Publications;Publishing;radio frequency;Radiology Specialty;remyelination;repaired;Reproducibility;Research;Resolution;Resources;Review Literature;Role;Scanning;Selection for Treatments;spatiotemporal;Spectrum Analysis;Structure of choroid plexus;System;systems research;targeted treatment;Techniques;Testing;Therapeutic;Therapeutic Intervention;therapeutic target;Three-Dimensional Imaging;Time;Tissues;transcriptomics;ultra high resolution;United States National Institutes of Health;Universities;Veins;Vision;Washington;white matter;Work;Writing,Multimodal MRI in Multiple Sclerosis,3119,NA,NA,NA,NA,15,NA,NA,5074716,NA
11194809,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003120,NA,NA,1ZIANS003120-15,NINDS:1143237\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,12000928 (contact),"LATOUR, LAWRENCE  (contact)",NA,NA,NA,Accident and Emergency department;Accounting;Acute;acute care;Adult;Area;biomarker identification;Blood;blood-based biomarker;Brain;Brain Concussion;Brain scan;Chronic;Classification;Clinical;clinical center;Cognitive;Cognitive deficits;cohort;Collaborations;cost;Coupled;Craniocerebral Trauma;cytotoxic;Data;Department of Defense;detection sensitivity;Diagnosis;Edema;Enrollment;experience;extracellular vesicles;Follow-Up Studies;Funding;Future;Hematology;Hemorrhage;high resolution imaging;Hospitals;Image;improved;Injury;Institutional Review Boards;Length of Stay;Lesion;Lifelong disability;Long-Term Care;Magnetic Resonance Imaging;Manuscripts;Meningeal;Meninges;mild traumatic brain injury;Names;National Institute of Neurological Disorders and Stroke;Natural History;neuroimaging;Neurosciences;Outcome;Outcome Measure;outcome prediction;Pathogenesis;Pathology;patient population;Patients;Persons;Physiological;Positron-Emission Tomography;Prevalence;Productivity;programs;Prospective Studies;Protocols documentation;Publishing;Quality of life;Radiology Specialty;Recording of previous events;recruit;Regenerative Medicine;Science;screening;Services;severe injury;Severities;Stroke;Study Subject;Subdural space;TBI Patients;therapy development;Trauma;Traumatic Brain Injury;United States;United States National Institutes of Health;Universities;vascular injury;vasogenic edema;Water;Work;X-Ray Computed Tomography,"Eval, Pathogenesis, Outcome of Subjects with or Suspected Traumatic Brain Injury",3120,NA,NA,NA,NA,15,NA,NA,1143237,NA
11194810,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003123,NA,NA,1ZIANS003123-14,NINDS:2797478\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,10789423 (contact),"YOULE, RICHARD JAMES (contact)",NA,NA,NA,Age;aged;Alleles;Animal Model;Autophagocytosis;Autophagosome;autosome;Biological;Cells;Cellular biology;cohort;Collaborations;cytokine;Cytosol;Defect;DNA;dopaminergic neuron;Drosophila melanogaster;Excision;fly;gene product;Genetic Screening;German population;Golgi Apparatus;Idiopathic Parkinson Disease;Immune signaling;Immunity;Impairment;in vivo;Inflammation;Inflammatory;innate immune function;Interferon Type I;Knock-out;Link;Locomotion;loss of function;Mammalian Cell;man;Mediating;Membrane;Mitochondria;Mitochondrial DNA;mitochondrial DNA mutation;Modeling;Molecular;Morphology;Motor;Mus;Muscle;mutant;Mutate;Mutation;Natural Immunity;Neurodegenerative Disorders;Neurons;neuroprotection;NF-kappa B;novel;Parkin;Parkinson Disease;Pathology;Pathway interactions;Patients;Penetrance;Persons;Phenotype;Phosphotransferases;PINK1 gene;Posture;prevent;Quality Control;recruit;response;restraint;RNA interference screen;Role;sensor;Signal Transduction;small molecule libraries;Testing;ubiquitin-protein ligase;whole genome;Wing;Work,Role of mitochondria in neurodegenerative diseases,3123,NA,NA,NA,NA,14,NA,NA,2797478,NA
11194811,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003127,NA,NA,1ZIANS003127-14,NINDS:1177601\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,10789423 (contact),"YOULE, RICHARD JAMES (contact)",NA,NA,NA,Adopted;Affinity;Autophagocytosis;Autophagosome;Bacteria;Biological;Brain;C-terminal;Cell Survival;Cells;Claw;Collaborations;Complex;Cryoelectron Microscopy;cytotoxic;Development;dimer;Ectopic Expression;Encapsulated;Eukaryotic Cell;extracellular;flexibility;Generations;Homeostasis;in vivo;Induced pluripotent stem cell derived human neuron;Investigation;Knockout Mice;Letters;Ligands;Link;Lipofuscin;Lysosomes;Maintenance;Maps;Mediating;Membrane;misfolded protein;Mitochondria;mitochondrial autophagy;Molecular;Molecular Weight;Mus;Mutation;N-terminal;Natural Immunity;Nerve Degeneration;Neurodegenerative Disorders;neuronal survival;Nutrient;Nutrient availability;Organelles;Parkin;Parkinson Disease;Pathway interactions;Pharmaceutical Preparations;Phosphotransferases;PINK1 gene;premature;protein aggregation;Proteins;proteotoxicity;Quality Control;receptor;recruit;scaffold;screening;Shapes;single molecule;Starvation;Stress;TBK1 gene;Therapeutic;Toxic effect;Ubiquitination,Mechanisms of Autophagy,3127,NA,NA,NA,NA,14,NA,NA,1177601,NA
11194812,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003130,NA,NA,1ZIANS003130-14,NINDS:6412094\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,11132761 (contact),"NATH, AVINDRA  (contact)",NA,NA,NA,Amyloid beta-Protein;Anti-Retroviral Agents;antiretroviral therapy;Antisense Oligonucleotides;antiviral drug development;Astrocytes;Autopsy;Biological Assay;Blocking Antibodies;Brain;brain tissue;Cell Differentiation process;Cell Line;Cells;Cerebrospinal Fluid;Chromosomes;Chronic;Chronic Fatigue Syndrome;Clinical Protocols;Clinical Trials;Complex;COVID-19;COVID-19 complications;Dengue Infection;Disease;efficacy testing;Encephalitis;Endogenous Retroviruses;env Gene Products;Functional disorder;Gene Activation;Goals;high throughput screening;HIV;HIV Infections;HIV tat Protein;immune activation;immune modulating agents;Immune system;Immunohistochemistry;Impaired cognition;In Vitro;in vivo Model;Individual;inducible gene expression;Infection;Laboratories;Life;Lymphocyte;Maps;MRI Scans;Neurodegenerative Disorders;Neuroimmune;neuroinflammation;Neurologic;Neuronal Injury;Neurons;Neuropathogenesis;neuropathology;neurotoxic;neurotoxicity;new therapeutic target;pathogen;Pathway interactions;Patients;Pharmaceutical Preparations;pharmacologic;placebo controlled study;Play;prevent;Process;Production;protein aggregation;Proteins;Protocols documentation;Retroviridae;Role;Site;small molecule;Syndrome;Therapeutic;therapeutic development;Tissues;trafficking;transmission process;Treatment Protocols;Viral;Viral Proteins;Viral reservoir;Virus;Virus Activation;Virus Diseases;Virus Latency,Neuropathogenesis of Retroviral Infections,3130,NA,NA,NA,NA,14,NA,NA,6412094,NA
11194813,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003132,NA,NA,1ZIANS003132-13,NINDS:251990\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,14285237 (contact),"CHITTIBOINA, PRASHANT  (contact)",NA,NA,NA,22q;Affect;Attention;autosome;Benign;bilateral vestibular Schwannoma;biomarker identification;Central Nervous System;Central Nervous System Neoplasms;Cephalic;Code;cohort;Counseling;Cranial Nerves;Cross-Sectional Studies;Data;deafness;Deglutition;Development;Disease;Disease Progression;Ependymoma;Excision;Exons;Fascicle;Functional disorder;Future;Genes;Genomics;Genotype;Germ Lines;Germ-Line Mutation;Glioma;Goals;Growth;Hearing;hearing impairment;Image;improved;Infratentorial Neoplasms;insertion/deletion mutation;Intervention;Karnofsky Performance Status;Knowledge;Location;longitudinal analysis;Longterm Follow-up;Magnetic Resonance Imaging;Measurement;Measures;Medical;meningioma;Methods;Monitor;Morbidity - disease rate;Mutation;Natural History;Nature;Neoplasms;neoplastic cell;Nerve;nerve injury;Nervous System;Neurilemmoma;neuro-oncology;Neurofibromatosis 2;Neurofibromin 2;Neurologic Deficit;Neuropathy;Numbness;Operative Surgical Procedures;Paralysed;Patient Self-Report;Patients;Pattern;Penetrance;Performance;Perilymph;Peripheral Nerve Schwannoma;Peripheral Nerves;Peripheral Nervous System;Peripheral Nervous System Diseases;Peripheral Nervous System Neoplasms;Pharmacotherapy;Phenotype;Population;prevent hearing loss;prospective;Proteins;Protocols documentation;Radiation therapy;Reporting;research clinical testing;Resolution;Risk;RNA Splicing;Severities;Severity of illness;Site;Speech;Spinal nerve structure;Structure;Symptoms;Syndrome;Therapeutic;Time;tool;Treatment outcome;trend;tumor;Tumor Biology;Tumor Burden;tumor growth;Tumor Suppressor Genes;Uncertainty;validation studies;Variant;Vestibular Nerve,Neurooncology of Benign Central and Peripheral Nervous System Tumors,3132,NA,NA,NA,NA,13,NA,NA,251990,NA
11194814,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003135,NA,NA,1ZIANS003135-13,NINDS:2787911\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,6980037 (contact),"KHALIQ, ZAYD M (contact)",NA,NA,NA,association cortex;Auditory;Auditory area;Axon;Basal Ganglia;Behavior;Behavioral;Biochemical Markers;Brain;Calcium;Calcium Signaling;Categories;Cell Nucleus;Chemosensitization;cholinergic;conditioning;Corpus striatum structure;Cues;Dendrites;Diazepam;Dopamine;dopamine system;dopaminergic neuron;Exhibits;experimental study;Future;GABA-A Receptor;Goals;Heterogeneity;Interneurons;Laser Scanning Microscopy;Learning;Ligands;Light;Measures;Memory;Midbrain structure;Motivation;motor disorder;motor learning;neuronal cell body;Neurons;neurophysiology;neuropsychiatric disorder;Nicotinic Receptors;optogenetics;Parkinson Disease;pars compacta;patch clamp;Pathway interactions;Pattern;Phase;Physiology;Picrotoxin;Play;Presynaptic Terminals;Property;receptor;recruit;Retrieval;Rewards;Role;Shapes;Signal Transduction;Slice;sound;Structure of subthalamic nucleus;Study Section;Substantia nigra structure;Synapses;Tail;Techniques;Testing;Tetanus Toxin;Tissues;Transgenic Animals;two-photon;Work,Synaptic integration and intrinsic firing properties of basal ganglia neurons,3135,NA,NA,NA,NA,13,NA,NA,2787911,NA
11194815,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003136,NA,NA,1ZIANS003136-13,NINDS:2932310\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9861017 (contact),"LU, WEI  (contact)",NA,NA,NA,Alcohols;Alzheimer&apos;s Disease;Amygdaloid structure;Analgesics;Animal Behavior;Animals;Anxiety;autism spectrum disorder;Behavioral;Binding;Binding Proteins;Biochemical;Brain;Canada;Cell Adhesion Molecules;Cell Nucleus;Cells;Chemosensitization;China;Chronic stress;Cognition;Collaborations;college;Complex;Data Reporting;Defect;Development;Diazepam;Disease;Electrophysiology (science);Epilepsy;frontier;Functional disorder;GABA-A Receptor;General Anesthesia;General anesthetic drugs;Genetic;gephyrin;Goals;Health;Hong Kong;Human;hypnotic;in vivo;Inhibitory Synapse;insight;Integral Membrane Protein;interest;Journals;London;Manuscripts;Mediating;Mental Depression;Mental disorders;Molecular;Mus;Mutation;National Institute of Neurological Disorders and Stroke;Nervous System Disorder;neural;neural circuit;neuroligin 2;neuromechanism;neuronal circuitry;Neurons;Neurosciences;neurotransmission;novel;Pathogenesis;Pathway interactions;pharmacologic;Population;Psychopharmacology;Publications;Publishing;Regulation;Reporting;Research;Research Project Grants;Role;Science;Signal Pathway;Social Behavior;Spinal cord injury;stem cells;Stress;Synapses;Synaptic plasticity;Synaptic Transmission;synaptogenesis;Technology;trafficking;transmission process;United States National Institutes of Health;Universities;Work,The regulation of synaptic transmission and neural circuit function,3136,NA,NA,NA,NA,13,NA,NA,2932310,NA
11194816,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003137,NA,NA,1ZIANS003137-12,NINDS:2209035\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,12000968 (contact),"YUAN, QUAN  (contact)",NA,NA,NA,aging brain;Animals;Area;Behavioral;behavioral plasticity;Binding Proteins;Biological Process;Brain;Candidate Disease Gene;Cell model;Cells;chemical genetics;Cholinergic Receptors;cholinergic synapse;circadian;Dendrites;Development;Drosophila acetylcholine receptor alpha-subunit;Drosophila genome;Drosophila genus;Ensure;Environment;Exhibits;experience;functional plasticity;Genetic;genetic approach;Genetic study;Goals;Homeostasis;Image;imaging approach;imaging study;in vivo;in vivo evaluation;Insecta;interest;Investigation;Label;Lateral;Learning;Ligand Binding;Lipid Binding;lipid transport;Lipids;Modeling;Molecular;Monitor;Morphogenesis;multiple omics;Nervous System;neural network;Neuroglia;neuronal excitability;Neuronal Plasticity;Neurons;Neuropeptides;neuroregulation;novel;Organism;Output;Oxidation-Reduction;Pathologic;Pathway interactions;Photoreceptors;Physiological;Pigments;postsynaptic;Process;Property;Proteins;Receptor Signaling;Regulation;Research;Resolution;response;Role;Sensory;Synapses;Therapeutic;trafficking;transcriptome;Translating;Visual,Experience-dependent regulation of dendrite morphogenesis and plasticity,3137,NA,NA,NA,NA,12,NA,NA,2209035,NA
11194817,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003139,NA,NA,1ZIANS003139-11,NINDS:1446233\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,12450666 (contact),"FORREST, LUCY  (contact)",NA,NA,NA,3-Dimensional;Address;Affect;Architecture;ATP Hydrolysis;Back;Behavior;Betaine;Binding;Binding Sites;Biochemical;Biophysics;Carrier Proteins;Cell membrane;Cellular Membrane;Chemistry;Collaborations;computer studies;Coupled;Data;design;Diabetes Mellitus;Drug Interactions;Energy-Generating Resources;Environment;Event;experimental study;Exposure to;flexibility;Human Genome;Integral Membrane Protein;Ions;laboratory experiment;Light;Lipid Bilayers;Lipids;Location;Measurement;Membrane;Membrane Proteins;Membrane Transport Proteins;Mental Depression;Mitochondria;Molecular;Molecular Conformation;molecular dynamics;Movement;Movement Disorders;natural flow;Neurons;Neurotransmitters;novel therapeutics;Nutrient;Organism;Pathway interactions;Pattern;Pharmacological Treatment;Physiological;Play;Process;Protein Conformation;protein protein interaction;Proteins;Publishing;pyruvate carrier;Regulation;response;Role;serotonin transporter;Shapes;Side;Site;small molecule;Specificity;Structure;symporter;Techniques;Transmembrane Transport;Work,Computational studies of membrane transport proteins,3139,NA,NA,NA,NA,11,NA,NA,1446233,NA
11194818,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003140,NA,NA,1ZIANS003140-11,NINDS:2272322\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416896 (contact),"ROCHE, KATHERINE  (contact)",NA,NA,NA,Amino Acids;autism spectrum disorder;Axon;axon guidance;Binding;Binding Proteins;Biochemistry;Biological;Biology;Brain;Brain-Derived Neurotrophic Factor;candidate identification;CDK5 gene;Cell Adhesion Molecules;Chemosensitization;Collaborations;Compensation;Cues;Cyclic AMP-Dependent Protein Kinases;Data;de novo mutation;Defect;density;Development;Disease;DNA Sequence Alteration;Electrophysiology (science);Embryo;Equilibrium;Etiology;Excitatory Synapse;experimental study;Extracellular Domain;Female;Functional disorder;Gene Family;Genes;Genetic Engineering;Genetic Predisposition to Disease;Growth;Growth Cones;high throughput screening;Human;human induced pluripotent stem cells;Image;in utero;Inhibitory Synapse;insight;Intellectual functioning disability;interest;Investigation;Link;Maintenance;male;Mediating;Mediator;Missense Mutation;Mitogens;Molecular;mouse model;Mutation;National Center for Advancing Translational Sciences;Neurodevelopmental Disorder;neuron development;Neuronal Differentiation;Neurons;NRCAM gene;Pathogenicity;Patients;Phenocopy;Phosphorylation;Phosphorylation Site;Phosphotransferases;Physiological;Point Mutation;Post-Translational Protein Processing;postsynaptic;Postsynaptic Membrane;presynaptic;Protein Family;Protein Isoforms;Protein Kinase C;protein protein interaction;Proteins;Publishing;rare variant;Regulation;Reporting;Research Personnel;response;Rodent;Role;Semaphorin-3A;sex;Sex Bias;Signal Transduction;small molecule;Specific qualifier value;Specificity;stable cell line;Surface;Synapses;Synaptic Cleft;Synaptic Transmission;synaptogenesis;trafficking;Variant;Vertebral column;Work;X Chromosome;Y Chromosome,Regulation of Neuroligins and Effects on Synapse Number and Function,3140,NA,NA,NA,NA,11,NA,NA,2272322,NA
11194819,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003143,NA,NA,1ZIANS003143-11,NINDS:779181\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,12450666 (contact),"FORREST, LUCY  (contact)",NA,NA,NA,3-Dimensional;Address;Amino Acid Sequence;Automation;Bioinformatics;biophysical techniques;Cell membrane;Cells;Cellular Membrane;Computing Methodologies;Data;data integration;Data Set;data visualization;database structure;Databases;Deuterium;Development;Electron Spin Resonance Spectroscopy;Elements;Encyclopedias;Evolution;fascinate;FDA approved;Future;genetic makeup;Goals;Human;Hydrogen;Hydrophobicity;improved;Individual;insight;interest;Knowledge;machine learning method;Membrane;Membrane Proteins;Methodology;Methods;Molecular;Molecular Conformation;molecular modeling;movie;National Institute of Neurological Disorders and Stroke;Nature;Organism;Outcome;Pattern;Pharmaceutical Preparations;Positioning Attribute;Procedures;Protein Conformation;protein function;protein structure;protein structure prediction;Proteins;public database;Publishing;Recording of previous events;Resources;Shapes;simulation;Standardization;structural biology;Structure;Techniques;Technology;Update;user-friendly;Water;web server;Work,Development and assessment of methods for membrane protein structure prediction,3143,NA,NA,NA,NA,11,NA,NA,779181,NA
11194820,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003144,NA,NA,1ZIANS003144-11,NINDS:3956644\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,12450670 (contact),"ZAGHLOUL, KAREEM  (contact)",NA,NA,NA,Anterior;Area;Attention;Brain;Categories;Cells;Clinical;clinical center;Cognition;Cognitive;cognitive function;cognitive task;combinatorial;Communication;control theory;Data;design;Diamond;Electric Stimulation;Electrodes;Electroencephalography;Epilepsy;Episodic memory;Etiology;Event;Exhibits;experience;Foundations;Functional Magnetic Resonance Imaging;Goals;Human;Image;Implanted Electrodes;Individual;information processing;insight;Interruption;Intractable Epilepsy;Knowledge;Learning;Manuscripts;member;Memory;memory encoding;memory retrieval;Methods;Modeling;Monitor;Nature;neural;neuromechanism;Neurons;neurophysiology;Neurosciences;neurosurgery;Neurosurgical Procedures;neurotransmission;Non-linear Models;Operative Surgical Procedures;Participant;patient engagement;Patients;Pattern;Periodicals;Physiologic pulse;Physiological;Play;Population;predicting response;Preparation;Process;Publications;Publishing;recruit;Research;response;Role;Seizures;Semantics;Shapes;Site;Stereotyping;Stimulus;Structure;success;Techniques;Temporal Lobe;temporal measurement;Time;tool;Travel;Work,Investigating the neural mechanisms of human cognitive function through intracranial recordings,3144,NA,NA,NA,NA,11,NA,NA,3956644,NA
11194821,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003150,NA,NA,1ZIANS003150-10,NINDS:1462124\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,14285237 (contact),"CHITTIBOINA, PRASHANT  (contact)",NA,NA,NA,adenoma;Anterior Pituitary Gland;Benign;Cell Cycle;Cell Physiology;Clinical;comparative;Controlled Environment;Corticotropin;Detection;Diagnosis;Disease;disease model;DNA Sequence Alteration;effective therapy;Epigenetic Process;epigenomics;Excision;Functional disorder;Gene Expression Profiling;Genes;Genetic;Genetic Transcription;Genomics;Goals;Hormone secretion;Human;Image;improved;improved outcome;In Vitro;induced pluripotent stem cell;Lead;life span;Light;Magnetic Resonance Imaging;Medical;Metabolic;metabolic imaging;Methylation;Modeling;Molecular;Morbidity - disease rate;Mutation;new therapeutic target;novel;Operative Surgical Procedures;Pathway interactions;Patient-Focused Outcomes;Patients;personalized medicine;Physiology;Pituitary Gland;Pituitary Gland Adenoma;Pituitary Neoplasms;Pituitary-dependent Cushing&apos;s disease;PMAIP1 gene;preservation;Research;Somatic Mutation;stem cell model;Technology;treatment choice;Treatment Failure;treatment strategy;tumor;tumorigenesis;USP8 gene,Improved Diagnosis and Treatment of Cushing's Disease,3150,NA,NA,NA,NA,10,NA,NA,1462124,NA
11194822,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003153,NA,NA,1ZIANS003153-09,NINDS:2538776\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,14763841 (contact),"LEVINE, ARIEL  (contact)",NA,NA,NA,Adult;Area;Atlases;Behavior;Behavioral;Brain;brain pathway;brain tract;Cell Physiology;Cell Size;cell type;Cells;Central Nervous System;Cues;Cytoskeleton;Development;Disease;dorsal horn;Feedback;Foundations;Genes;Genetic;Genetic Predisposition to Disease;Goals;Human;improved;Knowledge;Link;Mediating;Motor;motor behavior;motor control;motor learning;Motor Neurons;mouse genetics;Movement;Mus;neural;Neurons;Pathway interactions;Patients;Population;Posterior Horn Cells;programs;Recovery;recruit;Regulation;Sensorimotor functions;Sensory;single cell sequencing;single nucleus RNA-sequencing;Spinal;Spinal Cord;Spinal cord injury;Spinal cord posterior horn;Stroke;tool;Viral;Work,Mechanisms of Motor Control in the Spinal Cord,3153,NA,NA,NA,NA,9,NA,NA,2538776,NA
11194823,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003157,NA,NA,1ZIANS003157-09,NINDS:1451554\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,11132761 (contact),"NATH, AVINDRA  (contact)",NA,NA,NA,18 year old;2019-nCoV;adjudication;Admission activity;Age;aged;Area;Back;Bioenergetics;Biological;Brain;Brain region;Catechols;Cerebrospinal Fluid;Chronic;Chronic Fatigue Syndrome;Clinical;clinical center;Clinical Trials;Cognitive;Communication;Communities;COVID-19 patient;Cross-Sectional Studies;design;Diagnosis;Disabling;Electrophysiology (science);Enrollment;Evaluation;Exercise;Exercise Test;Exertion;experience;Fatigue;Female;Focus Groups;Functional disorder;Functional Magnetic Resonance Imaging;Gene Expression Profile;Generations;Guidelines;healthy volunteer;Hour;Immune;immune function;Immune system;immunomodulatory therapies;inclusion criteria;Infection;Inflammatory;Inpatients;Internet;Lyme Disease;Malaise;Measurement;Measures;meetings;Memory B-Lymphocyte;Metabolic;Metabolic Pathway;microbiome;mild cognitive impairment;Muscle;Nature;Neurocognition;neuroimaging;neurologic sequelae of COVID-19;Outcome Measure;Participant;participant enrollment;Pathway interactions;Patients;Pattern;Peripheral Blood Mononuclear Cell;Persons;Phenotype;physical conditioning;Physicians;post SARS-CoV-2 infection;Post-Acute Sequelae of SARS-CoV-2 Infection;preference;Procedures;Process;Protocols documentation;Publishing;Questionnaires;Recording of previous events;Reporting;Research;Sampling;screening;sex;Signal Transduction;Specimen;Stress;study population;Surveys;Symptoms;Syndrome;Techniques;Telephone Interviews;Time;Transcranial magnetic stimulation;United States National Institutes of Health;Viral;Visit;volunteer,Post-Viral Syndromes,3157,NA,NA,NA,NA,9,NA,NA,1451554,NA
11194824,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003158,NA,NA,1ZIANS003158-08,NINDS:11501\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,15213442 (contact),"STRATTON, PAMELA  (contact)",NA,NA,NA,Affect;Anatomy;angiogenesis;Anxiety;Biopsy;Blood;Central Nervous System;chronic depression;chronic pain;chronic painful condition;chronic pelvic pain;Chronic stress;Classification;Clinical Trials;Cohort Studies;comorbidity;Corticotropin;Corticotropin-Releasing Hormone;Data;disability;Disease;endometriosis;Endometrium;Enrollment;Estrogens;Evaluation;experience;Functional disorder;Future;Genetic;Goals;Growth Factor;Headache;Health;healthy volunteer;Hydrocortisone;hypothalamic-pituitary-adrenal axis;Immune;Investigation;Lesion;Location;Measures;Mental Depression;Methods;Michigan;Migraine;Nerve;neural;Neurosecretory Systems;Operative Surgical Procedures;Pain;Pain Threshold;Patients;Pelvic Pain;placebo controlled trial;Placebos;Predictive Factor;prospective;Quality of life;Race;racial diversity;Raloxifene;Randomized;Recording of previous events;response;Selective Estrogen Receptor Modulators;Severities;Specimen;Stratification;Symptoms;Syndrome;Testing;Tissues;Update;Urine;Woman;Women&apos;s cohort;Women&apos;s study;women&apos;s treatment,Neural Immune and Genetic Influences on Chronic Pelvic Pain and Endometriosis,3158,NA,NA,NA,NA,8,NA,NA,11501,NA
11194825,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003159,NA,NA,1ZIANS003159-08,NINDS:16101\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,15213442 (contact),"STRATTON, PAMELA  (contact)",NA,NA,NA,allostatic load;Analgesics;analog;Anxiety;botulinum neurotoxin injection;Botulinum Toxins;Caring;Case Study;central sensitization;chronic pain;chronic pelvic pain;clinical care;Clinical Trials;cohort;Complex;Data;Data Analyses;disability;Disease;Dystonia;effective therapy;Effectiveness;effectiveness evaluation;Elements;Eligibility Determination;endometriosis;Equipment and supply inventories;Esophageal achalasia;Etiology;experience;Fatigue;Functional disorder;Headache;Health Surveys;healthy volunteer;Hemifacial Spasm;Human;improved;Injections;Interstitial Cystitis;Irritable Bowel Syndrome;Measurement;Measures;Medical;Mental Depression;microbial;Muscle;Muscle Contraction;Myofascial Pain Syndromes;Nociception;Operative Surgical Procedures;Pain;Pathway interactions;patient response;Patients;Pelvic Floor Muscle;Pelvic floor structure;Pelvic Pain;Pelvis;Persistent pain;placebo controlled study;Placebos;primary outcome;Publishing;Quality of life;Questionnaires;Randomized;Recording of previous events;Rome;secondary outcome;Sleep;Sodium Chloride;Source;Spasm;spasticity;Standardization;Time;Toxin;treatment response;Visual;Water;Woman,The effectiveness of Botulinum toxin on persistent pelvic pain in women with endometriosis,3159,NA,NA,NA,NA,8,NA,NA,16101,NA
11194826,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003163,NA,NA,1ZIANS003163-08,NINDS:1499875\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,10687628 (contact),"ROLL-MECAK, ANTONINA  (contact)",NA,NA,NA,Affect;axon regeneration;beta Tubulin;Biochemical;Brain;C-terminal;Cell division;cell type;Cells;Code;combinatorial;Complex;Coupled;Cryoelectron Microscopy;Development;Disease;early onset;enzyme mechanism;Enzymes;Family;Feedback;Fluorescence;Glutamates;Goals;Human;Human Engineering;inhibitor;Intracellular Transport;Kinetics;Lead;Length;Link;Malignant Neoplasms;Maps;Mass Spectrum Analysis;Methods;Microtubule Polymerization;Microtubule-Associated Proteins;Microtubules;Modification;Molecular Conformation;Morphogenesis;Motor;Mutation;Nerve Degeneration;neuropathology;Pattern;polyglycine;Positioning Attribute;Post-Translational Protein Processing;Process;Protein Isoforms;Recombinants;Regulation;Resolution;Retinal Diseases;single molecule;Site;Structure;Substrate Specificity;Tail;Techniques;three dimensional structure;Tubulin;Work;Writing;X-Ray Crystallography,Mechanism of tubulin modification enzymes,3163,NA,NA,NA,NA,8,NA,NA,1499875,NA
11194827,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003164,NA,NA,1ZIANS003164-08,NINDS:1387147\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,10687628 (contact),"ROLL-MECAK, ANTONINA  (contact)",NA,NA,NA,Address;Affect;Antibodies;axon regeneration;Biochemical;biophysical properties;Biophysics;Cell division;Cells;Cellular biology;Chemicals;Code;Coupled;Development;Engineering;Enzymes;Exhibits;Future;Genetic;Genetic Variation;Glycine;Goals;Growth;Hereditary Spastic Paraplegia;Human;Human Engineering;In Vitro;Intracellular Transport;Isotopes;katanin;Laboratories;Malignant Neoplasms;Methods;Microtubule Polymerization;Microtubule-Associated Proteins;Microtubules;Modification;Molecular Motors;Morphogenesis;Neurodegenerative Disorders;Neurons;neuropathology;novel;Pattern;Post-Translational Protein Processing;Property;Protein Isoforms;Proteins;Proteome;Proteomics;Proxy;Recombinants;reconstitution;recruit;response;Role;Signal Transduction;spastin;structural biology;Structure;Techniques;Time;Tubulin;Work,Readout of the tubulin code by cellular effectors,3164,NA,NA,NA,NA,8,NA,NA,1387147,NA
11194828,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003165,NA,NA,1ZIANS003165-08,NINDS:634929\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,10687628 (contact),"ROLL-MECAK, ANTONINA  (contact)",NA,NA,NA,Affect;alpha Tubulin;Architecture;ATP Hydrolysis;ATP phosphohydrolase;beta Tubulin;Biogenesis;Biological Process;Cells;Centrioles;Chromosome Segregation;Cilia;Code;combinatorial;Complex;Coupled;Crosslinker;Cryoelectron Microscopy;Cytoskeleton;dimer;Disease;Distal;Elements;Enzymes;Etiology;Excision;Exhibits;fluorescence imaging;functional outcomes;Genes;Hereditary Spastic Paraplegia;Human body;in vivo;insight;katanin;Mechanics;Microcephaly;Microtubules;Modification;Morphology;Mutate;Mutation;Neurodegenerative Disorders;Neurodevelopmental Disorder;Neurons;Pathway interactions;Phase;Phototropism;Polymerase;Post-Translational Protein Processing;protein function;protein structure;Proteins;Reaction;Regulation;response;Signal Transduction;single molecule;spastin;Structure;synergism;Tail;Tubulin;Work,Mechanism of microtubule severing enzymes,3165,NA,NA,NA,NA,8,NA,NA,634929,NA
11194829,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003168,NA,NA,1ZIANS003168-07,NIMH:1542947\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,15721249 (contact),"GORDON, JOSHUA  (contact)",NA,NA,NA,22q11.2;Adult;Affect;age related;Animals;Area;avoidance behavior;Behavior;Behavioral;Brain;Brain region;Cells;Chemosensitization;Cognition;Cognition Disorders;Cognitive deficits;cognitive function;cognitive process;Collaborations;Communication;Computer Models;confocal imaging;Cortical Synchronization;Data;data analysis pipeline;design;Disease;Distal;Dorsal;Electrodes;Electrophysiology (science);entorhinal cortex;Excitatory Synapse;Female;Fiber;Fostering;Frequencies;Functional disorder;Genetic Predisposition to Disease;Genotype;glycogen synthase kinase 3 beta;Goals;Heterozygote;Hippocampus;Human;Impaired cognition;Impairment;implantation;improved;in vivo;inhibitor;Interneurons;Lasers;learned behavior;Life;Light;Link;male;Medial;Mental disorders;Methods;microdeletion;Modeling;Molecular Target;Monitor;mouse model;Mus;Mutation;National Institute of Drug Abuse;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;neural;neural circuit;neurodevelopment;neuronal circuitry;Neurons;neurophysiology;Neurosciences;novel;null mutation;Optics;optogenetics;Output;Pathogenesis;Pathway interactions;Pattern;Performance;Periodicals;Phase;Phenotype;Photometry;Physiological;Population;Prefrontal Cortex;Process;Property;Protein Isoforms;Publishing;recruit;Reporting;Research;Resolution;response;Reuniens Thalamic Nucleus;Role;Route;Sampling;Schizophrenia;schizophrenia risk;sex;Shapes;Short-Term Memory;Signal Transduction;Somatostatin;stem;Structure;Synapses;Synaptic Transmission;Syndrome;Task Performances;Techniques;Testing;Thalamic structure;theories;Time;Tissues;tool;transcriptome sequencing;transcriptomics;Transgenic Organisms;Wild Type Mouse;Work,Probing the neural circuit basis of normal and disease-relevant cognitive function in mice,3168,NA,NA,NA,NA,7,NA,NA,1542947,NA
11194830,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003170,NA,NA,1ZIANS003170-06,NINDS:145123\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416918 (contact),"KORETSKY, ALAN  (contact)",NA,NA,NA,2019-nCoV;Acceleration;Binding;Biological Assay;Blood - brain barrier anatomy;Blood capillaries;blood-brain barrier crossing;Brain;Brain Diseases;brain magnetic resonance imaging;contrast imaging;Contrast Media;Copper;cost;COVID-19 therapeutics;design;Detection;detection method;Development;Diagnosis;Diagnostic;dimer;Dose;drug discovery;Family;Funding;Goals;Health Sciences;Hour;Human;Human Resources;Image;imaging agent;improved;In Vitro;in vivo;Individual;Injections;Intramural Research Program;Intravenous;intravenous injection;Investigation;iron oxide nanoparticle;Joints;Kinetics;Laboratories;Lead;Magnetic Resonance Imaging;mathematical model;Methods;Modeling;Molecular;molecular modeling;molecular pathology;Mus;Mutant Strains Mice;nanobodies;National Institute of Neurological Disorders and Stroke;Nervous System Disorder;Neurologic;Neurosciences;novel therapeutics;Pathologic;Patients;Pharmacodynamics;Pharmacologic Substance;Positioning Attribute;Positron;Positron-Emission Tomography;Radiation exposure;Radiology Specialty;receptor;receptor binding;Regenerative Medicine;Reporting;Research Personnel;Research Project Grants;Resolution;response;Running;Signal Transduction;Site;Supervision;Testing;TFRC gene;therapeutic candidate;transcytosis;Transgenic Mice;United States National Institutes of Health;University Health Services;Visualization;Work,Development of Brain MRI Contrast Agents,3170,NA,NA,NA,NA,6,NA,NA,145123,NA
11194831,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003171,NA,NA,1ZIANS003171-06,NINDS:794325\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,2276433 (contact),"HOLMGREN, MIGUEL  (contact)",NA,NA,NA,Axon;axoplasm;Cell Nucleus;Cells;Chemistry;Complex;Dendrites;Development;Diameter;Elements;Exhibits;fluorophore;Fucose;glycosylation;Goals;Homologous Gene;Human;In Vitro;Incubated;Injections;Libraries;Lipids;Maintenance;Membrane;Membrane Proteins;membrane synthesis;Messenger RNA;meter;Molecular;Neurons;next generation sequencing;Organelles;Process;Protein Biosynthesis;Protein Glycosylation;Proteins;Ribosomal RNA;RNA;RNA analysis;Sampling;seal;Signal Recognition Particle;Squid;squid axon;sugar;Synaptic plasticity;System;Translating;Translations;Work,Membrane Protein synthesis in axons,3171,NA,NA,NA,NA,6,NA,NA,794325,NA
11194832,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009415,NA,NA,1ZIANS009415-05,NINDS:2320690\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,77858127 (contact),"GU, YI  (contact)",NA,NA,NA,Alzheimer&apos;s Disease;Alzheimer&apos;s disease patient;Anatomy;Animals;Auditory;Behavioral;Brain;Calcium;cell type;Cells;Characteristics;Cognition;Collaborations;cortex mapping;Cues;educational atmosphere;entorhinal cortex;Environment;Exhibits;FOS gene;Foundations;Functional disorder;Future;Goals;Hippocampus;Image;imaging approach;Impairment;improved;insight;Laboratories;Learning;Link;Maintenance;Mammals;Manuscripts;Maps;Measurement;Medial;Memory impairment;Modality;Molecular;molecular dynamics;mouse model;multimodality;multisensory;Mus;National Institute of Mental Health;Nervous System Disorder;neural;neuromechanism;novel;Optics;optogenetics;Phase;preference;Process;Publishing;Recurrence;Research;Research Project Grants;Resolution;response;Retrieval;Sensory;Shapes;Solid;spatial memory;Synaptic plasticity;Tauopathies;Technology;Testing;Theoretical model;Time;tool;two-photon;Veronica;virtual;virtual environment;virtual reality;virtual reality environment;Visual;visual information;Visuospatial;way finding,Neural mechanism of spatial navigation and memory,9415,NA,NA,NA,NA,5,NA,NA,2320690,NA
11194833,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009416,NA,NA,1ZIANS009416-05,NINDS:1918876\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,77865681 (contact),"ROLE, LORNA  (contact)",NA,NA,NA,Accounting;Acetylcholine;Address;Adult;Algorithms;Amygdaloid structure;Anterior;approach behavior;Aversive Stimulus;avoidance behavior;Axon;basal forebrain;Basal Nucleus of Meynert;Behavior;Behavioral;behavioral response;Bioinformatics;Biological Assay;Birth Order;Brain;cholinergic;cholinergic neuron;Code;Cognitive;cognitive function;Collaborations;Complex;Cues;Dependence;Desire for food;Development;Electrophysiology (science);Enrollment;entorhinal cortex;ERG gene;Extinction;forgetting;Genetic;Globus Pallidus;Goals;Heterogeneity;Hippocampus;Hour;Image;Immediate-Early Genes;Immunologics;in vivo;Label;Laboratories;Lateral;Learning;Limb structure;Location;Maps;Medial;member;Memory;memory encoding;memory retention;memory retrieval;Methods;Morphology;motivated behavior;National Institute of Neurological Disorders and Stroke;neural;Neurons;Neurosciences;Odors;optogenetics;performance tests;Phase;Physiology;Population;postsynaptic;Prefrontal Cortex;presynaptic;prevent;Property;Prosencephalon;Publications;recruit;Reporting;Research;response;Rest;Role;sensor;Shapes;Shock;Signal Transduction;Site;Source;Stimulus;Substantia Innominata;Synapses;System;Training;Viral Vector;Weight;Work,Acetylcholine in learning and memory,9416,NA,NA,NA,NA,5,NA,NA,1918876,NA
11194834,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009417,NA,NA,1ZIANS009417-05,NINDS:1724894\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,77863909 (contact),"JACKSON, SADHANA  (contact)",NA,NA,NA,Adult;Agonist;Animal Model;Blood - brain barrier anatomy;blood-brain barrier permeabilization;Brain;Brain region;brain tissue;Cells;chemotherapeutic agent;Child;Clinic;Clinical Research;Communication;contrast enhanced;Contrast Media;Endothelium;experimental study;G-Protein-Coupled Receptors;Glioma;Goals;Growth;hematopoietic stem cell self-renewal;Image;In Vitro;Invaded;Investigation;Investigational Therapies;Laboratories;Malignant Glioma;Malignant neoplasm of brain;Measures;Mediator;Microdialysis;novel;Pathway interactions;Penetration;Perfusion;Permeability;Pharmaceutical Preparations;pharmacologic;Proliferating;Proto-Oncogene Proteins c-akt;Research;Signal Pathway;standard measure;Study models;Tight Junctions;Time;treatment response;tumor;tumor microenvironment;Tumor Tissue,Modulating BBB Permeability in Malignant Glioma,9417,NA,NA,NA,NA,5,NA,NA,1724894,NA
11194835,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009418,NA,NA,1ZIANS009418-05,NINDS:5037\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,77844869 (contact),"NDUOM, EDJAH  (contact)",NA,NA,NA,Address;Adult;Affinity;Aftercare;American;Animals;anti-PD-L1 antibodies;anti-tumor immune response;Attitude;Biological Markers;Biological Models;Biology;biomarker development;Biopsy;Brain;Brain Neoplasms;Cell Line;Cells;Central Nervous System Neoplasms;Cerebrum;Clinical;clinical investigation;Clinical Research;Congresses;cytokine;Data;Data Collection;design;diffuse midline glioma;Enrollment;Evaluation;Future;Genetic Transcription;Glioblastoma;Glioma;Goals;Immune;immune checkpoint blockade;Immune checkpoint inhibitor;immune modulating agents;Immune response;Immunocompetent;Immunologic Monitoring;immunoregulation;Immunosuppression;Immunotherapeutic agent;Immunotherapy;Implant;insight;International;Investigation;Investments;Joints;Journals;Knowledge;Learning;Lesion;Luciferases;Malignant Neoplasms;Manuscripts;meetings;member;meningioma;Microdialysis;Modeling;mouse model;Mus;Myeloid Cells;Natural Killer Cells;neuro-oncology;Neurologic;Neurology;Neurosurgeon;neurosurgery;novel strategies;Operative Surgical Procedures;Patients;Pattern;Protocols documentation;Publishing;rare cancer;Reaction;Reporting;Sampling;Societies;Source;Surgeon;Surveys;Technology;Therapy trial;Time;Translational Research;tumor;tumor immunology;tumor microenvironment;tumor-immune system interactions;Untranslated RNA;Variant;Work,Clinical and Translational Investigations of Immune Suppression and Immune Modulation in Glioblastoma,9418,NA,NA,NA,NA,5,NA,NA,5037,NA
11194836,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009420,NA,NA,1ZIANS009420-05,NINDS:1279408\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,77869878 (contact),"SHEIKHBAHAEI, SHAHRIAR  (contact)",NA,NA,NA,Adult;Affect;Animal Behavior;Animal Vocalization;Animals;Area;Attention deficit hyperactivity disorder;autism spectrum disorder;Behavior;Behavioral;Biological;Brain;brain iron;Breathing;Cells;Central Nervous System;Communication;Complex;Data;Defect;Development;Developmental Stuttering;Disease;disorder control;Economics;Electrophysiology (science);Ethnic Origin;experimental study;Functional disorder;gene discovery;Generations;Genes;Genetic;Goals;Hereditary Disease;Histology;Homeostasis;Human;Image;Impairment;improved;In Vitro;in vivo Model;Investigation;Iron Chelation;Link;Maps;motor behavior;motor control;motor disorder;mouse model;Movement;Muscle;mutant;Mutate;Nervous System;neural;neural correlate;Neurodegenerative Disorders;Neurodevelopmental Disorder;Neuroglia;Neurologic;Neurons;neurotransmission;novel;novel therapeutics;Oligodendroglia;operation;Optical Methods;Parkinson Disease;Pathway interactions;Persons;Play;Population;preclinical study;Process;Production;programs;Property;Race;Reporting;Research;Rodent;skills;Sleep;Speech;Stuttering;Subgroup;Synapses;System;Techniques;Therapeutic Agents;tool;Transgenic Animals;Viral Vector;vocal control;vocalization;white matter,Neural correlates for cortical and subcortical control of vocalization,9420,NA,NA,NA,NA,5,NA,NA,1279408,NA
11194837,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009422,NA,NA,1ZIANS009422-05,NINDS:1757864\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,77865681 (contact),"ROLE, LORNA  (contact)",NA,NA,NA,Address;Affect;Age;Age Months;age related;age related changes;age related deterioration;Age-associated memory impairment;aged;Aging;aging process;Alzheimer&apos;s Disease;animal old age;Animals;Anterior;Area;Axon;basal forebrain;basal forebrain cholinergic neurons;Behavior;Behavioral Assay;Binding;biocytin;Biological Assay;Body Regions;Callithrix;Cell Nucleus;Cells;Cessation of life;cholinergic;cholinergic neuron;Cognition;Cognitive;Cognitive deficits;cognitive performance;cognitive task;Collaborations;comparative;Comparative Study;Complex;Cues;Dementia;density;Electrophysiology (science);Emotional;Enhancers;entorhinal cortex;Event;experience;Face;Fright;Frontotemporal Dementia;Functional disorder;Gene Expression;Gene Modified;Genes;Genetic;Goals;Health;Hippocampus;Human;Impaired cognition;Impairment;in vivo;Individual;juvenile animal;Knowledge;Label;Lateral;learned behavior;Learning;life span;Link;Literature;loved ones;Macaca;Memory;Memory Loss;memory recall;Methods;Microglia;Microtus;mild cognitive impairment;Mitochondria;mitochondrial dysfunction;Modeling;Molecular;Monkeys;Morphology;mouse model;Mus;Mutant Strains Mice;Nerve Degeneration;nerve supply;Neurodegenerative Disorders;Neurons;Neurosciences;normal aging;novel;object recognition;old mice;Parkinson Disease;Participant;Pathologic;pathological aging;Pathology;Pattern;Performance;Population;Positron-Emission Tomography;Predisposition;presynaptic;Presynaptic Terminals;Process;programs;Protocols documentation;reconstruction;Recycling;Research;Research Personnel;resilience;Rodent;Role;sex;Signal Transduction;single nucleus RNA-sequencing;Site;Social Interaction;Sorting;Stains;Subgroup;System;tau-1;Temporal Lobe;Testing;Time;Tissues;transcriptomics;ultra high resolution;Vesicle;Virus;Work;young adult,The cholinergic system during normal and pathological aging,9422,NA,NA,NA,NA,5,NA,NA,1757864,NA
11194838,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009423,NA,NA,1ZIANS009423-05,NINDS:1819009\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,77863911 (contact),"NGAI, JOHN  (contact)",NA,NA,NA,Ablation;Acute;Adult;adult neurogenesis;Afferent Neurons;Area;ATAC-seq;Axon;Basal Cell;beta catenin;Candidate Disease Gene;candidate identification;candidate validation;Cell Culture Techniques;Cell Differentiation process;Cell Proliferation;Cell Survival;Cells;Chromatin;Chromium;conditional knockout;Data;data analysis pipeline;Dependovirus;Development;Devices;Environment;Epidermal Growth Factor Receptor;Epigenetic Process;Epithelium;epithelium regeneration;Expression Library;fluorescence activated cell sorter device;Fluorescent in Situ Hybridization;gain of function;Gene Expression;gene regulatory network;Generations;Genes;Genetic;genetic analysis;Genetic Transcription;genetically modified cells;Gland;Goals;Heterogeneity;high throughput analysis;Hour;In Vitro;in vitro Model;in vivo;Individual;injured;Injury;interest;Knock-out;Learning;Libraries;Life;loss of function;Maintenance;Manuscripts;Metaplasia;migration;Modeling;Molecular;Molecular Neurobiology;mouse model;multiple omics;Multipotent Stem Cells;Mus;Natural regeneration;Nerve Regeneration;nerve stem cell;Nervous System;neural;Neurons;neuroregulation;Olfactory Epithelial Cell;Olfactory Epithelium;olfactory neurogenesis;Olfactory Pathways;Olfactory Receptor Neurons;overexpression;Pathway interactions;Plasmids;Population;postnatal;Preparation;Printing;progenitor;programs;Proliferating;Property;reconstitution;Regenerative capacity;Reporter;RNA;Role;Sensory;sensory mechanism;Signal Pathway;Signal Transduction;single cell sequencing;single nucleus RNA-sequencing;Specific qualifier value;Statistical Data Interpretation;stem cell function;stem cell proliferation;stem cells;sustentacular cell;Synapses;Testing;Tissues;transcription factor;transcriptome sequencing;Transfection;United States National Institutes of Health;Veins;virtual;WNT Signaling Pathway,Elucidating the molecular mechanisms of sensory regeneration,9423,NA,NA,NA,NA,5,NA,NA,1819009,NA
11194839,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009424,NA,NA,1ZIANS009424-04,NINDS:2073197\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,77863918 (contact),"TALMAGE, DAVID  (contact)",NA,NA,NA,Acetylcholine;Acute;adult neurogenesis;Affect;age related;Age-associated memory impairment;Alzheimer&apos;s Disease;Animals;ATAC-seq;Attention;Axon;axon growth;basal forebrain;Behavior;behavior influence;Behavioral;Biological Process;Birth;Brain;Brain region;Cell Nucleus;Cells;Central Nervous System;Cessation of life;cholinergic;cholinergic neuron;Chromatin;Code;Collaborations;Complex;Cytoplasmic Granules;Data;Data Set;Dendrites;dentate gyrus;Development;differential expression;Diffuse;Essential Genes;Event;experimental study;Family;flexibility;follow-up;Functional disorder;Gene Dosage;Gene Expression;gene network;Generations;Genes;Genetic;Genetic Markers;Genetic Transcription;Globus Pallidus;Glutamates;granule cell;Growth;Heterogeneity;Heterozygote;Hippocampus;Homozygote;Human;imaging study;Impaired cognition;In Vitro;in vivo;Individual;Informatics;insight;interest;Intervention;Investigation;Journals;Learning;loss of function mutation;Maintenance;Maps;Membrane;Memory;Mental disorders;Minor;Mitochondria;Modeling;Molecular;multiple omics;Mus;mutant;Mutation;Negative Valence;Nervous System;nervous system development;neural circuit;Neuregulin 1;Neurodegenerative Disorders;neurogenesis;Neurons;neuropsychiatric disorder;Neurosciences;neurotransmission;Nicotine;NRG1 gene;Nuclear;Odors;Parkinson Disease;Phenotype;Physiological;Polycomb;Population;Positioning Attribute;Post-Traumatic Stress Disorders;postnatal;Preparation;presynaptic;Prosencephalon;Protein Biosynthesis;Protein Isoforms;Regulation;Reporting;Repressor Proteins;Research;resilience;response;Retrieval;Role;scaffold;Schizophrenia;Series;Signal Transduction;Signaling Protein;single nucleus RNA-sequencing;Site;Structure;Synapses;synaptic function;Synaptic plasticity;synaptogenesis;synergism;System;targeted treatment;Testing;Time;Tissues;trafficking;transcriptome;transcriptome sequencing;transcriptomics;Transmembrane Domain;Wild Type Mouse;young adult,Molecular signaling during development and maturation of the nervous system,9424,NA,NA,NA,NA,4,NA,NA,2073197,NA
11194840,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009426,NA,NA,1ZIANS009426-04,NINDS:1784614\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78357868 (contact),"CORTESE, IRENE  (contact)",NA,NA,NA,Address;Affect;Autopsy;biomarker validation;Brain;Cells;Cerebrospinal Fluid;checkpoint inhibition;Clinical;cohort;Collaborations;Collection;Core Facility;Coupled;cytokine;Data;Depressed mood;Disease;disorder control;Enrollment;experience;Functional disorder;Goals;healthy volunteer;Histologic;Homeostasis;IL7 gene;Image;Immune;immune reconstitution;Immune response;Immune system;Immunologics;Immunology;Immunosuppression;Immunotherapeutic agent;in vitro Assay;Infection;Integration Host Factors;Intervention;Intervention Studies;JC Virus;Life;Magnetic Resonance Imaging;Mediating;Molecular;National Institute of Neurological Disorders and Stroke;Natural History;Nature;Organ;Outcome;Outcome Measure;Participant;participant enrollment;patient population;Patients;Peripheral Blood Mononuclear Cell;pharmacologic;Plasma;Predisposition;Progressive Multifocal Leukoencephalopathy;Radiology Specialty;Recombinants;reconstitution;Recovery;Reporting;Risk;risk minimization;Schedule;Serum;Standardization;systemic autoimmune disease;T-Lymphocyte;Testing;Time;Tissue Banks;translational study;Translations;treatment response;treatment strategy;Viral;Virus Diseases;virus host interaction,Translational Studies in Progressive Multifocal Leukoencephalopathy,9426,NA,NA,NA,NA,4,NA,NA,1784614,NA
11194841,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009431,NA,NA,1ZIANS009431-04,NINDS:1931524\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78357870 (contact),"INATI, SARA  (contact)",NA,NA,NA,Address;Anterior;Area;arterial spin labeling;blood perfusion;Brain;brain abnormalities;Cerebrovascular Circulation;Child;Clinical;Clinical assessments;cohort;Collaborations;Core Facility;Cortical Dysplasia;Data;Detection;Diffusion Magnetic Resonance Imaging;Distant;Drug resistance;effective therapy;Electrodes;Electroencephalography;Epilepsy;epileptiform;Evaluation;Excision;Family;Functional disorder;Functional Magnetic Resonance Imaging;Goals;healthy volunteer;Hippocampus;Hour;hypoperfusion;Image;image processing;imaging biomarker;imaging modality;imaging study;improved;indexing;individual patient;Intervention;invention;Ipsilateral;Knowledge;Language;Lateral;Magnetic Resonance Imaging;Magnetoencephalography;Manuscripts;Masks;Measures;Medial;medial temporal lobe;Medical center;Memory;Methods;Modeling;Morbidity - disease rate;mortality;National Institute of Neurological Disorders and Stroke;Neocortex;neuroimaging;neurophysiology;Neuropsychological Tests;Neuropsychology;non-invasive imaging;novel;novel marker;Operative Surgical Procedures;Outcome;Paper;Parahippocampal Gyrus;Partial Epilepsies;Patients;Pattern;Perfusion;posters;Postoperative Period;Preparation;productivity loss;prospective;psychosocial;Publishing;Research;Rest;Sampling;Sclerosis;Seizures;social stigma;Source;source localization;Structural defect;Structure;Surface;Temporal Lobe;Temporal Lobe Epilepsy;temporal measurement;Time;Tissues;tool;Travel;white matter;Work,Investigating Epileptic and Functional Networks in Patients with Drug Resistant Focal Epilepsy,9431,NA,NA,NA,NA,4,NA,NA,1931524,NA
11194842,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009433,NA,NA,1ZIANS009433-03,NINDS:1913214\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78333917 (contact),"BROWN, DESMOND  (contact)",NA,NA,NA,Apical;Bioinformatics;Biological Assay;Cell Cycle;Cell Line;cell motility;Cell Proliferation;Cells;Characteristics;chemoradiation;Cilia;cilium biogenesis;clinically relevant;Development;Disease;Excision;extracellular vesicles;Gene Expression;Genes;Glioblastoma;Glioma;Goals;Human;Immunosuppression;Immunotherapy;Impairment;Interleukin-6;knock-down;Malignant neoplasm of brain;Malignant Neoplasms;Mammalian Cell;Mediating;Microtubules;Molecular;Morphology;Myeloid-derived suppressor cells;neurosurgery;Newly Diagnosed;novel;novel therapeutics;Oncology;Organelles;particle;Pathogenesis;Pathway interactions;Patients;Play;Prognostic Marker;Proliferating;Proteins;public database;Radiation therapy;Regulation;Resistance;response;Role;Signal Pathway;Signal Transduction;stable cell line;standard of care;Surface;temozolomide;tumor;Tumor-Derived;Update;Work;wound healing,Neurosurgical Oncology Unit,9433,NA,NA,NA,NA,3,NA,NA,1913214,NA
11194843,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009434,NA,NA,1ZIANS009434-03,NINDS:2284620\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78873744 (contact),"WAGNER, MARK  (contact)",NA,NA,NA,Algorithms;Anatomy;Architecture;Attention;Auditory;autism spectrum disorder;Behavior;Behavioral;Biological;Brain;Cerebellum;Chronic;Cognitive;comorbidity;Computer Models;Custom;Data;design;Disparate;doctoral student;Dopamine;Elements;Engineering;Evolution;fiber cell;flexibility;Future;Goals;granule cell;Human;Image;imaging approach;Industry;Language;Learning;Link;Mammals;Microscope;Motor;motor behavior;Neocortex;neocortical;Neurons;next generation;operation;optogenetics;Physics;Physiology;Postbaccalaureate;Postdoctoral Fellow;Process;programs;Publications;Publishing;recruit;Recurrence;Research;Research Personnel;reward anticipation;reward processing;Rewards;Role;Schizophrenia;Short-Term Memory;Signal Transduction;Site;social;Speed;Structure;Students;Testing;Time;Tissue imaging;two-photon;United States National Institutes of Health;Visit;Work,Neocortex-cerebellum Circuitry Unit,9434,NA,NA,NA,NA,3,NA,NA,2284620,NA
11194844,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009435,NA,NA,1ZIANS009435-03,NINDS:1914733\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78333869 (contact),"GOTTESMAN, REBECCA F (contact)",NA,NA,NA,Atherosclerosis Risk in Communities;Blood Vessels;blood-based biomarker;Brain;brain health;Brain hemorrhage;Brain Injuries;CADASIL;Cerebral small vessel disease;Cerebrovascular Disorders;Clinical Protocols;Cognition;Cognitive;cognitive change;cognitive performance;cohort;Collaborations;Complement;Dementia;Disease;Disparity;disparity reduction;epidemiology study;Etiology;Evaluation;experience;Extramural Activities;Funding;Future;General Population;Genes;Goals;Health;Hemorrhage;High Prevalence;Human;imaging biomarker;Impaired cognition;Individual;Infarction;Inherited;Intervention;Intramural Research Program;Ischemic Stroke;Life Cycle Stages;Measurement;Methods;Microvascular Dysfunction;middle age;modifiable risk;National Institute of Neurological Disorders and Stroke;Neuroepidemiology;neuroimaging;Outcome;Pathway interactions;Pattern;Population Study;post stroke;post stroke cognitive impairment;Prevention;Recovery;Recurrence;Risk;Risk Factors;Role;social health determinants;Stroke;United States National Institutes of Health;vascular cognitive impairment and dementia;Vascular Diseases;vascular risk factor,"Stroke, Cognition and Neuroepidemiology Section",9435,NA,NA,NA,NA,3,NA,NA,1914733,NA
11194845,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009437,NA,NA,1ZIANS009437-03,NINDS:756000\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,11132761 (contact),"NATH, AVINDRA  (contact)",NA,NA,NA,Address;Algorithms;Anti-Retroviral Agents;Autopsy;Bar Codes;Bioinformatics;Biological Assay;Brain;Cell Extracts;Cell Line;Cells;Consensus;Data;Data Analyses;design;Detection;Devices;digital;DNA;DNA Fragmentation;DNA Library;DNA Probes;DNA sequencing;Endogenous Retroviruses;Environment;Evolution;frontal lobe;genetic evolution;Genomic DNA;Genomics;Globus Pallidus;Goals;Hippocampus;HIV;HIV Genome;Human Genome;improved;Infection;integration site;Jurkat Cells;Length;Liver;lymph nodes;Lymphoid;Lymphoid Tissue;Methods;Molecular;nanopore;National NeuroAids Tissue Consortium;next generation sequencing;novel strategies;Patients;Penetration;Peripheral;Persons;Pharmaceutical Preparations;Process;protein expression;Protocols documentation;Proviruses;RNA;Running;Sampling;sequencing platform;single molecule;Site;Spleen;Techniques;Thalamic structure;therapy design;Tissues;transcriptomics;Tube;Variant;Viral;Viral Genes;Viral Proteins;Viral reservoir;Virus Integration,Characterization of HIV Reservoirs in the Brain,9437,NA,NA,NA,NA,3,NA,NA,756000,NA
11194846,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009447,NA,NA,1ZIANS009447-03,NINDS:181734\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,10687628 (contact),"ROLL-MECAK, ANTONINA  (contact)",NA,NA,NA,alpha Tubulin;Antibodies;Award;beta Tubulin;cell type;cellular imaging;Chemicals;Code;Communication;Coupled;Environment;Human;Image;imaging modality;improved;Induced pluripotent stem cell derived human neuron;Life;Maps;Mechanics;Methods;Microscope;Microscopy;Microtubule-Associated Proteins;Microtubules;Modification;Molecular;molecular imaging;Motor;nanoscale;National Institute of Biomedical Imaging and Bioengineering;National Institute of Neurological Disorders and Stroke;Neurons;Polymers;Post-Translational Protein Processing;Process;Protocols documentation;Reader;recruit;Resolution;Sampling;single molecule;Tubulin,4D map of the tubulin code in the human neuron,9447,NA,NA,NA,NA,3,NA,NA,181734,NA
11194847,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009448,NA,NA,1ZIANS009448-03,NINDS:300000\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416904 (contact),"JACOBSON, STEVEN  (contact)",NA,NA,NA,Address;Antibodies;Antigens;B-Cell Antigen Receptor;B-Lymphocytes;Blood;Brain;CD8-Positive T-Lymphocytes;Cells;Cerebrospinal Fluid;Chromium;Clinical;Clonal Expansion;Clonality;Clone Cells;cohort;complementarity-determining region 3;Complementary DNA;Coupled;deep sequencing;Detection;Disease;Disease Progression;Dissection;DNA;Evaluation;Evolution;exhaustion;Frequencies;Gene Expression Profiling;Genomics;HIV;HIV Infections;HIV-associated neurocognitive disorder;Human T-lymphotropic virus 1;Immune;Immune response;Immunologic Memory;Individual;Infiltration;inflammatory milieu;Laboratories;lymphoid organ;Macrophage;Meninges;neuroAIDS;neuroinflammation;Neurologic;Open Reading Frames;Pathogenesis;Pathogenicity;Patients;Peripheral Blood Mononuclear Cell;Persons;Post-Acute Sequelae of SARS-CoV-2 Infection;Process;Reporting;response;Sequence Analysis;single cell sequencing;single-cell RNA sequencing;T-Cell Immunologic Specificity;T-Cell Receptor;T-cell receptor repertoire;T-Lymphocyte;Technology;Time;tool;treatment response;United States National Institutes of Health;Viral;Viral reservoir;Virus,Single Cell RNA Sequencing of Blood and CSF of Patients with NeuroAIDS,9448,NA,NA,NA,NA,3,NA,NA,300000,NA
11194848,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009449,NA,NA,1ZIANS009449-02,NINDS:222279\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78346056 (contact),"KWAN, JUSTIN  (contact)",NA,NA,NA,Address;Age;Age of Onset;Alzheimer&apos;s Disease;Alzheimer&apos;s disease related dementia;American;Biological;brain magnetic resonance imaging;C9ORF72;Clinic;Clinical;Clinical Data;clinical diagnosis;Clinical Trials;cognitive testing;Collection;Communities;Data Collection;data sharing;Development;Disease;DNA-Binding Proteins;effective therapy;Enrollment;Evaluation;Familial disease;Family;follow-up;Fostering;frontotemporal degeneration;Frontotemporal Dementia;Frontotemporal Lobar Degenerations;Genes;Goals;improved;Individual;Infrastructure;Inherited;Institutional Review Boards;MAPT gene;meetings;Molecular Weight;Mutation;Neurodegenerative Disorders;Neurologist;Participant;participant enrollment;Patients;PGRN gene;Physicians;Procedures;programs;protein aggregation;Protocols documentation;Questionnaires;Recommendation;Recording of previous events;recruit;Research;Research Personnel;Research Project Grants;Sampling;Scanning;Schedule;Scientist;Series;Site;Study Subject;Syndrome;tau Proteins;Testing;United States National Institutes of Health,ALLFTD: ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration,9449,NA,NA,NA,NA,2,NA,NA,222279,NA
11194849,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009453,NA,NA,1ZIANS009453-01,NINDS:130000\OD:130000\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78357868 (contact),"CORTESE, IRENE  (contact)",NA,NA,NA,Address;Algorithms;Alleles;biobank;blood product;cell bank;Cell Line;Cells;Characteristics;cohort;Databases;Development;effective therapy;Ensure;healthy volunteer;Immune;In Vitro;Life Expectancy;manufacture;Methods;Natural History;Outcome;Participant;Patients;Pilot Projects;Progressive Multifocal Leukoencephalopathy;Research;Source;T-Lymphocyte;Time;treatment strategy;United States National Institutes of Health;Viral Physiology;Virus;Work,Establishing a JCV specific T cell bank for progressive multifocal leukoencephalopathy,9453,NA,NA,NA,NA,1,NA,NA,260000,NA
11194850,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009454,NA,NA,1ZIANS009454-01,NINDS:300000\OD:300000\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,79988445 (contact),"STEINER, JOSEPH  (contact)",NA,NA,NA,Amino Acids;antagonist;antiretroviral therapy;Biodistribution;Biological Assay;Biological Products;brain tissue;Calcium;CCL2 gene;CCL3 gene;Cell Nucleus;Cells;Cerebrospinal Fluid;Detection;Development;Drug Kinetics;Genetic Transcription;glial activation;Goals;HIV;HIV Infections;HIV Long Terminal Repeat;innovation;Interleukin-6;Lead;Long Terminal Repeats;N-Methyl-D-Aspartate Receptors;neurotoxic;Oxidative Stress;Patients;Peripheral Blood Mononuclear Cell;Pharmacodynamics;Production;Promoter Regions;Property;Proteins;Role;T-Lymphocyte;tat Protein;Tissue Sample;TNF gene;Trans-Activators;Transactivation;Transcript;Transcription Coactivator;Transcriptional Activation;United States National Institutes of Health;Viral Load result;Virus;Virus Diseases;Virus Replication,Development of Tat antagonists to achieve a functional cure for HIV infection,9454,NA,NA,NA,NA,1,NA,NA,600000,NA
11194851,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009456,NA,NA,1ZIANS009456-01,NINDS:1838208\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,79988447 (contact),"MUGHAL, AMREEN  (contact)",NA,NA,NA,3-Dimensional;Animals;Arteries;arteriole;Attention;Blood;Blood capillaries;Blood Vessels;Brain;Brain Diseases;brain parenchyma;Breeding;Cells;cerebral blood volume;cerebral hemodynamics;cerebral vein;Cerebrovascular Circulation;Communication;Complex;Consumption;Data Set;density;Diamond;Electron Microscope;Electrophysiology (science);Endothelial Cells;Endothelium;Equipment;Excision;experimental study;Functional Magnetic Resonance Imaging;Genotype;Goals;Homeostasis;Human;Impairment;in vivo;instrumentation;Investments;Ion Channel;Lasers;learning progression;Light;material transfer agreement;Measurement;member;Metabolic;Microscope;Microvascular Dysfunction;Modeling;Molecular Target;mouse model;multiphoton microscopy;Mus;Myography;Neuroglia;Neurons;neurovascular coupling;neurovascular unit;Nutrient;operation;patch clamp;Pathologic;Pathway interactions;Penetration;Permeability;Pial Veins;Postbaccalaureate;Postdoctoral Fellow;pressure;prevent;Process;programs;Protocols documentation;Regulation;Research;Resistance;Rest;Stroke;Subarachnoid Hemorrhage;summer student;Therapeutic Intervention;Time;ultrasound;Universities;Vascular blood supply;vascular cognitive impairment and dementia;Vascular Dementia;Venous;venule;Vermont;Visual Cortex;wasting;Work,Neurovascular Coupling and Brain Homeostasis,9456,NA,NA,NA,NA,1,NA,NA,1838208,NA
11194852,ZIC,DE,1,N,NA,NA,NA,NA,ZICDE000751,NA,NA,1ZICDE000751-06,NIDCR:711241\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,16135734 (contact),"WANG, YAN  (contact)",NA,NA,NA,bioinformatics tool;Chromatography;Collaborations;Complex;Consultations;data acquisition;Data Analyses;Mass Spectrum Analysis;method development;Molecular Weight;National Institute of Dental and Craniofacial Research;Phosphorylation;Post-Translational Protein Processing;Preparation;protein profiling;Proteins;Proteomics;Research Personnel;Sampling;Services;Technology;Ubiquitination,Mass Spectrometry Facility,751,NA,NA,NA,NA,6,NA,NA,711241,NA
11194853,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002884,NA,NA,1ZICMH002884-18,NIMH:6280022\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,9416723 (contact),"BANDETTINI, PETER  (contact)",NA,NA,NA,Acoustic Stimulation;Address;Administrator;American College of Radiology;Anisotropy;Archives;Area;Auditory system;Book Chapters;Boston;Brain;Budgets;Characteristics;Chronology;clinical center;Collaborations;Communities;Computer software;Core Facility;Data;data acquisition;Data Storage and Retrieval;Dedications;Deposition;Development;Devices;Disasters;education resources;Electroencephalography;Electronics;Elements;Encyclopedias;Environment;Equipment;Event;Excision;experience;Experimental Designs;experimental study;Floor;Friends;Functional disorder;Functional Magnetic Resonance Imaging;functional magnetic resonance imaging/electroencephalography;Galvanic Skin Response;Goals;Group Meetings;Hearing;hemodynamics;high resolution imaging;Holly;Hour;Human;Human Experimentation;Hybrids;Image;Individual;Industry;Inflammation;Infrastructure;Institutional Review Boards;instrumentation;Interest Group;International;Intramural Research Program;Investigational Therapies;Iron;Joystick;lectures;Linux;Location;Magnetic Resonance Imaging;Maintenance;Medical;medical specialties;Metabolic;Metadata;Methodology;Methods;millisecond;Modeling;Modernization;Morphologic artifacts;Motion;multimodal neuroimaging;Myelin;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;National Institute on Alcohol Abuse and Alcoholism;neural;neurofeedback;neuroimaging;Neurology;Neurons;Neurosciences;neurotransmission;Noise;novel;Nurse Practitioners;open source;Operating System;pandemic disease;Performance;Peripheral;petabyte;Phase;Physics;Physiologic pulse;Physiological Processes;Principal Investigator;prisma;procedure safety;Productivity;Protocols documentation;Publishing;quality assurance;radio frequency;Radiology Specialty;reconstruction;Research;Research Personnel;Research Support;Resolution;Resources;Role;Scanning;Schedule;Scientist;Series;Services;Site;skills;Somatosensory Cortex;spatiotemporal;Specialist;symposium;System;Techniques;Technology;Testing;Time;tool;Training;Transcranial magnetic stimulation;Translating;transmission process;ultra high resolution;United States National Institutes of Health;Update;Vendor;virtual;virtual machine;Visual Cortex;visual tracking;web site;white matter;Work,Functional MRI Core Facility,2884,NA,NA,NA,NA,18,NA,NA,6280022,NA
11194854,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002888,NA,NA,1ZICMH002888-18,NIMH:2347803\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,78867621 (contact),"TAYLOR, PAUL  (contact)",NA,NA,NA,Age;Agreement;alcohol exposure;algorithm development;Algorithms;analytical method;Anatomy;animal data;anxiety symptoms;Area;Arithmetic;Atlases;Autopsy;Basic Science;Blood;Brain;Brain imaging;Brain region;Breathing;Canis familiaris;Child;Collaborations;college;Complex;Computer software;Computer Systems;computerized data processing;Consult;Consultations;Coronavirus;Correlation Studies;Data;Data Analyses;data handling;data quality;Data Set;Deep Brain Stimulation;design;Development;Diffusion;Diffusion Magnetic Resonance Imaging;Disease;Dryness;Education;Educational process of instructing;Engineering;Experimental Designs;experimental study;Fetal Alcohol Exposure;Fetal Alcohol Spectrum Disorder;flexibility;Functional Magnetic Resonance Imaging;functional MRI scan;Future;genetic information;gigabyte;Goals;Head;Heart Rate;Heritability;Hour;Human Activities;human data;Image;image warping;imaging study;improved;Institution;interest;Korea;learning materials;Linux;Literature;magnetic field;Magnetic Resonance Imaging;Maps;Measures;medical schools;meetings;member;Mental Depression;Methodology;Methods;Mexico;Mission;Modeling;Morphologic artifacts;Motion;National Institute of Mental Health;neurofeedback;neuroimaging;Neurons;Noise;Online Systems;open source;Output;Panic;Paper;Participant;Pathway interactions;Patients;Pattern;Performance;Persons;Photography;Physiological;Process;programs;Psyche structure;Public Health;Publications;Publishing;Quality Control;Reading;reading ability;repetitive transcranial magnetic stimulation;Reporting;Research;Research Personnel;Research Project Grants;research study;responders and non-responders;response;Rest;Sampling;Scanning;scientific computing;Slide;social;Societies;software development;Software Tools;Source Code;South Carolina;Statistical Computing;Statistical Data Interpretation;Techniques;Technology;Text;Time;Time Series Analysis;tool;Training;trait;Twin Studies;United States National Institutes of Health;Update;Vision;Visualization;web site;white matter;Work,Scientific and Statistical Computing Core,2888,NA,NA,NA,NA,18,NA,NA,2347803,NA
11194855,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002889,NA,NA,1ZICMH002889-18,NIMH:2525966\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,15692394 (contact),"NUGENT, ALLISON  (contact)",NA,NA,NA,Acceleration;Address;Algorithms;analysis pipeline;analytical method;Area;Auditory;Bathing;Brain;Brain imaging;BRAIN initiative;Calibration;Canada;Clinical;Code;Cognitive;cognitive task;Collaborations;combat;Communities;Compensation;Complex;Computer software;computerized data processing;Consultations;Core Facility;cortex mapping;COVID-19 pandemic;Custom;Data;data acquisition;Data Analyses;Data Analytics;Data Collection;data harmonization;data repository;Data Science;Data Set;data sharing;data standards;Data Storage and Retrieval;data structure;Dedications;deep neural network;design;Development;Devices;Disease;Educational process of instructing;Educational workshop;Electrocorticogram;Electrodes;Elements;Ensure;Equipment;Equipment Malfunction;Experimental Designs;Extramural Activities;falls;Functional Magnetic Resonance Imaging;Funding;Future;Genomics;Genotype;Goals;Grant;hackathon;Head;Health;Helium;High Performance Computing;Hour;Human;human data;human subject;Image;improved;Individual;Industry;industry partner;instrumentation;International;Journals;Knowledge;Liquid substance;magnetic field;Magnetic Resonance Imaging;Magnetism;Magnetoencephalography;Manuscripts;Maps;Measurement;Measures;meetings;Meta-Analysis;Methods;Mission;Modeling;Morphologic artifacts;National Institute of Mental Health;Neural Network Simulation;neuroimaging;Neurons;neurophysiology;neuropsychiatric disorder;North America;novel;open source;Optics;Participant;Patients&apos; Rooms;Phenotype;pilot test;Positioning Attribute;posters;Preparation;Procedures;Process;programs;Protocols documentation;Pump;Pythons;reconstruction;recruit;Research;research and development;Research Personnel;Resolution;Resource Sharing;response;Response to stimulus physiology;Scalp structure;Scanning;Scientist;sensor;Signal Transduction;simulation;software development;somatosensory;Source;Stimulus;superconducting quantum interference device;Surface;Suspensions;symposium;System;Techniques;Temperature;Testing;Time;Training;Training and Education;United States National Institutes of Health;Universities;volunteer;Weight;Work;working group;Writing,NIMH MEG Core Facility,2889,NA,NA,NA,NA,18,NA,NA,2525966,NA
11194856,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002894,NA,NA,1ZICMH002894-18,NIMH:832128\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,9416741 (contact),"SHEN, JUN  (contact)",NA,NA,NA,Acceleration;Acetates;Adopted;Alzheimer&apos;s Disease;Area;Basic Science;beta-Hydroxybutyrate;Binding;Biochemical;Biopsy;Brain;Carbon;Cerebrum;Chemical Shift Imaging;Chemicals;Choline;Clinical;Clinical Research;Clinical Sciences;Collaborations;Computer software;computerized data processing;Core Facility;Coupling;Creatine;Data;data acquisition;Data Analyses;Detection;detection method;Development;Dimensions;Dipeptides;Disease;Ensure;enzyme activity;experimental study;frontal lobe;Functional Imaging;gamma-Aminobutyric Acid;Glucose;glutamatergic signaling;Glutamates;Glutamine;Glutathione;Goals;Hospitals;Human;Image;imaging modality;imaging study;Imaging Techniques;improved;Individual;interest;Intravenous infusion procedures;invention;ketogenic diet;Label;macromolecule;magnetic field;Magnetic Resonance Imaging;Magnetic Resonance Spectroscopy;Maintenance;Manufacturer;Maps;Measurement;Measures;Mental disorders;metabolic profile;Methods;Motion;Movement;N-acetylaspartate;N-acetylaspartylglutamate;National Institute of Neurological Disorders and Stroke;Nervous System Disorder;neurochemistry;Neurons;Neurotransmitters;Noise;novel;Occipital lobe;Oxidative Stress;Participant;Pathway interactions;phase change;Phosphorus;Play;Positioning Attribute;Protocols documentation;Protons;Regional Anatomy;Research;Research Design;Research Personnel;Residual state;Resistance;Resolution;Role;Schizophrenia;Signal Transduction;simulation;Slice;spectroscopic imaging;Stroke;stroke patient;structural imaging;suburb;Techniques;Technology;Testing;Time;Tissues;tool;United States National Institutes of Health;Variant;Water,Magnetic Resonance Spectroscopy Core Facility,2894,NA,NA,NA,NA,18,NA,NA,832128,NA
11194857,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002899,NA,NA,1ZICMH002899-18,NIMH:2564139\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,77874251 (contact),"LEOPOLD, DAVID A (contact)",NA,NA,NA,Adopted;anatomic imaging;Anatomy;Area;Atlases;awake;basal forebrain;Biological;Blood;Blood flow;Brain;brain electrical activity;Brain imaging;Categories;Clinical;Cognition;Cognitive;cognitive process;cognitive task;combinatorial;Communities;comparative;Complex;Conceptions;Contrast Media;Core Facility;Coupling;Data;Data Analyses;Data Files;data sharing;Data Storage and Retrieval;Dedications;design;Development;Devices;Diffusion;Diffusion Magnetic Resonance Imaging;diffusion weighted;Disease;Electrodes;Electrophysiology (science);Elements;Engineering;Environment;Evaluation;Experimental Designs;experimental study;Fiber;Functional Imaging;Functional Magnetic Resonance Imaging;functional MRI scan;Future;Goals;Haplorhini;Health;Human;Image;imaging facilities;imaging modality;Imaging Techniques;Implant;improved;Individual;Injections;interest;Investigation;Joints;Laboratories;Learning;Magnetic Resonance Imaging;Mammals;Maps;Measures;Medicine;member;Methods;Microelectrodes;Modernization;MRI Scans;multimodality;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;Nature;neural;Neuroanatomy;neurophysiology;Neurosciences;Neurosciences Research;neurotransmission;Noise;operation;Operative Surgical Procedures;Pathway interactions;Pattern;Perception;pharmacologic;Physics;Play;Positioning Attribute;Positron-Emission Tomography;Primates;Procedures;Process;Production;Prosimii;Protocols documentation;Publishing;radio frequency;Regulation;Research;Research Personnel;Research Project Grants;response;Rest;Role;Scanning;Scientist;sensory stimulus;Series;Services;Signal Transduction;Site;skills;Statistical Computing;structural imaging;Structure;Supervision;Technology;Testing;Thinking;Time;tractography;Training;United States National Institutes of Health;Visualization;white matter;Work;X-Ray Computed Tomography,Neurophysiology Imaging Facility Core:  Functional and Structural MRI,2899,NA,NA,NA,NA,18,NA,NA,2564139,NA
11194858,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002903,NA,NA,1ZICMH002903-18,NIMH:4200964\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,11999790 (contact),"MARENCO, STEFANO  (contact)",NA,NA,NA,17q21;Acetylation;Age;age acceleration;aging mechanism;Alternative Splicing;Alzheimer&apos;s Disease;Amygdaloid structure;Anatomy;Anterior;Anxiety Disorders;Applications Grants;Archives;Atlases;Attention Deficit Disorder;Attention deficit hyperactivity disorder;Audiotape;Authorization documentation;autism spectrum disorder;Autopsy;Behavior;Bioinformatics;biological sex;Bipolar Disorder;Blood - brain barrier anatomy;Blood specimen;Brain;brain dysfunction;Brain region;brain tissue;Cadaver;cDNA Library;Cell Nucleus;Cells;Cessation of life;ChIP-seq;Chromosomes;chronic pain;chronic painful condition;Chronic stress;cingulate cortex;Classification;Clinical;Code;Collection;Communities;Consent;COVID-19;Craniocerebral Trauma;Data;Data Set;database of Genotypes and Phenotypes;Databases;Depressive disorder;Development;Diagnosis;Diagnostic;Disease;DNA;DNA Methylation;DNA sequencing;Dorsal;Down&apos;s Syndrome;Dura Mater;Electronic Mail;entorhinal cortex;Equipment and supply inventories;Equity;Evaluation;Exposure to;Extramural Activities;Family;Fibroblasts;Formalin;Freezing;Frozen Sections;Functional disorder;Genetic;Genetic study;genome sequencing;genomic data;Genomics;Genotype;Goals;Hair;Haplotypes;health data;healthy aging;Hippocampus;Histologic;Histology;Human;human data;Human Genome;Human Resources;Immunization;Immunologics;improved;Individual;Inhibitory Synapse;insight;Institution;Insula of Reil;International Classification of Diseases;Interview;Intramural Research Program;Label;Letters;Link;Long COVID;Major Depressive Disorder;Major Mental Illness;Medical;Medical Examiners;Medical Records;Menopausal Status;Mental Depression;Mental disorders;Mental Health;metabolome;Metastatic malignant neoplasm to brain;Methylation;Mission;Mitochondria;Molecular;multiple omics;Mutation;National Institute of Mental Health;Nerve Degeneration;Nervous System Disorder;Neuroanatomy;Neurons;neuropathology;new technology;novel therapeutics;Obsessive-Compulsive Disorder;Ovary;Parkinsonian Disorders;Patients;Population;Post-Traumatic Stress Disorders;Prefrontal Cortex;Preparation;Prevention strategy;Process;Progressive Multifocal Leukoencephalopathy;Proteome;Proteomics;Psychiatric Diagnosis;Psychotic Disorders;public database;putamen;Recording of previous events;Reporting;reproductive;Research;Research Personnel;Research Support;Resources;Risk;RNA;Role;sample collection;Sampling;SARS-CoV-2 exposure;SARS-CoV-2 infection;Schizoaffective Disorders;Schizophrenia;Serology test;Services;single cell analysis;single nucleus RNA-sequencing;Slice;Slide;small cell lung carcinoma;social health determinants;somatosensory;Specimen;Structure of choroid plexus;Structure of middle temporal gyrus;Structure of trigeminal ganglion;Substance abuse problem;Substance Use Disorder;subventricular zone;suicidal behavior;Suicide;Superior sagittal sinus;Superior temporal gyrus;Swab;Synapses;Synaptic plasticity;tau Proteins;Technology;Testing;Thalamic structure;Thick;Time;Tissue imaging;Tissue Sample;Tissues;tool;transcriptome;transcriptome sequencing;transcriptomic profiling;transcriptomics;United States National Institutes of Health;Virginia;Virus;web site;whole genome;Woman,Procurement and Characterization of Postmortem Brain Tissue,2903,NA,NA,NA,NA,18,NA,NA,4200964,NA
11194859,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002911,NA,NA,1ZICMH002911-17,NIMH:3060024\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,10687787 (contact),"DOLD, GEORGE  (contact)",NA,NA,NA,3-Dimensional;3D Print;Acceleration;Affect;Animals;Area;Assessment tool;Association Learning;Attention;Auditory;Behavior;behavior test;Behavioral;behavioral study;Brain;Clinical;Cognitive;Collaborations;Complex;Computer software;Consult;Core Facility;Cues;Custom;data acquisition;Data Analyses;Data Collection;Decision Making;Dedications;design;design and construction;Development;Devices;Drosophila genus;Effectiveness;electric field;Electroconvulsive Therapy;Electrodes;Electroencephalography;Electronic Mail;Electronics;Electrophysiology (science);Engineering;Ensure;Environment;Equipment;experience;experimental study;fabrication;Fiber Optics;Food;Functional disorder;Functional Magnetic Resonance Imaging;Goals;graphical user interface;Head;Hour;Human;Image;improved;Individual;Industrialization;Insecta;insight;instrument;instrumentation;Investigational Therapies;Learning;Light;locust;Magnetic Resonance Imaging;manufacture;Mechanics;Memory;Metals;Microscope;Mission;Monkeys;Motivation;Motor;Mus;National Center for Complementary and Integrative Health;National Institute of Child Health and Human Development;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;neuromechanism;new technology;Noise;novel;Occupations;Optics;Output;Pattern;Perfusion;Positioning Attribute;Primates;Process;product development;Production;Productivity;prototype;Radiochemistry;Recommendation;Research;Research Personnel;Research Project Grants;Research Support;Resolution;response;Reverse engineering;Rewards;Rodent;Running;Scientist;sensor;Shelter facility;Side;side effect;software development;Speed;Stimulus;Structure;System;Techniques;Technology;Telephone;Testing;Time;Titanium;tool;treatment-resistant depression;two photon microscopy;United States National Institutes of Health;user friendly software;Visual Perception;voltage;Walking,NIMH Instrumentation Core Facility,2911,NA,NA,NA,NA,17,NA,NA,3060024,NA
11194860,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002952,NA,NA,1ZICMH002952-09,NIMH:433049\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,14761204 (contact),"CHUDASAMA, YOGITA  (contact)",NA,NA,NA,"3-Dimensional;Address;Animal Behavior;Animals;Attention;Behavior;Behavior Disorders;behavior test;Behavioral;Behavioral Model;Behavioral Research;behavioral response;behavioral study;Biological Psychiatry;Body part;Brain;Brain Diseases;Calcium;Calcium Signaling;Calibration;Code;Cognition;Cognitive;Cognitive deficits;cognitive function;Collaborations;Complex;computer code;Computer software;Computer Vision Systems;Controlled Environment;Core Facility;Cues;Custom;Darkness;Data;data analysis pipeline;Data Set;Decision Making;deep learning;deep learning model;Deposition;Depth Perception;design;Destinations;Development;Discrimination;Ecology;Education;Emerging Technologies;Emotional;emotional behavior;Emotions;Ensure;Environment;Equipment;Ethology;experimental study;Fiber;flexibility;Fluorescence;Fostering;Goals;Health;Human;Image;Implant;improved;indexing;Individual;Infrastructure;innovation;Interdisciplinary Study;Investigation;Journals;large datasets;Learning;Lighting;Link;Location;Logic;Machine Learning;Maintenance;Measures;Memory;Methods;millisecond;miniaturize;Molecular;Motor;Motor Activity;motor behavior;Movement;Mus;National Heart, Lung, and Blood Institute;National Human Genome Research Institute;National Institute of Allergy and Infectious Disease;National Institute of Biomedical Imaging and Bioengineering;National Institute of Child Health and Human Development;National Institute of Diabetes and Digestive and Kidney Diseases;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;National Institute on Deafness and Other Communication Disorders;Nature;neural;Neuroanatomy;neurochemistry;Neurodegenerative Disorders;Neurodevelopmental Disorder;Neurons;neuropsychiatric disorder;Neurosciences;Nose;open source;optogenetics;Output;Pathology;Pattern;Peer Review;Photometry;Physiological;Principal Investigator;Printing;Problem Solving;Psychiatry;Publishing;Rattus;Reaction;Reproducibility;Research;research facility;Research Personnel;Resources;response;Rodent;Rodent Model;Science;Scientist;Sensory;Series;Short-Term Memory;Sorting;Speed;Standardization;statistics;stereoscopic;System;Techniques;Testing;Time;touchscreen;Transistors;translational medicine;translational neuroscience;Translational Research;United States National Institutes of Health;usability;Validity and Reliability;virtual;Visual;Wisconsin;Writing",Rodent Behavioral Core: The Analysis of Behavior,2952,NA,NA,NA,NA,9,NA,NA,433049,NA
11194861,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002960,NA,NA,1ZICMH002960-08,NIMH:1356127\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,14475705 (contact),"THOMAS, ADAM G (contact)",NA,NA,NA,Acceleration;Adolescent;Affective Symptoms;Age;Aging;biobank;Books;Brain;Brain imaging;Brain Mapping;Child;Clinical;Clinical assessments;Clinical Data;Code;Cognition;cognitive development;Collaborations;Communication;Communities;Complex;connectome;Data;data curation;data dissemination;data management;data repository;Data Science;Data Set;data sharing;data standards;Data Storage and Retrieval;data submission;Deposition;design;Development;Ecological momentary assessment;efficacy evaluation;Ensure;Evaluation;falls;Foundations;Functional Magnetic Resonance Imaging;Genetic;Genome;Genomics;Goals;Guidelines;Human;improved;innovation;insight;Intramural Research Program;Lead;Link;Machine Learning;machine learning method;Magnetic Resonance Imaging;meetings;member;Mentors;Methods;Mind;MRI Scans;National Institute of Mental Health;Nature;Neurocognitive;neurogenomics;neuroimaging;Neurologic;Neurons;Neurosciences;open data;Paper;Participant;Phenotype;phenotypic data;Policies;Positioning Attribute;posters;Printing;programs;Protocols documentation;public repository;Publications;Publishing;Reproducibility;Research;Research Personnel;residence;Residencies;Sampling;Scanning;Science;Scientist;Seasons;Sex Differences;simulation;South Korea;Standardization;Structure;symposium;Time;tool;Training;training data;United States National Institutes of Health;Universities;Update;volunteer;web site;Work;working group,Data Science and Sharing Team,2960,NA,NA,NA,NA,8,NA,NA,1356127,NA
11194862,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002961,NA,NA,1ZICMH002961-08,NIMH:2058550\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,15226869 (contact),"THURM, AUDREY  (contact)",NA,NA,NA,active duty;Adaptive Behaviors;Address;Area;autism spectrum disorder;Behavior;Behavior assessment;behavioral phenotyping;Biological Markers;brain based;Characteristics;Child;Child of Impaired Parents;Childhood;Clinical;Clinical Research;clinical trial readiness;Clinical Trials;Cognitive;cognitive function;Collaborations;Communication;Consultations;Creatine;Data;Data Analyses;Data Collection;data exploration;Detection;Development;Developmental Delay Disorders;Developmental Disabilities;Diagnosis;Diagnostic;Discipline;Disease;drug development;Drug Evaluation;Electrophysiology (science);Enrollment;epidemiology study;Evaluation;experience;Extramural Activities;Family;Functional impairment;Gangliosidoses;gene therapy;Genetic Diseases;Genotype;Goals;Grain;Human;Impairment;improved;Individual;innovation;Intellectual functioning disability;interest;Intervention Studies;Intramural Research Program;Investigation;ketotic hyperglycinemia;Light;longitudinal course;Measurement;Measures;Medical;meetings;Mental disorders;Metabolic Diseases;Mission;Modality;Molecular Abnormality;multidisciplinary;National Institute of Mental Health;Natural History;Nature;neurodevelopment;Neurodevelopmental Disability;Neurodevelopmental Disorder;neuroimaging;novel;novel therapeutics;Ontology;Outcome;Outcome Measure;participant enrollment;Patients;Performance;Persons;Phenotype;Population;Population Study;predictive marker;Process;programs;Property;protocol development;Protocols documentation;Psyche structure;psychologic;Psychometrics;Rare Diseases;repository;Research;Research Personnel;research study;Resources;Risk;Sampling;Services;skill acquisition;skills;social;Social Functioning;standardize measure;Symptoms;Syndrome;System;Tablets;Terminology;Testing;Therapeutic Agents;therapeutic gene;Time;tool;Translational Research;Treatment outcome;treatment trial;United States National Institutes of Health;Update;Validation;Work,Neurodevelopmental and Behavioral Phenotyping,2961,NA,NA,NA,NA,8,NA,NA,2058550,NA
11194863,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002963,NA,NA,1ZICMH002963-08,NIMH:1847248\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,15228735 (contact),"USDIN, THEODORE  (contact)",NA,NA,NA,3-Dimensional;Algorithms;analysis pipeline;Anatomy;Antibodies;Area;Atlases;Brain;Brain imaging;Brain Mapping;Brain region;calcium indicator;Callithrix;Callithrix jacchus jacchus;Carbon Dioxide;cell type;Cells;Code;Collaborations;Computer software;confocal imaging;Confocal Microscopy;Corpus striatum structure;COVID-19 pandemic;cryostat;Custom;Data;Data Set;denoising;design;detector;Development;Dimensions;Dopamine Receptor;Dorsal;Dynorphins;Equilibrium;Equipment;Female;Gene Activation;Gene Expression;Gene Expression Profile;Genetic;Histologic;Image;Image Analysis;image processing;Immediate-Early Genes;In Situ Hybridization;Individual;innovation;insight;instrument;interest;Intramural Research Program;Investigation;kappa opioid receptors;Label;Laboratories;Laser Scanning Confocal Microscopy;Lasers;Light;light microscopy;Lighting;Macaca;Machine Learning;Maintenance;male;Messenger RNA;Methods;Microscope;microscopic imaging;Microscopy;Microtome - medical device;Mission;Molecular;Morphology;Motivation;multi-photon;Mus;National Institute of Mental Health;Nature;Neurons;Neurosciences;Nucleic Acid Probes;operation;Opsin;Optics;Ovariectomy;Pathway interactions;Pattern;Performance;Physiologic pulse;Pilot Projects;Population;Prefrontal Cortex;Preparation;presynaptic;Procedures;programs;protein distribution;Proteins;Psychiatry;Psychological reinforcement;Publications;Pythons;raphe nuclei;reconstruction;Recurrence;Regulation;Research Personnel;Research Project Grants;Resolution;Resources;routine imaging;Sampling;Scanning;Shapes;Slide;social;Specific qualifier value;Stimulus;student training;System;Techniques;Technology;Thick;Time;Tissue imaging;tissue preparation;Tissues;tool;Training;transmission process;United States National Institutes of Health;Vendor;Visualization;Work,Systems Neuroscience Imaging Resource,2963,NA,NA,NA,NA,8,NA,NA,1847248,NA
11194864,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002968,NA,NA,1ZICMH002968-07,NIMH:2601856\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,15710963 (contact),"PEREIRA, FRANCISCO  (contact)",NA,NA,NA,Accounting;Address;Adolescent;Affective;Atlases;Bayesian Analysis;Behavior;Behavioral;Brain;Brain Mapping;Characteristics;child depression;Clinical;Code;Cognitive;Communities;Computer software;Confounding Factors (Epidemiology);Consultations;Consumption;COVID-19;COVID-19 pandemic;Data;Data Science;Data Set;data sharing;Databases;deep neural network;design;Development;dimension reduction;Dimensions;Distress;Drops;dynamic system;Ecological momentary assessment;Event;experience;Experimental Designs;experimental study;Extinction;Face;Family dynamics;Fiber;Functional Magnetic Resonance Imaging;Goals;Guidelines;high risk;Hour;Human;Image;improved;Individual;individual variation;interest;Intramural Research Program;Judgment;large language model;large-scale imaging data;Location;Loneliness;Machine Learning;machine learning method;Maps;Measurement;Measures;Medial;Mental Depression;mental representation;Methodology;Methods;Mission;Moods;Motivation;National Institute of Drug Abuse;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;National Institute on Alcohol Abuse and Alcoholism;neural;Neurons;Neurosciences;optogenetics;Outcome;pandemic disease;Participant;Performance;Persons;Phenotype;Photometry;Postbaccalaureate;Postdoctoral Fellow;Prefrontal Cortex;Preparation;presynaptic;Principal Investigator;Printing;Procedures;Process;Psychiatry;Psychology;Psychopathology;Publishing;Quality Control;Quantitative Evaluations;Questionnaires;randomized trial;Reading;Research;Research Activity;Research Personnel;Rest;Retrieval;Rewards;Services;Shapes;Signal Transduction;Social Distance;Space Models;Statistical Methods;statistics;Structural Models;Structure;Students;Surveys;Testing;Text;Thinking;Time;tool;Training;Transcranial magnetic stimulation;United States National Institutes of Health;usability;Validation;Well in self;Youth,Machine Learning Team,2968,NA,NA,NA,NA,7,NA,NA,2601856,NA
11194865,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS003008,NA,NA,1ZICNS003008-21,NINDS:1535167\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,11132757 (contact),"ROBEY, PAMELA  (contact)",NA,NA,NA,"3-Dimensional;Adenine;Aging;Animal Model;Antisense Oligonucleotide Therapy;Area;Atrophic;autosome;Bacteria;biological adaptation to stress;Cardiac;Cardiac Myocytes;cell community;Cell Culture Techniques;Cell Cycle;Cell Death;Cell Differentiation process;Cell Line;Cell Nucleus;cell type;Cells;Cessation of life;Chromosomal Stability;Clustered Regularly Interspaced Short Palindromic Repeats;Collaborations;comparative;CRISPR/Cas technology;Cytoplasm;Data;Deacetylase;Derivation procedure;Development;differentiation protocol;Dinucleoside Phosphates;Disease;disease model;DNA Repair;DNA Sequence Alteration;Down&apos;s Syndrome;drug discovery;Educational process of instructing;Endocrine;Exhibits;Fibroblasts;Formulation;gene editing technology;gene repression;Generations;Genes;Genetic Engineering;Genetic Recombination;Genome;Genome Stability;Genomics;Goals;Hormone replacement therapy;Hormones;Human;human embryonic stem cell;human induced pluripotent stem cells;human pluripotent stem cell;Hydrolase;Hydrolysis;Hypophysectomy;Hypopituitarism;Hypoxia;Immune;Immunofluorescence Immunologic;Immunomodulators;implantation;induced pluripotent stem cell;induced pluripotent stem cell technology;Informal Social Control;Inherited;insight;interest;Knock-out;Maintenance;Mammals;Manuscripts;member;Mentors;Meta-Analysis;Metabolic;metabolome;Methods;Microglia;Microtubules;Mission;Mitochondria;Monitor;Mosses;Motor Neurons;Mus;Muscle;mutant;Mutation;mutation correction;National Heart, Lung, and Blood Institute;National Human Genome Research Institute;National Institute of Environmental Health Sciences;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;nerve stem cell;Neuromuscular Diseases;Neurons;neuropsychiatry;Neurosphere;Nicotine;novel;Organ;Organism;Organoids;Oxidative Stress;Patients;Pattern;Peripheral Blood Mononuclear Cell;Pituitary Gland;Pituitary Gland Adenoma;Pituitary-dependent Cushing&apos;s disease;Play;pluripotency;pluripotent stem cell differentiation;Pluripotent Stem Cells;Poly Adenosine Diphosphate Ribose;pre-clinical;Preclinical Drug Development;Preparation;Process;Property;Proteins;Protocols documentation;Publishing;PubMed;Quality Control;Reporter;Research;Research Project Grants;Respiratory distress;response;Role;Sampling;Scientist;self-renewal;Sendai virus;Side;SIRT1 gene;Sirtuins;Societies;Spinal Cord;Spinal Muscular Atrophy;Spinal Muscular Atrophy with Respiratory Distress Type I;stem cell biology;stem cell biomarkers;stem cell growth;stem cell survival;stem cells;stress management;System;TP53 gene;Training;United States National Institutes of Health;Variant;Work",Human pluripotent stem cells,3008,NA,NA,NA,NA,21,NA,NA,1535167,NA
11194866,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS003044,NA,NA,1ZICNS003044-18,NINDS:3078971\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,12000928 (contact),"LATOUR, LAWRENCE  (contact)",NA,NA,NA,Accident and Emergency department;Accreditation;acute stroke;Blood Vessels;Cerebrum;Clinical;clinical center;Clinical Research;clinical research site;Clinical Services;computer network;Contractor;Data;Elements;Event;Fellowship;Foundations;Hospitals;Image;Infrastructure;Injury;Location;Magnetic Resonance Imaging;Maryland;Neurologist;Neurology;Nurses;participant enrollment;Patients;programs;Protocols documentation;recruit;Registries;Research;Research Infrastructure;Research Project Grants;Research Subjects;Research Support;screening;Services;Site;Source;Stroke;suburb;System;Training;Training Programs;Traumatic Brain Injury;United States National Institutes of Health;Washington,Clinical And Imaging Core Support Of Acute Stroke Research,3044,NA,NA,NA,NA,18,NA,NA,3078971,NA
11194867,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS003109,NA,NA,1ZICNS003109-16,NINDS:978286\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,15235415 (contact),"DEVINE, RITA  (contact)",NA,NA,NA,Animals;Area;Biophysics;Cellular biology;Clinical;Core Facility;cost effective;Environment;Epilepsy;Equipment;Evaluation;Excision;Friends;Genetic;Goals;improved;Infrastructure;Laboratories;Lighting;Location;Magnetic Resonance Imaging;Maintenance;Minor;Modification;National Institute of Neurological Disorders and Stroke;Neurology;Neurosciences;Operative Surgical Procedures;Phase;programs;Research;Research Support;Resources;Scientist;Stroke;System;United States National Institutes of Health;Water,Maintenance and Improvement of NINDS Infrastructure,3109,NA,NA,NA,NA,16,NA,NA,978286,NA
11194868,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS003149,NA,NA,1ZICNS003149-10,NINDS:1481330\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,11132761 (contact),"NATH, AVINDRA  (contact)",NA,NA,NA,Alzheimer&apos;s Disease;antagonist;Antibodies;Astrocytes;Attenuated;Binding;Biological Assay;Biological Products;Bipolar Disorder;Caenorhabditis elegans;Cell Culture Techniques;Cell Line;Cells;chemosensitizing agent;Chronic;Collaborations;Collection;Development;dopamine D3 receptor;Endogenous Retroviruses;env Gene Products;Epilepsy;Extramural Activities;Fluorescence;Fluorescence Microscopy;FRAP1 gene;Generations;Glioblastoma;Glioma;Goals;HIF1A gene;high throughput screening;HIV;HIV tat Protein;Human;Image;imaging platform;In Vitro;in vivo;induced pluripotent stem cell;Induced pluripotent stem cell derived neurons;inhibitor;Interferometry;Label;Laboratories;Lead;live cell imaging;Mediating;Modeling;Mutation;National Center for Advancing Translational Sciences;National Institute of Allergy and Infectious Disease;National Institute of Neurological Disorders and Stroke;neoplastic cell;Nerve Degeneration;Nerve Regeneration;nerve stem cell;Nervous System Disorder;nervous system infection;Neurons;neuroprotection;neurotoxic;neurotoxicity;North Dakota;novel therapeutics;Patients;Pituitary-dependent Cushing&apos;s disease;Population;Potassium;preclinical development;programs;Progress Reports;promoter;Property;protein purification;Proteins;Recombinant Proteins;Recombinants;Research Personnel;Research Project Grants;Role;Sampling;Schools;Scientist;screening;small molecule;small molecule libraries;stem cell niche;stemness;tat Protein;Therapeutic Agents;therapeutic target;Translational Research;Virus Replication;Work,Progress Report for Neurotherapeutics Unit,3149,NA,NA,NA,NA,10,NA,NA,1481330,NA
11194869,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS009425,NA,NA,1ZICNS009425-04,NINDS:2645200\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,9416918 (contact),"KORETSKY, ALAN  (contact)",NA,NA,NA,Address;Amplifiers;animal imaging;Animals;arterial spin labeling;Autopsy;Bite;Boston;Brain;Brain imaging;Callithrix;Cell Nucleus;Cells;Computer software;Coupled;Coupling;Data Reporting;Dedications;design;Detection;Development;Devices;Diameter;electric impedance;Electromagnetic Fields;Electronics;Elements;Engineering;experimental study;Frequencies;Functional Imaging;Functional Magnetic Resonance Imaging;Future;Generations;Goals;Head;Heating;Human;human imaging;human subject;Image;improved;in vivo;Infrastructure;Institutional Review Boards;instrumentation;interest;Intervention;Iron;Isopropanol;Label;Laboratories;magnetic field;Magnetic Resonance Imaging;Maps;Measurement;Measures;Mechanics;medical specialties;Methods;Modeling;molecular imaging;Monitor;nanofabrication;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;neuroimaging;Neurosciences;new technology;next generation;Noise;novel;Nuclear;nuclear imaging;operation;Operative Surgical Procedures;Optics;particle;Performance;Perfusion;perfusion imaging;Pituitary Gland;Polychlorinated Biphenyls;Povidone;Principal Investigator;Property;Protocols documentation;radio frequency;radiologist;Ramp;Recipe;Research;Resolution;response;Rhodium;Safety;safety assessment;safety testing;Schedule;Scheme;Sepharose;Shapes;Side;simulation;Source;success;System;Technology;Temperature;Testing;Thermometry;Time;Tissues;Transistors;transmission process;tumor;United States National Institutes of Health;Universities;Validation;Work,MRI Engineering Core,9425,NA,NA,NA,NA,4,NA,NA,2645200,NA
11194870,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS009438,NA,NA,1ZICNS009438-03,NINDS:867749\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,79334268 (contact),"NAIR, GOVIND  (contact)",NA,NA,NA,3D Print;Age;Animals;Area;Arterial Disorder;Atrophic;Autopsy;autosome;Brain;brain based;Brain region;brain tissue;brain volume;Categories;Cells;Cerebrum;Classification;Clinical;clinical center;Clinical Trials;Collaborations;Communities;Computer software;contrast enhanced;Contrast Media;Core Facility;Data Analyses;design;Digital Imaging and Communications in Medicine;falls;Freezing;Goals;graduate student;gray matter;Hematopoietic Stem Cell Transplantation;high resolution imaging;Histopathology;HIV;HIV Seropositivity;Human;Human Resources;Image;imaging facilities;imaging modality;Imaging Techniques;improved;In Situ;in vivo;in vivo imaging;interest;Label;Lesion;Long-Term Effects;Machine Learning;Magnetic Resonance;Magnetic Resonance Imaging;magnetic resonance imaging biomarker;Measures;medication safety;Metastatic malignant neoplasm to brain;Methods;Microscopy;Mission;MRI Scans;Multiple Sclerosis;multiple sclerosis patient;Mus;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;Nervous System Disorder;neuroimaging;Neurologic;Neurology;Neuropsychology;Organ;Outcome Measure;Participant;Pathologic;Pathologic Processes;pembrolizumab;Persons;Phase;Phenotype;Physiologic pulse;Post Technic;Post-Acute Sequelae of SARS-CoV-2 Infection;Postbaccalaureate;Postdoctoral Fellow;Postoperative Period;preservation;Progressive Multifocal Leukoencephalopathy;Research;Research Activity;Research Personnel;Resolution;Resources;RNA;Sampling;SARS-CoV-2 infection;Scanning;segmentation algorithm;Services;Slice;small cell lung carcinoma;socioeconomics;Software Engineering;Spinal Cord;spinal cord imaging;Stroke;Study Subject;Subcortical Infarctions;Subcortical Leukoencephalopathy;Techniques;Testing;Time;Tissue imaging;Tissues;tool;transfer learning;Treatment outcome;ultra high resolution;United States National Institutes of Health;Universities;user-friendly;Visualization;White Matter Hyperintensity;Work,NINDS Quantitative MRI Core Facility,9438,NA,NA,NA,NA,3,NA,NA,867749,NA
11194871,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS009439,NA,NA,1ZICNS009439-03,NINDS:566509\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78815845 (contact),"SMITH, CAROLYN  (contact)",NA,NA,NA,3-Dimensional;alpha synuclein;Amacrine Cells;Astrocytes;Autophagocytosis;Behavioral;beta-arrestin;Biological;biological adaptation to stress;Biological Markers;Biological Psychiatry;Brain;Breathing;Callithrix jacchus jacchus;Canada;Carbon Dioxide;Cardiac;Carotid Body;CDK5 gene;Cell Nucleus;Cells;Clathrin;Collaborations;Computer software;confocal imaging;constriction;Consultations;Core Facility;Dendritic Spines;Deposition;design;Developmental Stuttering;Diamond;Dopamine D2 Receptor;dopaminergic neuron;Drosophila genus;Endocrine;entorhinal cortex;Epilepsy;Equipment;fatty acid-binding proteins;fear memory;Fiber;G protein coupled receptor kinase;Goals;granule cell;Guanine Nucleotide Exchange Factors;Hares;Image;Image Analysis;image processing;imaging facilities;Immediate-Early Genes;Immune signaling;In Vitro;Individual;instrument;Internet;Journals;Knowledge;Label;Laboratories;Lasers;Learning;Lewy Bodies;Life;Light;Light Microscope;light microscopy;Lipids;Maps;Measures;Medial;Mediating;member;Membrane;Microscope;Microscopic;Mission;Morphology;mouse model;N-Methyl-D-Aspartate Receptors;National Institute of Neurological Disorders and Stroke;Nervous System;Nervous System Disorder;Neurobiology;neurogenic orthostatic hypotension;Neuroglia;Neurons;Neurosciences;noradrenergic;Olfactory dysfunction;open data;Optics;Organism;Patients;Persons;Phosphorylation;Piezo 2 ion channel;pituitary adenylate cyclase activating polypeptide;preBotzinger complex;Property;protein TDP-43;Publications;RAPGEF2 gene;raphe nuclei;receptive field;receptor;reconstruction;recruit;Regulation;Reporting;Research;Resolution;Resources;Sampling;Scanning;Science;Scientist;Secretory Vesicles;Sensory;Sex Functioning;Shapes;Signal Pathway;Slice;Sodium;spatial memory;Structure;Substantia nigra structure;success;Synapses;Techniques;Thick;Thinness;time interval;Training;Transgenic Mice;Ubiquitin;Universities;Variant;Ventral Tegmental Area;Visualization;Work;Yin,Light Imaging Core Facility,9439,NA,NA,NA,NA,3,NA,NA,566509,NA
11194872,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS009441,NA,NA,1ZICNS009441-03,NINDS:786201\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78873757 (contact),"MARIC, DRAGAN  (contact)",NA,NA,NA,Apoptotic;Basic Science;Basophils;Biological;Biological Assay;Biological Markers;Bone Marrow;Calcium;Calibration;Cell Culture Techniques;Cell Death;Cell Differentiation process;Cell membrane;Cell Nucleus;cell preparation;Cell Proliferation;Cell Separation;Cell surface;cell type;Cells;Cellular Assay;Cellular biology;Cerebrospinal Fluid;Clinical Research;Color;Complex;Core Facility;Cytometry;Cytoplasm;cytotoxic;Data;data acquisition;Data Analyses;design;Detection;Dyes;Eligibility Determination;Endothelial Cells;eosinophil;Equipment;Exclusion;experimental study;Flow Cytometry;Fluorescence-Activated Cell Sorting;Gene Expression;Genes;Genetic Markers;Hematopoietic;high throughput screening;Human Resources;Image;Image Cytometry;Imaging Techniques;Immunoprecipitation;In Situ;In Vitro;in vivo;Individual;insight;instrument;interest;investigator training;Journals;Laboratories;Leukocytes;Link;Logic;loss of function;Lymphocyte;Maintenance;Manuscripts;mast cell;Mesenchymal;Microglia;MicroRNAs;Mission;Mitochondria;Molecular;monocyte;multidisciplinary;National Institute of Neurological Disorders and Stroke;Necrosis;neural;Neuroglia;Neurons;neutrophil;novel;Nuclear;Peer Review;peripheral blood;Phenotype;Physiological;Population;Preparation;Productivity;programs;Property;protein expression;Proteins;Protocols documentation;Publications;Quality Control;Reporter;Research;research and development;Research Personnel;Research Project Grants;Research Support;Resources;Reverse Transcriptase Polymerase Chain Reaction;RNA;Sampling;Services;Side;Signal Transduction;Small Interfering RNA;Sorting;Source;specific biomarkers;Specific qualifier value;Spleen;Stains;Standardization;stem;stem cells;Students;Synaptosomes;Technology;Testing;Tissues;Training;transcriptome sequencing;Transfection;Translational Research;Transplantation;United States National Institutes of Health;Western Blotting;Work,Flow & Imaging Cytometry Core Facility,9441,NA,NA,NA,NA,3,NA,NA,786201,NA
11194873,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS009442,NA,NA,1ZICNS009442-03,NINDS:1011974\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78873759 (contact),"LI, YAN  (contact)",NA,NA,NA,2019-nCoV;Acetylation;alpha Tubulin;Anxiety;CDK5 gene;Core Facility;Devices;Disulfide Linkage;Goals;Growth;Hares;High Pressure Liquid Chromatography;Homeostasis;instrument;Intramural Research;Label;Life;LRRK2 gene;Mammalian Cell;mass spectrometer;Mass Spectrum Analysis;Measurement;Membrane;Methods;Mitochondrial Myopathies;Modification;Molecular Weight;Motor;nano;National Institute of Neurological Disorders and Stroke;operation;Paper;Phosphorylation;Post-Translational Protein Processing;Printing;protein TDP-43;Proteins;Proteomics;Regulation;Research Personnel;Research Support;Scientist;Services;Signal Pathway;Sorting;Stress;Synapses;System;Techniques;Training;Translational Protein Modification;Translations;Ubiquitination;United States National Institutes of Health;Work,Proteomics Core Facility,9442,NA,NA,NA,NA,3,NA,NA,1011974,NA
11194874,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS009443,NA,NA,1ZICNS009443-03,NINDS:2182259\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78826384 (contact),"JOHNSON, KORY  (contact)",NA,NA,NA,American Heart Association;Animals;Appropriateness Review;Area;ATAC-seq;Awareness;B-cell receptor repertoire sequencing;Bioinformatics;cell registry;ChIP-seq;Classification;Clinical;Clinical Data;Collection;Communication;Companions;Core Facility;Data;Data Analyses;Databases;design;Development;DNA methylation profiling;Endogenous Retroviruses;Equipment and supply inventories;expectation;experience;Generations;Genes;Guidelines;Health Professional;Hospitalization;Hospitals;human embryonic stem cell;human pluripotent stem cell;Image;Integral Membrane Protein;Journals;Lesion;Machine Learning;Maintenance;Manuscripts;Mass Spectrum Analysis;meetings;Messenger RNA;Methods;Microarray Analysis;MicroRNAs;middleware;mobile application;Modeling;molecular dynamics;Names;National Institute of Neurological Disorders and Stroke;next generation;Online Systems;pathogen;Patients;Phylogenetic Analysis;Process;Protein Analysis;Protein Microarray Assay;Proteins;recruit;Research;Research Personnel;RNA analysis;Schedule;Secure;Sequence Analysis;Severities;single-cell RNA sequencing;Site;Statistical Data Interpretation;stroke patient;Structure;Survival Analysis;symposium;System;T cell receptor repertoire sequencing;Technology;Testing;Time;tool;transcriptome sequencing;transcriptomics;United States National Institutes of Health;Variant;web app;Work,Bioinformatics Core Facility,9443,NA,NA,NA,NA,3,NA,NA,2182259,NA
11194875,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS009445,NA,NA,1ZICNS009445-03,NINDS:759785\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78826386 (contact),"TAO-CHENG, JUNG-HWA  (contact)",NA,NA,NA,Adult;age related;Biological Sciences;blood-brain tumor barrier;Brain;Cells;Clathrin;constriction;Consultations;Core Facility;Data;Electron Microscope;Electron Microscopy;experience;Fostering;Glioma;Goals;Growth;high resolution imaging;Hippocampus;Homeostasis;Image;Image Analysis;improved;Inhibitory Synapse;Iron;journal article;Label;Magnetic Resonance Imaging;Mediating;meetings;member;Membrane;Microscope;Microtomy;Mitochondrial Myopathies;Modeling;Molecular;Mus;National Institute of Neurological Disorders and Stroke;Neuroglia;Neurosciences;olfactory bulb;Paper;Preparation;Printing;Proteins;Publications;Research Personnel;Rest;Rodent;sample fixation;Sampling;Scientist;Stem cell transplant;Techniques;tissue preparation;tissue processing;Training;Translations;transmission process;Work;young adult,Electron Microscopy Core Facility,9445,NA,NA,NA,NA,3,NA,NA,759785,NA
11194876,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS009446,NA,NA,1ZICNS009446-03,NINDS:827865\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78873761 (contact),"WANG, DAVID  (contact)",NA,NA,NA,2019-nCoV;3-Dimensional;Adopted;Adult;Affect;Antibodies;Antisense Oligonucleotides;Artificial Intelligence;Astrocytes;Axon;Biological Assay;Blood - brain barrier anatomy;blood-brain barrier disruption;Brain;brain research;C9ORF72;CD34 gene;Cell Line;cell type;Cells;Coculture Techniques;Collaborations;Communicable Diseases;Communities;Congresses;Dengue Infection;Dengue Virus;design;Development;Diagnosis;diagnostic development;Disease;DNA;DNA Repair;Educational workshop;Embryoid bodies;Endogenous Retroviruses;Endothelial Cells;Epigenetic Process;Extramural Activities;Extravasation;gene correction;Genetic;Genetic study;Glial Differentiation;Goals;hematopoietic stem cell differentiation;Hematopoietic stem cells;Human;image processing;In Vitro;India;induced pluripotent stem cell;Inflammation;Inflammatory;interest;International;Journals;Label;Methods;Microfluidic Microchips;Microglia;Mitochondria;Modeling;Molecular Target;Monitor;Morphology;motor neuron degeneration;Motor Neurons;Mutation;National Institute of Neurological Disorders and Stroke;Nerve Degeneration;nerve stem cell;Nervous System Disorder;neural;neural model;neurodevelopment;Neurodevelopmental Disorder;neurogenesis;neuroimmunology;neuroinflammation;Neurology;Neurons;Neurosciences;neurotoxicity;Normalcy;novel;Organoids;Pathogenesis;Pathway interactions;patient derived induced pluripotent stem cells;Patients;Penetration;Peripheral;Phosphorylation;Play;pluripotent stem cell differentiation;Postdoctoral Fellow;preclinical study;preservation;prevent;Process;Production;Property;protein TDP-43;Proteins;Protocols documentation;Publications;Publishing;Recombinants;reconstitution;research and development;Research Personnel;response;Retroviridae;Role;Sampling;SARS-CoV-2 spike protein;screening;Serum;single-cell RNA sequencing;Site;Small Interfering RNA;Spain;Standardization;Stem Cell Research;stem cells;Stimulator of Interferon Genes;Testing;Tetradecanoylphorbol Acetate;therapeutic development;Therapeutic Intervention;three-dimensional modeling;Toxic effect;trafficking;Training;translational neuroscience;United States National Institutes of Health;Virus;Virus Activation;Virus Diseases;Western Blotting;Work;XRCC5 gene,Neurodifferentiation/Stem Cell Unit,9446,NA,NA,NA,NA,3,NA,NA,827865,NA
11194877,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS009450,NA,NA,1ZICNS009450-02,NINDS:960229\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,79365612 (contact),"HOROVITZ, SILVINA  (contact)",NA,NA,NA,"Administrator;brain morphology;Brain Neoplasms;Brain Pathology;Cerebellar Ataxia;Clinic;Clinical;Clinical Research;Clinical Research Protocols;Collection;Communities;community based research;community engaged approach;community engagement;comparative;cost;County;Data;Data Collection;demographics;disabled;Disease Progression;Enrollment;equity, diversity, and inclusion;field study;follow up assessment;follow-up;Fostering;Future;Goals;Grant;health equity;health inequalities;improved;Incidence;Individual;Institutional Review Boards;Magnetic Resonance Imaging;multimodality;National Institute of Neurological Disorders and Stroke;Nervous System Disorder;Neurodegenerative Disorders;Neuroepidemiology;Neurologic;Neurology;operation;Operations Research;Optical Coherence Tomography;outreach;Participant;Patients;Physicians;Pilot Projects;point of care;point of care testing;Population;programs;Protocols documentation;Research;Research Project Grants;screening;social health determinants;Stroke;System;Underserved Population;Vision;Work",Mobile Clinical Research,9450,NA,NA,NA,NA,2,NA,NA,960229,NA
11194878,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS009451,NA,NA,1ZICNS009451-02,NINDS:780858\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,79371594 (contact),"YU, ZANLIN  (contact)",NA,NA,NA,Address;Biological;Charge;Chills;Communities;Computer software;Core Facility;Cryoelectron Microscopy;Data Analyses;Data Collection;data management;Data Storage and Retrieval;Diagnosis;Electron Microscope;Electron Microscopy Facility;experience;Freezing;Goals;improved;Microscope;National Institute of Neurological Disorders and Stroke;operation;Preparation;Research Personnel;Resolution;Running;Sampling;screening;structural biology;Structure;Training;Update;Water,Cryo-EM Core Facility,9451,NA,NA,NA,NA,2,NA,NA,780858,NA
11194879,ZIC,NS,1,N,NA,NA,NA,NA,ZICNS009452,NA,NA,1ZICNS009452-02,NINDS:722142\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,79334272 (contact),"AMIN, NIRANJANA  (contact)",NA,NA,NA,Authorization documentation;Back;Biological;Biological Assay;Biological Specimen Banks;Blood specimen;Cataloging;Catalogs;chemokine;Clinical;Clinical Data;Clinical Protocols;Clinical Research;Collection;Color;Computer software;Core Facility;cytokine;Data;Databases;Development;DNA;experience;Flow Cytometry;Future;Genus Hippocampus;Goals;Human Resources;Individual;Institution;interest;Knowledge;Laboratories;Laboratory Research;Light;Link;Long COVID;Maintenance;Measures;meetings;member;Mission;Mitochondria;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;Nervous System Disorder;Nervous System Trauma;neurofilament;participant enrollment;Patients;peripheral blood;Procedures;Process;Proteins;Protocols documentation;Records;Recruitment Activity;repository;Research;Research Personnel;Resources;Running;sample collection;Sampling;Scientist;Services;Shipping;single molecule;skills;Sorting;Source;Specific qualifier value;Specimen;Specimen Handling;System;tau Proteins;Time;United States National Institutes of Health;web site;Workload,Biospecimen Repository Core,9452,NA,NA,NA,NA,2,NA,NA,722142,NA
11194880,ZID,MH,1,N,NA,NA,NA,NA,ZIDMH002912,NA,NA,1ZIDMH002912-17,NIMH:7910164\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,10422620 (contact),"PAO, MARYLAND  (contact)",NA,NA,NA,"2019-nCoV;Accreditation;advanced directive;Advertising;Advocacy;Annual Reports;anti-depressive agents;Authorization documentation;Autoimmune;Basic Science;Behavior;behavioral phenotyping;Bioethics;Brain;Brain Diseases;Budgets;career;Charge;Childhood;Clinical;clinical care;clinical center;Clinical Competence;clinical examination;clinical implementation;clinical practice;Clinical Protocols;Clinical Research;Clinical Services;clinical training;Clinical Trials;Clinical Trials Data Monitoring Committees;Cognitive;cognitive testing;Cognitive Therapy;Collaborations;Communication;Communities;community engagement;Community Outreach;Complex;Consent;Consultations;COVID-19;COVID-19 pandemic;Credentialing;data management;data sharing;design;Development;Devices;Diagnosis;Discipline of Nursing;Education;Ensure;equity, diversity, and inclusion;Ethics;Evaluation;experience;Faculty;Fellowship;flu;follow-up;Future;genome sequencing;Good Clinical Practice;Health Priorities;Health Professional;Health Services Research;high risk;Hospitals;Human Resources;human subject protection;improved;Individual;Informed Consent;innovation;Inpatients;Institutional Review Boards;Intramural Research Program;investigator training;Joints;Lawyers;Leadership;Legal;lens;Marketing;Medical center;Medical Education;Medical Students;meetings;member;mental disorder prevention;Mental Health;mental health education;Mission;Monitor;multidisciplinary;National Institute of Mental Health;neurodevelopment;Neuropsychology;neuroregulation;novel therapeutics;outpatient facility;outreach program;Participant;participant enrollment;Patient Recruitments;patient safety;Patients;Personal Communication;Personal Satisfaction;Pharmacy facility;Physicians;Police;Policies;Postdoctoral Fellow;Preparation;Procedures;Process;product development;programs;Protocols documentation;Provider;Psychiatrist;Psychiatry;Psychology;Psychoses;Qualifying;recruit;Regulation;Reporting;Research;Research Infrastructure;Research Personnel;Research Support;Research Training;Resources;response;Review Committee;Risk;Safety;safety practice;Science Policy;screening;Services;Sleep;social media;Strategic Planning;Structure;Students;suicidal risk;System;tenure track;Training;Training Activity;Training and Education;Training Programs;Translational Research;trend;United States National Institutes of Health;Visit;volunteer;web site;webinar;whole genome;Work;working group",NIMH Office of the Clinical Director-Core Activities,2912,NA,NA,NA,NA,17,NA,NA,7910164,NA
11194881,ZID,NS,1,N,NA,NA,NA,NA,ZIDNS003101,NA,NA,1ZIDNS003101-16,NINDS:18637868\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,11132761 (contact),"NATH, AVINDRA  (contact)",NA,NA,NA,Accreditation;Adherence;Adverse event;allied health education;Area;Award;Biopsy;Budgets;Career Transition Award;Caring;Childhood;Clinic;Clinical;clinical care;clinical center;Clinical Data;Clinical Investigator;clinical practice;Clinical Protocols;Clinical Research;Clinical Research Protocols;Clinical Trials;Clinical Trials Unit;Collaborations;Communication;Competence;Conduct Clinical Trials;Consent;Consult;Consultations;continuing medical education;Contracts;Credentialing;Data Analyses;design;Development;Devices;Diagnostic tests;Documentation;early phase clinical trial;Education;Educational Activities;Electroencephalography;Emergency Situation;Ensure;Epilepsy;Ethics;experience;Fellowship;Foundations;Funding;Future;Goals;Good Clinical Practice;Grant;Health;Health Personnel;high standard;Hospitals;Human Resources;human subject;human subject protection;imaging scientist;individual patient;Institution;inter-institutional;Internships;Intramural Research Program;Intraoperative Monitoring;Investigation;Investigational Drugs;Journals;Licensing;Magnetic Resonance Imaging;Medical;medical specialties;Medical Students;meetings;Mission;Monitor;Morbidity - disease rate;mortality;multidisciplinary;Muscle;National Institute of Neurological Disorders and Stroke;Nervous System Disorder;neuroAIDS;Neurodegenerative Disorders;neuroimmunology;Neurologic;Neurological Nursing;Neurology;Neuropsychological Tests;Neurosciences;Neurosciences Research;Nursing Faculty;Nursing Staff;Online Systems;Parkinson Disease;Participant;Patient Care;patient safety;Patients;Pediatric Neurology;Periodicals;Physicians;Policies;Principal Investigator;Process;profession allied to medicine;Professional Organizations;programs;prospective;protocol development;Protocols documentation;quality assurance;Recommendation;recruit;Recruitment Activity;Research;Research Methodology;Research Personnel;Research Training;Residencies;Resource Sharing;Resources;Review Committee;Rotation;Safety;Schedule;Services;sound;symposium;System;Training;training opportunity;Training Programs;Travel;United States National Institutes of Health;University Hospitals;Work,NINDS Office of the Clinical Director,3101,NA,NA,NA,NA,16,NA,NA,18637868,NA
11194882,ZID,NS,1,N,NA,NA,NA,NA,ZIDNS003167,NA,NA,1ZIDNS003167-07,NINDS:1347755\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78346056 (contact),"KWAN, JUSTIN  (contact)",NA,NA,NA,Affect;Amyotrophic Lateral Sclerosis;Cell Physiology;Clinic;Clinical;Clinical assessments;clinical phenotype;Clinical Research;Cognitive;cognitive testing;Collaborations;Collection;Complex;corticobasal syndrome;Defect;Diagnosis;Disease;DNA Sequence Alteration;Eligibility Determination;Epigenetic Process;Family;Frontotemporal Dementia;Functional Imaging;Future;Gene Mutation;gene product;Genes;Genetic;Health Personnel;Image;individual patient;interest;Knowledge;Laboratories;Language;Leukapheresis;Link;MAPT gene;Molecular;molecular imaging;motor symptom;multidisciplinary;mutant;nervous system infection;Neurodegenerative Disorders;Neurologic Symptoms;Neurologist;Neurology;Participant;Pathology;Patients;phenomenological models;Physicians;precision medicine;Primary Progressive Aphasia;Procedures;Progressive Supranuclear Palsy;protein TDP-43;Protocols documentation;Questionnaires;Registries;Research;research clinical testing;Research Personnel;research study;symposium;Symptoms;United States National Institutes of Health;Update,Complex Neurodegenerative Disorders Clinic,3167,NA,NA,NA,NA,7,NA,NA,1347755,NA
11194883,ZIE,MH,1,N,NA,NA,NA,NA,ZIEMH002939,NA,NA,1ZIEMH002939-12,NIMH:2260046\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,10422620 (contact),"PAO, MARYLAND  (contact)",NA,NA,NA,Academia;Accreditation;Achievement;Adolescent Psychiatry;Adult;Ally;American;Autoimmune;Award;Behavioral;Brain Diseases;Brain imaging;burnout;career;career development;Child;Child Psychiatry;Clinical;clinical center;Clinical Psychology;Clinical Research;clinical training;computational neuroscience;Consultations;Counseling;Development Plans;Doctor of Philosophy;doctoral student;Employee;Endocrinology;Evaluation;experience;Exposure to;externship;Faculty;falls;Fellowship;Fellowship Program;Foundations;Future;Goals;graduate medical education;graduate student;hands on research;Healthcare;hospice environment;Hospitals;Image;Individual;Industry;Information Dissemination;innovation;Intelligence Tests;interest;Interview;Intramural Research;Intramural Research Program;Joints;Lead;Learning;lectures;Major Mental Illness;Maryland;Massachusetts;Medical center;Medical Education;Medical Research;medical specialties;Medical Students;Memory;Mental Health;Mentors;Mentorship;Methodology;Molecular;National Institute of Mental Health;Neurobiology;neurodevelopment;neurogenetics;Neuropsychology;neuroregulation;Neurosciences;Neurosciences Research;novel;novel therapeutics;Nurse Practitioners;outreach;Palliative Medicine;pandemic disease;Personal Satisfaction;Persons;pharmacologic;Physicians;Positioning Attribute;Post Graduate Year;Principal Investigator;programs;Psychiatric epidemiology;Psychiatrist;Psychiatry;Psychologist;Psychology;Psychometrics;Psychopharmacology;Psychotherapy;Puerto Rico;Qualifying;recruit;Reporting;Research;Research Personnel;Research Training;Residencies;Resources;Rotation;Scholars Program;scientific organization;Series;Services;severe mental illness;Site;skills;Sleep;Social Workers;Sorting;statistics;Student Selections;Students;Testing;Time;Training;training opportunity;Training Programs;Training Support;Transcranial magnetic stimulation;United States;United States Food and Drug Administration;United States National Institutes of Health;Universities;University Hospitals;virtual;Visit;Washington;Wisconsin;Work;Writing,Psychiatry Clinical Research Training-NIMH Office of the Clinical Director,2939,NA,NA,NA,NA,12,NA,NA,2260046,NA
11194884,ZIG,MH,1,N,NA,NA,NA,NA,ZIGMH002924,NA,NA,1ZIGMH002924-16,NIMH:17717357\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,79347537 (contact),"ALLEN-WORTHINGTON, KRYSTAL  (contact)",NA,NA,NA,Accreditation;Administrative Personnel;Anesthesia procedures;animal care;Animal Care and Use Committees;Animal Husbandry;animal imaging;Animal Technicians;Animals;Bite;Breeding;Caring;Communities;comparative;Contractor;Contracts;Derivation procedure;Development;Disease;environmental enrichment for laboratory animals;Euthanasia;Government;Guidelines;Hamsters;Healthcare;Hemorrhage;Hour;Human Resources;Injections;International;Intramural Research Program;Laboratory Animal Science;Laboratory Animals;Laws;Magnetic Resonance Imaging;Maryland;Medical;Medical Research;Medicine;Mission;model development;Mus;National Institute of Mental Health;nonhuman primate;Operative Surgical Procedures;Participant;pathology imaging;Phenotype;Play;Policies;policy recommendation;Positioning Attribute;Positron-Emission Tomography;Preparation;Prevention;Principal Investigator;programs;Protocols documentation;radiological imaging;Rattus;Regulation;Research;Research Personnel;Research Support;restraint;Rodent;Role;Running;sample collection;Services;Techniques;Time;Training;United States National Institutes of Health;Veterinarians;Veterinary Medicine;Weaning,Veterinary Medicine Research Branch,2924,NA,NA,NA,NA,16,NA,NA,17717357,NA
11194885,ZIG,NS,1,N,NA,NA,NA,NA,ZIGNS009444,NA,NA,1ZIGNS009444-03,NINDS:11451792\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78873765 (contact),"NARVER, HEATHER  (contact)",NA,NA,NA,Accreditation;Amendment;animal care;Animal Care and Use Committees;animal facility;Animals;Behavioral;Biomedical Research;Callithrix;Callithrix jacchus jacchus;Caring;Censuses;Charge;Clinical;Genetic Enhancement;Health;Human Resources;Image;Knowledge;Laboratories;Laboratory Animals;Lead;Macaca;Mission;National Center for Complementary and Integrative Health;National Institute of Neurological Disorders and Stroke;National Institute on Deafness and Other Communication Disorders;Nervous System;Nervous System Disorder;Neurosciences Research;nonhuman primate;operation;physical conditioning;Process;programs;Protocols documentation;Research Support;Rodent;therapy development;Training;Veterinarians,Animal Care Program,9444,NA,NA,NA,NA,3,NA,NA,11451792,NA
11194886,ZIJ,MH,1,N,NA,NA,NA,NA,ZIJMH002916,NA,NA,1ZIJMH002916-17,NIMH:1630704\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,14276432 (contact),"CLARK, JANET  (contact)",NA,NA,NA,American Indians;Anniversary;Applications Grants;Archives;Authorship;Award;Behavior;Black race;Brain;career;Certification;Chalk;Clinical;Clinical Psychology;cohort;Collaborations;college;Communication;Communities;community building;Development;Doctor of Philosophy;Drops;Education;Educational Curriculum;Educational workshop;Ethics;Evaluation;Event;experience;Faculty;Feedback;Feeds;Fees;Fellowship;Foundations;Funding;Funding Mechanisms;graduate research fellowship program;graduate student;Grant;health disparity;Holly;Human Resources;Hybrids;Individual;International;Interview;Intramural Research;Intramural Research Program;Joints;K-Series Research Career Programs;Lead;lectures;LinkedIn;London;Mediation;Medical Students;meetings;member;Mental Health;Mentors;multidisciplinary;Museums;National Center for Advancing Translational Sciences;National Institute of Dental and Craniofacial Research;National Institute of Drug Abuse;National Institute of General Medical Sciences;National Institute of Mental Health;National Institute of Neurological Disorders and Stroke;National Institute on Deafness and Other Communication Disorders;Neurosciences;Persons;Phase;post-pandemic;Postbaccalaureate;Postdoctoral Fellow;posters;pre-doctoral;Principal Investigator;Privatization;Prize;Process;programs;Psychology;Publications;recruit;Research;Research Ethics;Research Personnel;Research Training;Resources;responsible research conduct;Running;Science;Scientific Advances and Accomplishments;Scientist;Series;Services;skills;social media;Societies;statistics;Students;summer internship;Surveys;symposium;Time;Training;training opportunity;Training Programs;Twitter;United States National Institutes of Health;Universities;virtual;Visit;Vocational Guidance;volunteer;Woman;Writing,Office of Fellowship Training,2916,NA,NA,NA,NA,17,NA,NA,1630704,NA
11194887,ZIK,MH,1,N,NA,NA,NA,NA,ZIKMH002925,NA,NA,1ZIKMH002925-16,NIMH:44189\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,14747731 (contact),"WONG, JENNIFER  (contact)",NA,NA,NA,Affect;Agreement;Area;Behavior;Biomedical Research;Brain;Clinical Trials;Collaborations;Complement;Cooperative Research and Development Agreement;Counseling;Creativeness;data integration;Databases;Development;Disclosure;Employee;Extramural Activities;Gifts;Goals;Human Resources;improved;innovation;interest;invention;Legal patent;Licensing;material transfer agreement;Mediation;member;Mental Health;Mind;Mission;Monitor;National Institute of Mental Health;Policies;Privatization;Procedures;Reporting;Research Personnel;Secure;Services;Technology Transfer;United States National Institutes of Health;working group,Office of Technology Transfer,2925,NA,NA,NA,NA,16,NA,NA,44189,NA
11194918,N01,AI,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-P00002-759102200012-1,NIAID:2805297\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,78864282 (contact),"OSBORNE, C.K.  (contact)",NA,2022-09-12,2029-09-16,Address;Adult;Adverse event;Age;Animals;Antibodies;antiretroviral therapy;attenuation;Biodistribution;CD4 Antigens;CD4 Lymphocyte Count;Common Terminology Criteria for Adverse Events;Deferoxamine;FDA approved;Half-Life;HIV;HIV drug resistance;HIV Infections;HIV-1;Human;IgG4;Image;imaging capabilities;Imaging technology;immune reconstitution;immunogenicity;Immunologist;in vivo;in vivo imaging;intravenous administration;lymph nodes;Lymphocyte Count;Lymphoid Tissue;Macaca;Matched Group;Measures;Mediating;Methods;Monoclonal Antibodies;Multi-Drug Resistance;Mus;National Institute of Allergy and Infectious Disease;nonhuman primate;open label;optical imaging;Patient Schedules;Patients;peripheral blood;Pharmaceutical Preparations;phase I trial;Photons;Positron;Positron-Emission Tomography;Production;programs;Quality Control;quantitative imaging;Radioimmunoconjugate;Radiolabeled;Recombinants;Reporting;Resolution;Rodent Model;Safety;Scientist;serial imaging;simian human immunodeficiency virus;single photon emission computed tomography;Site;SIV;Spleen;T-Cell Depletion;T-Lymphocyte;Tissues;trafficking;Visualization;whole body imaging;Zirconium,Non-Invasive In Vivo Imaging of CD4 pool in HIV-1 Infected Patients,0,NA,NA,NA,NA,NA,NA,NA,2805297,NA
11194919,N01,AI,NA,N,NA,NA,NA,NA,272201100021I,NA,NA,272201100021I-P00007-27200039-1,NIAID:73907\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,KENSINGTON,UNITED STATES,NA,08,094888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,NA,16584200 (contact),"FOUTS, TIMOTHY  (contact)",NA,2020-08-29,2021-08-28,AIDS prevention;Contractor;Contracts;Development;Documentation;flexibility;HIV vaccine;Investigational Drugs;Investigator-Initiated Research;Modality;National Institute of Allergy and Infectious Disease;Phase;preclinical development;Preclinical Testing;Process;Production;research clinical testing;research study;Support Contracts,NIAID Preclinical Development Support: Essential Core Activities,0,NA,NA,NA,NA,NA,NA,NA,73907,NA
11194920,N01,HD,NA,N,NA,NA,NA,NA,275201400003I,NA,NA,275201400003I-P00007-759401900127-1,NICHD:39114\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,ROCKVILLE,UNITED STATES,NA,08,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,NA,79355854 (contact),"MARTIN, BRITTANY  (contact)",NA,2019-09-19,2025-09-18,Address;Age;Bar Codes;Best Pharmaceuticals for Children Act;Biological Specimen Banks;Blood;Cells;Child;Childhood;Conduct Clinical Trials;Congresses;Contracts;Data;dose information;Drug Prescriptions;Dryness;Ensure;Equipment and supply inventories;Erythrocytes;Formulation;Funding;Goals;Human;Human Milk;improved;Knowledge;Label;Modification;Monitor;National Institute of Child Health and Human Development;Online Systems;Orphan;Pharmaceutical Preparations;Pharmacologic Substance;Plasma;repository;Research;Safety;Sampling;Serum;Services;Specimen;Spottings;System;Testing;Therapeutic;Tube,NICHD HUMAN BIOSPECIMEN REPOSITORY- REPOSITORY SERVICES FOR THE BEST PHARMACEUTICALS FOR CHILDREN ACT (BPCA) AND PEDIATRIC TRIALS NETWORK (PTN),0,NA,NA,NA,NA,NA,NA,NA,39114,NA
11194922,N02,DA,NA,N,NA,NA,NA,NA,75N95022C00036,NA,NA,75N95022C00036-P00005-9999-1,NIMH:437516\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,WILMINGTON,UNITED STATES,NA,07,362574527,US,4079901,PPD DEVELOPMENT LP,NC,284013331,NA,78877491 (contact),"KIRBY, MATTHEW  (contact)",NA,2023-09-28,2025-09-27,Clinical Research;clinical research site;Funding;Institution;Leadership;Monitor;National Institute of Mental Health;Recommendation;Research;research study;Services;Site,CLINICAL RESEARCH AND STUDY MONITORING SUPPORT FOR NIMH STUDIES,0,NA,NA,NA,NA,NA,NA,NA,437516,NA
11194923,N01,HD,NA,N,NA,NA,NA,NA,75N94020C00009,NA,NA,75N94020C00009-P00007-9999-1,NICHD:650000\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,BAR HARBOR,UNITED STATES,NA,02,042140483,US,7096501,JACKSON LABORATORY,ME,046091523,NA,77876595 (contact),"LUTZ, CATHLEEN  (contact)",NA,2020-09-22,2025-09-21,Advocacy;Affect;Alzheimer&apos;s Disease;American;Aneuploidy;Animal Model;Artificial Chromosomes;base;Basic Science;Behavioral Research;biobehavior;Biological Models;Biology;Body System;Breeding;Centromere;Chromosome 16;Chromosome 21;Chromosomes;Clinical Trials;cohort;Communities;community engagement;Contractor;Contracts;Cryopreservation;Cytogenetics;Development;Disease;disease model;Dissection;Down&apos;s Syndrome;Educational workshop;Embryo;embryo cryopreservation;Ensure;Epidemiology;Etiology;Female;Fertility;Functional disorder;Genes;Genetic;Germ Cells;high reward;high risk;Human;Human Chromosomes;Human Genome;human model;humanized mouse;Implant;Individual;Intellectual functioning disability;interest;Investigation;Investments;Late Onset Alzheimer Disease;life span;Maintenance;male;meetings;Methods;Modeling;Molecular;mouse genome;mouse model;Mouse Strains;mouse Trisomy 16;mouse Ts65Dn;Mus;National Institute of Child Health and Human Development;Participant;PPBP gene;prenatal;preservation;prevent;Prevention;Procedures;Production;programs;Qualifying;repository;Research;Research Personnel;Research Training;Resources;screening;Study models;Synteny;telomere;trait;Translational Research;transmission process;Trisomy;United States National Institutes of Health,REPOSITORY OF MOUSE MODELS FOR CYTOGENETIC RESEARCH,0,NA,NA,NA,NA,NA,NA,NA,650000,NA
11195192,P50,CA,3,N,2024-09-20,2024-08-01,2025-07-31,NA,P50CA265793,NA,PA-20-272,3P50CA265793-02S1,NCI:749771\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,SAINT LOUIS,UNITED STATES,NA,01,068552207,US,9083901,WASHINGTON UNIVERSITY,MO,631304862,NA,9171534 (contact),"MUTCH, DAVID G (contact)","BASA JANAKIRAM, NAVEENA",2023-08-23,2028-07-31,Advocacy;Advocate;Amendment;Bioinformatics;Biometry;Biostatistics Core;Body System;Budgets;career;Caring;Clinical Trials;Collaborations;Committee Members;Communication;Conduct Clinical Trials;Contracts;Decision Making;Development;Documentation;Electronics;Endometrial;Endometrial Carcinoma;Enrollment;Ensure;Equity;Ethics;Fostering;Goals;Grant;Human Resources;innovation;Institution;Institutional Review Boards;Instruction;Malignant Neoplasms;meetings;metabolomics;mindfulness;Mission;National Cancer Institute;New Mexico;Newsletter;next generation;Oklahoma;operation;Participant;Pathology;Patients;payment;programs;Progress Reports;Publications;Reporting;Research;Research Personnel;Route;Services;Site;Specialized Program of Research Excellence;success;Sum;Time;Underrepresented Minority;Universities;Washington;web site,Administrative Core,265793,ZCA1,ZCA1(M1)-S,5350,S1,2,683878,65893,NA,749771
11195200,OT2,OD,3,N,2024-09-24,2024-09-24,2025-08-31,368,OT2OD037644,SCHOOLS OF MEDICINE,OTA-22-006,3OT2OD037644-01S2,NIDA:1250000\,OTHERS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NEW HAVEN,UNITED STATES,INTERNAL MEDICINE/MEDICINE,03,043207562,US,9420201,YALE UNIVERSITY,CT,065208327,NA,3163082;1868382;2020115;14964291;10453826;10753735;1900244 (contact);79849374;9814079,"BOROWSKY, ALEXANDER D;GOODMAN, MARC T;HIATT, ROBERT A;KIM, SUE ELIZABETH;MEEKER, DANIELLA ;MONTALVO-ORTIZ, JANITZA LIZ;OHNO-MACHADO, LUCILA  (contact);SILVA, AMARILYS ;SITAPATI, AMY MONTAGUE","ALEXANDER-TROUPE, STEPHANIE MELANIA",2024-09-24,2025-08-31,Absenteeism at work;All of Us Research Program;Area;Awareness;Biomedical Research;Blood Banks;California;Catchment Area;Childhood;Church;Clinic;clinical infrastructure;clinical research site;Collaborations;collaborative environment;Collection;Communication;Communities;Community Healthcare;community organizations;community partners;Complement;Computers;Connecticut;Consent;Contract Services;cost;cost estimate;Costs and Benefits;Country;Creativeness;Data;data dictionary;data exchange;data sharing;Decision Making;Disease;Doctor of Philosophy;Education;Electronic Health Record;Enrollment;Equilibrium;ethnic minority population;Ethnic Origin;Ethnic Population;Event;experience;Faith-based organization;Geography;Goals;Grant;Growth;Health;Health Insurance Portability and Accountability Act;Health Personnel;Health system;Healthcare;Helping to End Addiction Long-term;Hot Spot;implementation science;improved;Income;Information Technology;Infrastructure;innovation;Institution;Internet;Joints;Knowledge;Latinx;Leadership;Learning;lens;Life Cycle Stages;literacy;Location;Low income;male;Marketing;Measurement;Medical center;member;Mission;Modeling;Monitor;multidisciplinary;novel;Opiate Addiction;Opioid;opioid misuse;Outcome;outreach;outreach program;Participant;patient outreach;Patient Schedules;Patients;pediatrician;Persons;Population;Population Heterogeneity;Poverty;Precision Health;precision medicine;precision nutrition;Process;programs;Provider;Public Health;Puerto Rico;Qualifying;Race;racial minority population;racial population;recruit;Research;Research Institute;retention rate;Retrieval;Rhode Island;Rural;rural area;rural setting;safety net;Schedule;Site;skills;Socioeconomic Status;socioeconomics;Spanish;Speed;success;Support Groups;System;Training;Underserved Population;United States;United States National Institutes of Health;Universities;urban setting;volunteer;Vulnerable Populations;wireless fidelity;Work;Youth,"All of Us Coast-to-Coast Strong UBR Recruitment, Retention, and Facilitation (C2C SURRF) through Innovation",37644,ZOD1,ZOD1-SRC(99),NA,S2,1,1162045,87955,1250000,NA
11195264,N43,CA,NA,N,NA,NA,NA,NA,75N91024C00067,NA,NA,75N91024C00067-0-9999-1,NCI:400000\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,SAN ANTONIO,UNITED STATES,NA,23,NA,US,10088841,ONCOBIOMIX INC.,TX,782552451,NA,79972659 (contact),"LEACH, CHARLES  (contact)",NA,2024-09-11,2025-09-10,adverse outcome;Area;Assessment tool;Awareness;Bioinformatics;Biological Assay;Biopsy;cancer diagnosis;cancer initiation;cancer risk;CLIA certified;Clinical;Clinical Research;Collection;commercialization;Consent;cost;Custom;Data;Decentralization;Decontamination;detection limit;Development;Diagnosis;DNA;Early Diagnosis;Enrollment;exhaust;experience;experimental study;Feasibility Studies;Feedback;Freezing;global health;gut microbiota;Human;Human Microbiome;improved;in silico;innovation;insight;Instruction;Laboratories;Malignant neoplasm of prostate;Malignant Neoplasms;Measures;men;microbiome;microbiome research;microbiome signature;novel;Online Systems;Participant;Patients;Performance;Phase;Procedures;Process;prostate cancer risk;Protocols documentation;PSA screening;quality assurance;Quality Control;recruit;Reference Standards;Reporting;Reproducibility;Research;Research Design;Risk Assessment;Role;Running;sample collection;Sample Size;Sampling;screening;Small Business Innovation Research Grant;Specificity;Specimen;Standardization;stool sample;Surveys;synthetic construct;Target Populations;Technology;Testing;Time;tool;tumor progression;United States;Validation;Visit;web site,TOPIC NUMBER: 458 SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE IONCOBIOMIX: MICROBIOME-BASED TEST FOR PROSTATE CANCER RISK,0,NA,NA,NA,NA,NA,NA,NA,400000,NA
11195402,ZIA,DK,1,N,NA,NA,NA,NA,ZIADK029019,NA,NA,1ZIADK029019-44,NIDDK:608074\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,6480601 (contact),"SZABO, ATTILA  (contact)",NA,NA,NA,Address;Affect;Area;Behavior;Biological Process;biological systems;Catalysis;Cells;Chemical Dynamics;chemical reaction;cold shock protein;Collaborations;Color;Data;Development;Diffusion;Enzymes;Equilibrium;experimental study;Fluorescence;Fluorescence Resonance Energy Transfer;Fluorescence Spectroscopy;G-substrate;Goals;Individual;Investigation;Kinetics;laser tweezer;Lasers;light emission;light intensity;macromolecule;Measures;Methods;Microscopic;Molecular Conformation;Nature;novel;Nuclear Magnetic Resonance;Output;Paper;Parameter Estimation;Performance;Photons;physical process;Play;Population;Process;protein folding;Proteins;Publications;Publishing;Relaxation;Reporting;Research;Scanning Probe Microscopes;Selection Bias;Selection Criteria;single molecule;Spottings;Structure;Theoretical Studies;theories;time interval,Theoretical Studies On The Dynamic Aspects Of Macromolecular Function,29019,NA,NA,NA,NA,44,NA,NA,608074,NA
11195403,ZIA,DK,1,N,NA,NA,NA,NA,ZIADK043308,NA,NA,1ZIADK043308-29,NIDDK:1827056\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,9736339 (contact),"KOPP, JEFFREY BURNETT (contact)",NA,NA,NA,Affect;African American population;African ancestry;AIDS-Associated Nephropathy;APOL1 gene;Blood Vessels;cell type;Cells;Cicatrix;Classification;Clinical;differential expression;Disease;Focal and Segmental Glomerulosclerosis;Genes;Genetic;genetic variant;Genetic Variation;HIV;Hyperplasia;Hypertrophy;Incidence;Individual;Interferon Type II;Keloid;Kidney Diseases;Mus;Obesity;Pathologic;PF4 Gene;podocyte;Proteins;Recurrence;Renal Mass;renal toxin;Sickle Cell Anemia;Syndrome;transcriptomics;Transgenic Mice;Variant,Focal Segmental Glomerulosclerosis: Genetics & Mechanisms,43308,NA,NA,NA,NA,29,NA,NA,1827056,NA
11195404,ZIA,DK,1,N,NA,NA,NA,NA,ZIADK043411,NA,NA,1ZIADK043411-18,NIDDK:522016\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,79990227 (contact),"HEYMANN, JURGEN  (contact)",NA,NA,NA,absorption;Affect;Aftercare;AIDS-Associated Nephropathy;APOL1 gene;Apoptosis;Biology;Cell Proliferation;Cells;Classification;Clinical;Data;Desmin;Differentiation Antigens;Distal;Distal convoluted renal tubule structure;Double-Stranded RNA;End stage renal failure;Epithelium;Focal and Segmental Glomerulosclerosis;Genes;Genetic;genetic variant;glomerulosclerosis;HIV;HIV-1;HIV/AIDS;Hyperplasia;Hypertrophy;Hyponatremia;Individual;Injury;Kidney;kidney cortex;Kidney Diseases;Mediating;Messenger RNA;Mineralocorticoid Receptor;mitochondrial dysfunction;Molecular;mouse model;Mus;Nephrons;Obesity;Oxidative Phosphorylation;Parietal;Pathogenesis;Pathologic;Pathway interactions;Patients;Phenotype;podocyte;PRKR gene;Protein Kinase;Proteins;Proteinuria;Renal Mass;renal toxin;response;Risk;risk variant;Role;sensor;Sickle Cell Anemia;single nucleus RNA-sequencing;SLC12A3 gene;Sodium;Sodium Chloride;South Africa;STAT protein;STAT3 gene;symporter;synaptopodin;Syndrome;System;Tetracyclines;transcriptome sequencing;transcriptomics;transgene expression;Transgenic Mice;Tubular formation;Variant;Viral Proteins;Virus Diseases;vpr Gene Products;wasting,Focal segmental glomerulosclerosis: HIV-associated nephropathy,43411,NA,NA,NA,NA,18,NA,NA,522016,NA
11195405,ZIA,DK,1,N,NA,NA,NA,NA,ZIADK043412,NA,NA,1ZIADK043412-18,NIDDK:261008\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,9736339 (contact),"KOPP, JEFFREY BURNETT (contact)",NA,NA,NA,Africa South of the Sahara;Agonist;AIDS-Associated Nephropathy;Cells;cellular targeting;Chronic Kidney Failure;Data;Disease;Focal and Segmental Glomerulosclerosis;Functional disorder;global health;HIV;Injury;Intervention;Investigation;Kidney;Laboratory Study;metabolomics;mitochondrial dysfunction;Molecular;multiple omics;Mus;Niacinamide;Nicotinamide adenine dinucleotide;nicotinamide-beta-riboside;novel therapeutics;Pathogenesis;Pathway interactions;podocyte;Production;receptor;Role;Testing;Transgenic Mice;Tubular formation,Focal segmental glomerulosclerosis: Treatment,43412,NA,NA,NA,NA,18,NA,NA,261008,NA
11195406,ZIA,DK,1,N,NA,NA,NA,NA,ZIADK060100,NA,NA,1ZIADK060100-29,NIDDK:938447\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,1921349 (contact),"HINSHAW, JENNY E (contact)",NA,NA,NA,"Alleles;Binding;Biological;Biological Assay;Cell membrane;Cells;Centronuclear myopathy;Charcot-Marie-Tooth Disease;Chemicals;Clathrin;Clathrin Adaptors;Clathrin Light Chains;Collaborations;Complex;constriction;cost;Coupled;Cryo-electron tomography;Cryoelectron Microscopy;Cytoskeleton;Defect;density;Devices;Disease;Drosophila genus;Dynamin;Dynamin I;Electron Microscopy;Elements;Endocytosis;Environment;Enzymes;Event;F-Actin;falls;Family member;Freezing;Funding;gang;Grant;GTP Binding;Guanosine Triphosphate;Guanosine Triphosphate Phosphohydrolases;Homologous Gene;Human;Hydrolysis;insight;Ion Channel;Length;Link;Lipid Bilayers;Lipid Binding;Lipids;Liposomes;Mammalian Cell;Mediating;member;Membrane;Membrane Proteins;Methods;millisecond;Modeling;Molecular Conformation;mutant;Mutation;National Heart, Lung, and Blood Institute;National Institute of Neurological Disorders and Stroke;Nature;Neck;New York;novel;Nutrient;overexpression;Pathway interactions;Peripheral Nervous System Diseases;PH Domain;Phosphatidylinositol 4,5-Diphosphate;phosphatidylinositol 4-phosphate;Phospholipids;Play;Polymers;Positioning Attribute;Preparation;Protein Family;Proteins;receptor;Recycling;Resolution;Role;Sampling;shibire gene product;Signal Transduction;Signaling Protein;Speed;structural biology;Structure;Synapses;Synaptic Membranes;Synaptic Vesicles;Temperature;Testing;three dimensional structure;Time;timeline;Tooth Diseases;trafficking;Tube;Vesicle;Work","Structure And Function Of Dynamin, A 100kd GTPase Involved In Endocytosis",60100,NA,NA,NA,NA,29,NA,NA,938447,NA
11195407,ZIA,DK,1,N,NA,NA,NA,NA,ZIADK060107,NA,NA,1ZIADK060107-18,NIDDK:938447\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,1921349 (contact),"HINSHAW, JENNY E (contact)",NA,NA,NA,Autosomal Dominant Optic Atrophy;Binding;Biogenesis;Biological;Biological Assay;Biological Process;Blindness;C-terminal;Cell Physiology;Cells;Characteristics;Childhood;Chloroplasts;Collaborations;Crista ampullaris;Cryoelectron Microscopy;Crystallography;Dimerization;Docking;Dynamin;Electrons;Endocytosis;Equilibrium;Event;Exhibits;Family member;Future;Goals;GTP Binding;Guanosine Triphosphate;Guanosine Triphosphate Phosphohydrolases;Hydrolysis;Inner mitochondrial membrane;insight;Integral Membrane Protein;Knock-in;Lead;Length;Lipid Bilayers;Lipids;Liposomes;Mammalian Cell;Maps;Mediating;Membrane;Membrane Fusion;Microscopy;Mitochondria;mitochondrial membrane;Molecular Conformation;Morphology;mutant;Mutation;Nature;Nucleotides;OPA1 gene;Organelles;Outer Mitochondrial Membrane;particle;Plants;Property;protein complex;Protein Family;Proteins;proteoliposomes;Resolution;Role;self assembly;SNAP receptor;Structure;Testing;Time;Transmembrane Domain;Viral Physiology;Visualization;Work,Structural analysis of dynamins involved in mitochondrial morphology,60107,NA,NA,NA,NA,18,NA,NA,938447,NA
11195408,ZIA,DK,1,N,NA,NA,NA,NA,ZIADK071014,NA,NA,1ZIADK071014-17,NIDDK:1546870\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,9693534 (contact),"CHEN, KONG  (contact)",NA,NA,NA,3-Dimensional;Adult;African American;Age;Agreement;Area;Basal metabolic rate;biological adaptation to stress;Blood;Body Composition;Body measure procedure;Body Surface Area;Body Temperature;Brown Fat;Child;Childhood;Clinical;clinical center;Clinical Protocols;Clinical Research;CLN3 gene;Clothing;Control Groups;Data;design;developmental disease;Dietary intake;Disease;Dual-Energy X-Ray Absorptiometry;Energy Intake;Energy Metabolism;environmental change;Equation;Ethnic Origin;Expenditure;Fasting;Fatty acid glycerol esters;Female;fighting;Food;Goals;healthy volunteer;Heart Rate;Hour;Human;improved;Indirect Calorimetry;Inherited;Inpatients;interest;Intervention;Lasers;male;Measurement;Measures;men;Metabolic;military operation;Movement;Natural History;Nervous System;novel strategies;Obesity;obesity development;Participant;Patients;PET/CT scan;Phase;Physical activity;Positron-Emission Tomography;Postbaccalaureate;Process;programs;Protocols documentation;Publications;Publishing;Race;Randomized;Regulation;Research;response;Rest;Role;Shivering;skeletal dysplasia;Skeletal Muscle;Skin;Techniques;Temperature;Thermogenesis;Thinness;Training;United States National Institutes of Health;urinary;volunteer;Weight;Women&apos;s cohort;X-Ray Computed Tomography,Development of obesity and metabolic clinical research programs,71014,NA,NA,NA,NA,17,NA,NA,1546870,NA
11195409,ZIA,EB,1,N,NA,NA,NA,NA,ZIAEB000046,NA,NA,1ZIAEB000046-18,NIBIB:2076832\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING,NA,NA,NA,9693608 (contact),"LEAPMAN, RICHARD  (contact)",NA,NA,NA,3-Dimensional;A kinase anchoring protein;Area;Biological;Brain;Brain imaging;Cell membrane;Cell Nucleus;Cells;Complex;Cryoultramicrotomy;Cysteine;Darkness;Data;Dendritic Spines;density;detection sensitivity;detector;DLG4 gene;Dose;Drug Metabolic Detoxication;Elasticity;Electron Beam;Electron energy loss spectroscopy;Electron Microscope;Electron Microscopy;electron tomography;Electrons;Elements;Endosomes;Epoxy Resins;Exocytosis;Face;Fluorescence;fluorescence imaging;Freeze Drying;Freeze Substitution;Freezing;frontier;Gallium;Golgi Apparatus;Hippocampus;Image;imaging approach;imaging modality;Implant;implementation facilitation;interest;Ions;knock-down;Knowledge;Label;Laboratories;lens;Magnetic Resonance Imaging;Manganese;Maps;Measurement;Measures;meter;Methods;Microscope;Microscopy;Microtome - medical device;Microtomy;Modernization;Mutate;Mutation;N-terminal;nanometer;nanoprobe;nanoscale;Neurons;Neurosciences;novel;Optics;Organelles;palmitoylation;Penetration;Photons;postsynaptic;Proteins;Rattus;reconstruction;Regulation;Reporting;Resistance;Resolution;Roentgen Rays;sample fixation;Sampling;Scanning;Scanning Electron Microscopy;Series;Serine;Signaling Protein;Slice;Source;Specimen;Stains;Structure;Subcellular structure;Surface;Synapses;Synaptic plasticity;Techniques;Testing;Thick;three dimensional structure;Time;tissue preparation;Tissues;tomography;Trace Elements;trafficking;Transmission Electron Microscopy;transmission process;uptake;Vesicle;Visualization;Work;X ray spectroscopy,Scanning Transmission Electron Tomography of Biological Structures,46,NA,NA,NA,NA,18,NA,NA,2076832,NA
11195410,ZIA,EB,1,N,NA,NA,NA,NA,ZIAEB000086,NA,NA,1ZIAEB000086-12,NIBIB:3245052\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING,NA,NA,NA,9693608 (contact),"LEAPMAN, RICHARD  (contact)",NA,NA,NA,3-Dimensional;Address;Adherence;Adopted;Alpha Granule;Animals;Arkansas;Atherosclerosis;Autoimmune Diseases;automated segmentation;Binding;Biogenesis;Biological;Biological Assay;biological systems;Blood coagulation;blood damage;Blood donor;Blood Platelets;Blood Vessels;Cardiovascular Diseases;Carotid Arteries;cell dimension;cell fixing;Cell Line;Cells;cellular imaging;Cellular Morphology;Chemoreceptors;chronic inflammatory disease;Clinical;Coagulation Process;Collaborations;Collagen;Computing Methodologies;convolutional neural network;Coupled;COVID-19;COVID-19 complications;COVID-19 patient;Data;deep learning;density;Diabetes Mellitus;Diagnostic;Diamond;Electron Microscope;Electron Microscopy;electron tomography;Electrons;Endothelial Cells;Endothelium;Evaluation;experience;Exposure to;Face;Gallium;Glass;Growth;Healthcare;Hemoglobin;Hemorrhage;Hemostatic function;Hospitalization;Human;Image;Implant;In Situ;Individual;inhibitor;injured;Injury;Ions;Kentucky;Knock-out;Laboratories;Lateral;Lead;Link;Liver;Liver neoplasms;LOC118430 gene;Lung;Machine Learning;Malignant Neoplasms;Mechanics;Medical;meter;Methodology;Methods;Mitochondria;Modeling;Molecular;Monitor;Morbidity - disease rate;Morphology;mortality;mouse model;Mus;Mutation;nanometer;nanoscale;National Institute of Biomedical Imaging and Bioengineering;Obesity;optical imaging;Organelles;Phase;Physiological;Platelet Activation;Platelet aggregation;prevent;Process;Proteinase-Activated Receptors;Proteins;Puncture wound;radioresistant;receptor;reconstruction;recruit;Reporting;Resolution;respiratory;response;Scanning;Scanning Electron Microscopy;Science;Series;Sickle Cell;Sickle Cell Anemia;Signal Transduction;Site;Solid;Specimen;Stains;Statistical Data Interpretation;Structure;Structure of jugular vein;Surface;System;Techniques;Thinness;Three-Dimensional Image;Thrombin;Thrombosis;thrombotic;Thrombus;Time;tissue reconstruction;Tissues;Translating;transmission process;Tunica Adventitia;ultra high resolution;Ultramicrotomy;Universities;Vascular Diseases;vascular injury;Work,Three-Dimensional Cell and Tissue Reconstruction by Serial Block Face SEM,86,NA,NA,NA,NA,12,NA,NA,3245052,NA
11195411,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000010,NA,NA,1ZIATR000010-09,NCATS:1066904\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380100 (contact),"HAUGABOOK, SHARIE  (contact)",NA,NA,NA,absorption;Adhesions;Adult;Anemia;beta Globin;beta Thalassemia;Birth;Blood Vessels;Brain;Canada;Cell Death;Cessation of life;Chronic disability;Clinical;Clinical Pharmacology;Clinical Trials;Compensation;Data;Defect;Development;dimer;Disease;Drug Interactions;Drug Kinetics;drug repurposing;effective therapy;efficacy study;Erythrocytes;European Union;Excretory function;Fatigue;fetal;Fetal Hemoglobin;Formulation;Genes;Genetic Diseases;Goals;Health;Heart;Hemoglobin;Hemoglobin A;Hemoglobin concentration result;Hemoglobinopathies;Investigational Drugs;Investigational New Drug Application;Lead;Lung;manufacture;Metabolism;Mutation;Organ;Oxygen;Pharmaceutical Preparations;Pharmacology Study;Phase;Point Mutation;Polymers;Production;Proteins;Recommendation;Sampling;Sickle Cell Anemia;Sickle Cell Trait;Symptoms;targeted treatment;thalassemia intermedia;Therapeutic;Therapeutics for Rare and Neglected Diseases;Toxicology;United States Food and Drug Administration,Repurposing an EU Therapeutic for Hemoglobinopathies,10,NA,NA,NA,NA,9,NA,NA,1066904,NA
11195412,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000013,NA,NA,1ZIATR000013-10,NCATS:920000\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79320042 (contact),"HUANG, WENWEI  (contact)",NA,NA,NA,Affect;Africa South of the Sahara;analog;Animals;Anti-malarials;Biological Assay;Bite;Chills;Culicidae;Data;design;Development;Diarrhea;Disease;Dose;Drug Kinetics;Evaluation;Fever;FRAP1 gene;Goals;Headache;Human;improved;in vivo;Infection prevention;Lead;lead optimization;Lipids;Malaria;malaria infection;malaria transmission;Modeling;mosquito-borne;Myalgia;National Center for Advancing Translational Sciences;novel drug class;Oral;Organ;Parasite Control;Parasites;Parasitic Diseases;Patients;Persons;Pharmaceutical Preparations;Phosphotransferases;Pilot Projects;Plasmodium falciparum;Preparation;Property;Recovery;reduce symptoms;Rodent;Scientist;Series;Sweating;Symptoms;Testing;Time;Toxicology;transmission blocking;transmission process;Vomiting;Work,Development of Malaria Transmission-Blocking Drugs,13,NA,NA,NA,NA,10,NA,NA,920000,NA
11195413,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000018,NA,NA,1ZIATR000018-10,NCATS:2200000\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380109 (contact),"ZHENG, WEI  (contact)",NA,NA,NA,2019-nCoV;Acceleration;ACE2;Action Potentials;Affect;Alagille Syndrome;Animal Model;anti-cancer;Anti-viral Agents;antiviral drug development;Area;Artificial Intelligence;artificial intelligence method;artificial intelligence model;assay development;Axon;Binding;Biological Models;Biotechnology;Brain;cancer cell;cancer drug resistance;Cardiac Myocytes;Cell Differentiation process;Cell Line;cell type;Cells;Cessation of life;chemotherapy;Clinical;Clinical Data;Clinical Treatment;Clinical Trials;Collaborations;Collection;colon cancer cell line;Communication;Computer Models;computerized;cost;COVID-19;Data;Data Analyses;Development;Disease;disease mechanisms study;disease model;disease phenotype;dopaminergic neuron;Drug Costs;drug development;drug discovery;drug efficacy;Drug Industry;drug repurposing;Drug resistance;Drug Targeting;Drug toxicity;experience;experimental study;Fluorouracil;frontier;Generations;Genetic;Genetic Diseases;Goals;Heparitin Sulfate;Hepatocyte;high throughput screening;Human;human induced pluripotent stem cells;Impairment;In Vitro;in vitro Assay;Incidence;induced pluripotent stem cell;induced pluripotent stem cell technology;Industry;Intellectual functioning disability;laboratory experiment;Lead;Length;Libraries;Liver;Malignant Neoplasms;Manuscripts;Medicine;Midbrain structure;Modeling;Motor Neurons;National Center for Advancing Translational Sciences;National Institute of Diabetes and Digestive and Kidney Diseases;Nature;neglect;Neuromuscular Junction;neuron development;Neurons;Neuropathy;new technology;new therapeutic target;novel;novel strategies;novel therapeutics;Organoids;Pathogenesis;patient derived induced pluripotent stem cells;Patients;Pharmaceutical Preparations;Phenotype;Platinum;Positioning Attribute;pre-clinical;Process;Protocols documentation;Publications;Publishing;rare genetic disorder;receptor;refractory cancer;Research Personnel;Resources;RNA Viruses;Sampling;SARS-CoV-2 entry inhibitor;SARS-CoV-2 spike protein;screening;Screening procedure;standard care;stem cells;Study models;System;Therapeutic;therapeutic candidate;therapeutic evaluation;Therapeutics for Rare and Neglected Diseases;Time;Training;United States National Institutes of Health;Universities;Viral;viral entry inhibitor;Viral Proteins;virtual;virtual screening;Virus;Work,Drug Repurposing Screening for Rare and Neglected Diseases,18,NA,NA,NA,NA,10,NA,NA,2200000,NA
11195414,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000019,NA,NA,1ZIATR000019-10,NCATS:1066907\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380093 (contact),"OTTINGER, ELIZABETH  (contact)",NA,NA,NA,Abdominal Pain;Anatomy;Biological Products;biomaterial compatibility;blood perfusion;Clinical;Clinical Research;Clinical Trials;controlled release;design;effective therapy;Formulation;Generations;Genes;Goals;Greater sac of peritoneum;imaging agent;Indwelling Catheter;Infection;Intercellular Fluid;intraperitoneal;intraperitoneal therapy;Intravenous;intravenous administration;Lead;Malignant neoplasm of pancreas;manufacture;Oncology;Oral Administration;Paclitaxel;particle;Particle Size;Patients;Penetration;Peritoneal;Pharmaceutical Preparations;Pharmacodynamics;Pharmacologic Substance;Polymers;pressure;prevent;Property;randomized trial;Research Personnel;small molecule therapeutics;Solid Neoplasm;System;Systemic Therapy;Toxic effect;Toxicology;tumor;vector;Work,Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer,19,NA,NA,NA,NA,10,NA,NA,1066907,NA
11195415,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000055,NA,NA,1ZIATR000055-10,NCATS:1104911\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79294820 (contact),"MATHÉ, EWY  (contact)",NA,NA,NA,Area;authority;Breathing;Categories;Chemical Structure;Chemicals;Classification;clinical investigation;Clinical Trials;Code;Collaborations;Computer software;Country;Data;data exchange;data modeling;Data Set;Disease;DNA Sequence;Drug Industry;Drug or Chemical;Electronics;Environment;Evaluation;Event;Future;global health;Goals;Health;improved;Information Systems;International;Language;Life Cycle Stages;Marketing;Medicine;Modeling;Names;National Center for Advancing Translational Sciences;Pharmacologic Substance;pharmacovigilance;Phase;Plants;post-market;Process;Production;Proteins;Research;Research Personnel;Safety;Scientist;software development;software systems;Source;Staging;Standardization;Structure;supply chain;System;Technology;Terminology;United States Food and Drug Administration;Work,Global Substance Registration System,55,NA,NA,NA,NA,10,NA,NA,1104911,NA
11195416,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000056,NA,NA,1ZIATR000056-10,NCATS:1104912\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79294820 (contact),"MATHÉ, EWY  (contact)",NA,NA,NA,Area;Case Report Form;Case Study;Cellular Phone;Clinical;clinical practice;Collaborations;collaboratory;Collection;Communicable Diseases;Communities;COVID-19;COVID-19 pandemic;Critical Pathways;crowdsourcing;Data;Data Collection;Development;Disease;Dose;drug candidate;drug development;drug repurposing;Drug usage;Electronic Health Record;experience;Fostering;handheld mobile device;Health Personnel;Health Professional;Human;individual patient;Internet;Intervention;Legal;Life;Marketing;Medical;Medical Device;Monkeypox;National Center for Advancing Translational Sciences;neglect;novel;novel therapeutics;Outcome;Pathway interactions;Pharmaceutical Preparations;Pilot Projects;Population;Reporting;repository;Research;Resources;Sarcoma;Societies;Therapeutic;United States Food and Drug Administration;United States National Institutes of Health;web site;World Health Organization,CURE ID App for Infectious Disease Case Reporting,56,NA,NA,NA,NA,10,NA,NA,1104912,NA
11195417,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000057,NA,NA,1ZIATR000057-10,NCATS:1104912\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79294820 (contact),"MATHÉ, EWY  (contact)",NA,NA,NA,Code;Communities;Comprehension;Data;Data Aggregation;Data Set;Databases;Development;Drug Targeting;Funding;Future;G-Protein-Coupled Receptors;Generations;Genome;Informatics;informatics tool;Ingestion;interest;Ion Channel;Knowledge Management Center;Maintenance;Malignant Neoplasms;mouse model;Pathway interactions;Phase;Phosphotransferases;Process;programs;Protein Family;Proteins;Publications;Research;Research Personnel;Resources;Source;Technology;Update;web portal;web site;Work,Knowledge Management Center for Illuminating the Druggable Genome,57,NA,NA,NA,NA,10,NA,NA,1104912,NA
11195418,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000249,NA,NA,1ZIATR000249-09,NCATS:650000\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14755723 (contact),"TAWA, GREGORY  (contact)",NA,NA,NA,Affect;Animals;B-Lymphocytes;Bioinformatics;Biological Markers;Biology;biomarker validation;Blood;cancer cell;canine model;Canis familiaris;cell killing;Cell Line;Cells;companion animal;comparative;Complex;data streams;Diagnosis;Disease;Drug Combinations;Exhibits;experimental study;gene conservation;Human;Lung Adenocarcinoma;Malignant Neoplasms;Melanoma;Methods;Modeling;multiple omics;Mus;Oncology;Osteosarcoma;patient derived xenograft model;Pharmaceutical Preparations;Proteins;Research;synergism;T-Cell Lymphoma;Testing;therapeutic candidate;Tissues;transcriptome sequencing;transcriptomics;trend;Work,"Canine models for characterization, diagnosis, and treatment of human cancers using comparative canine-human transcriptomics",249,NA,NA,NA,NA,9,NA,NA,650000,NA
11195419,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000276,NA,NA,1ZIATR000276-08,NCATS:600000\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79294820 (contact),"MATHÉ, EWY  (contact)",NA,NA,NA,Acceleration;Address;Biological;Biomedical Research;Cell Physiology;Chemicals;Clinic;Clinical;Clinical Data;Communities;Complex;Computer Assisted;computer scientist;computerized tools;computing resources;Data;data mining;data repository;data reuse;Data Scientist;Data Sources;data standards;data translator;design;Disease;disease classification;Disparate;Environmental Exposure;Etiology;Event;falls;Functional disorder;Generations;Genes;Goals;heterogenous data;Human;human disease;information gathering;insight;Knowledge;knowledge network;Left;Manuals;Medical;Molecular;multimodality;National Center for Advancing Translational Sciences;open source;Pharmaceutical Preparations;programs;Publishing;Research;Research Personnel;Resources;response;Scientist;Services;Signs and Symptoms;Source;Specific qualifier value;System;therapeutic development;tool;Translational Research,NCATS Biomedical Data Translator,276,NA,NA,NA,NA,8,NA,NA,600000,NA
11195420,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000281,NA,NA,1ZIATR000281-08,NCATS:2652815\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380093 (contact),"OTTINGER, ELIZABETH  (contact)",NA,NA,NA,Address;Animal Model;Animals;assay development;Biotechnology;Capsid;Cell model;cellular development;Childhood;clinical center;clinical development;clinical lot;Clinical Protocols;Clinical Research;Clinical Trials;Cobalamin;Collaborations;Congenital Myasthenic Syndromes;cost;Dependovirus;design;Development;Development Plans;Disease;Documentation;efficacy study;efficacy testing;Engineering;experience;Feedback;Foundations;gene delivery system;gene product;gene therapy;Gene Transduction Agent;Genes;immunogenicity;improved;ketotic hyperglycinemia;Lead;lead candidate;Learning;manufacture;manufacturing process;manufacturing scale-up;meetings;Methods;methylmalonic aciduria;molecular pathology;National Center for Advancing Translational Sciences;National Human Genome Research Institute;National Institute of Child Health and Human Development;National Institute of Neurological Disorders and Stroke;Natural History;operation;Orphan Drugs;Paper;Patients;Pharmaceutical Preparations;Phase;Pilot Projects;pre-Investigational New Drug meeting;preclinical development;preclinical study;Preparation;Process;Production;programs;Rare Diseases;research clinical testing;Research Design;Safety;safety study;scale up;Scientist;Speed;Surrogate Markers;Technology;Testing;Therapeutic;Therapeutics for Rare and Neglected Diseases;Toxicology;United States National Institutes of Health;vector,Gene Therapy Platform for Rare Diseases,281,NA,NA,NA,NA,8,NA,NA,2652815,NA
11195421,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000340,NA,NA,1ZIATR000340-08,NCATS:250000\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79334278 (contact),"MARKOSSIAN, SARINE  (contact)",NA,NA,NA,Academia;Address;Area;Artificial Intelligence;Basic Science;Biological Assay;Biology;Biotechnology;Boston;California;Case Study;Chemicals;Chemistry;Communities;Cysteine;design;Discipline;Doctor of Medicine;Doctor of Philosophy;drug development;drug discovery;Drug Industry;editorial;Educational workshop;electronic book;Ensure;experience;Goals;Government;Guidelines;high throughput screening;Industry;innovation;International;Laboratories;Lead;Machine Learning;Manuals;Medical;member;Molecular Biology;National Center for Advancing Translational Sciences;novel therapeutics;outreach;Pharmaceutical Chemistry;Pharmaceutical Preparations;Pharmacologic Substance;Phase;Physiological;pre-clinical;preclinical development;professor;programs;Proteins;Protocols documentation;Public Health;Research;Research Project Grants;Resources;Sampling;San Francisco;Science;Scientist;Series;Source;symposium;Technology;Therapeutic;Time;Training;Training and Education;Translational Research;translational scientist;Translations;Universities;Update;Vesnarinone;virtual;Waiting Lists;web site;webinar;Writing,Assay Guidance Manual,340,NA,NA,NA,NA,8,NA,NA,250000,NA
11195422,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000424,NA,NA,1ZIATR000424-05,NCATS:2066904\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79320053 (contact),"ROGERS, TRACEY  (contact)",NA,NA,NA,Acute Pain;Address;Animals;Antibodies;Autologous Transplantation;biodegradable scaffold;Biodistribution;Biological Response Modifier Therapy;BMP2 gene;BMP6 gene;bone;bone fracture repair;bone healing;Bone Malalignment;Bone Morphogenetic Proteins;Bone Regeneration;Bone Transplantation;Cell Differentiation Induction;Cell membrane;chronic pain;Clinical Trials;Complex;Data;Development;Disadvantaged;Dose;Drug Kinetics;efficacy evaluation;efficacy study;Evaluation;first-in-human;Fracture;Goat;Harvest;healing;Hemorrhage;Hospitalization;Human;Implant;in vivo;Inflammation;Injectable;Injury;Innovative Therapy;Investigational New Drug Application;Lead;long bone;manufacture;Medical;Mesenchymal Stem Cells;Methods;Morbidity - disease rate;new technology;Operating Rooms;Operative Surgical Procedures;Osteogenesis;Pain;Patient Compliance;Patient Recruitments;Patients;Pharmaceutical Preparations;Physiological;Pilot Projects;plasmid DNA;Plasmids;pre-clinical;preclinical development;Procedures;protein expression;Quality of life;Recombinant Proteins;regenerative healing;repaired;research clinical testing;Risk;Sampling;Scientist;Sheep;side effect;Site;sonoporation;Spine surgery;stem cells;Surgeon;Technology;Time;tissue stem cells;Toxicology;ultrasound;United States;United States Food and Drug Administration;Weight-Bearing state,Targeted Bone Regeneration via Activation of Resident Stem Cells,424,NA,NA,NA,NA,5,NA,NA,2066904,NA
11195423,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000425,NA,NA,1ZIATR000425-05,NCATS:1800000\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380093 (contact),"OTTINGER, ELIZABETH  (contact)",NA,NA,NA,Adult;Agonist;Animals;autosome;Blood;bone;Bone Matrix;Calcium;calcium absorption;Childhood;Chronic;Clinical;clinical center;Clinical Trials;Coupled;Defect;Development;Disease;Documentation;Drug Kinetics;Epiphysial cartilage;Equilibrium;Excretory function;first-in-human;Formulation;Generations;Goals;good laboratory practice;Good Manufacturing Process;Grant;GTP-Binding Proteins;Heterozygote;Hypercalcemia;Hypophosphatemia;improved;In Vitro;in vivo evaluation;inorganic phosphate;Investigational New Drug Application;Ions;juvenile animal;Kidney;Lead;Ligands;long bone;manufacture;Measures;Metaphyseal chondrodysplasia;Methods;Minerals;mouse model;Mus;mutant;Mutant Strains Mice;Mutation;Natural History;Orphan Drugs;Patients;pediatric patients;Peptides;Pharmaceutical Preparations;Phase I Clinical Trials;Phase II Clinical Trials;Phenotype;Physiology;preclinical development;preclinical study;Preparation;Process;Proteins;Qualifying;Rare Diseases;Rattus;receptor;research clinical testing;Safety;Sampling;Scientist;Signal Transduction;skeletal;skeletal abnormality;Skeletal Development;Standardization;Testing;Therapeutics for Rare and Neglected Diseases;Toxicology;Transgenic Mice;United States National Institutes of Health;Validation;Vitamin D,A Treatment for Patients with Jansens Metaphyseal Chondrodysplasia (JMC),425,NA,NA,NA,NA,5,NA,NA,1800000,NA
11195424,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000426,NA,NA,1ZIATR000426-05,NCATS:1100000\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380093 (contact),"OTTINGER, ELIZABETH  (contact)",NA,NA,NA,Advocate;anti-cancer research;bioinformatics resource;Biomedical Computing;Clinical;Clinical Data;Collaborations;Computational Science;computing resources;Data;Data Analyses;Data Collection;Data Correlations;data resource;Dedications;Development;Diagnosis;Disparate;Farber&apos;s lipogranulomatosis;Genetic;Genetic Predisposition to Disease;genetic variant;Genome;Genomics;Genotype;Goals;improved;Individual;Informatics;insight;interactive visualization;Laboratories;Literature;Manuals;Mining;Modeling;National Cancer Institute;Pathogenicity;Patients;Phenotype;programs;Publications;Publishing;Rare Diseases;Research Personnel;Software Framework;Source;text searching;therapeutic development;therapy development;tool;Update;Variant;web app,Developing an Integrated Rare Disease Bioinformatics Resource to Determine Phenotype to Genotype Correlations,426,NA,NA,NA,NA,5,NA,NA,1100000,NA
11195425,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000427,NA,NA,1ZIATR000427-05,NCATS:450000\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14755723 (contact),"TAWA, GREGORY  (contact)",NA,NA,NA,Animals;Bioinformatics;Biological;bisulfite sequencing;Brain Neoplasms;cancer type;candidate marker;Canis familiaris;Cell Cycle;companion animal;comparative;Data;Disease;diverse data;DNA Methylation;Erinaceidae;Exhibits;FOXM1 gene;Genes;Genetic;Glioma;Goals;Histiocytic sarcoma;Histologic;Histopathologic Grade;Human;IL2 Signaling Pathway;Immune;Inflammatory;Location;Malignant Neoplasms;meningioma;Methods;Modeling;Oncology;Ontology;Pathway interactions;Pharmaceutical Preparations;Research;RNA analysis;Sampling;Spinal;Structure of choroid plexus;therapeutic target;transcriptome sequencing;tumor;whole genome,Genetic Characterization of Canine Brain Tumors,427,NA,NA,NA,NA,5,NA,NA,450000,NA
11195426,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000429,NA,NA,1ZIATR000429-05,NCATS:1066904\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79320053 (contact),"ROGERS, TRACEY  (contact)",NA,NA,NA,absorption;Acute;acute symptom;Agonist;antagonist;Anxiety;Auditory Hallucination;Beverages;Binding;Brain;cannabinoid administration;cannabinoid receptor;Cannabinoids;Cannabis;Chemicals;Clinical;clinical material;Clinical Research;Clinical Trials;CNR1 gene;Consumption;Data;Development;Dose;Drug Kinetics;Emergency Care;Evaluation;Flowers;Food;Formulation;Goals;Hospitalization;Hour;improved;Individual;Inhalation;Injectable;Intramuscular Injections;intravenous injection;Investigational New Drug Application;Lead;Marijuana;medical attention;Medical emergency;Nausea;Oral Administration;Overdose;Paranoia;Pharmacodynamics;Plants;pre-clinical;preclinical development;Psychotropic Drugs;receptor;Reporting;Research;research clinical testing;Route;Scientist;Smoke;Smoking;Symptoms;synthetic cannabinoid;synthetic marijuana;Tetrahydrocannabinol;Therapeutic;tool;Toxicology;Visual Hallucination,Development of Drinabant for Treatment of Acute Cannabinoid Overdose,429,NA,NA,NA,NA,5,NA,NA,1066904,NA
11195427,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000439,NA,NA,1ZIATR000439-03,NCATS:1066904\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380093 (contact),"OTTINGER, ELIZABETH  (contact)",NA,NA,NA,3-Dimensional;Academia;acute toxicity;Affect;aging population;Algorithms;American;Amyotrophic Lateral Sclerosis;animal data;Animal Experiments;Animal Testing;Animals;Antisense Oligonucleotide Therapy;Antisense Oligonucleotides;Area;assay development;Benchmarking;Biological Assay;Biological Sciences;bioprinting;Biotechnology;cell type;Cells;Central Nervous System;Cessation of life;Chemical Structure;Clinic;Clinical;clinical center;Clinical Trials;Clinical Trials Design;Clustered Regularly Interspaced Short Palindromic Repeats;Collaborations;Competence;cost;cost efficient;Data;design;Development;Diagnosis;Disease;Dose;drug development;drug discovery;Drug Industry;effective therapy;empowerment;experimental study;first-in-human;Foundations;frontotemporal lobar dementia amyotrophic lateral sclerosis;Future;Gene Delivery;gene therapy;Gene Therapy Agent;gene-targeted therapy;Genes;Goals;Human;improved;In Vitro;in vitro Assay;in vivo;individualized medicine;Induced pluripotent stem cell derived human neuron;Informatics;innovation;Laboratories;Lead;lipid nanoparticle;manufacture;manufacturing facility;meetings;Methods;Modality;Motor Neurons;Mus;Mutation;nanoparticle;National Center for Advancing Translational Sciences;National Institute of Neurological Disorders and Stroke;neglect;Nerve Degeneration;Neurodegenerative Disorders;Neurons;new technology;novel;novel strategies;novel therapeutics;oligonucleotide delivery;Oral;Organoids;Patients;Persons;Pharmaceutical Preparations;Pharmacologic Substance;Pharmacology;Phase;Population;prediction algorithm;predictive modeling;Process;Productivity;Property;prospective;Rare Diseases;Research;Research Personnel;Resources;Respiratory Failure;RNA;Route;Safety;scale up;screening;side effect;Small Interfering RNA;Speed;Standardization;System;targeted treatment;Technology;technology platform;Testing;Therapeutic;therapeutic RNA;Time;timeline;Tissues;Toxic effect;Toxicology;United States National Institutes of Health;Universities;uptake;Work,Antisense Oligonucleotide (ASO) Development for Rare and Neglected Diseases,439,NA,NA,NA,NA,3,NA,NA,1066904,NA
11195428,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000441,NA,NA,1ZIATR000441-03,NCATS:125000\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380093 (contact),"OTTINGER, ELIZABETH  (contact)",NA,NA,NA,2019-nCoV;Acceleration;assay development;Biological Assay;Clinical;clinical candidate;clinical development;clinical efficacy;Clinical Investigator;Communities;COVID-19;COVID-19 pandemic;COVID-19 therapeutics;COVID-19 treatment;COVID-19 vaccine;Data;Data Collection;data portal;Data Set;Deposition;Development;drug development;Drug Kinetics;drug metabolism;drug repurposing;efficacy testing;Formulation;Government;GS-441524;Human;Industry;Leadership;manufacture;model development;Mutation;National Center for Advancing Translational Sciences;Neutralization Tests;open data;particle;Pharmaceutical Preparations;pharmacokinetic model;Positioning Attribute;preclinical development;Productivity;Protocols documentation;Public Health;public-private partnership;Research;Resources;response;SARS-CoV-2 spike protein;SARS-CoV-2 variant;Scientist;screening;sharing platform;Standardization;therapeutic development;Therapeutic Intervention;therapeutic vaccine;Toxicology;United States National Institutes of Health;Vaccinated;Vaccines;Variant;Viral Physiology;Work,COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2,441,NA,NA,NA,NA,3,NA,NA,125000,NA
11195429,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000474,NA,NA,1ZIATR000474-02,NCATS:1066904\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79320053 (contact),"ROGERS, TRACEY  (contact)",NA,NA,NA,Adverse effects;Aerobic;Affect;Amikacin;Aminoglycoside Antibiotics;Aminoglycosides;analytical method;Antibiotic Therapy;Antibiotics;Auditory;capsule;Cessation of life;clinical research site;Data;design;Disease;Dizziness;Drug Interactions;Drug Kinetics;efficacy evaluation;Encapsulated;Equilibrium;Excipients;Formulation;Hair Cells;hearing impairment;Human Volunteers;Impairment;Infection;Inner Hair Cells;Labyrinth;manufacture;mycobacterial;Natural Killer Cells;Oral;ototoxicity;Patients;Pharmaceutical Preparations;phase I trial;Phase II Clinical Trials;phase II trial;pre-clinical;Preparation;prevent;prevent hearing loss;Safety;side effect;small molecule;Validation;vestibular system,Developing ORC-13661 for Preventing Aminoglycoside Antibiotics-induced Hearing Loss,474,NA,NA,NA,NA,2,NA,NA,1066904,NA
11195430,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000496,NA,NA,1ZIATR000496-01,NINDS:1874696\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79320053 (contact),"ROGERS, TRACEY  (contact)",NA,NA,NA,Acceleration;Acute Pain;Address;Analgesics;Binding;blood-brain barrier crossing;Brain;Chronic;chronic pain management;Clinical Trials;delta opioid receptor;Dependence;Discipline;drug action;drug repurposing;drug seeking behavior;efficacy study;Encapsulated;endogenous opioids;Enkephalins;first-in-human;Formulation;Genetic;Helping to End Addiction Long-term;high throughput screening;Human Biology;human model;In Vitro;in vivo;Infrastructure;Intranasal Administration;Investigational New Drug Application;Leucine Enkephalin;manufacture;Methods;Molecular;mu opioid receptors;National Center for Advancing Translational Sciences;non-cancer chronic pain;novel;novel therapeutics;Opioid;opioid epidemic;opioid use disorder;Pain;pain model;pain relief;Peptide Hydrolases;Peripheral;Pharmaceutical Preparations;Pharmacologic Substance;Phase;Plasma;Play;preclinical development;preclinical study;Prodrugs;Role;safety assessment;Science;side effect;Technology;Testing;therapeutic candidate;therapeutic development;Toxic effect;Toxicology;United States Food and Drug Administration;United States National Institutes of Health;Ventilatory Depression,"Fast, Centrally Acting, Non-Addicting Novel Analgesic for Chronic Non-Cancer Pain",496,NA,NA,NA,NA,1,NA,NA,1874696,NA
11195431,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000497,NA,NA,1ZIATR000497-01,NCATS:1066904\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380100 (contact),"HAUGABOOK, SHARIE  (contact)",NA,NA,NA,Acceleration;Address;ADME Study;Agonist;Alkaloids;Asia;Buprenorphine;capsule;Clinical;clinical investigation;Clinical Research;Clinical Trials;Controlled Clinical Trials;Data;Development Plans;Discipline;Drug Administration Schedule;Drug Interactions;Drug Kinetics;drug metabolism;drug repurposing;Fentanyl;first-in-human;Formulation;Helping to End Addiction Long-term;Heroin;high throughput screening;Human Biology;human model;In Vitro;Infrastructure;Investigational Drugs;Investigational New Drug Application;manufacture;meetings;Mitragyna;mu opioid receptors;National Center for Advancing Translational Sciences;novel therapeutics;Opioid agonist;opioid epidemic;opioid use disorder;opioid withdrawal;Pain;pain relief;Pharmaceutical Preparations;Pharmacologic Substance;Play;pre-clinical;pre-Investigational New Drug meeting;preclinical development;preclinical study;Process;Production;research clinical testing;respiratory;Risk;Role;Science;Sodium Chloride;Standardization;Testing;Therapeutic;therapeutic candidate;therapeutic development;Toxicokinetics;Toxicology;United States Food and Drug Administration;United States National Institutes of Health,Developing a Mitragynine Formulation to Conduct Rigorously Controlled Clinical Trials with a Kratom Alkaloid Extract,497,NA,NA,NA,NA,1,NA,NA,1066904,NA
11195432,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000498,NA,NA,1ZIATR000498-01,NCATS:1066904\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380100 (contact),"HAUGABOOK, SHARIE  (contact)",NA,NA,NA,Ablation;ADME Study;Agonist;Behavior;biological systems;cancer immunotherapy;Cells;Clinical Trials;Development;Dose;drug distribution;Drug Kinetics;exhaust;Exhibits;Formulation;Future;Goals;Immune;immune modulating agents;Immunologics;Investigational New Drug Application;Malignant Neoplasms;Monoclonal Antibodies;Myeloid-derived suppressor cells;neoantigens;Organ;Pancreas;Perfusion;Phenotype;preclinical development;preclinical study;Preparation;programs;research clinical testing;Safety;small molecule;Solid;Stomach;T cell infiltration;T-Lymphocyte;Therapeutics for Rare and Neglected Diseases;Toxicology;Treatment Efficacy;triple-negative invasive breast carcinoma;tumor;tumor microenvironment;Tumor-associated macrophages,First-in-Class CD206 Agonist for Immunologically Cold Solid Organ Cancers,498,NA,NA,NA,NA,1,NA,NA,1066904,NA
11195433,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000499,NA,NA,1ZIATR000499-01,NCATS:1066904\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380100 (contact),"HAUGABOOK, SHARIE  (contact)",NA,NA,NA,Address;Area Analyses;Attention;Biomedical Research;Clinical;clinical care;Collaborations;Communities;Disparity;Ensure;Equity;Funding;Future;Health;health disparity;health equity;Inequity;Intervention;Knowledge;lens;Outcome;outcome disparities;Phase;Play;pre-clinical;pre-clinical research;preclinical development;Process;Rare Diseases;Recommendation;research and development;Resources;Role;Science;Therapeutic;therapeutic candidate;therapeutic development;tool;Visualization,Infusing Equity into Preclinical Research and Development,499,NA,NA,NA,NA,1,NA,NA,1066904,NA
11195434,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000500,NA,NA,1ZIATR000500-01,NCATS:1066904\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79320042 (contact),"HUANG, WENWEI  (contact)",NA,NA,NA,Anabolism;Breast Adenocarcinoma;cancer subtypes;Cell Death;Chemicals;Coenzyme Q10;Digit structure;Exhibits;inhibitor;Malignant Breast Neoplasm;Malignant Neoplasms;Modeling;Mus;novel;p38 Mitogen Activated Protein Kinase;Pathway interactions;Pharmaceutical Chemistry;Phosphotransferases;Role;Series;SKBR3;Structure;Therapeutic Agents;therapeutic candidate;virtual screening,Developing Therapeutic Candidates for Rare ADCK3-amplified Cancers,500,NA,NA,NA,NA,1,NA,NA,1066904,NA
11195435,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000501,NA,NA,1ZIATR000501-01,NINDS:1874696\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79990259 (contact),"WU, EDWARD  (contact)",NA,NA,NA,Acceleration;Address;Affect;antagonist;Behavior;Brain;Central Nervous System;chronic pain management;Clinical Trials;Discipline;drug repurposing;efficacy study;Encapsulated;Endocytosis;Endosomes;Ensure;first-in-human;Formulation;G Protein-Coupled Receptor Signaling;Helping to End Addiction Long-term;high throughput screening;Human Biology;human model;inflammatory pain;Infrastructure;innovation;Investigational New Drug Application;knock-down;lipid nanoparticle;Mediator;nanoparticle;nanoparticle drug;nanopolymer;National Center for Advancing Translational Sciences;Neurotransmitters;novel therapeutic intervention;novel therapeutics;opioid epidemic;opioid use disorder;Pain;Pain management;painful neuropathy;Peripheral Nervous System;Play;Posterior Horn Cells;Postoperative Pain;preclinical development;preclinical study;Process;Production;RNA-targeting therapy;Rodent;Role;Science;Small Interfering RNA;Spinal Cord;Spinal cord posterior horn;Synaptic Transmission;Testing;Therapeutic;Therapeutic Agents;therapeutic candidate;therapeutic development;therapeutic siRNA;transmission process;United States Food and Drug Administration;United States National Institutes of Health;Work,Targeting Endosomal GPCR (eGPCR) Signaling Platforms for the Treatment of Chronic Pain,501,NA,NA,NA,NA,1,NA,NA,1874696,NA
11195436,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000502,NA,NA,1ZIATR000502-01,NIDA:4016943\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79990259 (contact),"WU, EDWARD  (contact)",NA,NA,NA,Acceleration;addiction;Address;antagonist;blood pressure elevation;Brain;Cardiac;Clinical;Clinical Research;Clinical Trials;Cocaine;Collaborations;craving;Development;Discipline;Dopamine;dopamine D3 receptor;drug of abuse;drug repurposing;drug seeking behavior;first-in-human;Helping to End Addiction Long-term;high throughput screening;Human Activities;Human Biology;human model;In Vitro;Infrastructure;Investigational Drugs;Investigational New Drug Application;Lead;mesolimbic system;National Center for Advancing Translational Sciences;National Institute of Drug Abuse;novel therapeutic intervention;novel therapeutics;Opioid;opioid epidemic;opioid use disorder;Oxycodone;Pain;Pathway interactions;Pharmaceutical Preparations;pharmacologic;Play;Potassium Channel;Pre-Clinical Model;preclinical development;preclinical study;Production;Prosencephalon;receptor;Relapse;Rewards;Role;Science;Self Administration;Substance Use Disorder;System;Testing;therapeutic candidate;therapeutic development;Toxicology;United States Food and Drug Administration;United States National Institutes of Health,Development of D3 Antagonist for Substance Use Disorder,502,NA,NA,NA,NA,1,NA,NA,4016943,NA
11195437,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000503,NA,NA,1ZIATR000503-01,NINDS:1874696\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79990259 (contact),"WU, EDWARD  (contact)",NA,NA,NA,Acceleration;Address;Affect;Afferent Neurons;Animals;Attenuated;Biological Products;Body Weight;Botox;Botulinum Toxin Type A;Botulinum Toxins;Chemistry;Clinical Trials;Complex;cost effective;Development;Discipline;Drug Metabolic Detoxication;drug repurposing;first-in-human;Helping to End Addiction Long-term;high throughput screening;Human;Human Biology;human model;in vivo;Infrastructure;Investigational New Drug Application;manufacture;manufacturing process;National Center for Advancing Translational Sciences;nerve damage;neurotransmitter release;novel therapeutics;Opioid;opioid epidemic;opioid use disorder;Pain;pain relief;painful neuropathy;Paralysed;Pharmaceutical Preparations;Play;Population;preclinical development;preclinical study;Reporting;Rodent;Role;Safety;Science;side effect;Specificity;Testing;therapeutic candidate;therapeutic development;Therapeutic Uses;Toxic effect;United States Food and Drug Administration;United States National Institutes of Health,Development of a Non-Paralyzing BoNT-based Biopharmaceutical for the Treatment of Neuropathic Pain,503,NA,NA,NA,NA,1,NA,NA,1874696,NA
11195438,ZIC,DK,1,N,NA,NA,NA,NA,ZICDK071013,NA,NA,1ZICDK071013-17,NIDDK:1546870\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,9693534 (contact),"CHEN, KONG  (contact)",NA,NA,NA,2-arachidonylglycerol;Acids;Acyl Coenzyme A;adipokines;Adipose tissue;Adult;Age;Air;Amber;amino acid metabolism;analytical method;anandamide;Arachidonic Acids;Attenuated;behavior test;Bezafibrate;Biological Markers;Body Composition;Body mass index;Body Temperature;Body Weight;Branched-Chain Amino Acids;Brown Fat;Calorimetry;Cardiovascular Diseases;Central obesity;Clinical;Clinical Protocols;Clinical Research;cold stress;Collaborations;cytokine;Data Analyses;Defect;Deposition;design;Diabetes Mellitus;Diet;dietary;Docosahexaenoic Acids;Drug or chemical Tissue Distribution;Dual-Energy X-Ray Absorptiometry;Eicosapentaenoic Acid;Endocannabinoids;Energy Metabolism;Exercise Test;Exhibits;experience;Fatty acid glycerol esters;Fatty Acids;fibroblast growth factor 21;fitness;Food;Genetic;Genetic Transcription;Health Benefit;Heart Rate;Hereditary Disease;Human;improved;Inflammatory;inflammatory marker;Inpatients;instrument;Length of Stay;Linoleic Acids;Lipodystrophy;Lipomatosis;Liver;Lower Extremity;Malignant Neoplasms;Measurement;Measures;Medical;Metabolic;methylmalonic aciduria;methylmalonyl coA mutase deficiency;migration;Modification;mouse model;Mus;National Human Genome Research Institute;National Institute on Alcohol Abuse and Alcoholism;novel;Obesity;Obesity Epidemic;obesity treatment;Omega-3 Fatty Acids;Outpatients;Overweight;oxidation;Patients;Pattern;Phenotype;Physical activity;Physiological;Physiology;Plasma;Population;portability;Premenopause;Publications;Randomized;Regulation;Reporting;Research;Research Activity;Research Design;Research Personnel;respiratory;response;Rest;Scientist;small molecule;Strategic Planning;subcutaneous;Syndrome;System;Temperature;Thermogenesis;Transgenic Organisms;United States National Institutes of Health;Upper Extremity;Visceral fat;Woman,Human Energy and Body Weight Regulation Core,71013,NA,NA,NA,NA,17,NA,NA,1546870,NA
11195439,ZIC,TR,1,N,NA,NA,NA,NA,ZICTR000037,NA,NA,1ZICTR000037-10,NCATS:2962787\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,77854941 (contact),"LECLAIR, CHRISTOPHER ARTHUR (contact)",NA,NA,NA,"Acceleration;Acoustics;Address;Adopted;Adoption;Analytical Chemistry;analytical method;Anti-viral Agents;antiviral drug development;Appointment;Area;arm;Auranofin;Binding Proteins;Biocompatible Materials;Biological;Biology;Calibration;Career Choice;career development;Cells;Chemicals;Chemistry;Cholesterol;Chromatography;Circular Dichroism Spectroscopy;Collaborations;Collection;Communities;computer scientist;Coronavirus;COVID-19;COVID-19 pandemic;COVID-19 treatment;Data;data acquisition;Data Analyses;data management;Data Storage and Retrieval;design;Detection;Development;Disease;drug development;drug discovery;Education;Educational workshop;Emerging Technologies;Enhancers;Ensure;Enzymes;Equipment;Equipment and supply inventories;experience;Extramural Activities;Family;Goals;Gold;High Pressure Liquid Chromatography;high throughput screening;Hybrids;improved;Industry Standard;Injections;innovation;instrument;instrumentation;Intellectual Property;interest;kinase inhibitor;Knowledge;Laboratories;Learning;Libraries;Lipids;Liquid Chromatography;liquid chromatography mass spectrometry;Management Information Systems;Maryland;Mass Fragmentography;Mass Spectrum Analysis;medical schools;meetings;member;Mentorship;Methods;milligram;Mission;Modality;National Center for Advancing Translational Sciences;National Heart, Lung, and Blood Institute;National Institute of Diabetes and Digestive and Kidney Diseases;Nematoda;next generation;NMR Spectroscopy;novel;Nuclear Magnetic Resonance;Oral;pandemic disease;pandemic potential;Peer Review;Peptides;Performance;Pharmaceutical Chemistry;Pharmaceutical Preparations;Phosphatidylcholine-Sterol O-Acyltransferase;Phosphotransferases;Postbaccalaureate;Postdoctoral Fellow;posters;pre-clinical;preclinical development;Preparation;Procedures;Process;process optimization;Productivity;professional atmosphere;programs;Proteins;Proteomics;Protocols documentation;Publications;rare condition;Reporting;Reproducibility;Research;Research Personnel;Research Project Grants;Resolution;Resources;Rheumatoid Arthritis;Robotics;Sampling;Schedule;Scientist;screening;screening program;Serum;Services;Site;small molecule;small molecule inhibitor;Supercritical Fluid Chromatography;symposium;System;Techniques;Technology;telework;Therapeutic;therapeutic candidate;therapeutic target;Time;Tissues;tool;Training;Translational Research;translational scientist;Tube;Universities;Vibrational Circular Dichroism;Viral;Virus;Water;Work",Analytical Chemistry,37,NA,NA,NA,NA,10,NA,NA,2962787,NA
11195440,ZIC,TR,1,N,NA,NA,NA,NA,ZICTR000242,NA,NA,1ZICTR000242-10,NCATS:5765918\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,15198057 (contact),"MICHAEL, SAMUEL  (contact)",NA,NA,NA,Acoustics;Aptitude;arm;assay development;Astrocytes;Augmented Reality;Automation;Biological;Biological Assay;Biology;Biomanufacturing;Boston;Cancer Biology;cell bank;Cells;Chemical Structure;Chemicals;Clinical;Collaborations;Collection;Communities;Complex;Computer software;Country;Custom;Dana-Farber Cancer Institute;Data;Data Analyses;Databases;design;detector;Development;Device Designs;Devices;Dose;Drug Combinations;Emerging Technologies;Engineering;Equipment;Evaluation;Feedback;flasks;follow-up;Friends;high throughput screening;human induced pluripotent stem cells;Hybrids;Hypothalamic structure;Image;imager;improved;Incubators;induced pluripotent stem cell;instrument;instrumentation;Internet;Intramural Research Program;Laboratories;Libraries;Liquid substance;Maintenance;Measures;medical schools;member;Methods;Mission;National Center for Advancing Translational Sciences;Nature;Neurobiology;Neurons;Neurosciences;new technology;next generation;Nociceptors;operation;Patients;Pediatric Hospitals;Peripheral;Phase;preservation;Process;Production;Protocols documentation;Rare Diseases;Recording of previous events;Reporting;Research;Research Personnel;Research Support;Reservations;response;Retrieval;Robot;Robotics;Running;Sampling;scale up;Schedule;Scientist;screening;Services;Site;Small Business Innovation Research Grant;small molecule;Spottings;stem cells;System;Technology;Testing;Time;tissue culture;Training;trophoblast;Tube;Universities;Validation;Vial device;vigilance;Work,Research Services Core (RSC),242,NA,NA,NA,NA,10,NA,NA,5765918,NA
11195441,ZIC,TR,1,N,NA,NA,NA,NA,ZICTR000410,NA,NA,1ZICTR000410-05,NCATS:4051343\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,79294820 (contact),"MATHÉ, EWY  (contact)",NA,NA,NA,Acceleration;Area;Bioinformatics;Biomedical Research;cheminformatics;Clinic;Clinical Data;complex data;Computational Biology;Computer software;Custom;Data;Data Analyses;Data Analytics;data modeling;Data Science;Data Set;Development;Ensure;Goals;Grant;high throughput screening;Informatics;insight;Knowledge;Maintenance;Mass Spectrum Analysis;Measurement;Methods;Mission;mobile application;Modeling;multidisciplinary;Multiomic Data;multiple omics;National Center for Advancing Translational Sciences;Natural Language Processing;Ontology;Outcomes Research;Publications;Rare Diseases;Research;research and development;Research Support;scientific computing;social media;software development;Source;Toxic effect;Translational Research;Translations;web app;Work,Informatics Research,410,NA,NA,NA,NA,5,NA,NA,4051343,NA
11195442,ZIC,TR,1,N,NA,NA,NA,NA,ZICTR000438,NA,NA,1ZICTR000438-03,NCATS:7543211\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,15198057 (contact),"MICHAEL, SAMUEL  (contact)",NA,NA,NA,"Acceleration;Address;Affect;Agreement;Air;Algorithms;Analytical Chemistry;analytical method;application programming interface;Artificial Intelligence;Artificial Intelligence platform;Automation;Awareness;Benchmarking;Biological;Biological Assay;Biological Process;Biology;blockchain;chemical reaction;chemical synthesis;Chemicals;Chemistry;Chromatography;Cloud Computing;Collaborations;computational platform;Computer software;cooking;cost;dashboard;Data;Data Analyses;data management;data sharing;density;design;Development;Devices;Diagnosis;Disease;drug discovery;Ecosystem;effective therapy;Electrospray Ionization;Emerging Technologies;Equilibrium;Equipment;Equipment and supply inventories;evaporation;experimental study;Extramural Activities;falls;Glass;Goals;Government;Health;high throughput screening;improved;indigo dye;Informatics;informatics tool;Infrastructure;innovation;innovative technologies;instrument;instrumentation;Intellectual Property;Intelligence;Interdisciplinary Study;Intuition;ionization technique;knowledgebase;Laboratories;Laboratory Chemicals;Learning Module;Legal patent;Link;Liquid substance;Machine Learning;Manuals;manufacture;mass spectrometer;Mass Spectrum Analysis;Medicine;Methods;Microfluidics;Modeling;Modernization;National Center for Advancing Translational Sciences;next generation;novel;novel strategies;novel therapeutics;open source;operation;opioid use disorder;Organic Chemistry;Pain;Pathway Analysis;Patients;Pharmaceutical Chemistry;Pharmaceutical Preparations;Pharmacologic Substance;Pharmacology;Phase;Positioning Attribute;Preparation;Process;Production;Professional Organizations;programs;prototype;Public Domains;Qualitative Methods;Reaction;Reagent;Reproducibility;Research;Research Personnel;Route;Running;Sampling;Schedule;Science;Scientist;screening;Secure;Services;sharing platform;simulation;Solid;Specific qualifier value;Spectrometry, Mass, Electrospray Ionization;Standardization;Structure;System;Systems Biology;technological innovation;Technology;Testing;Time;timeline;tool;Translational Research;Translations;United States National Institutes of Health;Universities;virtual;Vision;Work",Development of A Specialized Platform for Innovative Research Exploration (ASPIRE),438,NA,NA,NA,NA,3,NA,NA,7543211,NA
11195443,ZIE,EB,1,N,NA,NA,NA,NA,ZIEEB000057,NA,NA,1ZIEEB000057-18,NIBIB:1038417\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING,NA,NA,NA,9693608 (contact),"LEAPMAN, RICHARD  (contact)",NA,NA,NA,Acceleration;Award;Biomedical Engineering;biomedical imaging;Biomedical Technology;Clinical;clinical center;clinical translation;Collaborations;Development;Engineering;Fellowship;Fellowship Program;graduate student;Image;improved;Intramural Research;Joints;Mission;National Institute of Biomedical Imaging and Bioengineering;physical science;Postbaccalaureate;Postdoctoral Fellow;pre-doctoral;programs;Radiology Specialty;Research Personnel;Science;Scientist;summer internship;Talents;Technology;Training;Training Programs;Translational Research;undergraduate student;United Kingdom;United States National Institutes of Health;university student;Visit,Intramural Training of NIH Biomedical Imaging and Bioengineering Researchers,57,NA,NA,NA,NA,18,NA,NA,1038417,NA
11195485,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-P00002-759102000032-1,NCI:7879910\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,77878840 (contact),"DMITROVSKY, ETHAN  (contact)",NA,2020-09-25,2029-09-18,Antineoplastic Agents;drug efficacy;drug testing;high throughput screening;Investigation;Modeling;Mutation;Organoids;Patients;Pharmaceutical Preparations;pre-clinical;predictive marker;Resistance;response biomarker;tumor;Tumor Tissue,PREDICTIVE DRUG TESTING IN ORGANOID MODELS,0,NA,NA,NA,NA,NA,NA,NA,7879910,NA
11195486,N02,HL,NA,N,NA,NA,NA,NA,75N92021C00028,NA,NA,75N92021C00028-P00010-9999-1,NIAMS:790981\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ROCKVILLE,UNITED STATES,NA,08,556875508,US,2768901,"KAI RESEARCH, INC",MD,208523093,NA,78396173 (contact),"YOU, HUIQING  (contact)",NA,2021-09-30,2025-01-24,"Arthritis;Clinical Research;Clinical Trials;Contracts;Musculoskeletal Diseases;musculoskeletal injury;National Institute of Arthritis, and Musculoskeletal, and Skin Diseases;operation;research study;Rheumatism;Services;skin disorder;Source;Support Contracts",CLINICAL STUDIES MANAGEMENT AND SUPPORT (CSMS) - SOLE SOURCE BRIDGE CONTRACT,0,NA,NA,NA,NA,NA,NA,NA,790981,NA
11195487,Y01,CA,NA,N,NA,NA,NA,NA,ACN23011001,NA,NA,ACN23011001-1-0-1,NCI:800000\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Antibodies;Biological Assay;Biological Markers;cancer biomarkers;candidate marker;Colon Carcinoma;Coupled;Department of Energy;detection limit;Diagnosis;Diagnostic;Diagnostic Services;Early Detection Research Network;Laboratories;Liquid Chromatography;Malignant Breast Neoplasm;Malignant neoplasm of liver;Malignant neoplasm of lung;Malignant neoplasm of ovary;Malignant neoplasm of pancreas;Malignant neoplasm of prostate;Malignant neoplasm of urinary bladder;Mass Spectrum Analysis;Measurement;Measures;Monitor;Pacific Northwest;Plasma;pressure;Prognosis;Reaction;Resolution;Resources;Screening for cancer;Serum;Specimen;tissue biomarkers;Tissues;Tumor Tissue;Urine;verification and validation;Work,NCI Early Detection Research Network: Biomarker Reference and Resource Center (BRRC),230110,NA,NA,NA,NA,NA,NA,NA,800000,NA
11195488,N01,DA,NA,N,NA,NA,NA,NA,75N95022C00041,NA,NA,75N95022C00041-P00004-9999-1,NINDS:1970467\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,"Common data elements development, oversight of clinical trials, support for clinical research",78884711 (contact),"HEFNER, KATHRYN  (contact)",NA,2022-09-30,2025-09-29,archive data;Area;Clinical;clinical center;Clinical Data;Clinical Research;Clinical Trials;Common Data Element;Communities;Contractor;Contracts;data acquisition;data archive;design;Development;Education;Future;Methodology;Monitor;National Institute of Neurological Disorders and Stroke;Patients;Performance;Physicians;Policies;Preparation;programs;quality assurance;Quality Control;Resources;Services;Translations;United States National Institutes of Health;Work,NINDS CENTER FOR CLINICAL TRIAL RESOURCES,0,NA,NA,NA,NA,NA,NA,NA,1970467,NA
11195489,N02,HL,NA,N,NA,NA,NA,NA,92022A00592022F00001,NA,NA,92022A00592022F00001-P00002-0-1,NHLBI:783720\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,RESEARCH TRIANGLE PARK,UNITED STATES,NA,04,004868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,NA,78884720 (contact),"SEVERYNSE-STEVENS, DIANA  (contact)",NA,2022-09-30,2025-09-29,"Acceleration;Award;Clinical Research;Contract Services;Development;Diagnosis;falls;first-in-human;Grant;Heart Diseases;Hematological Disease;Lung Diseases;Maintenance;National Heart, Lung, and Blood Institute;new technology;pre-clinical;preclinical development;preclinical study;Prevention;Process;programs;Reporting;Secure;Services;Sleep Disorders;Technology;technology development;translational pipeline;Work",NHLBI CATALYZE PROGRAM - PRECLINICAL SERVICES COMPONENT - ADMINISTRATIVE SERVICES,0,NA,NA,NA,NA,NA,NA,NA,783720,NA
11195802,K12,AR,3,N,2024-09-20,2024-09-20,2025-04-30,846,K12AR084226,SCHOOLS OF MEDICINE,RFA-OD-21-006,3K12AR084226-19S1,OD:225169\,OTHER RESEARCH-RELATED,2024,NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES,NA,Aurora,UNITED STATES,INTERNAL MEDICINE/MEDICINE,06,041096314,US,1199905,UNIVERSITY OF COLORADO DENVER,CO,800452571,"Project Narrative The areas of women’s health and sex differences research have long had an inadequate cadre of investigators with top quality training sufficient to make them competitive for limited research funding dollars. By using interdisciplinary training and excellent mentoring to develop the careers of the research leaders of tomorrow, we can address the most important, pressing questions in women's health and sex and gender differences. By equipping early career scientists to find the answers, we have every expectation that this grant will lead the way to tangible improvements in women's health in the United States.",1869031 (contact);6666568,"REGENSTEINER, JUDITH G. (contact);SANTORO, NANETTE F.","TIGNO, XENIA",2024-09-20,2027-04-30,Advisory Committees;Appointment;Bioinformatics;career;career development;Colorado;Complex;Educational Curriculum;Environment;evidence base;experience;Funding;Gender;Goals;Grant;Growth;health difference;improved;Individual;innovation;Institution;Interdisciplinary Study;K-Series Research Career Programs;Leadership;Learning;Medical;Medicine;Mentored Clinical Scientist Development Program;Mentors;Methods;programs;Publications;Publishing;Research;research and development;Research Design;research study;Scientist;sex;Sex Differences;skill acquisition;Talents;Time;tool;Training;Universities;Women&apos;s Health;Work,The Colorado Building Interdisciplinary Research Careers in Women's Health Program,84226,ZRG1,Special Emphasis Panel[ZRG1-PSE-W(50)],NA,S1,19,208490,16679,225169,NA
11195834,F30,AI,3,N,2024-09-20,2024-09-20,2025-01-15,855,F30AI181493,SCHOOLS OF MEDICINE,PA-21-049,3F30AI181493-01S1,NIAID:3000\,"TRAINING, INDIVIDUAL",2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NEW HAVEN,UNITED STATES,MICROBIOLOGY/IMMUN/VIROLOGY,03,043207562,US,9420201,YALE UNIVERSITY,CT,065208327,Project Narrative Intracellular bacterial pathogens remodel mammalian cell processes to replicate and cause disease. We propose to investigate how the intracellular pathogen Coxiella burnetii modulates the immune response to infection. This study will uncover fundamental details of the requirements for intracellular replication by bacterial pathogens and provide a possible therapeutic target for the treatment of these infections.,16051972 (contact),"DUNCAN-LOWEY, JEFFREY KARDAS (contact)","PERDUE, SAMUEL S",2024-01-16,2028-01-15,Acute;Address;antimicrobial;Binding;Biochemical;Biological Assay;C-terminal;career;Caspase;Cell Physiology;Cells;Chronic;chronic infection;Clinical Skills;clinical training;Communicable Diseases;Coxiella;Coxiella burnetii;Cysteine;cytokine;Cytoplasm;Development;Disease;Double-Stranded RNA;Engineering;Environment;experience;experimental study;Gene Expression;Gene Family;Genetic Epistasis;Genome;Goals;Human;Immune response;Immunoprecipitation;immunoregulation;improved;In Vitro;Infection;insight;Interferon Type I;Learning;Link;Luciferases;Lysosomes;Macrophage;Mammalian Cell;Maps;microbial;Modeling;Molecular;Molecular Target;Mutagenesis;mutant;N-terminal;pathogen;Pathogenesis;pathogenic bacteria;Pathway interactions;Patient Care;Peptide Hydrolases;permissiveness;Physicians;Preparation;Process;Productivity;programs;Proteins;Reporter;Research Personnel;RNA;RNA Binding;Role;Scientist;sensor;Signal Induction;Signal Transduction;skills;Specialist;Substrate Specificity;System;Testing;therapeutic target;Training;transcriptome sequencing;Ubiquitin;ubiquitin isopeptidase;Vacuole,The role of a Coxiella burnetii effector protein that inhibits RIG-I signaling,181493,ZRG1,Special Emphasis Panel[ZRG1-F07A-B(20)L],NA,S1,1,3000,0,3000,NA
11195835,Y01,CA,NA,N,NA,NA,NA,NA,ACO24005001,NA,NA,ACO24005001-1-0-1,NCI:469856\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Area;Bioinformatics;Contractor;design;Development;Documentation;Evaluation;improved;precision medicine;Process;Recommendation;systems research;Testing,Assessment of the Precision Medicine Analysis and Coordination Center (PMACC),240050,NA,NA,NA,NA,NA,NA,NA,469856,NA
11195836,Y01,CA,NA,N,NA,NA,NA,NA,ACO24004001,NA,NA,ACO24004001-1-0-1,NCI:422553\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Advisory Committees;cancer care;Collection;Consensus;Data;Data Collection;Data Element;data exchange;data interoperability;Data Set;data standards;Databases;Development;Diagnostic;effective therapy;Electronic Health Record;Elements;Fast Healthcare Interoperability Resources;Health system;innovation;Laboratories;Malignant Neoplasms;Medicaid;Medicare;Oncology;Prevention;programs;Public Health;Registries;Reproducibility;Research;Research Personnel;Source;Standardization;United States National Institutes of Health;Vendor;Work;working group,NIH - ONC Cancer Domain Collab,240040,NA,NA,NA,NA,NA,NA,NA,422553,NA
11195837,Y01,CA,NA,N,NA,NA,NA,NA,ACO21011001,NA,NA,ACO21011001-1-0-1,NA,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Academic Medical Centers;Budgets;Businesses;Cancer Center;Communication;Contractor;Contracts;cost effective;design;Development;Documentation;Federal Government;Future;Government;Guidelines;Health;information organization;Information Systems;Maintenance;Medical;Occupational activity of managing finances;operation;Paper;Patient Care;Policy Analysis;Procedures;programs;Recommendation;Regional Cancer;Reporting;Research;Resources;Service provision;Services;Support System;System;tool;Training;Training Support;Work,Portfolio Management Systems Support Services (PM3S),210110,NA,NA,NA,NA,NA,NA,NA,316313,NA
11195838,Y01,CA,NA,N,NA,NA,NA,NA,ACO20010001,NA,NA,ACO20010001-1-0-1,NIEHS:12000\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Academic Medical Centers;biomedical informatics;Biomedical Research;Cancer Center;Capital;Communication;Contractor;Contracts;Environment;experience;Federal Government;Health;information organization;Information Systems;Information Technology;Investments;Joints;Knowledge;Life Cycle Stages;Medical;medical specialties;Office Management;operation;Patient Care;Performance;Process;programs;Regional Cancer;Research;Service provision;Services;System;United States Dept. of Health and Human Services;Work,Program Management Office Support Services (PMOSS),200100,NA,NA,NA,NA,NA,NA,NA,12000,NA
11195842,R01,DE,7,N,2024-12-13,2024-09-20,2025-04-30,121,R01DE029200,SCHOOLS OF DENTISTRY/ORAL HYGN,PA-24-254,7R01DE029200-06,NIDCR:303445\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,LOS ANGELES,UNITED STATES,NONE,36,092530369,US,577505,UNIVERSITY OF CALIFORNIA LOS ANGELES,CA,900952000,"Project Narrative Inflammatory bone diseases such as periodontitis and peri-implantitis are very significant health issues that severely affect patients' quality of life and increase the risk of other systemic diseases. It is critical to understand the mechanism underlying bone remodeling in periodontitis and peri-implantitis and to develop effective strategies that prevent inflammatory bone loss and repair bone damaged. This proposal will elucidate a novel mechanism by which F-BOX Protein11 (FBXO11) regulates bone development and inflammation, and render FBXO11 signaling as a new therapeutic target to control and regenerate bone loss in periodontitis and peri-implantitis.",12679477 (contact),"CHANG, JIA  (contact)","WAN, JASON",2024-09-20,2025-04-30,NA,Molecular control of bone development and inflammation by FBXO11,29200,ODCS,"Oral, Dental and Craniofacial Sciences Study Section[ODCS]",NA,NA,6,193673,109772,303445,NA
11195859,P20,GM,1,N,2024-04-12,2024-04-15,2025-02-28,NA,P20GM152280,NA,PAR-22-250,1P20GM152280-01,NIGMS:245986\,RESEARCH CENTERS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,LAWRENCE,UNITED STATES,NA,01,076248616,US,1484302,UNIVERSITY OF KANSAS LAWRENCE,KS,660457552,NA,11105197 (contact),"AMBER WATTS, AMBER WATTS AMBER WATTS (contact)","CUPIT, PAULINE",2024-09-10,2029-02-28,Big Data;bioinformatics tool;cardiometabolic risk;Chronic;Cognition;cognitive benefits;cognitive function;cognitive performance;cognitive testing;effective therapy;Electronic Health Record;exercise intervention;Future;Goals;Health;Impairment;improved;innovation;Intervention;Measurement;Measures;Mediating;Menopause;moderate-to-vigorous physical activity;Neurobehavioral Manifestations;Participant;Patient Self-Report;Performance at work;Perimenopause;Physical activity;Physiological;Postmenopause;protective factors;Psychological Factors;psychological symptom;recruit;Reporting;Research;Risk;Risk Factors;Sampling;Sleep;Sleep disturbances;Societies;Symptoms;United States National Institutes of Health;vasomotor symptoms;Woman;Women&apos;s Health,Protective and Risk Factors for Cognitive Function in the Menopause Transition,152280,ZGM1,Special Emphasis Panel[ZGM1 RCB-9 (C1)],8223,NA,1,160775,85211,NA,245986
11195961,N02,LM,NA,N,NA,NA,NA,NA,75N97023F00098,NA,NA,75N97023F00098-P00001-0-1,NIAID:2500000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL LIBRARY OF MEDICINE,NA,FAIRFAX,UNITED STATES,NA,11,NA,US,10089012,BLACK CANYON CONSULTING LLC,VA,220336048,NA,79926308 (contact),"ESSER, HALEY  (contact)",NA,2024-09-28,2025-09-27,Alleles;Bacterial Drug Resistance;Bacterial Genome;Basic Science;beta-Lactamase;bioinformatics tool;colistin resistance;Collection;Combating Antibiotic Resistant Bacteria;Databases;Genes;Nomenclature;Organism;quinolone resistance;Research;Resistance;Resources;Services;tool;United States National Institutes of Health,Bioinformatics Tools and Services at NCBI for Combating Antibiotic Resistant Bacteria Research,0,NA,NA,NA,NA,NA,NA,NA,2500000,NA
11196002,ZIA,NR,1,N,NA,NA,NA,NA,ZIANR000019,NA,NA,1ZIANR000019-15,NINR:2547872\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NURSING RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NURSING RESEARCH,NA,NA,NA,10673179 (contact),"SALIGAN, LEOREY  (contact)",NA,NA,NA,Age;Anesthetics;Anxiety;Area;associated symptom;Autoimmune Diseases;behavioral health;bench to bedside;Bioenergetics;Biological;biopsychosocial factor;Brain-Derived Neurotrophic Factor;built environment;cancer biomarkers;Cancer Center;Cancer Patient;Cancer Survivor;cancer therapy;cancer-related cognitive impairment;Chronic;Chronic Disease;Chronic Fatigue Syndrome;climate change;Clinical;Clinical Research;Clinical Trials;Code;Collaborations;Colorectal Cancer;Communities;Complex;Dedications;Discrimination;Dose;Enrollment;Ensure;Environmental Risk Factor;Ethnic Origin;experience;Extramural Activities;farmer;Fatigue;Female;Female Breast Carcinoma;fibromyalgia patients;Financial Hardship;frailty;functional improvement;Functional Magnetic Resonance Imaging;functional outcomes;Genetic Polymorphism;Goals;gut microbiota;Health;health care settings;Health Promotion;Housing;Immigrant;improved;indexing;Individual;innovation;Intervention;Intravenous;Investigation;Ketamine;Knowledge;Laboratories;Link;Location;Long COVID;Magnetic Resonance Spectroscopy;male health;Malignant neoplasm of prostate;Malignant Neoplasms;Measures;Mental Depression;microbiota;Mission;Mitochondria;mortality;Muscle Mitochondria;National Cancer Institute;National Center for Complementary and Integrative Health;National Institute on Aging;neural circuit;Neurocognitive Deficit;novel therapeutics;Outcome;Outcome Study;Pain;painful neuropathy;Paper;Participant;Patient Self-Report;Patients;Perception;Performance;Persons;Phosphorus;physical conditioning;Physical environment;physical impairment;Population;Prevention;programs;Psychosocial Factor;Publications;Publishing;Quality of life;Race;Reporting;Research;Research Activity;Resources;Risk Factors;Rural;rurality;Scientist;Self Management;sex variable;Sexual Health;Skeletal Muscle;Sleep disturbances;social;Social Environment;social factors;Socioeconomic Status;symptom cluster;Symptoms;theories;Therapeutic;Translations;United States;United States National Institutes of Health;Urban Community;walkability;Work,Investigating Correlates and Therapeutics of Fatigue,19,NA,NA,NA,NA,15,NA,NA,2547872,NA
11196003,ZIA,NR,1,N,NA,NA,NA,NA,ZIANR000040,NA,NA,1ZIANR000040-02,NINR:580339\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NURSING RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NURSING RESEARCH,NA,NA,NA,79342249 (contact),"LAWAL, TOKUNBOR  (contact)",NA,NA,NA,Affect;Animal Model;Antioxidants;Biopsy;Birth;Calcium;Cell model;Cells;Coenzyme A;congenital myopathy;Contracts;Coupling;Disease;disease model;disease-causing mutation;experimental study;Functional disorder;Gatekeeping;Genes;genetic variant;Goals;improved;In Vitro;in vivo;Individual;Measures;Mesylates;mouse model;Muscle;Muscle Cells;Muscle Fibers;Muscle function;Muscle Weakness;Mutation;N-3 polyunsaturated fatty acid;Nicotinamide adenine dinucleotide;Oxidative Stress;Pathogenicity;Patients;pediatric patients;phase 1 study;Predisposition;Process;protein function;Proteins;release of sequestered calcium ion into cytoplasm;RyR1;safety testing;Sampling;Sarcoplasmic Reticulum;Skeletal Muscle;Skin;stem cells;Structure;Testing;Therapeutic;Tissue Banks;Variant;variant of unknown significance;Zebrafish,Functional characterization of genetic variants of uncertain significance in genes associated with excitation-contraction coupling disorders,40,NA,NA,NA,NA,2,NA,NA,580339,NA
11196004,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000435,NA,NA,1ZIATR000435-04,NCATS:870948\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380209 (contact),"HALL, MATTHEW  (contact)",NA,NA,NA,2019-nCoV;Acceleration;Address;atypical pneumonia;betacoronavirus;Biological Assay;biomedical scientist;Biotechnology;Clinical;Clinical Data;Communities;COVID-19;COVID-19 pandemic;COVID-19 pneumonia;COVID-19 therapeutics;dashboard;Data;data portal;Data Reporting;Data Set;data sharing;Disease;drug mechanism;drug repurposing;Economics;Goals;Government;high throughput screening;In Vitro;insight;Laboratories;lead candidate;Metadata;Names;National Center for Advancing Translational Sciences;novel;open data;pandemic disease;pandemic response;Pharmaceutical Preparations;Pharmacologic Substance;predictive modeling;Process;Protocols documentation;public database;Public Health;Publications;Publishing;Reporting;Research;Research Personnel;Resources;response;SARS-CoV-2 variant;screening;Site;Societies;Testing;Therapeutic;Therapeutic Intervention;therapy development;Time;tool;Update;user-friendly;Vaccines;Variant;Viral,An OpenData Portal to share SARS-CoV-2 drug repurposing data in real time,435,NA,NA,NA,NA,4,NA,NA,870948,NA
11196005,ZIA,TR,1,N,NA,NA,NA,NA,ZIATR000437,NA,NA,1ZIATR000437-03,NCATS:500000\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,14380209 (contact),"HALL, MATTHEW  (contact)",NA,NA,NA,2019-nCoV;3-Dimensional;Acceleration;Address;Adopted;Alpha Virus;Anti-viral Agents;anti-viral efficacy;antiviral drug development;Arenavirus;assay development;BCAR3 gene;Binding;Biochemical;Biological Assay;Biology;Bunyavirales;Cells;Cerebral endothelium;Chemicals;Chemistry;Chikungunya virus;clinical development;Clinical Trials;Collaborations;Collection;combat;Complex;Containment;Coronavirus;COVID-19 therapeutics;COVID-19 treatment;Data;Dedications;Dengue Virus;design;Development;Disease;disease model;DNA;DNA biosynthesis;drug development;drug discovery;Drug Evaluation;Drug Kinetics;drug metabolism;Eastern Equine Encephalitis Virus;Ebola;efficacy validation;emerging virus;endonuclease;Energy Transfer;Enterovirus 68;Evaluation;Exonuclease;Exposure to;Extramural Activities;Family;Family Picornaviridae;Flaviviridae;Flavivirus;Fostering;future pandemic;Goals;high throughput screening;high-throughput drug screening;Hospitalization;Human;human coronavirus;in silico;in vitro Assay;in vitro Model;in vivo;Infection;inhibitor;interest;Investigational Drugs;Investigational New Drug Application;Kunjin virus;Lassa virus;Lead;lead optimization;Length;Libraries;Liquid substance;Literature;Liver;Luciferases;Lung;Mayaro virus;member;Metals;Methyltransferase;Modeling;mutant;Mutation;nanoluciferase;National Center for Advancing Translational Sciences;neural;neurotropic virus;novel;novel therapeutics;Oral;outbreak concern;pandemic disease;pandemic potential;Papain;Paramyxovirus;Paxlovid;Peptide Hydrolases;Pharmaceutical Chemistry;pharmacophore;Physiological;Play;Pneumovirus;pre-clinical;preclinical development;Preparation;prevent;programs;Property;rapid testing;Reader;Recombinants;Reporter;Research Personnel;RNA-Directed RNA Polymerase;Role;Safety;SARS-CoV-2 inhibitor;SARS-CoV-2 protease;SARS-CoV-2 variant;screening;Serotyping;Severe Acute Respiratory Syndrome;Small Intestines;small molecule;small molecule libraries;spheroids;Structure-Activity Relationship;synergism;System;Technology;Testing;Therapeutic;Therapeutic Intervention;therapeutic target;Tissue Model;Togaviridae;Toxicology;United States Food and Drug Administration;United States National Institutes of Health;Validation;variants of concern;vascular bed;Venezuelan Equine Encephalitis Virus;Venezuelan Equine Encephalomyelitis;Viral;Viral Load result;viral outbreak;viral pandemic;Viral Physiology;Viral Proteins;virology;Virus;Virus Diseases;Virus Inhibitors;virus testing;West Nile virus;Work;working group;Zika Virus,Antiviral Program for Pandemics (APP) & NCATS: Accelerating Antiviral Development,437,NA,NA,NA,NA,3,NA,NA,500000,NA
11196006,ZIH,LM,1,N,NA,NA,NA,NA,ZIHLM010016,NA,NA,1ZIHLM010016-04,NLM:8002291\,INTRAMURAL RESEARCH,2024,NATIONAL LIBRARY OF MEDICINE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL LIBRARY OF MEDICINE,NA,NA,NA,78343103 (contact),"MORK, JAMES  (contact)",NA,NA,NA,Address;Africa;American;Area;base;biobank;Biological Models;biomedical informatics;Blood;career;Cataloging;Classification;Clinical;clinical center;Clinical Data;clinical imaging;Clinical Informatics;Clinical Research;Clinical Sciences;clinical trial protocol;Clinical Trials;Code;Collaborations;Color;Complex;computerized data processing;Data;data communication;Data Science;Data Set;data standards;deep learning;deep learning algorithm;design;Detection;Development;Electronic Health Record;Electronic Mail;Eligibility Determination;Environment;Extravasation;Fast Healthcare Interoperability Resources;Fluorescein Angiography;Fundus;fundus imaging;Goals;Guidelines;Health;Healthcare;HIV;HIV/AIDS;Hour;Human;Hygiene;Image;image processing;Immunology;improved;indexing;Individual;Informatics;innovation;Institution;Intellectual Property;interest;Internet;Investigation;Journals;large language model;Lead;Leadership;Legal patent;Machine Learning;Malaria;Measures;MEDLINE;meetings;MeSH Thesaurus;Microbiology;mobile application;Modeling;Molecular;Monitor;Needs Assessment;Optic Disk;optical disc;Outcome;Paper;parallel processing;Parasitemia;Parasites;Patients;Performance;Policies;Process;programs;prototype;Public Health Schools;Publications;Reporting;Research;Research Institute;Research Personnel;Resources;Retina;Retinal Vasculitis;Rodent;Rodent Model;sensor;smartphone application;SNOMED Clinical Terms;software development;special interest group;System;Systematized Nomenclature of Medicine;Terminology;Thoracic Radiography;Time;tool;tool development;Trademark;Training;Translating;Translational Research;Treaty;Tropical Medicine;United States;United States National Institutes of Health;United States National Library of Medicine;Update;Uveitis;Vision;web site;Work,Applied Clinical Informatics,10016,NA,NA,NA,NA,4,NA,NA,8002291,NA
11196009,Y01,AT,NA,N,NA,NA,NA,NA,AAT24001001,NA,NA,AAT24001001-1-0-1,NCCIH:1000000\,INTERAGENCY AGREEMENTS,2024,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,NA,(contact),NA,NA,NA,Adult;Caring;Centers for Disease Control and Prevention (U.S.);Child;Complementary Health;cost;Disease;Frequencies;Individual;Integrative Medicine;National Health Interview Survey;Prevalence;Questionnaires;Sampling,National Health Interview Survey by Centers for Disease Control and Prevention,240010,NA,NA,NA,NA,NA,NA,NA,1000000,NA
11196042,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-P00001-759102200016-1,NCATS:2448234\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,78864285 (contact),"MANGALAMPALLI, VENKATA  (contact)",NA,2022-09-12,2027-09-11,adeno-associated viral vector;analytical method;Bioreactors;cell bank;Chemistry;Clinical;Clinical Research;Cyclic GMP;Development;Equipment and supply inventories;gene therapy;Generations;Genes;interest;Investigational New Drug Application;manufacture;manufacturing process;National Center for Advancing Translational Sciences;open source;Pharmaceutical Preparations;Preparation;Process;Serotyping;Shipping;Testing,NCATS-DPI-22-0101 - CREATION OF AN OPEN-SOURCE PROCESS TO MANUFACTURE AAV VECTOR-BASED GENE THERAPY CANDIDATES FOR NON-COMMERCIAL CLINICAL STUDIES,0,NA,NA,NA,NA,NA,NA,NA,2448234,NA
11196043,N01,HD,NA,N,NA,NA,NA,NA,75N94022C00005,NA,NA,75N94022C00005-P00003-9999-1,NICHD:755423\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,MINNEAPOLIS,UNITED STATES,NA,05,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,NA,78885067 (contact),"GURVICH, VADIM  (contact)",NA,2022-09-29,2025-09-28,Agonist;analog;Androgens;antagonist;Area;Chemical Agents;chemical synthesis;Chemicals;Clinical Research;Contraceptive Agents;Contraceptive methods;Contractor;Contracts;Development;drug candidate;Estrogens;Evaluation;Female Contraceptive Agents;Fertility Agents;Goals;Good Manufacturing Process;Government;Human;Kilogram;Laboratories;Male Contraceptive Agents;manufacture;men;milligram;Natural Products;new chemical entity;Peptides;Pharmaceutical Preparations;preclinical safety;Preparation;Progestins;Program Development;programs;Proteins;Research Support;Role;safety study;small molecule;Steroids;Testing;Toxicology;unnatural amino acids;Woman,CHEMICAL SYNTHESIS FACILITY FOR CONTRACEPTIVE DEVELOPMENT,0,NA,NA,NA,NA,NA,NA,NA,755423,NA
11196049,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-P00008-759101900138-1,NCATS:5077161\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,16188225 (contact),"MITRA, GEORGE  (contact)",NA,2019-09-23,2027-09-18,Address;base;Chemistry;clinical development;clinical lot;Clinical Research;Clinical Trials;Data;Development;Freedom;gene therapy;Gene therapy trial;Genes;manufacture;manufacturing process;manufacturing process development;Methods;methylmalonic aciduria;National Center for Advancing Translational Sciences;pre-clinical;Process;Rare Diseases;Technology;technology development;vector;Work,CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS,0,NA,NA,NA,NA,NA,NA,NA,5077161,NA
11196117,ZIA,AI,1,N,NA,NA,NA,NA,ZIAAI001391,NA,NA,1ZIAAI001391-01,OD:390000\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,6479726 (contact),"MOIR, SUSAN  (contact)",NA,NA,NA,Address;Adherence;Affect;Anti-Retroviral Agents;Anti-retroviral drug resistance;Antibodies;Antibody Therapy;antiretroviral therapy;Architecture;B-Lymphocytes;Cessation of life;Child;Clinical Management;Clinical Research Protocols;Data;Detection;Developed Countries;Developing Countries;Development;Disease Progression;disorder risk;Elements;Evolution;experience;Formalin;Genomics;Goals;Health;HIV;HIV drug resistance;HIV envelope protein;HIV Infections;HIV resistance;HIV-1;Hospitalization;imaging platform;Immune response;improved;indexing;Infant;Infection;Integrase Inhibitors;lymph node biopsy;Lymph Node Tissue;Lymphoid;Lymphoid Tissue;Modernization;Mozambique;Multi-Drug Resistance;National Institute of Child Health and Human Development;neutralizing antibody;novel;novel therapeutics;Opportunistic Infections;Paraffin;Persons;Pharmaceutical Preparations;Phenotype;Pilot Projects;Plasma;Prevalence;Process;Proteins;Recommendation;Regimen;Research Personnel;Resistance;Resources;RNA;RNA Stability;Role;Sampling;screening;Serum;side effect;Specimen;Technology;Therapeutic;Therapeutic Uses;Toxic effect;transcriptomic profiling;transcriptomics;Treatment Failure;Treatment Protocols;Viral;Viremia;Virus;Virus Replication,Development and therapeutic use of broadly neutralizing antibodies in people living with human immunodeficiency virus,1391,NA,NA,NA,NA,1,NA,NA,390000,NA
11196118,ZIA,AI,1,N,NA,NA,NA,NA,ZIAAI001392,NA,NA,1ZIAAI001392-01,OD:199026\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,10269192 (contact),"FRASER, IAIN  (contact)",NA,NA,NA,Acetylmuramyl-Alanyl-Isoglutamine;Acquired Immunodeficiency Syndrome;beta-Glucans;Biological Assay;Brain;CD4 gene;CD4 Positive T Lymphocytes;Cell Line;Cells;Coculture Techniques;Collaborations;combinatorial;Cytotoxic T-Lymphocytes;Data Analyses;Disease;DNA;Funding;gene repression;Genomics;Goals;Highly Active Antiretroviral Therapy;Histone Deacetylase Inhibitor;Histones;HIV;HIV Genome;Human;Human immunodeficiency virus test;Immune;Immunity;Immunology;Inflammation;Inflammatory;Macaca;Macrophage;Metabolism;metabolomics;Microglia;Modeling;monocyte;Montana;Myeloid Cells;National Center for Advancing Translational Sciences;National Institute of Allergy and Infectious Disease;Natural Killer Cells;North Carolina;novel;Pathogenesis;Patients;Peripheral Blood Mononuclear Cell;Persons;reactivation from latency;Regulation;Research;Rheumatoid Arthritis;Sampling;Scientist;SIV;Small Interfering RNA;small molecule;Stimulus;T-Lymphocyte;Technology;Testing;Training;transcriptome sequencing;transcriptomics;Universities,Trained Immunity as a Strategy for HIV Latency Reactivation,1392,NA,NA,NA,NA,1,NA,NA,199026,NA
11196119,ZIA,AI,1,N,NA,NA,NA,NA,ZIAAI001393,NA,NA,1ZIAAI001393-01,OD:321500\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,6479774 (contact),"CONNORS, MARK  (contact)",NA,NA,NA,Animal Model;Antigens;antiretroviral therapy;Autologous;Biological Assay;Candidate Disease Gene;CD4 Positive T Lymphocytes;CD8-Positive T-Lymphocytes;Cell Physiology;Cells;Clinical Trials;CRISPR/Cas technology;Data;Defect;differential expression;Disease;Flow Cytometry;Functional disorder;gene product;Goals;HIV;HIV-1;Immunity;Immunologics;Immunotherapeutic agent;Immunotherapy;Impairment;Interruption;Knowledge;Malignant Neoplasms;Mediating;Monoclonal Antibodies;novel;Patients;perforin;preclinical development;Proliferating;Proteins;Proteomics;Research Personnel;T cell response;Testing;therapeutic vaccine;transcriptomics;Vaccines;Virus;Work,Pre-Clinical Development of Novel Immunotherapies for HIV-1,1393,NA,NA,NA,NA,1,NA,NA,321500,NA
11196120,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002917,NA,NA,1ZIAMH002917-17,NIMH:7409332\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,11999773 (contact),"AMARA, SUSAN  (contact)",NA,NA,NA,Basic Science;Behavior;Brain;Circadian Rhythms;Clinical;clinical care;clinical development;Clinical Research;cognitive neuroscience;Congresses;Diagnosis;Doctor of Philosophy;Educational workshop;Environment;Ethics;Extramural Activities;Fostering;Funding;genome sequencing;interest;Intramural Research Program;Leadership;member;mental disorder prevention;Mental disorders;Mental Health;Mission;National Institute of Mental Health;neuroimaging;Productivity;Psychiatry;Research;Research Activity;Research Project Grants;Research Subjects;Resources;Scientist;Training;Translational Research;United States National Institutes of Health;whole genome;Work,Office of the Scientific Director,2917,NA,NA,NA,NA,17,NA,NA,7409332,NA
11196121,ZIA,MH,1,N,NA,NA,NA,NA,ZIAMH002946,NA,NA,1ZIAMH002946-12,NIMH:1944597\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,11999773 (contact),"AMARA, SUSAN  (contact)",NA,NA,NA,Acute;Address;Affect;Agonist;Amines;Amphetamines;Antipsychotic Agents;Attention Deficit Disorder;Attention deficit hyperactivity disorder;behavioral phenotyping;Biochemical;Biological;Carrier Proteins;Cell membrane;Cell Physiology;Cell surface;cell type;Cells;Chemosensitization;Child;Chronic;Cyclic AMP;Cyclic AMP-Dependent Protein Kinases;Data;Disease;Dopamine;Dopamine D2 Receptor;dopamine transporter;dopaminergic neuron;drug action;Drug usage;ecstasy;Endoplasmic Reticulum;Event;Excision;excitatory amino acid transporter 3;experimental study;extracellular;G-Protein-Coupled Receptors;Gene Expression;Glutamate Transporter;Glutamates;Goals;GTP-Binding Protein alpha Subunits;GTP-Binding Proteins;Homeostasis;Human;Incidence;Ion Channel;Laboratories;Learning;Ligands;Major Depressive Disorder;Mediating;Membrane Proteins;Membrane Transport Proteins;Mental disorders;Methamphetamine;Monomeric GTP-Binding Proteins;Movement;neuronal excitability;Neurons;neuropsychiatric disorder;neurotransmission;neurotransmitter reuptake;neurotransmitter transport;Neurotransmitters;Norepinephrine;novel;Pathway interactions;Pharmaceutical Preparations;Pharmacology;Pharmacotherapy;Phase;Phase II Clinical Trials;Physiological;Post-Traumatic Stress Disorders;presynaptic;Property;protein activation;receptor;Receptor Activation;Regulation;Research;Role;Schizophrenia;sensor;Serotonergic System;Serotonin;Serotonin Receptor 5-HT1A;serotonin transporter;Signal Pathway;Signal Transduction;Structure;subcellular targeting;System;Therapeutic;Therapeutic Effect;transcriptomics;Transgenic Mice;Work,"Structure, Function and Pharmacology of Neurotransmitter Reuptake Systems",2946,NA,NA,NA,NA,12,NA,NA,1944597,NA
11196122,ZIC,MH,1,N,NA,NA,NA,NA,ZICMH002901,NA,NA,1ZICMH002901-18,NIMH:902796\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,11999773 (contact),"AMARA, SUSAN  (contact)",NA,NA,NA,adeno-associated viral vector;Animal Experimentation;Animal Model;Animals;Behavior;Biochemical;blood-brain barrier crossing;Brain;brain cell;brain research;Callithrix;Cells;Circulation;Clustered Regularly Interspaced Short Palindromic Repeats;Collaborations;Complex;Core Facility;Cryopreservation;Derivation procedure;design;Development;Disease;Drug Delivery Systems;Electrophysiology (science);Embryo;Frequencies;Functional disorder;Gene Expression;Genes;genetic manipulation;Genetic study;Genome;Goals;Home;Human;innovation;Institution;International;Laboratories;Link;Liver;Mental disorders;Methods;migration;Monkeys;National Institute of Mental Health;Nervous System Physiology;neural;Neurosciences Research;new technology;Patients;Peripheral;Primates;Production;Rat Transgene;Research;Resources;Rodent;Role;Science;Symptoms;System;Techniques;Therapeutic;Transgenes;Transgenic Animals;Transgenic Mice;Transgenic Model;Transgenic Organisms;United States National Institutes of Health;Variant;vector;Virus,Transgenic Resources for Neuroscience Research,2901,NA,NA,NA,NA,18,NA,NA,902796,NA
11196123,ZII,MH,1,N,NA,NA,NA,NA,ZIIMH002947,NA,NA,1ZIIMH002947-10,NIMH:1096401\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NA,NA,11999773 (contact),"AMARA, SUSAN  (contact)",NA,NA,NA,Behavior;Behavioral;Brain;clinical center;clinical investigation;Cognitive;Collection;Dedications;design;Diagnosis;Environment;Epidemiology;Excision;Functional Imaging;Genetic;Housing;Human;imaging facilities;improved;Intramural Research;Intramural Research Program;Investigational Therapies;Leadership;Magnetic Resonance Imaging;Magnetoencephalography;Maintenance;meetings;Memory;Mental disorders;Modification;Molecular;molecular imaging;National Institute of Mental Health;neurophysiology;Neurosciences;nonhuman primate;Phase;Prevention;Productivity;Research;Research Project Grants;Resources;Scientist;social;sound;System;tissue culture;Work,"NIMH Space Activation, Maintenance, and Improvement",2947,NA,NA,NA,NA,10,NA,NA,1096401,NA
11196125,R01,EB,7,N,2024-11-29,2024-11-29,2025-05-31,286,R01EB032959,BIOMED ENGR/COL ENGR/ENGR STA,PA-24-254,7R01EB032959-04,NIBIB:329856\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING,NA,HOUSTON,UNITED STATES,ENGINEERING (ALL TYPES),09,050299031,US,9291001,RICE UNIVERSITY,TX,770051827,"Project Narrative Obesity affects more than 1.4 billion adults worldwide and is a significant risk factor for chronic diseases such as hypertension, diabetes, and cardiovascular diseases. However, present non-operative treatment options of obesity are woefully inadequate – intragastric balloons have been demonstrated to be effective in enabling temporary weight loss (~25-30% of excess body weight) but are fundamentally limited to very selected patients as a temporary treatment or as a bridging intervention to bariatric surgery. The proposed research will overcome the limitations of IGB by creating an ingestible gastric-resident electronic-enhanced metamaterial architecture (iGEM) that can transform obesity treatment with a digital-based personalized and dynamic obesity treatment strategy that can be optimized based on safety consideration, patient’s treatment goals, and the quality of life.",15216311 (contact),"KONG, YONG LIN  (contact)","FALCONE, JESSICA",2022-09-01,2026-05-31,NA,Ingestible gastric-resident electronic metamaterials architecture (iGEM) for the treatment of obesity,32959,ISD,Instrumentation and Systems Development Study Section[ISD],NA,NA,4,220500,109356,329856,NA
11196154,N01,HD,NA,N,NA,NA,NA,NA,75N94019D00005,NA,NA,75N94019D00005-P00002-759402300001-1,NICHD:140000\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,CHICAGO,UNITED STATES,NA,05,005436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606114579,NA,9468639 (contact),"GERSHON, RICHARD  (contact)",NA,2023-09-28,2025-08-31,Age Months;Archives;Assessment tool;Child;Child Behavior;Clinical;Cognition;Contractor;Contracts;Data;Data Collection;Development;Equipment and supply inventories;Evaluation;executive function;feasibility testing;Human Resources;Individual;Infant;Informal Social Control;instrument;Language;Learning;Legal Guardians;Manuals;mathematical ability;Measurement;Measures;Motor;Operating System;Output;Participant;Population;Publishing;Reporting;Research;Scientist;screening;Social Functioning;software systems;Standardization;Time;Toddler;tool;Training;United States National Institutes of Health;Validation;web site;Work;Writing,"MAKE READY THE NIH BABY TOOLBOX FOR END USERS: FINALIZE ALL PARTICIPANT-LEVEL DATA COLLECTION, ANALYSES, AND DISSEMINATION",0,NA,NA,NA,NA,NA,NA,NA,140000,NA
11196156,N01,AI,NA,N,NA,NA,NA,NA,75N93021C00009,NA,NA,75N93021C00009-P00009-9999-1,OD:137994\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MOUNT PLEASANT,UNITED STATES,NA,01,602545654,US,10006777,"XEQUEL BIO, INC.",SC,29464,NA,78095963 (contact),"CHATNEKAR, GUATAM  (contact)",NA,2021-03-16,2025-02-28,Acceleration;animal rule;Anti-Inflammatory Agents;Cutaneous;Development;efficacy study;efficacy validation;Gel;medical countermeasure;Peptides;porcine model;Property;Radiation Dose Unit;Radiation Injuries;Research;Safety;safety study;Skin wound healing;Therapeutic;Topical application;Validation,GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY,0,NA,NA,NA,NA,NA,NA,NA,137994,NA
11196157,N01,HD,NA,N,NA,NA,NA,NA,75N94021D00017,NA,NA,75N94021D00017-P00003-759402100001-1,NICHD:2500\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,NA,78397925 (contact),"WILCOX, WILLIAM  (contact)",NA,2021-09-28,2025-09-27,Advisory Committees;Affect;American;Authorization documentation;Cessation of life;Child;Child Health;Clinical;Collaborations;Contracts;Developmental Disabilities;Disabling condition;Disease;Early Diagnosis;Early treatment;Evaluation;Goals;Hereditary Disease;Intellectual functioning disability;Left;Medical Genetics;medical schools;Neonatal Screening;Nervous System Trauma;Newborn Infant;physically handicapped;Pilot Projects;Rare Diseases;Recommendation;Reporting;screening guidelines;Severities;tool,SUPPORT FOR THE NEWBORN SCREENING PILOT STUDIES RELATED ACTIVITIES,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11196158,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-P00002-759102300009-1,NCATS:564711\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79384981 (contact),"MOORE, MAX  (contact)",NA,2023-07-03,2026-07-02,CD4 Positive T Lymphocytes;Clinical;Contractor;cytokine;Development;Failure;gene therapy;Gene Transduction Agent;Human;human subject;immunogenicity;in silico;innovation;National Center for Advancing Translational Sciences;new technology;novel therapeutics;pre-clinical;preclinical development;programs;Protein Sequence Analysis;Rare Diseases;research clinical testing;response;T-Cell Activation;T-Lymphocyte Epitopes;Testing;therapeutic development,INSILICO AND EX-VIVO IMMUNOGENICITY ANALYSIS OF NCATS GENE THERAPY TEST,0,NA,NA,NA,NA,NA,NA,NA,564711,NA
11196339,R21,AI,7,N,2024-12-27,2024-09-24,2025-07-31,855,R21AI185998,SCHOOLS OF MEDICINE,PA-24-254,7R21AI185998-02,NIAID:251918\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,CHICAGO,UNITED STATES,MICROBIOLOGY/IMMUN/VIROLOGY,05,005436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606114579,"NARRATIVE. Syphilis is a sexually transmitted infection that causes significant human disease throughout the world. New diagnostics that accurately detect the syphilis agent, early in disease, would greatly improve patient outcomes by accelerating access to potentially life-saving treatment. We have discovered that the bacterium that causes syphilis sheds unique pieces of its’ cell-wall into its environment as it grows. In this proposal we will develop a diagnostic tool that specifically detects these unusual, released cell wall fragments, and critically assess its performance in human syphilis patient samples.",14919944 (contact),"JUTRAS, BRANDON LYON (contact)","GLOCK, JONATHAN A",2024-08-01,2026-07-31,Acceleration;accurate diagnostics;Animal Experimentation;Animal Model;Animals;Antibiotic Therapy;Antigen Targeting;aptamer;Bacteria;Bacterial Infections;Basic Science;Benchmarking;biobank;Biological Assay;Biological Markers;Biology;Birth;Cell Cycle;cell growth;Cell Wall;Cessation of life;Chemicals;Child;Clinic;Communicable Diseases;Communities;Congenital Syphilis;Data;Detection;Development;Diagnosis;Diagnostic;diagnostic platform;Diagnostic tests;diagnostic tool;Disease;DNA;early detection biomarkers;Early Diagnosis;effective therapy;Environment;Excretory function;Experimental Animal Model;extracellular;fetal;General Population;Generations;Genome;Growth;Health;Hour;Human;human disease;Immune response;Immunocompromised Host;improved;Individual;Infection;Knowledge;Label;Lesion;Life;Location;Lyme Disease;Medical;Methods;Monoclonal Antibodies;next generation;novel;novel diagnostics;novel strategies;Order Spirochaetales;Painless;Parents;Patient-Focused Outcomes;Patients;Peptidoglycan;Performance;point-of-care diagnosis;Populations at Risk;Pregnancy;Proteins;Publishing;Radioisotopes;rapid detection;Recombinants;Recycling;Reporting;Research Personnel;Resolution;response;Sampling;Sensitivity and Specificity;Serology;Serology test;Serum;sex;Sexual Transmission;Sexually Transmitted Diseases;Specificity;stillbirth;success;Syphilis;System;targeted treatment;Technology;Testing;transmission process;Treponema;Treponema pallidum;United States;Urine;virtual,Released peptidoglycan fragments are a biomarker for early stages of syphilis,185998,ZAI1,ZAI1-FDS-M(M1),NA,NA,2,176560,75358,251918,NA
11196342,R00,DE,4,N,2024-09-23,2024-07-01,2025-06-30,121,R00DE031784,SCHOOLS OF DENTISTRY/ORAL HYGN,PAR-19-144,4R00DE031784-03,NIDCR:248993\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,SAN ANTONIO,UNITED STATES,DENTISTRY,20,800772162,US,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,TX,782293901,"PROJECT NARRITIVE Periodontal disease remains a significant public health problem, and efforts in regenerating the periodontal tissues have shown limited success due to the inability to resolve inflammation and are insufficient to obtain complete and reliable periodontal regeneration. The goal of this proposal is to test the potential for translation of specialized molecules to control inflammation in stem cell based therapy for periodontal regeneration. The Yorkshire pig will be used as a large animal periodontal regeneration model to test stem cell therapy for periodontal regeneration and expedite the translation of stem cell based regenerative approaches to humans.",10966219 (contact),"RAKIAN, AUDREY  (contact)","VERBRIDGE, SCOTT SPENCER",2022-07-05,2029-06-30,Acceleration;Adopted;adult stem cell;Affect;Agonist;alveolar bone;American;Anabolism;Animal Model;Animals;antagonist;Anti-Inflammatory Agents;Area;Autologous;Bacterial Infections;Binding;Biochemical Process;biological systems;BMP2 gene;bone;bone healing;Bone Marrow;Bone Transplantation;CD59 Antigen;Cells;Chronic;chronic inflammatory disease;Clinical;clinical practice;Clinical Trials;Comparative Study;Craniofacial Abnormalities;craniofacial complex;cytokine;Data;Dental;Dentists;design;Development;dysbiosis;Enzyme Inhibitor Drugs;Etiology;Exhibits;Experimental Models;Family suidae;Funding;gene regulatory network;Goals;GPR6 gene;healing;Health;Homeostasis;Human;human disease;human stem cells;Immunology;immunoregulation;implantation;improved outcome;Inflammation;Inflammatory;inflammatory milieu;Inflammatory Response;Injury;innovation;Investigation;Knowledge;Learning;Leucine-Rich Repeat;lipid mediator;Lipoxins;Mediating;Mediator;Mentors;Mentorship;Metabolism;Mission;National Institute of Dental and Craniofacial Research;Natural regeneration;novel;Operative Surgical Procedures;Oral;oral microbiome;Osteoblasts;osteogenic;osteoprogenitor cell;Pain;Pathology;Pathway interactions;Periodontal Diseases;Periodontal Ligament;Periodontitis;Periodontium;Phase;Population;porcine model;Positioning Attribute;Postdoctoral Fellow;preference;Production;Property;Proteins;Public Health;receptor;regeneration model;regenerative;regenerative approach;regenerative therapy;regenerative tissue;Research;Residencies;Resolution;response;Role;Scientist;self-renewal;Signal Transduction;skills;stem cell biomarkers;stem cell therapy;stem cells;Strategic Planning;success;System;Systems Biology;Technology;Testing;Texas;therapeutic evaluation;tissue regeneration;tissue repair;Tissues;Tooth Tissue;Training;transcriptome sequencing;translation to humans;translational potential;Translational Research;Translations;Trauma;United States;United States National Institutes of Health;Universities;wound healing,Specialized Proresolving Lipid Mediator-Enhanced Stem Cell Therapy and Tissue Regeneration,31784,DSR,National Institute of Dental and Craniofacial Research Special Grants Review Committee[DSR],NA,NA,3,163932,85061,248993,NA
11196343,R00,DE,4,N,2024-09-25,2024-08-01,2025-07-31,121,R00DE031345,BIOMED ENGR/COL ENGR/ENGR STA,PAR-21-271,4R00DE031345-03,NIDCR:249000\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,CLEMSON,UNITED STATES,BIOMEDICAL ENGINEERING,03,042629816,US,1626401,CLEMSON UNIVERSITY,SC,296340001,"Project Narrative  Females experience temporomandibular disorders at higher rates compared to males, and African Americans have higher temporomandibular disorder incidence, yet lower prevalence compared to white Americans; the causes of these sex and race disparities remain largely unknown. The goal of the proposed study is to investigate how sex- and race-specific differences in human temporomandibular lateral capsule-ligament (LCL) complex properties may affect the temporomandibular joint loading environment. Sex- and race-specific differences in human LCL complex properties could result in a temporomandibular loading environment with variable resiliency and sensitivity to pathologic displacements between sexes and racial groups, creating disparities in temporomandibular joint disorder incidence and prevalence.",15435709 (contact),"HILL, CHERICE NATASHA (contact)","BACCAGLINI, LORENA",2022-08-04,2027-07-31,Adult;Affect;African American population;Appointment;Articulation;Biochemical;Biological Assay;Biology;biomechanical test;Biomechanics;Biomedical Engineering;capsule;caucasian American;Characteristics;Charge;Chemicals;Chronic;clinical care;Collagen;Complex;craniofacial;density;Development;dimorphism;Dislocations;Disparity;Elements;Environment;Enzyme-Linked Immunosorbent Assay;Etiology;Evaluation;experience;Faculty;Family;Fellowship;Female;Generations;Glycosaminoglycans;Goals;Grant;high risk;Human;Incidence;Investigation;joint destruction;joint loading;Joints;Lateral;Ligaments;Literature;Low Prevalence;male;Mandibular Condyle;Manuscripts;Mechanics;men;Mentors;Microscopy;Modeling;Molecular;Molecular and Cellular Biology;Morphology;Pain;Pathologic;Pathology;Pathway interactions;Patients;Phase;Population Heterogeneity;post-doctoral training;Postdoctoral Fellow;Preparation;Prevalence;programs;Property;Protocols documentation;Race;racial difference;racial disparity;racial population;Relaxation;Reporting;Research;Research Personnel;Research Proposals;resilience;resilience factor;Resource Development;Resources;responsible research conduct;Risk;Risk Assessment;Risk Estimate;Risk Factors;Sampling;second harmonic;sex;sex determination;Sex Differences;sex disparity;sex variable;sexual dimorphism;skill acquisition;social;statistics;Stress;Structure;success;Symptoms;System;Temporal bone structure;Temporomandibular Joint;Temporomandibular Joint Disorders;Testing;Tissues;Training;Translational Research;United States;United States National Institutes of Health;Universities;viscoelasticity;Woman;Work;Writing,Tissue structure and mechanical function relationships of the human temporomandibular lateral capsule-ligament: Investigation of sexual and racial dimorphisms,31345,DSR,National Institute of Dental and Craniofacial Research Special Grants Review Committee[DSR],NA,NA,3,161688,87312,249000,NA
11196446,P50,CA,3,N,2024-09-25,2023-06-01,2024-05-31,NA,P50CA217691,NA,PA-20-272,3P50CA217691-05S1,NCI:128040\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,"NARRATIVE The Administrative Core provides centralized functions for the Emory University Lung Cancer SPORE program to administer, coordinate, and oversee all meetings, budgets, financial and scientific reports, data management and sharing, project planning and evaluation, identification of new translational opportunities, problem solving, daily operations, and ethical conduct of the SPORE clinical studies. The Core will also provide support and administration for Developmental Research and Career Enhancement Programs, and coordination of the Executive Committee and Internal/External Advisory Boards. Core personnel will collaborate with NCI SPORE officials and with the members of other lung cancer SPORE programs nationally.",8576769 (contact),"RAMALINGAM, SURESH S (contact)","UJHAZY, PETER",2019-07-10,2025-05-31,Accounting;Administrative Supplement;Advocate;Basic Science;Budgets;Cancer Patient;career;clinical application;Clinical Ethics;Clinical Research;Clinical Trials;Collaborations;Committee Members;Companions;data management;data sharing;Dedications;design;Development;Educational workshop;Ensure;Ethics;Evaluation;Funding;Goals;Grant;Human Resources;Institution;Malignant neoplasm of lung;meetings;member;Mission;Monitor;operation;organizational structure;patient engagement;Patients;Performance;Pilot Projects;Play;Problem Solving;programs;Progress Reports;Regulation;remediation;Reporting;Research;Research Personnel;Research Project Grants;Resources;Role;Translating;translational potential;Translational Research;Travel;Universities,Administrative Core,217691,NA,NA,5511,S1,5,81815,46225,NA,128040
11196447,P50,CA,3,N,2024-09-25,2023-06-01,2024-05-31,NA,P50CA217691,NA,PA-20-272,3P50CA217691-05S1,NCI:128039\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,"PROJECT NARRATIVE The SPORE Pathology Core will provide expertise in lung cancer pathology to ensure efficient and highly- coordinated procurement, archiving, and storage of both fresh and archived lung cancer tissue specimens to support the Emory University Lung Cancer SPORE projects. These efforts will further advance our understanding of the biology of lung cancer, and will help define novel strategies for the treatment of lung cancer.",10878653 (contact),"SICA, GABRIEL LARKIN (contact)","UJHAZY, PETER",2019-07-10,2025-05-31,Administrative Supplement;American Joint Committee on Cancer;Animals;Antibodies;Archives;biobank;Biological Markers;Biology;biomedical informatics;Biometry;Blood;Cancer Patient;career;Catalogs;Cells;Classification;Clinical Data;Clinical Trials;clinically relevant;Collaborations;Collection;Communication;Confidentiality of Patient Information;Consent;Data;design;design and construction;Development;Diagnostic;Ensure;Equipment;experience;Flow Cytometry;Formalin;Freezing;Fresh Tissue;Funding;Histocytochemistry;Histopathology;human tissue;Immunohistochemistry;Infrastructure;Institution;Investigation;Laboratories;Link;Lung;Lung Neoplasms;Malignant neoplasm of lung;Malignant Neoplasms;Molecular Genetics;novel strategies;Nursing Research;Paraffin Embedding;Pathologic;Pathologist;Pathology;patient derived xenograft model;Patients;Peer Review;Procedures;Process;programs;prospective;Pulmonary Pathology;Recording of previous events;repository;Research;Research Personnel;Research Project Grants;Resources;Sampling;Scientist;Services;Specimen;Specimen Handling;Staging;Stains;Standardization;Technical Expertise;Tissue Banks;Tissue Embedding;Tissue Microarray;Tissue Sample;Tissue Viability;Tissues;Translational Research;translational study;treatment strategy;United States National Institutes of Health;Universities;Validation,Core 2:  Pathology Core,217691,NA,NA,5512,S1,5,81814,46225,NA,128039
11196449,P50,CA,3,N,2024-09-25,2023-06-01,2024-05-31,NA,P50CA217691,NA,PA-20-272,3P50CA217691-05S1,NCI:128039\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,"Our group has identified stem-like T cells that undergo proliferation after immune checkpoint inhibition. We will characterize these cells in lung tumors, draining lymph nodes and peripheral blood, and study their correlation with treatment outcome. In addition, we will study a novel combination regimen of mTOR inhibition and PD1 inhibition in lung cancer patients.",1869189 (contact),"AHMED, RAFI  (contact)","UJHAZY, PETER",2019-07-10,2025-05-31,Address;Adjuvant Study;Administrative Supplement;Aftercare;anti-cancer;Blood;Cancer Patient;cancer therapy;CD28 Antigens;CD28 gene;CD8-Positive T-Lymphocytes;Cells;Characteristics;checkpoint inhibition;Clinical;clinical efficacy;Combined Modality Therapy;cytokine;Data;Deuterium;draining lymph node;Effector Cell;efficacy study;Epigenetic Process;Excision;exhaust;exhaustion;FRAP1 gene;Funding;Genetic Transcription;Goals;Immune checkpoint inhibitor;Immune response;Immunity;Immunofluorescence Immunologic;Immunologic Factors;Immunologics;Immunotherapy;improved;in vivo;Infiltration;Investigation;Label;Location;Lung Neoplasms;Malignant neoplasm of lung;Measures;Monitor;mouse model;mTOR inhibition;mTOR Inhibitor;Neoadjuvant Study;Neoadjuvant Therapy;neoplastic cell;Non-Small-Cell Lung Carcinoma;novel;Operative Surgical Procedures;Patients;PD-1 blockade;peripheral blood;Phenotype;Play;Population;predictive marker;programmed cell death protein 1;Proliferating;Regimen;Resected;response;Role;Signal Transduction;Site;stem;stemness;T cell receptor repertoire sequencing;T-Cell Proliferation;T-Lymphocyte;T-Lymphocyte Subsets;targeted treatment;Techniques;Testing;Therapy trial;Tissues;Treatment outcome;tumor;Tumor Tissue,Project 1: Evaluating stem-like T cells and improving efficacy of checkpoint inhibitors in NSCLC,217691,NA,NA,5513,S1,5,81814,46225,NA,128039
11196450,P50,CA,3,N,2024-09-25,2023-06-01,2024-05-31,NA,P50CA217691,NA,PA-20-272,3P50CA217691-05S1,NCI:128039\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,Project Narrative: This proposal includes a phase 1b clinical trial of MRX-2843 and osimertinib in patients with advanced EGFRMT NSCLC and may lead to development of more effective and less toxic therapies to improve survival and quality of life for lung cancer patients. Correlative studies are included in the trial to identify potential biomarkers that could be used to monitor target inhibition and/or immune response in patients treated with the combination. Preclinical studies will also be conducted using animal models to expand our understanding of the direct and immune-mediated mechanisms by which MERTK contributes to tumorigenesis and resistance to EGFR inhibition in EGFRMT NSCLC.,1945686 (contact),"GRAHAM, DOUGLAS K (contact)","UJHAZY, PETER",2019-07-10,2025-05-31,ABCG2 gene;Address;Administrative Supplement;Aftercare;Animal Model;Binding;Biological Markers;Biopsy;Biopsy Specimen;Blood;Blood specimen;Bone Marrow;Cancer Etiology;Cancer Model;Cancer Patient;Caring;Cell Culture Techniques;cell killing;Cell Line;Cells;Cessation of life;chemokine;Clinical;clinical application;Clinical Research;Clinical Trials;cohort;Collection;Correlative Study;cytokine;cytotoxic;Cytotoxic Chemotherapy;Data;Dedications;Development;Dose;EGFR inhibition;Enrollment;Epidermal Growth Factor Receptor;Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor;Family;FDA approved;first-in-human;Funding;Generations;Genetic;Guidelines;Human;Immune;immune cell infiltrate;immune function;Immune response;Immune system;Immunologic Markers;Immunosuppression;Implant;improved;improved outcome;inhibitor;inhibitor therapy;Innate Immune Response;International;kinase inhibitor;Knock-out;Knockout Mice;Ligands;Lung;lung cancer cell;Malignant neoplasm of lung;Malignant Neoplasms;Mediating;Mediator;MERTK gene;Modeling;Monitor;mouse model;Multicenter Studies;Mus;mutant;Mutate;Mutation;mutational status;National Comprehensive Cancer Network;Natural Immunity;Neoplasm Metastasis;neoplastic cell;New Agents;Newly Diagnosed;Non-Small-Cell Lung Carcinoma;novel;novel strategies;Oncogenic;patient derived xenograft model;patient response;Patient-Focused Outcomes;Patients;permissiveness;Pharmaceutical Preparations;pharmacodynamic biomarker;Pharmacodynamics;Phase;Phase Ib Clinical Trial;Phenotype;Phosphorylation;potential biomarker;pre-clinical;preclinical study;Prognosis;programs;Quality of life;Receptor Protein-Tyrosine Kinases;Recombinants;Recommendation;Research Personnel;Resistance;Resistance development;resistance mechanism;resistance mutation;response biomarker;Role;Safety;Sampling;Signal Transduction;small hairpin RNA;subcutaneous;targeted treatment;Testing;Therapeutic;Therapeutic Effect;therapeutic target;Translating;tumor;tumor growth;Tumor Immunity;tumor microenvironment;Tumor-associated macrophages;tumorigenesis;Tyrosine Kinase Inhibitor,Project 2: Targeting MERTK to improve outcomes for EGFR-mutated NSCLC,217691,NA,NA,5514,S1,5,81814,46225,NA,128039
11196451,P50,CA,3,N,2024-09-26,2024-08-01,2025-07-31,397,P50CA221745,NA,PAR-14-353,3P50CA221745-05S1,NCI:896275\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,12,064931884,US,5079202,SLOAN-KETTERING INST CAN RESEARCH,NY,100656007,"Project Narrative We are applying the latest discoveries in cancer genomics and immunobiology to guide discovery efforts in cancer susceptibility, treatment decision-making, clinical trial development, and drug discovery for patients with urothelial cancer. This program will facilitate the identification and validation of biomarkers designed to guide treatment selection to maximize patient benefit. These comprehensive efforts target the entire spectrum of patients who are affected by urothelial cancer—from those with genomic susceptibility for developing the disease to those at risk for premature death from advanced disease.",3141690 (contact);6266361,"BAJORIN, DEAN F. (contact);SOLIT, DAVID B.","SCROGGINS, BRADLEY TODD",2018-08-24,2025-07-31,Address;advanced disease;Affect;anti-PD-L1;Attenuated;BCG Live;Bioinformatics;Biological Specimen Banks;Biology;biomarker validation;Biometry;Bladder;Blood;Cancer Biology;cancer genetics;cancer genomics;cancer immunobiology;Cancer Patient;career;Caring;Cells;Cessation of life;chemotherapy;Clinical;Clinical Data;Clinical Management;Clinical Research;Clinical Trials;combinatorial;Community Clinical Oncology Program;Computational Biology;Cystectomy;data integration;data platform;Decision Making;design;Development;Diagnosis;Disease;DNA Damage;drug discovery;drug sensitivity;efficacy testing;Ensure;Evolution;Expenditure;FDA approved;Future;Future Generations;Gene Mutation;Genetic Predisposition to Disease;Genomic Instability;genomic signature;Genomics;Genus Mycobacterium;Germ Lines;Germ-Line Mutation;Goals;guided inquiry;Heritability;Heterogeneity;Human;human tissue;Immune;immune checkpoint blockade;Immune checkpoint inhibitor;Immune response;Immune Targeting;Immunologic Stimulation;Immunotherapy;improved;improved outcome;Individual;individual patient;Inherited;insight;Investigational Therapies;Laboratory Research;Localized Disease;Malignant neoplasm of urinary bladder;Malignant Neoplasms;Medical;Mentorship;Minority;Molecular;Molecular Analysis;molecular pathology;Molecular Profiling;Monitor;Morbidity - disease rate;Multicenter Trials;multidisciplinary;muscle invasive bladder cancer;Mutation;mycobacterial;new therapeutic target;non-muscle invasive bladder cancer;novel;novel marker;Organ;Outcome;Palpable;Pathway interactions;patient population;patient subsets;Patients;Pattern;personalized care;predictive marker;predictive signature;Predisposition;premature;Preparation;pressure;Prevalence;Primary Neoplasm;programs;prospective;Public Health;Randomized;Recording of previous events;Recurrence;refractory cancer;Regimen;Renal pelvis;research clinical testing;Research Personnel;Research Project Grants;Resistance;resistance mechanism;response;response biomarker;Risk;screening;Selection for Treatments;Site;Specialized Program of Research Excellence;Systemic Therapy;The Cancer Genome Atlas;Therapeutic;Time;Translational Research;translational scientist;Transurethral Resection;Treatment Cost;treatment response;Tuberculosis;tumor;Tumor Tissue;United States;Ureter;Urethra;Urothelium,SPORE in Bladder Cancer,221745,ZCA1,ZCA1-RPRB-N(M1),NA,S1,5,509247,387028,896275,NA
11196452,P50,CA,3,N,2024-09-26,2022-08-01,2023-07-31,NA,P50CA221745,NA,PAR-14-353,3P50CA221745-05S1,NCI:132265\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,12,064931884,US,5079202,SLOAN-KETTERING INST CAN RESEARCH,NY,100656007,PROJECT NARRATIVE The Administrative Core will provide centralized scientific and administrative oversight and management of the SPORE in Bladder Cancer at Memorial Sloan Kettering Cancer Center to facilitate the accomplishment of the translational research objectives of the program.,3141690 (contact),"BAJORIN, DEAN F. (contact)","SCROGGINS, BRADLEY TODD",2018-08-24,2025-07-31,authority;career;Clinical;Collaborations;Communication;Communities;Data;data management;Decision Making;Development;editorial;Education;Ensure;Fostering;Genomics;Grant;Human Resources;Infrastructure;Institution;Link;Malignant neoplasm of urinary bladder;Manuscripts;Medical;meetings;member;Memorial Sloan-Kettering Cancer Center;Molecular;National Cancer Institute;Occupational activity of managing finances;Office of Administrative Management;operation;Patient Compliance;patient privacy;Pilot Projects;Principal Investigator;programs;Publications;Regulation;Reporting;Reproduction spores;Request for Applications;Research;Research Personnel;Research Project Grants;Running;scientific organization;Services;Training;Translational Research;Work,Administrative Core,221745,ZCA1,ZCA1-RPRB-N,5106,S1,5,75150,57115,NA,132265
11196453,P50,CA,3,N,2024-09-25,2023-06-01,2024-05-31,NA,P50CA217691,NA,PA-20-272,3P50CA217691-05S1,NCI:128039\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,"Our group has identified stem-like T cells that undergo proliferation after immune checkpoint inhibition. We will characterize these cells in lung tumors, draining lymph nodes and peripheral blood, and study their correlation with treatment outcome. In addition, we will study a novel combination regimen of mTOR inhibition and PD1 inhibition in lung cancer patients.",6877992 (contact),"DENG, XINGMING  (contact)","UJHAZY, PETER",2019-07-10,2025-05-31,Administrative Supplement;Agonist;analog;Animal Cancer Model;anti-cancer;Antineoplastic Agents;Apoptosis;Apoptotic;Attenuated;Bax protein;Binding;Biological;C-terminal;Cancer Patient;cancer therapy;Cell Death;cell killing;Cells;checkpoint inhibition;Chemical Structure;chemoradiation;chemotherapy;Chemotherapy and/or radiation;Cisplatin;Development;draining lymph node;Failure;Family member;Funding;Genetic Engineering;Homo;Human;In Vitro;Induction of Apoptosis;Ionizing radiation;KRAS2 gene;KRASG12D;Lead;Link;lung cancer cell;Lung Neoplasms;Malignant neoplasm of lung;Malignant Neoplasms;MAPK3 gene;Mediating;MEKs;member;Mitochondria;mitochondrial membrane;Modeling;Molecular Conformation;mTOR inhibition;mTOR Inhibitor;mutant;Mutation;Non-Small-Cell Lung Carcinoma;novel;novel strategies;Pathway interactions;patient derived xenograft model;Patients;PDPK1 gene;peripheral blood;Pharmaceutical Preparations;Phosphorylation;Phosphorylation Site;Phosphotransferases;Physiological;PI3K/AKT;PIK3CG gene;Play;predictive marker;Prognostic Marker;programmed cell death protein 1;Proliferating;Property;Protein Dephosphorylation;Proto-Oncogene Proteins c-akt;Radiation;radiation resistance;Radiation therapy;Radio;radioresistant;Regimen;Reporting;Repression;Resistance;Role;Serine;Signal Induction;Signal Transduction;Site;small molecule;stem;T-Lymphocyte;Tail;Testing;Therapeutic Intervention;therapeutic target;therapy resistant;TP53 gene;Treatment outcome;tumor;Tumor Tissue;Xenograft procedure,Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLC,217691,NA,NA,5517,S1,5,81814,46225,NA,128039
11196454,P50,CA,3,N,2024-09-26,2022-08-01,2023-07-31,NA,P50CA221745,NA,PAR-14-353,3P50CA221745-05S1,NCI:128633\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,12,064931884,US,5079202,SLOAN-KETTERING INST CAN RESEARCH,NY,100656007,"PROJECT NARRATIVE As a public health concern, bladder cancer is the fifth most common cancer in the United States, has a high rate of recurrence, and has limited treatment options for advanced disease. The Biospecimen Repository Core will support the work of the SPORE in Bladder Cancer at Memorial Sloan Kettering Cancer Center to advance our understanding of the clinical, biologic, and genetic basis of urothelial cancer (cancer of the renal pelvis, ureter, bladder, and urethra) to improve patient outcomes by facilitating a range of scientific activities that could lead to new genomic- and proteomic-based interventions and by developing new biomarkers with diagnostic, prognostic, and therapeutic relevance to this disease.",9460193 (contact),"AL-AHMADIE, HIKMAT  (contact)","SCROGGINS, BRADLEY TODD",2018-08-24,2025-07-31,advanced disease;Animals;anti-cancer research;Antibodies;Bacillus Calmette-Guerin Therapy;BCG Live;Bioinformatics;Biological;Biological Assay;Biological Markers;Biological Specimen Banks;Biometry;Blood;Blood specimen;cell free DNA;Cell Separation;Cisplatin;Clinical;Clinical Chemistry;Clinical Laboratory Improvement Amendments;Clinical Research;clinical sequencing;Collaborations;Communities;Consent;Consultations;Data;data quality;design;Diagnostic;digital;Disease;Disease Management;DNA;DNA analysis;DNA Damage;Doctor of Philosophy;Documentation;Ensure;Evaluation;Excision;exome sequencing;exosome;follow-up;Formalin;Freezing;Fresh Tissue;Gene Expression Profiling;Genes;Genetic;genetic analysis;Genomics;Germ Lines;Goals;Guidelines;Heterogeneity;Human;human tissue;Image;immune checkpoint blockade;Immunohistochemistry;improved;In Situ Hybridization;Inherited;Institutional Review Boards;Intervention;Label;Laboratories;laser capture microdissection;Leadership;Malignant neoplasm of ureter;Malignant neoplasm of urinary bladder;Malignant Neoplasms;Measures;Memorial Sloan-Kettering Cancer Center;Methodology;Microdissection;Modeling;Molecular;molecular diagnostics;Morphology;mouse model;Mus;Mutate;Mutation;Needle biopsy procedure;Neoplasm Metastasis;neoplasm resource;next generation sequencing;novel;novel marker;Nucleic Acids;Paraffin Embedding;participant enrollment;Pathologic;Pathology;patient privacy;Patient-Focused Outcomes;Patients;Pelvic Cancer;Phenotype;Pilot Projects;Plasma;Play;predictive marker;Preparation;Process;prognostic;programmed cell death ligand 1;prospective;prospective test;Proteomics;Protocols documentation;Public Health;quality assurance;Quality Control;Radical Cystectomy;Recording of previous events;Recurrence;relational database;Renal Carcinoma;Research;Research Personnel;Research Project Grants;Resource Sharing;response;response biomarker;Risk;RNA;Role;Sampling;Scanning;Serum;Services;Specimen;Standardization;T cell clonality;T cell receptor repertoire sequencing;Therapeutic;Therapeutic Research;tissue archive;Tissue Embedding;Tissue Microarray;Tissue Procurements;Tissue Sample;Tissues;transcriptome sequencing;Translational Research;Transurethral Resection;Tube;tumor;United States;Urethral Cancer;Urethral Neoplasms;Urine;Urothelium;Whole Blood;Work;Xenograft Model,Biospecimen Repository Core,221745,ZCA1,ZCA1-RPRB-N,5107,S1,5,73087,55546,NA,128633
11196455,P50,CA,3,N,2024-09-25,2023-06-01,2024-05-31,NA,P50CA217691,NA,PA-20-272,3P50CA217691-05S1,NCI:128039\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,"PROJECT NARRATIVE The SPORE Developmental Research Program (DRP) provides funding to support new and innovative pilot projects in lung cancer that have the potential to expand into full research projects in the future, including those of high risk-high reward nature. The DRP aims to foster collaborative research between Emory investigators and investigators at other institutions, and to enhance translational research in lung cancer by increasing the number of meritorious investigators working on lung cancer.",1893676 (contact),"FU, HAIAN  (contact)","UJHAZY, PETER",2019-07-10,2025-05-31,Administrative Supplement;American Cancer Society;anti-cancer research;Award;career development;Clinical Research;Collaborations;Development;Evolution;Extramural Activities;Fostering;Foundations;Funding;Future;Goals;Grant;Head and Neck Cancer;high reward;high risk;innovation;Institution;Investments;Malignant neoplasm of lung;Malignant Neoplasms;Medical;Monitor;Nature;novel;Outcome;Patient Care;Peer Review;Peer Review Grants;Pilot Projects;preclinical study;Process;Program Research Project Grants;programs;Publications;Request for Proposals;Research;Research Personnel;Research Project Grants;Research Proposals;Series;Source;success;Translational Research;translational study;United States National Institutes of Health;Universities,Developmental Research Program,217691,NA,NA,5519,S1,5,81814,46225,NA,128039
11196456,P50,CA,3,N,2024-09-26,2022-08-01,2023-07-31,NA,P50CA221745,NA,PAR-14-353,3P50CA221745-05S1,NCI:75956\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,12,064931884,US,5079202,SLOAN-KETTERING INST CAN RESEARCH,NY,100656007,PROJECT NARRATIVE The Biostatistics and Bioinformatics Core will provide direct support for study design and timely execution of data analysis for all research projects and developmental projects in the MSK SPORE in Bladder Cancer.,8822569 (contact),"OSTROVNAYA, IRINA  (contact)","SCROGGINS, BRADLEY TODD",2018-08-24,2025-07-31,Address;Algorithms;analytical method;Bioinformatics;bioinformatics pipeline;Biological Specimen Banks;Biometry;Clinical Data;Clinical Research;clinical trial analysis;Consult;Data;Data Analyses;data format;Databases;Dedications;Deposition;design;Development;diverse data;Doctor of Philosophy;Ensure;experience;Experimental Designs;Formulation;genomic data;Goals;Graph;human tissue;Individual;Laboratories;laboratory experiment;Leadership;Malignant neoplasm of urinary bladder;Malignant Neoplasms;Manuscripts;member;Methodology;Modification;Molecular;Monitor;Nature;novel;Preparation;public repository;Publications;Reporting;Reproducibility;Research;Research Design;Research Personnel;Research Project Grants;Role;Sample Size;Science;Statistical Data Interpretation;System;translational goal;Urothelium;Validation;Work;Writing,Biostatistics and Bioinformatics Core,221745,ZCA1,ZCA1-RPRB-N,5108,S1,5,43157,32799,NA,75956
11196457,P50,CA,3,N,2024-09-25,2023-06-01,2024-05-31,NA,P50CA217691,NA,PA-20-272,3P50CA217691-05S1,NCI:128039\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,"PROJECT NARRATIVE The Emory Lung Cancer SPORE Career Enhancement Program (CEP) intends to support pilot projects and the mentoring of early career academic physician-scientists, clinician-investigators, and laboratory-based scientists who wish to develop a career in translational research in the areas of diagnosis, imaging, prevention, treatment, and improvement in quality of life in lung cancer. The proposed CEP aims to provide an environment that enables talented early career investigators to engage in a 2-year mentored research program, to facilitate their success and their academic career development in terms of achieving independent investigator status, and to enhance diversity among the lung cancer research community.",7797023 (contact),"MARCUS, ADAM I. (contact)","UJHAZY, PETER",2019-07-10,2025-05-31,Academic advising;Administrative Supplement;anti-cancer research;Area;Award;Biology;career;career development;Communities;Dedications;Diagnosis;Disabled Persons;Environment;Fostering;Funding;Goals;Grant;Head and Neck Cancer;Health Sciences;Hematology;Image;improved;Institution;Laboratories;Malignant neoplasm of lung;Malignant Neoplasms;Medical Oncology;medical schools;Mentors;Minority Groups;molecular oncology;Oncology;Peer Review;physician-scientist training program;Physicians;Pilot Projects;Prevention;Program Development;programs;Publishing;Quality of life;Research;Research Personnel;Scientist;Secure;success;Talents;Training;translational physician;Translational Research;United States National Institutes of Health;Universities;Woman,Career Enhancement Program,217691,NA,NA,5521,S1,5,81814,46225,NA,128039
11196458,P50,CA,3,N,2024-09-26,2022-08-01,2023-07-31,NA,P50CA221745,NA,PAR-14-353,3P50CA221745-05S1,NCI:323676\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,12,064931884,US,5079202,SLOAN-KETTERING INST CAN RESEARCH,NY,100656007,"Project Narrative This project is based on the scientific premise that molecular profiling before treatment can identify patients with muscle-invasive bladder cancer for whom transurethral resection of the bladder tumor and systemic chemotherapy will be curative, without the need for radical cystectomy. Targeted and whole exome sequencing in patients enrolled on a prospective clinical trial will be used to better define the population of patients for whom such an approach would be most appropriate. The project will also investigate the use of cell-free DNA from blood and urine as a platform for early identification of minimal residual disease and to explore tumor heterogeneity as a mechanism of drug resistance.",6266361 (contact),"SOLIT, DAVID B. (contact)","SCROGGINS, BRADLEY TODD",2018-08-24,2025-07-31,Acceleration;Adjuvant Chemotherapy;Basic Science;Bioinformatics;Biological Assay;Biological Markers;Biological Specimen Banks;Biometry;Biopsy;Bladder;Bladder Neoplasm;Blood;Cancer Patient;cell free DNA;Chemoresistance;chemotherapy;Cisplatin;Clinical;Clinical Sciences;Clinical Trials;Clonal Evolution;co-clinical trial;cohort;Collaborations;Combination Drug Therapy;Combined Modality Therapy;curative treatments;Cystectomy;Cystoscopy;Data;Detection of Minimal Residual Disease;Diagnostic;Disease;DNA analysis;DNA Damage;Dose;Drug resistance;Early identification;Eligibility Determination;ERCC2 gene;Exhibits;exome sequencing;Future;gemcitabine;Gene Mutation;Genes;Genomics;Germ Lines;Guidelines;Heritability;Heterogeneity;Image;Immunotherapy;In complete remission;In Vitro;Malignant neoplasm of urinary bladder;Malignant Neoplasms;Mediating;Medical;Methods;Modeling;Molecular;Molecular Profiling;Multi-Institutional Clinical Trial;muscle invasive bladder cancer;Mutation;mutational status;Neoadjuvant Therapy;next generation sequencing;novel;Nucleotide Excision Repair;Oncology;Organ;Organoids;participant enrollment;Pathologic;patient population;patient response;Patient Selection;Patients;predicting response;predictive marker;predictive signature;preservation;primary endpoint;prospective;Publishing;Radical Cystectomy;radiological imaging;Recurrence;Recurrent disease;Residual Neoplasm;response;response biomarker;Sampling;Site;Somatic Mutation;Specific qualifier value;Staging;standard of care;Systemic Therapy;Testing;Therapy trial;Time;Toxicity due to chemotherapy;Transitional Cell Carcinoma;Transurethral Resection;treatment responders;treatment response;tumor;tumor heterogeneity;Urine;Urothelium;variant of unknown significance,RP-1: Defining Predictors of Sensitivity to Cisplatin-Based Chemotherapy in Urothelial Cancer,221745,ZCA1,ZCA1-RPRB-N,5109,S1,5,183907,139769,NA,323676
11196459,P50,CA,3,N,2024-09-26,2024-07-01,2025-06-30,NA,P50CA225450,NA,PA-20-272,3P50CA225450-05S1,NCI:182271\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,12,121911077,US,5998304,NEW YORK UNIVERSITY SCHOOL OF MEDICINE,NY,10016,"PROJECT NARRATIVE SPORE programs are highly complex translational research enterprises that require cohesive organization and effective leadership to meet proposed scientific and programmatic aims. The Admin Core will work directly with research project and core investigators to evaluate progress, facilitate communication, and provide financial management for all activities of the NYU Melanoma SPORE. The Admin Core’s management of the SPORE will ensure the efficient use of NYULH resources, increase inter-SPORE and industry cooperation, and expand outreach to melanoma patients, enhancing our efforts to translate novel personalized biomarkers for melanoma patient management to the clinical setting.",1938112 (contact),"OSMAN, IMAN  (contact)","KUZMIN, IGOR A",2021-07-19,2025-06-30,Address;Award;Bioinformatics;Biometry;Body System;Budgets;Cancer Center;career;Clinic;Clinical;Clinical Management;Collaborations;Communication;Communities;community engagement;Complex;Development;Educational workshop;effective therapy;Ensure;Evaluation;expectation;Federal Government;Goals;Health;health administration;Health Policy;Health Resources;Industry;industry partner;Infrastructure;Institution;Institutional Policy;Investigation;Leadership;Local Government;material transfer agreement;meetings;Melanoma;Melanoma patient;National Cancer Institute;New York;novel;Occupational activity of managing finances;outreach;patient outreach;Patients;personalized biomarkers;Policies;programs;Progress Reports;Reproduction spores;Research;Research Personnel;Research Project Grants;Resource Sharing;Resources;Risk;Skin Cancer;Strategic Planning;tool;Translating;Translational Research;translational research program;Travel;United States National Institutes of Health;Universities;Work,Admin Core,225450,NA,NA,8506,S1,5,107534,74737,NA,182271
11196461,P50,CA,3,N,2024-09-26,2024-07-01,2025-06-30,NA,P50CA225450,NA,PA-20-272,3P50CA225450-05S1,NCI:127398\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,12,121911077,US,5998304,NEW YORK UNIVERSITY SCHOOL OF MEDICINE,NY,10016,"PROJECT NARRATIVE High quality, annotated biospecimens are critical to support a patient-centered melanoma translational research program. Core B is integrated within the structure of the SPORE, and is well positioned to stimulate research opportunities that uncover novel improvements for melanoma patients by providing researchers with biospecimens and clinical data from patients treated at NYU and internationally as part of phase III trials. We aim to facilitate the development of clinically impactful prognostic and predictive biomarkers for better management of patients with resectable melanoma.",1938112 (contact),"OSMAN, IMAN  (contact)","KUZMIN, IGOR A",2021-07-19,2025-06-30,Aliquot;biobank;Biological Specimen Banks;Biological Specimen database;Blood;Blood specimen;career;Caring;Cell Separation;Clinical;Clinical Data;clinical development;Clinical Trials;Collaborations;Collection;Communities;Data;Databases;design;Development;Ensure;Feces;follow-up;Goals;Health;Human;Human Resources;improved;Industry;industry partner;Informed Consent;innovation;Institution;International;Link;Lymphocyte;Melanoma;Melanoma patient;Metastatic Melanoma;Mission;Molecular;novel;Nucleic Acids;participant enrollment;Pathologic;Pathology;patient oriented;patient privacy;Patient Rights;Patients;Peripheral Blood Mononuclear Cell;personalized management;Phase III Clinical Trials;phase III trial;Plasma;Positioning Attribute;predictive marker;Preparation;Process;Prognostic Marker;Program Research Project Grants;programs;prospective;Protocols documentation;Quality Control;repository infrastructure;Research;Research Infrastructure;Research Personnel;Research Project Grants;Resectable;Resected;Resources;Scientist;Serum;Services;Site;Skin Cancer;stool sample;Structure;T-Lymphocyte;Tissue Sample;Tissues;tool;Translational Research;translational research program;Unresectable;Whole Blood;Work,Core B - Biospecimen/Pathology Core,225450,NA,NA,8507,S1,5,75161,52237,NA,127398
11196462,P50,CA,3,N,2024-09-26,2022-08-01,2023-07-31,NA,P50CA221745,NA,PAR-14-353,3P50CA221745-05S1,NCI:235745\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,12,064931884,US,5079202,SLOAN-KETTERING INST CAN RESEARCH,NY,100656007,"Project Narrative  Immune checkpoint blockade is the most important advance in the treatment of urothelial carcinoma in over 20  years, although only a minority of patients benefit from treatment, and robust predictive biomarkers are lacking.  This project will not only test whether antiangiogenic therapy in combination with immune checkpoint blockade  improves outcomes in urothelial cancer in a randomized clinical trial, but also interrogate the tumor  microenvironment and immune system to identify mechanisms of resistance to immune checkpoint blockade.  By identifying potential predictive biomarkers of response and determinants of resistance, this project will  identify new targets that could drive development of more effective combination therapies for metastatic  urothelial cancer.",8697234 (contact),"ROSENBERG, JONATHAN ERIC (contact)","SCROGGINS, BRADLEY TODD",2018-08-24,2025-07-31,"acquired drug resistance;Angiogenesis Inhibitors;anti-PD-1;anti-PD1 therapy;Antibodies;antitumor effect;Basic Science;bevacizumab;Binding;Biological Markers;Blood;Blood specimen;Cancer Patient;Cell Physiology;cell type;chemotherapy;Cisplatin;Clinical;clinical decision-making;clinical predictors;Clinical Sciences;Clinical Trials;Clonality;Collection;combinatorial;Combined Modality Therapy;comparative efficacy;Data;Dendritic Cells;Development;Disease;Dissection;Doctor of Philosophy;FDA approved;Genomics;Goals;immune checkpoint blockade;Immune checkpoint inhibitor;Immune system;Immunologic Markers;Immunologics;immunoregulation;Immunotherapy;improved;improved outcome;Malignant neoplasm of urinary bladder;Malignant Neoplasms;Minority;Modeling;Molecular;Monoclonal Antibodies;Multicenter Studies;Mutation;Myeloid-derived suppressor cells;neoantigens;novel therapeutics;Outcome;patient subsets;Patients;Peripheral;Pharmaceutical Preparations;predictive marker;programmed cell death ligand 1;prospective;Randomized;randomized, clinical trials;Recurrence;Regulatory T-Lymphocyte;Research Project Grants;Resistance;Resistance development;resistance mechanism;response;response biomarker;Sampling;Stains;standard of care;T cell clonality;T memory cell;T-Lymphocyte;targeted agent;Testing;The Cancer Genome Atlas;Time;trafficking;Transitional Cell Carcinoma;tumor;tumor microenvironment;tumor-immune system interactions;Urothelium;Vascular Endothelial Growth Factors;Vegf inhibition;Vegf Inhibitor",RP-3: Elucidating Mechanisms of Sensitivity and Resistance to Checkpoint Blockade Therapy for Rational Multi-Drug Immunotherapy in Urothelial Cancers,221745,ZCA1,ZCA1-RPRB-N,5111,S1,5,133946,101799,NA,235745
11196467,P50,CA,3,N,2024-09-26,2024-07-01,2025-06-30,NA,P50CA225450,NA,PA-20-272,3P50CA225450-05S1,NCI:243390\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,12,121911077,US,5998304,NEW YORK UNIVERSITY SCHOOL OF MEDICINE,NY,10016,"PROJECT 2 NARRATIVE A substantial number of patients do not benefit from promising new immune checkpoint inhibitor therapies that stimulate the immune system to target melanoma. In our study, we propose to discover the genomic factors in host immune cells that influence response to these novel therapies, providing an opportunity to significantly improve treatment and survival outcomes for patients with melanoma.",9342154 (contact),"KIRCHHOFF, TOMAS  (contact)","KUZMIN, IGOR A",2021-07-19,2025-06-30,Acceleration;Adjuvant;Adjuvant Therapy;Affect;Antitumor Response;Autoimmune;Binding Sites;Biological Markers;biomarker identification;Blood Cells;cancer infiltrating T cells;CD4 Positive T Lymphocytes;CD8-Positive T-Lymphocytes;CD8B1 gene;Cell Physiology;Cells;Cessation of life;checkpoint inhibition;checkpoint therapy;Chromatin;Clinical;Clinical Trials;cohort;CTLA4 gene;cytotoxic;Data;data integration;density;Distant Metastasis;Enhancers;Epigenetic Process;Exhibits;exome sequencing;Freedom;Genes;Genetic;genetic risk factor;Genetic Transcription;Genetic Variation;Genome;genome sequencing;genome-wide analysis;Genomic Imprinting;Genomics;Germ Lines;high risk;Immune;Immune checkpoint inhibitor;Immune system;Immune Targeting;Immunity;Immunologic Adjuvants;Immunologic Stimulation;Immunologics;Immunophenotyping;Immunotherapy;improved;Individual;Infiltration;Inherited;innovation;ipilimumab;Malignant Neoplasms;Maps;Mediating;Melanoma;Melanoma patient;microbiome;Molecular;Mutation;Nivolumab;novel;novel therapeutics;Outcome;outcome prediction;Pathway interactions;Patient-Focused Outcomes;Patients;peripheral blood;personalized predictions;Phase;Phenotype;predictive marker;predictive signature;primary outcome;programmed cell death protein 1;promoter;Proteins;Proteomics;Publishing;rare variant;receptor;Recurrence;Regulation;Regulatory Element;Relapse;relapse patients;relapse prediction;Reporting;Research Design;Resected;Resistance;response;Role;Sampling;Sequence Analysis;survival outcome;T cell differentiation;T-cell diversity;T-Lymphocyte;T-Lymphocyte Subsets;Testing;Time;trait;transcription factor;Transcriptional Regulation;transcriptome;transcriptome sequencing;Treatment outcome;tumor;tumor microenvironment;Untranslated RNA;Validation;Variant;whole genome,Project 2,225450,NA,NA,8510,S1,5,143593,99797,NA,243390
11196469,P50,CA,3,N,2024-09-26,2024-07-01,2025-06-30,NA,P50CA225450,NA,PA-20-272,3P50CA225450-05S1,NCI:343215\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,12,121911077,US,5998304,NEW YORK UNIVERSITY SCHOOL OF MEDICINE,NY,10016,"PROJECT 3 NARRATIVE Project 3 has three key goals: 1) Refine and clinically validate a baseline autoantibody signature that identifies melanoma patients at high risk of developing severe immune toxicity from immune checkpoint inhibitors, using pre-treatment sera. 2) Identify a causative role for baseline autoantibodies in toxicity development. 3) Conduct a biomarker-driven phase-II clinical trial testing prophylactic anti-TNF- to mitigate development of immune toxicity from checkpoint inhibitors in patients at high risk of immune-related adverse events.",8622646 (contact),"KROGSGAARD, MICHELLE  (contact)","KUZMIN, IGOR A",2021-07-19,2025-06-30,Adjuvant;Adjuvant Study;American;anti-CTLA4;anti-PD-1;Antibodies;Autoantibodies;Autoimmune;Autoimmune Diseases;B-Lymphocytes;Biological Assay;Biological Markers;biomarker driven;biomarker identification;biomarker signature;Bladder;Cancer Patient;cancer type;Certification;checkpoint inhibition;Clinical;Clinical Laboratory Improvement Amendments;Clinical Trials;cohort;Colitis;college;Data;Dermatologic;Development;Diarrhea;Endocrine;experience;experimental study;Exposure to;gastrointestinal;Goals;Hepatic;high risk;Human;humanized mouse;Immune;Immune checkpoint inhibitor;immune-related adverse events;Immunoglobulin G;Immunologic Adjuvants;Immunologic Markers;Immunosuppression;Inflammatory Bowel Diseases;infliximab;interest;ipilimumab;Kidney;Laboratories;Length;Lung;Malignant Neoplasms;Manuscripts;Melanoma;Melanoma patient;Morbidity - disease rate;mouse model;Nivolumab;Oncologist;Organ;Pathogenicity;Pathologist;patient subsets;Patients;pembrolizumab;Phase;phase 2 study;Phase II Clinical Trials;phase II trial;Placebo Control;Placebos;Preclinical Testing;predicting response;predictive test;predictive tools;Predisposition;prevent;Prevention;Prevention strategy;prophylactic;Proteins;Proteome;Proteomics;Publishing;Randomized;Recurrence;Regimen;Renal Cell Carcinoma;Resected;response;Role;Selection for Treatments;Serum;System;T-Lymphocyte;Testing;Therapeutic;Thyroiditis;TNF gene;tool;Toxic effect;treatment optimization;treatment strategy;tumor;Ulcerative Colitis;Validation;Work,Project 3,225450,NA,NA,8511,S1,5,202487,140728,NA,343215
11196484,P50,CA,3,N,2024-09-26,2023-06-01,2024-05-31,NA,P50CA236733,NA,PA-20-272,3P50CA236733-05S2,NCI:81071\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NASHVILLE,UNITED STATES,NA,07,079917897,US,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,TN,372320011,"PROJECT NARRATIVE: Administrative Core The Administrative Core will be responsible for the organizational, administrative, and scientific management (both basic and clinical research) of the Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal (GI) Cancer program, which focuses on translational research that will substantially improve the management of colorectal cancer. This management and support will be accomplished through a series of oversight committees and organized administrative and scientific meetings of GI SPORE investigators, institutional representatives, and external advisors.",1901947 (contact),"COFFEY, ROBERT J. (contact)","NOTHWEHR, STEVEN F",2024-06-01,2025-05-31,Academic Medical Centers;Advocate;Basic Science;Biological Sciences;Biology;Cancer Center;career;Clinical and Translational Science Awards;Clinical Research;Collaborations;Colorectal Cancer;Communication;Communities;Development;Digestive System Disorders;Education;Ensure;Epithelium;Evaluation;Fostering;gastrointestinal;improved;Institution;Malignant Breast Neoplasm;Malignant neoplasm of gastrointestinal tract;Malignant neoplasm of pancreas;Malignant Neoplasms;medical schools;meetings;Monitor;Mucositis;National Cancer Institute;Occupational activity of managing finances;outreach;Patient advocacy;Patients;Pharmacologic Substance;programs;Regulation;Report (document);Reporting;Reproduction spores;Research;Research Personnel;Research Project Grants;Resources;Schedule;Series;Tennessee;Translational Research;Universities,Administrative Core,236733,NA,NA,8241,S2,5,41956,39115,NA,81071
11196486,P50,CA,3,N,2024-09-26,2023-06-01,2024-05-31,NA,P50CA236733,NA,PA-20-272,3P50CA236733-05S2,NCI:70714\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NASHVILLE,UNITED STATES,NA,07,079917897,US,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,TN,372320011,"PROJECT NARRATIVE: Tissue Pathology and Cellular Analysis Core The Translational Pathology and Cellular Analysis Core plays an essential role by providing annotated human biospecimens, immunohistochemistry, pathology interpretation, and single cell analysis. Without these services, which provide technologies to bridge animal models of cancer and basic science discoveries to patient care, the translational mission of the Vanderbilt GI SPORE to make a profound impact on the prevention, early detection, diagnosis and treatment of colorectal cancer would not be possible.",6682462 (contact),"WASHINGTON, MARY KAY (contact)","NOTHWEHR, STEVEN F",2024-06-01,2025-05-31,Academic Medical Centers;Animal Cancer Model;Antibodies;Basic Science;Behavior;biobank;Bioinformatics;Biological Assay;Biological Process;Biometry;cancer biomarkers;Cancer Center;Cancer Science;Cells;cellular imaging;Collaborations;Collection;Colorectal Cancer;colorectal cancer treatment;Colorectal Neoplasms;Computer Analysis;Confidentiality of Patient Information;Consult;Consultations;Cooperative Human Tissue Network;cost effective;Custom;Cytometry;Data;Data Analyses;data de-identification;data quality;Databases;Diagnosis;Digestive System Disorders;digital;Disease;Early Diagnosis;Ensure;Epithelial Cells;Epithelium;Evaluation;flexibility;Formalin;Freezing;Gastrointestinal Neoplasms;Gene Expression;Generations;Genetic Complementation Test;Histologic;Histology;Histopathology;Human;human disease;Image;image processing;Immunofluorescence Immunologic;Immunohistochemistry;Informatics;Informed Consent;Infrastructure;instrument;laser capture microdissection;Malignant neoplasm of gastrointestinal tract;Mission;Molecular;molecular imaging;Morphology;mouse model;Mus;next generation;Normal tissue morphology;novel;operation;Paraffin Embedding;Pathology;Patient Care;Patients;Play;Pre-Clinical Model;Preparation;Prevention;Process;protein expression;Publishing;Qualifying;Quality Control;Reagent;repository;Reproduction spores;Research;Research Activity;Research Personnel;Resource Sharing;Role;Running;Sampling;screening;Services;Signal Transduction;single cell analysis;single-cell RNA sequencing;Specimen;synergism;Technology;The Vanderbilt-Ingram Cancer Center at the Vanderbilt University;Time;Tissue Banks;Tissue Microarray;Tissue Sample;Tissues;tool;translational goal;Translational Research;Validation;Washington;Work,Core 1: Tissue Pathology and Cellular Analysis,236733,NA,NA,8242,S2,5,36596,34118,NA,70714
11196498,P50,CA,3,N,2024-09-26,2023-06-01,2024-05-31,NA,P50CA236733,NA,PA-20-272,3P50CA236733-05S2,NCI:142183\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NASHVILLE,UNITED STATES,NA,07,079917897,US,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,TN,372320011,"PROJECT NARRATIVE: Mouse and Human Molecular Imaging Core The Mouse and Human Molecular Imaging (MHMI) Core will play a central role in the translational research mission of the Vanderbilt-Ingram Cancer Center (VICC) SPORE in Gastrointestinal (GI) Cancer, providing state-of-the-art imaging resources for three projects, future pilot and feasibility studies, and developmental research. The MHMI Core will leverage existing, institutionally-supported equipment and infrastructure to offer a full range of small animal and human functional, molecular, and anatomical imaging resources, including magnetic resonance imaging (MRI), computed tomography (CT), digital X-ray, optical, single photon emission computed tomography (SPECT), and positron emission tomography (PET). A unique feature of this core, the VICC GI SPORE investigators will also have access to novel probe development resources that leverage the capabilities of the Vanderbilt Center for Molecular Probes (CMP), including high-throughput, diversity-oriented synthesis capabilities suitable for developing novel imaging compounds, as well as world-class preclinical and cGMP resources of the CMP radiochemistry facility.",8028499 (contact),"MANNING, HENRY CHARLES (contact)","NOTHWEHR, STEVEN F",2024-06-01,2025-05-31,anatomic imaging;animal imaging;Bioinformatics;Biological;Biometry;Cancer Center;Clinical Research;Colorectal Cancer;Coupled;Cyclic GMP;Data;Data Analyses;data de-identification;Development;Digital X-Ray;Equipment;Feasibility Studies;Functional Imaging;Future;gastrointestinal;Genomic approach;Human;human imaging;Human Resources;Image;imaging biomarker;imaging facilities;imaging modality;Individual;Infrastructure;Institution;liquid biopsy;Magnetic Resonance Imaging;Malignant neoplasm of gastrointestinal tract;Measures;Mission;Molecular;molecular imaging;Molecular Probes;Mus;novel;Optics;Pathology;Phenotype;Pilot Projects;Play;Positron-Emission Tomography;pre-clinical;pre-clinical research;Quality Control;Radiochemistry;Reproduction spores;Research;Research Personnel;research study;Resource Development;Resources;Role;single photon emission computed tomography;Specimen;Tissues;translational goal;Translational Research;tumor;Work;X-Ray Computed Tomography,Core 2: Mouse and Human Molecular Imaging,236733,NA,NA,8243,S2,5,99122,43061,NA,142183
11196500,P50,CA,3,N,2024-09-26,2023-06-01,2024-05-31,NA,P50CA236733,NA,PA-20-272,3P50CA236733-05S2,NCI:40497\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NASHVILLE,UNITED STATES,NA,07,079917897,US,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,TN,372320011,"PROJECT NARRATIVE: Biostatistics and Bioinformatics Core The relevance of the Biostatistics and Bioinformatics Core (BBC) lies in our provision of services essential for the conduct of high-quality collaborative gastrointestinal cancer research. Sound biostatistical/bioinformatic inputs are provided throughout the lifespan of a research project, from conception to completion. To ensure the needs of the investigators are met thoroughly and efficiently, key biostatisticians and/or bioinformaticians are assigned to each project.",3167353 (contact),"SHYR, YU  (contact)","NOTHWEHR, STEVEN F",2024-06-01,2025-05-31,Animals;anti-cancer research;Bioinformatics;Biometry;Cancer Center;Clinical Research;Collaborations;Conceptions;Data;Data Analyses;data quality;Databases;Development;Ensure;epidemiology study;Experimental Designs;gastrointestinal;Human;Human Resources;Laboratories;life span;Malignant neoplasm of gastrointestinal tract;Manuscripts;member;Methods;molecular imaging;Mus;Participant;Pathology;power analysis;Quality Control;Reporting;Reproduction spores;research and development;Research Design;Research Personnel;Research Project Grants;Sample Size;Service provision;sound;Tissues;translational study;Work;Writing,Core 3: Biostatistics and Bioinformatics,236733,NA,NA,8245,S2,5,20958,19539,NA,40497
11196501,P50,CA,3,N,2024-09-26,2023-06-01,2024-05-31,NA,P50CA236733,NA,PA-20-272,3P50CA236733-05S2,NCI:275447\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NASHVILLE,UNITED STATES,NA,07,079917897,US,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,TN,372320011,"PROJECT NARRATIVE: P1. Interrogating Distinct Tumor-Initiating Cells Cancer stem cells, designated tumor-initiating cells (TICs) in this application, are thought to have the propensity to resist therapy and induce tumor recurrence. We will use single-cell technologies to interrogate distinct populations of colorectal cancer TICs in response to therapies. Our goal is to understand how these TICs behave in order to design strategies to inhibit their function(s).",1901947 (contact),"COFFEY, ROBERT J. (contact)","NOTHWEHR, STEVEN F",2024-06-01,2025-05-31,Ablation;Affect;Aftercare;Alleles;Architecture;Behavior;cancer cell;Cancer Center;Cancer Model;Cancer Prognosis;cancer recurrence;cancer stem cell;cancer therapy;cell behavior;Cells;Cellular biology;Characteristics;chemotherapy;Classification;Clinical Trials;Colon;Colon Carcinoma;Colonoscopy;Colorectal Cancer;combinatorial;conventional therapy;Dependence;design;Distal;EGF gene;Epidermal Growth Factor Receptor;Fluorouracil;Goals;Homeostasis;Human;Immunofluorescence Immunologic;in vivo;Individual;irinotecan;LGR5 gene;Maintenance;Malignant - descriptor;Malignant neoplasm of gastrointestinal tract;Malignant Neoplasms;Maps;Modeling;molecular marker;Monitor;Monoclonal Antibodies;Mus;novel;Optics;Organoids;Pathway interactions;patient response;Patients;Play;Population;predicting response;predictive modeling;Primary Neoplasm;prognostic;Property;prospective;Recurrent tumor;Reporter Genes;repository;response;Role;Sampling;Signal Transduction;single cell technology;single-cell RNA sequencing;Site;stem;stem cell population;stem cells;stemness;System;Testing;Therapeutic;Therapeutic Intervention;therapy resistant;Time;Tissue Microarray;Tissues;tool;transcriptomics;Translating;translational goal;Treatment Efficacy;treatment response;tumor;tumor growth;tumor initiation;tumorigenic;Work,Project 1: Interrogating Distinct Tumor-Initiating Cells in CRC,236733,NA,NA,8246,S2,5,179544,95903,NA,275447
11196503,P50,CA,3,N,2024-09-26,2023-06-01,2024-05-31,NA,P50CA236733,NA,PA-20-272,3P50CA236733-05S2,NCI:142081\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NASHVILLE,UNITED STATES,NA,07,079917897,US,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,TN,372320011,"PROJECT NARRATIVE: P2. Targeting Glutamine Metabolism to Enhance EGFR Blockade in WT RAS CRC Epidermal growth factor receptor (EGFR) neutralizing monoclonal antibodies are approved for treatment of advanced wild-type (WT) RAS colorectal cancer (CRC) and commonly used as targeted therapies for late-stage metastatic CRC. However, durable responses to anti-EGFR monotherapy occur in only 12–17% of patients and resistance to monoclonal antibody (mAb) therapy commonly occurs. Prioritizing glutamine metabolism as an actionable vulnerability in WT RAS CRC, we propose a two-pronged translational approach to optimize EGFR therapy that includes a novel way to prioritize patients for EGFR-targeted therapy, novel positron emission tomography (PET) imaging as a predictive marker, and a novel therapeutic combination.",3054726 (contact),"BERLIN, JORDAN D (contact)","NOTHWEHR, STEVEN F",2024-06-01,2025-05-31,Address;Anabolism;Avidity;Biological Assay;Biological Markers;Biological Sciences;cancer cell;Cancer Cell Growth;Cancer Center;Cancer Etiology;Carbon;cell growth;Cell Proliferation;Cessation of life;Cetuximab;chemotherapy;Citric Acid Cycle;Classification;Clinical;Clinical Trials;colon cancer patients;Colorectal Cancer;combinatorial;Combined Modality Therapy;Complex;cytotoxic;Data;Development;Disease;efficacy evaluation;Enzymes;Epidermal Growth Factor Receptor;Exhibits;Future;genetic signature;Glucose;Glutamates;Glutaminase;Glutamine;Goals;Growth;improved;In Vitro;in vivo;inhibitor;Investigation;Laboratory Study;Link;Malignant neoplasm of gastrointestinal tract;Malignant Neoplasms;Mediating;member;Metabolic;Metabolism;metastatic colorectal;Mitochondria;Mitogen-Activated Protein Kinases;Molecular;Monoclonal Antibodies;Monoclonal Antibody Therapy;mouse model;neutralizing monoclonal antibodies;Nitrogen;novel;novel therapeutic intervention;novel therapeutics;Nutrient;panitumumab;participant enrollment;Pathogenesis;Pathway interactions;patient derived xenograft model;Patients;Pharmacodynamics;pharmacologic;Phase I Clinical Trials;Phase II Clinical Trials;Play;Positron-Emission Tomography;precision medicine;preclinical study;predicting response;Prediction of Response to Therapy;predictive marker;Production;Proliferating;proteogenomics;Reactive Oxygen Species;receptor-mediated signaling;Refractory;refractory cancer;Regimen;Resistance;response;Role;Signal Transduction;Solid Neoplasm;Source;statistics;System;targeted treatment;Therapeutic;Tracer;transcriptome sequencing;translational approach;translational goal;Translations;tumor;tumor metabolism,Project 2: Targeting Glutamine Metabolism to Enhance EGFR Blockade in Wild-Type RAS CRC,236733,NA,NA,8248,S2,5,138111,3970,NA,142081
11196516,P50,CA,3,N,2024-09-26,2023-06-01,2024-05-31,NA,P50CA236733,NA,PA-20-272,3P50CA236733-05S2,NCI:144281\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NASHVILLE,UNITED STATES,NA,07,079917897,US,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,TN,372320011,"PROJECT NARRATIVE: P3. Targeting MYC MYC is an oncoprotein and transcription factor that plays a critical pro-tumorigenic role in many cancers, including colorectal cancer (CRC). Although MYC is generally considered undruggable, we have identified a new strategy to target MYC in cancer cells by disrupting interaction with the essential MYC co-factor WDR5. Completion of this project will generate first-in-class MYC WDR5 inhibitors that are validated for efficacy in CRC and ready to proceed to Investigational New Drug (IND)-enabling studies.",1898854 (contact),"BEAUCHAMP, ROBERT DANIEL (contact)","NOTHWEHR, STEVEN F",2024-06-01,2025-05-31,Acute;Affinity;Animals;Antineoplastic Agents;APC mutation;Attenuated;Binding;Binding Proteins;Biochemistry;Biological;Biological Markers;Biological Models;cancer cell;Cancer Center;Cancer Model;cancer type;candidate marker;candidate validation;Cells;Characteristics;Chromatin;Clinical;clinical candidate;Clinical Trials;cofactor;colon cancer cell line;colon cancer patients;colon tumorigenesis;Colorectal Cancer;colorectal cancer prevention;colorectal cancer treatment;Dose;Drug Combinations;Drug Design;drug discovery;Drug Kinetics;drug metabolism;Drug or chemical Tissue Distribution;drug-like compound;Effectiveness;efficacy testing;efficacy validation;Functional disorder;Funding;Genes;Genetic;Genome;Genomic approach;Goals;Human;Hydrophobicity;improved;In Vitro;in vivo;in vivo evaluation;inhibitor;innovation;Investigational Drugs;KRAS2 gene;Lead;Malignant neoplasm of gastrointestinal tract;Malignant Neoplasms;Maximum Tolerated Dose;Modeling;Molecular;Molecular Analysis;Monitor;mouse model;Mus;Mutation;nanomolar;Oncogenic;Oncoproteins;Outcome;overexpression;patient derived xenograft model;Pharmaceutical Chemistry;Pharmaceutical Preparations;pharmacodynamic biomarker;Pharmacodynamics;pharmacologic;Play;pre-clinical;preclinical safety;prevent;programs;Property;Recurrence;Reproduction spores;research clinical testing;Resources;response;Role;Safety;safety assessment;Scaffolding Protein;Series;Site;small molecule;structural biology;Structure;Surface;Time;tool;Toxicokinetics;transcription factor;translational goal;tumor;Tumor Promotion;tumorigenic;Variant,Project 3: Targeting MYC in CRC,236733,NA,NA,8250,S2,5,144281,0,NA,144281
11196569,R25,HG,3,N,2024-09-25,2022-09-26,2025-06-30,172,R25HG010026,SCHOOLS OF PUBLIC HEALTH,PAR-16-345,3R25HG010026-05S1,NHGRI:121246\,OTHER RESEARCH-RELATED,2024,NATIONAL HUMAN GENOME RESEARCH INSTITUTE,NA,BALTIMORE,UNITED STATES,MISCELLANEOUS,07,001910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212182680,"The proposed R25 Research Education Program is devoted to building a 15-month research mentorship program at the Johns Hopkins Berman Institute of Bioethics (BI) for students from diverse, underrepresented groups and backgrounds, to help diversify the pool of ELSI researchers and thus enrich scholarship in genomics and society studies. Trainees will learn research skills, build networks, and gain exposure to the range of possible training and career options in ELSI research. Student trainees will contribute to genomics and society research that 1) examines the ethical, legal, social, historical and policy issues confronting the application of genomics to the prevention, outbreak control, and treatment of infectious diseases, which pose an enormous health burden in the U.S. and globally; and 2) studies the impact of genetic testing for hereditary disease on at-risk families, to help understand and improve how genetic risk information is communicated with families and within them.",3086999 (contact),"MATHEWS, DEBRA JH (contact)","STERLING, RENE",2018-09-18,2025-06-30,"Area;Baltimore;Bioethics;career;cohort;Communicable Diseases;Communication;Communities;County;Development;Education Projects;education research;ethical, legal, and social implication;Event;experience;Exposure to;Faculty;faculty research;Family;Funding;Future;Genetic Risk;genetic testing;Genomics;Goals;Health;Hereditary Disease;Home;Housing;improved;Individual;infectious disease treatment;Infrastructure;Institution;interest;Learning;Maryland;Mentors;Mentorship;Methods;outbreak control;outreach;Policies;Population;Prevention;programs;Recording of previous events;recruit;Research;Research Personnel;Risk;Scholarship;Science;skill acquisition;skills;Societies;Structure;Student recruitment;Students;summer internship;summer program;Time;Training;Travel;undergraduate research experience;undergraduate student;Underrepresented Populations;Universities",Enhancing Diversity among Future ELSI Researchers,10026,ZHG1,ZHG1-HGR-P(O1),NA,S1,5,113440,7806,121246,NA
11196612,N01,CA,NA,N,NA,NA,NA,NA,75N91024D00008,NA,NA,75N91024D00008-0-759102400001-1,NCI:3500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,ALBANY,UNITED STATES,NA,NA,NA,US,NA,NA,NY,12203,NA,NA,(contact),NA,2024-09-16,2024-11-15,Area;assay development;Award;Biological Products;Businesses;Communities;Contractor;Contracts;Development;Development Plans;Documentation;Evaluation;Extramural Activities;Future;Goals;Malignant Neoplasms;manufacture;meetings;Mission;pre-clinical;preclinical development;Preclinical Drug Development;Preventive;Principal Investigator;Procedures;Process;product development;Program Development;programs;Reporting;Research;Research Peer Review;Research Support;Resources;Schedule;Services;Structure;virtual,Contract Orientation & Kickoff Meeting for PREVENT Cancer Preclinical Drug Development Program: CGMP Pool,0,NA,NA,NA,NA,NA,NA,NA,3500,NA
11196650,ZIA,DK,1,N,NA,NA,NA,NA,ZIADK036117,NA,NA,1ZIADK036117-24,NIDDK:521059\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,9693516 (contact),"KRAUSE, MICHAEL  (contact)",NA,NA,NA,Anatomy;Anterior;Biological Models;Blast Cell;Caenorhabditis elegans;Cell Fate Control;cell fate specification;cell type;Cells;Collaborations;Development;Developmental Gene;Ethers;Event;Fertility;forward genetics;Gene Expression;Gene Expression Regulation;Genes;Genetic;genetic approach;Genetic Transcription;Human;Human Development;interest;Knowledge;Laboratories;Logic;loss of function;male fertility;mating behavior;Mediating;Mesoderm Cell;Muscle;mutant;Mutation;Nematoda;O-GlcNAc transferase;Phenotype;Post-Translational Protein Processing;Postembryonic;Proliferating;Regulation;Resolution;reverse genetics;RNA Interference;Role;Sorting;Specific qualifier value;Subcutaneous Tissue;System;Systems Development;Tissues;tool;transcription factor;Transcriptional Regulation;transgene expression;United States National Institutes of Health,Developmental Gene Expression In C elegans,36117,NA,NA,NA,NA,24,NA,NA,521059,NA
11196651,ZIA,NR,1,N,NA,NA,NA,NA,ZIANR000037,NA,NA,1ZIANR000037-07,NLM:461000\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NURSING RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NURSING RESEARCH,NA,NA,NA,79993875 (contact),"ZENK, SHANNON  (contact)",NA,NA,NA,3-Dimensional;Age;Apple;Articulation;Attention;Behavior;behavior measurement;Biological;Brain;Brain imaging;Cancer Survivor;cancer therapy;Care given by nurses;Chronic;Clinical;Clinical Data;Clinical Research;Cognition;Cognitive;Communities;Complex;Computer software;Consent Forms;Custom;cytokine;Data;Data Science;design;Development;Devices;dietary;dietary restriction;digital;Disease;electronic data;Engineering;Environment;experience;Fatigue;Fatty acid glycerol esters;Feasibility Studies;Food;Functional Magnetic Resonance Imaging;Future;Genes;Goals;Head;Home;Home Care Services;Human;Individual;informant;insight;instrumental activity of daily living;interest;International;Journals;Laboratories;lectures;Managed Care;Manuscripts;Medical;Medical Informatics;Medication Management;Modification;Motion;Music;Noise;Nutrition Labeling;Pain;Paper;Patients;Persons;Physical activity;Physiological;Population;Postbaccalaureate;posters;Potassium;programs;Protocols documentation;Publications;Reporting;Research;Research Personnel;Research Project Grants;response;Retirement;Sampling;Science;Scientist;Self Care;Self Management;Series;Slide;Sodium;Sodium-Restricted Diet;sound;square foot;Technology;technology platform;usability;User-Computer Interface;virtual;virtual environment;virtual reality;virtual reality environment;Visualization;Work,Advanced Visualization Branch,37,NA,NA,NA,NA,7,NA,NA,461000,NA
11196652,ZIC,DK,1,N,NA,NA,NA,NA,ZICDK062009,NA,NA,1ZICDK062009-17,NIDDK:782556\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,9693462 (contact),"ANDERSON, DAVID  (contact)",NA,NA,NA,Adopted;Annual Reports;Area;Back;base;Biological;Biopolymers;Calibration;Capital;Chromatography;Communities;Complex;Core Facility;cost;Cost Effectiveness Analysis;crosslink;dalton;Data;Data Analyses;Economics;Elements;Equipment;experience;experimental study;Extramural Activities;Federal Government;Gatekeeping;hazard;high risk;Hybrids;improved;instrument;instrumentation;Isotopes;Label;Ligation;Liquid substance;Liver diseases;macromolecule;mass spectrometer;Mass Spectrum Analysis;Measurement;Measures;member;method development;Methodology;Methods;Modernization;Molecular;Molecular Structure;Molecular Weight;Morals;National Institute of Diabetes and Digestive and Kidney Diseases;National Institute of Drug Abuse;Natural Products;novel strategies;Outsourcing;Peptide Fragments;Performance;Philosophy;Play;Probability;Problem Solving;protein complex;Proteins;Proteomics;Research;Research Project Grants;Resolution;Resources;Rice;Role;Running;Sampling;Science;shift work;small molecule;Software Tools;Structure;Synthesis Chemistry;System;Techniques;Time;tool;Update;Work,Advanced Mass Spectrometry Facility,62009,NA,NA,NA,NA,17,NA,NA,782556,NA
11196653,ZIC,NR,1,N,NA,NA,NA,NA,ZICNR000042,NA,NA,1ZICNR000042-01,NINR:5923695\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NURSING RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NURSING RESEARCH,NA,NA,NA,79993875 (contact),"ZENK, SHANNON  (contact)",NA,NA,NA,Admission activity;Applications Grants;Appointment;Area;Autoimmune Diseases;Awareness;Basic Science;Big Data;Brain-Derived Neurotrophic Factor;Breast Cancer survivor;Cancer Survivor;Cells;certificate program;Clinical;clinical application;Clinical Data;Clinical Investigator;Clinical Protocols;Clinical Research;Clustered Regularly Interspaced Short Palindromic Repeats;cognitive function;Communities;community engagement;Community Health;community intervention;Coupling;Credentialing;Cross-Sectional Studies;Data Analytics;Data Collection;data management;Development;Devices;Discipline of Nursing;Disease;Electroporation;Ensure;Environment;Equipment;Event;Fatigue;Feasibility Studies;Generations;Genes;Genetic Polymorphism;genetic variant;Goals;grasp;Hand;Health;health data;health equity;Incentives;Intramural Research;Laboratories;laboratory equipment;Maintenance;Malignant Neoplasms;Manuscripts;Methods;microbiome;Mission;Myoblasts;nasal swab;Nursing Research;Nursing Students;operation;Paper;Pathogen detection;patient engagement;Patients;Peer Review;Pilot Projects;Policies;population health;Postdoctoral Fellow;Prevention;Primary Care;Protocols documentation;Public Health Informatics;Publications;quality assurance;recruit;Research;Research Activity;Research Personnel;Research Support;Safety;sample collection;Sampling;Science;Scientist;Services;Sinusitis;Site;social health determinants;Strategic Planning;Supervision;Symptoms;Technology;tenure track;Testing;Therapeutic;Training;Travel;undergraduate student;Universities;Work,Optimizing health for all,42,NA,NA,NA,NA,1,NA,NA,5923695,NA
11196675,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00070,NA,NA,75N93024C00070-0-9999-1,NIAID:1794234\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAINT LOUIS,UNITED STATES,NA,01,068552207,US,9083901,WASHINGTON UNIVERSITY,MO,631304862,NA,NA,(contact),NA,2024-09-16,2025-09-15,NA,Functional B-cell Epitope Discovery for Arthropod-Borne Diseases,0,NA,NA,NA,NA,NA,NA,NA,1794234,NA
11196677,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00071,NA,NA,75N93024C00071-0-9999-1,NIAID:1569483\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,PHILADELPHIA,UNITED STATES,NA,03,034055645,US,4419201,INTEGRAL MOLECULAR,PA,191045504,NA,NA,(contact),NA,2024-09-16,2025-09-15,NA,B cell Epitope Discovery and Mechanisms of Antibody Protection for Enterovirus and Bunyavirus Entry Proteins,0,NA,NA,NA,NA,NA,NA,NA,1569483,NA
11196678,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00072,NA,NA,75N93024C00072-0-9999-1,NIAID:1395030\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NASHVILLE,UNITED STATES,NA,07,079917897,US,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,TN,372320011,NA,NA,(contact),NA,2024-09-16,2025-09-15,NA,Genetic and Structural Basis for Virus Neutralization of Paramyxoviruses,0,NA,NA,NA,NA,NA,NA,NA,1395030,NA
11196783,N01,AI,NA,N,NA,NA,NA,NA,75N93022C00052,NA,NA,75N93022C00052-P00004-9999-4,NIAID:800000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,STANFORD,UNITED STATES,NA,16,009214214,US,8046501,STANFORD UNIVERSITY,CA,943052004,NA,79905494 (contact),"PULENDRAN, BALI  (contact)",NA,2022-09-01,2027-08-31,adaptive immune response;Adjuvant;Antigens;clinically relevant;COVID-19 vaccine;Data Analyses;data management;Fingerprint;Goals;Human;Immune;Immunologics;Innate Immune Response;Mus;Organoids;programs;Side;Tissues;Tonsil;Vaccines;Work,Adjuvant Comparison and Characterization,0,NA,NA,NA,NA,NA,NA,NA,800000,NA
11196784,N01,AI,NA,N,NA,NA,NA,NA,75N93019C00045,NA,NA,75N93019C00045-P00023-9999-4,NIAID:358674\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MISSOULA,UNITED STATES,NA,01,010379790,US,1381006,UNIVERSITY OF MONTANA,MT,598124104,NA,79983208 (contact),"EVANS, JAY  (contact)",NA,2021-09-30,2025-09-30,Adjuvant;aptamer;Contractor;Development;Disease;Formulation;immunogenicity;Infection;influenza virus vaccine;Interleukin-1 Receptors;Libraries;Pharmaceutical Chemistry;Recombinant Vaccines;Side;small molecule;synthetic peptide;Testing;Tuberculosis Vaccines;Vaccine Adjuvant;vaccine evaluation;Vaccines,Development of an Optimized Adjuvanted TB Vaccine,0,NA,NA,NA,NA,NA,NA,NA,358674,NA
11196785,N01,AI,NA,N,NA,NA,NA,NA,75N93022C00041,NA,NA,75N93022C00041-P00004-9999-2,NIAID:800000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SYDNEY,AUSTRALIA,NA,NA,752389338,AS,8178701,UNIVERSITY OF SYDNEY,NA,2006,NA,79921093 (contact),"BRITTON, WARWICK  (contact)",NA,2022-09-30,2027-09-29,Adjuvant;Aerosols;Animals;Antigens;Cause of Death;Cells;clinical candidate;clinical development;Development;Disease;Dose;Evaluation;Formulation;Goals;HIV;Human;Immune;Immunity;Immunologics;In Vitro;Inbred Mouse;Infectious Agent;Macaca mulatta;Modeling;mouse model;Mus;Mycobacterium tuberculosis;Mycobacterium tuberculosis antigens;nonhuman primate;novel;Persons;Preventive;programs;Research;Research Personnel;Risk;Side;Treatment outcome;Tuberculosis;tuberculosis treatment;Tuberculosis Vaccines;Vaccine Adjuvant;Vaccines;Work,Advancing Vaccine adjuvant Research for Tuberculosis (TB),0,NA,NA,NA,NA,NA,NA,NA,800000,NA
11196795,N01,AI,NA,N,NA,NA,NA,NA,75N93023C00003,NA,NA,75N93023C00003-P00004-9999-2,NIAID:4020000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,DOYLESTOWN,UNITED STATES,NA,01,167281851,US,10005877,BARUCH S. BLUMBERG INSTITUTE,PA,189028400,NA,79732029 (contact),"CHANG, JINHONG  (contact)",NA,2022-11-15,2025-04-17,Advanced Development;antiviral drug development;candidate selection;Chemistry;Clinical assessments;combat;Coronavirus;efficacy evaluation;emerging virus;lead optimization;manufacture;pandemic disease;pathogenic virus;pre-clinical;product development;programs;research and development;Research Support;safety assessment;Therapeutic;therapeutic candidate;therapeutic development;Viral;Virus Diseases;Yellow Fever,Development of an Antiviral to Combat Viral Infections,0,NA,NA,NA,NA,NA,NA,NA,4020000,NA
11196799,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00052,NA,NA,75N93024C00052-0-9999-1,NIAID:2443961\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MENLO PARK,UNITED STATES,NA,15,094826738,US,10061207,"CLEAR LABS, INC.",CA,940251065,NA,79907730 (contact),"KHAKSAR, RAMIN  (contact)",NA,2024-08-01,2026-07-31,antimicrobial resistant infection;Area;Bacterial Antibiotic Resistance;biodefense;biothreat;Blood;Detection;Development;diagnostic development;diagnostic technologies;Emerging Communicable Diseases;Gram-Negative Bacteria;Gram-Positive Bacteria;improved;in-vitro diagnostics;Infection;Methods;microbial;Nucleic acid sequencing;pathogen;Performance;Proteins;Toxin,"Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections, and Emerging Infectious Diseases",0,NA,NA,NA,NA,NA,NA,NA,2443961,NA
11196801,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00051,NA,NA,75N93024C00051-0-9999-1,NIAID:4211973\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NISKAYUNA,UNITED STATES,NA,20,NA,US,10073271,"GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC",NY,123091027,NA,79983705 (contact),"LENIGK, RALF  (contact)",NA,2024-09-18,2029-09-17,antimicrobial resistant infection;Area;Bacterial Antibiotic Resistance;biodefense;biothreat;Blood;Detection;Development;diagnostic development;diagnostic technologies;Emerging Communicable Diseases;Gram-Negative Bacteria;Gram-Positive Bacteria;improved;in-vitro diagnostics;Infection;Methods;microbial;Nucleic acid sequencing;pathogen;Performance;Proteins;Toxin,"Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections(AMR), and Emerging Infectious Diseases",0,NA,NA,NA,NA,NA,NA,NA,4211973,NA
11196803,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00009,NA,NA,75N93024C00009-0-9999-1,NIAID:4889710\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LONG BEACH,UNITED STATES,NA,42,080144185,US,10058097,"ANIVIVE LIFESCIENCES, INC",CA,908085312,NA,79893873 (contact),"BRUYETTE, DAVID  (contact)",NA,2024-06-07,2026-06-01,Advanced Development;Animal Model;biodefense;Clinical;Coccidioides posadasii;Communicable Diseases;Contracts;Disease Outbreaks;efficacy evaluation;efficacy testing;Emerging Communicable Diseases;Formulation;immunogenicity;Individual;manufacture;response;Safety;stability testing;Toxicology;vaccine candidate;vaccine development;Vaccines,Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,4889710,NA
11196806,N01,AI,NA,N,NA,NA,NA,NA,75N93021C00007,NA,NA,75N93021C00007-P00006-9999-4,NIAID:146648\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,Rockville,UNITED STATES,NA,08,100350748,US,10007457,"DIGITAL INFUZION, INC.",MD,20852,NA,79701744 (contact),"BOUR, STEPHAN  (contact)",NA,2021-04-01,2025-03-31,Animals;Basic Science;Cohort Studies;cross immunity;Development;Disease Outcome;Environmental Risk Factor;Evolution;Human;Immune;Immune response;Immunologic Factors;improved;Influenza;influenza infection;Influenza vaccination;influenzavirus;Molecular;National Institute of Allergy and Infectious Disease;Pathogenicity;Research;response;Sampling;transmission process;Vaccination,NIAID Centers of Excellence for Influenza Research and Response,0,NA,NA,NA,NA,NA,NA,NA,146648,NA
11196807,N01,AI,NA,N,NA,NA,NA,NA,75N93021C00007,NA,NA,75N93021C00007-P00006-9999-5,NIAID:1505020\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,Rockville,UNITED STATES,NA,08,100350748,US,10007457,"DIGITAL INFUZION, INC.",MD,20852,NA,79701744 (contact),"BOUR, STEPHAN  (contact)",NA,2021-04-01,2025-03-31,Animals;Basic Science;Cohort Studies;cross immunity;Development;Disease Outcome;Environmental Risk Factor;Evolution;Human;Immune;Immune response;Immunologic Factors;improved;Influenza;influenza infection;Influenza vaccination;influenzavirus;Molecular;National Institute of Allergy and Infectious Disease;Pathogenicity;Research;Research Activity;response;Sampling;transmission process;universal influenza vaccine;Vaccination,NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities,0,NA,NA,NA,NA,NA,NA,NA,1505020,NA
11196812,N01,AI,NA,N,NA,NA,NA,NA,75N93021C00017,NA,NA,75N93021C00017-P00012-9999-5,NIAID:1706283\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,NA,79704048 (contact),"LOWEN, ANICE  (contact)",NA,2021-04-01,2026-09-17,Animals;Basic Science;Cohort Studies;cross immunity;Development;Disease Outcome;Environmental Risk Factor;Evolution;Human;Immune;Immune response;Immunologic Factors;improved;Influenza;influenza infection;Influenza vaccination;influenzavirus;Molecular;National Institute of Allergy and Infectious Disease;Pathogenicity;Research;response;Sampling;transmission process;Vaccination,NIAID Centers of Excellence for Influenza Research and Response,0,NA,NA,NA,NA,NA,NA,NA,1706283,NA
11196830,N02,DA,NA,N,NA,NA,NA,NA,263201800055I,NA,NA,263201800055I-0-759502400003-1,NIAAA:25000\NICHD:50000\NIMH:50000\NIMHD:5000\OD:90000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,876875154,US,3122901,"IQ SOLUTIONS, INC.",MD,208523046,NA,79990358 (contact),"QUINTAS, ILEANA  (contact)",NA,2024-09-27,2025-09-26,Adolescence;Adolescent;Adolescent Development;adverse outcome;Affect;Age;Alcohols;Behavioral;Biological;Biological Factors;Biology;Birth;Blood;Brain;Brain imaging;Caffeine;Cannabis;Child;Child Development;Child Health;Childhood;Cognitive;cognitive development;cognitive function;cohort;Country;Data Analyses;Development;early childhood;Emotional;emotional functioning;Enrollment;Environmental Risk Factor;experience;Exposure to;Family;Funding;Genetic;Goals;Growth;healing;Health;Health Professional;Health Promotion;Individual;Infant;Informatics;Injury;Knowledge;Longitudinal Studies;Marijuana;Measures;Medical;Medical History;Mental disorders;Neurosciences;Nicotine;Opioid;Outcome;Participant;perinatal period;Personal Satisfaction;Physical activity;Policy Maker;postnatal;Pregnancy;pregnant;prenatal;promote resilience;Recording of previous events;recruit;Research;research and development;Research Personnel;Research Support;resilience factor;Resources;Role;Sampling;Schools;Scientist;Services;Severities;Site;Sleep;sleep pattern;Smoking;social;social factors;Social Functioning;social media;Sports;stressor;substance use;success;teacher;Technology;Tobacco;Trauma;tv watching;Twin Multiple Birth;United States;United States National Institutes of Health;Urine;Video Games;young adult;Youth,RESEARCH SUPPORT SERVICES FOR THE ADOLESCENT BRAIN COGNITIVE DEVELOPENT (ABCD) STUDY AND HEALTHY BRAIN & CHILD DEVELOPMENT (HBCD) STUDY,0,NA,NA,NA,NA,NA,NA,NA,220000,NA
11196836,N01,HD,NA,N,NA,NA,NA,NA,275201800003I,NA,NA,275201800003I-0-759402400001-1,NICHD:343265\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,DURHAM,UNITED STATES,NA,04,044387793,US,2221101,DUKE UNIVERSITY,NC,277054673,NA,79992473 (contact),"BENJAMIN, DANIEL  (contact)",NA,2024-09-23,2028-09-22,Address;Adolescent;Area;artificial intelligence method;assay development;Basic Science;Best Pharmaceuticals for Children Act;Biological Products;Child;Childhood;Clinical;clinical infrastructure;Clinical Research;Clinical Trials;Clinical Trials Network;Collaborations;Community Healthcare;Conduct Clinical Trials;Contracts;Data Science;Devices;Disease;drug development;Ecosystem;Exposure to;flexibility;Funding;Genomics;Human Development;improved;infancy;Infant;Infrastructure;International;knowledge base;Label;Laboratories;Lactation;Lead;Learning;Maternal Health;Medical Device;Mentorship;Methods;Mission;Modeling;multiple omics;National Institute of Child Health and Human Development;novel;Obstetric pharmacology;pediatric pharmacology;Pediatrics;Pharmaceutical Preparations;Pharmacologic Substance;Pharmacology;pharmacometrics;Phenotype;Postpartum Period;Pregnancy;Prevention strategy;Primary Care;programs;regenerative tissue;Reproductive Health;Research;Research Support;Resources;response;Safety;Site;System;Technology;Therapeutic;therapeutic development;Therapeutic Research;Tissue constructs;tool;Training;transition to adulthood;Translational Research;treatment strategy;United States National Institutes of Health;Work,NICHD PEDIATRIC AND MATERNAL RESOURCE CENTER: BRIDGING PHARMACOLOGY AND THE REAL WORLD - BPCA PTN,0,NA,NA,NA,NA,NA,NA,NA,343265,NA
11196837,N01,HD,NA,N,NA,NA,NA,NA,75N94019D00004,NA,NA,75N94019D00004-0-759402400001-1,NICHD:994099\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,MORRISVILLE,UNITED STATES,NA,02,803902113,US,1501,"HEALTH DECISIONS, INC.",NC,275606950,NA,79992356 (contact),"DART, CLINT  (contact)",NA,2024-09-25,2025-12-24,Affinity;Androgen Receptor;androgenic;Androgens;Binding;cis-male;Clinical;Clinical Research;Clinical Trials;Clinical Trials Design;Clinical Trials Network;Contraceptive Agents;contraceptive efficacy;Contraceptive methods;Contractor;Contracts;Data;Data Analyses;Data Collection;data exchange;Databases;Development;Evaluation;Food and Drug Administration Drug Approval;Gonadotropins;Good Clinical Practice;Guidelines;Hypothalamic structure;Impairment;Levonorgestrel;meetings;men;Mission;Monitor;Multi-Institutional Clinical Trial;Nandrolone;National Clinical Trials Network;National Institute of Child Health and Human Development;New Drug Approvals;novel;Ovarian;Pharmaceutical Preparations;Phase;Pituitary Gland;Population;Population Heterogeneity;preclinical development;Preparation;Product Approvals;Production;Progesterone Receptors;Program Development;Protocols documentation;Qualifying;Regulation;Reporting;research clinical testing;Research Personnel;Safety;Services;Site;Specific qualifier value;sperm cell;volunteer;Woman;Work,"PROTOCOL FINALIZATION, START-UP, COORDINATION, MONITORING, AND ALL OTHER ASSOCIATED ACTIVITIES FOR CLINICAL TRIALS EVALUATING PROGESTOGENIC ANDROGENS AS CONTRACEPTIVE AGENTS",0,NA,NA,NA,NA,NA,NA,NA,994099,NA
11196842,N01,AI,NA,N,NA,NA,NA,NA,75N93021C00014,NA,NA,75N93021C00014-P00020-9999-6,NIAID:500000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NEW YORK,UNITED STATES,NA,13,078861598,US,3839801,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,NY,100296574,NA,79711235 (contact),"GARCIA-SASTRE, ADOLFO  (contact)",NA,2021-04-01,2025-09-17,Animals;Basic Science;Cohort Studies;cross immunity;Development;Disease Outcome;Environmental Risk Factor;Evolution;Human;Immune;Immune response;Immunologic Factors;improved;Influenza;influenza infection;Influenza vaccination;influenzavirus;Molecular;National Institute of Allergy and Infectious Disease;Pathogenicity;Research;Research Activity;response;Sampling;transmission process;universal influenza vaccine;Vaccination,NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities,0,NA,NA,NA,NA,NA,NA,NA,500000,NA
11196862,N44,CA,NA,N,NA,NA,NA,NA,75N91024C00093,NA,NA,75N91024C00093-0-9999-1,NCI:2000000\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,WASHINGTON,UNITED STATES,NA,98,080160727; 080160688,US,10041230,"OMICSCRAFT, LLC",DC,200013805,NA,79988557 (contact),"RESSOM, TOM  (contact)",NA,2024-09-16,2026-09-15,Address;Algorithmic Analysis;anti-cancer research;Clinical;cloud based;Complex;computational pipelines;computer framework;Computing Methodologies;Data;Data Analyses;Data Analytics;Data Commons;deep learning;Development;Event;Image;Imaging technology;innovation;Medical Imaging;Methods;Molecular;multimodal data;Multiomic Data;multiple omics;novel;Outcome;Performance;Phenotype;Proteomics;prototype;Research Personnel;Resources;Techniques;Testing;The Cancer Genome Atlas;The Cancer Imaging Archive;tool;tumor,ISYSMET: AI-POWERED PLATFORM FOR INTEGRATIVE ANALYSIS OFMULTIMODAL DATA,0,NA,NA,NA,NA,NA,NA,NA,2000000,NA
11197434,ZIA,CL,1,N,NA,NA,NA,NA,ZIACL090026,NA,NA,1ZIACL090026-15,NA,INTRAMURAL RESEARCH,2024,CLINICAL CENTER,NA,NA,NA,NA,NA,NA,NA,NA,CLINICAL CENTER,NA,NA,NA,8212291 (contact),"SOLOMON, STEVEN  (contact)",NA,NA,NA,"Adhesions;Adverse effects;Affinity;Age;Alveolar;Anemia;Animals;Antibiotics;Bacteria;Bacterial Infections;Bacterial Pneumonia;Binding;Blinded;Blood;Blood Banks;Blood donor;Blood Transfusion;canine model;Canis familiaris;Carbohydrates;Cardiac;Cardiac Output;Cell model;Cell Survival;Cells;Cessation of life;Chromium;Clinical;Clinical Medicine;Clinical Trials;clinically relevant;Complex;Critical Illness;Cryopreservation;Data;design;Development;Dose;Endothelial Cells;Endothelium;Erythrocyte Transfusion;Erythrocytes;experimental study;Filtration;glycosylated-nitric oxide complex hemoglobin A;Growth;Haptoglobins;Hematological Disease;hemodynamics;Hemoglobin;Hemoglobin concentration result;Hemolysis;Hemorrhage;Hemorrhagic Shock;Histologic;Hour;Human;improved;improved outcome;in vivo;Infection;Inflammation;Inflammatory;Infusion procedures;Injury;intravenous administration;Iron;Lesion;Life;life span;Lipids;Liver;liver function;Lung;lung injury;lung pressure;Measurable;Measures;Membrane;Metabolic;microvesicles;Modeling;Modernization;mortality;mortality risk;Nitric Oxide;Norepinephrine;Nutrient;Operative Surgical Procedures;organ injury;Outcome;oxidative damage;Oxygen;Oxyhemoglobin;Pathogenesis;patient population;Patients;Performance;Plasma;Plasma Cells;Pneumonia;pneumonia model;Poison;Polyvinyl Chloride;Population;Potassium;pre-clinical;Preparation;pressure;prevent;Proteins;Randomized;randomized, controlled study;Recovery;Refrigeration;Reperfusion Therapy;response;Risk;Risk Marker;Role;Sepsis;septic;Septic Shock;Severities;Shapes;Shock;Sickle Cell Anemia;Staphylococcus aureus;Survival Rate;Temperature;Testing;Thalassemia;Time;tissue injury;Toxin;Transfusion;Trauma;trend;unethical;United States;vasoconstriction;Virulent;Work",Is there a difference between transfusing old vs fresh blood in critical illness,90026,NA,NA,NA,NA,15,NA,NA,0,NA
11197435,ZIA,CL,1,N,NA,NA,NA,NA,ZIACL090065,NA,NA,1ZIACL090065-05,NA,INTRAMURAL RESEARCH,2024,CLINICAL CENTER,NA,NA,NA,NA,NA,NA,NA,NA,CLINICAL CENTER,NA,NA,NA,8212291 (contact),"SOLOMON, STEVEN  (contact)",NA,NA,NA,Acute;Adult;Animal Model;Animals;Biochemical;biological adaptation to stress;Blood;Blood Pressure;Blood Vessels;Cardiac;Cardiac Edema;cardiac magnetic resonance imaging;Cardiac Output;Cardiomyopathies;Catecholamines;Cessation of life;Colloids;comparative;Consensus;Contracts;crystalloid;design;Development;Dimensions;Drops;Echocardiography;Edema;EFRAC;Electron Microscopy;Epinephrine;Exclusion;experience;falls;Functional disorder;Heart;Heart failure;heart function;Heart Injuries;hemodynamics;Histologic;Hour;Human;Hypotension;Immune system;Impairment;Infection;Infusion procedures;insight;Ischemia;Left;Left Ventricular Ejection Fraction;Left Ventricular Mass;Left ventricular structure;light microscopy;Liquid substance;Low Cardiac Output;Magnetic Resonance Imaging;Maintenance;Modeling;Multiple Organ Failure;Muscle Cells;Myocardial;Myocardial dysfunction;novel;Patients;pediatric patients;Perfusion;Peripheral;pneumonia model;pressure;Protocols documentation;Randomized;Recovery;Recovery of Function;reparative capacity;reparative process;Resistance;response;restoration;Resuscitation;Sedation procedure;Sepsis;septic;Septic Shock;Shock;Stress;Stress cardiomyopathy;Survivors;Syndrome;Testing;Therapeutic;Thinness;Time;Tissues;Toxic effect;Troponin;vascular injury;ventilation;Ventricular;Water,The Comparative Pathobiology of Stress-induced and Sepsis-induced Cardiomyopathy,90065,NA,NA,NA,NA,5,NA,NA,0,NA
11197436,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL001027,NA,NA,1ZIAHL001027-42,NHLBI:631590\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,8453160 (contact),"BROOKS, BERNARD R (contact)",NA,NA,NA,Acceleration;aerosolized;Algorithms;Amber;Amino Acid Sequence;Anisotropy;Binding;Biochemistry;Biological;Chemicals;Classification;Communities;Complex;Computational Technique;Computer software;Computing Methodologies;cost;Data;deep learning;density;Dependence;Disease;disease-causing mutation;Docking;Elasticity;Electron Microscopy;electron tomography;Energy consumption;experimental study;Fluorescence Resonance Energy Transfer;Gases;Goals;heuristics;Homologous Protein;Hybrids;Image;improved;Infusion procedures;Knowledge;Lasers;Lead;Liquid substance;Location;Machine Learning;macromolecular assembly;macromolecule;Maps;Mass Spectrum Analysis;Methods;Modeling;models and simulation;Modernization;Molecular;molecular assembly/self assembly;Molecular Conformation;molecular modeling;molecular size;Molecular Structure;Monte Carlo Method;Movement;nanoparticle;nanorod;neural network;NMR Spectroscopy;Normal Statistical Distribution;Output;particle;Pathway interactions;Pattern Recognition;peptide structure;Physics;Physiologic pulse;Property;protein folding;Protein Region;protein structure;protein structure prediction;Proteins;Research;Research Support;Resolution;Roentgen Rays;Sampling;Sequence Alignment;Shock;Signal Transduction;simulation;Source;Spectrum Analysis;Statistical Computing;structural biology;Structure;System;Techniques;Technology;Temperature;Tertiary Protein Structure;three dimensional structure;Time;tomography;tool;Variant;Work;X-Ray Crystallography;x-ray free-electron laser,Three-dimensional Structures Of Biological Macromolecules,1027,NA,NA,NA,NA,42,NA,NA,631590,NA
11197437,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL001050,NA,NA,1ZIAHL001050-27,NHLBI:1052650\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,8453160 (contact),"BROOKS, BERNARD R (contact)",NA,NA,NA,"Action Potentials;Active Sites;Address;Affect;Agreement;alpha-bungarotoxin receptor;Antibiotic Resistance;Basic Science;Behavior;Binding;Biological;Biological Process;biophysical properties;Biophysics;Blindness;blood treatment;Brain;cancer therapy;Cell division;Cell membrane;Cells;Cellular Membrane;Charge;Chemicals;Chemotaxis;cholinergic;Communication;Complex;Computational Biology;Computer Models;Computer Simulation;Cooperative Behavior;Coupled;CRISPR/Cas technology;Cytoskeleton;Data;Dependence;design;Development;Differential Equation;dimer;DNA;DNA Binding;DNA biosynthesis;DNA Primase;drug discovery;electric field;Electron Microscopy;Electrophysiology (science);Electrostatics;Engineering;Environment;Enzymes;evaluation/testing;Extracellular Domain;Free Energy;Gangliosides;Gene Expression Microarray Analysis;Gene Expression Profiling;Genetic;Glycine Receptors;Glycolipids;Growth;Guanosine Triphosphate;Hematological Disease;Histones;Hodgkin-Huxley model;Hydrogen Bonding;Hydrolysis;Image Analysis;improved;insight;interest;Ion Channel;Ion Channel Gating;Ions;Iron;Kinetics;Laboratories;Lateral;Ligands;Lipid Bilayers;Lipids;macromolecule;Malignant Neoplasms;Measures;Membrane;Methods;Microtubules;Modeling;Molecular;Molecular Conformation;molecular dynamics;molecular mechanics;molecular modeling;monomer;Monte Carlo Method;mutant;National Heart, Lung, and Blood Institute;Natural regeneration;Nervous System;oxidation;Oxidation-Reduction;Pharmaceutical Preparations;Phase;phospho-L-arginine;Play;Polysaccharides;Positioning Attribute;Process;programs;Proteins;Quantum Mechanics;Radial;Reaction;receptor;Research;Research Project Grants;RNA;RNA primers;Role;Rotation;Running;Sampling;Science;Scientist;Side;Sigmoid colon;Signal Transduction;Signaling Protein;simulation;small molecule;Speed;Statistical Models;Streptococcus pyogenes;Stroke;Structure;Sulfur;Surface Tension;System;Techniques;Testing;Thermodynamics;Time;time use;tool;trafficking;Transmembrane Domain;transmission process;Tubulin;Variant;Work;wound healing",Molecular Dynamics Simulations Of Biological Macromolecules,1050,NA,NA,NA,NA,27,NA,NA,1052650,NA
11197438,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL001051,NA,NA,1ZIAHL001051-27,NHLBI:1473710\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,8453160 (contact),"BROOKS, BERNARD R (contact)",NA,NA,NA,"Active Sites;Algorithms;Amber;Amino Acid Sequence;Area;Basic Science;Behavior;Binding Sites;Biochemical Pathway;Biochemical Process;Biochemical Reaction;Biological;Biological Process;Biological Products;biological systems;Biophysics;Catalysis;Cells;chemical property;Chemicals;cofactor;Communities;Computational Biology;Computational Technique;Computer Assisted;Computers;Computing Methodologies;computing resources;Coupled;Crystallography;Custom;Data;Data Set;Databases;Decision Trees;Descriptor;design;Development;Drug Design;Elasticity;Electron Microscopy;Electron Transport;electronic structure;Electrons;Electrostatics;Ensure;Enzymes;Equilibrium;evaluation/testing;experimental study;Free Energy;Freedom;Frequencies;functional group;Gene Expression Microarray Analysis;Gene Expression Profiling;gene function;Generations;Goals;Grain;Graph;Hardness;Health;Human;human disease;Image;Image Analysis;improved;induced pluripotent stem cell;interest;Ions;Iron;Laboratories;Ligands;Linear Regressions;Link;Machine Learning;machine learning model;machine learning prediction;macromolecule;Manuals;Maps;Measurement;Membrane Proteins;metallicity;metalloenzyme;Metalloproteins;Metals;Methodology;Methods;Modeling;models and simulation;Molecular;molecular dynamics;molecular mechanics;molecular modeling;multi-scale modeling;Names;National Heart, Lung, and Blood Institute;neural network classifier;novel;Nucleic Acids;oxidation;Oxidation-Reduction;Oxygen;parallelization;Pathway Analysis;Pharmaceutical Preparations;photosystem II;Physiological;Play;programs;Property;protein data bank;Protein Databases;Proteins;Pythons;quantum;Quantum Mechanics;Radial;Radiation induced damage;Reaction;Recommendation;Reporting;Research;Research Project Grants;Resources;Roentgen Rays;Role;Science;Scientist;simulation;Site;small molecule;software development;Solvents;Specificity;Structure;Sulfur;Surface;System;Techniques;Temperature;Testing;text searching;theories;Therapeutic Intervention;therapeutic lead compound;therapy design/development;tool;Update;Validation",Development Of Theoretical Methods For Studying Biological Macromolecules,1051,NA,NA,NA,NA,27,NA,NA,1473710,NA
11197439,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL002338,NA,NA,1ZIAHL002338-27,NHLBI:4088866\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,16151768 (contact),"HONG, SO GUN  (contact)",NA,NA,NA,Address;Antibodies;Antibody-drug conjugates;Autologous;Behavior Therapy;Biological Models;Blood Component Removal;Bone Marrow;Cardiac;Cardiac Myocytes;Cell Therapy;cell type;Cells;Clinical Research;Clonality;Clustered Regularly Interspaced Short Palindromic Repeats;Collaborations;Collection;Communication;conditioning;CRISPR/Cas technology;Disease;Dose;Engraftment;enhanced green fluorescent protein;Erythrocytes;Extramural Activities;fertility preservation;Future;Gene Expression;Gene Modified;gene therapy;Gene Transfer;Genes;Genetic;Goals;Growth;Health;Heart Diseases;Hematological Disease;Hematopoiesis;Hematopoietic;Hematopoietic Stem Cell Mobilization;Hematopoietic stem cells;Hemoglobin;Human;human subject;Immune;immune reconstitution;Immunology;improved;In Vitro;in vitro Model;in vivo;induced pluripotent stem cell;innovative technologies;insight;Iodides;Journals;lentivirally transduced;Lentivirus Vector;life span;Longevity;Macaca mulatta;Macrophage;Methodology;Methods;Modality;Modeling;Modification;National Institute of Allergy and Infectious Disease;Nature;non-invasive imaging;nonhuman primate;novel;Pluripotent Stem Cells;Population;Positron-Emission Tomography;post-transplant;Pre-Clinical Model;preclinical development;Primates;programs;Proto-Oncogene Protein c-kit;Publishing;reconstitution;regenerative therapy;Regimen;Reporter Genes;Reporting;Resources;Retroviral Vector;Rhesus;risk/benefit ratio;Rodent;Rodent Model;Safety;Sodium;stem cell biology;stem cells;symporter;T-Lymphocyte;Technology;Testing;therapeutic development;therapeutic gene;therapy design;Tissues;transduction efficiency;Transplantation;Transplantation Conditioning;Universities;vector;Washington,Genetic Modification and Novel Cell Therapies in Non-Human Primate Hematopoietic Cells,2338,NA,NA,NA,NA,27,NA,NA,4088866,NA
11197440,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL002346,NA,NA,1ZIAHL002346-20,NHLBI:3201150\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,8507549 (contact),"WIESTNER, ADRIAN U (contact)",NA,NA,NA,acquired drug resistance;Adaptor Signaling Protein;Adhesions;Agammaglobulinaemia tyrosine kinase;B-Cell Activation;B-Cell Antigen Receptor;Binding;Biological;Bone Marrow;candidate validation;Cells;Chronic Lymphocytic Leukemia;chronic lymphocytic leukemia cell;Classification;Clinical;Clinical Trials;cohort;Complex;Conduct Clinical Trials;CXCR4 gene;Data;Data Correlations;disorder risk;Dose;Enrollment;Event;exome sequencing;experience;follow-up;Gene Expression Profiling;Gene set enrichment analysis;genetic signature;Globulins;Hour;Immunity;improved;In complete remission;in vivo;Inferior;inhibitor;inhibitor therapy;Innovative Therapy;Integrin alpha4beta1;Intervention;Lactate Dehydrogenase;Link;lymph node microenvironment;lymph nodes;Lymphocytosis;Macrophage;Mantle Cell Lymphoma;Mature B-Lymphocyte;Measures;Mediating;memory CD4 T lymphocyte;Minor;Modality;Modeling;Molecular;Multivariate Analysis;mutant;Mutation;Mutation Detection;nanomolar;neoplastic cell;NF-kappa B;NFKB Activation Pathway;novel strategies;Oncogenic;Outcome;participant enrollment;Pathogenesis;Pathogenicity;Pathway interactions;patient stratification;Patients;peripheral blood;PF4 Gene;Pharmaceutical Preparations;phase 2 study;Phase II Clinical Trials;PLCG2 gene;population based;pre-clinical;Pre-Clinical Model;prevent;Process;prognostic;Prognostic Marker;prognostic model;prognostic significance;prognostic value;progression risk;Proliferating;prospective;Proteins;Receptor Signaling;Recording of previous events;recruit;Reporting;Resistance;response;Risk;RNA;Role;Sampling;Shapes;Signal Transduction;single-cell RNA sequencing;small molecule inhibitor;Subgroup;Systems Biology;T-cell inflamed;T-Lymphocyte;targeted treatment;Testing;Therapeutic Intervention;therapeutic target;therapy resistant;Time;TP53 gene;transcriptome;transcriptome sequencing;transcriptomic profiling;treatment response;tumor;tumor microenvironment;Tumor-Derived Activated Cell;Tyrosine Kinase Inhibitor;ubiquitin-protein ligase;Validation,"Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy",2346,NA,NA,NA,NA,20,NA,NA,3201150,NA
11197441,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006003,NA,NA,1ZIAHL006003-17,NIDDK:652305\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,9694372 (contact),"RODGERS, GRIFFIN  (contact)",NA,NA,NA,13q12;13q14;14q;Adult;advanced prostate cancer;American;Anterior;Bioinformatics;Biological;Biological Process;BRCA2 gene;C57BL/6 Mouse;Cadherins;Cancer Cell Growth;Cancer Etiology;cancer type;Cathepsins;Cell Adhesion;Cell Physiology;Cell Proliferation;Cell surface;Cells;Cessation of life;Chromosomes;Colon Carcinoma;Colonic Neoplasms;Development;Diagnosis;Ectopic Expression;Epithelial Cells;Epithelium;Evaluation;Exons;Family;Family member;forkhead protein;FOXO1A gene;Gene Expression Regulation;Genes;Genitourinary system;Goals;Homeostasis;Human;Human Genome;improved;In Vitro;in vivo;Inflammation;Invaded;Lectin;Loss of Heterozygosity;male;Malignant Breast Neoplasm;Malignant neoplasm of prostate;malignant stomach neoplasm;Mediating;men;Messenger RNA;Metadata;Metastatic Neoplasm to the Bone;Modeling;Molecular;Mus;Natural Immunity;Neoplasm Metastasis;novel;olfactomedin;OLFM4 gene;Organoids;postnatal development;Prognosis;Proliferating;Prostate;prostate cancer cell;prostate cancer progression;Prostatic Epithelium;Prostatic Neoplasms;Proteins;RB1 gene;Reporter;Reporting;Retinoblastoma;Seminal fluid;Serum;Signal Pathway;single-cell RNA sequencing;Solid Neoplasm;Stomach Neoplasms;Stromal Cell-Derived Factor 1;Susceptibility Gene;three dimensional cell culture;Tissues;Tube;Tumor Suppressor Genes;Tumor Suppressor Proteins;Up-Regulation;Urethra;Xenobiotic Metabolism,Olfactomedin 4 Suppresses Prostate Cancer Cell Growth and Metastasis via Negativ,6003,NA,NA,NA,NA,17,NA,NA,652305,NA
11197442,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006004,NA,NA,1ZIAHL006004-17,NIDDK:652305\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,9694372 (contact),"RODGERS, GRIFFIN  (contact)",NA,NA,NA,Affect;alpha-latrotoxin receptor;Amino Acid Sequence;Apoptosis;Attenuated;cancer cell;CDC2 gene;Cell Cycle;Cell Cycle Arrest;Cell Cycle Progression;Cell Proliferation;Cells;Co-Immunoprecipitations;Colonic inflammation;CSF3 gene;cyclin B1;Down-Regulation;Epithelium;experimental study;Family;G2/M Arrest;Gastric Adenocarcinoma;gastric cancer cell;gastrointestinal infection;Genes;Glycoproteins;Granulocyte Colony-Stimulating Factor;Hematopoietic;Human;In Vitro;in vivo;Inflammation;Inflammatory Bowel Diseases;Interferons;knock-down;Laboratories;Link;M cell;Malignant Neoplasms;malignant stomach neoplasm;Mediating;member;MicroRNAs;Molecular;Mucous Membrane;Myelogenous;Natural Immunity;neutrophil;Noelin-1;nucleocytoplasmic transport;Nude Mice;olfactomedin;OLFM4 gene;Oncogenic;overexpression;Play;precursor cell;Proliferating;Proteins;Regulation;Reporting;Role;Small Intestinal Adenocarcinoma;therapeutic target;Translations;Tretinoin;tumor;tumor growth;ubiquitin-protein ligase;Yeasts,"Olfactomedin 4- a key regulator of human neutrophil function, role in small intestinal adenocarcinoma.",6004,NA,NA,NA,NA,17,NA,NA,652305,NA
11197443,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006005,NA,NA,1ZIAHL006005-15,NIDDK:672071\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,9694372 (contact),"RODGERS, GRIFFIN  (contact)",NA,NA,NA,Abeta clearance;Actins;Address;Alzheimer&apos;s Disease;Amyloid beta-42;Amyloid beta-Protein;Biological;Biological Process;Blood;Categories;Cell Lineage;Cell Surface Receptors;cell type;Cells;Clinic;Data;Development;Disease;Dysmyelopoietic Syndromes;Erythroid;Exposure to;Functional disorder;Gene Expression Profile;Gene Expression Profiling;gene product;Genes;Genetic Transcription;Glia Maturation Factor;Global Change;Granulopoiesis;Hematopoiesis;Hematopoietic;Hematopoietic stem cells;Immune;inhibiting antibody;insight;knock-down;leukemia;Leukemic Cell;Link;Liquid substance;Macrophage;MAPK8 gene;Maps;Mediating;Methods;Microglia;monocyte;Mus;Mutation;Myelogenous;Myeloid Progenitor Cells;Myeloproliferation;novel;Nuclear Pore Complex;Oncogenes;Ontology;overexpression;Peripheral;Phagocytes;Phagocytosis;Phosphorylation;Polyubiquitination;Population;posttranscriptional;prevent;protein expression;Proteins;response;Role;scavenger receptor;Signal Pathway;Signal Transduction;slow potential;stem cell population;Structure;Suggestion;System;Techniques;Therapeutic;Time;tool;transcription factor;Trees;Two-Dimensional Gel Electrophoresis;uptake,Glia maturation factor-gamma modulation of signaling pathways in macrophages,6005,NA,NA,NA,NA,15,NA,NA,672071,NA
11197444,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006070,NA,NA,1ZIAHL006070-15,NHLBI:1371922\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,8507549 (contact),"WIESTNER, ADRIAN U (contact)",NA,NA,NA,Affinity;Agreement;Allogenic;anti-CD20;Antibodies;antibody libraries;Antibody Therapy;Antigen Targeting;Antigens;arm;Autologous;B lymphoid malignancy;B-Lymphocytes;BCL2 gene;Binding;biological adaptation to stress;Bispecific Antibodies;Blood;Bone Marrow;cancer immunotherapy;CD19 gene;CD8-Positive T-Lymphocytes;cell killing;Cell Line;Cell surface;cell type;Cells;Cellular Immunity;chemotherapy;chimeric antigen receptor T cells;Chronic Lymphocytic Leukemia;chronic lymphocytic leukemia cell;Clinic;Clinical;clinical development;Clinical Trials;cohort;comparison control;Complement;Complement 3d;Complement Activation;Conduct Clinical Trials;COVID-19 booster;COVID-19 pandemic;COVID-19 vaccination;COVID-19 vaccine;Cytolysis;cytotoxic;cytotoxicity;Deposition;Dose;engineered T cells;Epitopes;Evaluable Disease;Fc Receptor;FDA Emergency Use Authorization;Frequencies;Futility;Glycoproteins;Hepatitis B Vaccines;Human;IgG1;Immune response;Immunotherapy;Impairment;improved;In Vitro;in vivo;inhibitor;Injections;Innovative Therapy;insight;Interruption;Intervention;invention;Investigation;Leukemic Cell;Lymphoma;Malignant lymphoid neoplasm;Measures;Mediating;Medical;Modeling;Monoclonal Antibodies;Monoclonal Antibody CD20;Monoclonal Antibody Therapy;mouse model;MS4A1 gene;Multiple Myeloma;Mus;neoantigens;neoplastic cell;novel strategies;open label;Oryctolagus cuniculus;overexpression;pandemic disease;patient derived xenograft model;patient response;Patients;Peripheral Blood Mononuclear Cell;primary endpoint;Progressive Disease;prospective;Reaction;Recombinants;Recommendation;recruit;Reporting;Resistance;response;rituximab;Role;ROR1 gene;Sampling;Secondary Immunization;Series;Serology;sialic acid binding Ig-like lectin;Stem cell transplant;success;T cell differentiation;T memory cell;T-Lymphocyte;Testing;Time;tositumomab;tumor growth;Vaccination;vaccination strategy;vaccine development;vaccine response;vaccine trial;Vaccines;Variant;Work;Xenograft Model;Xenograft procedure;Zoster Vaccine,Immunotherapy of low grade lymphoid malignancies,6070,NA,NA,NA,NA,15,NA,NA,1371922,NA
11197445,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006168,NA,NA,1ZIAHL006168-12,NHLBI:280071\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,15197968 (contact),"POWELL-WILEY, TIFFANY  (contact)",NA,NA,NA,Academia;acceptability and feasibility;Adult;African American;African American population;African American Women;Agriculture;Amines;Amygdaloid structure;Aorta;Area;Assessment tool;atherogenesis;behavior change;Behavior Therapy;Biological;Biological Aging;Biological Markers;Black church;Blood Vessels;Body Image;Body mass index;Body Size;built environment;Cardiovascular Diseases;cardiovascular health;cardiovascular risk factor;Catecholamines;CCR5 gene;Cessation of life;Characteristics;Chronic;Chronic stress;Church;Clinic;clinical center;Clinical Protocols;Clinical Trials;cohort;Collaborations;Communities;community advisory board;community based participatory research;community collaboration;Community Health;Community Healthcare;community intervention;community partners;Consult;Crime;Data;Data Collection;depressive symptoms;deprivation;design;Diabetes Mellitus;Dietary intake;digital;disorder risk;District of Columbia;Dopamine;Dopamine D2 Receptor;Early identification;Economic Development;Environment;Environmental Risk Factor;Epigenetic Process;Event;experimental study;Faith;Focus Groups;Food;Future;future implementation;Goals;handheld equipment;Health;health assessment;Health behavior;Health behavior and outcomes;health disparity;Health Personnel;Healthcare;Hematopoietic System;High Density Lipoprotein Cholesterol;High Density Lipoproteins;high risk population;hypercholesterolemia;Hyperlipidemia;Hypertension;IL18 gene;Immune;Immunologic Factors;Immunologics;implementation evaluation;improved;In Vitro;Income;indexing;Individual;Inflammation;Interleukin-1 beta;Intervention;Laboratories;LDL Cholesterol Lipoproteins;Leisures;Link;Lipids;Lipoproteins;Location;Low income;low socioeconomic status;Measurement;Measures;Mediating;Mediation;member;Methods;mHealth;microbial;microbiome;mobile application;Modeling;Monitor;monocyte;mortality;Needs Assessment;Neighborhoods;neural;novel;nutrition;Obesity;Obesity Epidemic;obesity prevention;obesity risk;Online Systems;Outcome;Oxides;Participant;Pathogenicity;Pathway interactions;Patients;Perception;phenotypic data;Physical activity;Play;Population;population based;Population Heterogeneity;Populations at Risk;preference;Prevalence;Prevention strategy;Property;Proprotein Convertases;Proteome;Protocols documentation;Proxy;Psychosocial Factor;Psychosocial Stress;receptor;Recommendation;Records;recruit;Research;Research Personnel;Resource-limited setting;Resources;Risk;Risk Factors;Role;Sampling;satisfaction;Scoring Method;screening;sedentary;Serum;Signal Pathway;Signal Transduction;simulation;social cohesion;Social Conditions;social determinants;Social Environment;Socioeconomic Status;socioeconomics;Source;Stress;Subtilisins;Suggestion;Sympathetic Nervous System;System;Target Populations;Technology;technology intervention;Time;TNF gene;tool;United States National Institutes of Health;Universities;uptake;Violence;ward;Washington;wearable data;wearable device;wireless;Work;wristband,Cardiovascular Health and Needs Assessment in Washington D.C.,6168,NA,NA,NA,NA,12,NA,NA,280071,NA
11197446,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006170,NA,NA,1ZIAHL006170-12,NHLBI:3476077\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,12000815 (contact),"JOHNSON, ANDREW  (contact)",NA,NA,NA,Accounting;African ancestry;Aging;Alcohols;anti-depressive agents;Area;Atherosclerosis;Biochemical;Bioinformatics;Biological Assay;Biology;Blood;Blood Platelets;Blood Pressure;Boston;calcification;Candidate Disease Gene;Cardiovascular Diseases;Cardiovascular system;Catalogs;Cells;Chromosome Mapping;Circulation;cohort;Collaborations;Communication;Coronary Arteriosclerosis;COVID-19;COVID-19 pandemic;Data;data cleaning;Data Collection;Data Set;Diabetes Mellitus;Disease;disorder risk;DNA;Epidemiologic Factors;Epidemiology;epidemiology study;Epigenetic Process;Event;exome;experimental study;Fibrin fragment D;Fibrinogen;follow-up;Framingham Heart Study;Gene Chips;gene discovery;Gene Expression;Genes;Genetic;genetic analysis;Genetic Databases;Genetic Markers;Genetic study;genome wide association study;Genomics;Genotype;Goals;GRK5 gene;Health;Hemostatic Agents;Human;Individual;Jackson Heart Study;Journals;Knockout Mice;Knowledge;Link;Lipids;Manuscripts;meetings;Megakaryocytes;men;Metabolic Diseases;Micro Array Data;Mus;Nature;new therapeutic target;novel;Oral;Paper;Pathway interactions;personalized medicine;Pharmaceutical Preparations;Plasminogen Activator Inhibitor 1;Platelet Count measurement;platelet function;Population;Population Genetics;Population Heterogeneity;Population Study;Postdoctoral Fellow;Process;programs;Publishing;Puerto Rican;Pulmonary Embolism;repository;Research;Resources;response;Risk Factors;RNA;Role;Sampling;Scanning;Signal Transduction;Stroke;Therapeutic Intervention;therapeutic target;Thrombin;Thrombosis;Tissue-Specific Gene Expression;Tissues;trait;Trans-Omics for Precision Medicine;transcriptome;transcriptome sequencing;treatment response;United States National Institutes of Health;Update;Validation;Variant;Venous;venous thromboembolism;Veterans;Work;Writing,Cardiovascular Genomics and Bioinformatics projects,6170,NA,NA,NA,NA,12,NA,NA,3476077,NA
11197447,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006172,NA,NA,1ZIAHL006172-12,NHLBI:1497052\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,12000818 (contact),"LAROCHELLE, ANDRE  (contact)",NA,NA,NA,Acceleration;Address;Adenine;Affect;Agonist;Annual Reports;Antibodies;Antigens;Attenuated;Autologous;Autologous Transplantation;base editing;base editor;Basic Science;Binding;Biodistribution;Biological Assay;Bone Marrow;Bone marrow failure;bone marrow failure syndrome;CCR5 gene;CD34 gene;Cell Nucleus;Cell Physiology;Cells;chemical conjugate;chemotherapy;Chimeric Proteins;Chloroquine;Clinical;clinical efficacy;clinical practice;Clinical Trials;Clustered Regularly Interspaced Short Palindromic Repeats;cohort;Colchicine;conditioning;Confocal Microscopy;cost;CRISPR/Cas technology;cytokine;Cytosol;Defect;Dendrimers;design;Development;Dextran Sulfate;Dichloromethylene Diphosphonate;dimer;Diphtheria Toxin;Disease;disulfide bond;DNA;DNA Damage;DNA Double Strand Break;DNA Repair;dosage;Dose;Double Strand Break Repair;effective therapy;Effectiveness;Electroporation;Eligibility Determination;Encapsulated;endoplasmic reticulum stress;Endosomes;Engineering;Engraftment;Ensure;Enzyme-Linked Immunosorbent Assay;Esters;Evaluation;Event;Exposure to;Face;Fanconi Anemia Complementation Group A Protein;Fanconi&apos;s Anemia;fitness;Flow Cytometry;Fluorescence Resonance Energy Transfer;Formulation;gene correction;Gene Delivery;gene delivery system;Gene Modified;gene therapy;gene-editing approach;Genes;Genetic Engineering;genetic manipulation;Granulocyte Colony-Stimulating Factor;Harvest;Hematological Disease;Hematopoietic;Hematopoietic stem cells;Hematopoietic System;Hemolysis;Human;Human Herpesvirus 4;Hydrophobicity;Hypersensitivity;Hypoxia;Immune;immunogenicity;Impairment;improved;In Vitro;in vivo;Individual;Inflammation;Inflammation Mediators;Inflammatory;Infusion procedures;Inherited;Inherited bone marrow failure;inhibitor;innate immune pathways;Innate Immune Response;insertion/deletion mutation;insight;integration site;Investigation;lipid nanoparticle;Lipids;Liposomes;Malignant - descriptor;Malignant Neoplasms;manufacture;Marrow;Mediating;Messenger RNA;Methods;Modification;Monitor;Mononuclear;MPL gene;Mus;mutation correction;nanoparticle delivery;Neutropenia;Non-Viral Vector;nonhuman primate;novel;novel strategies;nucleic acid delivery;Nucleic Acids;Organ;Pancytopenia;Participant;Patients;peripheral blood;Phagocytes;phase II trial;Point Mutation;Population;post-transplant;Pre-Clinical Model;Process;programs;Proteomics;Protocols documentation;Reagent;Recombinants;Recovery;Regenerative Medicine;Regimen;Reporter;Reporter Genes;Research;resilience;response;Risk;Role;Safety;self-renewal;sensor;SLC5A5 gene;small molecule;Specialized Center;Stress;System;Tail;Therapeutic;tool;Toxic effect;TP53 gene;transcription factor;transcriptomics;Transformed Cell Line;Translating;Translational Research;Transplantation;Transplantation Conditioning;Transposase;Treatment Factor;vector;Viral;Viral Vector;Xenograft Model;Xenograft procedure,Gene Therapy for Inherited Blood Disorders,6172,NA,NA,NA,NA,12,NA,NA,1497052,NA
11197448,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006200,NA,NA,1ZIAHL006200-10,NHLBI:2423956\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,79995843 (contact),"FENNELLY, KEVIN  (contact)",NA,NA,NA,2019-nCoV;Academia;Address;Aerosols;Affect;airway epithelium;Antibiotics;Attention;Biotechnology;Blood specimen;Bronchiectasis;Bronchoalveolar Lavage;Caring;Characteristics;Chest;Chronic;chronic infection;Chronic Obstructive Pulmonary Disease;chronic respiratory disease;clinical center;Clinical Research;Clinical Trials;Clinical Trials Design;cohort;Complex;COVID-19;Cystic Fibrosis;Cystic Fibrosis Transmembrane Conductance Regulator;Data;Databases;Development;Diagnosis;Disease;Disease Progression;drug development;Drug Targeting;early phase clinical trial;Educational workshop;Environmental Risk Factor;Epithelial Cells;ethnic diversity;Ethnic Population;Foundations;Genetic;Genetic Diseases;Genetic Risk;genetic risk factor;Genomics;Genus Mycobacterium;Geographic Locations;Goals;Guidelines;Hawaiian;Health;heritable connective tissue disorder;High Prevalence;high risk;Home;Host Defense;Human;IgE;Immunocompetent;improved;Incidence;Industry;Infection;Integration Host Factors;interest;Investigation;Island;Lung;Lung Diseases;Lung infections;Marfan Syndrome;Measures;member;Microbe;model development;Modeling;modifiable risk;mortality;mouse model;Mucociliary Clearance;Mus;Mutation;mycobacterial;Mycobacterium avium Complex;Mycobacterium Infections;Mycobacterium tuberculosis;Natural History;new therapeutic target;non-tuberculosis mycobacteria;Nose;novel;Occupations;Organism;Oryctolagus cuniculus;Outcome Measure;Pathogenesis;Pathway interactions;Patient Isolation;Patient Outcomes Assessments;patient population;patient registry;Patients;Penetration;Persons;Pharmaceutical Preparations;Phenotype;Population;Population Study;Population-Based Registry;pre-clinical;Pre-Clinical Model;Predisposition;Prevalence;Primary Ciliary Dyskinesias;Protocols documentation;Pseudomonas;Publishing;Rare Diseases;Regimen;Research;Research Personnel;Resources;Respiratory System;Respiratory Tract Infections;Risk;Risk Factors;risk variant;Role;safety assessment;Site;Societies;Source;Sputum;Standardization;STAT3 gene;Symptoms;Syndrome;Testing;Therapeutic;therapeutic development;therapeutic target;tool;transmission process;Treatment Protocols;Tuberculosis;United States National Institutes of Health;Virulence;Virulence Factors;Virus;Walking;Work;Zebrafish,Bronchiectasis and chronic airway infection,6200,NA,NA,NA,NA,10,NA,NA,2423956,NA
11197449,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006205,NA,NA,1ZIAHL006205-10,NHLBI:1122789\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,12000818 (contact),"LAROCHELLE, ANDRE  (contact)",NA,NA,NA,12 year old;Acceleration;Acute Myelocytic Leukemia;Address;Adverse effects;Adverse event;Affect;Allogenic;Alternative Therapies;American Society of Hematology;Androgens;Anemia;Aplastic Anemia;Autologous;Basic Science;Biological Availability;Blood;Bone Marrow;Bone marrow failure;bone marrow failure syndrome;cancer cell;Cell Count;Cells;chelation;Chemotherapy and/or radiation;Child;Childhood;clinical practice;Clinical Trials;clinically significant;Collection;conditioning;CRISPR/Cas technology;cytokine;cytopenia;Data;Defect;design;Disease;Disease Progression;DNA Double Strand Break;Dose;Double Strand Break Repair;Dysmyelopoietic Syndromes;effective therapy;Enrollment;Erythroid;Evaluable Disease;Evaluation;Event;Exhibits;experience;Failure;Fanconi Anemia Complementation Group A Protein;Fanconi&apos;s Anemia;Fibrosis;Funding;Future;gene therapy;Genetic;Genome Stability;Hematological Disease;Hematology;Hematopoiesis;Hematopoietic;Hematopoietic stem cells;Hematopoietic System;Human;Hypersensitivity;improved;indexing;Individual;Inflammation Mediators;Inflammatory;Inherited;Inherited bone marrow failure;insight;Institutional Review Boards;Interferons;Investigation;iron deficiency;iron supplementation;knock-down;Link;Malignant Neoplasms;Marrow;Mediating;mimetics;minimal risk;Molecular;Monosomy 7;neutrophil;Nonhomologous DNA End Joining;Oral;Outcome;Participant;Pathway interactions;patient subsets;Patients;peripheral blood;Pharmaceutical Preparations;Phase I/II Clinical Trial;Platelet Count measurement;Population;progenitor;programs;Property;prospective;receptor;Refractory anemias;Regenerative Medicine;Regimen;repaired;Reporting;Research;Research Personnel;Residual state;response;Risk;Safety;Series;side effect;Signal Induction;Signal Pathway;Signal Transduction;small molecule;Solid;Solid Neoplasm;stem;Stem cell transplant;Therapeutic;Therapeutic immunosuppression;Thrombopoietin;Time;Translating;Translational Research;Transplant Recipients;treatment duration;Withholding Treatment;Work,Eltrombopag for the Treatment of Fanconi Anemia,6205,NA,NA,NA,NA,10,NA,NA,1122789,NA
11197450,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006211,NA,NA,1ZIAHL006211-09,NHLBI:3354118\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,12450464 (contact),"FITZHUGH, COURTNEY  (contact)",NA,NA,NA,Academic Medical Centers;Acute;Acute Graft Versus Host Disease;alemtuzumab;Allogenic;Antibodies;Anticoagulation;Autoimmune;Autologous;beta Thalassemia;Bone Marrow Purging;Bone Marrow Transplantation;Brain;CD3 Antigens;Cells;Chicago;Child;Chimerism;chronic graft versus host disease;chronic thromboembolic pulmonary hypertension;Cirrhosis;clinical remission;clinical risk;cohort;Collaborations;conditioning;Congenital Anemia;Control Groups;curative treatments;Cyclophosphamide;Data;Development;Disease;Dose;End stage renal failure;Engraftment;Evans Syndrome;Event;experience;falls;Family member;follow-up;genetic risk assessment;genetic risk factor;Goals;graft failure;Graft Rejection;Graft Survival;graft vs host disease;Health;Heart;Heart Diseases;Heart failure;Hematopoiesis;Hemoglobin;high risk;Hospitals;Human Herpesvirus 4;Illinois;immunoregulation;Immunosuppression;improved;Incidence;Individual;Inflammatory;Infusion procedures;Kidney;Kidney Diseases;Laboratories;Liver;Long-Term Effects;Low Dose Radiation;Lung;Lung Diseases;Lymphoproliferative Disorders;Morbidity - disease rate;mortality;mouse model;Multiple Organ Failure;Mus;Myelogenous;Myeloproliferative disease;Neurocognitive;neurotoxicity;novel;Organ;participant enrollment;Patients;Peripheral Blood Stem Cell;Peripheral Stem Cell Transplantation;personalized approach;Phase;Phase I/II Trial;Phenotype;post-transplant;primary endpoint;Proto-Oncogene Protein c-kit;Protocols documentation;Pulmonary Hypertension;Reaction;Recording of previous events;Refractory;Regimen;Research Personnel;retransplantation;Risk;second transplant;Siblings;Sickle Cell Anemia;sickling;Sirolimus;Stroke;success;Toxic effect;Translational Research;transplant centers;Transplantation;Umbilical cord structure;Universities;Viral;Whole-Body Irradiation,Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemias,6211,NA,NA,NA,NA,9,NA,NA,3354118,NA
11197451,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006214,NA,NA,1ZIAHL006214-09,NHLBI:1484122\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,78390318 (contact),"KELLMAN, PETER  (contact)",NA,NA,NA,"Agreement;Artificial Intelligence;Breathing;Calibration;Cardiac;Clinical;clinical imaging;Clinical Trials;Communities;computational platform;Cooperative Research and Development Agreement;Data;data acquisition;Data Analyses;data anonymization;Data Reporting;Development;Fatty acid glycerol esters;Feedback;Foundations;Goals;heart imaging;Hospitals;Image;Image Analysis;Image Enhancement;image reconstruction;imaging system;Imaging technology;improved;Industrialization;Intelligence;invention;Life Cycle Stages;Magnetic Resonance Imaging;Maps;Methods;Modeling;National Heart, Lung, and Blood Institute;open source;Patients;Performance;Perfusion;pre-trained transformer;Reporting;Research;research and development;Resolution;Scanning;Site;software infrastructure;Speed;Training;Water",Gadgetron Global Network and Intelligence Computing: Clinical Imaging Application Development and Software Infrastructure,6214,NA,NA,NA,NA,9,NA,NA,1484122,NA
11197452,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006217,NA,NA,1ZIAHL006217-09,NHLBI:1122789\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,12000818 (contact),"LAROCHELLE, ANDRE  (contact)",NA,NA,NA,Activins;Address;Agonist;Annual Reports;ATAC-seq;Autologous;Basic Science;beta catenin;bioinformatics pipeline;Biological Assay;Blood Vessels;Bone Marrow;Bone marrow failure;bone marrow failure syndrome;Cadherins;CD34 gene;Cell Adhesion Molecules;Cell Count;Cell Differentiation process;Cell Lineage;Cell Therapy;cell type;Cells;chemokine receptor;ChIP-seq;clinical application;clinical practice;Clinical Trials;comparative;comparison control;Complex;Control Groups;CRISPR-mediated transcriptional activation;curative treatments;CXCR4 gene;Data;Data Set;Defect;design;Development;differentiation protocol;DNA;DNA Double Strand Break;dosage;Double Strand Break Repair;Ectopic Expression;effective therapy;Embryonic Development;engineered stem cells;Engraftment;Enhancers;Ensure;Epigenetic Process;experimental study;EZH2 gene;Fanconi&apos;s Anemia;flexibility;Formulation;Frequencies;Future;Gene Chips;Gene Expression;Gene Expression Profile;Gene Expression Profiling;gene repression;gene therapy;Generations;Genetic;Goals;Hematological Disease;Hematology;Hematopoiesis;Hematopoietic;hematopoietic engraftment;hematopoietic stem cell fate;Hematopoietic Stem Cell Specification;Hematopoietic stem cells;Hematopoietic System;Home;Homing;Human;human induced pluripotent stem cells;improved;In Vitro;Individual;induced pluripotent stem cell;Inflammation Mediators;Inherited;Inherited bone marrow failure;inhibitor;insight;Integrins;Investigation;Knowledge;Legal patent;Libraries;Licensing;Lymphoid;Marrow;Mediating;Mediator;Messenger RNA;Methodology;Methods;mimetics;Mitogen-Activated Protein Kinases;Molecular;Molecular Profiling;Mus;nerve stem cell;neural model;Neurons;Nodal;novel therapeutics;null mutation;Open Reading Frames;Output;overexpression;participant enrollment;Pathway interactions;Patients;peripheral blood;pharmacologic;Pharmacological Treatment;Phase I/II Clinical Trial;Phenotype;pluripotent stem cell differentiation;Polycomb;Population;Production;progenitor;programs;Protocols documentation;PTPRC gene;Publishing;receptor;Regenerative Medicine;Repressor Proteins;Research;Reserve Stem Cell;Safety;Selectins;Self Assessment;self-renewal;Signal Pathway;Signal Transduction;Specific qualifier value;stem cell population;stem cell technology;stem cells;synergism;System;Testing;therapeutic candidate;Thrombopoietin;transcription factor;Transforming Growth Factor beta;Translating;Translational Research;Transplantation;United States National Institutes of Health;vector;Work;Xenograft procedure,Generation of Hematopoietic Stem and Progenitor Cells from Human iPSCs,6217,NA,NA,NA,NA,9,NA,NA,1122789,NA
11197453,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006220,NA,NA,1ZIAHL006220-08,NHLBI:2976157\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,15202516 (contact),"CHEN, MARCUS  (contact)",NA,NA,NA,"Address;American;Anatomy;Ancillary Study;Aorta;aortic valve replacement;Area;Arteries;Blood Vessels;calcification;Cardiac;Cardiology;Cardiovascular system;Clinical Research;Communities;Complex;Coronary;Coronary Angiography;Coronary artery;coronary computed tomography angiography;Coronary Stenosis;Data;detector;Diagnostic;diagnostic accuracy;Diagnostic Imaging;Dose;Enrollment;Functional disorder;Health;heart imaging;Image;Implant;improved;Intervention;Investigation;Ischemia;Laboratories;Legal patent;Life;low dose computed tomography;Low Dose Radiation;Magnetic Resonance Imaging;Medical;Methods;Multicenter Trials;Myocardial perfusion;National Heart, Lung, and Blood Institute;Needs Assessment;non-invasive imaging;patient subsets;Patients;Perfusion;Phenotype;Physiological;Procedures;programs;Protocols documentation;Radiation exposure;rare genetic disorder;recruit;Research;Research Personnel;Resolution;Risk;Safety;Severities;single photon emission computed tomography;Site;Stenosis;Stents;Stress;structural heart disease;Techniques;Technology;Testing;Uncertainty;United States National Institutes of Health;X-Ray Computed Tomography",Cardiovascular CT Clinical Research,6220,NA,NA,NA,NA,8,NA,NA,2976157,NA
11197454,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006221,NA,NA,1ZIAHL006221-08,NHLBI:2257172\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,15190223 (contact),"GLANCY, BRIAN  (contact)",NA,NA,NA,3-Dimensional;Acute;Adult;Aging;Animals;Cells;Chronic;Development;Drosophila genus;Electron Microscopy;Energy Supply;Enzymes;Goals;Homeostasis;improved;in vivo;insight;interest;light microscopy;Location;Measures;Metabolic Diseases;Methods;Mitochondria;mouse model;multi-photon;multiphoton microscopy;Mus;Muscle;Muscle Cells;Muscle Contraction;Muscle Development;Muscle Fibers;Muscle Mitochondria;Obesity;Physiological;Process;programs;protein function;Regulation;Research;Reticulum;Shapes;Signal Transduction;Signaling Molecule;Skeletal Muscle;targeted treatment;Techniques;Therapeutic Intervention;Time;Transgenic Mice;ultra high resolution;Up-Regulation,Development and Regulation of the Muscle Mitochondrial Reticulum,6221,NA,NA,NA,NA,8,NA,NA,2257172,NA
11197455,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006222,NA,NA,1ZIAHL006222-08,NHLBI:764142\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,15197977 (contact),"KEMPER, CLAUDIA  (contact)",NA,NA,NA,Ablation;Affect;Animals;Arteries;Biological;Biology;Brain;Candida;Cardiovascular Diseases;Cell Compartmentation;Cells;Collaborations;Complement;Complement Activation;Complement Factor B;complement system;Development;Disease;Event;Future;Goals;Hand;High Fat Diet;Human;in vivo;Incubated;Infection;Inflammation;inhibitor;International;Intervention;Laboratories;LoxP-flanked allele;Macrophage;Medical;methicillin resistant Staphylococcus aureus;Mitochondria;Modeling;Molecular;monocyte;mouse model;Mus;Myeloid Cells;neuroinflammation;neutrophil;novel;Pathway interactions;Patients;Permeability;Production;Regulation;Research;Residencies;Role;Signal Transduction;Sterility;T cell response;Tissues;United States National Institutes of Health,The role of the intracellular complement system - the complosome - in monocytes,6222,NA,NA,NA,NA,8,NA,NA,764142,NA
11197456,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006223,NA,NA,1ZIAHL006223-08,NHLBI:1986770\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,15197977 (contact),"KEMPER, CLAUDIA  (contact)",NA,NA,NA,adaptive immunity;Algorithms;Amino Acids;Anaphylatoxins;arginase;Arginine;autocrine;Autoimmune Diseases;Autoimmunity;Binding;Biology;C3 gene;C3AR1 gene;CD4 Positive T Lymphocytes;CD46 Antigen;CD8-Positive T-Lymphocytes;Cell Lineage;Cell Nucleus;Cell Physiology;Cell surface;Cells;Cellular biology;Chronic;Collaborations;comparative;Complement;Complement 3b;Complement Activation;complement C3 precursor;complement system;Contracts;cytotoxic CD8 T cells;Data;Development;disability;Disease;Economic Burden;Enzymes;Event;Extracellular Space;Fatty Acids;Gene Expression;Genes;Glutamine;Glycolysis Induction;Goals;Health;Healthcare Systems;Human;Human Activities;Hyperactivity;Immune;Immunity;Inflammasome;Inflammation;Inflammatory;Inflammatory Bowel Diseases;influenza infection;Insulin-Dependent Diabetes Mellitus;Integrins;Interleukin-10;Knowledge;Laboratories;Lipids;Macrophage;Manuscripts;Mediating;Memory;Metabolic;Metabolism;microorganism;Molecular;Natural Immunity;new therapeutic target;novel;Oxidative Phosphorylation;Oxygen;Patients;pharmacologic;Phenotype;Play;Preparation;Probability;Production;programs;Publications;receptor;recurrent infection;reduce symptoms;Regulation;Reporting;Resolution;response;Rheumatoid Arthritis;Role;Scleroderma;Signal Transduction;single-cell RNA sequencing;Sorting;T cell response;T-Cell Activation;T-Lymphocyte;Th1 Cells;Time;Tissues;transcription factor;Work,The role of the intracellular complement system - the complosome - in Th1 biology,6223,NA,NA,NA,NA,8,NA,NA,1986770,NA
11197457,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006225,NA,NA,1ZIAHL006225-08,NHLBI:1400356\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,15197968 (contact),"POWELL-WILEY, TIFFANY  (contact)",NA,NA,NA,Accelerometer;adaptive intervention;Address;Adoption;Adult;Affect;African American;African American population;African American Women;Area;Automation;Awareness;behavior measurement;Behavior Therapy;Blood Pressure;built environment;burden of illness;Cardiometabolic Disease;cardiometabolic risk;cardiometabolism;Cardiovascular Diseases;cardiovascular health;Cardiovascular system;Charge;chemokine;Chronic;cigarette smoking;Clinical;clinically significant;cohort;Cohort Studies;Communities;community based participatory approach;community based participatory research;community based research;community collaboration;community engagement;community intervention;community partners;community violence;Computer software;cooking;Cost Savings;cytokine;Data;depressive symptoms;Development;Dietary intake;digital applications;digital health;Education;Educational Materials;Enrollment;Environment;epidemiologic data;Ethnic Population;Event;Exercise;exercise intervention;experience;Fasting;fitbit;Focus Groups;Future;Glucose;Gold;Group Interviews;Health;health assessment;Health Care Costs;health disparity;Health Promotion;Health Technology;Heart Rate;High Risk Woman;Hour;improved;Individual;Inflammatory;Informatics;insight;Intervention;intervention effect;Jackson Heart Study;Knowledge;lifestyle factors;Link;Lipids;Location;Measures;Mediating;Mediator;member;Methods;metropolitan;mHealth;mhealth interventions;Minority Groups;Mississippi;mobile application;mobile computing;Mobile Health Application;Modeling;models and simulation;Motivation;Needs Assessment;Neighborhoods;Notification;novel;nutrition;Obesity;Obesity Epidemic;Overweight;Participant;Pathway interactions;patient engagement;Patient Self-Report;Perception;Phenotype;Physical activity;Physical environment;physical inactivity;Pilot Projects;pilot test;Population;Populations at Risk;Prevalence;Process;prospective;psychologic;psychosocial;racial population;Recreation;Reduce health disparities;Reporting;Research;Resource-limited setting;Resources;Risk;Safety;sedentary;sedentary lifestyle;Sequential Multiple Assignment Randomized Trial;Serology;Sleep;social cohesion;Social Environment;social health determinants;Social isolation;socioeconomic disparity;Standardization;stem;Stress;Structure;Surveys;Technology;technology intervention;telecoaching;Testing;therapy design;Time;tool;trend;Washington;wearable device;Weight;Well in self;Woman;Youth,"Tailoring Mobile Health Technology to Reduce Obesity and ImproveCardiovascular Health in Resource-Limited Neighborhood Environments: A Multi-Level, Community-Based Physical Activity Intervention",6225,NA,NA,NA,NA,8,NA,NA,1400356,NA
11197458,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006244,NA,NA,1ZIAHL006244-06,NHLBI:620187\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,14753614 (contact),"KOZEL, BETH  (contact)",NA,NA,NA,Affect;Age;Aging;Alleles;Alternative Splicing;Aneurysm;Animal Model;Aorta;Aortic Valve Stenosis;Area;Biological Process;Blood Vessels;Cell Cycle Regulation;Cell Line;Cell-Cell Adhesion;Cells;Chemicals;Chromosome 7;Chronic Obstructive Pulmonary Disease;Connective Tissue;CRISPR/Cas technology;Data;Data Set;Defect;Deposition;Development;differential expression;Disease;Disease Outcome;Distal;Elastic Cartilage;Elastic Fiber;Elastic Tissue;Elasticity;Elastin;Endoplasmic Reticulum;Enhancers;Exons;experience;experimental study;Extracellular Matrix;falls;Family;FBLN5 gene;Fiber;Gene Expression;gene product;Genes;Genetic Transcription;genome sequencing;Genomics;Human;Immunofluorescence Immunologic;improved;Individual;induced pluripotent stem cell;interest;Introns;Knowledge;Length;Literature;LOX gene;Lung;Manuscripts;Mediating;Messenger RNA;Minority;Molecular;Molecular Chaperones;Morbidity - disease rate;mortality;mouse genome;Mus;Mutation;novel;novel therapeutics;old mice;patient derived induced pluripotent stem cells;Patients;Play;Process;Production;Protein Analysis;Protein Secretion;protein transport;Proteins;Rare Diseases;Regulation;RNA Splicing;Role;Serum-Free Culture Media;Skin;Smooth Muscle Myocytes;Techniques;Testing;Time;Tissues;Transcript;transcriptome sequencing;transcriptomics;Variant;Vascular Diseases;Vascular Smooth Muscle;Vesicle;Western Blotting;Work,Connective Tissue Mediated Vascular Disease,6244,NA,NA,NA,NA,6,NA,NA,620187,NA
11197459,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006252,NA,NA,1ZIAHL006252-05,NHLBI:1120284\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,15197968 (contact),"POWELL-WILEY, TIFFANY  (contact)",NA,NA,NA,Academic Medical Centers;Accelerometer;Address;Adult;Affect;African American;African American Women;Age;Amygdaloid structure;Antibodies;atherogenesis;Attenuated;Behavior;Behavior Therapy;Biological;Biological Markers;Biology;Black Populations;Blood Banks;Blood donor;Blood Platelets;Blood specimen;Blood Vessels;Blood Volume;Brain;brain behavior;cardiovascular health;cardiovascular risk factor;Cardiovascular system;caucasian American;Caucasians;Cells;Cellular Phone;Censuses;Characteristics;chemokine;Chicago;Chronic;Chronic stress;clinically relevant;cohort;Cohort Studies;Collaborations;Communities;community violence;Complete Blood Count;COVID-19 pandemic;Crime;cytokine;Data;depressive symptoms;deprivation;Development;Dietary intake;Discrimination;District of Columbia;Ecological momentary assessment;economic indicator;Environment;Environmental Exposure;Environmental Risk Factor;epidemiologic data;Epidemiologic Methods;ethnic difference;Ethnic Population;Female;Flow Cytometry;Functional Magnetic Resonance Imaging;Global Positioning System;granulocyte;Health behavior;health disparity;Hydrocortisone;Immune;immune activation;immune function;immune system function;Immunologic Markers;improved;indexing;Individual;Inflammatory;innovation;Interdisciplinary Study;interest;Intervention;Jackson Heart Study;Knowledge;Lead;Length;leukocyte transformation;Leukocytes;Link;lipidomics;Lipids;Lymphocyte;Lymphocyte Count;Measures;Mediating;Mediator;men;Mental Depression;Methods;Mexican Americans;Minority Groups;Modeling;monocyte;Moods;multilevel analysis;Myocardial Infarction;National Health and Nutrition Examination Survey;Natural Killer Cells;neighborhood disadvantage;Neighborhoods;neural;Neurotransmitters;Not Hispanic or Latino;novel;Outcome;Pathway interactions;perceived stress;Perception;PET/CT scan;Phenotype;Physical activity;Physiological;Pilot Projects;Platelet aggregation;Policies;Population;Poverty;Protocols documentation;psychosocial;Psychosocial Factor;Psychosocial Stress;psychosocial stressors;racial difference;racial population;Reporting;Research;response;Rest;Risk;Risk Marker;Sampling;sedentary;sedentary activity;sedentary lifestyle;Severities;Sleep;social cohesion;social deficits;Social Environment;social stress;socioeconomic disadvantage;Socioeconomic Status;socioeconomics;Stains;Stress;stress symptom;stressor;structural determinants;Surveys;Technology;telomere;Telomere Shortening;Testing;Time;tool;Translational Research;Underserved Population;United States;Universities;uptake;vascular inflammation;ward;Washington;Whole Blood;Woman;Work,Pilot Study for Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women,6252,NA,NA,NA,NA,5,NA,NA,1120284,NA
11197460,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006255,NA,NA,1ZIAHL006255-05,NHLBI:461751\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,16110019 (contact),"SHET, ARUN  (contact)",NA,NA,NA,"Acute;African ancestry;Biological Assay;Biological Markers;Blood Vessels;Cells;Coagulation Process;cohort;Cohort Studies;Collaborations;Complex;Data Analyses;Deposition;Development;Endothelial Cells;Enrollment;Ethnic Origin;extracellular vesicles;Extramural Activities;factor IXa-factor VIIIa;Factor X;Factor Xa;Fibrin;follow-up;Generations;Individual;Inflammatory;Laboratories;Laboratory Research;material transfer agreement;Medicine;monocyte;National Heart, Lung, and Blood Institute;Notification;Participant;Pathway interactions;Patients;Plasma;Principal Investigator;prospective;Protocols documentation;Recording of previous events;recruit;Recruitment Activity;Recurrence;Reporting;Research Personnel;Research Subjects;Role;Sampling;Sickle Cell Anemia;sickle cell crisis;Sickle Cell Trait;sickling;System;Telephone;Testing;Thrombelastography;Thrombin;Thrombophilia;Thromboplastin;Thrombosis;thrombotic;United States National Institutes of Health;Venous;venous thromboembolism;Venous Thrombosis;Vesicle;vesicular release;Visit",Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait,6255,NA,NA,NA,NA,5,NA,NA,461751,NA
11197461,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006256,NA,NA,1ZIAHL006256-04,NHLBI:461751\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,16110019 (contact),"SHET, ARUN  (contact)",NA,NA,NA,Adherence;Adsorption;Anticoagulation;Antigens;atherothrombosis;Attenuated;Biological Markers;Blood;Blood coagulation;Blood Coagulation Disorders;Blood Platelets;Blood Vessels;Cell surface;Clinical;Clinical Trials Design;Coagulants;Coagulation Process;Deposition;Development;dietary;Disease;Dose;Endothelial Cells;Endothelium;Erythrocytes;Exposure to;extracellular vesicles;Factor Va;Fibrin;Fibrinolytic Agents;Flavonoids;Future;Gene Expression;Generations;Hemin;Hemorrhage;Homeostasis;Human;Hypoxia;improved;In Vitro;Inflammation;Inflammatory Response;inhibitor;Injury;Intake;Isomerase;isoquercetin;Leukocytes;Malignant Neoplasms;Measures;Mediating;Membrane Proteins;Molecular;monocyte;mortality;Mus;NF-kappa B;novel;novel strategies;Oral;Oxidoreductase;P-Selectin;Pathway interactions;Patients;Pattern;Peptide Initiation Factors;pharmacologic;phase II trial;Placebos;Plasma;Plasma Proteins;Platelet Activation;Platelet aggregation;pre-clinical;predictive marker;primary endpoint;primary outcome;Production;Protein Disulfide Isomerase;Quercetin;Recurrence;Risk;Safety;safety assessment;secondary outcome;Sickle Cell;Sickle Cell Anemia;sickling;side effect;Sulfhydryl Compounds;Surface;Switzerland;Thrombin;thromboinflammation;Thrombophilia;Thromboplastin;Thrombosis;thrombotic;Time;translational study;vascular injury;vaso-occlusive crisis;Venous;venous thromboembolism;Venous Thrombosis,A Study to Evaluate the Effects of fixed dose Flavonoid Isoquercetin on thrombo-inflammatory biomarkers in subjects with stable Sickle Cell Disease,6256,NA,NA,NA,NA,4,NA,NA,461751,NA
11197462,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006292,NA,NA,1ZIAHL006292-02,NHLBI:690745\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,79361823 (contact),"TORABI-PARIZI, PARIZAD  (contact)",NA,NA,NA,Acute;Acute Lung Injury;Acute Respiratory Distress Syndrome;Address;Affect;Alveolar Cell;Animal Model;Animals;Annual Reports;Architecture;Bacterial Pneumonia;Binding;Biology;biomarker discovery;bronchial epithelium;Bronchoalveolar Lavage;Caring;Cells;Data;Endothelial Cells;Endotoxins;Epithelial Cells;experimental study;Family;frontier;gain of function;Gene Expression;healthy volunteer;Human;Immune;Immunology;immunoregulation;In Situ;In Situ Hybridization;Infiltration;Inflammation;Inflammatory;Inflammatory Response;Innate Immune Response;Intravenous;Investigation;knockout animal;Lavage;loss of function;Lung;Lung Lavage Fluid;Membrane;migration;Natural Immunity;neuron development;neutrophil;Neutrophil Infiltration;Organ;Patients;Phenotype;Plasma;plexin;protein biomarkers;Protein Secretion;Proteins;Publications;Publishing;Pulmonary Inflammation;receptor;Reporting;Role;Semaphorins;Serum;Signal Pathway;Signal Transduction;Smooth Muscle Myocytes;Source,Investigations of the role of Semaphorin 5A in innate immunity,6292,NA,NA,NA,NA,2,NA,NA,690745,NA
11197463,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006293,NA,NA,1ZIAHL006293-02,NHLBI:460497\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,79361823 (contact),"TORABI-PARIZI, PARIZAD  (contact)",NA,NA,NA,A/J Mouse;Acute;Acute Lung Injury;adaptive immune response;Address;Adverse effects;Adverse event;Affect;Animals;Antibodies;Antineoplastic Agents;Apoptotic;Body System;Cancer Patient;Cell Physiology;Cells;Cessation of life;checkpoint therapy;China;Clinical;comorbidity;Coronavirus;Country;COVID-19;CTLA4 gene;Cytotoxic T-Lymphocytes;Death Rate;Detection;Development;Disease;Dose;European;experience;experimental study;Fatality rate;Flow Cytometry;Frequencies;Goals;Health;Histology;Hospitalization;Human;human coronavirus;Human Pathology;Immune;immune checkpoint;immune checkpoint blockade;Immune checkpoint inhibitor;Immune response;Immune system;immune-related adverse events;Immunity;Immunosuppression;Inbred Strains Mice;Infection;infection risk;Inflammation;Inflammatory;Injury;Innate Immune Response;Ligands;Liver;Lung;lung injury;Malignant Neoplasms;Manuscripts;Modeling;Monoclonal Antibodies;Morbidity - disease rate;mortality;mouse development;mouse model;Mouse Strains;Murine hepatitis virus;Mus;Nerve Tissue;Nucleocapsid Proteins;Patients;Persons;Phenotype;Pneumonia;pneumonia model;preclinical study;programmed cell death ligand 1;programmed cell death protein 1;Proteins;Protocols documentation;Pulmonary Inflammation;Regimen;Registries;Respiratory Tract Infections;response;Rhea;Risk;Role;SARS coronavirus;SARS-CoV-2 infection;seasonal influenza;severe COVID-19;side effect;Structure of parenchyma of lung;Treatment Protocols;tumor;United States;Viral Proteins;Virus;Work,The Effects of Prior Checkpoint Inhibitor (CPI) Therapy on Mouse Hepatitis Coronavirus Induced Pneumonia,6293,NA,NA,NA,NA,2,NA,NA,460497,NA
11197464,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006294,NA,NA,1ZIAHL006294-02,NHLBI:1151242\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,79361823 (contact),"TORABI-PARIZI, PARIZAD  (contact)",NA,NA,NA,2019-nCoV;Air;animal mortality;Animals;Blood;Blood gas;Bronchoalveolar Lavage;Cells;Cessation of life;Clinical;Clinical Trials;Coronavirus;COVID-19 patient;COVID-19 pneumonia;COVID-19 treatment;Data Collection;design;Development;Evaluation;experimental study;Exposure to;Flow Cytometry;Histology;Hospitals;Hypoxemia;Hypoxia;Hypoxia Inducible Factor;Inflammatory;Inflammatory Response;Intensive Care;Liver;Lung;lung injury;Lymphopenia;Measurement;Measures;Medical;Medicine;Metabolism;Modeling;mortality;mouse model;Murine hepatitis virus;Mus;Outcome;Oxygen;Oxygen Therapy Care;oxygen toxicity;Pathogenicity;Pathway interactions;Patients;Phase;Pneumonia;pneumonia model;preclinical study;prevent;Proteins;Publishing;Randomized;Reactive Oxygen Species;Respiratory Failure;Review Literature;Rhea;SARS-CoV-2 infection;Side;Spleen;supplemental oxygen;systematic review;Testing;Therapeutic;Therapeutic Uses;Thrombocytopenia;thrombotic;Time;Tissue Banks;tissue injury;Tissues;Toxic effect;Viral;Virus,The Effects of Oxygen Therapy on Mouse Hepatitis Coronavirus Induced Pneumonia,6294,NA,NA,NA,NA,2,NA,NA,1151242,NA
11197465,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006301,NA,NA,1ZIAHL006301-01,NHLBI:1530994\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,15197968 (contact),"POWELL-WILEY, TIFFANY  (contact)",NA,NA,NA,Affect;African;African American;African American population;Algorithms;American;Architecture;behavior influence;Behavioral;biobank;Biological Assay;Biological Markers;biological systems;Biosocial;Blood;Blood Pressure;Blood Vessels;Cardiometabolic Disease;cardiometabolism;Cardiovascular Diseases;Cardiovascular system;catalyst;cloud based;Cloud Computing;cluster computing;cohort;Communities;Complex;Computer Analysis;computer infrastructure;Controlled Clinical Trials;coronary artery calcium;Data;data infrastructure;Data Set;Data Sources;depressive symptoms;Dietary Sodium;dimension reduction;Disease;disorder risk;DNA methylation profiling;Double-Blind Method;Elasticity;Enrollment;Environmental Risk Factor;Epigenetic Process;epigenome;Etiology;exome;Exposure to;Family health status;Gene Expression;Genes;Genetic;Genetic study;Genome;genome resource;genome sequencing;genomic data;Genomics;Genotype;Goals;Health;health disparity;Human;Hypertension;Image;Individual;insight;Intake;interest;Intervention;Intervention Trial;Investigation;Link;Measures;Mediator;metabolic abnormality assessment;metabolome;microbiome;MicroRNAs;Minority Health Research;miRNA expression profiling;Modeling;Molecular;mRNA sequencing;multi-ethnic;novel;Obesity;Outcome Measure;overtreatment;Participant;Pathway interactions;phenome;Phenotype;Placebos;polygenic risk score;Population;Predisposing Factor;Predisposition;programs;Proteome;Race;Renal function;Research;Research Design;Resources;response;Science;Series;Signal Pathway;social;social determinants;social disparities;social influence;Sodium;Standardization;statistical and machine learning;Structure;System;Techniques;Technology;telomere;trait;transcriptome;Urine;Variant;Vision;Whole Blood;whole genome,Genetics and Epigenetics of Cardiovascular Disease,6301,NA,NA,NA,NA,1,NA,NA,1530994,NA
11197466,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002859,NA,NA,1ZIANS002859-33,NINDS:1626790\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,10789423 (contact),"YOULE, RICHARD JAMES (contact)",NA,NA,NA,"Affinity;Alzheimer&apos;s disease related dementia;Autophagocytosis;Autophagosome;Binding;Binding Sites;California;Collaborations;design;Drug Targeting;drug use screening;Engineering;Goals;National Center for Advancing Translational Sciences;National Heart, Lung, and Blood Institute;Neuroanatomy;Organelles;pharmacologic;preclinical development;protein aggregation;Proteins;Risk;Series;small molecule;tau aggregation;tau Proteins;Technology;Therapeutic;tool;United States National Institutes of Health;Work",Targeting Protein Aggregates for Autophagosomal Degradation,2859,NA,NA,NA,NA,33,NA,NA,1626790,NA
11197467,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS002978,NA,NA,1ZIANS002978-26,NINDS:1492052\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,2411906 (contact),"COHEN, LEONARDO GREGORIO (contact)",NA,NA,NA,Activities of Daily Living;acute stroke;Adult;Age;age effect;age group;Architecture;Basic Science;Behavior;Behavioral;Brain;brain computer interface;Brain Diseases;Brain Injuries;Caring;Central Nervous System;Chronic;Clinical;Cognition;cohort;design;Development;Disease;E-learning;economic implication;effective intervention;Elderly;Eligibility Determination;Event;evidence base;Family;finger movement;forgetting;Goals;Hand;Health;healthy volunteer;Home;Hour;Human;human subject;Hybrids;Impairment;improved;Individual;Intervention;Journals;Knowledge;Learning;Learning Skill;Left;Lesion;Location;Machine Learning;Magnetoencephalography;Manuscripts;meetings;Memory;memory consolidation;memory encoding;Memory Loss;millisecond;Mission;Motor;motor deficit;motor function recovery;motor impairment;motor learning;motor rehabilitation;Motor Skills;Muscle;neural;neurological rehabilitation;Neurologist;Neurology;Neurosciences;novel;older adult;Older Population;Participant;Patients;Pattern;Peer Review;Performance;physical therapist;Physiology;Positioning Attribute;preservation;Process;programs;psychologic;Psychologist;Recovery of Function;Rehabilitation therapy;Research;Resolution;Rest;Role;Science;sensory feedback;skill acquisition;skills;skills training;Sleep;social implication;Societies;Source;Spinal cord injury;Stroke;Testing;Time;Training;Translating;Traumatic Brain Injury;Wakefulness;Work,Cortical reorganization and plasticity In the healthy brain,2978,NA,NA,NA,NA,26,NA,NA,1492052,NA
11197468,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003030,NA,NA,1ZIANS003030-18,NINDS:1264335\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,2411906 (contact),"COHEN, LEONARDO GREGORIO (contact)",NA,NA,NA,acute COVID-19;Adult;Age;Animal Model;Brain;brain dysfunction;brain fog;Cephalic;Clinical;clinical effect;Clinical Research;clinically relevant;cognitive function;cohort;Collaborations;Compensation;Consensus;Control Groups;cost;COVID-19 pandemic;COVID-19 patient;Data;design;disability;Disease;Electric Stimulation;Executive Dysfunction;experimental study;Functional disorder;Gender;Goals;Human;improved;Injury;International;Intervention;Intramural Research Program;Journals;Knowledge;Knowledge acquisition;Laboratories;Learning;Learning Skill;Lesion;Link;Long COVID;loss of function;Magnetism;Measures;Memory;memory consolidation;Memory impairment;Metadata;Motor;Motor disability;Motor Skills;Music;National Institute of Neurological Disorders and Stroke;neural repair;neurological rehabilitation;Neurology;neuromechanism;neurophysiology;noninvasive brain stimulation;novel;novel strategies;novel therapeutic intervention;Outcome Measure;pandemic response;Paper;Patients;Performance;persistent symptom;pharmacologic;pre-clinical;pre-clinical research;pre-pandemic;primary outcome;procedural memory;Process;Protocols documentation;Publications;Publishing;Recommendation;Recovery of Function;Rehabilitation Outcome;rehabilitation strategy;Rehabilitation therapy;Reporting;Research;Research Methodology;Research Personnel;Researching COVID to Enhance Recovery;response;SARS-CoV-2 infection;secondary outcome;sex;skills;social;somatosensory;Standardization;Stroke;stroke rehabilitation;Symptoms;Task Performances;Techniques;Therapeutic Effect;Translating;Translations;Traumatic Brain Injury;United States National Institutes of Health;Work,Modulating brain plasticity in rehabilitation of stroke and other brain lesions,3030,NA,NA,NA,NA,18,NA,NA,1264335,NA
11197469,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003129,NA,NA,1ZIANS003129-14,NINDS:4278301\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,78873714 (contact),"BÖNNEMANN, CARSTEN  (contact)",NA,NA,NA,Address;Adolescent;Affect;Afferent Neurons;Animal Model;Antisense Oligonucleotide Therapy;Atrophic;base editing;Biological Markers;Biopsy;Breathing;Case Study;causal variant;Cell model;Centronuclear myopathy;Child;Childhood;Clinic;Clinical;Clinical assessments;clinical outcome measures;clinical translation;Clinical Trials;Clustered Regularly Interspaced Short Palindromic Repeats;Code;cohort;Cohort Studies;COL6A1;COL6A2;Collaborations;Collagen Type VI;Compensation;congenital muscular dystrophy;Congenital Myasthenic Syndromes;congenital myopathy;Dedications;Development;Disease;disease model;Dominant-Negative Mutation;Dose;Drug Kinetics;early onset;Engineering;Etiology;Evaluation;exome;exosuit;Extracellular Matrix;falls;FHL1 gene;first-in-human;Gait;gene therapy;Gene therapy trial;Gene Transfer;Genes;Genetic;genome sequencing;Genomic approach;genomic data;Genomics;giant axonal neuropathy;Goals;Growth Factor;Human;humanized mouse;Image;Imaging Device;immunoregulation;improved;induced pluripotent stem cell;Infrastructure;International;Joints;Laboratories;loss of function;Magnetic Resonance Imaging;Mediating;member;Modality;Molecular;mouse model;Muscle;Mutation;Myopathy;National Center for Advancing Translational Sciences;Natural History;Natural regeneration;neurogenetics;neuromuscular;Neuromuscular Diseases;Neuromuscular Junction Diseases;next generation;next generation sequencing;novel;Outcome Measure;Outcome Study;Pain;Pathway interactions;Patients;Pharmacologic Substance;Phase;Phenotype;phenotypic data;Piezo 2 ion channel;Positioning Attribute;precision medicine;preservation;programs;Proprioception;Protocols documentation;Rare Diseases;receptor;Research;Respiratory Muscles;RNA Interference;RNA Splicing;safety assessment;Sensory;sensory prosthesis;Signal Transduction;Syndrome;Technology;Testing;Therapeutic;therapeutic gene;Tissue Model;tool;Touch sensation;Transcript;transcriptome sequencing;Translating;Translations;trial design;United States National Institutes of Health;Validation;Visualization;whole genome;Work;X-linked myotubular myopathy,Molecular and Clinical Manifestations of Matrix and Aggregate Myopathies,3129,NA,NA,NA,NA,14,NA,NA,4278301,NA
11197470,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003154,NA,NA,1ZIANS003154-09,NINDS:1931448\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,14763843 (contact),"SCHOLZ, SONJA  (contact)",NA,NA,NA,age related;atypical parkinsonism;Autopsy;clinical diagnosis;Complex;Data;Dementia with Lewy Bodies;Development;disabling disease;disease model;Evaluation;Functional disorder;functional genomics;Genes;Genetic;genetic architecture;Genetic study;genetic variant;genome analysis;genomic data;genomic tools;Genomics;improved;International;Knowledge;Learning;Lewy Body Dementia;Mission;Modernization;Molecular;Multiple System Atrophy;Nerve Degeneration;Neurodegenerative Disorders;Neurologic;Oligodendroglia;Pathogenesis;Pathway interactions;Patients;Pre-Clinical Model;Research;risk variant;Susceptibility Gene;Syndrome;targeted treatment;Therapeutic;Translating,Genetic characterization of atypical parkinsonism,3154,NA,NA,NA,NA,9,NA,NA,1931448,NA
11197471,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003155,NA,NA,1ZIANS003155-09,NINDS:2208322\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,14763845 (contact),"WARD, MICHAEL  (contact)",NA,NA,NA,Alzheimer&apos;s disease related dementia;Amyotrophic Lateral Sclerosis;analog;Autopsy;Axon;Axonal Transport;Base Excision Repairs;Binding;Biological Markers;Biology;Biophysics;Biotin;Brain;Cell Differentiation process;Cell Line;Cell model;Cell Nucleus;Cell Physiology;Cells;ChIP-seq;chromatin remodeling;Clustered Regularly Interspaced Short Palindromic Repeats;Collaborations;Communities;Conceptions;CRISPR interference;Cytoplasmic Granules;data repository;Data Set;demethylation;Development;disease phenotype;Distal;DNA;DNA Single Strand Break;Doxycycline;effective therapy;Enhancers;Ensure;Event;Exons;familial Alzheimer disease;forward genetics;Frontotemporal Dementia;Frontotemporal Lobar Degenerations;frontotemporal lobar dementia amyotrophic lateral sclerosis;Funding;Future;Gene Expression;Genes;Genetic Screening;Genome;genome editing;Genome engineering;Genome Stability;genome wide association study;genome-wide;Genomics;Glutamates;human data;human induced pluripotent stem cells;Image;improved;induced pluripotent stem cell;Induced pluripotent stem cell derived human neuron;Induced pluripotent stem cell derived neurons;Inherited;International;Link;Location;Lysosomes;Manuscripts;Maps;Mediating;Methods;Modeling;Molecular;Molecular Biology;multiple omics;mutant;Mutation;National Institute of Neurological Disorders and Stroke;Nature;Nerve Degeneration;Neurodegenerative Disorders;neuronal survival;Neurons;Neurosciences;next generation sequencing;novel;Paper;Pathogenesis;Pathologic;Pathology;Pathway interactions;Patients;phenotypic data;Plasma;Play;postmitotic;Process;Production;protein TDP-43;Proteins;Proteomics;Protocols documentation;Publishing;Recurrence;repaired;Reporting;Repression;Reproducibility;Research;Research Personnel;Risk;RNA;RNA Splicing;RNA Transport;RNA-Binding Proteins;Robotics;Rodent;Seminal;Single-Stranded DNA;Site;stem cells;synaptic function;System;Techniques;Technology;Thymidine;Transcript;Translations;ward,Mechanisms of inherited neurodegenerative diseases,3155,NA,NA,NA,NA,9,NA,NA,2208322,NA
11197472,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003169,NA,NA,1ZIANS003169-06,NINDS:3176786\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,16169728 (contact),"NARENDRA, DEREK  (contact)",NA,NA,NA,aging population;Alleles;Amyotrophic Lateral Sclerosis;amyotrophic lateral sclerosis therapy;Antisense Oligonucleotide Therapy;Autophagocytosis;Benign;biological adaptation to stress;Brown Fat;burden of illness;Cell Line;Cell Nucleus;Cells;Clinic;clinical center;Collaborations;Complement;Crista ampullaris;Cytosol;Data Set;Disease;early onset;Engineering;Family;Frontotemporal Dementia;Gene Expression;Genetic;genome wide screen;Goals;Growth;induced pluripotent stem cell;Inner mitochondrial membrane;Intramural Research Program;Investigation;Knock-in;Knock-in Mouse;Knock-out;Liver;loss of function;Maintenance;Mammals;Measures;Mediating;Membrane;Mendelian disorder;metabolic imaging;Methods;Mitochondria;Mitochondrial DNA;mitochondrial dysfunction;Mitochondrial Myopathies;Mitochondrial Proteins;Modeling;Molecular Diagnosis;mouse model;Mus;Muscle;mutant;Mutation;Myocardium;Myopathy;nanoscale;Nerve Degeneration;Neurodegenerative Disorders;Neurologist;Neurons;novel;OPA1 gene;paralogous gene;Parkin;Parkinson Disease;Pathogenesis;Pathogenicity;Pathway interactions;Patients;Peptide Hydrolases;PINK1 gene;postmitotic;Precision therapeutics;prevent;programs;Protein Biosynthesis;protein degradation;protein misfolding;Proteins;Proteomics;Reporter;response;Signal Transduction;Skeletal Muscle;sporadic Parkinson&apos;s Disease;Stress;therapy development;Tissues;United States National Institutes of Health;Variant,Mitochondrial stress responses in neurodegeneration,3169,NA,NA,NA,NA,6,NA,NA,3176786,NA
11197473,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009455,NA,NA,1ZIANS009455-01,NINDS:2411309\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,79995869 (contact),"GRUNSEICH, CHRISTOPHER  (contact)",NA,NA,NA,Accelerometer;Adaptor Protein Complex 2;Affect;Alleles;amphiphysin;Amyotrophic Lateral Sclerosis;analog;Androgen Receptor;Auxilins;Binding;Biological Markers;Biology;biomarker identification;Cell Line;Cells;Cerebrospinal Fluid;Clinical;Clinical Markers;Clinical Research;Clinical Trials;Collaborations;CRISPR interference;Curcumin;Development;Disease;Disease Progression;efficacy evaluation;Endocytosis;EPS15 gene;epsin;exome sequencing;Family member;Future;Genes;Genetic Screening;genetic testing;Goals;Health;Hereditary Spastic Paraplegia;Image;improved;indexing;induced pluripotent stem cell;Infrastructure;Inherited;instrument;Intellectual functioning disability;Limb structure;Liquid substance;Magnetic Resonance Imaging;Measurement;Measures;Missense Mutation;Modality;Molecular;molecular marker;Motor Cortex;motor neuron degeneration;Motor Neuron Disease;Motor Neurons;Muscle;Muscle function;mutant;Mutation;Natural History;Nerve;Nerve Degeneration;neuromuscular;Neuromuscular Diseases;Neurons;novel;novel strategies;oligonucleotide therapeutics;Outcome Measure;Pathway interactions;Patient Outcomes Assessments;Patients;Pharmacodynamics;Physical Function;Process;Proteins;Reproducibility;Research;Safety;Sampling;Seizures;Serum;Severities;Small Interfering RNA;specific biomarkers;Spectrum Analysis;spinal and bulbar muscular atrophy;Testing;TFRC gene;Therapeutic;therapeutic candidate;Therapeutic Studies;therapy development;Tissue Sample;Tissues;tool;Toxic effect;ultrasound;Universities;Validation;Work,Studies of inherited neuromuscular diseases,9455,NA,NA,NA,NA,1,NA,NA,2411309,NA
11197474,ZIH,HL,1,N,NA,NA,NA,NA,ZIHHL001052,NA,NA,1ZIHHL001052-27,NHLBI:1052650\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,8453160 (contact),"BROOKS, BERNARD R (contact)",NA,NA,NA,Acceleration;Address;Advanced Development;Agreement;Algorithms;Architecture;Benzene;Biological Models;Chemicals;Code;Common Core;Communication;computer grid;Computer Hardware;Computer software;computerized tools;Computers;Consumption;cost;cost effective;Coupled;Data;Data Set;density;Development;Diffusion;Directories;Electrostatics;Evaluation;Fourier Transform;Free Energy;Graph;High Performance Computing;Home;Hydrogen Bonding;improved;induced pluripotent stem cell;interest;Lead;Linux;Literature;Machine Learning;Maps;Mechanics;Methods;Modeling;Modernization;Molecular;Molecular Analysis;Molecular Conformation;molecular dynamics;molecular mechanics;Network-based;neural network;novel strategies;open source;Operating System;parallel computer;parallelization;particle;Peptides;Performance;Personal Computers;Probability;protein folding;Pythons;Quantum Mechanics;Radial;Random Allocation;Resources;Running;Sampling;Scheme;scientific computing;simulation;software development;solute;Solvents;Speed;Structure;System;Techniques;Technology;Testing;Time;Training;two-dimensional;United States National Aeronautics and Space Administration;Update;Uracil;Water;Work;Writing,Development Of Advanced Computer Hardware And Software,1052,NA,NA,NA,NA,27,NA,NA,1052650,NA
11197551,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-P00008-759102000035-1,NCI:522295\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,77878846 (contact),"DMITROVSKY, ETHAN  (contact)",NA,2020-09-28,2027-09-24,Agreement;Aliquot;Brain;Brain Neoplasms;Cancer Model;chemoradiation;Childhood;Clinical;Clinical Data;Communities;Contracts;Data;Data Element;data sharing;Diffuse intrinsic pontine glioma;DNA;DNA sequencing;Enrollment;follow-up;Funding;Generations;Genomic Data Commons;human subject;Infrastructure;Institutional Review Boards;Laboratories;Malignant Childhood Neoplasm;Malignant Neoplasms;Modeling;Normal tissue morphology;Operative Surgical Procedures;Parents;Patients;Policies;Process;programs;Protocols documentation;Reporting;Resources;sample collection;Sampling;Solid;Time;Tissues;transcriptome sequencing;Treatment outcome;tumor;Tumor Tissue,CANCER MODELS FROM PEDIATRIC BRAIN AND SOLID CANCERS (CMDC),0,NA,NA,NA,NA,NA,NA,NA,522295,NA
11197626,N01,AI,NA,N,NA,NA,NA,NA,272201700040I,NA,NA,272201700040I-P00003-759302200006-2,NIAID:420758\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,GALVESTON,UNITED STATES,NA,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,NA,79983649 (contact),"BEASLEY, DAVID  (contact)",NA,2022-09-23,2024-10-11,2019-nCoV;Animal Model;Animals;Basic Science;Contracts;Coronavirus Infections;COVID-19 test;Development;Evaluation;Human;Lung;microphysiology system;Modeling,Task C14: Advancing Human Lung Microphysiological Systems to Model Coronavirus Infection and Test Candidate Countermeasures,0,NA,NA,NA,NA,NA,NA,NA,420758,NA
11197627,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00020,NA,NA,75N93024D00020-0-759302400002-1,NIAID:80435\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,ROCKVILLE,UNITED STATES,NA,08,965180610,US,10028042,"SIGMOVIR BIOSYSTEMS, INC.",MD,208506330,NA,79956400 (contact),"BOUKHVALOVA, MARINA  (contact)",NA,2024-09-01,2025-01-30,Basic Science;Collection;Contracts;Development;Evaluation;in vivo;infectious disease model;Metadata;Virus,Task A07: Collection of Metadata from In Vivo Studies Performed Under Previous IDIQ Contract Mechanisms,0,NA,NA,NA,NA,NA,NA,NA,80435,NA
11197628,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00042,NA,NA,75N93024D00042-0-759302400005-1,NIAID:174528\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,GALVESTON,UNITED STATES,NA,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,NA,79972692 (contact),"BEASLEY, DAVID  (contact)",NA,2024-08-30,2025-05-30,Basic Science;Collection;Contracts;Development;Evaluation;in vivo;infectious disease model;Metadata;Virus,Task A06: Collection of Metadata from In Vivo Studies Performed Under Previous IDIQ Contract Mechanisms,0,NA,NA,NA,NA,NA,NA,NA,174528,NA
11197629,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00009,NA,NA,75N93024D00009-0-759302400003-1,NIAID:56795\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,FORT COLLINS,UNITED STATES,NA,02,785979618,US,1725201,COLORADO STATE UNIVERSITY,CO,805232002,NA,79972689 (contact),"SLAYDEN, RICHARD  (contact)",NA,2024-09-02,2025-01-30,Basic Science;Collection;Contracts;Development;Evaluation;in vivo;infectious disease model;Metadata;Virus,Task A05: Collection of Metadata from In Vivo Studies Performed Under Previous IDIQ Contract Mechanisms,0,NA,NA,NA,NA,NA,NA,NA,56795,NA
11197630,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00043,NA,NA,75N93024D00043-0-759302400002-1,NIAID:163768\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LOGAN,UNITED STATES,NA,01,072983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,NA,79992500 (contact),"GOWEN, BRIAN  (contact)",NA,2024-09-23,2025-05-31,Basic Science;Collection;Contracts;Development;Evaluation;in vivo;infectious disease model;Metadata;Virus,Task A08: Collection of Metadata from In Vivo Studies Performed Under Previous IDIQ Contract Mechanisms,0,NA,NA,NA,NA,NA,NA,NA,163768,NA
11197631,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00042,NA,NA,75N93024D00042-0-759302400006-1,NIAID:1010897\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,GALVESTON,UNITED STATES,NA,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,NA,79992497 (contact),"BEASLEY, DAVID  (contact)",NA,2024-09-20,2025-09-19,Animals;Basic Science;Contracts;Development;Evaluation;infectious disease model;Lassa virus;medical countermeasure;Modeling;Viral Physiology;Virus Diseases,Task A02: Development of Small Animal Lassa Virus infection Model for the Assessment of Anti-Viral Activity of Medical Countermeasures Efficacy,0,NA,NA,NA,NA,NA,NA,NA,1010897,NA
11197632,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00007,NA,NA,75N93024D00007-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,ROCKVILLE,UNITED STATES,NA,08,012043055,US,1965903,"BIOQUAL, INC.",MD,208503336,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197633,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00023,NA,NA,75N93024D00023-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,BAR HARBOR,UNITED STATES,NA,02,042140483,US,7096501,JACKSON LABORATORY,ME,046091523,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197634,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00035,NA,NA,75N93024D00035-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,ATHENS,UNITED STATES,NA,10,004315578,US,676602,UNIVERSITY OF GEORGIA,GA,306021589,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197635,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00004,NA,NA,75N93024D00004-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MANASSAS,UNITED STATES,NA,10,057954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197636,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00042,NA,NA,75N93024D00042-0-759302400004-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,GALVESTON,UNITED STATES,NA,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197637,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00009,NA,NA,75N93024D00009-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,FORT COLLINS,UNITED STATES,NA,02,785979618,US,1725201,COLORADO STATE UNIVERSITY,CO,805232002,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197638,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00005,NA,NA,75N93024D00005-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197639,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00005,NA,NA,75N93024D00005-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197640,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00030,NA,NA,75N93024D00030-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,BOSTON,UNITED STATES,NA,07,039318308,US,8422704,TUFTS UNIVERSITY BOSTON,MA,021111901,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197641,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00010,NA,NA,75N93024D00010-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SALISBURY,UNITED KINGDOM,NA,NA,232609375,UK,10000516,DEFENCE SCIENCE & TECHNOLOGY LABORATORY,NA,SP4 0JQ,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197642,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00024,NA,NA,75N93024D00024-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,HERSHEY,UNITED STATES,NA,10,129348186,US,1524204,PENNSYLVANIA STATE UNIV HERSHEY MED CTR,PA,170332360,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197643,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00029,NA,NA,75N93024D00029-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAN ANTONIO,UNITED STATES,NA,20,800772162,US,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,TX,782293901,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197644,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00011,NA,NA,75N93024D00011-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197645,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00024,NA,NA,75N93024D00024-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,HERSHEY,UNITED STATES,NA,10,129348186,US,1524204,PENNSYLVANIA STATE UNIV HERSHEY MED CTR,PA,170332360,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197646,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00005,NA,NA,75N93024D00005-0-759302400003-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197647,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00021,NA,NA,75N93024D00021-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,BIRMINGHAM,UNITED STATES,NA,07,006900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197648,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00035,NA,NA,75N93024D00035-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,ATHENS,UNITED STATES,NA,10,004315578,US,676602,UNIVERSITY OF GEORGIA,GA,306021589,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197649,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00042,NA,NA,75N93024D00042-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,GALVESTON,UNITED STATES,NA,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197666,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00012,NA,NA,75N93024D00012-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,CHICAGO,UNITED STATES,NA,01,005447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197667,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00022,NA,NA,75N93024D00022-0-759302400003-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAN ANTONIO,UNITED STATES,NA,20,007936834,US,7660801,TEXAS BIOMEDICAL RESEARCH INSTITUTE,TX,782275302,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197668,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00033,NA,NA,75N93024D00033-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,CINCINNATI,UNITED STATES,NA,01,041064767,US,1523902,UNIVERSITY OF CINCINNATI,OH,452210001,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197669,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00008,NA,NA,75N93024D00008-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,CAMBRIDGE,UNITED STATES,NA,07,066587478,US,964201,CHARLES STARK DRAPER LABORATORY,MA,021393539,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197670,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00037,NA,NA,75N93024D00037-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,FORT WORTH,UNITED STATES,NA,12,110091808,US,6108502,UNIVERSITY OF NORTH TEXAS HLTH SCI CTR,TX,761072699,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197671,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00034,NA,NA,75N93024D00034-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,GAINESVILLE,UNITED STATES,NA,03,969663814,US,513806,UNIVERSITY OF FLORIDA,FL,326115500,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197672,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00022,NA,NA,75N93024D00022-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAN ANTONIO,UNITED STATES,NA,20,007936834,US,7660801,TEXAS BIOMEDICAL RESEARCH INSTITUTE,TX,782275302,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197673,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00042,NA,NA,75N93024D00042-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,GALVESTON,UNITED STATES,NA,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197674,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00022,NA,NA,75N93024D00022-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAN ANTONIO,UNITED STATES,NA,20,007936834,US,7660801,TEXAS BIOMEDICAL RESEARCH INSTITUTE,TX,782275302,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197675,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00032,NA,NA,75N93024D00032-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SALISBURY,UNITED KINGDOM,NA,NA,233388961,UK,10007041,UK HEALTH SECURITY AGENCY,NA,NA,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197676,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00021,NA,NA,75N93024D00021-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,BIRMINGHAM,UNITED STATES,NA,07,006900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197677,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00004,NA,NA,75N93024D00004-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MANASSAS,UNITED STATES,NA,10,057954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197678,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00030,NA,NA,75N93024D00030-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,BOSTON,UNITED STATES,NA,07,039318308,US,8422704,TUFTS UNIVERSITY BOSTON,MA,021111901,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197679,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00020,NA,NA,75N93024D00020-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,ROCKVILLE,UNITED STATES,NA,08,965180610,US,10028042,"SIGMOVIR BIOSYSTEMS, INC.",MD,208506330,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197680,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00025,NA,NA,75N93024D00025-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SYRACUSE,UNITED STATES,NA,22,058889106,US,5992619,UPSTATE MEDICAL UNIVERSITY,NY,132102306,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197681,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00039,NA,NA,75N93024D00039-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,PITTSBURGH,UNITED STATES,NA,12,004514360,US,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PA,152133320,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197682,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00032,NA,NA,75N93024D00032-0-759302400003-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SALISBURY,UNITED KINGDOM,NA,NA,233388961,UK,10007041,UK HEALTH SECURITY AGENCY,NA,NA,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197683,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00036,NA,NA,75N93024D00036-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LOUISVILLE,UNITED STATES,NA,03,057588857,US,4679701,UNIVERSITY OF LOUISVILLE,KY,402920001,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197684,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00042,NA,NA,75N93024D00042-0-759302400003-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,GALVESTON,UNITED STATES,NA,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197685,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00026,NA,NA,75N93024D00026-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,CHICAGO,UNITED STATES,NA,01,005421136,US,1413601,UNIVERSITY OF CHICAGO,IL,606372612,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197686,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00016,NA,NA,75N93024D00016-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,GAITHERSBURG,UNITED STATES,NA,06,079170146,US,10038016,"MIMETAS US, INC.",MD,20878,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197687,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00014,NA,NA,75N93024D00014-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,BALTIMORE,UNITED STATES,NA,07,001910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212182680,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197688,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00004,NA,NA,75N93024D00004-0-759302400003-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MANASSAS,UNITED STATES,NA,10,057954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197689,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00040,NA,NA,75N93024D00040-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SASKATOON,CANADA,NA,NA,207413170,CA,7328301,UNIVERSITY OF SASKATCHEWAN,SK,S7N 5C9,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197690,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00031,NA,NA,75N93024D00031-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NEW ORLEANS,UNITED STATES,NA,01,053785812,US,8424601,TULANE UNIVERSITY OF LOUISIANA,LA,701185665,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197691,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00032,NA,NA,75N93024D00032-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SALISBURY,UNITED KINGDOM,NA,NA,233388961,UK,10007041,UK HEALTH SECURITY AGENCY,NA,NA,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197692,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00027,NA,NA,75N93024D00027-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,CHAPEL HILL,UNITED STATES,NA,04,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275995023,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197693,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00019,NA,NA,75N93024D00019-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAINT LOUIS,UNITED STATES,NA,01,050220722,US,7915401,SAINT LOUIS UNIVERSITY,MO,631032006,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197694,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00039,NA,NA,75N93024D00039-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,PITTSBURGH,UNITED STATES,NA,12,004514360,US,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PA,152133320,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197697,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00040,NA,NA,75N93024D00040-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SASKATOON,CANADA,NA,NA,207413170,CA,7328301,UNIVERSITY OF SASKATCHEWAN,SK,S7N 5C9,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197698,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00007,NA,NA,75N93024D00007-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,ROCKVILLE,UNITED STATES,NA,08,012043055,US,1965903,"BIOQUAL, INC.",MD,208503336,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197699,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00010,NA,NA,75N93024D00010-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SALISBURY,UNITED KINGDOM,NA,NA,232609375,UK,10000516,DEFENCE SCIENCE & TECHNOLOGY LABORATORY,NA,SP4 0JQ,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197700,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00017,NA,NA,75N93024D00017-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NEW TAIPEI CITY,TAIWAN,NA,NA,658873501; 657591921,TW,10042179,"PHARMACOLOGY DISCOVERY SERVICES TAIWAN, LTD.",NA,24891,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197701,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00018,NA,NA,75N93024D00018-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAN FRANCISCO,UNITED STATES,NA,11,094878337,US,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",CA,941432510,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197702,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00028,NA,NA,75N93024D00028-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MEMPHIS,UNITED STATES,NA,09,941884009,US,578302,UNIVERSITY OF TENNESSEE HEALTH SCI CTR,TN,381034903,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197703,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00012,NA,NA,75N93024D00012-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,CHICAGO,UNITED STATES,NA,01,005447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197704,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00013,NA,NA,75N93024D00013-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,Schenectady,UNITED STATES,NA,20,030614406,US,10034802,INSTITUTE FOR CLINICAL PHARMACODYNAMICS,NY,12305,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197705,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00043,NA,NA,75N93024D00043-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LOGAN,UNITED STATES,NA,01,072983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197706,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00041,NA,NA,75N93024D00041-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MOBILE,UNITED STATES,NA,01,172750234,US,130401,UNIVERSITY OF SOUTH ALABAMA,AL,366880002,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197707,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00040,NA,NA,75N93024D00040-0-759302400003-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SASKATOON,CANADA,NA,NA,207413170,CA,7328301,UNIVERSITY OF SASKATCHEWAN,SK,S7N 5C9,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197708,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00009,NA,NA,75N93024D00009-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,FORT COLLINS,UNITED STATES,NA,02,785979618,US,1725201,COLORADO STATE UNIVERSITY,CO,805232002,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197709,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00038,NA,NA,75N93024D00038-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,PHILADELPHIA,UNITED STATES,NA,03,042250712,US,6463801,UNIVERSITY OF PENNSYLVANIA,PA,191046205,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197710,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00031,NA,NA,75N93024D00031-0-759302400002-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NEW ORLEANS,UNITED STATES,NA,01,053785812,US,8424601,TULANE UNIVERSITY OF LOUISIANA,LA,701185665,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197711,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00006,NA,NA,75N93024D00006-0-759302400001-1,NIAID:2500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,ROCKVILLE,UNITED STATES,NA,08,076137314,US,838205,BIOMEDICAL RESEARCH INSTITUTE,MD,208503345,NA,NA,(contact),NA,2024-07-15,2031-07-14,Contracts;Development;infectious disease model;medical countermeasure;Modeling;Pre-Clinical Model;Reagent,Pre-Clinical Models of Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,2500,NA
11197717,N01,AI,NA,N,NA,NA,NA,NA,272201700039I,NA,NA,272201700039I-0-759302400001-1,NIAID:340810\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAN ANTONIO,UNITED STATES,NA,20,800772162,US,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,TX,782293901,NA,79751824 (contact),"PATTERSON, THOMAS  (contact)",NA,2024-05-01,2025-04-30,Coccidioides immitis;Coccidioides posadasii;Contracts;Development;Diagnostic;Evaluation;fungus;infectious disease model;mouse model;Mycoses;Testing;therapeutic development,Task A89: Candidate Testing in Murine Models of Fungal Infections,0,NA,NA,NA,NA,NA,NA,NA,340810,NA
11197718,N01,AI,NA,N,NA,NA,NA,NA,272201700041I,NA,NA,272201700041I-0-759302400001-1,NIAID:886965\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LOGAN,UNITED STATES,NA,01,072983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,NA,79768317 (contact),"GOWEN, BRIAN  (contact)",NA,2024-05-13,2025-05-12,Alpha Virus;Animal Model;Arenavirus;biodefense;Contracts;Development;Evaluation;infectious disease model;therapeutic development;Vaccines;Virus,Task A91: Small Animal Models for Biodefense Viruses,0,NA,NA,NA,NA,NA,NA,NA,886965,NA
11197719,N01,AI,NA,N,NA,NA,NA,NA,272201700040I,NA,NA,272201700040I-0-759302400002-1,NIAID:1610509\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,GALVESTON,UNITED STATES,NA,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,NA,7942185 (contact),"BEASLEY, DAVID  (contact)",NA,2024-06-25,2027-06-24,Contracts;Development;Ebola;Evaluation;infectious disease model;medical countermeasure;model development;nonhuman primate;therapeutic development,Task B16: Model Development and Medical Countermeasures (MCMs) for BSL-4 Agents in NHPs,0,NA,NA,NA,NA,NA,NA,NA,1610509,NA
11197721,N01,AI,NA,N,NA,NA,NA,NA,272201700036I,NA,NA,272201700036I-0-759302400001-1,NIAID:637479\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,CHAPEL HILL,UNITED STATES,NA,04,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275995023,NA,79893859 (contact),"BARIC, RALPH  (contact)",NA,2017-07-14,2024-08-13,Anti-viral Agents;anti-viral efficacy;Contracts;Coronavirus;Development;Evaluation;infectious disease model;Middle East Respiratory Syndrome;Middle East Respiratory Syndrome Coronavirus;Modeling;Mus;therapeutic development;Virus,Task A92: Efficacy of Antiviral Therapeutics Against MERS-CoV in a Mouse-Adapted Virus Model,0,NA,NA,NA,NA,NA,NA,NA,637479,NA
11197722,N01,AI,NA,N,NA,NA,NA,NA,272201700032I,NA,NA,272201700032I-0-759302400001-1,NIAID:106869\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,BOSTON,UNITED STATES,NA,07,039318308,US,8422704,TUFTS UNIVERSITY BOSTON,MA,021111901,NA,79895584 (contact),"TZIPORI, SAUL  (contact)",NA,2024-07-11,2025-07-10,Contracts;Development;efficacy study;Evaluation;Infection;infectious disease model;minimal inhibitory concentration;Modeling;Oryctolagus cuniculus;Testing;therapeutic development;Treponema pallidum;Treponema pallidum subspecies pallidum,Task A95: Minimal Inhibitory Concentration (MIC) Testing and Efficacy Studies in a Rabbit Model of Treponema Pallidum Infection,0,NA,NA,NA,NA,NA,NA,NA,106869,NA
11197723,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00019,NA,NA,75N93024D00019-0-759302400002-1,NIAID:400773\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAINT LOUIS,UNITED STATES,NA,01,050220722,US,7915401,SAINT LOUIS UNIVERSITY,MO,631032006,NA,79983717 (contact),"TOTH, KAROLY  (contact)",NA,2024-09-13,2025-09-12,Adenoviruses;Contracts;Development;Evaluation;Hamsters;Human;infectious disease model;Modeling;therapeutic development,Task A09: Hamster Model for Human Adenovirus,0,NA,NA,NA,NA,NA,NA,NA,400773,NA
11197833,N01,AI,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-P00010-759102000025-4,NIAID:2140115\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79951134 (contact),"DMITROVSKY, ETHAN  (contact)",NA,2020-09-28,2028-09-24,2019-nCoV;acute infection;Biology;Blinded;Cause of Death;clinical investigation;Communicable Diseases;Coronavirus;Data;Disease;Emerging Communicable Diseases;Emerging infection;Funding;Human;improved;Incidence;Infectious Agent;innovation;Medical;Medical Research;pathogen;Pathogenesis;Patient-Focused Outcomes;previous outbreak;Protocols documentation;Publishing;Randomized;respiratory virus;Safety;Therapeutic,"LEIDOS FUNDING TO25, OPTION 1 MEASLES",0,NA,NA,NA,NA,NA,NA,NA,2140115,NA
11197862,N01,AI,NA,N,NA,NA,NA,NA,261201500003I,NA,NA,261201500003I-P00018-26100059-6,NIAID:121045\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,NA,(contact),NA,2018-09-30,2028-09-21,Area;clinical research site;Collaborations;Communicable Diseases;Contractor;cost;data management;Ebola;Emerging Communicable Diseases;Funding;Human Resources;improved;Information Technology;Infrastructure;Internet;Location;Medical;meetings;Needs Assessment;Patient-Focused Outcomes;Preparation;Protocols documentation;recruit;Research Support;Role;Services;Site;Teleconferences;Telephone;Training;web site;Work,"LEIDOS FUNDING TO59, OPTION 3",0,NA,NA,NA,NA,NA,NA,NA,121045,NA
11197894,N01,HD,NA,N,NA,NA,NA,NA,275201400003I,NA,NA,275201400003I-0-759402400005-1,NICHD:35264\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,ROCKVILLE,UNITED STATES,NA,08,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,NA,79992470 (contact),"MARTIN, BRITTANY  (contact)",NA,2024-09-23,2025-09-22,Address;Age;Authorization documentation;Bar Codes;Best Pharmaceuticals for Children Act;Blood;Cells;Child;Childhood;Clinical Data;Conduct Clinical Trials;Congresses;Contracts;Data;dose information;Drug Prescriptions;Dryness;Ensure;Equipment and supply inventories;Erythrocytes;Formulation;Funding;Future;Goals;Human Milk;improved;Instruction;Knowledge;Label;Modification;Monitor;National Institute of Child Health and Human Development;Online Systems;Orphan;Pharmaceutical Preparations;Pharmacologic Substance;Plasma;repository;Research;Safety;Sampling;Serum;Services;Specimen;Spottings;System;Testing;Therapeutic;Time;Tube;Work,CONTINUED REPOSITORY SERVICES FOR THE BEST PHARMACEUTICALS FOR CHILDREN ACT (BPCA),0,NA,NA,NA,NA,NA,NA,NA,35264,NA
11197902,N01,HD,NA,N,NA,NA,NA,NA,275201400003I,NA,NA,275201400003I-0-759402400004-1,NICHD:42603\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,ROCKVILLE,UNITED STATES,NA,08,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,NA,79992467 (contact),"MARTIN, BRITTANY  (contact)",NA,2024-09-23,2025-09-22,"Affect;Air;Air Pollutants;Air Pollution;Algorithm Design;Antigens;Asthma;asthma exacerbation;asthmatic;Autoantigens;base;Bioinformatics;Biological;Biometry;Biostatistical Methods;Budgets;Cell Proliferation;Cells;Chronic Disease;Clinical;Clinical Research;Collection;Computing Methodologies;Contractor;Contracts;Defect;dietary antioxidant;Environmental Exposure;Environmental Risk Factor;experience;Exposure to;Fetus;First Pregnancy Trimester;Funding;Genetic;Hypersensitivity;Immune;immune function;Immune response;Immune system;improved;interest;Intramural Research;Knowledge;Life;Maintenance;maternal immune system;Mediating;National Institute of Child Health and Human Development;pathogen;Patients;Play;population health;Postpartum Period;Predictive Factor;Pregnancy;pregnancy immunology;Pregnancy Outcome;Pregnant Women;preservation;Process;Prospective, cohort study;Pulmonary Inflammation;Regulatory T-Lymphocyte;repository;Research;Research Contracts;research study;Residual state;Role;Sampling;Services;Severities;Specimen;study population;Subgroup;Th2 Cells;Woman",B WELL MOM ASTHMA STUDY REPOSITORY CONTINUANCE - FISHER BIOSERVICES,0,NA,NA,NA,NA,NA,NA,NA,42603,NA
11197964,R01,HL,3,N,2024-09-25,2024-07-01,2025-06-30,837,R01HL164348,BIOMED ENGR/COL ENGR/ENGR STA,PA-23-189,3R01HL164348-02S1,NHLBI:82177\,NON-SBIR/STTR RPGS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,IRVINE,UNITED STATES,ENGINEERING (ALL TYPES),47,046705849,US,577504,UNIVERSITY OF CALIFORNIA-IRVINE,CA,926970001,"PROJECT NARRATIVE  Stem cell-based regenerative therapies or in vitro investigations of cardiovascular disease pathophysiology, drug screening, and toxicology studies heavily rely on stem cell quality. Here, peptide nanostructures will be engineered to enable cells to be light responsive in a wireless and non-genetic manner, which can ultimately be utilized as a strategy for converting optical cues to stimulatory signals that can improve the structural and functional maturity of human stem cell-derived cardiomyocytes. With this new approach, we hope to alleviate the major technical barrier of CM immaturity, and therefore, better enable stem cell-based cardiovascular research and related fields to flourish.",15589207 (contact),"ARDOÑA, HERDELINE ANN MALLARI (contact)","THAKAR, RAHUL GAUTAM",2023-09-01,2027-06-30,Action Potentials;Address;Adult;Animal Model;Anisotropy;Architecture;Automobile Driving;Behavior;Binding;biomaterial interface;Biophysics;Calcium;Cardiac;Cardiac Myocytes;cardiac tissue engineering;Cardiovascular Diseases;Cardiovascular system;Cell Culture Techniques;Cell Survival;Cells;Charge;Chemical Stimulation;chromophore;combinatorial;conditioning;Cues;design;disease mechanisms study;drug discovery;Drug Screening;Electric Stimulation;Electrodes;Engineering;Ensure;Epitopes;extracellular;Film;Frequencies;Functional disorder;Gene Expression;Generations;genetically modified cells;Goals;Heart Diseases;Heart Injuries;Heating;high throughput screening;human induced pluripotent stem cells;human stem cell-derived;improved;In Vitro;indexing;infection risk;innovation;instrumentation;Investigation;irradiation;Light;Measurement;Measures;Mechanics;Mediating;Metabolism;Methods;Microelectrodes;minimally invasive;Modeling;Monitor;monomer;Muscle Cells;Nanostructures;Neonatal;non-genetic;novel strategies;Optics;optogenetics;Pattern;Peptide Library;Peptides;personalized medicine;Phenotype;Polymers;Process;Protocols documentation;Rattus;Reaction;regenerative therapy;Reporting;Research;Resolution;response;Risk Assessment;Risk Reduction;scale up;Side;Signal Transduction;Source;spatiotemporal;species difference;stem;stem cell based approach;stem cells;Stimulus;Stress;Structure;success;Surface;Technology;temporal measurement;Testing;Therapeutic;Tissues;Toxicology;Transducers;Transfection;Ventricular;wireless,Diversity Supplement: Optically Promoting Cardiac Maturation Using Engineered Peptides,164348,BMBI,Biomaterials and Biointerfaces Study Section[BMBI],NA,S1,2,60417,21760,82177,NA
11198078,R01,CA,3,N,2024-09-25,2024-05-01,2025-04-30,395,R01CA257814,BIOMED ENGR/COL ENGR/ENGR STA,PAR-20-004,3R01CA257814-04S1,NCI:80047\,NON-SBIR/STTR RPGS,2024,NATIONAL CANCER INSTITUTE,NA,HOUSTON,UNITED STATES,BIOSTATISTICS & OTHER MATH SCI,09,050299031,US,9291001,RICE UNIVERSITY,TX,770051827,NA,8880690;8261071 (contact),"FULLER, CLIFTON DAVID;SCHAEFER, ANDREW J (contact)","BUCHSBAUM, JEFFREY",2021-05-01,2025-04-30,Address;Adoption;advanced analytics;Affect;Aging;Algorithms;Anatomy;Area;base;Behavior;Cancer Control;cancer radiation therapy;Capital;chemoradiation;Clinical;Clinical Data;clinical implementation;Clinical Treatment;Communities;Community Hospitals;Complication;Computer software;connected health;cost;Coupled;Data;Data Set;Decision Making;Decision Support Systems;design;Development;Devices;Diagnosis;Dose;Economics;Emerging Technologies;Environment;Equipment;Evaluation;evidence base;Evolution;Goals;Head and Neck Cancer;head and neck cancer patient;Head and neck structure;Health;Health Policy;Health Technology;Healthcare;Human;Human Resources;Image;image guided radiation therapy;improved;in silico;Incentives;Individual;individual patient;individualized medicine;innovation;insight;Instruction;Insurance Carriers;Life;Linear Accelerator Radiotherapy Systems;low and middle-income countries;Magnetic Resonance Imaging;malignant mouth neoplasm;Malignant neoplasm of larynx;Malignant neoplasm of pharynx;Malignant Neoplasms;Medical Device;Medicare;Methodology;Methods;Modeling;models and simulation;Modernization;Monitor;Morbidity - disease rate;multidisciplinary;Neck Cancer;new technology;next generation;Normal tissue morphology;novel;Operations Research;Organ;Outcome;Overdose;Patient Care;Patient imaging;Patients;Physicians;Policies;Probability;Process;programs;Property;prototype;Provider;Radiation;Radiation therapy;radiation-induced injury;Regimen;Research;Resources;response;Risk;risk stratification;Schedule;Science;Self-Help Devices;Series;side effect;SMART health;soft tissue;Software Tools;standard care;Structure;support tools;Survivors;System;Systems Integration;Techniques;Technology;technology intervention;theories;Time;tool;Toxic effect;treatment planning;treatment response;treatment stratification;tumor;Tumor Volume;Uncertain Risk;Uncertainty;Validation;Variant;Work,SCH: Personalized Rescheduling of Adaptive Radiation Therapy for Head & Neck Cancer,257814,ZRG1,Special Emphasis Panel[ZRG1-MOSS-V(50)],NA,S1,4,56430,23617,80047,NA
11198215,Y01,OD,NA,N,NA,NA,NA,NA,AOD24006001,NA,NA,AOD24006001-1-0-1,OD:2493460\,INTERAGENCY AGREEMENTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,(contact),NA,NA,NA,Acute;Address;Affect;age difference;animal model development;Anticonvulsants;Biochemical;carboxylesterase;chemical countermeasure;chemical threat;Chemicals;Chronic;Collaborations;design;Development;efficacy study;efficacy testing;Electrons;Environment;Evaluation;Exposure to;fluorophosphate;Funding;Gene Modified;Genomics;Hospitals;Human;Hydrazines;In Vitro;in vivo;Injury;inorganic phosphate;Investigation;medical countermeasure;Microscopic;Modeling;Molecular;Monomethylhydrazine;Morbidity - disease rate;mortality;mouse model;Mus;National Institute of Allergy and Infectious Disease;Nervous System;Neuropathy;Neuroprotective Agents;neurotoxic;novel;Organophosphates;Paraoxon;Pharmaceutical Preparations;Physiological;Plasma;Poison;Poisoning;Population;Pregnancy;Rattus;Research;research and development;response;Route;Sarin;screening;Security;Seizures;Sex Differences;Soman;therapeutic evaluation;Time;Toxic effect;toxic organophosphate insecticide exposure;Toxicology;United States National Institutes of Health,Chemical Countermeasures Collaboration: Chemical Threats Affecting the Nervous System,240060,NA,NA,NA,NA,NA,NA,NA,2493460,NA
11198224,Y01,OD,NA,N,NA,NA,NA,NA,AOD24007001,NA,NA,AOD24007001-1-0-1,OD:2389471\,INTERAGENCY AGREEMENTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,(contact),NA,NA,NA,Acetylfentanyl;Acute;Acute Respiratory Distress Syndrome;Address;Aerosols;Affect;African Green Monkey;animal model development;antagonist;Biochemical;carfentanil;chemical countermeasure;chemical threat;Chemicals;Chronic;Collaborations;Continuous Positive Airway Pressure;design;Development;efficacy study;efficacy testing;Electrons;Environment;Evaluation;Exposure to;FDA approved;Funding;Genomics;Hospitals;Human;in silico;In Vitro;in vivo;Inhalation;Injury;Kinetics;Lung;medical countermeasure;Microscopic;model development;Modeling;Molecular;Morbidity - disease rate;mortality;Mustard Gas;National Institute of Allergy and Infectious Disease;Opioid Antagonist;Pharmaceutical Preparations;Phosgene;Physiological;Poison;Poisoning;Population;Powder dose form;Research;research and development;respiratory;Route;screening;Security;synthetic opioid;System;Therapeutic;Time;Toxic effect;Toxicology;Treatment Efficacy;United States National Institutes of Health,Chemical Countermeasures Collaboration: Chemical Threats Affecting the Respiratory/Pulmonary System,240070,NA,NA,NA,NA,NA,NA,NA,2389471,NA
11198231,Y01,OD,NA,N,NA,NA,NA,NA,AOD24008001,NA,NA,AOD24008001-1-0-1,OD:1607103\,INTERAGENCY AGREEMENTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,(contact),NA,NA,NA,"2,4-Dinitrophenol;Acrylonitrile;Acute;Address;Affect;animal model development;Biochemical;Cell Respiration;cellular targeting;chemical countermeasure;chemical threat;Chemicals;Chronic;Collaborations;Cyanides;Cyclodextrins;design;Development;efficacy study;efficacy testing;Electrons;Environment;Evaluation;Exposure to;Funding;Genomics;Hospitals;Human;in silico;In Vitro;in vivo;Injury;medical countermeasure;Metabolic;Microscopic;Modeling;Molecular;Morbidity - disease rate;mortality;National Institute of Allergy and Infectious Disease;Neurologic;Nitriles;Pharmaceutical Preparations;Phosphines;Physiological;Poisoning;Population;Rattus;Research;research and development;Route;screening;Security;Therapeutic;Time;Toxic effect;Toxicology;United States National Institutes of Health",Chemical Countermeasures Collaboration: Chemical Threats Affecting Cellular Respiration,240080,NA,NA,NA,NA,NA,NA,NA,1607103,NA
11198233,Y01,OD,NA,N,NA,NA,NA,NA,AOD24009001,NA,NA,AOD24009001-1-0-1,OD:1448110\,INTERAGENCY AGREEMENTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,(contact),NA,NA,NA,Acrolein;Acute;Address;Affect;animal model development;Biochemical;chemical countermeasure;chemical threat;Chemicals;Chronic;Collaborations;design;Development;efficacy study;efficacy testing;Electrons;Environment;Evaluation;Exposure to;Eye;Eye Injuries;Funding;Genome;Genomics;Hospitals;Human;in silico;In Vitro;in vivo;Injury;medical countermeasure;Membrane;Microscopic;model development;Modeling;Molecular;Morbidity - disease rate;mortality;mouse model;Mucous Membrane;Mustard Gas;National Institute of Allergy and Infectious Disease;Pharmaceutical Preparations;Physiological;Poisoning;Population;Research;research and development;Route;screening;Security;Skin;Therapeutic;Time;Toxic effect;toxicant;Toxicology;United States National Institutes of Health,"Chemical Countermeasures Collaboration: Chemical Threats Affecting the Skin, Eyes, and Mucous Membranes",240090,NA,NA,NA,NA,NA,NA,NA,1448110,NA
11198241,Y01,OD,NA,N,NA,NA,NA,NA,AOD24051001,NA,NA,AOD24051001-1-0-1,OD:500000\,INTERAGENCY AGREEMENTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,(contact),NA,NA,NA,Acute;Address;Animal Model;Chemicals;Chronic;Development;Evaluation;Eye;Eye Injuries;Funding;Human;in vivo Model;medical countermeasure;Mustard Gas;National Institute of Allergy and Infectious Disease;Poisoning;Research;screening;Security;Toxic effect;United States National Institutes of Health,Supplemental funding for ROTR CHEM 1005 Development of Human Relevant Small Animal Models of Sulfur Mustard Toxicities,240510,NA,NA,NA,NA,NA,NA,NA,500000,NA
11198297,U01,MD,3,N,2024-09-25,2024-09-01,2025-08-31,NA,U01MD019540,NA,PA-23-189,3U01MD019540-02S1,NIMHD:141006\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES,NA,ARLINGTON,UNITED STATES,NA,25,064234610,US,578402,UNIVERSITY OF TEXAS ARLINGTON,TX,760190145,NA,11297739 (contact),"SANCHEZ, KATHERINE  (contact)","FERNANDEZ, ANGELA R",2024-09-01,2028-05-31,NA,Train and EMPOWER A Community Health workforce to achieve equity and reduce disparities in mental health (TEACH),19540,ZRG1,Special Emphasis Panel[ZRG1(54)-R],9025,S1,2,127006,14000,NA,141006
11198794,K08,HL,7,N,2024-11-14,2024-11-15,2025-03-31,837,K08HL165047,SCHOOLS OF MEDICINE,PA-24-254,7K08HL165047-03,NHLBI:132448\,OTHER RESEARCH-RELATED,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,DALLAS,UNITED STATES,INTERNAL MEDICINE/MEDICINE,30,800771545,US,578404,UT SOUTHWESTERN MEDICAL CENTER,TX,753909105,"PROJECT NARRATIVE This proposal will define how interferon-gamma, a major T-cell cytokine abundant in atherosclerotic plaques, alters fuel utilization by the vascular cells that line the innermost layer of the coronary arteries, thereby making these vessels susceptible to atherosclerosis progression. This study, if successful, will improve our understanding of the adverse changes involving vascular metabolism in atherosclerosis and may lead to new therapeutic strategies to prevent heart attacks, strokes, and limb loss.",15565202 (contact),"LEE, LAUREL Y (contact)","CHEON, YEWON",2023-04-01,2028-03-31,NA,Endothelial Metabolic Reprogramming by Interferon-gamma in Coronary Artery Disease,165047,MCBS,NHLBI Mentored Clinical and Basic Science Study Section[MCBS(JA)],NA,NA,3,122731,9717,132448,NA
11198870,ZIA,CL,1,N,NA,NA,NA,NA,ZIACL060085,NA,NA,1ZIACL060085-12,NA,INTRAMURAL RESEARCH,2024,CLINICAL CENTER,NA,NA,NA,NA,NA,NA,NA,NA,CLINICAL CENTER,NA,NA,NA,12471577 (contact),"BRAYLAN, RAUL  (contact)",NA,NA,NA,Abnormal megakaryocyte;Acute Megakaryocytic Leukemias;Acute Myelocytic Leukemia;Affect;Antigens;aspirate;Biopsy;Blood Platelets;Bone Marrow;Bone Marrow Aspiration;Buffers;Cell Lineage;Cell Maturation;Cells;Classification;Clinical;Collecting Cell;Complex;Consumption;cost;cytopenia;Data;density;Diagnostic;diagnostic value;Disease;disease diagnosis;DNA analysis;Dysmyelopoietic Syndromes;Electron Microscopy;Elements;Evaluation;Excision;Exhibits;Face;Filtration;Flow Cytometry;Fluorescence-Activated Cell Sorting;Frequencies;Germany;Glutaral;Goals;Hematological Disease;Hematology;Hematopoietic;Heterogeneity;Human;Idiopathic Thrombocytopenic Purpura;immunodeficiency;ITGB3 gene;Label;Laboratories;Large Megakaryocyte;Lobe;Lymphoid Cell;magnetic beads;Manuals;Marrow;Megakaryocytes;Methods;Microscopic;Monitor;Morphology;Myeloproliferative disease;Nuclear;Nylons;Patients;Ploidies;Polyploid Cells;Population;Preparation;Procedures;Process;Production;Proliferating;Proliferation Marker;rapid detection;Sample Size;Sampling;Stains;Suspensions;Techniques;Time;Visual;Wright-Giemsa Staining Method,Rapid and Simple Isolation and Concentration Procedure for Human Megakaryocytes,60085,NA,NA,NA,NA,12,NA,NA,0,NA
11198871,ZIA,DE,1,N,NA,NA,NA,NA,ZIADE000438,NA,NA,1ZIADE000438-38,NIDCR:2721426\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,2419431 (contact),"AMBUDKAR, INDU S. (contact)",NA,NA,NA,"Adopted;Affect;Affinity;Agonist;Amino Acid Sequence;Amino Acids;Autophagocytosis;Back;Binding;Binding Proteins;biophysical properties;Biophysics;Calcium;Cell membrane;Cells;Characteristics;Charge;chelation;comparative;Consensus Sequence;Data;Deglutition Disorders;Dental caries;design;Dose;EF Hand Motifs;EF-Hand Domain;Environment;Fluids and Secretions;Functional disorder;Generations;Geometry;Gland;Goals;Hour;Hydrolysis;insight;Ions;irradiation;Liquid substance;Maintenance;Malignant Neoplasms;Mediating;Mitochondria;Molecular;Molecular Conformation;molecular dynamics;monomer;Morphology;mouse model;Mus;mutant;Mutation;N-terminal;Neurotransmitters;novel;Oral health;oral infection;Osmosis;Phenotype;Phosphatidylinositol 4,5-Diphosphate;Physiological;Play;Positioning Attribute;prevent;Property;Protein Sequence Analysis;Proteins;recruit;Regulation;release of sequestered calcium ion into cytoplasm;Reporting;Research;response;Rest;Role;Saliva;Salivary Glands;SAM Domain;senescence;sensor;Series;Signal Transduction;STIM1 gene;Stimulus;Structure;Suggestion;thermostability;Time;Tubular Aggregate Myopathies;Tubular formation;Xerostomia",Molecular Mechanisms Regulating Calcium Flux In Salivary Glands,438,NA,NA,NA,NA,38,NA,NA,2721426,NA
11198874,ZID,DE,1,N,NA,NA,NA,NA,ZIDDE000728,NA,NA,1ZIDDE000728-16,NIDCR:6822795\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,14282250 (contact),"LEE, JANICE  (contact)",NA,NA,NA,Back;Biometry;Caring;Clinic;Clinical;clinical center;Clinical Protocols;Clinical Research;Clinical Research Protocols;Consultations;Credentialing;Data;Databases;Dental;Dental Staff;dental surgery;Development;Emergency Situation;Epidemiology;Goals;Hospitals;human subject;improved;Infection Control;Institutional Review Boards;Maintenance;Measures;Metabolic Bone Diseases;Monitor;National Institute of Dental and Craniofacial Research;Nursing Research;operation;Oral Surgical Procedures;patient safety;Patients;Performance;pre-pandemic;Process;Protocols documentation;Quality Control;Reporting;Research;research and development;Research Support;Safety;Saran;Schedule;Services;simulation;Study Subject;United States National Institutes of Health;virtual;Visit;Writing,NIDCR DIR Clinical Support Services,728,NA,NA,NA,NA,16,NA,NA,6822795,NA
11198875,ZIE,DE,1,N,NA,NA,NA,NA,ZIEDE000727,NA,NA,1ZIEDE000727-16,NIDCR:661308\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,14282250 (contact),"LEE, JANICE  (contact)",NA,NA,NA,Annual Reports;Award;career;career development;Clinical;clinical center;Clinical Research;Clinical Sciences;clinical training;craniofacial;Data;Dental;Dentists;Development;Disease;Education;Educational Activities;Ensure;Faculty;Fellowship;Fellowship Program;Goals;Grant;Health;Hybrids;improved;Individual;interest;Intramural Research;K-Series Research Career Programs;lectures;meetings;Mentors;Morbidity - disease rate;mortality;National Institute of Dental and Craniofacial Research;Nursing Faculty;Oral;Positioning Attribute;Program Development;programs;Publications;Reporting;Research;Research Activity;Research Personnel;research study;Research Training;Scientist;symposium;System;Talents;teacher;Training;training opportunity;Training Support;Translational Research;United States National Institutes of Health;virtual,NIDCR DIR Clinical Training,727,NA,NA,NA,NA,16,NA,NA,661308,NA
11198876,ZIG,DE,1,N,NA,NA,NA,NA,ZIGDE000740,NA,NA,1ZIGDE000740-13,NIDCR:1224240\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,11593728 (contact),"DAVIDSON, LAUREN  (contact)",NA,NA,NA,Accreditation;Amendment;Animal Care and Use Committees;Animal Experimentation;animal facility;animal resource;Animals;Annual Reports;Breeding;Caring;Committee Members;Consultations;Dedications;Education;Gene Targeting;Health;Housing;Human Resources;International;Intramural Research Program;Modification;Mus;National Institute of Dental and Craniofacial Research;operation;Policies;Principal Investigator;programs;Protocols documentation;quality assurance;Regulation;Research;Research Personnel;research study;Resources;Review Committee;Rodent;Safety;Scientist;Services;Training;Transgenic Animals;Transgenic Mice;United States Department of Agriculture;United States National Institutes of Health;Writing,NIDCR Annual Reports - Veterinary Resources Core,740,NA,NA,NA,NA,13,NA,NA,1224240,NA
11198877,ZIJ,DE,1,N,NA,NA,NA,NA,ZIJDE000745,NA,NA,1ZIJDE000745-10,NIDCR:843546\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,77860034 (contact),"HAUSER, BELINDA  (contact)",NA,NA,NA,"Address;adeno-associated viral vector;Applications Grants;Award;Biomedical Research;Biotechnology;career;career development;Chalk;Clinical;clinical center;Clinical Research;Collaborations;college;Communication;craniofacial;Data;Dental;Dental Clinics;Dental Students;Development;Development Plans;Doctor of Philosophy;Educational Curriculum;Educational workshop;Electronics;Employee;Event;experience;Faculty;Fellowship;Funding;gene therapy;Goals;Government;graduate student;Grant;High School Student;Hispanic;improved;Individual;Industry;interest;Interview;Joints;K-Series Research Career Programs;Lead;Leadership;Medical;Mentors;Mexican Americans;minority student;National Human Genome Research Institute;National Institute of Arthritis, and Musculoskeletal, and Skin Diseases;National Institute of Child Health and Human Development;National Institute of Dental and Craniofacial Research;Native Americans;Neurology;Ohio;Ophthalmology;Oral;Oral health;outreach;outreach program;Participant;Performance at work;Persons;Play;Policies;Population;Postbaccalaureate;Postdoctoral Fellow;pre-doctoral;Preparation;professor;programs;Public Speaking;recruit;Research;Research Personnel;Resources;Role;Schedule;Science;Scientist;Series;skills;Slide;Societies;Structure;Student recruitment;Students;Study Section;summer internship;summer program;summer research;Surveys;symposium;System;tenure track;Training;Training and Education;training opportunity;Training Programs;United States National Institutes of Health;Universities;Update;virtual;Vocational Guidance;Work;Writing",NIDCR Office of Training and Education,745,NA,NA,NA,NA,10,NA,NA,843546,NA
11198968,N01,ES,NA,N,NA,NA,NA,NA,273201700005C,NA,NA,273201700005C-P00022-9999-21,NIEHS:471261\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,COLUMBUS,UNITED STATES,NA,NA,926695685,US,NA,BATTELLE MEMORIAL INSTITU,OH,432012681,NA,78856050 (contact),"SPARROW, BARNEY  (contact)",NA,2017-09-26,2025-09-25,Blood Pressure;cardiovascular effects;cardiovascular health;Cardiovascular system;Chemicals;design;Development;Devices;Dose;Evaluation;Heart Rate;Implant;innovation;programs;Rattus;respiratory;Telemetry;Testing;Toxicology,Evaluation of multiple test agents for functional cardiovascular changes in rats,0,NA,NA,NA,NA,NA,NA,NA,471261,NA
11198969,N02,HD,NA,N,NA,NA,NA,NA,75N94023C00019,NA,NA,75N94023C00019-P00002-9999-1,NINDS:24687\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,FAIRFAX,UNITED STATES,NA,NA,078355846,US,NA,NA,VA,220333738,NA,79376211 (contact),"KHOSLA, MRINAL  (contact)",NA,2023-09-22,2025-09-21,Achievement;Chronic;Communication;Communities;cost;Country;Disease;Educational workshop;Funding;Funding Agency;Health;implementation research;Income;Indigenous;Joints;knowledge base;Leadership;Location;Logistics;low and middle-income countries;meetings;National Institute of Child Health and Human Development;prevent;Prevention;programs;Reporting;Research;Research Personnel;Research Training;Resources;Series;Services;skills;Training Programs;United States National Institutes of Health;web site;working group,NICHD SERVICES: FIC LOGISTICS SUPPORT,0,NA,NA,NA,NA,NA,NA,NA,24687,NA
11199021,N01,HD,NA,N,NA,NA,NA,NA,75N94019D00004,NA,NA,75N94019D00004-0-759402400002-1,NICHD:1199999\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,MORRISVILLE,UNITED STATES,NA,02,803902113,US,1501,"HEALTH DECISIONS, INC.",NC,275606950,NA,80000519 (contact),"DART, CLINT  (contact)",NA,2024-09-25,2025-09-24,Clinical;Clinical Trials;Clinical Trials Network;Collaborations;Contraceptive Agents;Contracts;cost;Development;efficacy trial;Estradiol;Evaluation;Formulation;Good Manufacturing Process;Government;Health;Investigational New Drug Application;Laboratories;manufacture;manufacturing organization;men;Mission;National Clinical Trials Network;National Institute of Child Health and Human Development;Nestorone;New York;Phase;phase III trial;Population;Production;prototype;Qualifying;Reporting;Sampling;Site;Specific qualifier value;Supervision;Technology Transfer;Therapeutic Equivalency;timeline;Vaginal Ring;Vendor;Woman;Work,ACQUISITION OF THE NESTORONE ESTRADIOL (NES/E2) VAGINAL RING AS CONTRACEPTIVE,0,NA,NA,NA,NA,NA,NA,NA,1199999,NA
11199027,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00022,NA,NA,75N91019D00022-P00001-759102200001-2,NCI:515612\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,PHILADELPHIA,UNITED STATES,NA,02,064367329,US,1190002,RESEARCH INST OF FOX CHASE CAN CTR,PA,191112434,NA,1885626 (contact),"CLAPPER, MARGIE L. (contact)",NA,2022-06-15,2025-05-15,Acceleration;adenoma;Adult;Adverse effects;African American;Age;aged;American;Animals;Antibiotics;Antigens;APC gene;ApcMin/+ mice;Bacillus;Bacteria;Bacteroides fragilis;base;Binding;Biological;biomaterial compatibility;Cancer Etiology;cancer risk;Cell Physiology;Cell-Mediated Cytolysis;Chemopreventive Agent;Child;cigarette smoking;Clinical;Codon Nucleotides;Colitis;Colon;Colonoscopy;Colorectal;Colorectal Adenoma;Colorectal Cancer;colorectal cancer risk;colorectal cancer screening;Colorectal Neoplasms;Colorectal Polyp;Containment;COVID-19;COVID-19 vaccine;Cytoprotection;Data;Dental Plaque;design;Development;Diagnosis;Disease;Distant;Distant Metastasis;DNA;draining lymph node;Dysplasia;Early Diagnosis;effector T cell;efficacy testing;Encapsulated;Enhancers;Epitopes;Familial Adenomatous Polyposis Syndrome;Family history of;Feces;Fortification;Fusobacteria;Fusobacterium;Fusobacterium nucleatum;gene repair;Genetic;Germ-Line Mutation;glycerophosphodiester phosphodiesterase;Goals;Gram-Negative Bacteria;Helicobacter pylori;Hepatitis B Virus;Hereditary Nonpolyposis Colorectal Neoplasms;Human;Human Papilloma Virus Vaccine;Immune;Immune Sera;Immunity;immunogenic;immunogenicity;Immunoglobulins;Immunosuppression;improved;in vivo;Incidence;Individual;Infection;Infection prevention;infection rate;Infectious Agent;Inflammatory Bowel Diseases;Inherited;Innate Immune Response;Intervention;ITIM;Lesion;lipid nanoparticle;Malignant Breast Neoplasm;Malignant neoplasm of cervix uteri;Malignant neoplasm of gastrointestinal tract;Malignant Neoplasms;malignant stomach neoplasm;Measures;Mediating;Membrane;Messenger RNA;Methodology;microbiota;Microsatellite Instability;Mismatch Repair;Mismatch Repair Deficiency;Modeling;Modification;Morbidity - disease rate;mortality;mouse model;mutation carrier;Natural Killer Cells;Neoplasm Metastasis;neoplastic cell;Non-Insulin-Dependent Diabetes Mellitus;Nonsense Mutation;Obesity;Oncogenic;Operative Surgical Procedures;Oral;Organ;pathogen;Patients;Phase;Population;Preclinical Drug Development;preclinical efficacy;premalignant;Prevalence;prevent;Prevention strategy;Preventive;Preventive measure;Preventive vaccine;Primary carcinoma of the liver cells;Program Development;prophylactic;Proteins;Proteomics;Pseudouridine;Race;receptor;Recommendation;Recording of previous events;Regimen;Regulatory T-Lymphocyte;Reporter;Resistance;Risk;Risk Factors;RNA;RNA vaccine;Role;scale up;screening;Small Intestinal Neoplasm;Survival Rate;Syndrome;System;T-Lymphocyte;Time;Tissues;tumor;Tumor Escape;tumor growth;tumor microenvironment;Tumor Promotion;tumorigenesis;tumorigenic;United States;United States Preventative Services Task Force;Update;Vaccination;Vaccine Antigen;vaccine platform;Vaccines;vaccinology;Vesicle;Virulence Factors;Wild Type Mouse,BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM:  PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIA,0,NA,NA,NA,NA,NA,NA,NA,515612,NA
11199061,OT3,HL,3,N,2024-09-26,2018-08-10,2027-09-30,837,OT3HL147154,NA,OTA-18-020,3OT3HL147154-01SA,NHLBI:5000000\,OTHERS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,CHAPEL HILL,UNITED STATES,NA,04,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275995023,NA,14399364 (contact),"KRISHNAMURTHY, ASHOK KUMAR (contact)","MILLER, CHRISTOPHER MANDEL",2018-08-10,2027-09-30,"Address;Big Data Methods;Blood;Communication;Communities;community empowerment;community engaged approach;community engagement;Community of Practice;computing resources;Coupled;Data;Data Commons;data resource;Data Science;Data Set;Data Storage and Retrieval;design;Disease;diverse data;Elements;empowerment;Ensure;Environment;Exhibits;expectation;experience;Fostering;Geography;Goals;Health;Heart;Heart Diseases;Hematological Disease;Infrastructure;insight;interest;Knowledge;knowledge integration;Knowledge Management;Leadership;Learning;light weight;Lung;Lung Diseases;Methods;Mission;multiple datasets;National Heart, Lung, and Blood Institute;National Research Council;Nature;novel;organizational structure;Outcome;Performance;Persons;Process;programs;Reporting;Research;Research Institute;Research Personnel;Risk;Science;Series;Services;Sleep;Sleep Disorders;Sociology;software development;Source;Strategic vision;synergism;Talents;United States National Academy of Sciences;United States National Institutes of Health;Vision;Work",NHLBI Data Stage Coordinating Center,147154,ZHL1,ZHL1-SRC(99),NA,SA,1,5000000,0,5000000,NA
11199066,P50,CA,3,N,2024-09-26,2024-09-01,2025-08-31,NA,P50CA257911,NA,PAR-20-305,3P50CA257911-03S1,NCI:86682\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,CHAPEL HILL,UNITED STATES,NA,04,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275995023,NA,9084260 (contact),"YEH, JEN JEN  (contact)","NOTHWEHR, STEVEN F",2022-09-16,2027-08-31,NA,"Project 3: Transcriptomic subtypes, response predictions, and therapy selection",257911,ZCA1,ZCA1-RPRB-8(O1)S,8368,S1,3,59792,26890,NA,86682
11199072,N02,HL,NA,N,NA,NA,NA,NA,75N92022D00015,NA,NA,75N92022D00015-0-759202400003-1,OD:300000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,NA,NA,(contact),NA,2024-09-30,2026-09-29,Acceleration;design;Development;Diagnostic tests;Health Technology;HIV;innovation;point of care;programs;RADx;RADx Tech;technology validation;Testing;United States National Institutes of Health;Viral Load result,RADx Innovation Funnel for Health Technologies - Validation Center,0,NA,NA,NA,NA,NA,NA,NA,300000,NA
11199085,R01,CA,3,N,2024-09-26,2024-05-01,2025-04-30,395,R01CA257814,BIOMED ENGR/COL ENGR/ENGR STA,PAR-20-004,3R01CA257814-04S2,NCI:81353\,NON-SBIR/STTR RPGS,2024,NATIONAL CANCER INSTITUTE,NA,HOUSTON,UNITED STATES,BIOSTATISTICS & OTHER MATH SCI,09,050299031,US,9291001,RICE UNIVERSITY,TX,770051827,NA,8880690;8261071 (contact),"FULLER, CLIFTON DAVID;SCHAEFER, ANDREW J (contact)","BUCHSBAUM, JEFFREY",2021-05-01,2025-04-30,Address;Adoption;advanced analytics;Affect;Aging;Algorithms;Anatomy;Area;base;Behavior;Cancer Control;cancer radiation therapy;Capital;chemoradiation;Clinical;Clinical Data;clinical implementation;Clinical Treatment;Communities;Community Hospitals;Complication;Computer software;connected health;cost;Coupled;Data;Data Set;Decision Making;Decision Support Systems;design;Development;Devices;Diagnosis;Dose;Economics;Emerging Technologies;Environment;Equipment;Evaluation;evidence base;Evolution;Goals;Head and Neck Cancer;head and neck cancer patient;Head and neck structure;Health;Health Policy;Health Technology;Healthcare;Human;Human Resources;Image;image guided radiation therapy;improved;in silico;Incentives;Individual;individual patient;individualized medicine;innovation;insight;Instruction;Insurance Carriers;Life;Linear Accelerator Radiotherapy Systems;low and middle-income countries;Magnetic Resonance Imaging;malignant mouth neoplasm;Malignant neoplasm of larynx;Malignant neoplasm of pharynx;Malignant Neoplasms;Medical Device;Medicare;Methodology;Methods;Modeling;models and simulation;Modernization;Monitor;Morbidity - disease rate;multidisciplinary;Neck Cancer;new technology;next generation;Normal tissue morphology;novel;Operations Research;Organ;Outcome;Overdose;Patient Care;Patient imaging;Patients;Physicians;Policies;Probability;Process;programs;Property;prototype;Provider;Radiation;Radiation therapy;radiation-induced injury;Regimen;Research;Resources;response;Risk;risk stratification;Schedule;Science;Self-Help Devices;Series;side effect;SMART health;soft tissue;Software Tools;standard care;Structure;support tools;Survivors;System;Systems Integration;Techniques;Technology;technology intervention;theories;Time;tool;Toxic effect;treatment planning;treatment response;treatment stratification;tumor;Tumor Volume;Uncertain Risk;Uncertainty;Validation;Variant;Work,SCH: Personalized Rescheduling of Adaptive Radiation Therapy for Head & Neck Cancer,257814,ZRG1,Special Emphasis Panel[ZRG1-MOSS-V(50)],NA,S2,4,81353,0,81353,NA
11199147,Y01,AI,NA,N,NA,NA,NA,NA,AAI24020001,NA,NA,AAI24020001-1-0-1,NIAID:1224451\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,(contact),NA,NA,NA,Development;inhibitor;Orthopoxvirus;Pharmaceutical Preparations;Poxviridae;small molecule;small molecule inhibitor;therapeutic development,Identification and Development of Small Molecule Orthopoxvirus Inhibitors,240200,NA,NA,NA,NA,NA,NA,NA,1224451,NA
11199161,N44,CA,NA,N,NA,NA,NA,NA,75N91024C00071,NA,NA,75N91024C00071-0-9999-1,NCI:2000000\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,12,NA,US,10088836,"MEDNET, INC.",NY,100106069,NA,14461320 (contact),"HOUSRI, NADINE  (contact)",NA,2024-09-16,2026-09-15,"Awareness;cancer prevention;cancer therapy;clinical trial enrollment;Clinical Trials;Collaborations;cost;demographics;Development;Disease;Eligibility Determination;Enrollment;Goals;improved;Information Resources;Location;National Cancer Institute;Oncologist;online community;participant enrollment;Patients;Phase;Physicians;point of care;Population Heterogeneity;predictive tools;Randomized;Randomized, Controlled Trials;Recommendation;Recording of previous events;recruit;Site;Small Business Innovation Research Grant;social;Southwest Oncology Group;Technology;Testing;tool;trial enrollment;United States",2024 SBIR TOPIC 465: CANCER PREVENTION AND TREATMENT CLINICAL TRIALS TOOLS FOR RECRUITMENT AND RETENTION OF DIVERSE POPULATIONS,0,NA,NA,NA,NA,NA,NA,NA,2000000,NA
11199168,Y01,AI,NA,N,NA,NA,NA,NA,AAI24031001,NA,NA,AAI24031001-1-0-1,NIAID:2108870\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,(contact),NA,NA,NA,Antimicrobial Resistance;Clinical Trials;efficacy evaluation;Gonorrhea;gonorrhea vaccine;Immunization;Neisseria meningitidis;Pharmaceutical Preparations;Phase;prevent;randomized placebo controlled study;Resistance;vaccine development;Vaccines,Meningococcal Immunization Against Gonococcal Infection Clinical Trial,240310,NA,NA,NA,NA,NA,NA,NA,2108870,NA
11199178,N44,CA,NA,N,NA,NA,NA,NA,75N91024C00060,NA,NA,75N91024C00060-0-9999-1,NCI:2049966\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,CHAPPAQUA,UNITED STATES,NA,17,116905433,US,10060891,VIZLITICS INC.,NY,105141000,NA,79988554 (contact),"SHEARER, CHAD  (contact)",NA,2024-09-16,2026-09-15,Address;Authorization documentation;Awareness;Breast;Cancer Patient;Characteristics;Chest;Clinic;Clinical;clinical trial enrollment;clinical trial recruitment;Clinical Trials;Communication;Communities;Comprehensive Cancer Center;Computer software;Contracts;dashboard;Data;data modeling;Disease;Documentation;drug development;Eligibility Determination;Enrollment;Evaluation;Failure;Feedback;gastrointestinal;Genitourinary system;Goals;Head and neck structure;Human;improved;Individual;innovation;insight;Link;Lung;Malignant Neoplasms;Measurement;Medical;member;Notification;Nurses;Participant;patient health information;Patients;Performance;Population Heterogeneity;Provider;recruit;Recruitment Activity;Reporting;Rest;screening;Screening procedure;Secure;Site;Software Tools;statistics;Structure;System;systematic review;Testing;Time;tool;Universities;verification and validation;Work,ONTRIAL: AI-DRIVEN AND EMR INTEGRATED CLINICAL TRIAL RECRUITMENT TOOL USED BY CLINICAL TRIAL AND PROVIDER TEAMS FOR RECRUITMENT OF DIVERSE POPULATIONS.,0,NA,NA,NA,NA,NA,NA,NA,2049966,NA
11199235,Y01,AI,NA,N,NA,NA,NA,NA,AAI24037001,NA,NA,AAI24037001-1-0-1,NIAID:437000\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,(contact),NA,NA,NA,Antimicrobial Resistance;Bacterial Infections;Bacteriophages;Gram-Negative Bacteria;Infection;pathogen;pre-clinical assessment;preclinical study;Resistance;safety assessment;Staphylococcus aureus;therapeutic development,Preclinical Assessment of Phage Therapy for Pathogen Decolonization,240370,NA,NA,NA,NA,NA,NA,NA,437000,NA
11199245,N01,OD,NA,N,NA,NA,NA,NA,75N98024F00371,NA,NA,75N98024F00371-0-0-1,OD:5439995\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,MC LEAN,UNITED STATES,NA,11,040540304,US,324202,MITRE CORPORATION,VA,221027539,NA,79981743 (contact),"KUNZMAN, JON  (contact)",NA,2024-09-09,2025-09-08,Address;African American;Age;All of Us Research Program;Biomedical Research;clinical investigation;clinical trial participant;cohort;Communities;Development;disability;Enrollment;Ensure;Ethnic Origin;Federally Qualified Health Center;Gender;Geography;Glean;Health Personnel;Hispanic;Hispanic Populations;improved;member;Monitor;operation;Phase;Population;Precision Medicine Initiative;programs;Race;sex;socioeconomics;Support Contracts;United States Dept. of Health and Human Services;United States National Institutes of Health;volunteer;Work,MITRE CORP:1105900 [24-002923],0,NA,NA,NA,NA,NA,NA,NA,5439995,NA
11199248,Y01,AI,NA,N,NA,NA,NA,NA,AAI24040001,NA,NA,AAI24040001-1-0-1,NIAID:1000000\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,(contact),NA,NA,NA,2019-nCoV;COVID-19 vaccine;Development;efficacy testing;Immune response;Immunological Models;Influenza;lymph nodes;lymphoid organ;medical countermeasure;microphysiology system;nonhuman primate;Tissues;vaccine development;Vaccines;Viral Vaccines,Non-Human Primate Lymphoid Organ Chips for Vaccine Assessment,240400,NA,NA,NA,NA,NA,NA,NA,1000000,NA
11199252,Y01,AI,NA,N,NA,NA,NA,NA,AAI24043001,NA,NA,AAI24043001-1-0-1,NIAID:58352\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,(contact),NA,NA,NA,Clinical Research;Cyclic GMP;enterotoxigenic Escherichia coli;Human;vaccine development;Vial device,Provision of cGMP Vials of Challenge Strain of Enterotoxigenic E. coli for use in Clinical Studies,240430,NA,NA,NA,NA,NA,NA,NA,58352,NA
11199400,R03,DE,7,N,2024-12-20,2024-10-01,2026-01-31,121,R03DE031838,SCHOOLS OF DENTISTRY/ORAL HYGN,PA-24-254,7R03DE031838-03,NIDCR:64066\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,COLUMBUS,UNITED STATES,DENTISTRY,03,832127323,US,6218701,OHIO STATE UNIVERSITY,OH,432101016,"Project Narrative The proposed research is relevant to public health because the understanding of the role of heparan sulfate- Sclerostin interaction in bone formation is ultimately expected to provide novel therapeutic targets in treating many diseases associated with exaggerated bone loss. Thus, the proposed research is relevant to the part of NIH’s mission that pertains to seeking fundamental knowledge that will help to reduce illness and enhance health.",15445682 (contact),"LI, MIAOMIAO  (contact)","WAN, JASON",2024-10-01,2026-01-31,NA,Demystify Heparan Sulfate–Sclerostin Interactions in Bone Formation,31838,DSR,National Institute of Dental and Craniofacial Research Special Grants Review Committee[DSR],NA,NA,3,40677,23389,64066,NA
11199520,R01,AG,7,N,2025-01-02,2025-01-15,2025-04-30,866,R01AG080925,NA,PA-24-254,7R01AG080925-03,NIA:623141\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE ON AGING,NA,HOUSTON,UNITED STATES,NA,09,185641052,US,10005742,METHODIST HOSPITAL RESEARCH INSTITUTE,TX,77030,PROJECT NARRATIVE  The proposed research will identify molecular changes in the extracellular matrix in the heart that occur with aging. The project will also evaluate the role of sex hormones and inflammation in these processes.,8412133 (contact),"CIESLIK, KATARZYNA A. (contact)","GAO, HONGWEI",2023-08-01,2028-04-30,NA,Proteomics based mapping of cardiac extracellular matrix to define sex and age-dependent changes.,80925,MPPA,Integrative Myocardial Physiology/Pathophysiology A Study Section [MPPA],NA,NA,3,385846,237295,623141,NA
11199565,ZIA,AI,1,N,NA,NA,NA,NA,ZIAAI005172,NA,NA,1ZIAAI005172-01,OD:684922\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,77882456 (contact),"ZHOU, TONGQING  (contact)",NA,NA,NA,2019-nCoV;Acceleration;Address;Affinity;Animal Model;Antigens;Area;ART protein;artificial intelligence model;Binding;Biological Assay;Characteristics;clinical application;computer framework;Cryoelectron Microscopy;Data;Dedications;design;design and construction;Development;Diffusion;effectiveness evaluation;Engineering;Epitope Mapping;Epitopes;Formulation;future pandemic;generative artificial intelligence;Genetic;Genetic Variation;graph neural network;HIV envelope protein;HIV-1;Immune response;Immunization;immunogenicity;in silico;Individual;innovation;large language model;Libraries;Maps;Methodology;Modeling;mosaic;nanoparticle;neutralizing antibody;next generation;novel;pandemic preparedness;Pathway interactions;pre-clinical;preclinical trial;Process;Proteins;Research;scaffold;self assembly;System;Techniques;Technology;tool;vaccination strategy;vaccine development;Vaccines;Validation;Variant;Viral Proteins,Generative AI-guided design of HIV-1 cocktail immunogen,5172,NA,NA,NA,NA,1,NA,NA,684922,NA
11199566,ZIA,DE,1,N,NA,NA,NA,NA,ZIADE000746,NA,NA,1ZIADE000746-10,NIDCR:1719278\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,14282250 (contact),"LEE, JANICE  (contact)",NA,NA,NA,3-Dimensional;age related;Aging;Animal Model;Animals;Basic Science;Biological Assay;Bone Marrow Examination;Bone Marrow Stem Cell;Bone Regeneration;Clinical Research;Clinical Treatment;Clinical Trials;cohort;cone-beam computed tomography;craniofacial;Craniofacial Abnormalities;craniofacial complex;Databases;Deformity;Dental;dentofacial;Development;Diagnosis;Disease;Disease Management;DNA Sequence Alteration;Dysmorphology;Early Intervention;Environment;Face;Genomics;Genotype;Goals;Growth and Development function;human disease;Image;imaging modality;improved;Knock-in Mouse;Loeys-Dietz Syndrome;Mandible;Mathematics;Methodology;Methods;Modeling;mouse model;Mus;Musculoskeletal;Natural History;Natural regeneration;Operative Surgical Procedures;Oral;Oral health;Osteogenesis Imperfecta;osteoprogenitor cell;Patients;Phenotype;Pre-Clinical Model;programs;Protocols documentation;Quality of life;rib bone structure;Risk;RNA Sequences;Role;skeletal abnormality;skull base;Statistical Data Interpretation;stem cell function;Technology;Testing;Three-Dimensional Imaging;Tooth Abnormalities;Tooth structure;Transforming Growth Factor beta Receptors;Translational Research;Variant,Craniofacial Anomalies and Regeneration,746,NA,NA,NA,NA,10,NA,NA,1719278,NA
11199628,N01,AI,NA,N,NA,NA,NA,NA,272201300002I,NA,NA,272201300002I-P00008-27200013-1,NIAID:114158\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,KENSINGTON,UNITED STATES,NA,08,094888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,NA,14264428 (contact),"PAL, RANAJIT  (contact)",NA,2015-09-18,2019-06-30,Advanced Development;African;AIDS Vaccines;Award;Clinical;Complement;Contracts;Development;Evaluation;Evaluation Studies;Funding;Grant;HIV vaccine;HIV-1;Immune response;Immunotherapy;Investigator-Initiated Research;Local Microbicides;Modality;National Institute of Allergy and Infectious Disease;Newcastle disease virus;nonhuman primate;pre-clinical;preclinical evaluation;preclinical study;Prevention;Prevention strategy;programs;Proteins;Research Personnel;Resources;vaccine candidate;Vaccine Design;vaccine development;vaccine evaluation;Vaccine Research;Vaccines,Conduct Study P193: Evaluation of Immune Responses after Priming with Newcastle Disease Virus and Boosting with Trimeric gp145 Proteins from Indian and African Clade C HIV-1 Isolates,0,NA,NA,NA,NA,NA,NA,NA,114158,NA
11199629,N01,AI,NA,N,NA,NA,NA,NA,272201300002I,NA,NA,272201300002I-P00006-759301900131-1,NIAID:11916\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,KENSINGTON,UNITED STATES,NA,08,094888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,NA,16132571 (contact),"PAL, RANAJIT  (contact)",NA,2019-08-20,2022-04-30,Advanced Development;Agonist;AIDS Vaccines;aluminum sulfate;Award;Clinical;Complement;Contracts;Development;env Glycoproteins;Evaluation;Evaluation Studies;Funding;Grant;HIV vaccine;HIV-1;immunogenicity;Immunotherapy;Intramuscular;Investigator-Initiated Research;Local Microbicides;Modality;National Institute of Allergy and Infectious Disease;nonhuman primate;pre-clinical;preclinical evaluation;preclinical study;Prevention;Prevention strategy;programs;Research Personnel;Resources;Route;vaccine candidate;Vaccine Design;vaccine development;vaccine evaluation;Vaccine Research;Vaccines,Evaluation of the Immunogenicity and Efficacy of HIV-1 Clade A BG505 SOSIP.664 Env Glycoprotein Trimer Vaccine Administered with TLR Agonist or Alum Adjuvants,0,NA,NA,NA,NA,NA,NA,NA,11916,NA
11199630,N01,AI,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-P00010-759102000009-1,NIAID:13721004\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,16448284 (contact),"BASELER, BETH  (contact)",NA,2020-04-03,2028-07-31,Adult;Blinded;Categories;Clinical;Coagulation Process;Consent;Coronavirus;COVID-19;COVID-19 patient;Data;Disease Progression;double-blind placebo controlled trial;Enrollment;Ensure;Functional disorder;Funding;Future;Hospitalization;Immunoglobulins;individual patient;Inpatients;International;Intravenous Immunoglobulins;Life;Medical;mortality;National Institute of Allergy and Infectious Disease;Organ;Organ failure;Outcome;Participant;participant enrollment;Patients;Pharmaceutical Preparations;Placebos;prevent;primary endpoint;Protocols documentation;Randomized;randomized trial;remdesivir;Research Personnel;Respiration Disorders;Safety;Sample Size;Site;standard of care;study population;Symptoms,"ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I.	A RANDOMIZED BLINDED CONTROLLED TRIAL OF TH",0,NA,NA,NA,NA,NA,NA,NA,13721004,NA
11199631,N01,AI,NA,N,NA,NA,NA,NA,272201300002I,NA,NA,272201300002I-P00011-27200015-1,NIAID:85597\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,KENSINGTON,UNITED STATES,NA,08,094888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,NA,78139002 (contact),"SILVERA, PETER  (contact)",NA,2016-08-15,2021-06-30,Advanced Development;AIDS Vaccines;Award;Clinical;Complement;Contracts;Development;Evaluation Studies;Funding;Grant;HIV envelope protein;HIV vaccine;HIV-1 vaccine;Immunotherapy;Investigator-Initiated Research;Local Microbicides;Macaca mulatta;Modality;Mucous Membrane;National Institute of Allergy and Infectious Disease;nonhuman primate;pre-clinical;preclinical evaluation;preclinical study;Prevention;Prevention strategy;programs;Research Personnel;Resources;vaccine candidate;Vaccine Design;vaccine development;vaccine efficacy;vaccine evaluation;Vaccine Research;Vaccines;Virus,Comparison of Bivalent vs Pentavalent Subtype C Envelope HIV-1 Vaccine Efficacy Following Mucosal Virus Challenge,0,NA,NA,NA,NA,NA,NA,NA,85597,NA
11199632,N01,HD,NA,N,NA,NA,NA,NA,275201300024I,NA,NA,275201300024I-P00007-27500007-1,NICHD:301890\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,TORRANCE,UNITED STATES,NA,44,069926962,US,2543101,LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER,CA,905022006,NA,14262986 (contact),"WANG, CHRISTINA  (contact)",NA,2015-09-15,2025-12-31,Androgens;avoid pregnancy;birth control;Clinical Trials;Contraceptive Agents;contraceptive efficacy;Contraceptive methods;Couples;Dose;efficacy clinical trial;Gel;Goals;Gonadotropins;Male Contraceptive Agents;men;Methods;Nestorone;Production;Progestins;Regimen;Research;research clinical testing;Safety;Site;sperm cell;Spermatogenesis;Testing;Testosterone,CCTN - CLINICAL EVALUATION OF NESTORONE GEL AND TESTOSTERONE - SITES FOR MALE CONTRACEPTIVE RESEARCH,0,NA,NA,NA,NA,NA,NA,NA,301890,NA
11199664,N01,HD,NA,N,NA,NA,NA,NA,75N94021D00018,NA,NA,75N94021D00018-0-759402400001-1,NICHD:1033058\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,MENANDS,UNITED STATES,NA,20,002436061,US,5966001,"NYSDOH/HEALTH RESEARCH, INC.",NY,122042893,NA,80001840 (contact),"CAGGANA, MICHELLE  (contact)",NA,2024-09-26,2026-09-25,Adolescent;Adult;Advisory Committees;Affect;Age;Age of Onset;Alleles;American;Arylsulfatases;Austria;Authorization documentation;autosome;Behavioral;Biochemical;Biological Assay;Birth;Blood;Brain;brain magnetic resonance imaging;Cessation of life;Characteristics;Child;Child Health;Clinic;Clinical;clinical subtypes;Cognitive;Confusion;Consensus;Contractor;Contracts;Demyelinations;Detection;Development;Developmental Disabilities;Diagnosis;Diagnostic tests;Disabling condition;Disease;Disease Progression;Dryness;Early Diagnosis;early onset;Early treatment;Environment;enzyme activity;enzyme deficiency;Evaluation;Exclusion;follow-up;gene therapy;Genes;genetic testing;Genotype;Germany;Goals;Guidelines;Health Personnel;Hereditary Disease;improved;Individual;infancy;Infant;Intellectual functioning disability;Laboratories;Left;Leukocytes;Liquid Chromatography;loss of function;Measurement;Measures;Medical Genetics;medical schools;medical specialties;Metachromatic Leukodystrophy;Monitor;Motor;MTCH1 gene;Mutation;Neonatal Screening;Nervous System Trauma;Newborn Infant;Onset of illness;Pathogenicity;Peripheral Nervous System Diseases;physically handicapped;Pilot Projects;Population;Prevalence;Privatization;prospective;Randomized;Rare Diseases;Reagent;Recommendation;Reporting;Sampling;screening;screening guidelines;screening panel;screening program;Sensitivity and Specificity;Severities;Spottings;Sulfoglycosphingolipids;Symptoms;tandem mass spectrometry;Testing;Treatment outcome;Urine;Validation;Variant;white matter,NEWBORN SCREENING PILOT STUDY FOR METACHROMATIC LEUKODYSTROPHY (MLD),0,NA,NA,NA,NA,NA,NA,NA,1033058,NA
11199734,U2F,FD,3,N,2024-09-27,2024-05-01,2025-04-30,103,U2FFD007646,NA,RFA-FD-22-021,3U2FFD007646-03S2,FDA:52564\,NON-SBIR/STTR RPGS,2024,FOOD AND DRUG ADMINISTRATION,NA,YORK,UNITED STATES,NA,10,194580973,US,959901,ASSOCIATION OF FOOD AND DRUG OFFICIALS,PA,17401,"RFA-FD-22-021 AFDO’s System for Agriculture, Food, Health, E-Inspections and Registration (SAFHER): Project Narrative The Association of Food and Drug Officials’ (AFDO) efforts under this cooperative agreement are intended to support the planning, development, implementation, operation, and maintenance of data management system to be utilized by State, Local, Tribal, and Territorial (SLTT) partners in both human and animal food programs. AFDO will build on an already established user community of stakeholders to enhance FDA’s ORA Data Exchange capabilities by utilizing software development methodologies (i.e. Agile) to ensure a long-term sustainable data management system that is easy to use and maintain by state regulatory partners during and after this cooperative agreement. Through effective governance, vendor procurement, and resource management, this project will deliver a national regulatory data repository that will work towards achieving a national Integrated Food Safety System (IFSS) while promoting One Health and supporting domestic mutual reliance initiatives to protect the food supply and advance public health.",10889095 (contact),"MANDERNACH, STEVEN  (contact)","LAC, ANH",2022-09-15,2025-04-30,NA,"System for Agriculture, Food, Health, E-inspection, and Registration (SAFHER)",7646,ZFD1,ZFD1-ORA-K(02)1,NA,S2,3,52564,0,52564,NA
11199800,N02,DA,NA,N,NA,NA,NA,NA,75N95023P00692,NA,NA,75N95023P00692-P00001-0-2,NINDS:27295\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,SAN JOSE,UNITED STATES,NA,17,602744732,US,2083701,"CCS ASSOCIATES, INC.",CA,95130,NA,15762037 (contact),"SIGMAN, CAROLINE C (contact)",NA,2023-09-14,2025-09-13,Area;Discipline;drug development;drug discovery;experience;gene therapy;Industry;Leadership;Medical;programs;Services;United States National Institutes of Health;Writing,MEDICAL WRITING CONSULTING SERVICES,0,NA,NA,NA,NA,NA,NA,NA,27295,NA
11199807,N01,DA,NA,N,NA,NA,NA,NA,75N95024P00040,NA,NA,75N95024P00040-0-0-1,NINDS:4200\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,CLIFTON,UNITED STATES,NA,NA,178149998,US,NA,NA,VA,201242550,NA,NA,(contact),NA,2023-11-28,2024-11-27,Area;Biological Assay;Biological Products;Biological Response Modifier Therapy;Biometry;Cell Therapy;Chemistry;Contracts;Development;drug development;drug discovery;Drug Kinetics;gene therapy;manufacture;Medical;National Institute of Neurological Disorders and Stroke;novel therapeutics;Pharmacodynamics;product development;Program Development;quality assurance;Quality Control;Recommendation;Regulatory Affairs;Services;therapeutic development;Toxicology;United States National Institutes of Health;Writing,Biological Therapeutics Product Development Subject Matter Expert Consulting Services,0,NA,NA,NA,NA,NA,NA,NA,4200,NA
11199808,N01,DA,NA,N,NA,NA,NA,NA,75N95024P00040,NA,NA,75N95024P00040-0-0-2,NINDS:5600\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,CLIFTON,UNITED STATES,NA,NA,178149998,US,NA,NA,VA,201242550,NA,NA,(contact),NA,2023-11-28,2024-11-27,Area;Biological Assay;Biological Products;Biological Response Modifier Therapy;Biometry;Cell Therapy;Chemistry;clinical pain;Contracts;Development;drug development;drug discovery;Drug Kinetics;gene therapy;Helping to End Addiction Long-term;manufacture;Medical;National Institute of Neurological Disorders and Stroke;novel therapeutics;Pain;Pain management;Pharmacodynamics;product development;Program Development;quality assurance;Quality Control;Recommendation;Regulatory Affairs;Services;Speed;therapeutic development;Toxicology;United States National Institutes of Health;Writing,Biological Therapeutics Product Development Subject Matter Expert Consulting Services,0,NA,NA,NA,NA,NA,NA,NA,5600,NA
11199809,N01,DA,NA,N,NA,NA,NA,NA,75N95024P00051,NA,NA,75N95024P00051-0-0-1,NINDS:9130\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ALEXANDRIA,UNITED STATES,NA,NA,033068821,US,NA,NA,VA,22314,NA,NA,(contact),NA,2023-12-13,2024-12-12,Award;Biological Products;Biological Response Modifier Therapy;Contracts;Development;drug development;drug discovery;National Institute of Neurological Disorders and Stroke;Recommendation;Services;therapeutic development,Biologics - gap analysis services,0,NA,NA,NA,NA,NA,NA,NA,9130,NA
11199812,N01,NS,NA,N,NA,NA,NA,NA,75N95A24P00065,NA,NA,75N95A24P00065-0-0-1,NINDS:9900\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,ARDMORE,UNITED STATES,NA,NA,117537973,US,NA,NA,PA,190031504,NA,NA,(contact),NA,2024-05-01,2025-04-30,Area;Biological Products;Biological Response Modifier Therapy;Contractor;drug development;drug discovery;experience;Feedback;Leadership;member;Program Development;programs;Research;Services;United States National Institutes of Health,"This service is to provide Leadership an experienced executive level professional in research and it requires an external advisory experts directed to provide independent advice. POP: May 1, 2024 to A",0,NA,NA,NA,NA,NA,NA,NA,9900,NA
11199813,N01,NS,NA,N,NA,NA,NA,NA,75N95A24P00070,NA,NA,75N95A24P00070-0-0-1,NINDS:9900\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,BRONX,UNITED STATES,NA,NA,NA,US,NA,NA,NY,104712908,NA,NA,(contact),NA,2024-06-04,2025-06-03,Area;Biological Products;Biological Response Modifier Therapy;Contractor;drug development;drug discovery;experience;Feedback;Leadership;member;Program Development;programs;Services;United States National Institutes of Health,This service is for the External Oversight Committee (EOC) of the Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) is an external advisory group of experts directed to provide indepen,0,NA,NA,NA,NA,NA,NA,NA,9900,NA
11199815,N01,NS,NA,N,NA,NA,NA,NA,75N95A24P00073,NA,NA,75N95A24P00073-0-0-1,NINDS:9900\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,ARCADIA,UNITED STATES,NA,NA,NA,US,NA,NA,CA,910062424,NA,NA,(contact),NA,2024-06-05,2025-06-04,Area;Biological Products;Biological Response Modifier Therapy;Contractor;drug development;drug discovery;experience;Feedback;Leadership;member;Program Development;programs;Services;Travel;United States National Institutes of Health,This service is for consulting and travel reimbursement.  POP: 06/05/2024 to 06/04/2025,0,NA,NA,NA,NA,NA,NA,NA,9900,NA
11199831,N01,NS,NA,N,NA,NA,NA,NA,75N95A24P00076,NA,NA,75N95A24P00076-0-0-1,NINDS:9900\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,ANN ARBOR,UNITED STATES,NA,NA,141618269,US,NA,NA,MI,481053019,NA,NA,(contact),NA,2024-06-06,2025-06-05,Area;Biological Products;Biological Response Modifier Therapy;Consultations;Contractor;drug development;drug discovery;experience;Feedback;Leadership;member;Program Development;programs;Recommendation;Services;Travel;United States National Institutes of Health,This service is for Consultation review and recommendations of BPN-Biologics Projects and travel. POP: 06/06/2024 to 06/05/2025.,0,NA,NA,NA,NA,NA,NA,NA,9900,NA
11199848,N01,NS,NA,N,NA,NA,NA,NA,75N95A24P00092,NA,NA,75N95A24P00092-0-0-1,NINDS:10000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,SYKESVILLE,UNITED STATES,NA,03,117951622,US,10064586,"NEUIMMUNE BIOLOGICS, INC.",MD,217848213,NA,NA,(contact),NA,2024-07-10,2025-07-09,Area;Biological Products;Biological Response Modifier Therapy;Consultations;Contractor;drug development;drug discovery;experience;Feedback;Leadership;member;Program Development;programs;Services;United States National Institutes of Health,Biological Therapeutics consultation services,0,NA,NA,NA,NA,NA,NA,NA,10000,NA
11199861,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00130,NA,NA,75N95024P00130-0-0-1,NINDS:18000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,BROOKEVILLE,UNITED STATES,NA,NA,NA,US,NA,NA,MD,208331235,NA,NA,(contact),NA,2024-02-15,2025-02-14,Biological Products;Biological Response Modifier Therapy;Cell Therapy;Chemistry;Contracts;Development;drug development;drug discovery;gene therapy;manufacture;National Institute of Neurological Disorders and Stroke;novel therapeutics;product development;Program Development;Recommendation;Services;therapeutic development;United States National Institutes of Health,BIOLOGICAL THERAPEUTICS PRODUCT DEVELOPMENT SUBJECT MATTER EXPERT CONSULTING SERVICES TO SUPPORT THE DEVELOPMENT OF CELL AND GENE THERAPY PRODUCTS,0,NA,NA,NA,NA,NA,NA,NA,18000,NA
11199862,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00130,NA,NA,75N95024P00130-0-0-2,NINDS:49500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,BROOKEVILLE,UNITED STATES,NA,NA,NA,US,NA,NA,MD,208331235,This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.,NA,(contact),NA,2024-02-15,2025-02-14,Biological Products;Biological Response Modifier Therapy;Cell Therapy;Chemistry;clinical pain;Contracts;Development;drug development;drug discovery;gene therapy;Helping to End Addiction Long-term;manufacture;National Institute of Neurological Disorders and Stroke;novel therapeutics;Pain;Pain management;product development;Program Development;Recommendation;Services;Speed;therapeutic development;United States National Institutes of Health,BIOLOGICAL THERAPEUTICS PRODUCT DEVELOPMENT SUBJECT MATTER EXPERT CONSULTING SERVICES TO SUPPORT THE DEVELOPMENT OF CELL AND GENE THERAPY PRODUCTS,0,NA,NA,NA,NA,NA,NA,NA,49500,NA
11199869,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00008,NA,NA,75N95024P00008-0-0-1,NINDS:71775\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,CINCINNATI,UNITED STATES,NA,NA,117451929,US,NA,NA,OH,452201401,NA,NA,(contact),NA,2023-10-16,2026-10-15,Biochemistry;Biological Products;Biological Response Modifier Therapy;Chemistry;Development;experience;gene therapy;Individual;manufacture;National Institute of Neurological Disorders and Stroke;oligonucleotide therapeutics;Process;programs;Services;therapeutic development;United States National Institutes of Health,"THERAPEUTIC OLIGONUCLEOTIDE PLATFORM BIOLOGICS CHEMISTRY, MANUFACTURING AND CONTROLS (CMC), SUBJECT MATTER EXPERT CONSULTING SERVICES.",0,NA,NA,NA,NA,NA,NA,NA,71775,NA
11199962,Y01,CA,NA,N,NA,NA,NA,NA,ACO24003001,NA,NA,ACO24003001-1-0-1,NCI:110114\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Address;Adoption;Advisory Committees;Agreement;American;American Cancer Society;American Society of Clinical Oncology;Area;cancer prevention;care coordination;Caring;Clinical;clinical care;Clinical Laboratory Information Systems;Collaborations;Common Data Element;Communities;Community Health;Complex;Data;Data Collection;Data Element;data exchange;data quality;Data Set;data standards;Decision Making;Diagnosis;Ecosystem;Education;Educational Activities;Electronic Health Record;Evaluation;Exercise;Fast Healthcare Interoperability Resources;Future;Government;Health;health equity;health inequalities;health information technology;health organization;Health Personnel;Health Services Accessibility;Healthcare;Human Resources;Improve Access;improved;Information Systems;innovation;interest;interoperability;Joints;Laboratories;Malignant Neoplasms;Maps;Measurement;meetings;Methods;National Cancer Institute;Oncology;Patient-Focused Outcomes;Patients;Persons;Policies;Population Surveillance;programs;Provider;Public Health;Radiation Oncology;Recommendation;Registries;Reproducibility;Research;Research Personnel;Resources;Societies;System;Tribes;United States;United States National Institutes of Health;Work,NIH-ONC Cancer Domain Collab FTE,240030,NA,NA,NA,NA,NA,NA,NA,110114,NA
11200092,ZIA,AT,1,N,NA,NA,NA,NA,ZIAAT000024,NA,NA,1ZIAAT000024-12,NCCIH:899268\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,77854889 (contact),"SHURTLEFF, DAVID  (contact)",NA,NA,NA,Advertisements;Analgesics;Anatomy;Attention;Brain;Brain region;Cerebrum;chronic pain;chronic pain patient;chronic widespread pain;clinical trial recruitment;Data;data acquisition;Data Analyses;dopamine system;Double-Blind Method;Emotions;endogenous opioids;Environment;Fibromyalgia;gray matter;healthy volunteer;Individual;Institutional Review Boards;intravenous administration;Magnetic Resonance Imaging;Methods;Naloxone;neural;Neurotransmitters;Newspapers;Opioid;Opioid Antagonist;Pain;Pain management;pain patient;pain processing;pain relief;Paper;patient population;Patients;Persons;placebo analgesia;Placebo Effect;Placebos;Population;Preparation;Protocols documentation;Psychological Factors;Psychophysics;Publishing;Randomized;recruit;Role;Saline;social media;System;Testing;Training;United States National Institutes of Health,Brain Mechanisms of Pain Processing and Modulation,24,NA,NA,NA,NA,12,NA,NA,899268,NA
11200093,ZIA,AT,1,N,NA,NA,NA,NA,ZIAAT000032,NA,NA,1ZIAAT000032-09,NCCIH:899268\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,77854889 (contact),"SHURTLEFF, DAVID  (contact)",NA,NA,NA,Absence of pain sensation;Address;Affective;Analgesics;Animals;Blood Pressure;Cervical spine;Clinical;comparison control;Crossover Design;Data;depressive symptoms;Double-Blind Method;Ear;Electric Stimulation;Esthesia;experimental study;External Ear;Galvanic Skin Response;Goals;Heart Rate;heart rate variability;Human;improved;Left;Literature;Measures;Mediating;men;Moods;negative mood;Pain;Pain intensity;pain perception;pain reduction;Pain Threshold;positive mood;Randomized;recruit;Respiration;response;Role;screening;Site;Spinal nerve structure;Stimulus;treatment-resistant depression;vagus nerve stimulation;Vagus nerve structure;Visit;Woman,Effects of external ear stimulation on pain perception and mood,32,NA,NA,NA,NA,9,NA,NA,899268,NA
11200094,ZIA,AT,1,N,NA,NA,NA,NA,ZIAAT000033,NA,NA,1ZIAAT000033-08,NCCIH:1798536\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,77854889 (contact),"SHURTLEFF, DAVID  (contact)",NA,NA,NA,Brain imaging;Congenital Pain Insensitivity;Data;Data Collection;DNA Sequence Alteration;Enrollment;Esthesia;Individual;Merkel Cells;Methods;Nerve Fibers;Neurologic;Neurons;Pain;pain perception;Participant;Pathway interactions;Patients;Peripheral;Piezo 2 ion channel;Proprioception;Proteins;receptor;Role;Sensory;somatosensory;Structural defect;Testing;Touch sensation;Variant,Patients with Altered Somatosensory or Pain Perception,33,NA,NA,NA,NA,8,NA,NA,1798536,NA
11200095,ZIA,AT,1,N,NA,NA,NA,NA,ZIAAT000037,NA,NA,1ZIAAT000037-06,NCCIH:2697804\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,77854889 (contact),"SHURTLEFF, DAVID  (contact)",NA,NA,NA,Address;Adolescence;Age;behavior measurement;Brain;chronic pain;chronic pain patient;Clinical;Clinical Research;Data Analyses;Data Collection;design;Emotional;Ethnic Origin;Evaluation;Functional Imaging;Functional Magnetic Resonance Imaging;Gender;healthy volunteer;Human;Interview;Laboratories;Magnetic Resonance Imaging;Measurement;Medical History;Medical Records;Nationalities;neuromechanism;Outcome Measure;Pain;Pain Disorder;Pain management;Participant;Patient Outcomes Assessments;Persons;Phenotype;Physiological;Preparation;Psychophysics;Publications;Publishing;Role;Sensory;structural imaging;study population;Testing;tool;Touch sensation,General Studies of Chronic Pain,37,NA,NA,NA,NA,6,NA,NA,2697804,NA
11200096,ZIC,AT,1,N,NA,NA,NA,NA,ZICAT000039,NA,NA,1ZICAT000039-06,NCCIH:1348902\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,77854889 (contact),"SHURTLEFF, DAVID  (contact)",NA,NA,NA,Affect;Attention;Basic Science;Behavioral;Brain;Brain imaging;Clinical Research;Complementary Health;Doctor of Philosophy;Emotions;Environment;Exposure to;Functional Magnetic Resonance Imaging;Genetic;Health;Healthcare;healthy volunteer;improved;innovation;Integrative Medicine;Intervention;Intramural Research Program;Investigation;Leadership;Mission;model organism;Molecular;National Center for Complementary and Integrative Health;Neurosciences;new technology;novel strategies;Pain;Pain management;pain perception;pain processing;Patients;Productivity;programs;Research;Research Personnel;Research Project Grants;Resources;Role;Safety;Scientist;Series;System;Transcranial magnetic stimulation;Translational Research;United States National Institutes of Health;Work,Office of the Scientific Director,39,NA,NA,NA,NA,6,NA,NA,1348902,NA
11200097,ZID,AT,1,N,NA,NA,NA,NA,ZIDAT000040,NA,NA,1ZIDAT000040-06,NCCIH:1348902\,INTRAMURAL RESEARCH,2024,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,NA,NA,77854889 (contact),"SHURTLEFF, DAVID  (contact)",NA,NA,NA,Affective;Ambulatory Care Facilities;Appointments and Schedules;Clinical;clinical center;clinical investigation;clinical practice;Clinical Protocols;Clinical Research;Contracts;cost;Credentialing;Data Analyses;Databases;Development;Ear;Fellowship;Infrastructure;Institutional Review Boards;Laboratories;Medical;Moods;National Center for Complementary and Integrative Health;next generation;Nurse Practitioners;Nursing Research;Operations Research;Pain;Patient Admission;Patients;Phenotype;Physicians;Preparation;pressure;programs;Protocols documentation;Regulation;repository;Research Personnel;Research Support;Resolution;Resources;Science;Services;Touch sensation;Training;Translational Research;Travel;United States National Institutes of Health,Clinical Support Services,40,NA,NA,NA,NA,6,NA,NA,1348902,NA
11200098,OT2,HL,3,N,2024-09-27,2024-09-25,2025-09-30,837,OT2HL180049,NA,OTA-24-021,3OT2HL180049-01S1,NHLBI:26600000\,OTHERS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ROCKVILLE,UNITED STATES,NA,08,049508120,US,9611701,"WESTAT, INC.",MD,208503129,NA,78492086 (contact),"MONTALVAN, REBECCA  (contact)",NA,2024-09-25,2029-09-30,"Address;Area;Artificial Intelligence;authority;Award;Behavioral;Biological Process;Biomedical Research;catalyst;Chronic lung disease;Clinical;Clinical Data;Collaborations;Data;Data Set;database of Genotypes and Phenotypes;Dedications;Disease;Disparity;Ecosystem;Environmental Exposure;Exhibits;experience;Familiarity;Gender;genome sequencing;Health;Heart Diseases;Hematological Disease;idiopathic pulmonary fibrosis;Image;improved;Infrastructure;innovation;interest;Internet;Intervention;Lung Diseases;Machine Learning;machine learning method;Measures;Medical;Medical Imaging;Methods;Molecular;National Heart, Lung, and Blood Institute;Nature;novel;operation;organizational structure;Outcome;petabyte;Phenotype;Positioning Attribute;Precision Medicine Initiative;Prevention;Procedures;Process;programs;Progress Reports;Radiogenomics;radiomics;Research;Research Institute;Research Personnel;Research Project Grants;Research Proposals;Research Subjects;Risk Factors;Role;Running;sex;Sex Differences;Sleep Disorders;Structure;success;synergism;System;Therapeutic;Time;Trans-Omics for Precision Medicine;Update;whole genome;Woman;Women&apos;s Health;Work",Trans-Omics for Precision Medicine (TOPMed) Artificial Intelligence Coordinating Center (AI-CC),180049,ZHL1,ZHL1-SRC(99),NA,S1,1,26600000,0,26600000,NA
11200172,ZIA,DE,1,N,NA,NA,NA,NA,ZIADE000649,NA,NA,1ZIADE000649-30,NIDCR:2578134\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,9414991 (contact),"COLLINS, MICHAEL  (contact)",NA,NA,NA,Abnormal Cell;Achondroplasia;American;American Heart Association;Area;autosome;Benign;Biological;Biological Markers;Biological Process;Biology;Blood Vessels;bone;bone mass;Bone Resorption;burden of illness;calcification;Calcium;Calcium ion;calcium phosphate;Calcium-Sensing Receptors;Cell Lineage;Cell surface;Cellularity;Child;Clinical;Clinical Research;Clinical Treatment;Collaborations;Dedications;Dental;Deposition;Development;Disease;Dose;Durapatite;Dysplasia;Enrollment;extracellular;Familial tumoral calcinosis;Family;fibroblast growth factor 23;Fibroblast Growth Factor Receptors;fibroblast-activating factor;Fibrous Dysplasia;functional disability;G-Protein-Coupled Receptors;gain of function;Goals;Homeostasis;human disease;Hydroxyapatites;hydroxyl group;Hypocalcemia;Hypoparathyroidism;imaging modality;improved;Individual;Inflammation;inorganic phosphate;International;Investigation;Ions;Life;Ligands;Maintenance;Maps;McCune-Albright Syndrome;meetings;member;Mesenchymal Cell Neoplasm;mineralization;Minerals;Mission;mutant;National Institute of Dental and Craniofacial Research;Osteoclasts;osteogenic;Osteomalacia;Paper;Paraneoplastic Syndromes;Pathogenesis;Patients;PET/CT scan;Pharmaceutical Preparations;phase 2 study;phase 3 study;phase III trial;Physiology;Play;Principal Investigator;Process;Productivity;programs;PTH gene;public-private partnership;Rare Diseases;Research;Research Support;response;Role;Scanning;Secondary to;skeletal disorder;skeletal stem cell;small molecule;Societies;Techniques;therapy development;Tissues;TNFSF11 gene;Tooth structure;Training;transcriptomics;translational physician;translational scientist;translational study;tumor;Tyrosine Kinase Inhibitor;United States National Institutes of Health;Update;Variant;Vascular calcification;Work,Skeletal Disorders and Mineral Homeostasis Section,649,NA,NA,NA,NA,30,NA,NA,2578134,NA
11200209,N02,CA,NA,N,NA,NA,NA,NA,261201500003I,NA,NA,261201500003I-P00011-26100080-1,NCI:2997980\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,16231723 (contact),"JACKSON, SHANNON  (contact)",NA,2018-09-24,2026-10-02,Address;Chemicals;exhaust;Height;Modification;System,"NCI OD-Frederick; 125073 Bldg. 560, Roof Exhaust Stacks; 9/24/2018 - 3/18/2022",0,NA,NA,NA,NA,NA,NA,NA,2997980,NA
11200239,R21,CA,7,N,2024-12-18,2024-09-01,2025-04-30,395,R21CA273282,SCHOOLS OF MEDICINE,PA-24-254,7R21CA273282-03,NCI:182090\,NON-SBIR/STTR RPGS,2024,NATIONAL CANCER INSTITUTE,NA,DURHAM,UNITED STATES,PEDIATRICS,04,044387793,US,2221101,DUKE UNIVERSITY,NC,277054673,"Project Narrative The genomics era was anticipated to bring with it the capacity to use molecular biology tools to identify specific cancer-causing mutations and translate that information into better therapy. This problem has not been realized for most children with cancer, especially diseases like fusion-positive rhabdomyosarcoma (FP-RMS) that harbors few highly recurrent mutations. Our project will develop two new tools – a Bayesian-based, integrative analyses of genomic and epigenetic features of FP-RMS, and FP-RMS PDX models and cell lines where the oncogenic fusion protein can be rapidly and reversibly switched “on” and “off” – which will reveal cancer drivers and tumor suppressors, and how they can be influenced by the fusion protein and, potentially, targeted.",1879886 (contact);11600386,"SKAPEK, STEPHEN X (contact);XU, LIN","COVELL, DAVID G",2023-05-16,2025-04-30,NA,Nominating vulnerabilities in fusion oncoprotein-driven rhabdomyosarcoma,273282,ZCA1,ZCA1-SRB-P(J1),NA,NA,3,111031,71059,182090,NA
11200469,R01,HD,7,N,2024-12-11,2024-12-11,2025-07-31,865,R01HD109248,SCHOOLS OF VETERINARY MEDICINE,PA-24-254,7R01HD109248-04,NICHD:522487\,NON-SBIR/STTR RPGS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,FORT COLLINS,UNITED STATES,VETERINARY SCIENCES,02,785979618,US,1725201,COLORADO STATE UNIVERSITY,CO,805232002,"Project Narrative While it is universally accepted that undernutrition negatively impacts the reproductive success of an individual, relatively little is known about the central mechanisms whereby inadequate food intake suppresses GnRH/LH secretion. This project seeks to investigate the role of a neuronal-mediated (agouti- related peptide signaling) and a central immune-mediated (interleukin-1β signaling) mechanism in the regulation of LH secretion during undernutrition and realimentation. The results of this proposal will help to identify central targets useful for future therapeutic strategies to prevent or lower the risk of disorders such as cardiovascular disease and depression that are associated with delayed puberty.",11573404 (contact),"NESTOR, CASEY C (contact)","WINER, KAREN",2022-09-01,2027-07-31,NA,Nutritional Regulation of Luteinizing Hormone Secretion,109248,ICER,Integrative and Clinical Endocrinology and Reproduction Study Section[ICER],NA,NA,4,352946,169541,522487,NA
11200535,Y01,AI,NA,N,NA,NA,NA,NA,AAI24006001,NA,NA,AAI24006001-1-0-2,NIAID:620297\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,(contact),NA,NA,NA,Acquired Immunodeficiency Syndrome;AIDS clinical trial group;Biological Products;Cell Aging;Clinical Trials;Dasatinib;Funding;HIV;HIV-1;HIV/AIDS;improved;Names;National Institute of Allergy and Infectious Disease;Pharmacologic Substance;pilot trial;Price;programs;Services;Vendor,NIAID-DLA Pharmaceutical Vendor Program: HIV/AIDS Study Support,240060,NA,NA,NA,NA,NA,NA,NA,620297,NA
11200570,R01,AI,7,N,2024-11-06,2024-10-01,2025-05-31,855,R01AI155621,NA,PA-24-254,7R01AI155621-05,NIAID:579583\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NASHVILLE,UNITED STATES,NA,07,079917897,US,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,TN,372320011,"PROJECT NARRATIVE Mycobacterium tuberculosis (Mtb) is the number one infectious disease killer in the world. Altering mitochondrial homeostasis has been repeatedly associated with susceptibility to Mtb and exacerbation of Mtb pathogenesis. By understanding how crosstalk between Mtb virulence factors and mitochondria influences immune outcomes, we might one day be able to therapeutically target mitochondria as part of tuberculosis patient treatment plans.",9803040;9427418 (contact),"PATRICK, KRISTIN LEIGH;WATSON, ROBERT OWEN (contact)","EICHELBERG, KATRIN",2021-06-10,2026-05-31,NA,Mitochondria as crucial regulators of innate immune outcomes during Mycobacterium tuberculosis infection,155621,HIBP,Host Interactions with Bacterial Pathogens Study Section[HIBP],NA,NA,5,335418,244165,579583,NA
11200747,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL002345,NA,NA,1ZIAHL002345-24,NHLBI:4926222\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,6792853 (contact),"CHILDS, RICHARD  (contact)",NA,NA,NA,Accounting;Acute Graft Versus Host Disease;Adoptive Immunotherapy;Adult;Affinity;Allogenic;Allografting;Alloimmunization;Antibodies;Antigen Targeting;Antigens;antitumor effect;Aplastic Anemia;Area;Autologous;Back;Bone Marrow;bone marrow failure syndrome;Bortezomib;cancer immunotherapy;Cancer Patient;Cancer Vaccines;CCR5 gene;CD34 gene;Cell Proliferation;Cell Separation;Cells;Cellular Immunity;Cellular immunotherapy;chimeric antigen receptor T cells;Chimerism;chronic graft versus host disease;Clear Cell;Clear cell carcinoma;Clear cell renal cell carcinoma;Clinical;Clinical Research;Clinical Trials;Clone Cells;Clustered Regularly Interspaced Short Palindromic Repeats;cohort;Collaborations;Colony-Stimulating Factor Receptors;conditioning;CSF3 gene;Cyclophosphamide;cytokine;Cytotoxic T-Lymphocytes;Data;demethylation;Depsipeptides;Development;Disadvantaged;Disease-Free Survival;DNA;Donor person;donor stem cell;Dose;Effector Cell;Endogenous Retroviruses;Engraftment;Equus caballus;expression cloning;FCGR3B gene;first-in-human;flasks;fludarabine;follow-up;Future;gene induction;Genes;genetic manipulation;genetically modified cells;Goals;Graft Rejection;Hematologic Neoplasms;Homing;Human;Hypoxia;Hypoxia Inducible Factor;Immunity;Immunodeficient Mouse;Immunologics;immunotherapy trials;improved;In Vitro;in vivo;Infusion procedures;insight;Institutional Review Boards;Kidney Neoplasms;Laboratory Research;leukemia;Ligands;Malignant Epithelial Cell;Malignant Neoplasms;Mediating;Metastatic Renal Cell Cancer;Methods;Minor;Monoclonal Antibodies;Multiple Myeloma;Multivariate Analysis;Natural Killer Cells;Neoplasm Metastasis;neoplastic cell;Neutropenia;neutrophil;Non-Neoplastic Hematologic and Lymphocytic Disorder;Normal tissue morphology;novel;overexpression;paroxysmal nocturnal hemoglobinuria;participant enrollment;Patients;Pattern;Peptides;peripheral blood;phase 1 study;Phase I Clinical Trials;Phenotype;Population;post-transplant;prevent;primary endpoint;Production;programs;Proteins;Proviruses;Recovery;Refractory;Regimen;Renal Carcinoma;Renal Cell Carcinoma;Reporting;Research Personnel;Retroviridae;Risk Reduction;Secondary to;selective expression;Serology;Solid Neoplasm;Source;Specificity;Speed;Stem cell transplant;stem cells;Survival Rate;System;T-Cell Depletion;T-Cell Receptor Therapy;T-Lymphocyte;Testing;TNFSF10 gene;transcription factor;Transfusion;Translational Research;Transplant Recipients;Transplantation;tumor;Tumor Antigens;Tumor Immunity;Umbilical Cord Blood;Umbilical Cord Blood Transplantation;Universities;VHL Gene Inactivation;Viral;Whole-Body Irradiation;Work,Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders,2345,NA,NA,NA,NA,24,NA,NA,4926222,NA
11200748,ZIA,HL,1,N,NA,NA,NA,NA,ZIAHL006271,NA,NA,1ZIAHL006271-03,NHLBI:259275\,INTRAMURAL RESEARCH,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,6792853 (contact),"CHILDS, RICHARD  (contact)",NA,NA,NA,Anemia;Clinical Trials;cytopenia;Dose;Immune;Immune response;Mediating;Monitor;participant enrollment;Patients;Pharmaceutical Preparations;Phosphotransferases;post-transplant;primary outcome;Resolution;response;SYK gene;Thrombocytopenia;Toxic effect;week trial,Fostamatinib to Treat Post-Transplant Immune-mediated Cytopenias,6271,NA,NA,NA,NA,3,NA,NA,259275,NA
11200749,ZIA,LM,1,N,NA,NA,NA,NA,ZIALM202401,NA,NA,1ZIALM202401-01,NLM:22991\,INTRAMURAL RESEARCH,2024,NATIONAL LIBRARY OF MEDICINE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL LIBRARY OF MEDICINE,NA,NA,NA,80003613 (contact),"SCHEUERMANN, RICHARD  (contact)",NA,NA,NA,analysis pipeline;artificial intelligence method;cell type;Cells;Characteristics;Communities;comparative;computer based Semantic Analysis;Data;data format;data repository;Development;Diagnostic;diagnostic biomarker;differential expression;Disease;Elements;epigenomics;experimental study;Exposure to;Extramural Activities;Funding;Gene Expression;Genes;Genetic Markers;Goals;graph database;high throughput analysis;Individual;interoperability;Intramural Research;Knowledge;knowledgebase;Link;Literature;Metadata;Natural Language Processing pipeline;novel diagnostics;Output;Pathway interactions;Pattern;Peer Review;Pharmaceutical Preparations;Phenotype;phenotypic data;Preparation;Process;Production;Publications;Publishing;PubMed;Reporting;repository;Research;Resources;response;Sampling;Semantics;single cell genomics;Source;Specimen;Standardization;Stream;Structure;Technology;Text;therapeutic target;Therapeutic Uses;Tissues;transcriptomics;United States National Institutes of Health;United States National Library of Medicine;whole genome,Analysis and semantic representation of cell phenotype characteristics,202401,NA,NA,NA,NA,1,NA,NA,22991,NA
11200751,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003039,NA,NA,1ZIANS003039-18,NINDS:1016097\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,1887151 (contact),"DIAMOND, JEFFREY S (contact)",NA,NA,NA,Action Potentials;analog;Anatomy;base;Behavior;Calcium Channel;Cells;Characteristics;Communication;Dependence;Docking;Electron Microscopy;electron tomography;Electroretinography;Ensure;experimental study;Freezing;Functional disorder;Goals;Heterogeneity;In Vitro;Light;Manuscripts;Mediating;Membrane Potentials;Morphology;mouse model;nanometer resolution;neural network;Neurons;Output;Pathologic;Physiological;Population;pressure;presynaptic;Presynaptic Terminals;Probability;Process;Retina;Retinal Ganglion Cells;Retinitis Pigmentosa;ribbon synapse;Rod;Role;Signal Pathway;signal processing;Signal Transduction;Site;Specificity;Structure;Synapses;Synaptic Membranes;Synaptic Transmission;Synaptic Vesicles;Testing;Tissues;Vesicle;vesicular release;Vision;Visual;visual processing;voltage;Work,Synaptic Mechanisms in the Mammalian Retina,3039,NA,NA,NA,NA,18,NA,NA,1016097,NA
11200752,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS003145,NA,NA,1ZIANS003145-11,NINDS:1016097\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,1887151 (contact),"DIAMOND, JEFFREY S (contact)",NA,NA,NA,Algorithms;Amacrine Cells;Biological Models;Blood capillaries;Blood Vessels;Book Chapters;Calcium Signaling;cell type;Cells;Complex;Cone;Darkness;Data;Dopamine;experimental study;Feedback;ganglion cell;Gap Junctions;Genetic;Goals;graduate student;Image;Individual;Inherited;interest;Journals;Learning;Light;Machine Learning;Manuscripts;Mediating;Methods;Morphology;Muller&apos;s cell;Mus;Neurons;Output;Pathway interactions;Pericytes;Photophobia;Physiological;Preparation;presynaptic;Process;Publishing;response;Retina;Rod;signal processing;Signal Transduction;Stimulus;Synapses;synaptic inhibition;tool;Visual;visual processing;Work,Circuit function and visual signal processing in the retina,3145,NA,NA,NA,NA,11,NA,NA,1016097,NA
11200804,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00043,NA,NA,75N93024D00043-0-759302400003-1,NIAID:496800\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LOGAN,UNITED STATES,NA,01,072983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,NA,80000513 (contact),"COOK, MIKAYLA  (contact)",NA,2024-09-24,2025-09-23,"Avian Influenza;Birds;Contracts;Development;Evaluation;Human;infectious disease model;Influenza A virus;Influenza A Virus, H1N1 Subtype;Influenza A Virus, H5N1 Subtype;Influenza B Virus;influenza virus strain;mouse model;pandemic potential;seasonal influenza;therapeutic development;therapeutic evaluation",Task A04: Mouse Models for Evaluation of Therapeutics against Human Seasonal Influenza and Avian Influenza Strains with Pandemic Potential,0,NA,NA,NA,NA,NA,NA,NA,496800,NA
11200820,N01,AI,NA,N,NA,NA,NA,NA,75N93021D00027,NA,NA,75N93021D00027-0-759302400001-1,NIAID:3850000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,HINCKLEY,UNITED STATES,NA,07,966783706,US,10023022,"ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.",OH,442339801,NA,80000489 (contact),"WRIGHT, TED  (contact)",NA,2024-09-16,2029-08-31,clinical application;Clinical Research;Clinical Trials;Communicable Diseases;Contracts;Good Clinical Practice;National Institute of Allergy and Infectious Disease;Operations Research;programs;quality assurance;Regulation;Research;response;Support Contracts;Vendor,Vendor Audit Support Through the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP) Contract,0,NA,NA,NA,NA,NA,NA,NA,3850000,NA
11200824,N01,AI,NA,N,NA,NA,NA,NA,75N93021D00027,NA,NA,75N93021D00027-0-759302400001-2,NIAID:5264944\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,HINCKLEY,UNITED STATES,NA,07,966783706,US,10023022,"ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.",OH,442339801,NA,80000489 (contact),"WRIGHT, TED  (contact)",NA,2024-09-16,2029-08-31,clinical application;Clinical Research;Clinical Trials;Communicable Diseases;Contracts;Good Clinical Practice;National Institute of Allergy and Infectious Disease;Operations Research;programs;quality assurance;Regulation;Research;response;Support Contracts;Vendor,Vendor Audit Support Through the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP) Contract,0,NA,NA,NA,NA,NA,NA,NA,5264944,NA
11200837,N01,AI,NA,N,NA,NA,NA,NA,272201800007I,NA,NA,272201800007I-0-759302400002-1,NIAID:85320\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAINT CHARLES,UNITED STATES,NA,02,078652667,US,10089014,"EUROFINS PANLABS, INC.",MO,633045685,NA,79992463 (contact),"BODE, JACOB  (contact)",NA,2018-05-01,2025-04-30,Antimicrobial Resistance;Biological;Biological Assay;Chemistry;Combating Antibiotic Resistant Bacteria;Communicable Diseases;Development;Development Plans;Drug Kinetics;Evaluation;Gram-Negative Bacteria;Gram-Positive Bacteria;In Vitro;in vivo;Interventional Agent Development;Lead;lead optimization;manufacture;pathogen;pre-clinical;product development;programs;Property;Rodent;Safety;screening;Services;Therapeutic;therapeutic development;Toxicology;Toxin,"Task E14: Lead Optimization Screening Assays for ADMET, Safety Profiling, Rodent Pharmacokinetics and MTD",0,NA,NA,NA,NA,NA,NA,NA,85320,NA
11200894,K08,CA,7,N,2024-12-20,2024-11-01,2025-06-30,398,K08CA286765,NA,PA-24-254,7K08CA286765-02,NCI:172190\,OTHER RESEARCH-RELATED,2024,NATIONAL CANCER INSTITUTE,NA,BUFFALO,UNITED STATES,NA,26,824771034,US,3934901,ROSWELL PARK CANCER INSTITUTE CORP,NY,142630001,"PROJECT NARRATIVE Despite optimization of intensive multi-agent chemotherapy regimens, infants with B-cell acute lymphoblastic leukemia (ALL), most often characterized by chromosomal rearrangements involving KMT2A (KMT2A-R), have aggressive disease and dismal outcomes. Chimeric antigen receptor T cells targeting CD19 (CD19CART) have demonstrated unprecedented efficacy in children with relapsed or refractory pediatric ALL; however, many CD19CART-treated patients will experience ALL relapse after initial response. This study aims to improve immunotherapeutic treatment of KMT2A-R ALL by investigating rational combinatorial therapeutic approaches with CD19CART and small molecule inhibitors that target key biologic vulnerabilities of this high-risk pediatric leukemia subtype.",11165605 (contact),"NISWANDER, LISA MADALEN (contact)","BIAN, YANSONG",2024-07-17,2029-06-30,NA,Leveraging small molecule inhibitors to improve CD19 CAR T cell immunotherapy for KMT2A-rearranged ALL,286765,NCI,Career Development Study Section (J)[NCI-J],NA,NA,2,159435,12755,172190,NA
11200917,Y01,OD,NA,N,NA,NA,NA,NA,AOD23050001,NA,NA,AOD23050001-1-0-2,OD:3340000\,INTERAGENCY AGREEMENTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,(contact),NA,NA,NA,Advisory Committees;Advocate;Agreement;All of Us Research Program;Biomedical Research;cohort;Data;Data Aggregation;data quality;design;Disease;Evaluation;experience;Goals;handheld mobile device;Health;health administration;Health Personnel;Healthcare;Individual;Knowledge;Mediator;Modeling;Observational Study;Participant;patient engagement;precision medicine;preference;programs;Provider;Quality Control;Research;Source;United States Department of Veterans Affairs;United States National Institutes of Health;Veterans Health Administration;volunteer;wearable device;working group,IAA between the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) and National Institutes of Health (NIH),230500,NA,NA,NA,NA,NA,NA,NA,3340000,NA
11200931,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00016,NA,NA,75N95022D00016-0-759502400002-1,NIMH:376358\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,RESEARCH TRIANGLE PARK,UNITED STATES,NA,04,004868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,NA,79829720 (contact),"MASCARELLA, WAYNE  (contact)",NA,2024-06-16,2025-06-15,Agonist;antagonist;Area;Basic Science;Behavioral;Biochemical;Brain imaging;Central Nervous System;chemical synthesis;Clinical Research;Clinical Trials;drug distribution;drug of abuse;Functional Magnetic Resonance Imaging;Good Manufacturing Process;Human;Legal patent;Ligands;Longitudinal Studies;Mental Health;Molecular;National Institute of Mental Health;novel;Pharmaceutical Preparations;Pharmacology;Positron-Emission Tomography;Primates;programs;Psychotropic Drugs;Radiolabeled;receptor;Signal Transduction;single photon emission computed tomography;Source,"NIMH SYNTHESIS AND DISTRIBUTION OF DRUGS OF ABUSE AND RELATED COMPOUNDS. JUNE 16, 2024 - JUNE 15, 2025. TASK ORDER 75N95024F00002 (TO7). N01DA-22-8944.",0,NA,NA,NA,NA,NA,NA,NA,376358,NA
11200934,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-1,NCI:12869612\OD:374922\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,80003717 (contact),"DMITROVSKY, ETHAN  (contact)",NA,2024-09-28,2025-08-30,Acquired Immunodeficiency Syndrome;Area;Budgets;Computers;Contract Services;Contractor;Contracts;data management;Development;Diagnosis;Funding;Head;Health;HIV Infections;HIV/AIDS;Human Herpesvirus 8;improved;In Vitro;in vivo;International;Laboratory Animal Science;Libraries;Maintenance;Malignant Neoplasms;Modeling;Molecular Virology;multidisciplinary;nonhuman primate;Office of Administrative Management;operation;Prevention;Principal Investigator;programs;repaired;repository;Research;research and development;Safety;Satellite Viruses;Services;statistical service;Technology;tumor;Viral Epidemiology;Virus;Work,AIDS AND CANCER VIRUS PROGRAMS (ACVP),0,NA,NA,NA,NA,NA,NA,NA,13244534,NA
11201113,U54,CA,3,N,2024-10-02,2024-09-01,2025-08-31,NA,U54CA221704,NA,PA-20-272,3U54CA221704-07S1,NCI:200000\,RESEARCH CENTERS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,12,620127915,US,1605019,HUNTER COLLEGE,NY,100655024,NA,10812477 (contact),"KRAMPIS, KONSTANTINOS  (contact)","SAN MIGUEL-MAJORS, SANDRA L",2018-09-18,2028-08-31,Acceleration;Address;Advanced Malignant Neoplasm;African;Algorithms;American;Applications Grants;Artificial Intelligence;artificial intelligence algorithm;Asian;Bioinformatics;biological systems;Biometry;Biostatistics Core;Cancer Biology;cancer genetics;cancer health disparity;cancer prevention;career;Cell division;ChIP-seq;Clinical;clinical application;Clinical Informatics;Clinical Trials;Collaborations;Collection;Communities;computer infrastructure;Consultations;cost effective;Data;Data Analyses;Data Protection;data resource;Data Set;Database Management Systems;Development;Diverse Workforce;DNA sequencing;Doctor of Philosophy;Education;Environment;Epigenetic Process;epigenomics;Equity;ethnic minority population;experience;Experimental Designs;Fostering;Funding;Future;Genetic;Genomics;Goals;Grant;graph neural network;Health Disparities Research;High Performance Computing;Informatics;Infrastructure;innovation;Institution;instrument;interest;Investigation;Knowledge Extraction;Laboratories;Latinx;Leadership;Link;Machine Learning;Malignant Neoplasms;Manuscripts;Medical Genetics;member;Methods;minority investigator;minority trainee;Mission;Molecular;Multiomic Data;New Jersey;New York City;novel;Phase;Philadelphia;Pilot Projects;Play;Population Sciences;preclinical study;Productivity;protein function;protein protein interaction;Proteins;Proteomics;Publishing;Qualitative Research;racial minority population;Research;Research Design;Research Methodology;Research Personnel;Research Project Grants;Research Proposals;Research Support;Research Training;Resource Sharing;Retrieval;Ribosomal RNA;Role;Science;Secure;Services;single-cell RNA sequencing;skills;software development;statistics;Students;Surface;System;systemic barrier;Technology;tool;Training;transcriptome sequencing;Underrepresented Minority;Writing,Biostatistics and Bioinformatics Core (BBC),221704,ZCA1,ZCA1,5083,S1,7,127389,72611,NA,200000
11201133,R21,GM,7,N,2024-11-28,2024-09-02,2025-06-30,859,R21GM150136,NA,PA-24-254,7R21GM150136-03,NIGMS:206897\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,Fairfax,UNITED STATES,NA,11,054427455,US,1274802,INOVA HEALTH CARE SERVICES,VA,220314868,"Project Narrative This project will contribute to the field by creating small volume sample collection, processing, and storage practices that are rigorous, reproducible, and validated for use in multi-omic studies. We will use machine learning methods to develop new models of neonatal sepsis from stool, blood, skin, and saliva for detection, differential diagnoses, and/or prediction of systemic inflammatory to infection. Our multi-omic network will establish molecular targets (pathways, genes, and metabolites) for future experimental studies to validate proposed causal mechanisms in sepsis progression and recovery.",16503604 (contact),"PRESCOTT, STEPHANIE  (contact)","ZHAO, XIAOLI",2023-07-03,2025-06-30,NA,The Scientific Value of Premature Infant Biospecimens Collection,150136,ICSC,Interdisciplinary Clinical Care in Specialty Care Settings Study Section[ICSC],NA,NA,3,140630,66267,206897,NA
11201149,N01,AI,NA,N,NA,NA,NA,NA,75N93019C00071,NA,NA,75N93019C00071-P00024-9999-2,NIAID:2451280\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,BOSTON,UNITED STATES,NA,07,149617367,US,3212904,HARVARD SCHOOL OF PUBLIC HEALTH,MA,021156028,NA,79944283 (contact),"FORTUNE, SARAH  (contact)",NA,2019-09-30,2025-09-29,Animal Model;Animals;cohort;Computer Models;Goals;HIV;Human;Immune;Immune Evasion;Immune response;Immune Targeting;Immunity;Immunologics;improved;multidisciplinary;Mus;Mycobacterium Infections;Mycobacterium tuberculosis;non-tuberculosis mycobacteria;nonhuman primate;programs;Research Activity;Research Personnel;response;Sampling;SIV;Technology;Testing;Tissues;Translating;Tuberculosis;Tuberculosis Vaccines;vaccine strategy,Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB),0,NA,NA,NA,NA,NA,NA,NA,2451280,NA
11201171,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00054,NA,NA,75N93024C00054-0-9999-1,NIAID:1504937\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,PHOENIX,UNITED STATES,NA,03,118069611,US,10001715,TRANSLATIONAL GENOMICS RESEARCH INST,AZ,850042274,NA,80000495 (contact),"ALTIN, JOHN  (contact)",NA,2024-09-30,2025-09-29,Africa South of the Sahara;African;Alleles;alpha-beta T-Cell Receptor;Antigens;Bar Codes;Binding;Biological Assay;burden of illness;CD4 Positive T Lymphocytes;Clonal Expansion;cohort;Complex;Contractor;Data;Dimensions;Disease;DNA;Epitopes;Generations;HLA Antigens;innovation;Length;Link;Location;Maps;Measures;Mycobacterium tuberculosis;Mycobacterium tuberculosis antigens;novel;pathogen genome;Pathogenesis;Peptides;Peripheral Blood Mononuclear Cell;Phenotype;Population;Proteins;Proteome;Resources;Role;Sampling;single cell sequencing;Specific qualifier value;Specificity;T cell response;T-cell receptor repertoire;T-Lymphocyte;T-Lymphocyte Epitopes;Testing;Time;transcriptome;Tuberculosis;two-dimensional;Validation,MYCOBACTERIUM TUBERCULOSIS PROTEOME-WIDE EPITOPE DISCOVERY AND HOST TRANSCRIPTOME-WIDE T CELL PHENOTYPING IN HIGH DISEASE BURDEN POPULATIONS,0,NA,NA,NA,NA,NA,NA,NA,1504937,NA
11201259,N01,DA,NA,N,NA,NA,NA,NA,271201500005I,NA,NA,271201500005I-0-759502400001-1,NINDS:1089593\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ALBANY,UNITED STATES,NA,20,787793900,US,3294801,"ALBANY MOLECULAR RESEARCH, INC.",NY,122035121,NA,79988545 (contact),"MEITZ, SUSAN  (contact)",NA,2024-09-17,2030-09-16,Acceleration;analytical method;Clinical Trials;Contractor;Contracts;Data;Development;Documentation;Dosage Forms;drug candidate;drug development;drug distribution;early phase clinical trial;efficacy study;Formulation;good laboratory practice;Good Manufacturing Process;Grant;Human;Investigational Drugs;Investigational New Drug Application;Label;manufacture;method development;novel therapeutics;Pharmaceutical Preparations;Pharmacologic Substance;preclinical efficacy;Preparation;Process;Production;programs;Regulation;small molecule;support network;Testing;Toxicology;United States Food and Drug Administration;United States National Institutes of Health;Validation;Work,BPN PROJECT BPN-36938,0,NA,NA,NA,NA,NA,NA,NA,1089593,NA
11201334,K01,DK,7,N,2024-11-29,2024-12-01,2025-04-30,847,K01DK125639,SCHOOLS OF VETERINARY MEDICINE,PAR-18-419,7K01DK125639-06,NIDDK:103879\,OTHER RESEARCH-RELATED,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,RALEIGH,UNITED STATES,VETERINARY SCIENCES,02,042092122,US,578204,NORTH CAROLINA STATE UNIVERSITY RALEIGH,NC,276957514,Project Narrative The vital single-cell lining (epithelium) of digestive organs is sustained by cells that lie beneath it (mesenchyme) and provide known and unknown signals. This proposal aims to provide new insights into the mesenchymal compartment’s role during fetal development and restoration of intestinal stem cells after lethal cell injury. The studies will improve understanding of how interactions between the epithelium and mesenchyme may be harnessed in the future to develop new treatment approaches toward inflammatory bowel disorders and cancers.,10253703 (contact),"MCCARTHY, NEIL  (contact)","SASLOWSKY, DAVID E",2020-07-17,2025-04-30,Ablation;Address;Adult;Agonist;Anatomy;antagonist;base;Biological Assay;Biology;Birth;Bone Morphogenetic Proteins;Cancer Etiology;CD81 gene;cell injury;Cell Line;Cell Separation;cell type;Cells;Cessation of life;Coculture Techniques;Colorectal Cancer;Constitution;crypt cell;Data;Development;Disease;Elements;Embryo;Environment;epithelial repair;Epithelium;Equilibrium;Exhibits;experimental study;fetal;Fetal Development;Fingers;Future;Gene Expression Profile;Genetic;Growth;Growth Factor;Homeostasis;improved;In Vitro;in vivo;Inflammatory Bowel Diseases;Injury;insight;intestinal crypt;intestinal epithelium;intestinal homeostasis;Intestines;Knock-out;Ligands;Malignant Neoplasms;Mesenchymal;Mesenchyme;Methods;Microscopy;Molecular;Molecular Profiling;Mus;Natural regeneration;novel;novel therapeutic intervention;Organ;Organoids;Pathway interactions;PDGFRA gene;Population;Process;progenitor;Proliferating;protein function;Protein Inhibition;Reaction;Recombinants;regenerative;Regenerative response;Regulation;Resolution;response;Rest;restoration;Role;Signal Transduction;Signaling Protein;single-cell RNA sequencing;Small Intestines;Stem Cell Development;stem cell homeostasis;stem cell niche;stem cell proliferation;stem cell self renewal;stem cells;Structure;Testing;Tissues;transcriptome sequencing;Tube;United States;Villous;Villus,Mesenchymal regulation of fetal intestinal development and adult regeneration,125639,DDK,Digestive Diseases and Nutrition C Study Section[DDK-C],NA,NA,6,96184,7695,103879,NA
11201474,R01,AT,7,N,2024-12-24,2024-12-20,2025-05-31,213,R01AT011772,SCHOOLS OF MEDICINE,PA-24-254,7R01AT011772-04,NCCIH:436220\,NON-SBIR/STTR RPGS,2024,NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH,NA,LA JOLLA,UNITED STATES,PSYCHIATRY,50,804355790,US,577507,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",CA,920930621,"PROJECT NARRATIVE Millions of Americans suffer from chronic pain, opioid misuse, and opioid use disorder. New intervention strategies that integrate mindfulness, physical therapy, and/or medications for opioid use disorder (MOUD) are needed to improve health outcomes in these vulnerable patients. To accomplish this aim, we propose the Opioid and Pain Effectiveness research Network for Mindfulness and Integrative Health Intervention Development (OPEN-MIIND), a multidisciplinary research center dedicated to addressing the opioid crisis.",11725793 (contact);10407478,"GARLAND, ERIC LEE (contact);ZEIDAN, FADEL","QUINLAN, ERIN BURKE",2022-09-01,2027-05-31,NA,Analgesic and Opioid Sparing Brain Mechanisms of Mindfulness-Oriented Recovery Enhancement for Chronic Low Back Pain,11772,BMHO,Biobehavioral Medicine and Health Outcomes Study Section[BMHO],NA,NA,4,274352,161868,436220,NA
11201661,ZIA,DK,1,N,NA,NA,NA,NA,ZIADK075186,NA,NA,1ZIADK075186-01,OD:238880\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,6570188 (contact),"TYCKO, ROBERT  (contact)",NA,NA,NA,Acquired Immunodeficiency Syndrome;Capsid;Capsid Proteins;Dependence;Electron Microscopy;Equipment;Freezing;Funding;gag Gene Products;HIV-1;innovation;Intramural Research Program;Laboratories;light scattering;Measurement;Methods;microwave electromagnetic radiation;Molecular;Molecular Structure;monomer;National Institute of Diabetes and Digestive and Kidney Diseases;nephelometry;novel;Nuclear Magnetic Resonance;Peptide Hydrolases;Phytic Acid;Preparation;Process;programs;Research;Sampling;self assembly;solid state nuclear magnetic resonance;Source;Time;Virion;X-Ray Crystallography,Time-resolved studies of HIV-1 capsid protein self-assembly,75186,NA,NA,NA,NA,1,NA,NA,238880,NA
11201662,ZIA,DK,1,N,NA,NA,NA,NA,ZIADK075187,NA,NA,1ZIADK075187-01,OD:427000\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,9415259 (contact),"BEWLEY, CAROLE  (contact)",NA,NA,NA,Affinity;Animal Model;Antibodies;antibody-dependent cell cytotoxicity;Bacterial Antibodies;Binding;biophysical analysis;Cells;Complement-Dependent Cytotoxicity;Complex;design and construction;Drug Kinetics;glycosylation;Goals;HIV;HIV envelope protein;HIV Envelope Protein gp120;HIV Infections;HIV/AIDS;IgG Receptors;Immune response;improved;In Vitro;in vivo;inhibitor;Kinetics;Lectin;Link;Mammalian Cell;Mannose;milligram;nanomolar;Neonatal;neonatal Fc receptor;novel;Oligosaccharides;Parents;Plasma;Plasmids;Polysaccharides;prevent;Process;Production;Proteins;receptor;Research;Serum;Signal Transduction;Surface;Surface Plasmon Resonance;Testing;Toxicity Tests;Work,Antibody-protein conjugates as inhibitors of HIV/AIDS,75187,NA,NA,NA,NA,1,NA,NA,427000,NA
11201811,N02,HD,NA,N,NA,NA,NA,NA,75N94024P00710,NA,NA,75N94024P00710-0-0-1,NICHD:117500\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,OAKLAND,UNITED STATES,NA,12,128663390,US,1618201,PUBLIC HEALTH INSTITUTE,CA,946074046,NA,80002105 (contact),"YOUNG HOLT, BETHANY  (contact)",NA,2024-09-30,2025-09-29,Anti-Infective Agents;Architecture;Archives;Bacterial Vaginosis;Chlamydia;Congresses;Contraceptive Agents;Contraceptive methods;Contracts;Data;data dictionary;Data Sources;data standards;data submission;Databases;design;Development;Evaluation;experience;Funding Agency;Goals;HIV;HIV Infections;informant;information gathering;interest;Interview;Maintenance;men;National Institute of Child Health and Human Development;novel;Participant;pathogen;Peer Review;Phase;Population;Pregnancy;prevent;Prevention;Preventive;Property;Publishing;Research;Research Personnel;Resources;Series;sexual and reproductive health;Sexually Transmitted Diseases;Source;STI prevention;Structure;System;system architecture;Technology;technology development;Testing;Travel;Update;Woman;Work,DEVELOPING A DATABASE FOR SEXUALLY TRANSMITTED INFECTIONS (STI) PREVENTATIVES TO FACILITATE INFORMATION EXCHANGE FOR MULTIPURPOSE PREVENTION TECHNOLOGIES of Contraception Research,0,NA,NA,NA,NA,NA,NA,NA,117500,NA
11201899,Y01,ES,NA,N,NA,NA,NA,NA,AES23006001,NA,NA,AES23006001-1-0-1,NIEHS:398286\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,NA,"Characterizing occupational exposures provides a real-world context for NIEHS toxicology studies. To achieve this, NIOSH will characterize occupational exposures using a multidisciplinary approach to include toxicology, epidemiology, engineering, industrial science, and occupational medicine. These studies contribute to the prevention of diseases or adverse effects caused by environmental exposure to chemical or physical agents by identifying sources of exposure and strategies for mitigation.",NA,(contact),NA,NA,NA,Adverse effects;Agreement;Air;air monitoring;analytical method;Animal Model;chemical property;Chemicals;Cholesterol;Communication;Complement;Construction Materials;consumer product;Contracts;design;Development;disorder prevention;Electronic Mail;Engineering;Enrollment;Environment;Environmental Exposure;Epidemiology;exposed human population;Exposure to;Food Handling;Goals;Government;Hazard Assessment;Hazard Identification;Health;Human;in vivo;Industrialization;Industry;insight;interdisciplinary approach;Manuals;Marketing;Medical Device;Methodology;Methods;National Institute of Environmental Health Sciences;Occupational;Occupational Exposure;Occupational Medicine;Outcome;Participant;perfluorooctane;perfluorooctanoic acid;pharmacokinetic model;physical property;Poly-fluoroalkyl substances;Population;Preparation;Production;recruit;Recruitment Activity;Research;Research Priority;Research Proposals;Resistance;Review Literature;sample collection;Sampling;Science;Site Visit;Source;Stains;Sulfate;symposium;Telephone;Textiles;Thyroid Function Tests;Toxicology;Workplace,Occupational Exposure Assessment of Emerging Per- and Polyfluoroalkyl Substances (PFAS),230060,NA,NA,NA,NA,NA,NA,NA,398286,NA
11201912,R03,EB,7,N,2024-10-23,2024-08-19,2025-03-31,286,R03EB034817,NA,PA-20-200,7R03EB034817-02,NIBIB:73000\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING,NA,COLORADO SPRINGS,UNITED STATES,NA,05,186192829,US,1199903,UNIVERSITY OF COLORADO,CO,809183733,NARRATIVE Current approaches do not have enough resolution to distinguish the heterogeneity of the identical NPs’ PC composition. In this study we aim to develop a highly sensitive MagLev system to probe the small variations in the PC composition of the same identical NPs in terms of number and/or type of the proteins.,78217315 (contact),"ASHKARRAN, ALIAKBAR  (contact)","CHEN, JERMONT",2024-05-01,2026-03-31,Adsorption;analytical tool;Biochemistry;Biodistribution;Biologic Characteristic;Biological;Biophysics;Blood;clinical translation;Communication;Complex;Core Facility;Data;density;Development;Devices;Diagnostic;Equilibrium;Evolution;Exposure to;Failure;Goals;Height;Heterogeneity;Human;in vivo;Knowledge;liquid chromatography mass spectroscopy;Liquid substance;Literature;Magnetism;Masks;Mass Spectrum Analysis;Measurement;Methods;Minor;Modeling;Morphologic artifacts;nanomaterials;nanomedicine;nanoparticle;Nature;Nylons;Outcome;particle;Physiology;Plasma;Population;portability;Predictive Factor;Preparation;Procedures;Process;Property;Protein Analysis;Proteins;Proteomics;prototype;Publications;Research;Resolution;rho;Rotation;Safety;Serum;Structure;success;Surface;System;Techniques;therapeutic nanoparticles;tool;Treatment Efficacy;Variant,Heterogeneity of protein corona (PC) composition using highly sensitive magnetic levitation (MagLev) system,34817,ZRG1,Special Emphasis Panel[ZRG1-BBBT-M(82)S],NA,NA,2,50000,23000,73000,NA
11202211,P20,GM,5,N,2024-09-18,2024-09-20,2025-07-31,NA,P20GM113126,NA,PAR-19-312,5P20GM113126-09,NIGMS:164139\,RESEARCH CENTERS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,LINCOLN,UNITED STATES,NA,01,555456995,US,578103,UNIVERSITY OF NEBRASKA LINCOLN,NE,685032427,NA,15236672 (contact),"SHAW, JARED BRYAN (contact)","CUPIT, PAULINE",2024-09-20,2026-07-31,Amines;Amino Acids;analytical method;Antibodies;Antibody Diversity;Antibody Response;Area;B-Lymphocytes;Base Pairing;Biological;biopharmaceutical industry;C-terminal;Cells;Charge;Chemicals;Clone Cells;Communication;Communities;Complementarity Determining Regions;Complex;cost;Cysteine;Derivation procedure;Detection;Development;Digestion;Dimensions;Discipline;Dissociation;disulfide bond;Electrons;emerging pathogen;Ensure;experimental study;Gases;Health;Higher Order Chromatin Structure;Human;Hybridomas;Hybrids;Immune response;Immunoglobulin Fragments;Immunooncology;Immunotherapy;improved;informatics tool;innovation;instrument;instrumentation;ionization;Ions;Light;Malignant Neoplasms;mass spectrometer;Methods;Modeling;Monoclonal Antibodies;Nebraska;novel;Patients;Peptides;Performance;Phase;polyclonal antibody;Preparation;Proteins;Proteome;Proteomics;Quality Control;Resources;Sampling;Serum;tandem mass spectrometry;Techniques;Technology;Therapeutic antibodies;Therapeutic Monoclonal Antibodies;therapeutic protein;Time;ultraviolet;Vaccines,De novo proteomics platform for therapeutic antibody discovery,113126,ZGM1,ZGM1-RCB-3(C2),9700,NA,9,105263,58876,NA,164139
11202280,N01,HD,NA,N,NA,NA,NA,NA,75N94020D00003,NA,NA,75N94020D00003-0-759402400003-1,NICHD:2369376\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,MENLO PARK,UNITED STATES,NA,16,009232752,US,8042701,SRI INTERNATIONAL,CA,940253493,NA,80000522 (contact),"BURNIN, DEBRA  (contact)",NA,2024-09-23,2026-09-22,ADME Study;androgenic;Androgens;Animal Model;Animals;Area;Biological Products;Biological Testing;Blood;candidate identification;chemical synthesis;Chemicals;Chronic;Clinical;clinical lot;Clinical Research;Clinical Trials;Clinical Trials Network;Contraceptive Agents;Contraceptive Devices;Contraceptive methods;Contractor;Contracts;Data;design;Development;Devices;drug candidate;drug development;Drug Evaluation;Drug Formulations;Drug Kinetics;Embryonic Development;Endocrine;Enrollment;estrogenic;Evaluation;Excretory function;Female Contraceptive Agents;Fertility;Formulation;Goals;good laboratory practice;Good Manufacturing Process;Hormones;In Vitro;in vitro Assay;in vivo;Injectable;Investigational New Drug Application;Levonorgestrel;lot production;Male Contraceptive Agents;manufacture;men;Metabolic;Methods;Microsomes;Mission;Modeling;National Institute of Child Health and Human Development;new chemical entity;novel;novel therapeutics;Oral;Ovulation;Pharmaceutical Preparations;Pharmacodynamics;pharmacokinetics and pharmacodynamics;Pharmacologic Substance;Pharmacology;Phase;Plasma;Play;population health;pre-clinical;preclinical development;preclinical study;Process;Prodrugs;product development;Production;Progestins;Program Development;programs;Property;Proteins;Protocols documentation;recruit;Report (document);Research;research and development;research clinical testing;Research Personnel;Research Support;Role;Route;Safety;screening;Services;sperm cell;sperm function;stability testing;System;Testing;Tissues;Toxic effect;Toxicokinetics;Toxicology;Woman;Work,BIOLOGICAL TESTING FACILITY (BTF) – GOOD LABORATORY PRACTICE (GLP) TOXICOLOGY AND FERTILITY AND EARLY EMBRYONIC DEVELOPMENT (FEED) STUDIES AND PRECLINICAL STUDIES OF CONTRACEPTIVES,0,NA,NA,NA,NA,NA,NA,NA,2369376,NA
11202302,N01,AI,NA,N,NA,NA,NA,NA,75N93022D00016,NA,NA,75N93022D00016-P00002-759302300001-2,NIAID:245549\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,FREDERICK,UNITED STATES,NA,06,014130053,US,10001472,"DYNPORT VACCINE COMPANY, LLC",MD,217024734,NA,79597441 (contact),"LONG, CASEY  (contact)",NA,2023-05-15,2024-10-07,clinical trial implementation;Clinical Trials;Clinical Trials Unit;Communicable Diseases;COVID-19 therapeutics;Dose;Double-Blind Method;early phase clinical trial;Intervention;Investigation;National Institute of Allergy and Infectious Disease;New Agents;phase 1 study;Phase I Clinical Trials;Placebo Control;Prevention;Randomized;Study Subject,"Task C1: A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of SARS-CoV-2 Therapeutics",0,NA,NA,NA,NA,NA,NA,NA,245549,NA
11202303,N01,AI,NA,N,NA,NA,NA,NA,75N93022D00015,NA,NA,75N93022D00015-0-759302400001-1,NIAID:3205231\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,CARY,UNITED STATES,NA,02,117578942,US,10089011,ALLUCENT GOVERNMENT SERVICES (US) LLC,NC,275135756,NA,79943966 (contact),"BRUCE, MCCLENATHAN  (contact)",NA,2024-08-15,2024-11-01,clinical trial implementation;Clinical Trials;Clinical Trials Unit;Communicable Diseases;early phase clinical trial;Influenza Therapeutic;Intervention;Investigation;New Agents;Phase I Clinical Trials;Prevention,Task C1: Phase I Clinical Trial to Evaluate Influenza Therapeutics,0,NA,NA,NA,NA,NA,NA,NA,3205231,NA
11202351,N01,AI,NA,N,NA,NA,NA,NA,75N93019D00021,NA,NA,75N93019D00021-0-759302400002-1,NIAID:22948\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LOGAN,UNITED STATES,NA,01,072983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,NA,79992488 (contact),"HURST, BRETT  (contact)",NA,2024-09-23,2025-09-22,Advanced Development;Anti-viral Agents;antimicrobial;Biological Assay;Cell Line;Contracts;Development;Human;In Vitro;in vitro testing;Maintenance;Respiratory syncytial virus;respiratory virus;Rhinovirus;therapeutic development;Viral;Virus,Task B25: In Vitro Assessment for Antimicrobial Activity Against Respiratory Viruses,0,NA,NA,NA,NA,NA,NA,NA,22948,NA
11202355,N01,AI,NA,N,NA,NA,NA,NA,75N93019D00021,NA,NA,75N93019D00021-0-759302400002-2,NIAID:206532\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LOGAN,UNITED STATES,NA,01,072983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,NA,79992488 (contact),"HURST, BRETT  (contact)",NA,2024-09-23,2025-09-22,2019-nCoV;Advanced Development;Anti-viral Agents;antimicrobial;Biological Assay;Cell Line;Contracts;Development;In Vitro;in vitro testing;Influenza Therapeutic;Maintenance;Middle East Respiratory Syndrome Coronavirus;respiratory virus;SARS coronavirus;Viral;Virus,"Task B25: In Vitro Assessment for Antimicrobial Activity Against Respiratory Viruses, SARS-CoV-2",0,NA,NA,NA,NA,NA,NA,NA,206532,NA
11202366,N01,AI,NA,N,NA,NA,NA,NA,75N93019D00021,NA,NA,75N93019D00021-P00001-759302300001-2,NIAID:572\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LOGAN,UNITED STATES,NA,01,072983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,NA,79671099 (contact),"HURST, BRETT  (contact)",NA,2023-06-15,2024-06-14,Advanced Development;Anti-viral Agents;antimicrobial;Biological Assay;Cell Line;Contracts;Development;Human;In Vitro;in vitro testing;Maintenance;Respiratory syncytial virus;respiratory virus;therapeutic development;Viral;Virus,Task B19: In Vitro Assessment for Antimicrobial Activity Against Respiratory Viruses,0,NA,NA,NA,NA,NA,NA,NA,572,NA
11202374,N02,DA,NA,N,NA,NA,NA,NA,75N95024D00039,NA,NA,75N95024D00039-0-759502400001-1,NIMH:299108\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,HORSHAM,UNITED STATES,NA,04,064341449,US,3207801,"NATIONAL MEDICAL SERVICES, INC.",PA,190442208,NA,80002010 (contact),"KENDRICK, KRISTIN  (contact)",NA,2024-09-27,2025-09-26,Autopsy;Biological Assay;Blood;Blood specimen;Brain;brain tissue;Cost Savings;Databases;drug of abuse;Ensure;Government;Human;National Institute of Mental Health;Neurosciences Research;Pharmaceutical Preparations;Pharmacologic Substance;Research;Research Personnel;Sampling;screening;Secure;Site;Specimen;Test Result;Testing;testing services;Therapeutic;Tissue Sample;Tissues;Toxic Environmental Substances;Toxicology;United States National Institutes of Health;Vendor,TO PROVIDE THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) WITH NBB TISSUE TOXICOLOGY TESTING SERVICES,0,NA,NA,NA,NA,NA,NA,NA,299108,NA
11202385,N01,NS,NA,N,NA,NA,NA,NA,271201600005I,NA,NA,271201600005I-0-759502400002-1,NIDA:305772\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,WILMINGTON,UNITED STATES,NA,07,362574527,US,4079901,PPD DEVELOPMENT LP,NC,284013331,NA,79882537 (contact),"PEROUTKA, STEPHEN  (contact)",NA,2016-07-08,2026-06-30,Academia;Basic Science;Biotechnology;Chemistry;Clinic;clinical candidate;Clinical Protocols;Clinical Trials;Contractor;Data;Development;Dose;Double-Blind Method;drug development;drug discovery;Drug Formulations;Drug Kinetics;Elements;experience;Funding;Goals;Grant;Human;Institution;Intellectual Property;Lead;Licensing;manufacture;Methamphetamine use disorder;Nervous System;Nervous System Disorder;Neurosciences Research;novel;novel therapeutics;Patients;Pharmaceutical Chemistry;Pharmaceutical Preparations;Phase;Phase I Clinical Trials;phase I trial;placebo controlled study;programs;Property Rights;Protocols documentation;Randomized;Research;research clinical testing;Research Design;Research Personnel;Research Support;Risk;safety assessment;small molecule;success;Testing;Toxicology;Translating;United States National Institutes of Health,"PHASE I RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS",0,NA,NA,NA,NA,NA,NA,NA,305772,NA
11202386,N01,AI,NA,N,NA,NA,NA,NA,272201800002I,NA,NA,272201800002I-0-759302400001-1,NIAID:85231\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,RESEARCH TRIANGLE PARK,UNITED STATES,NA,04,004868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,NA,79759855 (contact),"BLOUGH, BRUCE  (contact)",NA,2024-05-02,2024-11-01,Biological;Chemistry;Communicable Diseases;Development;Development Plans;Drug Kinetics;Evaluation;In Vitro;in vivo;Interventional Agent Development;Lead;manufacture;pathogen;pre-clinical;product development;programs;Safety;scale up;Services;Therapeutic;therapeutic development;Toxicology;Toxin,Task B30: Scale Up Synthesis of VKT-034,0,NA,NA,NA,NA,NA,NA,NA,85231,NA
11202387,N01,AI,NA,N,NA,NA,NA,NA,272201800001I,NA,NA,272201800001I-0-759302400004-1,NIAID:260145\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MENLO PARK,UNITED STATES,NA,16,009232752,US,8042701,SRI INTERNATIONAL,CA,940253493,NA,79944277 (contact),"MIRASILAS, JON  (contact)",NA,2024-08-30,2025-08-29,Biological;Chemistry;Communicable Diseases;Development;Development Plans;Drug Kinetics;Evaluation;In Vitro;in vivo;Interventional Agent Development;Lead;manufacture;pathogen;pre-clinical;product development;programs;Safety;Services;Therapeutic;therapeutic development;Toxicology;Toxin,Task D17: Non-Clinical Services for Development of Interventional Agents for Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,260145,NA
11202402,N01,AI,NA,N,NA,NA,NA,NA,272201800001I,NA,NA,272201800001I-0-759302400005-1,NIAID:452091\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MENLO PARK,UNITED STATES,NA,16,009232752,US,8042701,SRI INTERNATIONAL,CA,940253493,NA,79981695 (contact),"MIRSALIS, JON  (contact)",NA,2024-09-15,2025-09-14,Biological;Chemistry;Communicable Diseases;Development;Development Plans;Drug Kinetics;Evaluation;In Vitro;in vivo;Interventional Agent Development;Lead;manufacture;pathogen;pre-clinical;product development;programs;Safety;Services;Therapeutic;therapeutic development;Toxicology;Toxin,Task D18: Non-Clinical Services for Development of Interventional Agents for Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,452091,NA
11202411,N01,AI,NA,N,NA,NA,NA,NA,272201800007I,NA,NA,272201800007I-0-759302400002-2,NIAID:127980\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAINT CHARLES,UNITED STATES,NA,02,078652667,US,10089014,"EUROFINS PANLABS, INC.",MO,633045685,NA,79992463 (contact),"BODE, JACOB  (contact)",NA,2018-05-01,2025-04-30,Biological;Biological Assay;Chemistry;Communicable Diseases;Development;Development Plans;Drug Kinetics;Evaluation;In Vitro;in vivo;Interventional Agent Development;Lead;lead optimization;manufacture;pathogen;pre-clinical;product development;programs;Property;Rodent;Safety;screening;Services;Therapeutic;therapeutic development;Toxicology;Toxin,"Task E14: Lead Optimization Screening Assays for ADMET, Safety Profiling, Rodent Pharmacokinetics and MTD",0,NA,NA,NA,NA,NA,NA,NA,127980,NA
11202412,N01,AI,NA,N,NA,NA,NA,NA,272201800007I,NA,NA,272201800007I-0-759302400002-3,NIAID:232504\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAINT CHARLES,UNITED STATES,NA,02,078652667,US,10089014,"EUROFINS PANLABS, INC.",MO,633045685,NA,79992463 (contact),"BODE, JACOB  (contact)",NA,2018-05-01,2025-04-30,Biological;Biological Assay;Chemistry;Communicable Diseases;Development;Development Plans;Drug Kinetics;Evaluation;In Vitro;in vivo;Interventional Agent Development;Lead;lead optimization;manufacture;pathogen;pre-clinical;product development;programs;Property;Rodent;Safety;screening;Services;Therapeutic;therapeutic development;Toxicology;Toxin,"Task E14: Lead Optimization Screening Assays for ADMET, Safety Profiling, Rodent Pharmacokinetics and MTD",0,NA,NA,NA,NA,NA,NA,NA,232504,NA
11202427,N01,AI,NA,N,NA,NA,NA,NA,272201800001I,NA,NA,272201800001I-0-759302400003-2,NIAID:1568951\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MENLO PARK,UNITED STATES,NA,16,009232752,US,8042701,SRI INTERNATIONAL,CA,940253493,NA,79772656 (contact),"MIRASILAS, JON  (contact)",NA,2024-05-16,2025-05-15,Biological;Chemistry;Communicable Diseases;Development;Development Plans;Drug Kinetics;Evaluation;In Vitro;in vivo;Interventional Agent Development;Lead;manufacture;pathogen;pre-clinical;product development;programs;Safety;Services;Therapeutic;therapeutic development;Toxicology;Toxin,Task D16: Non-Clinical Services for Development of Interventional Agents for Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,1568951,NA
11202428,N01,AI,NA,N,NA,NA,NA,NA,272201800001I,NA,NA,272201800001I-0-759302400003-3,NIAID:666515\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MENLO PARK,UNITED STATES,NA,16,009232752,US,8042701,SRI INTERNATIONAL,CA,940253493,NA,79772656 (contact),"MIRASILAS, JON  (contact)",NA,2024-05-16,2025-05-15,Biological;Chemistry;Communicable Diseases;Development;Development Plans;Drug Kinetics;Evaluation;In Vitro;in vivo;Interventional Agent Development;Lead;manufacture;pathogen;pre-clinical;product development;programs;Safety;Services;Therapeutic;therapeutic development;Toxicology;Toxin,Task D16: Non-Clinical Services for Development of Interventional Agents for Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,666515,NA
11202510,N44,CA,NA,N,NA,NA,NA,NA,75N91024C00086,NA,NA,75N91024C00086-0-9999-1,NCI:1999994\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,IRVING,UNITED STATES,NA,06,080278280,US,10062142,"PIECES TECHNOLOGIES, INC.",TX,750393765,NA,9835008 (contact),"AMARASINGHAM, RUBEN  (contact)",NA,2024-09-16,2026-09-15,Artificial Intelligence;Cancer Center;Cancer Patient;cancer therapy;Caring;Categories;chatbot;Client;Client satisfaction;Clinical;Clinical Trials;Community Services;Data;Data Analyses;data streams;Databases;design;Development;effectiveness measure;electronic health record system;Environment;Ethics;Evaluation;Feedback;improved;improved outcome;Inpatients;Institutional Review Boards;intelligent agent;Intervention;Measures;Methods;Notification;Oncology;Outcome;Outpatients;Output;patient population;Patient Recruitments;Patients;Performance;Phase;Play;Process;Prognosis;programs;Protocols documentation;Questionnaires;Reporting;Research;response;responsible artificial intelligence;Role;screening;Screening procedure;Site;Small Business Innovation Research Grant;social health determinants;Surveys;System;Testing;tool,"FY24 SBIR PHASE IITOPIC NO. 423 PROJECT TITLE: ""PASSIVE AND ACTIVE AI SCREENING FOR SOCIAL DETERMINANTS OF HEALTH AND INTERVENTIONS TO IMPROVE OUTCOMES IN THE CANCER PATIENT POPULATION"".",0,NA,NA,NA,NA,NA,NA,NA,1999994,NA
11202551,N43,CA,NA,N,NA,NA,NA,NA,75N91024C00095,NA,NA,75N91024C00095-0-9999-1,NCI:398714\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,LUTZ,UNITED STATES,NA,NA,NA,US,NA,NA,FL,33548,NA,79992045 (contact),"LI, BORUI  (contact)",NA,2024-09-23,2025-09-22,3-Dimensional;Acceleration;acoustic imaging;Address;Adoption;Algorithms;Amplifiers;Cancer Center;Clinical;Controlled Environment;cost effective;data acquisition;Deposition;design;Development;Devices;Dose;Dose Rate;dosimetry;Electrons;Elements;Emerging Technologies;Environment;Evaluation;experimental study;Film;Goals;Image;image reconstruction;Imaging technology;instrument;invention;Ionizing radiation;Maps;Measures;Methods;Michigan;Modeling;Monitor;Motor;Noise;Performance;performance tests;Physiologic pulse;Polychlorinated Biphenyls;Positioning Attribute;prototype;quality assurance;Radiation;Radiation Dose Unit;Radiation therapy;reconstruction;Research;Resolution;Speed;Structure;System;Systems Development;Time;tool;Transducers;Universities;Work,TOPIC #461 DEVELOPMENT OF A FLASH DOSIMETRY SYSTEM BASED ON IONIZING RADIATION ACOUSTIC IMAGING,0,NA,NA,NA,NA,NA,NA,NA,398714,NA
11202593,N44,CA,NA,N,NA,NA,NA,NA,75N91024C00096,NA,NA,75N91024C00096-0-9999-1,NCI:1999956\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,Santa Clara,UNITED STATES,NA,17,079645501,US,10038849,"TIBARAY, INC.",CA,950511301,NA,78774201 (contact),"TOUFEXIS, FILIPPOS  (contact)",NA,2024-09-16,2026-09-15,Academic Medical Centers;Behavior;cancer care;Charge;Clinical;clinical implementation;Contracts;design;Documentation;Dose;Dose Rate;Electrons;Feedback;Goals;Human;Image;interest;Letters;Linear Accelerator Radiotherapy Systems;manufacture;Measures;millisecond;Monitor;Performance;Phase;Photons;Physiologic pulse;pre-clinical;programs;Protons;prototype;Radiation Oncology;Radiation therapy;real time monitoring;Reproducibility;Research;Roentgen Rays;Small Business Innovation Research Grant;System;Testing;Time;Universities;Update;usability;Vendor,FY24 SBIR PHASE IITOPIC NO. 434PROJECT TITLE:  ULTRA-RAID RF-BASED BEAM MONITOR FOR REAL-TIME FLASH BEAM CONTROL,0,NA,NA,NA,NA,NA,NA,NA,1999956,NA
11202708,ZIA,HG,1,N,NA,NA,NA,NA,ZIAHG000215,NA,NA,1ZIAHG000215-22,NHGRI:3548423\,INTRAMURAL RESEARCH,2024,NATIONAL HUMAN GENOME RESEARCH INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL HUMAN GENOME RESEARCH INSTITUTE,NA,NA,NA,9694195 (contact),"GAHL, WILLIAM  (contact)",NA,NA,NA,"absorption;Academy;Achievement;Advocacy;Albinism;Alkaptonuria;Alleles;Arterial calcification due to deficiency of CD73;arthropathies;authority;Award;Bacterial Infections;base;Basic Science;Biochemical;Biochemical Genetics;Biochemical Pathway;Biochemistry;Biological;Biological Sciences;bisphosphonate;Bleeding time procedure;Blood Platelets;Bone Diseases;Brazil;Caring;Catabolism;Cells;Cellular Assay;Cellular biology;chediak-higashi syndrome;CHS1 gene;Clinical;Clinical Protocols;Clinical Research;Clinical Trials;cohort;Collaborations;Communities;Congenital disorders of glycosylation;Congo;Cooperative Research and Development Agreement;Country;Cysteamine;Cystine;Cystinosis;Cytoplasmic Granules;cytotoxic;Data;Defect;Developing Countries;Diagnosis;Diagnostic;Disease;Doctor of Philosophy;Eating;Endocannabinoids;Enrollment;Enzymes;Exocytosis;Focal and Segmental Glomerulosclerosis;Food and Drug Administration Drug Approval;Formulation;Fostering;Foundations;Freeze Drying;Future;gene therapy;Genes;Genetic;Genetic Diseases;Genetic study;genetic testing;Genome;Genotype;Ghana;Glutamate Receptor;Glycoproteins;Goals;Hemorrhage;Hemostatic Agents;Hermanski-Pudlak Syndrome;Histiocytosis;Homogentisic Acid;Human;human disease;Human Genome;Human Resources;Impairment;India;Individual;Inhalation;inhibitor;insight;interest;International;international center;Intervention Studies;Kidney Failure;Knock-in Mouse;Lead;Leadership;Lymphocyte;Lysosomal Storage Diseases;Lysosomes;Mali;Manuscripts;Measures;Medical;meetings;member;Methods;Modeling;Molecular;Molecular Diagnosis;mouse model;Mutation;Myopathy;N-acetylmannosamine;National Center for Advancing Translational Sciences;National Heart, Lung, and Blood Institute;National Human Genome Research Institute;National Institute of Diabetes and Digestive and Kidney Diseases;National Institute of Neurological Disorders and Stroke;National Institute on Alcohol Abuse and Alcoholism;Natural History;Nature;neglect;nephropathic cystinosis;Neurologic;Neurology;Neuromuscular Diseases;Neurons;New Drug Approvals;New York;NOS2A gene;novel;Oculocutaneous Albinism;Oral;Outcome Measure;Pakistan;participant enrollment;Patient Care;patient derived induced pluripotent stem cells;Patients;Persons;Pharmaceutical Preparations;Pharmacologic Substance;Phenotype;Physicians;Plasma;Play;Principal Investigator;Production;Prognosis;programs;Property;protein function;Proteinuria;Protocols documentation;Publishing;Pulmonary Fibrosis;randomized placebo controlled study;Rare Diseases;receptor;Reporting;Research;Research Personnel;Research Project Grants;research study;Role;Rome;safety testing;Science;Scientist;Services;Sialic Acids;Specimen;Study Section;Surveys;symposium;T-Lymphocyte;Testing;Time;translational research program;Tyrosine;United States National Institutes of Health;Update;Variant;Vascular calcification;Vesicle;virtual;Work;Writing",Human Biochemical Genetics,215,NA,NA,NA,NA,22,NA,NA,3548423,NA
11202709,ZIC,CA,1,N,NA,NA,NA,NA,ZICCO020007,NA,NA,1ZICCO020007-16,NCI:2528337\,INTRAMURAL RESEARCH,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NCI",NA,NA,NA,78871689 (contact),"KOMSCHLIES MCCONVILLE, KRISTIN  (contact)",NA,NA,NA,Acceleration;Acquired Immunodeficiency Syndrome;animal facility;Animals;Biomedical Research;cancer care;Cancer Etiology;cancer therapy;Clinical;commercialization;Communities;Congresses;cost;Development;Diagnostic tests;Disease;evidence base;flexibility;Funding;Goals;Government;health care delivery;Healthcare;Home;improved;Investments;Laboratories;Laboratory Research;Lead;Malignant Neoplasms;meetings;Nanotechnology;New Drug Approvals;nonhuman primate;novel diagnostics;Patients;Persons;Pharmaceutical Preparations;Private Sector;programs;prototype;public-private partnership;Research;research and development;Research Personnel;response;Scientist;Services;Speed;Technology;technology development;Time;Translations;Universities;vaccine evaluation;Vaccines;Washington,NCI-Frederick Support and Technical Services,20007,NA,NA,NA,NA,16,NA,NA,2528337,NA
11202710,ZIH,CA,1,N,NA,NA,NA,NA,ZIHCO030002,NA,NA,1ZIHCO030002-03,NCI:22183715\,INTRAMURAL RESEARCH,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NCI",NA,NA,NA,10274902 (contact),"SHILLING, JEFFREY  (contact)",NA,NA,NA,Area;artificial intelligence method;Clinical;Clinical Data;Collaborations;Complement 3d;computing resources;cost efficient;Data;Data Aggregation;Data Analyses;data and analysis portal;data exchange;Data Files;data integration;data interoperability;data management;data resource;data sharing;Data Storage and Retrieval;Development;digital pathology;Dimensions;Ensure;Environment;Fostering;Foundations;Genomics;Histopathology;Image;Image Analysis;Licensing;Medical Records;metabolomics;Metadata;microbiome;Modeling;Modernization;multimodality;National Center for Advancing Translational Sciences;Participant;Process;Production;programs;Proteomics;Research;Resources;Scanning;scientific computing;Secure;Site;Slide;Software Engineering;System;Systems Analysis;United States National Institutes of Health,NCI Central Scientific Computing Resources,30002,NA,NA,NA,NA,3,NA,NA,22183715,NA
11202711,ZII,CA,1,N,NA,NA,NA,NA,ZIICO020002,NA,NA,1ZIICO020002-16,NCI:20246310\,INTRAMURAL RESEARCH,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NCI",NA,NA,NA,79381930 (contact),"KHOSHBIN, JEAN-PATRICE  (contact)",NA,NA,NA,Area;Contractor;Contracts;cost;cost effective;design;Emergency Situation;Grant;innovation;Mission;Monitor;National Cancer Institute;operation;Process;programs;Property;Services;symposium;United States National Institutes of Health,Space and Facilities Management,20002,NA,NA,NA,NA,16,NA,NA,20246310,NA
11202712,ZII,CA,1,N,NA,NA,NA,NA,ZIICO030001,NA,NA,1ZIICO030001-07,NCI:1663555\,INTRAMURAL RESEARCH,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NCI",NA,NA,NA,79381930 (contact),"KHOSHBIN, JEAN-PATRICE  (contact)",NA,NA,NA,Air Pressure;Cell Therapy;Cells;Cellular immunotherapy;Cyclic GMP;design;Guidelines;Human;human subject;Industry;Infrastructure;Infusion procedures;manufacture;Manufacturer;participant enrollment;Patients;Pharmaceutical Preparations;Phase;Primary Cell Cultures;Primary Neoplasm;Sterility;Tissues;Tumor Expansion;Tumor-Infiltrating Lymphocytes;United States National Institutes of Health,TIL Rosenberg Modular Processing Facility (T30 building),30001,NA,NA,NA,NA,7,NA,NA,1663555,NA
11202713,ZIK,CA,1,N,NA,NA,NA,NA,ZIKCO020001,NA,NA,1ZIKCO020001-16,NCI:14114627\,INTRAMURAL RESEARCH,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NCI",NA,NA,NA,79381933 (contact),"FRISBIE, SUZANNE  (contact)",NA,NA,NA,Academia;Agreement;Biotechnology;Client;Clinical Research;Clinical Trials;Collaborations;Commercial Sectors;Confidential Information;Contracts;Cooperative Research and Development Agreement;Data;data exchange;Development;Devices;Disclosure;Employee;Extramural Activities;Industry;Intellectual Property;invention;Laboratories;Laws;Legal patent;Licensing;Marketing;material transfer agreement;Mediation;meetings;Monitor;National Cancer Institute;New Agents;Nonprofit Organizations;Pharmacologic Substance;Policies;Procedures;programs;Recommendation;Regulation;Reporting;Research;research and development;Research Personnel;Research Support;Resources;Safety;Services;symposium;Technology;technology development;Technology Transfer;Transact;Transfer Agreement;United States National Institutes of Health;Universities,Technology Transfer Center,20001,NA,NA,NA,NA,16,NA,NA,14114627,NA
11202793,N01,AI,NA,N,NA,NA,NA,NA,75N93022C00023,NA,NA,75N93022C00023-P00003-9999-3,NIAID:4192129\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,ROCKVILLE,UNITED STATES,NA,08,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,NA,79953724 (contact),"EYLER, DENNIS  (contact)",NA,2022-09-21,2025-09-20,Adherence;Clinical;clinical material;Clinical Research;Clinical Trials;Communicable Diseases;Contracts;Ensure;Good Clinical Practice;good laboratory practice;Good Manufacturing Process;Microbiology;programs;Services;Shipping;Specimen,Division of Microbiology and Infectious Diseases (DMID): Clinical Materials Services (CMS),0,NA,NA,NA,NA,NA,NA,NA,4192129,NA
11202794,N01,AI,NA,N,NA,NA,NA,NA,75N93022C00023,NA,NA,75N93022C00023-P00003-9999-4,NIAID:1000000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,ROCKVILLE,UNITED STATES,NA,08,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,NA,79953724 (contact),"EYLER, DENNIS  (contact)",NA,2022-09-21,2025-09-20,Adherence;Clinical;clinical material;Clinical Research;Clinical Trials;Communicable Diseases;Contracts;Ensure;Good Clinical Practice;good laboratory practice;Good Manufacturing Process;Microbiology;Monkeypox;programs;Services;Shipping;Specimen,Division of Microbiology and Infectious Diseases (DMID): Clinical Materials Services (CMS): mpox Studies,0,NA,NA,NA,NA,NA,NA,NA,1000000,NA
11202795,N01,AI,NA,N,NA,NA,NA,NA,75N93023D00018,NA,NA,75N93023D00018-0-759302400001-1,NIAID:746197\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,STERLING,UNITED STATES,NA,10,031013926,US,10039176,"RESOURCEPATH, LLC",VA,201664344,NA,79983702 (contact),"HILL, DANA ASHLEY  (contact)",NA,2023-06-20,2030-06-19,2019-nCoV;Biological Assay;COVID-19 diagnostic;Development;diagnostic development;Human;Infectious Agent;product development;Services,Development of SARS-CoV-2 Diagnostics,0,NA,NA,NA,NA,NA,NA,NA,746197,NA
11202798,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00004,NA,NA,75N93024C00004-0-9999-5,NIAID:2000000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,BETHESDA,UNITED STATES,NA,08,057052391,US,1603501,"TECHNICAL RESOURCES INTERNATIONAL, INC.",MD,208171197,NA,79704051 (contact),"ELLIS, JESSICA  (contact)",NA,2024-04-01,2025-03-31,Clinical Research;clinical research site;Clinical Trials;Data;Monitor;Operations Research;programs;Research Personnel;Resources;Safety;Services;Site;Training,DMID Clinical Research Operations & Management Support (CROMS),0,NA,NA,NA,NA,NA,NA,NA,2000000,NA
11202800,N01,AI,NA,N,NA,NA,NA,NA,272201800011I,NA,NA,272201800011I-0-759302400001-2,NIAID:1678100\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,DESSAU-ROSSLAU,GERMANY,NA,NA,332119734,GM,10089015,IDT BIOLOGIKA GMBH,NA,06861,NA,79693906 (contact),"TRUSHEIM, HEIDI  (contact)",NA,2018-05-15,2028-05-14,Adjuvant;Biological Products;cell bank;Clinical Research;Communicable Diseases;Contracts;COVID-19 vaccine;Cyclic GMP;Development;Development Plans;manufacture;next generation;novel vaccines;Phase;product development;Services;System;United States Food and Drug Administration;vaccine delivery;vaccine development;Vaccines,Task V34: Master Cell Banks Manufacturing for Next Generation SARS-CoV-2 Vaccines,0,NA,NA,NA,NA,NA,NA,NA,1678100,NA
11202801,N01,AI,NA,N,NA,NA,NA,NA,272201800009I,NA,NA,272201800009I-P00001-759302300001-2,NIAID:88071\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,KENSINGTON,UNITED STATES,NA,08,094888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,NA,79761563 (contact),"FOUTS, TIM  (contact)",NA,2023-01-20,2025-07-30,Adjuvant;Bacterial Drug Resistance;Biological Products;Candida auris;Clinical Research;Communicable Diseases;Contracts;Cyclic GMP;Development;Development Plans;fungus;manufacture;novel vaccines;pathogen;Phase;Process;product development;Services;System;United States Food and Drug Administration;vaccine delivery;vaccine development;Vaccines,Task V31: Process Development for Panfungal Vaccine,0,NA,NA,NA,NA,NA,NA,NA,88071,NA
11202802,N01,AI,NA,N,NA,NA,NA,NA,272201800013I,NA,NA,272201800013I-P00003-759302100002-2,NIAID:6134108\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79558569 (contact),"RUDGE, THOMAS  (contact)",NA,2021-09-17,2024-07-31,Area;Biological;Biological Products;Bioterrorism;Clinical;Communicable Diseases;Contracts;COVID-19 testing;COVID-19 vaccine;Development;Educational workshop;efficacy testing;Emerging Communicable Diseases;evaluation/testing;Feasibility Studies;immunogenicity;Immunology procedure;Investigational New Drug Application;Licensing;novel vaccines;Office of Administrative Management;product development;Qualifying;Reporting;Safety;Sampling;Services;Site Visit;Testing;testing services;Toxicity Tests;Toxicology;Training;vaccine candidate;vaccine development;Vaccines;Validation,"Task V11: General Safety Toxicity Testing, SARS-CoV-2",0,NA,NA,NA,NA,NA,NA,NA,6134108,NA
11202803,N01,AI,NA,N,NA,NA,NA,NA,272201800013I,NA,NA,272201800013I-P00003-759302100002-3,NIAID:605930\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79558569 (contact),"RUDGE, THOMAS  (contact)",NA,2021-09-17,2024-07-31,Area;Biological;Biological Products;Bioterrorism;Clinical;Communicable Diseases;Contracts;Development;Educational workshop;efficacy testing;Emerging Communicable Diseases;evaluation/testing;Feasibility Studies;immunogenicity;Immunology procedure;Investigational New Drug Application;Licensing;novel vaccines;Office of Administrative Management;product development;Qualifying;Reporting;Safety;Sampling;Services;Site Visit;Testing;testing services;Toxicity Tests;Toxicology;Training;vaccine candidate;vaccine development;Vaccines;Validation,Task V11: General Safety Toxicity Testing,0,NA,NA,NA,NA,NA,NA,NA,605930,NA
11202804,N01,AI,NA,N,NA,NA,NA,NA,272201800013I,NA,NA,272201800013I-P00002-759302200004-2,NIAID:632480\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79607379 (contact),"RUDGE, THOMAS  (contact)",NA,2022-09-01,2024-09-30,Area;assay development;Biological;Biological Products;Bioterrorism;Clinical;Communicable Diseases;Contracts;Development;Educational workshop;efficacy testing;Emerging Communicable Diseases;evaluation/testing;Feasibility Studies;immunogenicity;Immunology procedure;Investigational New Drug Application;Licensing;Monkeypox;novel vaccines;Office of Administrative Management;product development;Qualifying;Reagent;Reporting;Safety;Sampling;Services;Site Visit;Testing;testing services;Toxicology;Training;vaccine candidate;vaccine development;Vaccines;Validation,Task V15: Development of Assays and Reagents for mpox Vaccines,0,NA,NA,NA,NA,NA,NA,NA,632480,NA
11202805,N01,AI,NA,N,NA,NA,NA,NA,272201800013I,NA,NA,272201800013I-0-759302400001-1,NIAID:2365162\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79979746 (contact),"RUDGE, THOMAS  (contact)",NA,2024-09-06,2026-09-05,Area;Biological;Biological Products;Bioterrorism;Clinical;Communicable Diseases;Contracts;COVID-19 vaccine;Development;Educational workshop;efficacy testing;Emerging Communicable Diseases;evaluation/testing;Feasibility Studies;Hamsters;immunogenicity;Immunology procedure;Investigational New Drug Application;Licensing;Modeling;novel vaccines;Office of Administrative Management;product development;Qualifying;Reporting;Safety;Sampling;Sarbecovirus;Services;Site Visit;Testing;testing services;Toxicology;Training;vaccine candidate;vaccine development;vaccine evaluation;Vaccines;Validation,Task V20: Hamster Sarbecovirus Challenge Model for SARS-CoV-2 Vaccine Testing,0,NA,NA,NA,NA,NA,NA,NA,2365162,NA
11202821,N01,AI,NA,N,NA,NA,NA,NA,75N93024D00002,NA,NA,75N93024D00002-0-759302400002-2,NIAID:221281\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,COLUMBIA,UNITED STATES,NA,03,NA,US,10089010,"ADVARRA, INC.",MD,210443368,NA,79730417 (contact),"ATKINSON, REBECCA  (contact)",NA,2024-04-01,2027-03-31,Bacteria;Clinical Trials;Communicable Diseases;Institutional Review Boards;National Institute of Allergy and Infectious Disease;Services;Site;Treponema pallidum subspecies pallidum,Single Institutional Review Board (sIRB),0,NA,NA,NA,NA,NA,NA,NA,221281,NA
11202848,N02,OD,NA,N,NA,NA,NA,NA,75N99020D00007,NA,NA,75N99020D00007-0-759902400005-1,OD:227998\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,WASHINGTON,UNITED STATES,NA,NA,806345344,US,NA,NA,DC,200073614,NA,NA,(contact),NA,2024-09-13,2028-09-30,Code;design;design and construction;Development;Engineering;Ensure;Extramural Activities;Funding;Grant Review;Mission;Phase;Process;programs;Published Comment;Qualifying;Regulation;research facility;Research Infrastructure;Resolution;Resources;Technical Expertise;United States National Institutes of Health,FY24 GRANT REVIEWS PERFORMED BY DTR,0,NA,NA,NA,NA,NA,NA,NA,227998,NA
11202903,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00020,NA,NA,75N93024C00020-0-9999-1,NIAID:1435380\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,BOSTON,UNITED STATES,NA,07,076593722,US,1504801,BOSTON CHILDREN'S HOSPITAL,MA,021155724,NA,1928111 (contact),"LEVY, OFER  (contact)",NA,2024-09-30,2029-09-29,Adjuvant;Adjuvanticity;Adult;aluminum sulfate;aqueous;Blood;Cells;Contractor;Elderly;Evaluation;Formulation;Human;Immunity;Immunization;in silico;in vivo;influenza virus vaccine;Investigation;Lead;Libraries;Liposomes;Mononuclear;nanoparticle;Newborn Infant;novel;Peripheral Blood Mononuclear Cell;Pharmaceutical Chemistry;Preparation;programs;receptor;Route;screening;Signal Pathway;Sister;small molecule;small molecule libraries;System;T cell response;Vaccine Adjuvant;vaccinology,VACCINE ADJUVANT DISCOVERY PROGRAM (VADP),0,NA,NA,NA,NA,NA,NA,NA,1435380,NA
11202983,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00021,NA,NA,75N93024C00021-0-9999-1,NIAID:1563776\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,PLAN-LES-OUATES,SWITZERLAND,NA,NA,480448918,SZ,10067414,VACCINE FORMULATION INSTITUTE (CH) LTD,NA,1228,NA,NA,(contact),NA,2024-09-30,2029-09-29,Adjuvant;Adjuvanticity;Agonist;Animal Model;Benchmarking;C-Type Lectins;Cell Line;Cells;Chemicals;Contractor;design;Formulation;Human;Immunologic Adjuvants;In Vitro;Inflammasome;Knockout Mice;Lead;lead candidate;Libraries;Macrophage;Mycobacterium tuberculosis;Natural Products;novel;Pathway interactions;Peripheral Blood Mononuclear Cell;Pre-Clinical Model;receptor;Reporter;scaffold;screening;Specificity;Structure-Activity Relationship;synergism;Testing,"Synthetic Macrophage-inducible C-type lectin (Mincle) Agonists: Screening, Design, and Formulation in combination Th17 adjuvants",0,NA,NA,NA,NA,NA,NA,NA,1563776,NA
11202992,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00022,NA,NA,75N93024C00022-0-9999-1,NIAID:2601750\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LA JOLLA,UNITED STATES,NA,50,804355790,US,577507,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",CA,920930621,NA,79992347 (contact),"CARSON, DENNIS  (contact)",NA,2024-09-30,2029-09-29,2019-nCoV;Adjuvant;analog;Antigen-Presenting Cells;Antigens;Biochemical;Biological Assay;Cell Survival;Cells;COVID-19 vaccine;cytotoxicity;design;Dose;Formulation;Genetic;high throughput screening;Human;Immune;immune activation;Immunology procedure;innate immune pathways;Intramuscular;Lead;lipid nanoparticle;Messenger RNA;Modeling;Molecular;Molecular Weight;mouse model;Mus;novel;preclinical study;Preparation;protective efficacy;Protein Biosynthesis;Proteins;RNA vaccine;Safety;scaffold;scale up;Structure-Activity Relationship;Transfection;vaccine formulation;Work,Discovery of Adjuvants for mRNA Vaccines,0,NA,NA,NA,NA,NA,NA,NA,2601750,NA
11202993,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00023,NA,NA,75N93024C00023-0-9999-1,NIAID:1989733\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,CHICAGO,UNITED STATES,NA,01,005421136,US,1413601,UNIVERSITY OF CHICAGO,IL,606372612,NA,79992350 (contact),"ESSER-KAHN, AARON  (contact)",NA,2024-09-30,2029-09-29,Adjuvant;Agonist;Antibodies;Cells;Contractor;cytokine;Derivation procedure;drug-like compound;Formulation;Goals;Ha antigen;Immune;improved;In Vitro;in vivo;in vivo evaluation;Influenza vaccination;influenza virus vaccine;Innate Immune Response;Libraries;Modeling;Molecular;mouse model;novel;Pathway interactions;Phenotype;predicting response;Property;Proteins;response;RNA vaccination;RNA vaccine;Safety;screening;Signal Pathway;System;T-Lymphocyte;Tuberculosis;Vaccination;Vaccines,Discovery of Adjuvants that Direct T-cell Fates for Improved Safety and Efficacy in  Vaccines Against Influenza and Tuberculosis,0,NA,NA,NA,NA,NA,NA,NA,1989733,NA
11203002,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00024,NA,NA,75N93024C00024-0-9999-1,NIAID:1637656\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MISSOULA,UNITED STATES,NA,01,010379790,US,1381006,UNIVERSITY OF MONTANA,MT,598124104,NA,79992353 (contact),"EVANS, JAY  (contact)",NA,2024-09-30,2029-09-29,Adjuvant;age related;Agonist;Antigens;Cells;Coccidioidomycosis;Contractor;efficacy study;Formulation;Human;Immune;Immunity;Lead;lead candidate;Libraries;Ligands;Mediating;Modeling;Mus;Mycobacterium tuberculosis;novel;pathogenic bacteria;pathogenic fungus;Phenotype;Preclinical Testing;screening;Testing;Vaccine Adjuvant,Identification of Novel Syk/Raf-1 Mediated CLR Ligands as Vaccine Adjuvants,0,NA,NA,NA,NA,NA,NA,NA,1637656,NA
11203144,N01,AI,NA,N,NA,NA,NA,NA,75N93020D00011,NA,NA,75N93020D00011-0-759302400001-1,NIAID:873466\OD:2561932\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MENLO PARK,UNITED STATES,NA,16,009232752,US,8042701,SRI INTERNATIONAL,CA,940253493,NA,3086600 (contact),"CHANG, POLLY YEE (contact)",NA,2024-09-30,2026-09-29,Academia;Acute;Advanced Development;Contracts;Development;dosimetry;drug development;Foundations;Funding;Government;Government Agencies;Industry;Licensure;Medical center;medical countermeasure;National Institute of Allergy and Infectious Disease;Nuclear;nuclear countermeasure;Pathway interactions;product development;Radiation;Radiation exposure;Radiation Toxicity;Radioisotopes;research and development;Research Support;screening;Testing;Work,Radiation/Nuclear Medical Countermeasure (MCM) Product Development Support,0,NA,NA,NA,NA,NA,NA,NA,3435398,NA
11203169,N44,AI,NA,N,NA,NA,NA,NA,75N93024C00087,NA,NA,75N93024C00087-0-9999-1,NIAID:1084824\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LAKE CLEAR,UNITED STATES,NA,NA,079547325,US,NA,NA,NY,129452009,NA,NA,(contact),NA,2024-09-30,2026-09-29,Address;Antibodies;Award;Binding;Biological Assay;Biotinylation;Cells;Communities;Contractor;cross reactivity;cytokine;Enzyme-Linked Immunosorbent Assay;Ferrets;Fluorochrome;Hamsters;Human;Immune;Immune response;Immunity;infectious disease model;Label;manufacturing scale-up;Memory;Modification;Monoclonal Antibodies;Mus;Pathogenesis;Phase;Reagent;Respiratory Tract Infections;Small Business Innovation Research Grant;Tissues;vaccine efficacy;Validation,Further characterization and validation of monoclonal antibodies to study respiratory infections in the ferret,0,NA,NA,NA,NA,NA,NA,NA,1084824,NA
11203269,N44,AI,NA,N,NA,NA,NA,NA,75N93024C00073,NA,NA,75N93024C00073-0-9999-1,NIAID:1488107\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,ROCKVILLE,UNITED STATES,NA,06,070893032,US,4501801,"TETRACORE, INC.",MD,208503986,NA,79969328 (contact),"COCKRELL, LISA  (contact)",NA,2024-09-03,2027-09-02,Biological Assay;Development;diagnostic development;Molecular;point-of-care detection;Small Business Innovation Research Grant;Treponema pallidum,SBIR Topic 108: Development of Rapid Molecular Assay for Point of Care Detection of Treponema Pallidum,0,NA,NA,NA,NA,NA,NA,NA,1488107,NA
11203270,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00084,NA,NA,75N93024C00084-0-9999-1,NIAID:1500000\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NEWTON CENTER,UNITED STATES,NA,04,NA,US,10088742,CURE SYSTEMS LLC,MA,024591122,NA,79990374 (contact),"MILLER, JACQUELINE  (contact)",NA,2024-09-18,2027-09-17,Basic Science;combat;Development;Intervention;Malaria;Mediating;Monoclonal Antibodies;Small Business Innovation Research Grant,SBIR Topic 109: Development of Monoclonal Antibody- Mediated Interventions to Combat Malaria,0,NA,NA,NA,NA,NA,NA,NA,1500000,NA
11203271,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00032,NA,NA,75N93024C00032-0-9999-1,NIAID:299914\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MONROVIA,UNITED STATES,NA,31,168312028,US,10005243,"CHROMOLOGIC, LLC",CA,910164244,NA,80000492 (contact),"JIMENZ, JORGE  (contact)",NA,2024-09-25,2025-09-24,alternative treatment;Benzathine Penicillin;Small Business Innovation Research Grant;Syphilis;therapeutic development,SBIR Topic 134: Alternatives to Benzathine Penicillin for Treatment of Syphilis,0,NA,NA,NA,NA,NA,NA,NA,299914,NA
11203278,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00061,NA,NA,75N93024C00061-0-9999-1,NIAID:299914\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,IRVINE,UNITED STATES,NA,47,117298399,US,10057552,"VULCAN BIOLOGICS, INC.",CA,926174064,NA,79979782 (contact),"GREEN, BRIAN  (contact)",NA,2024-09-10,2025-09-09,Antibiotic Resistance;Antibiotics;Bacteriophages;Biological Assay;design;Development;Disease;Genus Mycobacterium;Immune response;mycobacterial;Mycobacterium Infections;non-tuberculous mycobacterial infection;Phase;pre-clinical;pre-clinical research;preclinical development;Property;Resistance;Route;Small Business Innovation Research Grant;Technology;Therapeutic;therapeutic development;Variant,SBIR Topic 131: Development of Bacteriophage for Treatment of Mycobacterial Infections,0,NA,NA,NA,NA,NA,NA,NA,299914,NA
11203283,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00060,NA,NA,75N93024C00060-0-9999-1,NIAID:297740\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,HUNTSVILLE,UNITED STATES,NA,05,185169620,US,2805101,CFD RESEARCH CORPORATION,AL,358062922,NA,79979779 (contact),"BHATT, KETAN  (contact)",NA,2024-09-10,2025-09-09,Antibiotic Resistance;Antibiotics;Bacteriophages;Biological Assay;design;Development;Disease;Genus Mycobacterium;Immune response;mycobacterial;Mycobacterium Infections;non-tuberculous mycobacterial infection;Phase;pre-clinical;pre-clinical research;preclinical development;Property;Resistance;Route;Small Business Innovation Research Grant;Technology;Therapeutic;therapeutic development;Variant,SBIR Topic 131: Development of Bacteriophage for Treatment of Mycobacterial Infections,0,NA,NA,NA,NA,NA,NA,NA,297740,NA
11203288,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00062,NA,NA,75N93024C00062-0-9999-1,NIAID:299993\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MIAMI,UNITED STATES,NA,26,NA,US,10075241,TOLKA.AI INC,FL,331361112,NA,79983708 (contact),"WIKSTROM, JOHAN  (contact)",NA,2024-09-10,2025-09-09,Antibiotic Resistance;Antibiotics;Bacteriophages;Biological Assay;design;Development;Disease;Genus Mycobacterium;Immune response;mycobacterial;Mycobacterium Infections;non-tuberculous mycobacterial infection;Phase;pre-clinical;pre-clinical research;preclinical development;Property;Resistance;Route;Small Business Innovation Research Grant;Technology;Therapeutic;therapeutic development;Variant,SBIR Topic 131: Development of Bacteriophage for Treatment of Mycobacterial Infections,0,NA,NA,NA,NA,NA,NA,NA,299993,NA
11203290,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00045,NA,NA,75N93024C00045-0-9999-1,NIAID:300000\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,Framingham,UNITED STATES,NA,05,080462707,US,10044686,"KEPHERA DIAGNOSTICS, LLC",MA,017026767,NA,79969325 (contact),"LEVIN, ANDREW  (contact)",NA,2024-09-10,2025-09-09,Detection;Development;diagnostic development;Herpesvirus 1;Human Herpesvirus 2;Infection;Serology test;Small Business Innovation Research Grant,SBIR Topic 133: Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections,0,NA,NA,NA,NA,NA,NA,NA,300000,NA
11203294,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00046,NA,NA,75N93024C00046-0-9999-1,NIAID:300000\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,Carlsbad,UNITED STATES,NA,49,078391520,US,10031193,"QOOLABS, INC.",CA,92008,NA,79977819 (contact),"QI, HONG  (contact)",NA,2024-09-10,2025-09-09,Detection;Development;diagnostic development;Herpesvirus 1;Human Herpesvirus 2;Infection;Serology test;Small Business Innovation Research Grant,SBIR Topic 133: Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections,0,NA,NA,NA,NA,NA,NA,NA,300000,NA
11203298,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00044,NA,NA,75N93024C00044-0-9999-1,NIAID:300000\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,IRVINE,UNITED STATES,NA,47,159838106,US,10002068,"IMMPORT THERAPEUTICS, INC.",CA,926182343,NA,79979776 (contact),"CAMERINI, DAVID  (contact)",NA,2024-09-10,2025-09-09,Detection;Development;diagnostic development;Herpesvirus 1;Human Herpesvirus 2;Infection;Serology test;Small Business Innovation Research Grant,SBIR Topic 133: Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections,0,NA,NA,NA,NA,NA,NA,NA,300000,NA
11203530,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00055,NA,NA,75N93024C00055-0-9999-1,NIAID:1116758\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SEATTLE,UNITED STATES,NA,07,605799469,US,9087701,UNIVERSITY OF WASHINGTON,WA,981959472,NA,80000498 (contact),"KOELLE, DAVID  (contact)",NA,2024-09-30,2025-09-29,Alleles;Biological Assay;Blood;CD8-Positive T-Lymphocytes;Cell Line;Cells;Chlamydia trachomatis;cohort;Complex;Contracts;Cytoprotection;Dose;Epitopes;Herpesvirus 1;Human;Human Herpesvirus 2;Immune;Knowledge;Length;Libraries;Link;microbial;pathogen;Patients;Peptides;Proteins;Reporter;Research;response;Severity of illness;Sexually Transmitted Diseases;Simplexvirus;Syphilis;T-Lymphocyte;T-Lymphocyte Epitopes;Tissues;Treponema pallidum;Validation,Large-Scale T Cell Immune Epitope Discovery and Mechanisms of T Cell Protection,0,NA,NA,NA,NA,NA,NA,NA,1116758,NA
11203574,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00056,NA,NA,75N93024C00056-0-9999-1,NIAID:1124982\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LA JOLLA,UNITED STATES,NA,50,603880287,US,2465301,LA JOLLA INSTITUTE FOR IMMUNOLOGY,CA,920371387,NA,80000501 (contact),"FABRITZKY, BRANDON  (contact)",NA,2024-09-30,2025-09-29,Address;Antigens;Arenavirus;Binding;Chikungunya virus;Contracts;Coronavirus;Dengue Virus;Epitopes;Family;Family Picornaviridae;Flaviviridae;Human poliovirus;Immunize;immunogenic;Lassa;Measles;National Institute of Allergy and Infectious Disease;pandemic potential;pandemic preparedness;Paramyxovirus;Pathogenesis;pathogenic virus;prototype;T-Lymphocyte;Togaviridae;Vaccines;Validation;Viral;Virus;Virus Diseases;volunteer,THE IDENTIFICATION AND VALIDATION OF EPITOPES CONSERVED IN VIRAL PATHOGEN FAMILIES WITH PANDEMIC POTENTIAL,0,NA,NA,NA,NA,NA,NA,NA,1124982,NA
11203615,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00057,NA,NA,75N93024C00057-0-9999-1,NIAID:1123365\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LA JOLLA,UNITED STATES,NA,50,603880287,US,2465301,LA JOLLA INSTITUTE FOR IMMUNOLOGY,CA,920371387,NA,80000504 (contact),"PETERS, BJOERN  (contact)",NA,2024-09-30,2025-09-29,Adult;Antigens;Bacteria;Binding;Bioinformatics;Biological Assay;cohort;Common Epitope;Communities;community acquired pneumonia;Contractor;Contracts;Custom;Diagnosis;Epitopes;Ethnic Origin;Flow Cytometry;Geography;Haemophilus influenzae;Immunity;Individual;Infection;Morbidity - disease rate;mortality;Mycoplasma pneumoniae;pathogen;pathogenic bacteria;patient screening;Patients;Peptides;Persons;Phenotype;Pneumonia;response;Selection Criteria;single cell sequencing;Sri Lanka;Staphylococcus aureus;Streptococcus pneumoniae;T cell response;T-cell receptor repertoire;T-Lymphocyte;T-Lymphocyte Epitopes;transmission process,IDENTIFICATION AND CHARACTERIZATION OF T CELL EPITOPES FROM BACTERIAL PATHOGENS CAUSING PNEUMONIA,0,NA,NA,NA,NA,NA,NA,NA,1123365,NA
11203645,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00085,NA,NA,75N93024C00085-0-9999-1,NIAID:1200000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,WORCESTER,UNITED STATES,NA,02,603847393,US,850903,UNIV OF MASSACHUSETTS MED SCH WORCESTER,MA,016550002,NA,79998653 (contact),"STERN, LAWRENCE  (contact)",NA,2024-09-30,2025-09-29,Affect;Antigens;Autoimmune Diseases;Autoimmunity;autoinflammatory diseases;autoreactive T cell;CD8-Positive T-Lymphocytes;Cell Physiology;Clinical;Contractor;cross reactivity;diagnostic value;Disease;Endogenous Retroviruses;Environment;Epitopes;Lead;Libraries;Mass Spectrum Analysis;Memory;MHC binding peptide;novel;Organ;Pathogenesis;Pathogenicity;Proteins;receptor;Regulatory T-Lymphocyte;Research;Role;screening;single cell sequencing;T-Cell Activation;T-Lymphocyte;T-Lymphocyte Epitopes;Tissues;tool,CD4 AND CD8 T CELL EPITOPES RECOGNIZED IN AUTOIMMUNE AND AUTOINFLAMMATORY DISEASES,0,NA,NA,NA,NA,NA,NA,NA,1200000,NA
11203827,Y01,AI,NA,N,NA,NA,NA,NA,AAI24030001,NA,NA,AAI24030001-1-0-1,NIAID:1093500\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,(contact),NA,NA,NA,aged;airborne allergen;Allergens;Alternaria;Ambrosia;Aspergillus fumigatus;Asthma;Atopic Dermatitis;Betula Genus;Canis familiaris;Cashew nut;Cattle;Cladosporium;Cods;Contractor;cost;Cynodon;dander;Data;Data Collection;Dermatophagoides farinae;Dermatophagoides pteronyssinus;Dictyoptera;egg;Felis catus;Fishes;food allergen;Food Hypersensitivity;German population;Hypersensitivity;IgE;Juglans;Lolium;Manuals;Milk;Mus;National Health and Nutrition Examination Survey;Participant;Penicillium;Proteins;Protocols documentation;pyroglyphid;Questionnaires;Rhinitis;Salsola;Sampling;Serum;Sesame - dietary;Shrimp;soy;Testing;Training;United States National Center for Health Statistics;Urine;Wheat,"National Health and Nutrition Examination Survey, Allergy Component/Study",240300,NA,NA,NA,NA,NA,NA,NA,1093500,NA
11203871,R01,HG,7,N,2024-12-23,2024-10-04,2025-02-28,172,R01HG012853,SCHOOLS OF ARTS AND SCIENCES,PA-24-254,7R01HG012853-03,NHGRI:354295\,NON-SBIR/STTR RPGS,2024,NATIONAL HUMAN GENOME RESEARCH INSTITUTE,NA,ALBANY,UNITED STATES,CHEMISTRY,20,152652822,US,5992604,STATE UNIVERSITY OF NEW YORK AT ALBANY,NY,122220001,"PROJECT NARRATIVE Although more than 170 RNA modifications have been identified so far, we only know the function of a few of these, mainly due to technological limitations. The goal of the proposed research is to bring the power of mass laddering technology from proteomics to RNA for developing a direct RNA sequencing and quantitative mapping tool for multiple RNA modifications at single-base resolution all in a single analysis, as a critical step toward elucidating their possible impact on human health.",12473424 (contact),"ZHANG, SHENGLONG  (contact)","NOVA, IAN CURTIS",2023-03-01,2027-02-28,NA,Development of Next-Generation Mass Spectrometry-based de novo RNA Sequencing for all Modifications,12853,ZHG1,ZHG1-HGR-M(O1),NA,NA,3,236694,117601,354295,NA
11203921,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00014,NA,NA,75N93024C00014-0-9999-1,NIAID:594566\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,EAST AURORA,UNITED STATES,NA,23,NA,US,10069733,"FLAG BIO, INC.",NY,145052301,NA,79946571 (contact),"ANDRIANOVA, KATERINA  (contact)",NA,2024-09-01,2026-08-31,"Agonist;anti-influenza;California;cellular transduction;Contractor;COVID-19 vaccine;de-immunization;Dependence;design;Dose;efficacy evaluation;Formulation;Hemagglutinin;Immune response;In Vitro;Influenza;Influenza A Virus, H1N1 Subtype;Influenza Hemagglutinin;influenza infection;Messenger RNA;mouse model;mRNA lipid nano particle vaccine;Mus;Pharmacodynamics;polypeptide;preclinical efficacy;RNA vaccine;Series;Specificity;TLR5 gene;Toxicology;Transcript;Vaccinated;Vaccine Adjuvant;vaccine development;Vaccines;Variant",MRNA VACCINE DEVELOPMENT,0,NA,NA,NA,NA,NA,NA,NA,594566,NA
11203936,N44,AI,NA,N,NA,NA,NA,NA,75N93024C00016,NA,NA,75N93024C00016-0-9999-1,NIAID:2999999\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LAWRENCE,UNITED STATES,NA,01,080189550,US,10042562,"DESIGN-ZYME, LLC",KS,660473944,NA,1865967 (contact),"PETILLO, PETER A (contact)",NA,2024-09-30,2027-09-29,Adjuvant;Antigens;Borrelia;Contractor;Development;Dose;efficacy study;head-to-head comparison;Hyaluronic Acid;Hyaluronic Acid Binding;immunogenicity;Lyme Disease;Lyme Disease Vaccines;Modeling;mosaic;Mus;OspC protein;Production;Tick-Borne Infections;Vaccine Adjuvant;vaccine efficacy;Vaccines,DEVELOPMENT OF COVALENTLY BOUND HYALURONIC ACID AS AN ADJUVANT FOR MULTIVALENT LYME DISEASE VACCINE,0,NA,NA,NA,NA,NA,NA,NA,2999999,NA
11203954,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00017,NA,NA,75N93024C00017-0-9999-1,NIAID:2999352\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,RANCHO DOMINGUEZ,UNITED STATES,NA,44,058878682,US,3719901,"MOLECULAR EXPRESS, INC.",CA,902205610,NA,9707662 (contact),"HO, SAMON  (contact)",NA,2024-09-01,2027-08-31,Adjuvant;Agonist;Antigens;Aspergillosis;Contractor;Contracts;Development;Liposomes;manufacture;manufacturing process;Neisseria gonorrhoeae;Procedures;Process;Recombinant Proteins;scale up;stability testing;System;TLR7 gene;Vaccine Adjuvant;Vaccines,VESIVAX TLR7 FORMULA,0,NA,NA,NA,NA,NA,NA,NA,2999352,NA
11204002,R35,GM,7,N,2024-11-13,2024-08-15,2025-06-30,859,R35GM147441,SCHOOLS OF ARTS AND SCIENCES,PA-24-254,7R35GM147441-04,NIGMS:294175\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,KNOXVILLE,UNITED STATES,CHEMISTRY,02,003387891,US,578304,UNIVERSITY OF TENNESSEE KNOXVILLE,TN,379192333,"Project Narrative  To meet the increasing demands for safer, yet effective medicines, scientists are using deuterated small molecules to develop novel therapeutics. Despite the tremendous advantages and recent success of deuterated medicines, highly selective chemical reactions to access novel deuterated small molecules and the analytical spectroscopic techniques to support developing these reactions are severely lagging. The proposed research is designed to modernize the synthesis of deuterated small molecules and to advance the field of regioselective aryl alkyne hydrofunctionalization chemistry.",12036409 (contact),"CLARK, JOSEPH  (contact)","ASLAN, KADIR",2022-07-15,2027-06-30,NA,Highly Selective Cu-Catalyzed Reactions for Precision Deuteration and Alkyne Hydrofunctionalization,147441,ZRG1,Special Emphasis Panel[ZRG1-BCMB-B(55)R],NA,NA,4,192271,101904,294175,NA
11204136,K01,DC,7,N,2024-10-16,2024-08-03,2025-07-31,173,K01DC018852,SCHOOLS OF MEDICINE,PA-24-254,7K01DC018852-06,NIDCD:115601\,OTHER RESEARCH-RELATED,2024,NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS,NA,OMAHA,UNITED STATES,OTHER BASIC SCIENCES,02,053309332,US,1943701,CREIGHTON UNIVERSITY,NE,681780133,"Project Narrative Neural circuits that transmit sound from the ear to the brain rely on precise connections with their appropriate partners. Disruption of this can lead to sensorineural hearing loss, or “nerve deafness”. The work described here, aims to understand how neural circuits in the auditory system are established in normal hearing to better understand disease, and improve prevention and treatment strategies.",10513429 (contact),"WEBBER, JEMMA LOUISE (contact)","RIVERA-RENTAS, ALBERTO L",2020-08-06,2025-07-31,NA,Development of Afferent and Efferent Innervation in the Inner Ear,18852,CDRC,Communication Disorders Review Committee[CDRC],NA,NA,6,107038,8563,115601,NA
11205412,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00075,NA,NA,75N93024C00075-0-9999-1,NIAID:1313458\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,STANFORD,UNITED STATES,NA,16,009214214,US,8046501,STANFORD UNIVERSITY,CA,943052004,NA,80001837 (contact),"BOYD, SCOTT  (contact)",NA,2024-09-30,2025-09-29,Allergens;Allergic;Antibodies;B-Cell Antigen Receptor;B-Lymphocyte Epitopes;B-Lymphocytes;Blood specimen;Cashew nut;Cattle;Cell Degranulation;chicken egg;Clinical;Clone Cells;Epitopes;Exposure to;Food;food allergen;food challenge;Food Hypersensitivity;Goals;Heterogeneity;Human;Hypersensitivity;IgE;IgG1;IgG4;innovation;mast cell;Milk;oral immunotherapy;Patients;Plasma;Proteins;response;Serology;Shrimp;Specificity;Tissue Sample,Innovations in Functional B Cell Epitope Discovery for Food Allergy,0,NA,NA,NA,NA,NA,NA,NA,1313458,NA
11205626,N02,HL,NA,N,NA,NA,NA,NA,75N92022D00013,NA,NA,75N92022D00013-0-759202400004-1,NIAID:400000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,HADLEY,UNITED STATES,NA,02,110907578,US,10041458,VENTUREWELL,MA,010359462,NA,80002102 (contact),"MARINO, MARK  (contact)",NA,2024-09-30,2026-09-29,Acceleration;Clinical;commercialization;Diagnostic;diagnostic technologies;Diagnostic tests;Goals;Hepatitis B;innovation;point-of-care diagnostics;RADx;Resources;Services;United States National Institutes of Health,RADx Innovation Funnel for Hepatitis B Diagnostics – Commercialization Center,0,NA,NA,NA,NA,NA,NA,NA,400000,NA
11205647,N02,HL,NA,N,NA,NA,NA,NA,75N92022D00015,NA,NA,75N92022D00015-0-759202400003-2,NIAID:410000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,NA,80000486 (contact),"LAM, WILBUR  (contact)",NA,2024-09-30,2026-09-29,Acceleration;Development;Diagnostic;diagnostic technologies;Diagnostic tests;Hepatitis B;innovation;point-of-care diagnostics;programs;RADx;RADx Tech;United States National Institutes of Health;Validation,RADx Innovation Funnel for Hepatitis B Diagnostics - Validation Center,0,NA,NA,NA,NA,NA,NA,NA,410000,NA
11205649,N02,HL,NA,N,NA,NA,NA,NA,75N92022D00014,NA,NA,75N92022D00014-0-759202400003-1,NIAID:190000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,BOSTON,UNITED STATES,NA,08,073130411,US,4907701,MASSACHUSETTS GENERAL HOSPITAL,MA,021142621,NA,80001997 (contact),"SCHACHTER, STEVEN C.  (contact)",NA,2024-09-30,2026-09-29,Acceleration;Development;Diagnostic;diagnostic technologies;Diagnostic tests;Hepatitis B;innovation;point-of-care diagnostics;programs;RADx;RADx Tech;United States National Institutes of Health,RADx Innovation Funnel for Hepatitis B Diagnostics  - Coordination Center,0,NA,NA,NA,NA,NA,NA,NA,190000,NA
11205657,R01,AG,7,N,2025-01-15,2025-01-15,2025-06-30,866,R01AG069679,SCHOOLS OF MEDICINE,PA-24-254,7R01AG069679-06,NIA:366985\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE ON AGING,NA,WINSTON-SALEM,UNITED STATES,INTERNAL MEDICINE/MEDICINE,05,937727907,US,9021205,WAKE FOREST UNIVERSITY HEALTH SCIENCES,NC,271570001,"Narrative. Metformin has a wide range of beneficial health effects, including promoting healthy aging, and yet the primary molecular mechanism of action of metformin is still unresolved. This project will investigate whether metformin, similar to other positively charged molecules, works by inducing a mild decrease in the efficiency of energy transformation, a primary mechanism that could account for the protection against numerous aging-related diseases.",1914743 (contact),"NEUFER, P DARRELL (contact)","BOYCE, AMANDA T",2020-09-15,2025-06-30,NA,Bioenergetics of Metformin Action and Aging,69679,ZAG1,ZAG1-ZIJ-U(A1),NA,NA,6,236764,130221,366985,NA
11205803,N02,CA,NA,N,NA,NA,NA,NA,75N98022D00027,NA,NA,75N98022D00027-P00001-759102300001-3,NCI:200000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,MCLEAN,UNITED STATES,NA,NA,171830748,US,NA,NA,VA,221023838,NA,NA,(contact),NA,2024-05-13,2025-05-12,Clinical;Funding;Image;SEER Program;Services,SUPPORT SERVICES FOR SEER PROGRAM CURES funding,0,NA,NA,NA,NA,NA,NA,NA,200000,NA
11205892,N02,CA,NA,N,NA,NA,NA,NA,91023A00191023F00001,NA,NA,91023A00191023F00001-P00013-0-1,NCI:86025\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,ARLINGTON,UNITED STATES,NA,08,139727148,US,10054304,"ACCENTURE FEDERAL SERVICES, LLC",VA,222031807,NA,79768326 (contact),"MAHONEY, LISA  (contact)",NA,2022-11-15,2025-05-14,Adopted;Agreement;Businesses;Data;design;Ensure;Environment;Funding;Goals;improved;Information Technology;Malignant Childhood Neoplasm;Mission;National Cancer Institute;Research;software development;Software Engineering;Technology;trend,NCI - SOFTWARE ENGINEERING AND SUPPORT_CCDI,0,NA,NA,NA,NA,NA,NA,NA,86025,NA
11206063,K08,NS,7,N,2024-12-18,2024-10-05,2024-12-31,853,K08NS112580,SCHOOLS OF MEDICINE,PA-24-254,7K08NS112580-06,NINDS:96120\,OTHER RESEARCH-RELATED,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,CHARLESTON,UNITED STATES,INTERNAL MEDICINE/MEDICINE,06,183710748,US,7575301,MEDICAL UNIVERSITY OF SOUTH CAROLINA,SC,294074636,Many premature infants suffer brain injury due to bleeding within the fluid-filled spaces of the brain that occurs shortly after birth. Currently there is no medical therapy to reduce brain injury in these children. This study will examine the causes of this neonatal brain injury and test therapies to reduce the injury.,8204899 (contact),"MILLER, BRANDON A (contact)","HEWETT, SANDRA JEANNE",2024-10-05,2025-12-31,NA,Reversing inflammatory macrophage activation as treatment for neonatal intraventricular hemorrhage and hydrocephalus,112580,NST,NST-1 Study Section[NST-1],NA,NA,6,89000,7120,96120,NA
11206098,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00525,NA,NA,75N91024P00525-0-0-1,NCI:30000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,MINNEAPOLIS,UNITED STATES,NA,05,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,NA,79862596 (contact),"WICHTERMAN, BENJAMIN  (contact)",NA,2024-07-01,2025-06-30,Databases;Food;Frequencies;Nutrient;Questionnaires,Support for PUBLIC USE FOOD FREQUENCY QUESTIONNAIRE.,0,NA,NA,NA,NA,NA,NA,NA,30000,NA
11206214,N01,HL,NA,N,NA,NA,NA,NA,75N92024C00001,NA,NA,75N92024C00001-0-9999-1,NHLBI:462045\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,OKEMOS,UNITED STATES,NA,07,809483670,US,3480701,MICHIGAN PUBLIC HEALTH INSTITUTE,MI,488646001,NA,79065473 (contact),"FAULKNER, MEGHAN  (contact)",NA,2024-05-01,2025-04-30,"Address;Adolescent;Agreement;Algorithms;authority;Autopsy;Bereavement;biobank;Categories;Centers for Disease Control and Prevention (U.S.);Cessation of life;Child;Collection;Consent;Contracts;Data;Data Coordinating Center;data registry;Data Sources;Deposition;DNA;DNA Sequence;Equipment;Evaluation;Family member;family support;Funding;Goals;Home;Incidence;Institutional Review Boards;Investigation;Learning;Location;loved ones;Maintenance;Medical;Michigan;National Heart, Lung, and Blood Institute;National Institute of Neurological Disorders and Stroke;Population;population based;prevent;Prevention;Prevention program;Process;Progress Reports;Protocols documentation;Registries;Reporting;repository;Research;Research Personnel;Research Support;Resources;review of reported cases;Risk Factors;Sampling;Services;Standardization;Sudden Death;Sudden infant death syndrome;System;Training;United States National Institutes of Health;Universities;Work",SUDDEN DEATH IN THE YOUNG CASE REGISTRY (SDY) - DATA COORDINATING CENTER BIOSPECIMEN AND CONSENT ACTIVITIES,0,NA,NA,NA,NA,NA,NA,NA,462045,NA
11206242,R35,GM,7,N,2024-12-13,2024-11-01,2025-05-31,859,R35GM155460,BIOMED ENGR/COL ENGR/ENGR STA,PA-24-254,7R35GM155460-02,NIGMS:403748\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,HADLEY,UNITED STATES,BIOMEDICAL ENGINEERING,02,153926712,US,850904,UNIVERSITY OF MASSACHUSETTS AMHERST,MA,010359450,"NARRATIVE Sepsis is a rapid-developing and life-threatening condition caused by the body’s extreme reaction to an infection. Early detection of sepsis-causing agents enables precise treatment and higher chance of survival for patients, but current molecular diagnostic technologies still depend on lengthy blood culture. This MIRA project aims to develop a blood culture-independent sensing device to accurately detect sepsis-causing pathogens in about 2 hours after blood sampling.",14940567 (contact),"LIU, CHANG  (contact)","ZHAO, XIAOLI",2024-07-01,2029-05-31,NA,Rapid Culture-Independent Detection of Sepsis Causing Microorganism Directly from Blood,155460,MRAD,Maximizing Investigators' Research Award - D Study Section[MRAD],NA,NA,2,249999,153749,403748,NA
11207073,N01,AI,NA,N,NA,NA,NA,NA,75N93021D00038,NA,NA,75N93021D00038-0-759302400001-2,NIAID:63400\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,BETHESDA,UNITED STATES,NA,08,057052391,US,1603501,"TECHNICAL RESOURCES INTERNATIONAL, INC.",MD,208171197,NA,NA,(contact),NA,2024-04-15,2025-04-14,NA,COVID-19: NIAID Regulatory Support Center,0,NA,NA,NA,NA,NA,NA,NA,63400,NA
11208104,Y01,DE,NA,N,NA,NA,NA,NA,ADE24002001,NA,NA,ADE24002001-1-0-1,NIDCR:25000\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH,NA,NA,NA,NA,(contact),NA,NA,NA,Age;Agreement;Collaborations;craniofacial;Data;Data Analyses;Dental;Dental caries;Disease;Early Diagnosis;Fluorides;Health;Home;Household;Imaging technology;Implant;improved;improved outcome;Interview;Knowledge;Mission;Mouth Diseases;National Health and Nutrition Examination Survey;National Institute of Dental and Craniofacial Research;Oral;oral condition;Oral Examination;Oral health;Participant;Prevalence;Prevention;Procedures;Quality of life;sealant;Surveys;Testing;Tooth structure;Translating;treatment strategy;United States National Center for Health Statistics;United States National Institutes of Health;Visual;water sampling,"National Health and Nutrition Examination Survey, Oral Health Component/Study",240020,NA,NA,NA,NA,NA,NA,NA,25000,NA
11208176,N02,HL,NA,N,NA,NA,NA,NA,316201500034W,NA,NA,316201500034W-P00002-759202300001-1,NHLBI:2481890\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,CHANTILLY,UNITED STATES,NA,11,089896737,US,10052403,"FOUR POINTS TECHNOLOGY, LLC",VA,201513834,NA,79685741 (contact),"LUCAS, LAURIE  (contact)",NA,2023-09-19,2025-03-18,"Administrator;Agreement;Area;Attention;Automation;Award;Business Rules;Categories;Classification;Clinical Trials;Code;Collaborations;Communication;Computer software;Conflict of Interest;Contractor;Contracts;Controlled Vocabulary;Custom;Data;data access;Data Analyses;data format;data management;data quality;Data Set;data sharing;Data Sources;Databases;Decision Making;Dedications;design;Development;Device or Instrument Development;Devices;Discipline;Documentation;drug development;Ecosystem;effectiveness analysis;Equity;Evaluation;Evaluation Studies;experience;Experimental Designs;Funding;Funding Mechanisms;Geography;Grant;Guidelines;Impact evaluation;improved;indexing;Individual;Information Systems;Information Technology;Institution;International;Internet;Journals;large datasets;Leadership;Legal patent;Libraries;Machine Learning;Maintenance;Manuals;Manuscripts;Mediation;Medical Device;meetings;member;MeSH Thesaurus;Methodology;mobile application;Modeling;Multi-Institutional Clinical Trial;National Heart, Lung, and Blood Institute;Natural Language Processing;new technology;news;Online Systems;Ontology;open source;Outcome Assessment;Outcomes Research;Output;Peer Review;Performance;Pharmaceutical Preparations;Play;Policies;Process;Program Evaluation;Program Research Project Grants;programs;Property;Protocols documentation;Proxy;Publications;Published Comment;Publishing;Qualifying;Recommendation;Reporting;Research;Research Activity;research and development;Research Institute;Research Personnel;Resource Allocation;Resources;Science;search engine;Secure;Semantics;Services;Shapes;Site;skills;social media;software systems;Source;Standardization;structured data;Study Section;System;Systematized Nomenclature of Medicine;Taxonomy;Technology;Testing;Text;text searching;Time;tool;Training;Unified Medical Language System;United States National Institutes of Health;Update;Validation;virtual;Visualization;Visualization software;web app;web services;web site;Work;Writing",NHLBI SCIENTIFIC REVIEW AND SCIENTIFIC PORTFOLIO ANALYSIS (SR/SPA) SOLUTION AND SUPPORT SERVICES WITH ARPA-H SUPPORT (SR/SPA) SERVICES,0,NA,NA,NA,NA,NA,NA,NA,2481890,NA
11208340,N02,DA,NA,N,NA,NA,NA,NA,316201200038W,NA,NA,316201200038W-0-759502400001-1,NIMH:8189869\NINDS:200000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NA,NA,NA,NA,802314120,NA,NA,NA,NA,NA,NA,NA,(contact),NA,2012-06-01,2025-06-06,Acceleration;Affect;Archives;autism spectrum disorder;biomedical informatics;Brain Diseases;Communication;Data;data archive;Data Collection;data platform;Databases;Diagnosis;flexibility;Genetic;interest;National Institute of Mental Health;Persons;Prevention;repository;Research;Retrieval;Series;System;United States National Institutes of Health;Work,THE PURPOSE OF THIS TASK ORDER IS TO SUPPORT THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) DATA ARCHIVE (NDA) IN ACCORDANCE WITH THE INCORPORATED ATTACHMENT 1: STATEMENT OF WORK.,0,NA,NA,NA,NA,NA,NA,NA,8389869,NA
11208886,Y01,TR,NA,N,NA,NA,NA,NA,ATR24003001,NA,NA,ATR24003001-1-0-1,NCATS:520000\,INTERAGENCY AGREEMENTS,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,(contact),NA,NA,NA,3-Dimensional;Acute;Award;Biological;Biological Models;Biomedical Engineering;Body System;Chemical Exposure;Chronic;Clinical Trials Design;Complex;Disease;drug development;Engineering;Environment;Environmental Exposure;Evolution;Exposure to;Human;improved;in vitro Model;Investigation;Joints;Longevity;microphysiology system;Modeling;Physiological;Process;Research;Space Flight;Specific qualifier value;stressor;Technology;Time;Tissue Microarray;Tissue Viability;Tissues;Translations;United States National Aeronautics and Space Administration;United States National Institutes of Health,BIOENGINEERING OF 3D TISSUES AND MICROPHYSIOLOGICAL SYSTEMS TOWARDS LONGEVITY EXTENSION FOR MODELING OF ACUTE AND CHRONIC EXPOSURES TO STRESSORS,240030,NA,NA,NA,NA,NA,NA,NA,520000,NA
11209094,P01,AI,7,N,2024-11-20,2024-11-01,2025-07-31,NA,P01AI177688,NA,PA-24-254,7P01AI177688-03,NIAID:40354\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MINNEAPOLIS,UNITED STATES,NA,05,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,NA,1940486 (contact),"GALE, MICHAEL  (contact)","WARREN, JON T",2023-08-01,2028-07-31,NA,Admin-Core-001,177688,ZAI1,ZAI1-DNV-A(M1),9814,NA,3,26204,14150,NA,40354
11209095,P01,AI,7,N,2024-11-20,2024-11-01,2025-07-31,NA,P01AI177688,NA,PA-24-254,7P01AI177688-03,NIAID:297878\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MINNEAPOLIS,UNITED STATES,NA,05,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,NA,1940486 (contact),"GALE, MICHAEL  (contact)","WARREN, JON T",2023-08-01,2028-07-31,NA,Project-002,177688,ZAI1,ZAI1-DNV-A(M1),9815,NA,3,199332,98546,NA,297878
11209096,P01,AI,7,N,2024-11-20,2024-11-01,2025-07-31,NA,P01AI177688,NA,PA-24-254,7P01AI177688-03,NIAID:449505\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MINNEAPOLIS,UNITED STATES,NA,05,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,NA,1940486 (contact),"GALE, MICHAEL  (contact)","WARREN, JON T",2023-08-01,2028-07-31,NA,Core-001,177688,ZAI1,ZAI1-DNV-A(M1),9816,NA,3,449505,0,NA,449505
11209097,P01,AI,7,N,2024-11-20,2024-11-01,2025-07-31,NA,P01AI177688,NA,PA-24-254,7P01AI177688-03,NIAID:439969\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MINNEAPOLIS,UNITED STATES,NA,05,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,NA,1940486 (contact),"GALE, MICHAEL  (contact)","WARREN, JON T",2023-08-01,2028-07-31,NA,Core-002,177688,ZAI1,ZAI1-DNV-A(M1),9817,NA,3,285694,154275,NA,439969
11209160,N01,TR,NA,N,NA,NA,NA,NA,7588104,NA,NA,7588104-0-0-1,NCATS:1600000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,(contact),NA,NA,NA,3-Dimensional;Address;Adoption;Algorithms;Area;Biological;Biomedical Research;biomedical scientist;Clinical;clinical application;Collaborations;Color;Communication;Defect;Detection;Development;Devices;Diagnostic;diagnostic development;Diamond;Discipline;Disease Marker;early detection biomarkers;Early Diagnosis;Engineering;Functional Imaging;Generations;Health Sciences;Hybrids;imaging modality;improved;Interferometry;International;Light;Magnetic Resonance Imaging;Microscopy;Modality;multidisciplinary;nanodiamond;Noise;Optics;photon-counting detector;photonics;Photons;Physics;quantum;quantum computing;quantum information science;quantum optics;quantum sensing;quantum technologies;real world application;Resources;Scientist;sensor;sensor technology;solid state;Source;Spectrum Analysis;Techniques;Technology;technology development;Testing;therapeutic development;Thermometry;translational impact;United States National Institutes of Health;Validation;Work,NIH Quantum Sensing Technology Challenge,0,NA,NA,NA,NA,NA,NA,NA,1600000,NA
11209325,N01,TR,NA,N,NA,NA,NA,NA,7588101,NA,NA,7588101-0-0-1,NCATS:400000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,(contact),NA,NA,NA,Address;Adopted;Algorithms;Area;Biological;biomedical imaging;Classification;clinical risk;Communication;Complex;Computational Science;Data Analyses;Department of Energy;Development;Diagnosis;Discipline;DNA;drug discovery;Engineering;Formulation;Generations;genomic data;Hybrids;improved;interest;International;Machine Learning;materials science;Mathematics;Medical Imaging;Methods;Modality;Molecular;novel;Physics;Proteins;quantum;quantum computing;quantum information science;Quantum Mechanics;quantum technologies;risk prediction;RNA Folding;Science;Sequence Analysis;simulation;Speed;Technology;Therapeutic;Treatment Effectiveness;United States National Institutes of Health,NIH Quantum Computing Challenge Solve translational biomedical problems with quantum computing,0,NA,NA,NA,NA,NA,NA,NA,400000,NA
11209442,N01,TR,NA,N,NA,NA,NA,NA,7583246,NA,NA,7583246-0-0-1,NCATS:50000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,(contact),NA,NA,NA,Administrator;Biomedical Research;certificate program;Communication;Communities;community organizations;design;Disease;Dissemination and Implementation;Education;Educational workshop;Health;innovation;Knowledge;Literature;Modeling;National Center for Advancing Translational Sciences;novel;outreach;Participant;patient advocacy group;Persons;Prize;Process;programs;Research;Science;science education;Scientist;Series;skills;symposium;Training and Education;training opportunity;translational model;translational progress;Translational Research;web site,NCATS Translational Science Education and Training Challenge,0,NA,NA,NA,NA,NA,NA,NA,50000,NA
11209521,N02,CA,NA,N,NA,NA,NA,NA,75N91020D00011,NA,NA,75N91020D00011-P00005-759102200001-1,OD:115241\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,Arlington,UNITED STATES,NA,08,019121586,US,10037609,"DELOITTE CONSULTING, LLP",VA,22209,NA,79850429 (contact),"KOPCHIC, BENJAMIN  (contact)",NA,2022-09-19,2025-07-05,cancer epidemiology;Development;epidemiologic data;web app,WEB APPLICATION FOR CANCER EPIDEMIOLOGY DATA,0,NA,NA,NA,NA,NA,NA,NA,115241,NA
11209522,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00498,NA,NA,75N91024P00498-0-0-1,NCI:130000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,CHICAGO,UNITED STATES,NA,07,068478452,US,245101,AMERICAN COLLEGE OF SURGEONS,IL,606113234,NA,79850444 (contact),"MADERA, MARTIN  (contact)",NA,2024-07-01,2025-06-30,Active Sites;Collection;correctional system;Diagnostic Neoplasm Staging;Licensing;Manuals;Performance;Staging System;Update,CORRECT THE PERIOD OF PERFORMANCE FOR CLIN 4: ACCESS TO THE 8TH EDITION OF THE CANCER STAGING MANUAL AND THE VERSION 9 CANCER STAGING SYSTEM REQUIRES AN ACTIVE SITE LICENSE. TO CONTINUE COLLECTION AND,0,NA,NA,NA,NA,NA,NA,NA,130000,NA
11209811,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00604,NA,NA,75N91024P00604-0-0-1,NCI:31741\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,LAKE SUCCESS,UNITED STATES,NA,NA,112007062,US,NA,NA,NY,110421055,NA,NA,(contact),NA,2024-08-07,2025-07-06,Institutional Review Boards;minimal risk;Registries,CENTRALIZED INSTITUTIONAL REVIEW BOARD (CIRB) FOR MINIMAL RISK REGISTRY LINKAGE STUDIES- FY24,0,NA,NA,NA,NA,NA,NA,NA,31741,NA
11210394,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00038,NA,NA,75N92019D00038-0-759202400001-1,NHLBI:2702179\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,SAN FRANCISCO,UNITED STATES,NA,11,006902498,US,10004326,VITALANT,CA,941051638,NA,NA,(contact),NA,2024-07-01,2026-06-30,NA,REDS-IV-P BRAZIL HUB,0,NA,NA,NA,NA,NA,NA,NA,2702179,NA
11210421,Y01,HL,NA,N,NA,NA,NA,NA,AHL23015001,NA,NA,AHL23015001-1-0-1,NHLBI:450000\,INTERAGENCY AGREEMENTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,(contact),NA,NA,NA,"Advisory Committees;Blood;Blood Donations;Blood donor;Collaborations;Geography;Hepatitis B;Hepatitis C;HIV;Infection;Intervention;Investigation;meetings;Monitor;National Heart, Lung, and Blood Institute;Organ;Policies;programs;Public Health;Recommendation;Resources;Risk;Risk Factors;Risk Marker;Safety;System;Time;Tissues;Transfusion;transmission process;trend;United States;United States Agency for Healthcare Research and Quality;United States Health Resources and Services Administration;United States National Institutes of Health;Vascular blood supply;Voting",Transfusion-Transmissible Infections Monitoring System,230150,NA,NA,NA,NA,NA,NA,NA,450000,NA
11210423,Y01,HL,NA,N,NA,NA,NA,NA,AHL23011001,NA,NA,AHL23011001-1-0-1,NHLBI:639000\,INTERAGENCY AGREEMENTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,(contact),NA,NA,NA,"American;beneficiary;Censuses;Cessation of life;cohort;Communities;Community Surveys;Data;Databases;Economics;Elderly;Environment;Ethnic Origin;health care service utilization;Healthcare;indexing;Information Centers;Medicaid;Medicare/Medicaid;men;Modification;mortality;mortality disparity;mortality statistics;National Heart, Lung, and Blood Institute;Neighborhoods;Occupational;Outcome;Patient Self-Report;Persons;Prospective Studies;Race;social;sociodemographics;socioeconomics;United States Centers for Medicare and Medicaid Services;Vital Statistics;Woman",Mortality Disparities in American Communities Study (MDAC),230110,NA,NA,NA,NA,NA,NA,NA,639000,NA
11210424,Y01,HL,NA,N,NA,NA,NA,NA,AHL24002001,NA,NA,AHL24002001-1-0-1,NHLBI:900000\,INTERAGENCY AGREEMENTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,(contact),NA,NA,NA,"20 year old;Address;Autopsy;Bereavement;Categories;Centers for Disease Control and Prevention (U.S.);Childhood;Collaborations;Communities;Data;design;Epidemiology;Evaluation;Event;evidence base;Family;Family member;family support;Geographic Locations;Goals;Incidence;Investigation;Knowledge;loved ones;Medical;National Heart, Lung, and Blood Institute;National Institute of Neurological Disorders and Stroke;Population;population based;prevent;Prevention;prospective;Public Health;Registries;Research;Resources;Risk Factors;Standardization;sudden cardiac death;Sudden Death;Sudden infant death syndrome;sudden unexpected death in epilepsy;Surveillance Program;United States;United States National Institutes of Health",Sudden Death in the Young (SDY) Case Registry,240020,NA,NA,NA,NA,NA,NA,NA,900000,NA
11210425,Y01,HL,NA,N,NA,NA,NA,NA,AHL24003001,NA,NA,AHL24003001-1-0-1,NHLBI:10892\,INTERAGENCY AGREEMENTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,(contact),NA,NA,NA,"20 year old;Address;Autopsy;Bereavement;Categories;Centers for Disease Control and Prevention (U.S.);Childhood;Collaborations;Communities;Data;design;Epidemiology;Evaluation;Event;evidence base;Family;Family member;family support;Geographic Locations;Goals;Incidence;Investigation;Knowledge;loved ones;Medical;National Heart, Lung, and Blood Institute;National Institute of Neurological Disorders and Stroke;Population;population based;prevent;Prevention;prospective;Public Health;Registries;Research;Resources;Risk Factors;Standardization;sudden cardiac death;Sudden Death;Sudden infant death syndrome;sudden unexpected death in epilepsy;Surveillance Program;United States;United States National Institutes of Health",Sudden Death in the Young (SDY) Case Registry,240030,NA,NA,NA,NA,NA,NA,NA,10892,NA
11210426,Y01,HL,NA,N,NA,NA,NA,NA,AHL23010001,NA,NA,AHL23010001-1-0-1,NHLBI:3264000\,INTERAGENCY AGREEMENTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,NA,NA,NA,NA,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NA,NA,NA,(contact),NA,NA,NA,Cardiovascular Diseases;National Health and Nutrition Examination Survey;respiratory health;United States National Center for Health Statistics,"National Health and Nutrition Examination Survey, Cardiovascular Disease and Respiratory Health Component/Study (NHANES)",230100,NA,NA,NA,NA,NA,NA,NA,3264000,NA
11210434,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00023,NA,NA,75N95022D00023-0-759502400002-1,NINDS:5609495\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,KENSINGTON,UNITED STATES,NA,08,094888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.”,79267239 (contact),"MAYER, CHRISTINA  (contact)",NA,2022-09-30,2030-09-29,clinical pain;Cyclic GMP;Helping to End Addiction Long-term;manufacture;Pain;Pain management;Speed;United States National Institutes of Health,CGMP MANUFACTURE OF VHCA8* FOR THE TREATMENT OF PAIN,0,NA,NA,NA,NA,NA,NA,NA,5609495,NA
11210479,N02,DA,NA,N,NA,NA,NA,NA,75N95022D00020,NA,NA,75N95022D00020-P00003-759502400001-1,NINDS:169638\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,WILMINGTON,UNITED STATES,NA,07,362574527,US,4079901,PPD DEVELOPMENT LP,NC,284013331,NA,79933136 (contact),"KIRKBY, MATTHEW  (contact)",NA,2024-04-09,2029-04-08,Acceleration;Address;Animal Testing;Award;bench to bedside;biomaterial compatibility;Clinical;Clinical Research;commercialization;Contractor;Contracts;design;Development;Device or Instrument Development;Devices;Diagnosis;Documentation;Face;first-in-human;Funding;Goals;Government;Incubators;Industry;industry partner;Intellectual Property;Investments;manufacture;Marketing;Medical;Medical Device;meetings;Mission;Monitor;Needs Assessment;Nervous System Disorder;new technology;Patients;Phase;pre-clinical;Preparation;programs;prototype;Readiness;Regulatory Affairs;Regulatory Pathway;Research;Research Contracts;Research Personnel;Resources;Risk;Services;System;Technology;Testing;Translations;United States Food and Drug Administration;United States National Institutes of Health,CONTRACT RESEARCH ORGANIZATION (CRO) SUPPORT FOR BLUEPRINT MEDTECH (BPMT) REGULATORY AFFAIRS SUPPORT AND RELATED SERVICES. REGULATORY PATHWAY AND MARKET ACCESS SUPPORT. TASK ORDER 03. 04/09/2024 - 04/,0,NA,NA,NA,NA,NA,NA,NA,169638,NA
11210491,Y01,OD,NA,N,NA,NA,NA,NA,AOD22022001,NA,NA,AOD22022001-1-0-1,OD:1007847\,INTERAGENCY AGREEMENTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,(contact),NA,NA,NA,Academy;Agreement;All of Us Research Program;Architecture;Artificial Intelligence;Cities;cloud based;Collaborations;Complex;Computational Science;computing resources;Data;Data Science;Data Set;Department of Defense;flexibility;Human Resources;Informatics;Information Systems;Mediation;Military Personnel;Modeling;New York;nutrition;Precision Health;precision nutrition;Research Personnel;Resources;System;tool;tool development;United States;United States National Institutes of Health;Universities;Work,"Artificial Intelligence, Modeling, and Informatics for Nutrition Guidance and Systems (AIMINGS) Center",220220,NA,NA,NA,NA,NA,NA,NA,1007847,NA
11210619,Y01,ES,NA,N,NA,NA,NA,NA,AES23009001,NA,NA,AES23009001-1-0-1,NIEHS:118919\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,NA,"Characterizing occupational exposures provides a real-world context for NIEHS toxicology studies. To achieve this, NIOSH will characterize occupational exposures using a multidisciplinary approach to include toxicology, epidemiology, engineering, industrial science, and occupational medicine. These studies contribute to the prevention of diseases or adverse effects caused by environmental exposure to chemical or physical agents by identifying sources of exposure and strategies for mitigation.",NA,(contact),NA,NA,NA,Acetates;Acute;Address;Adhesives;Adverse effects;adverse maternal outcomes;Affect;Agreement;air sampling;Area;Birth;Budgets;chemical association;Chemical Exposure;Chemicals;community organizations;Complement;Congenital Abnormality;Contracts;Data;Development;developmental disease;disorder prevention;Employee;Engineering;Enrollment;Environmental Exposure;Epidemiology;epidemiology study;experience;Exposure to;Formaldehyde;Future;Geographic Locations;Gestational Diabetes;Goals;Hazard Assessment;Hazard Identification;Health;Human;Human Subject Research;Industrialization;inorganic phosphate;Institutional Review Boards;interdisciplinary approach;interest;Link;maternal outcome;Measurable;Measurement;Measures;Nail plate;National Institute of Environmental Health Sciences;Occupational;Occupational Exposure;Occupational Medicine;Occupations;Office Management;Ohio;Outcome;Participant;Pennsylvania;Philadelphia;Plasticizers;Polishes;Population;Pregnancy;Protocols documentation;Questionnaires;Recording of previous events;recruit;Reporting;reproductive;Reproductive Health;reproductive outcome;Retrospective Studies;Risk;Sampling;Science;Services;Site Visit;Solvents;Source;Spontaneous abortion;Techniques;Toluene;tool;toxicant;Toxicology;United States;volatile organic compound;Work,Assessment of task-based exposures that may affect reproductive health in nail salon employees,230090,NA,NA,NA,NA,NA,NA,NA,118919,NA
11210622,N01,AI,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400032-1,NIAID:7985002\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79979749 (contact),"ENGEL, THERESA  (contact)",NA,2024-09-09,2027-09-08,"Advanced Development;Affect;Animals;Avian Influenza A Virus;Birds;Cattle;Clinical Trials;Data;Disease Outbreaks;Goals;Influenza;Influenza A Virus, H5N1 Subtype;influenza virus vaccine;National Institute of Allergy and Infectious Disease;Pathogenicity;Phase;phase II trial;Public Health;vaccine development;Vaccines;Variant",Clinical Trails to Evaluate H5N1 Influenza Variant Vaccines,0,NA,NA,NA,NA,NA,NA,NA,7985002,NA
11210628,Y01,ES,NA,N,NA,NA,NA,NA,AES23001001,NA,NA,AES23001001-1-0-1,NIEHS:163366\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,NA,These projects characterize the potential exposure to and potential health effects of fungal contamination in the built environment.,NA,(contact),NA,NA,NA,Acoustics;Address;Aerosols;Agreement;Air;air sampling;Aspergillus;Aspergillus fumigatus;Biological Markers;Brain;built environment;Cardiac;Cardiopulmonary;Cells;Collaborations;Computers;Data;Development;Environment;exposed human population;Exposure to;fungus;Gene Modified;Genomics;Goals;Growth;Health;Health Hazards;Heart;Human;human model;Immunologics;improved;indoor air;Indoor environment;Inhalation;Inhalation Exposure;insight;Knowledge;Liquid substance;Lung;Lung immune response;Methodology;microbial;Mission;Modeling;Molds;mouse model;Mouse Strains;Mus;Mycotoxins;National Institute of Environmental Health Sciences;Neurologic;Occupational;particle;Public Health;Publications;Publishing;Pulmonary arterial remodeling;Reagent;Recovery;Report (document);Reporting;respiratory;response;Stachybotrys;System;systemic toxicity;Tissues;Toxicology,Assessment of Inhalation Exposures to Indoor and Occupational Aerosols - Murine Models of Repeated Fungal Inhalation Exposure,230010,NA,NA,NA,NA,NA,NA,NA,163366,NA
11210637,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00033,NA,NA,75N92019D00033-0-759202400001-1,NHLBI:2160438\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,SAN FRANCISCO,UNITED STATES,NA,11,006902498,US,10004326,VITALANT,CA,941051638,NA,2053846 (contact),"NORRIS, PHILIP J. (contact)",NA,2024-07-01,2026-06-30,"Adult;Attention;Blood;Blood donor;Blood Transfusion;Brazil;Caring;Charge;Child;Childhood;Collaborations;Collection;Community Hospitals;Contracts;Data;Data Analyses;Data Coordinating Center;Databases;Development;Effectiveness;Ensure;Epidemiology;epidemiology study;Evaluation Studies;Funding;Hospitals;improved;International;Laboratories;Laboratory Study;Link;Manuals;medical specialties;meetings;National Heart, Lung, and Blood Institute;neonate;operation;Pediatric Research;Phase;Procedures;programs;Protocols documentation;Publications;Reporting;Research;Research Personnel;research study;Resources;response;Safety;Services;Site;Test Result;Testing;Training;Transfusion;transmission process;Vascular blood supply;Veins;Work",REDS-IV-P CENTER FOR TRANSFUSION LABORATORY STUDIES,0,NA,NA,NA,NA,NA,NA,NA,2160438,NA
11210638,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00036,NA,NA,75N92019D00036-0-759202400001-1,NHLBI:1548389\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NEW HAVEN,UNITED STATES,NA,03,043207562,US,9420201,YALE UNIVERSITY,CT,065208327,NA,8385955 (contact),"HENDRICKSON, JEANNE E (contact)",NA,2024-07-01,2026-06-30,"Adult;Area;Attention;Blood;Blood Banks;Blood donor;Blood Transfusion;Brazil;Caring;Charge;Child;Childhood;Collaborations;Community Hospitals;Contracts;Data;Data Analyses;Data Collection;Data Coordinating Center;data exchange;Databases;Development;Effectiveness;Epidemiology;epidemiology study;Evaluation Studies;Goals;Hospitals;improved;Infrastructure;Laboratories;Laboratory Study;Link;Manuals;medical specialties;meetings;Mentors;National Heart, Lung, and Blood Institute;neonate;operation;Pediatric Research;Phase;Pilot Projects;Policies;Procedures;programs;Protocols documentation;Publications;Research;Research Personnel;research study;Resources;Safety;Services;Shipping;Site;symposium;Transfusion;transfusion medicine;transmission process;United States;Vascular blood supply;Veins",REDS-IV-P DOMESTIC HUBS,0,NA,NA,NA,NA,NA,NA,NA,1548389,NA
11210643,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00034,NA,NA,75N92019D00034-0-759202400001-1,NHLBI:2104121\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,SAN FRANCISCO,UNITED STATES,NA,11,006902498,US,10004326,VITALANT,CA,941051638,NA,79853193 (contact),"CUSTER, BRIAN  (contact)",NA,2024-07-01,2026-06-30,"Adult;Area;Attention;Blood;Blood Banks;Blood donor;Blood Transfusion;Brazil;Caring;Charge;Child;Childhood;Collaborations;Community Hospitals;Contracts;Data;Data Analyses;Data Collection;Data Coordinating Center;data exchange;Databases;Development;Effectiveness;Epidemiology;epidemiology study;Evaluation Studies;Goals;Hospitals;improved;Infrastructure;Laboratories;Laboratory Study;Link;Manuals;medical specialties;meetings;Mentors;National Heart, Lung, and Blood Institute;neonate;operation;Pediatric Research;Phase;Pilot Projects;Policies;Procedures;programs;Protocols documentation;Publications;Research;Research Personnel;research study;Resources;Safety;Services;Shipping;Site;symposium;Transfusion;transfusion medicine;transmission process;United States;Vascular blood supply;Veins",REDS-IV-P DOMESTIC HUBS,0,NA,NA,NA,NA,NA,NA,NA,2104121,NA
11210644,Y01,ES,NA,N,NA,NA,NA,NA,AES23001001,NA,NA,AES23001001-1-0-2,NIEHS:135814\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,NA,These projects characterize the potential exposure to and potential health effects of fungal contamination in the built environment.,NA,(contact),NA,NA,NA,Acoustics;Aerosols;Agreement;air sampling;Biological Markers;built environment;Computers;Data;Development;Dust;elementary school;Environment;Epidemiology;Evaluation;Event;exposed human population;Exposure to;field study;Floods;Floor;fungus;Future;Genomics;Goals;Health;Health Hazards;Hurricane;improved;indoor air;Inhalation Exposure;Lung immune response;Methodology;Methods;microbial;Mission;Modeling;Molds;Mycotoxins;National Institute of Environmental Health Sciences;next generation sequencing;Occupational;Philadelphia;Public Health;Publications;Publishing;Reagent;Research;Respiratory Tract Infections;response;Risk Assessment;Sampling;Schools;secondary metabolite;Statistical Data Interpretation;symposium;System;Toxicology;Water,Exposure Assessment of Indoor and Occupational Aerosols,230010,NA,NA,NA,NA,NA,NA,NA,135814,NA
11210645,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00035,NA,NA,75N92019D00035-0-759202400001-1,NHLBI:1656613\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,MILWAUKEE,UNITED STATES,NA,04,057163172,US,5304801,"VERSITI WISCONSIN, INC.",WI,532332121,NA,1901250 (contact),"MAST, ALAN E (contact)",NA,2024-07-01,2026-06-30,"Adult;Area;Attention;Blood;Blood Banks;Blood donor;Blood Transfusion;Brazil;Caring;Charge;Child;Childhood;Collaborations;Community Hospitals;Contracts;Data;Data Analyses;Data Collection;Data Coordinating Center;data exchange;Databases;Development;Effectiveness;Epidemiology;epidemiology study;Evaluation Studies;Goals;Hospitals;improved;Infrastructure;Laboratories;Laboratory Study;Link;Manuals;medical specialties;meetings;Mentors;National Heart, Lung, and Blood Institute;neonate;operation;Pediatric Research;Phase;Pilot Projects;Policies;Procedures;programs;Protocols documentation;Publications;Research;Research Personnel;research study;Resources;Safety;Services;Shipping;Site;symposium;Transfusion;transfusion medicine;transmission process;United States;Vascular blood supply;Veins",REDS-IV-P DOMESTIC HUBS,0,NA,NA,NA,NA,NA,NA,NA,1656613,NA
11210647,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00037,NA,NA,75N92019D00037-0-759202400001-1,NHLBI:1656603\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NEW YORK,UNITED STATES,NA,13,621889815,US,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NY,100323725,NA,9618222 (contact),"HOD, ELDAD ARIE (contact)",NA,2024-07-01,2026-06-30,"Adult;Area;Attention;Blood;Blood Banks;Blood donor;Blood Transfusion;Brazil;Caring;Charge;Child;Childhood;Collaborations;Community Hospitals;Contracts;Data;Data Analyses;Data Collection;Data Coordinating Center;data exchange;Databases;Development;Effectiveness;Epidemiology;epidemiology study;Evaluation Studies;Goals;Hospitals;improved;Infrastructure;Laboratories;Laboratory Study;Link;Manuals;medical specialties;meetings;Mentors;National Heart, Lung, and Blood Institute;neonate;operation;Pediatric Research;Phase;Pilot Projects;Policies;Procedures;programs;Protocols documentation;Publications;Research;Research Personnel;research study;Resources;Safety;Services;Shipping;Site;symposium;Transfusion;transfusion medicine;transmission process;United States;Vascular blood supply;Veins",REDS-IV-P DOMESTIC HUBS,0,NA,NA,NA,NA,NA,NA,NA,1656603,NA
11210718,R01,HL,7,N,2024-10-22,2024-10-22,2025-02-28,837,R01HL142214,SCHOOLS OF MEDICINE,PA-24-254,7R01HL142214-06,NHLBI:570910\,NON-SBIR/STTR RPGS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,GAINESVILLE,UNITED STATES,INTERNAL MEDICINE/MEDICINE,03,969663814,US,513806,UNIVERSITY OF FLORIDA,FL,326115500,"Project Narrative More than 37 million people in the United States have diabetes. Despite many medications for diabetes, the number of deaths resulting from coronary vascular complications, including coronary microvascular disease, is still high among patients with diabetes. This study is designed to identify the cellular defects that cause the abnormalities of small coronary arteries in diabetic patients and to develop new therapeutic approaches for coronary endothelial dysfunction in diabetes.",11802739;8448292 (contact),"LEE, YUN SOK ;MAKINO, AYAKO  (contact)","CHEN, JUE",2018-03-01,2028-02-29,angiogenesis;Anti-Inflammatory Agents;Apoptosis;Apoptotic;Arteries;arteriole;Atherosclerosis;Attenuated;Blood capillaries;Blood flow;Blood Vessels;Cardiac;Cardiomyopathies;Cardiovascular Diseases;Cell Separation;Cell-Cell Adhesion;Cells;Cessation of life;Chronic;Compensation;Contracts;Coronary;Coronary Arteriosclerosis;Coronary artery;Coronary Vessel Anomalies;Data;Defect;density;design;Development;Diabetes Mellitus;diabetic;diabetic cardiomyopathy;Diabetic mouse;diabetic patient;Distal;Down-Regulation;Endothelial Cells;endothelial dysfunction;Endothelium;Epidemic;Epidermal Growth Factor;Exhibits;Functional disorder;Glycoproteins;Goals;Heart;Heart Diseases;Heart Hypertrophy;Immunosuppressive Agents;improved;Incidence;Inflammation;Inflammatory;Injury;insight;Investigation;Lead;Left ventricular structure;Lipids;Macrophage;Mediating;Microvascular Dysfunction;migration;milk fat globule;Mitochondrial DNA;Molecular;mortality;Mus;Myocardial Ischemia;novel;novel therapeutic intervention;novel therapeutics;Patients;Persons;Phagocytes;Pharmaceutical Preparations;Phenotype;Play;Population;programs;Relaxation;Reporting;Risk Factors;Role;Splenomegaly;Stenosis;Stroke;Testing;Therapeutic Intervention;therapeutically effective;tissue injury;tissue regeneration;tissue repair;Tissues;Treatment Factor;United States;Vascular Endothelial Growth Factors;Vascular Endothelium-Dependent Relaxation;Vascular remodeling;vasoconstriction;Vasodilation,Coronary Endothelial Cell Dysfunction in Diabetes: Role of MFGE8,142214,IVPP,Integrative Vascular Physiology and Pathology Study Section[IVPP],NA,NA,6,374114,196796,570910,NA
11210772,N43,CA,NA,N,NA,NA,NA,NA,75N91024C00062,NA,NA,75N91024C00062-0-9999-1,NCI:397626\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,MIDDLETON,UNITED STATES,NA,02,788084705,US,3443701,"STANDARD IMAGING, INC.",WI,535621461,NA,78413202 (contact),"HOLMES, SHANNON M (contact)",NA,2024-09-15,2025-09-14,"Biological;Clinical;clinical translation;Dependence;design,build,test;detector;Development;Doctor of Philosophy;Dose;Dose Rate;dosimetry;Frequencies;Goals;Image;International;irradiation;Measurement;Measures;nanosecond;Normal tissue morphology;novel;optical fiber;Physiologic pulse;preclinical study;Principal Investigator;prototype;radiation detector;Radiation therapy;Reporting;Resolution;response;Structure;System;Technology;Testing;Time;Tissues;tumor;University of Texas M D Anderson Cancer Center",TOPIC 461: A NOVEL SCINTILLATION DETECTOR SYSTEM FOR FLASH RADIATION THERAPY,0,NA,NA,NA,NA,NA,NA,NA,397626,NA
11210780,N43,CA,NA,N,NA,NA,NA,NA,75N91024C00083,NA,NA,75N91024C00083-0-9999-1,NCI:394578\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,LEBANON,UNITED STATES,NA,02,079605332,US,10037749,"DOSEOPTICS, LLC",NH,037661441,NA,15121007 (contact),"BRUZA, PETR  (contact)",NA,2024-09-16,2025-09-15,Adhesions;Advanced Development;Aftercare;Agreement;Chest;Clinical;clinical implementation;Complex;Computer software;design;detector;Dose;Dose Rate;dosimetry;Electron Beam;Electronics;Electrons;Elements;Geometry;Goals;Health;Housing;Image;imaging capabilities;in vivo;Location;manufacture;Maps;Methodology;optical imaging;Patients;Phase;Physiologic pulse;Production;proton beam;Protons;prototype;quality assurance;Radiation therapy;Resolution;Shapes;software development;Speed;Structure;Surface;Surveys;System;Technology;temporal measurement;Testing;Time;tool;usability;Validation;Width,PHASE I FAST TRACK TOPIC 461 CONFORMABLE SCINTILLATOR ARRAY FOR IN VIVO DOSIMETRY DURING RT,0,NA,NA,NA,NA,NA,NA,NA,394578,NA
11210792,N01,HL,NA,N,NA,NA,NA,NA,75N92024D00005,NA,NA,75N92024D00005-0-759202400002-1,NHLBI:1200908\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,FREDERICK,UNITED STATES,NA,06,078706021,US,10034768,"PRECISION BIOSERVICES, INC.",MD,217014765,NA,79765750 (contact),"LANGENBACH, KURT  (contact)",NA,2024-05-10,2025-04-30,"Aliquot;Area;biobank;Biocompatible Materials;Biological;Biological Specimen Banks;Collaborations;Collection;Contractor;Contracts;data repository;Electronics;Equipment and supply inventories;Guidelines;Maintenance;National Heart, Lung, and Blood Institute;programs;quality assurance;Quality Control;Research;Resources;Retrieval;Sampling;Site;Specimen",MAINTENANCE OF THE NHLBI BIOLOGIC SPECIMEN REPOSITORYTASK AREA B AND TASK AREA C,0,NA,NA,NA,NA,NA,NA,NA,1200908,NA
11210794,N01,HL,NA,N,NA,NA,NA,NA,75N92024D00005,NA,NA,75N92024D00005-0-759202400001-1,NHLBI:1644822\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,FREDERICK,UNITED STATES,NA,06,078706021,US,10034768,"PRECISION BIOSERVICES, INC.",MD,217014765,NA,79701738 (contact),"LANGENBACH, KURT  (contact)",NA,2024-04-01,2029-03-31,"biobank;Biocompatible Materials;Biological Specimen Banks;Collaborations;Collection;Contractor;Contracts;data repository;Electronics;Equipment and supply inventories;Guidelines;National Heart, Lung, and Blood Institute;programs;quality assurance;Quality Control;Research;Resources;Retrieval",NHLBI BIOLOGIC SPECIMEN REPOSITORY,0,NA,NA,NA,NA,NA,NA,NA,1644822,NA
11210981,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00637,NA,NA,75N91024P00637-0-0-1,NCI:19900\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,MIDDLETON,UNITED STATES,NA,NA,622781578,US,NA,NA,WI,535623748,NA,79933419 (contact),"FINE, JASON  (contact)",NA,2024-08-26,2025-08-25,Contracts;Measures;Methods;Modeling;predictive modeling;Risk;risk prediction;Time,PREDICTION ERROR MEASURES FOR CONTINUOUS TIME COMPETING RISK MODEL,0,NA,NA,NA,NA,NA,NA,NA,19900,NA
11211104,N02,ES,NA,N,NA,NA,NA,NA,75N96024C00002,NA,NA,75N96024C00002-0-9999-1,NIEHS:5888567\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,STERLING,UNITED STATES,NA,10,066769217,US,9648301,EXPERIMENTAL PATHOLOGY LABORATORIES,VA,201664302,NA,79711086 (contact),"STEINBACH, THOMAS  (contact)",NA,2024-03-29,2025-03-28,analog;Archives;Biological;Biological Specimen Banks;Blood;blood fractionation;Collection;Contractor;Contracts;Data;data repository;digital;digital imaging;DNA;Dust;electronic data;Equipment;Film;Formalin;Freezing;Glass;Hair;Histologic;Human Resources;Intramural Research;Microfilm;Nail plate;National Institute of Environmental Health Sciences;National Toxicology Program;nutrition;Paper;Paraffin Embedding;programs;Qualifying;Records;repository;Research;Research Design;RNA;Sampling;Secure;Services;Slide;Soil;Source;Specimen;Tissue Banks;Tissue Embedding;Tissues;Toxicology;Water,MANAGEMENT AND SUPPORT OF AN ARCHIVES AND REPOSITORY CONTRACT FOR THE NATIONAL TOXICOLOGY PROGRAM (NTP) AND THE NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES (NIEHS) DIVISIONS OF TRANSLATIONAL T,0,NA,NA,NA,NA,NA,NA,NA,5888567,NA
11211220,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00661,NA,NA,75N95024P00661-0-0-1,NINDS:65000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NEWARK,UNITED STATES,NA,NA,946776036,US,NA,NA,DE,"19711,545",This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.”,NA,(contact),NA,2024-09-23,2025-09-22,clinical pain;Helping to End Addiction Long-term;Pain;Pain management;Speed;testing services;United States National Institutes of Health,QPS - PTTP HEAL PK TESTING SERVICES,0,NA,NA,NA,NA,NA,NA,NA,65000,NA
11211225,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00622,NA,NA,75N95024P00622-0-0-1,NINDS:14350\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,CLIFTON,UNITED STATES,NA,NA,178149998,US,NA,NA,VA,201242550,This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.”,NA,(contact),NA,2024-09-30,2025-09-29,clinical pain;Helping to End Addiction Long-term;Pain;Pain management;Services;Speed;United States National Institutes of Health,CMC SME CONSULTING SERVICES,0,NA,NA,NA,NA,NA,NA,NA,14350,NA
11211227,N01,HD,NA,N,NA,NA,NA,NA,275201400003I,NA,NA,275201400003I-0-759402400003-1,NICHD:678367\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,ROCKVILLE,UNITED STATES,NA,08,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,NA,79985129 (contact),"MARTIN, BRITTANY  (contact)",NA,2024-09-16,2025-09-15,Biological Specimen Banks;Child Development;Child Health;Childhood;Climate;Collection;Contractor;Contracts;cost;Data;Data Collection;Development;Disease;grandchild;Health;Human Development;Maintenance;National Institute of Child Health and Human Development;offspring;Participant;Perinatal;Perinatal Exposure;Process;Research;Research Activity;research study;Resources;sample collection;Sampling;secondary analysis;Services;Shipping;Specimen;Temperature;Time,NICHD BIOSPECIMEN REPOSITORY FOR THE LEGACY COLLECTION,0,NA,NA,NA,NA,NA,NA,NA,678367,NA
11211241,N02,CA,NA,N,NA,NA,NA,NA,91020A00191024F00007,NA,NA,91020A00191024F00007-0-0-1,OD:300000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,BETHESDA,UNITED STATES,NA,08,175358027,US,2473201,NOVA RESEARCH COMPANY,MD,208146900,NA,79880988 (contact),"EWING, AMY  (contact)",NA,2024-07-15,2025-07-14,Collaborations;Communication;Communities;Contractor;Creativeness;design;Discipline;Disparate;Educational workshop;Event;experience;Fostering;innovation;Logistics;meetings;novel;novel strategies;Participant;Problem Solving;programs;Secure;Support Groups;Time;Travel;Work;working group,SCIENTIFIC MEETINGS AND WORKING GROUP SUPPORT FOR NCI.,0,NA,NA,NA,NA,NA,NA,NA,300000,NA
11211245,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00038,NA,NA,75N95024D00038-0-759502400001-1,NINDS:11772171\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,Paramus,UNITED STATES,NA,05,004812744,US,4147301,"PSYCHOGENICS, INC.",NJ,07652,This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.”,79977826 (contact),"HANANIA, TALEEN  (contact)",NA,2024-09-06,2026-09-05,clinical pain;Helping to End Addiction Long-term;National Institute of Neurological Disorders and Stroke;Pain;Pain management;pre-clinical;screening;Speed;United States National Institutes of Health,SCREENING OF INVESTIGATIONAL AGENTS THROUGH THE NINDS PRECLINICAL SCREENING PLATFORM FOR PAIN (PSPP),0,NA,NA,NA,NA,NA,NA,NA,11772171,NA
11211246,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00017,NA,NA,75N95022D00017-0-759502400004-1,NIDA:113621\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,NA,79907736 (contact),"MCCORMACK, JENNIFER  (contact)",NA,2024-08-01,2026-03-31,Helping to End Addiction Long-term;improved;Opiate Addiction;Opioid;opioid epidemic;opioid misuse;opioid use disorder;Prevention trial;Public Health;Research;Speed;Support Contracts;United States National Institutes of Health;Work,"SUBTHRESHOLD OPIOID USE DISORDER PREVENTION TRIAL (CTN-0101). AUGUST 1, 2024 TO MARCH 31, 2026. N01DA-22-2253. TASK ORDER NO. 75N95024F00004 (TO20).",0,NA,NA,NA,NA,NA,NA,NA,113621,NA
11211247,N01,DA,NA,N,NA,NA,NA,NA,271201500006I,NA,NA,271201500006I-0-759502400001-1,NINDS:729864\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,KANSAS CITY,UNITED STATES,NA,05,007173453,US,5282001,MIDWEST RESEARCH INSTITUTE,MO,641102241,This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.”,79933100 (contact),"TOMBAUGH, JEANETTE  (contact)",NA,2024-08-08,2029-08-07,clinical pain;Helping to End Addiction Long-term;Pain;Pain management;Speed;United States National Institutes of Health,HEAL PROJECT-IHP-102,0,NA,NA,NA,NA,NA,NA,NA,729864,NA
11211251,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00330,NA,NA,75N95024P00330-0-0-1,NINDS:15000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,POWAY,UNITED STATES,NA,NA,NA,US,NA,NA,CA,920644970,This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.,NA,(contact),NA,2024-07-15,2025-07-14,Biological Products;clinical pain;Helping to End Addiction Long-term;Pain;Pain management;Pharmaceutical Chemistry;Speed;United States National Institutes of Health,"SUBJECT MATTER EXPERT CONSULTANT FOR MEDICINAL CHEMISTRY. NIH BLUEPRINT NEUROTHERAPEUTICS NETWORK(BPN) AND BPN HEAL, BIOLOGICS.",0,NA,NA,NA,NA,NA,NA,NA,15000,NA
11211252,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00334,NA,NA,75N95024P00334-0-0-1,NINDS:3920\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,LITHIA SPRINGS,UNITED STATES,NA,NA,NA,US,NA,NA,GA,301224304,This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.,NA,(contact),NA,2024-07-15,2025-07-14,Biological Products;clinical pain;Helping to End Addiction Long-term;Pain;Pain management;Pharmaceutical Chemistry;Speed;United States National Institutes of Health,"SUBJECT MATTER EXPERT CONSULTANT FOR MEDICINAL CHEMISTRY. NIH BLUEPRINT NEUROTHERAPEUTICS NETWORK(BPN) AND BPN HEAL, BIOLOGICS.",0,NA,NA,NA,NA,NA,NA,NA,3920,NA
11211253,N01,DA,NA,N,NA,NA,NA,NA,271201600005I,NA,NA,271201600005I-0-759502400001-1,NINDS:2773098\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,WILMINGTON,UNITED STATES,NA,07,362574527,US,4079901,PPD DEVELOPMENT LP,NC,284013331,This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.,79862592 (contact),"BOYLE, CRAIG  (contact)",NA,2016-07-08,2026-06-30,clinical pain;Dose;Helping to End Addiction Long-term;Pain;Pain management;phase 1 study;Speed;United States National Institutes of Health,\SINGLE ASCENDING DOSE (SAD) PHASE I STUDY,0,NA,NA,NA,NA,NA,NA,NA,2773098,NA
11211257,N01,NS,NA,N,NA,NA,NA,NA,75N95A24P00002,NA,NA,75N95A24P00002-0-0-1,NINDS:10000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,FRISCO,UNITED STATES,NA,NA,NA,US,NA,NA,TX,75033,NA,NA,(contact),NA,2023-10-24,2024-10-23,Biological Products;Biological Response Modifier Therapy;Chemistry;Clinical Chemistry;Contracts;Development;drug development;drug discovery;Electronic Mail;Feedback;gene therapy;manufacture;member;National Institute of Neurological Disorders and Stroke;novel therapeutics;Phase;pre-clinical;Program Development;Recommendation;Services;symposium;therapeutic development;United States National Institutes of Health,This is for Consulting services. POP 10/24/2023 to 10/23/2024,0,NA,NA,NA,NA,NA,NA,NA,10000,NA
11211258,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00328,NA,NA,75N95024P00328-0-0-1,NINDS:6000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,MOUNT PLEASANT,UNITED STATES,NA,NA,NA,US,NA,NA,SC,294667011,This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.,NA,(contact),NA,2024-06-15,2025-06-14,Biological Response Modifier Therapy;Cell Therapy;clinical pain;Development;gene therapy;Helping to End Addiction Long-term;Pain;Pain management;product development;Services;Speed;United States National Institutes of Health,BIOLOGICAL THERAPEUTICS PRODUCT DEVELOPMENT SUBJECT MATTER EXPERT CONSULTING SERVICES TO SUPPORT THE DEVELOPMENT OF CELL AND GENE THERAPY PRODUCTS,0,NA,NA,NA,NA,NA,NA,NA,6000,NA
11211267,N02,DA,NA,N,NA,NA,NA,NA,75N95022P00383,NA,NA,75N95022P00383-P00003-0-2,NINDS:22000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,SANBORNTON,UNITED STATES,NA,NA,968353594,US,NA,NA,NH,032692813,NA,NA,(contact),NA,2022-07-27,2025-07-26,Address;Chemical Structure;Chemistry;clinical pain;Clinical Research;Collaborations;Contractor;Data;design;Development;drug development;drug discovery;Electronic Mail;Feedback;Helping to End Addiction Long-term;Individual;Lead;lead optimization;member;Methodology;Pain;Pain management;Pharmaceutical Chemistry;Principal Investigator;Process;programs;Reporting;Research;Research Contracts;Role;Services;Speed;Strategic Planning;symposium;Telephone;Testing;United States National Institutes of Health;Visit,MEDICINAL CHEMISTRY CONSULTING SUPPORT SERVICES,0,NA,NA,NA,NA,NA,NA,NA,22000,NA
11211268,N02,DA,NA,N,NA,NA,NA,NA,75N95022P00467,NA,NA,75N95022P00467-P00003-0-2,NINDS:20000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,LYME,UNITED STATES,NA,NA,967593588,US,NA,NA,CT,063713307,NA,NA,(contact),NA,2022-08-10,2025-08-09,Address;assay development;Biochemical;Biological Assay;Biological Products;Biological Testing;Cells;Clinical;clinical pain;Clinical Research;Collaborations;Consultations;Contractor;design;Development;Development Plans;Electronic Mail;evaluation/testing;experimental study;Helping to End Addiction Long-term;in vitro Assay;Individual;Investigational Drugs;Lead;lead optimization;Logistics;manufacture;Measures;member;Pain;Pain management;Pharmaceutical Preparations;pharmacokinetics and pharmacodynamics;pre-clinical;preclinical evaluation;Principal Investigator;product development;programs;Published Comment;Qualifying;Recommendation;Resources;Role;safety study;safety testing;Serum;Services;Speed;Strategic Planning;Telephone;therapeutic development;timeline;Tissue Sample;Toxicology;United States National Institutes of Health;Validation;validation studies,BIOACTIVITY ASSAY DEVELOPMENT CONSULTING SERVICES,0,NA,NA,NA,NA,NA,NA,NA,20000,NA
11211270,N02,DA,NA,N,NA,NA,NA,NA,75N95022P00349,NA,NA,75N95022P00349-P00003-0-2,NINDS:63000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,BOULDER,UNITED STATES,NA,NA,045377676,US,NA,NA,CO,"80303,296",NA,NA,(contact),NA,2022-07-01,2025-06-30,Address;assay development;Chemistry;clinical pain;Clinical Research;Contractor;Data;Data Analyses;design;Development;drug development;drug discovery;Drug Kinetics;drug metabolism;Electronic Mail;Experimental Designs;Formulation;Helping to End Addiction Long-term;Investigational Drugs;Lead;lead optimization;Pain;Pain management;programs;Protocols documentation;Recommendation;Reporting;Services;Speed;Telephone;United States National Institutes of Health,DRUG METABOLISM PHARMACOKINETICS (DMPK) CONSULTING SUPPORT SERVICES,0,NA,NA,NA,NA,NA,NA,NA,63000,NA
11211319,N01,DA,NA,N,NA,NA,NA,NA,75N95024P00068,NA,NA,75N95024P00068-0-0-1,NINDS:9900\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,BROOKEVILLE,UNITED STATES,NA,NA,NA,US,NA,NA,MD,208331235,NA,NA,(contact),NA,2024-01-03,2025-01-02,assay development;Biological Assay;Biological Products;Biological Response Modifier Therapy;Biotechnology;Cell Therapy;Contracts;Development;drug development;drug discovery;Lentivirus;Modality;Monoclonal Antibodies;National Institute of Neurological Disorders and Stroke;novel therapeutics;Nucleic Acids;peptide drug;Peptides;Program Development;Proteins;Qualifying;Recommendation;Services;Therapeutic;therapeutic development;United States National Institutes of Health;Validation;Viral Vector,Biological Therapeutics Bioassay Subject Matter Expert Consulting Services to Support the Development of Therapeutic Biotechnology Products (Biologics),0,NA,NA,NA,NA,NA,NA,NA,9900,NA
11211322,N02,DA,NA,N,NA,NA,NA,NA,75N95022P00352,NA,NA,75N95022P00352-P00006-0-2,NINDS:46020\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,CARY,UNITED STATES,NA,02,117578942,US,10089011,ALLUCENT GOVERNMENT SERVICES (US) LLC,NC,275135756,NA,NA,(contact),NA,2022-07-01,2025-06-30,Address;assay development;Chemistry;Clinical Research;Contractor;Data;Data Analyses;design;Development;drug development;drug discovery;Drug Kinetics;drug metabolism;Electronic Mail;Experimental Designs;Formulation;Investigational Drugs;Lead;lead optimization;programs;Protocols documentation;Recommendation;Reporting;Services;Telephone;United States National Institutes of Health,DRUG METABOLISM AND PHARMACOKINETICS (DMPK) CONSULTING SUPPORT SERVICES,0,NA,NA,NA,NA,NA,NA,NA,46020,NA
11211342,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00020,NA,NA,75N95024P00020-P00001-0-1,NINDS:42000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,BROOKEVILLE,UNITED STATES,NA,NA,NA,US,NA,NA,MD,208331235,NA,NA,(contact),NA,2023-11-17,2024-11-16,assay development;Biological Assay;Biological Products;Biological Response Modifier Therapy;Cell Therapy;Contracts;Development;drug development;drug discovery;Lentivirus;Modality;Monoclonal Antibodies;National Institute of Neurological Disorders and Stroke;novel therapeutics;Nucleic Acids;peptide drug;Peptides;product development;Program Development;Proteins;Qualifying;Recommendation;Services;Therapeutic;United States National Institutes of Health;Validation;Viral Vector,BIOLOGICAL THERAPEUTICS PRODUCT DEVELOPMENT SUBJECT MATTER EXPERT CONSULTING SERVICES,0,NA,NA,NA,NA,NA,NA,NA,42000,NA
11211343,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00020,NA,NA,75N95024P00020-P00001-0-2,NINDS:79500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,BROOKEVILLE,UNITED STATES,NA,NA,NA,US,NA,NA,MD,208331235,NA,NA,(contact),NA,2023-11-17,2024-11-16,assay development;Biological Assay;Biological Products;Biological Response Modifier Therapy;Cell Therapy;clinical pain;Contracts;Development;drug development;drug discovery;Helping to End Addiction Long-term;Lentivirus;Modality;Monoclonal Antibodies;National Institute of Neurological Disorders and Stroke;novel therapeutics;Nucleic Acids;Pain;Pain management;peptide drug;Peptides;product development;Program Development;Proteins;Qualifying;Recommendation;Services;Speed;Therapeutic;United States National Institutes of Health;Validation;Viral Vector,BIOLOGICAL THERAPEUTICS PRODUCT DEVELOPMENT SUBJECT MATTER EXPERT CONSULTING SERVICES,0,NA,NA,NA,NA,NA,NA,NA,79500,NA
11211345,N01,DA,NA,N,NA,NA,NA,NA,75N95021D00026,ORGANIZED RESEARCH UNITS,NA,75N95021D00026-0-759502400001-1,NINDS:82128\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,CHICAGO,UNITED STATES,NA,01,005447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,NA,79666423 (contact),"O'RYAN, MICHAEL  (contact)",NA,2024-03-01,2025-02-28,Area;clinical candidate;Communication;Consultations;Contracts;data management;Development;drug development;Drug Kinetics;infrastructure development;Investigational New Drug Application;Lead;Maintenance;Nervous System Disorder;operation;Performance;Pharmacology and Toxicology;pre-clinical;Preparation;programs;research clinical testing;Safety;Stroke;technical report;Testing;Therapeutic;Toxicology;United States National Institutes of Health,IITRI - PERFORMANCE AREA 1 TO2,0,NA,NA,NA,NA,NA,NA,NA,82128,NA
11211352,N01,DA,NA,N,NA,NA,NA,NA,75N95021D00026,ORGANIZED RESEARCH UNITS,NA,75N95021D00026-0-759502400003-1,NINDS:224716\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,CHICAGO,UNITED STATES,NA,01,005447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,NA,79680686 (contact),"O'RYAN, MICHAEL  (contact)",NA,2024-03-15,2024-09-14,base;Biological Response Modifier Therapy;Body System;Development;Dose;drug development;drug discovery;Evaluation;Histology;In Vitro;in vivo;in vivo evaluation;lead optimization;Maximum Tolerated Dose;Microscopic;National Institute of Neurological Disorders and Stroke;Nervous System Disorder;Pain;pre-clinical;Preparation;Process;programs;Series;small molecule;therapeutic candidate;Toxic effect,MTD-DRF STUDIES-TO 4,0,NA,NA,NA,NA,NA,NA,NA,224716,NA
11211391,N44,CA,NA,N,NA,NA,NA,NA,75N91024C00091,NA,NA,75N91024C00091-0-9999-1,NCI:1980915\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,Waltham,UNITED STATES,NA,05,933575748,US,2668201,"PYRAMID TECHNICAL CONSULTANTS, INC.",MA,024528463,NA,1964901 (contact),"BOISSEAU, RAYMOND P (contact)",NA,2024-09-16,2026-09-15,Ablation;Address;Amplifiers;analog;Animals;Architecture;Area;beamline;Charge;Clinical;clinical application;clinical development;Clinical Research;Collaborations;commercialization;conventional therapy;design;Detection;detector;Development;Devices;Diagnostic Equipment;Dimensions;Dose;Dose Rate;Electric Capacitance;electric impedance;Electrodes;Electron Beam;Electronics;Electrons;Electrostatics;Elements;External Beam Radiation Therapy;fabrication;Failure;Feedback;ferrite;Film;Gases;Goals;improved;innovation;innovative technologies;interest;Ionizing radiation;Ions;irradiation;Lasers;magnetic dipole;Magnetism;Maps;Measures;Medical;Monitor;Nature;Operating System;outreach;Overdose;Patients;Performance;Phase;Photons;Physiologic pulse;Positioning Attribute;Preparation;Process;proton beam;proton therapy;prototype;radiation detector;radiation resistance;Radiation therapy;Reaction Time;Reading;Recording of previous events;Research;Resolution;response;Roentgen Rays;Running;Safety;Scanning;Side;signal processing;Signal Transduction;Small Business Innovation Research Grant;Speed;Structure;System;Techniques;Technology;Testing;Thinness;Time;time interval;transmission process;two-dimensional;Update;Vendor;Work;Writing,SBIR TOPIC 434 PHASE II: ULTRA-FAST DOSE RATE (FLASH) RADIATION DETECTORS AND SAFETY SYSTEMSPERIOD OF PERFORMANCE: 16 SEPTEMBER 2024 - 15 SEPTEMBER 2026FIRM FIXED PRICE,0,NA,NA,NA,NA,NA,NA,NA,1980915,NA
11211392,N44,CA,NA,N,NA,NA,NA,NA,75N91024C00084,NA,NA,75N91024C00084-0-9999-1,NCI:1999930\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,SAINT LOUIS,UNITED STATES,NA,01,080194879,US,10041506,"TETRAIMAGING, LLC",MO,631082979,NA,78416974 (contact),"JIANG, HAO  (contact)",NA,2024-09-16,2026-09-15,3-Dimensional;Algorithms;Clinic;Computer software;Data;data acquisition;Development;Devices;Dose;Dose Rate;Electron Beam;Electrons;Goals;Investigation;Ions;Measurement;Measures;Methodology;Modality;Patients;Performance;Phase;Protons;quality assurance;Race;Radiation Oncology;Radiation therapy;reconstruction;Reporting;side effect;Small Business Innovation Research Grant;System;Translating;user friendly software;Validation,SBIR TOPIC 434 PHASE II: DEVELOPMENT OF MULTILAYER STRIP ION CHAMBER DEVICE FOR THE MEASUREMENT OF FLASH-RT BEAMSPERIOD OF PERFORMANCE: 9/16/24-9/15/26,0,NA,NA,NA,NA,NA,NA,NA,1999930,NA
11211434,Y01,AI,NA,N,NA,NA,NA,NA,AAI24013001,NA,NA,AAI24013001-1-0-1,NIAID:7098800\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,(contact),NA,NA,NA,Acquired Immunodeficiency Syndrome;active duty;Acute;Agreement;Antimicrobial Resistance;Area;beneficiary;Clinical Research;Clinical Trials;Collaborations;Communicable Diseases;COVID-19;design;Disease;Evaluation;HIV;Infection;Infectious disease threat;Infectious Skin Diseases;Influenza;Intervention;Measurement;methicillin resistant Staphylococcus aureus;Military Personnel;Multi-Drug Resistance;multi-drug resistant pathogen;National Institute of Allergy and Infectious Disease;Natural History;Outcome;prevent;Prevention;programs;Publishing;randomized trial;Recording of previous events;Research;Resources;Respiratory Disease;Respiratory Tract Diseases;Services;Sexually Transmitted Diseases;STI prevention;Trauma;Travel;Traveler&apos;s diarrhea;Universities;Wound Infection,The Infectious Diseases Clinical Research Program (IDCRP),240130,NA,NA,NA,NA,NA,NA,NA,7098800,NA
11211447,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00672,NA,NA,75N91024P00672-0-0-1,NCI:74240\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,NEW YORK,UNITED STATES,NA,NA,078625208,US,NA,NA,NY,100164308,NA,NA,(contact),NA,2024-09-11,2025-09-10,Contractor;Data;Gender Identity;Manuscripts;Monograph;Publishing;Sex Orientation,A MONOGRAPH ON SEXUAL ORIENTATION AND GENDER IDENTITY (SOGI) DATA,0,NA,NA,NA,NA,NA,NA,NA,74240,NA
11211459,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00686,NA,NA,75N91024P00686-0-0-1,NCI:70000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,NORTHFIELD,UNITED STATES,NA,09,081026197,US,1683401,COLLEGE OF AMERICAN PATHOLOGISTS,IL,600932719,NA,79973110 (contact),"MOLDWIN, RICHARD  (contact)",NA,2024-09-09,2025-09-08,Databases;Histology;Malignant Neoplasms;Services;Site;Source;tumor,CANCER PATHCHART DATABASE DEVELOPER SUPPORT SERVICES FOR UNIFIED TUMOR SITE- HISTOLOGY STANDARDS.,0,NA,NA,NA,NA,NA,NA,NA,70000,NA
11211609,N01,DA,NA,N,NA,NA,NA,NA,75N95021D00026,ORGANIZED RESEARCH UNITS,NA,75N95021D00026-0-759502400002-1,NINDS:220123\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,CHICAGO,UNITED STATES,NA,01,005447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,NA,79666426 (contact),"O'RYAN, MICHAEL  (contact)",NA,2024-03-01,2025-02-28,base;Biological Response Modifier Therapy;Contractor;Data;Development;Dose;drug development;drug discovery;Equipment;Generations;Government;Helping to End Addiction Long-term;Human Resources;In Vitro;in vivo;in vivo evaluation;lead optimization;Maximum Tolerated Dose;Nervous System Disorder;Pain;Pathology;pre-clinical;Process;programs;Qualifying;Rodent;Series;Services;small molecule;therapeutic candidate;Toxic effect;Work,IITRI - PTTP DRF BPN STUDY - TO3,0,NA,NA,NA,NA,NA,NA,NA,220123,NA
11211644,U19,AI,3,N,2024-11-05,2024-05-01,2025-04-30,NA,U19AI089992,NA,PA-23-189,3U19AI089992-13S1,NIAID:84018\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NEW HAVEN,UNITED STATES,NA,03,043207562,US,9420201,YALE UNIVERSITY,CT,065208327,NA,1924351 (contact),"MONTGOMERY, RUTH R (contact)","DONG, GANG",2010-07-12,2028-04-30,Address;Advisory Committees;Communication;Consultations;cost effective;Data;data repository;data sharing;Data Storage and Retrieval;Decision Making;Ensure;Goals;Human;Immune;Immunology;Institution;Intellectual Property;meetings;Monitor;Publications;Research;Research Project Grants;Resources;success;Technology;vaccine response;Vulnerable Populations,Administrative Core,89992,ZAI1,ZAI1,7040,S1,13,50160,33858,NA,84018
11211794,N02,CA,NA,N,NA,NA,NA,NA,75N91022D00010,NA,NA,75N91022D00010-0-759102400001-1,NCI:29037\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,WASHINGTON,UNITED STATES,NA,NA,NA,US,NA,NA,DC,200371542,NA,79983675 (contact),"KLEIN, AMANDA  (contact)",NA,2024-09-18,2025-09-17,cancer genome;genome sequencing;Logistics;meetings;patient engagement,LOGISTICS AND NETWORK COORDINATION FOR THE PATIENT ENGAGEMENT AND CANCER GENOME SEQUENCING (PE-CGS) NETWORK,0,NA,NA,NA,NA,NA,NA,NA,29037,NA
11211981,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00023,NA,NA,75N95022D00023-0-759502400001-1,NINDS:1899037\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,KENSINGTON,UNITED STATES,NA,08,094888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,NA,79629226 (contact),"RETTERER, CARY  (contact)",NA,2024-02-09,2027-02-08,analytical method;cell bank;Cyclic GMP;Development;document outlines;Filtration;Formulation;manufacture;manufacturing test;method development;Nature;Oligonucleotides;Pharmaceutical Preparations;Preclinical Testing;Procedures;Process;Production;Qualifying;Reference Standards;Research;scale up;Site;stability testing;Sterility;Testing;vector;Viral;Work,MANUFACTURE AND PRECLINICAL TESTING OF SITE BLOCKING OLIGONUCLEOTIDES (SBO),0,NA,NA,NA,NA,NA,NA,NA,1899037,NA
11212016,N02,CA,NA,N,NA,NA,NA,NA,75N91024C00024,NA,NA,75N91024C00024-0-9999-1,NCI:9054450\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,NA,79942105 (contact),"VALMONTE, CLAUDINE  (contact)",NA,2024-09-01,2025-08-31,cancer clinical trial;Clinical Trials;Country;Dedications;Ethics;Human;Individual;Institution;Institutional Review Boards;Methods;Participant;participant enrollment;Research;Research Personnel;Rights;Site;welfare,LOGISTICAL AND IT SUPPORT FOR THE NCI CENTRAL INDIVIDUAL REVIEW BOARD (CIRB),0,NA,NA,NA,NA,NA,NA,NA,9054450,NA
11212035,N01,DA,NA,N,NA,NA,NA,NA,75N95021D00026,ORGANIZED RESEARCH UNITS,NA,75N95021D00026-0-759502400004-1,NINDS:201969\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,CHICAGO,UNITED STATES,NA,01,005447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,NA,79893882 (contact),"O'RYAN, MICHAEL  (contact)",NA,2024-07-22,2025-07-21,Area;Biological;Communication;Communities;Consultations;Contract Services;Contracts;data management;Development;Dose;experience;Goals;indexing;Industry;Infrastructure;Maintenance;National Institute of Neurological Disorders and Stroke;operation;Peptides;Performance;Pharmaceutical Chemistry;Phase;Phase I Clinical Trials;Preparation;programs;Research;research clinical testing;Research Personnel;service providers;Services;small molecule;technical report;Therapeutic;therapeutic development;United States National Institutes of Health;virtual,IITRI - NON-GLP DOSE RANGE FINDING (DRF) STUDIES-DEC. 2023 #2,0,NA,NA,NA,NA,NA,NA,NA,201969,NA
11212348,R21,AR,7,N,2024-11-27,2024-11-01,2025-11-30,846,R21AR082129,NA,PA-24-254,7R21AR082129-03,NIAMS:63882\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES,NA,HOBOKEN,UNITED STATES,NA,08,064271570,US,8109201,THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY,NJ,070305906,"NARRATIVE The key to successfully treat prevalent skeletal disorders such as osteoporosis relies on understanding changes in the tissue associated with the observed reduced bone quality and increased fracture risk. Here, we propose a unique approach to investigate in clinical biopsies the complex relationship between multiple bone nanoscale compositional properties and typical histopathological and morphometric findings of osteoporotic bones. This innovative project will reveal valuable insights into the nanoscale origins of impaired bone health, contributing to elucidating osteoporosis pathogenesis and to inform future clinical studies into new therapeutic tissue targets to improve bone quality.",15006607 (contact),"QUERIDO, WILLIAM  (contact)","NICKS, KRISTY",2023-12-01,2025-11-30,"3-Dimensional;Address;age related changes;aging population;artificial neural network;Biopsy;bone;Bone Density;bone fragility;bone health;bone quality;bone strength;Bone Tissue;Clinical;Clinical assessments;Clinical Management;Clinical Research;Collagen;Collagen Fibril;Complex;crystallinity;Data;Data Set;deep learning;Diagnosis;Disease;Elements;Evaluation;Fracture;fracture risk;Future;Goals;Heterogeneity;Histologic;Image;imaging system;Impairment;improved;Incidence;Individual;infrared spectroscopy;innovation;insight;Knowledge;Least-Squares Analysis;Machine Learning;machine learning method;markov model;meter;microCT;mineralization;Minerals;Modeling;Morphology;morphometry;nanoscale;Nature;novel therapeutics;Optics;Osteon;Osteoporosis;osteoporotic bone;Outcome;Outcomes Research;Pathogenesis;Performance;Persons;Pharmacotherapy;Play;Polishes;Polymethyl Methacrylate;Property;Public Health;recurrent neural network;Research;research study;Resolution;Role;Sampling;Scanning Electron Microscopy;skeletal disorder;Specificity;Spectroscopy, Fourier Transform Infrared;Standard Preparations;stoichiometry;Structure;submicron;Techniques;Tissues;Validation;X ray spectroscopy",Multifactorial contribution of bone nanoscale composition to tissue quality in osteoporosis,82129,MTE,Musculoskeletal Tissue Engineering Study Section[MTE],NA,NA,3,48191,15691,63882,NA
11212395,N02,HL,NA,N,NA,NA,NA,NA,75N92023D00016,NA,NA,75N92023D00016-0-759202400001-1,NHLBI:1160471\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,NEW YORK,UNITED STATES,NA,10,078473711,US,10032222,NEW YORK GENOME CENTER,NY,100131941,NA,79992320 (contact),"RIZAJ, KHULANGOO  (contact)",NA,2024-09-23,2025-09-22,"Area;Atlases;Award;Biological Assay;Biomedical Research;BRAIN initiative;Cancer Center;cancer genomics;Cell Nucleus;Cells;Contracts;Data;deep sequencing;DNA Methylation;DNA Sequencing Facility;experience;Funding;Genetic Diseases;Genome;genome sequencing;genome wide methylation;genomic data;Genomics;Grant;Heart Diseases;Hematological Disease;human tissue;Libraries;Lung Diseases;Mosaicism;National Heart, Lung, and Blood Institute;National Human Genome Research Institute;New York;Process;programs;Resources;Risk Factors;RNA;Sampling;single cell genomics;Sleep Disorders;Somatic Mutation;Technology;Trans-Omics for Precision Medicine;transcriptome sequencing;transcriptomics;tumor;United States National Institutes of Health;whole genome",NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) FOR THE CENTRALIZED OMICS RESOURCE (CORE) - RNA-SEQ - 2024 TASK ORDER,0,NA,NA,NA,NA,NA,NA,NA,1160471,NA
11212416,N02,HL,NA,N,NA,NA,NA,NA,75N92023D00015,NA,NA,75N92023D00015-0-759202400001-1,NHLBI:1558454\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,STANFORD,UNITED STATES,NA,16,009214214,US,8046501,STANFORD UNIVERSITY,CA,943052004,NA,79992317 (contact),"ECONOMY, IRENE  (contact)",NA,2024-09-23,2025-09-22,"absorption;Acceleration;Affinity;Antibodies;Area;ATAC-seq;Biological Assay;Biological Process;Biological Sciences;Cardiovascular Diseases;Cell Nucleus;Cells;cost;Cost Savings;cytokine;Data;Detection;Drug Targeting;Epitopes;Excision;Exhibits;falls;Funding;genome-wide;Inflammation;instrument;large scale data;Mass Spectrum Analysis;Measurement;Measures;Methods;multiple omics;National Heart, Lung, and Blood Institute;Peptides;Phenotype;Plasma;Plasma Proteins;Post-Translational Protein Processing;protein complex;Protein Databases;protein profiling;Proteins;Proteome;Proteomics;Resources;RNA;Sampling;Signal Transduction;single nucleus RNA-sequencing;Small Nuclear RNA;Specificity;Technology;Therapeutic;Trans-Omics for Precision Medicine;transcriptome sequencing;Trypsin",NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) FOR THE CENTRALIZED OMICS RESOURCE (CORE) - TASK AREAS 4 AND 5 - 2024 TASK ORDER,0,NA,NA,NA,NA,NA,NA,NA,1558454,NA
11212436,K01,MD,7,N,2024-11-01,2024-11-02,2025-02-28,307,K01MD019730,NA,PA-24-254,7K01MD019730-02,NIMHD:127370\,OTHER RESEARCH-RELATED,2024,NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES,NA,SEATTLE,UNITED STATES,NA,07,048682157,US,1531401,SEATTLE CHILDREN'S HOSPITAL,WA,981053901,Project Narrative The goal is to understand how social media can be used as tool to promote minority youth mental health and resilience in the context of climate change. We will explore minority youth experiences with climate activism on social media and co-design a climate social media campaign to build capacity and resilience of minority youth.,15899633 (contact),"PARNES, MCKENNA  (contact)","GILLMAN, ARIELLE SAMANTHA",2024-08-15,2028-02-28,NA,Youth climate activism on social media: Building psychosocial resilienceamong minority youth,19730,ZMD1,ZMD1-DRI(M2),NA,NA,2,118825,8545,127370,NA
11212437,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00021,NA,NA,75N95022D00021-0-759502400002-1,NINDS:1924589\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79695932 (contact),"PANG, KAITLIN  (contact)",NA,2024-03-26,2027-03-25,assay development;Biological;biological development;Biological Products;Biological Response Modifier Therapy;Contracts;Development;Dose;Drug Interactions;Drug Kinetics;Formulation;Funding;In Vitro;Industry;Investigational Drugs;manufacture;Nervous System Disorder;Neurosciences;Peptides;Pharmaceutical Preparations;Phase I Clinical Trials;programs;Research Personnel;Services;Toxic effect;Toxicology;United States National Institutes of Health,NON-GLP DOSE-RANGE FINDING AND GLP TOXICITY STUDIES AND IN VITRO DRUG-DRUG INTERACTION STUDIES FOR A SMALL PEPTIDE,0,NA,NA,NA,NA,NA,NA,NA,1924589,NA
11212584,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00021,NA,NA,75N95022D00021-0-759502400001-1,NINDS:1553595\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79675228 (contact),"GRIDLEY, JAMES  (contact)",NA,2024-03-11,2027-03-10,Biologic Development;Biological Assay;Contracts;Development;Dose;drug development;Funding;Industry;Investigational Drugs;Nervous System Disorder;Neurosciences;Phase I Clinical Trials;programs;Research Personnel;Services;therapeutic development;Toxicology;United States National Institutes of Health;Validation,VALIDATION OF BIOANALYTICAL ASSAYS AND IND- ENABLING GLP PD/PK TOXICOLOGY STUDIES,0,NA,NA,NA,NA,NA,NA,NA,1553595,NA
11212628,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00023,NA,NA,75N95022D00023-0-759502400003-1,NINDS:497895\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,KENSINGTON,UNITED STATES,NA,08,094888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,NA,79888457 (contact),"REDDY, KUMAR  (contact)",NA,2024-07-19,2026-07-18,Antibodies;Biological Products;candidate identification;Drug Kinetics;Duchenne muscular dystrophy;Funding;Investigational Drugs;lead candidate;manufacture;Monoclonal Antibodies;National Institute of Neurological Disorders and Stroke;programs;Toxicology,LEAD CANDIDATE IDENTIFICATION PK AND TOXICOLOGY STUDIES FOR ANTIBODY PROJECT IN BLUEPRINT NEUROTHERAPEUTICS (BPN) BIOLOGICS PROGRAM,0,NA,NA,NA,NA,NA,NA,NA,497895,NA
11212867,N01,DA,NA,N,NA,NA,NA,NA,75N95024C00003,NA,NA,75N95024C00003-P00002-9999-1,NHLBI:1000000\NIDDK:250000\NIMHD:500000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,049508120,US,9611701,"WESTAT, INC.",MD,208503129,NA,79853241 (contact),"CARUSI, CHARLES  (contact)",NA,2024-02-01,2029-01-31,Country;Food;Health;Longitudinal Studies;Performance;Persons;Pharmaceutical Preparations;Population Assessment of Tobacco and Health;Research;Tobacco;Tobacco use;United States;United States National Institutes of Health,POPULATION ASSESSMENT OF TOBACCO AND HEALTH (PATH) STUDY PERIOD OF PERFORMANCE: 02/01/2024 - 01/31/2029,0,NA,NA,NA,NA,NA,NA,NA,1750000,NA
11212870,N02,HL,NA,N,NA,NA,NA,NA,75N92023D00020,NA,NA,75N92023D00020-0-759202400001-1,NHLBI:2153458\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,SEATTLE,UNITED STATES,NA,07,605799469,US,9087701,UNIVERSITY OF WASHINGTON,WA,981959472,NA,79992323 (contact),"RHODES, CAROL  (contact)",NA,2024-09-23,2025-09-22,"catalyst;Cells;Contractor;Data;database of Genotypes and Phenotypes;Databases;Development;Disease;DNA Methylation;functional genomics;Funding;genome sequencing;genomic data;Goals;Heart;Hematological Disease;Lung;Multiomic Data;National Heart, Lung, and Blood Institute;Phase;precision medicine;Process;programs;Research Personnel;Resolution;Resources;Sleep Disorders;Trans-Omics for Precision Medicine;whole genome",NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) FOR THE CENTRALIZED OMICS RESOURCE (CORE) - DNA METHYLATION - 2024 TASK ORDER,0,NA,NA,NA,NA,NA,NA,NA,2153458,NA
11212875,N02,HL,NA,N,NA,NA,NA,NA,75N92023D00013,NA,NA,75N92023D00013-0-759202400001-1,NHLBI:23600775\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,CAMBRIDGE,UNITED STATES,NA,07,623544785,US,10021177,"BROAD INSTITUTE, INC.",MA,021421027,NA,79998641 (contact),"MURPHY, BRIDGET  (contact)",NA,2024-09-23,2025-09-22,"Alleles;Alternative Splicing;Area;cohort;Communities;CpG Islands;Data;data repository;DNA Methylation;Enhancers;experience;Genes;genome sequencing;Genomics;Genotype;improved;Individual;instrument;Laboratories;Learning;Measures;member;Metabolic;metabolomics;Methods;Methylation;National Heart, Lung, and Blood Institute;next generation sequencing;novel;Pattern;Process;Productivity;programs;Proteomics;Quality Control;Research Personnel;Resources;response;RNA Sequences;Sampling;Science;Specificity;Trans-Omics for Precision Medicine;Transcript;transcriptome;transcriptome sequencing;whole genome","NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) FOR THE CENTRALIZED OMICS RESOURCE (CORE) - TASK AREAS 2, 3, AND 4 - 2024 TASK ORDER",0,NA,NA,NA,NA,NA,NA,NA,23600775,NA
11213231,R01,AG,7,N,2024-11-29,2024-12-01,2025-04-30,866,R01AG065330,SCHOOLS OF MEDICINE,PA-24-254,7R01AG065330-06,NIA:212839\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE ON AGING,NA,NEW YORK,UNITED STATES,OTHER HEALTH PROFESSIONS,12,060217502,US,1514803,WEILL MEDICAL COLL OF CORNELL UNIV,NY,100654805,"Project Narrative In this proposal, our interdisciplinary team proposes to use novel approaches and innovative combinations of data to galvanize the use of EHR networks and population based cohorts to advance EHR-based risk predictions for 1) population level inference; 2) making individualized predictions of absolute risk, and 3) improving reproducibility and cross-site validation. We will predict risk of subsequent incident cardiovascular disease (CVD) in older patients (age 50 and older) with type 2 diabetes (T2DM).",10853072 (contact),"ZHONG, HUA JUDY (contact)","ZIEMAN, SUSAN",2020-08-15,2025-04-30,NA,EHR-based vs population-based CVD risk predictions for older patients with diabetes,65330,ASG,Aging Systems and Geriatrics Study Section[ASG],NA,NA,6,125569,87270,212839,NA
11213488,Y01,CA,NA,N,NA,NA,NA,NA,APC24002001,NA,NA,APC24002001-1-0-1,NCI:83764\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Agreement;cancer survival;Cessation of life;Consultations;Contractor;Databases;Epidemiology;Health;Human;Individual;interest;neoplasm registry;Participant;Persons;Registries;Reporting;Research;SEER Program;Services;statistics;Study Subject;Update;Vital Status;Writing,SSA: SEER Related Vital Status,240020,NA,NA,NA,NA,NA,NA,NA,83764,NA
11213505,Y01,CA,NA,N,NA,NA,NA,NA,APC24001001,NA,NA,APC24001001-1-0-1,NCI:6454\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Agreement;cancer health disparity;Cities;Country;Data;Data Linkages;Immigration;Individual;Monitor;National Cancer Institute;Records;Research;Security;statistics;United States;United States National Institutes of Health;United States Social Security Administration,SSA SEER Birthplace Data Linkage,240010,NA,NA,NA,NA,NA,NA,NA,6454,NA
11213517,Y01,CA,NA,N,NA,NA,NA,NA,APC21005001,NA,NA,APC21005001-1-0-1,NCI:150000\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Contractor;Data Files;Data Set;Documentation;Health;Link;Medicare;Outcome;Process;programs;Schedule;SEER Program;statistics;Surveys;Update,"Technical Support for Surveillance, Epidemiology, and End Results (SEER)-Medicare Health Outcomes Survey (MHOS) Data Set",210050,NA,NA,NA,NA,NA,NA,NA,150000,NA
11213529,Y01,CA,NA,N,NA,NA,NA,NA,APC23005001,NA,NA,APC23005001-1-0-2,NCI:40000\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Age Years;base;Censuses;County;Hispanic;Population;Race;sex;Sum,Census Bureau:  Estimates of Resident Population for Counties,230050,NA,NA,NA,NA,NA,NA,NA,40000,NA
11213552,Y01,CA,NA,N,NA,NA,NA,NA,APC20006001,NA,NA,APC20006001-1-0-2,NCI:2074773\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Architecture;Caliber;Contractor;Contracts;Databases;Development;Division of Cancer Control and Population Sciences;Grant;Informatics;Information Systems;Information Technology;Maintenance;operation;Research;Services;Strategic Planning,DOI: Calibre Database Support/Information Technology Services and Support (ITSS),200060,NA,NA,NA,NA,NA,NA,NA,2074773,NA
11213692,IK6,VA,7,N,2024-10-14,2024-05-01,2024-09-30,999,IK6BX005800,NA,BX-21-022,7IK6BX005800-04,NA,OTHERS,2024,Veterans Affairs,NA,PORTLAND,UNITED STATES,NA,01,089461255,US,481073,PORTLAND VA MEDICAL CENTER,OR,972392964,"Project Narrative My major research focus is to understand the fundamental mechanisms of gene regulation and function in the development of cardiovascular disease, a major health burden for our veterans. Our overarching goals are to translate the findings into identification of novel molecular targets and strategies for prevention and intervention of cardiovascular disease. With the ongoing collaboration with physician scientists and basic scientists at the Birmingham VA medical center and UAB, our ongoing investigations will not only elucidate the precise molecular and cellular mechanisms governing vascular smooth muscle cell reprograming in the pathogenesis of vascular disease and aging; but also provide novel molecular insights facilitating further studies to translate these findings into therapeutic strategies for patient care, so as to improve the veterans’ health, life span and quality of life, and reduce health care costs.",8079676 (contact),"CHEN, YABING  (contact)",NA,2021-10-01,2028-09-30,Aging;Alabama;Animal Model;Atherosclerosis;Award;Blood Vessels;bone;calcification;Cardiovascular Diseases;cardiovascular health;career;Cell Physiology;Cell Reprogramming;Cells;Circadian Dysregulation;circadian pacemaker;Collaborations;Development;Diabetes Mellitus;diabetic;Funding;Gene Expression Regulation;gene function;General Population;Goals;graduate student;Grant;Health;Health Care Costs;Hyperglycemia;improved;innovation;insight;Intervention;Investigation;knockout gene;Knockout Mice;life span;Macrophage;Medical center;Mentors;Military Personnel;Mission;Molecular;Molecular Target;mouse model;new therapeutic target;next generation;novel;osteogenic;Oxidative Stress;Pathogenesis;Patient Care;Phenotype;Physicians;Postdoctoral Fellow;Prevention strategy;programs;Quality of life;Regulation;Research;Research Personnel;Research Project Grants;Role;Scientist;Services;Smooth Muscle Myocytes;stem cells;Therapeutic;Tissues;Training;transcription factor;Translating;United States National Institutes of Health;Universities;Up-Regulation;Vascular calcification;Vascular Diseases;Vascular Smooth Muscle;Veterans,BLRD Research Career Scientist Award Renewal,5800,ZRD1,ZRD1-RCSR-K(01),NA,NA,4,NA,NA,NA,NA
11214723,DP1,DA,7,N,2024-12-20,2024-10-15,2025-03-31,279,DP1DA051144,NA,PA-24-254,7DP1DA051144-06,NIDA:716839\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,SILVER SPRING,UNITED STATES,NA,08,080507421,US,10052525,"AUTONOMOUS THERAPEUTICS, INC.",MD,209021643,"PROJECT NARRATIVE Persons who inject drugs (PWID) represent a key `superspreader' population for HIV/AIDS that drives the epidemic in the US and other countries and it is exceptionally difficult to identify and reach these high-risk populations with existing intervention strategies (e.g., ART and PrEP). This proposal will develop and test a novel gene-drive concept to target the high-risk superspreaders who most need therapy. Gene drives would be particularly useful for treating PWID and those who engage in injection drug use in resource-limited settings, including the rural US.",8236762 (contact),"WEINBERGER, LEOR S (contact)","MANDLER, RAUL N",2020-04-15,2025-03-31,Acquired Immunodeficiency Syndrome;Animals;Biological Assay;Brazil;Burkina Faso;Cells;Clinical;Clinical Trials;cohort;Communicable Diseases;Complement;cost;Country;County;Data;Development;Disease;Disease Outbreaks;disorder control;Drug usage;end of life;Engineering;Epidemic;Epidemiologist;Epidemiology;Failure;female sex worker;gene drive system;gene therapy;Genes;genotoxicity;Gifts;high risk;high risk behavior;high risk population;HIV;HIV Infections;HIV therapy;HIV/AIDS;humanized mouse;immunogenicity;In Vitro;Incidence;Indiana;Injecting drug user;injection drug use;Intervention;Intervention Trial;Location;Malaria;Measures;Modeling;Modernization;Nature;nonhuman primate;novel;pathogen;Patients;Phase;Population;pre-exposure prophylaxis;prototype;Reporting;Resistance;Resource-limited setting;Risk Factors;RNA Interference;Rural;Safety;safety testing;synthetic construct;Testing;transmission process;United States National Academy of Sciences;Update;Variant;Viremia,A Gene Drive Therapy for HIV: Single-Administration Intervention for High-RiskGroups,51144,ZDA1,ZDA1-HXO-H(12)R,NA,NA,6,379280,337559,716839,NA
11214907,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00010,NA,NA,75N93024C00010-0-9999-1,NIAID:299208\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,LEWES,UNITED STATES,NA,00,NA,US,10073282,JOHN SNOW LABS INC,DE,199583608,NA,79564123 (contact),"UL HAQ, HASHAM  (contact)",NA,2024-09-05,2025-09-04,artificial intelligence model;base;Benchmarking;biomedical ontology;Biomedical Research;Clinical;Code;Data;data management;Data Set;data sharing;Disease;Immune;improved;Information Retrieval;interoperability;knowledge graph;large language model;Mediating;Medical;Metadata;Modeling;Names;Natural Language Processing;novel strategies;Ontology;Phase;Process;Production;Research;Research Personnel;Resolution;Small Business Innovation Research Grant;Standardization;Technology;Text;Time;Training;unstructured data,"SBIR TOPIC 135:Applying Large Language Models for Automated Entity Recognition, Relation Extraction/Ontology Metadata Enrichment from Free-Text Clinical Notes in Infectious/Immune-Mediated Diseases",0,NA,NA,NA,NA,NA,NA,NA,299208,NA
11214908,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00033,NA,NA,75N93024C00033-0-9999-1,NIAID:298988\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MIAMI,UNITED STATES,NA,27,035354070,US,4474801,"INFOTECH SOFT, INC.",FL,331313207,NA,79972674 (contact),"SABATINO, SAMANTHA  (contact)",NA,2024-09-05,2025-09-04,Big Data;biomedical ontology;Biomedical Research;Collection;Communities;Data;Data Aggregation;Data Set;data streams;Disease;Ensure;Generations;Immune;Immunologics;Immunology;Knowledge;knowledge graph;knowledge integration;Mediating;Modeling;multiple data sources;Phase;Productivity;Publishing;Research;Semantics;Small Business Innovation Research Grant;Technology;time use;usability;user centered design,SBIR 136 - INFOTECH: Integrated Knowledge Spaces for Infectious and Immune-mediated Disease Research,0,NA,NA,NA,NA,NA,NA,NA,298988,NA
11214909,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00034,NA,NA,75N93024C00034-0-9999-1,NIAID:300000\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,TALLAHASSEE,UNITED STATES,NA,02,078872070,US,10040684,"INSILICOM, LLC",FL,323126743,NA,9634235 (contact),"ZHANG, JINFENG  (contact)",NA,2024-09-05,2025-09-04,Address;complex data;Coupled;Data;Disease;Evolution;Future;Growth;high throughput technology;Immune;improved;Information Retrieval;Knowledge;Knowledge Discovery;knowledge graph;Literature;Manuals;Mediating;Modeling;National Institute of Allergy and Infectious Disease;Ontology;open source;public database;Publishing;PubMed;Research;Research Personnel;Small Business Innovation Research Grant;Structure;success;Techniques;Text;Training;Update,"""SBIR TOPIC 136 - INSILICOM: Enhancing a large-scale biomedical knowledge graph for infectious- and immune-mediated disease  research""",0,NA,NA,NA,NA,NA,NA,NA,300000,NA
11214910,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00035,NA,NA,75N93024C00035-0-9999-1,NIAID:299999\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,CLIFTON PARK,UNITED STATES,NA,20,010926207,US,4014501,"KITWARE, INC.",NY,120653104,NA,79977816 (contact),"BAUMES, JEFF  (contact)",NA,2024-09-06,2025-09-05,artificial intelligence model;Communicable Diseases;Data;Feedback;graph database;Human;interactive visualization;Intuition;Knowledge;knowledge curation;knowledge graph;large language model;Link;Literature;metabolomics;novel;Ontology;Paper;prompt engineering;prototype;Research;Small Business Innovation Research Grant;structured data;System;Time;tool;Validation;web app,SBIR 136 - KITWARE:  Viime Extract: An AI-powered Knowledge Graph Extraction System for Metabolomics,0,NA,NA,NA,NA,NA,NA,NA,299999,NA
11214913,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00036,NA,NA,75N93024C00036-0-9999-1,NIAID:275942\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,CHEVY CHASE,UNITED STATES,NA,08,078737373,US,10048402,"MY OWN MED, INC.",MD,208155547,NA,79972680 (contact),"SEYFERT-MARGOLIS, VICKI  (contact)",NA,2024-09-05,2025-09-04,Algorithms;Artificial Intelligence;Basic Science;Biomedical Research;Clinical;Clinical Research;Communities;Computer software;Data;Data Reporting;Data Set;design;Development;Disease;Ensure;Immune;Infection;Knowledge;Knowledge Extraction;knowledge graph;large language model;Learning;Literature;Mediating;Medical;Natural Language Processing pipeline;Patients;Phase;Process;programs;prototype;Psychological reinforcement;Publications;Publishing;Research Personnel;Small Business Innovation Research Grant;Students;teacher;web services,SBIR 136 - MY OWN MED: Development of automated LLM KG extraction to inform clinical research of infectious & immune mediated diseases,0,NA,NA,NA,NA,NA,NA,NA,275942,NA
11214915,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00037,NA,NA,75N93024C00037-0-9999-1,NIAID:299957\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAN DIEGO,UNITED STATES,NA,51,117298031,US,10058009,OMNISYNC INCORPORATED,CA,921234446,NA,79972683 (contact),"HUANG, NORMAN  (contact)",NA,2024-09-05,2025-09-04,Communities;Computer software;Data;Data Compromising;data integrity;Databases;effectiveness evaluation;Generations;Graph;indexing;innovation;insight;Intuition;Journals;Knowledge;knowledge graph;knowledge integration;large language model;machine learning model;Maps;Methodology;Modernization;Nature;Paper;Performance;Publications;Research;Science;Small Business Innovation Research Grant;Source;Standardization;Structure;success;Techniques;Technology;Time;training data;Triplet Multiple Birth;vector;Visual;Work,SBIR 136 - OMNISYNC: A Real-Time Comprehensive Knowledge Graph for the Biomedical Science Community,0,NA,NA,NA,NA,NA,NA,NA,299957,NA
11214917,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00038,NA,NA,75N93024C00038-0-9999-1,NIAID:298262\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,RALEIGH,UNITED STATES,NA,02,117131092,US,10056535,"PREDICTIVE, LLC",NC,276147631,NA,79972686 (contact),"TROPSHA, ALEX  (contact)",NA,2024-09-05,2025-09-04,Address;Biological;Chemicals;Clinical;Communicable Diseases;Data;diverse data;drug discovery;emerging pathogen;Genomics;Knowledge;knowledge base;knowledge graph;Maps;Mining;Modernization;novel;Pathway interactions;Pharmaceutical Preparations;Pilot Projects;Small Business Innovation Research Grant;Structure;Technology;tool;web portal,SBIR 136 - PREDICTIVE: Knowledge Graphs for Infectious Diseases,0,NA,NA,NA,NA,NA,NA,NA,298262,NA
11214942,N02,HL,NA,N,NA,NA,NA,NA,263201800055I,NA,NA,263201800055I-0-759202400001-1,NIAMS:1968167\NIDDK:50000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ROCKVILLE,UNITED STATES,NA,08,876875154,US,3122901,"IQ SOLUTIONS, INC.",MD,208523046,NA,79637883 (contact),"ROBINSON, NATE  (contact)",NA,2024-02-15,2025-02-14,Adolescent;Asian;Asian Women;Awareness;Bone Diseases;bone health;Communication;Dedications;Early Diagnosis;Early treatment;Education;General Population;Health Professional;Hispanic Women;Hyperparathyroidism;Individual;Information Dissemination;Knowledge;Language;Link;Low Literacy Population;men;Metabolic Bone Diseases;Osteitis Deformans;Osteogenesis Imperfecta;Osteoporosis;outreach;Pamphlets;Patients;Physicians;Populations at Risk;Prevention;Resources;Spanish;United States Dept. of Health and Human Services;United States National Institutes of Health;Visual impairment,PROFESSIONAL COMMUNICATIONS AND OUTREACH SUPPORT,0,NA,NA,NA,NA,NA,NA,NA,2018167,NA
11214947,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00023,NA,NA,75N91019D00023-0-759102400001-1,NIDDK:50000\OD:50000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,ROCKVILLE,UNITED STATES,NA,08,049508120,US,9611701,"WESTAT, INC.",MD,208503129,NA,79660231 (contact),"MILLER, AMY  (contact)",NA,2024-03-15,2025-03-14,Contractor;Dietary Assessment;Hour;Self Administration;Services;System;Update,"THE CONTRACTOR SHALL PROVIDE SERVICES TO SUPPORT, UPDATE, MAINTAIN, FURTHER DEVELOP AND REFINE THE EXISTING AUTOMATED SELF-ADMINISTERED 24-HOUR DIETARY ASSESSMENT SYSTEM (HENCEFORTH REFERRED TO AS THE",0,NA,NA,NA,NA,NA,NA,NA,100000,NA
11214952,N02,HD,NA,N,NA,NA,NA,NA,75N94024C00001,NA,NA,75N94024C00001-0-9999-1,NIDDK:2725799\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,MINNEAPOLIS,UNITED STATES,NA,05,068195064,US,2321401,HENNEPIN HEALTHCARE RESEARCH INSTITUTE,MN,554151623,NA,79668034 (contact),"JOHANSEN, KIRSTEN  (contact)",NA,2024-03-08,2025-03-07,Contracts;Modification,MODIFICATION TO THE CONTRACT TO REVISE SECTION J ATTACHMENTS,0,NA,NA,NA,NA,NA,NA,NA,2725799,NA
11214962,N02,HD,NA,N,NA,NA,NA,NA,75N94024P00051,NA,NA,75N94024P00051-0-0-1,NIDDK:69567\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,MINNEAPOLIS,UNITED STATES,NA,05,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,NA,15059498 (contact),"GRZYWACZ, BARTOSZ J (contact)",NA,2023-11-29,2024-05-28,Minnesota;Universities,REGENTS OF THE UNIVERSITY OF MINNESOTA:1107499 [24-002026],0,NA,NA,NA,NA,NA,NA,NA,69567,NA
11214980,N02,HD,NA,N,NA,NA,NA,NA,75N94024F00042,NA,NA,75N94024F00042-0-0-1,NIDDK:370280\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,BETHESDA,UNITED STATES,NA,NA,061214263,US,NA,HILL GROUP THE,MD,208171818,NA,79693918 (contact),"SEHHAT, BEVERLY  (contact)",NA,2024-03-26,2025-03-25,National Institute of Diabetes and Digestive and Kidney Diseases;Services,NIDDK EPOD ACTIVITIES ADMINISTRATIVE SUPPORT SERVICES TASK ORDER,0,NA,NA,NA,NA,NA,NA,NA,370280,NA
11215029,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00029,NA,NA,75N92019D00029-0-759202400001-1,NHLBI:283553\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,EAGLE BUTTE,UNITED STATES,NA,00,180957714,US,3109602,"MISSOURI BREAKS RESEARCH, INC.",SD,576251824,NA,NA,(contact),NA,2024-02-15,2025-08-14,NA,"STRONG HEART STUDY (SHS)-MISSOURI BREAKS INDUSTRIES RESEARCH, INC.- FIELD CENTER (FC), TASK AREA B.3, YEAR 3",0,NA,NA,NA,NA,NA,NA,NA,283553,NA
11215033,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00028,NA,NA,75N92019D00028-0-759202400001-1,NHLBI:333373\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,OKLAHOMA CITY,UNITED STATES,NA,05,878648294,US,1524003,UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,OK,731043609,NA,79637907 (contact),"ALI, TAUQEER  (contact)",NA,2024-02-15,2025-08-14,"American Indians;Area;Collaborations;Communities;Contractor;Data;Disabled Persons;disadvantaged background;Disparity population;Ethnic Population;experience;follow-up;Funding;Funding Opportunities;Health;Heart;Investigation;Investigator-Initiated Research;member;Mentors;Mission;National Heart, Lung, and Blood Institute;Oklahoma;Pilot Projects;Postdoctoral Fellow;programs;racial population;Research;Research Personnel;Research Project Grants;tribal college;tribal community;Tribes;Universities;university student","STRONG HEART STUDY (SHS)- UNIVERSITY OF OKLAHOMA-FIELD CENTER (FC), TASK AREA B.3, YEAR 3",0,NA,NA,NA,NA,NA,NA,NA,333373,NA
11215036,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00027,NA,NA,75N92019D00027-0-759202400002-1,NHLBI:89124\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,OKLAHOMA CITY,UNITED STATES,NA,05,878648294,US,1524003,UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,OK,731043609,NA,79637904 (contact),"ZHANG, YING  (contact)",NA,2024-02-15,2025-12-14,"American Indians;Area;Collaborations;Communities;Contractor;Data;Disabled Persons;disadvantaged background;Disparity population;Ethnic Population;experience;follow-up;Funding;Funding Opportunities;Health;Heart;Investigation;Investigator-Initiated Research;member;Mentors;Mission;National Heart, Lung, and Blood Institute;Pilot Projects;Postdoctoral Fellow;programs;racial population;Research;Research Personnel;Research Project Grants;tribal college;tribal community;Tribes;university student","STRONG HEART STUDY (SHS)- COORDINATING CENTER (CC)- TASK AREA B.3, YEAR 3",0,NA,NA,NA,NA,NA,NA,NA,89124,NA
11215037,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00030,NA,NA,75N92019D00030-0-759202400001-1,NHLBI:168202\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,HYATTSVILLE,UNITED STATES,NA,04,189030067,US,4046605,MEDSTAR HEALTH RESEARCH INSTITUTE,MD,207822031,NA,NA,(contact),NA,2024-02-15,2025-08-14,NA,"STRONG HEART STUDY (SHS)-MEDSTAR HEALTH RESEARCH INSTITUTE- FIELD CENTER (FC), TASK AREA B.3, YEAR 3",0,NA,NA,NA,NA,NA,NA,NA,168202,NA
11215039,R01,HL,7,N,2025-01-06,2025-01-06,2025-03-31,837,R01HL157659,SCHOOLS OF MEDICINE,PA-24-254,7R01HL157659-05,NHLBI:386505\,NON-SBIR/STTR RPGS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,WINSTON-SALEM,UNITED STATES,INTERNAL MEDICINE/MEDICINE,05,937727907,US,9021205,WAKE FOREST UNIVERSITY HEALTH SCIENCES,NC,271570001,"Project Narrative – Public Health Relevance Peripheral arterial disease (PAD) is caused by atherosclerosis in the legs where blood flow is restricted. The central focus of PAD research for decades has been to understand and alter endothelial cell biology, yet no progress has been made towards effective therapeutic design. We will combine our use of innovative mouse genetic models, established PAD relevant laboratory models, innovative tools (gene therapy designed expression viruses), and a heterogeneous PAD patient population to fully interrogate the role of BAG3 as both a potential cause of pathology (in the case of the variants pre-disposing African Americans to severe disease outcomes) and as a potential target for therapeutic development.",8624559 (contact),"MCCLUNG, JOSEPH MATTHEW (contact)","REID, DIANE M",2021-04-01,2025-03-31,Adenoviruses;Affect;African American;African American population;African ancestry;Amino Acids;Amputation;angiogenesis;Apoptosis;Arteries;Atherosclerosis;Automobile Driving;BCL2 gene;biobank;Bioenergetics;Biological;Blood flow;Blood Vessels;Cardiac;Cardiomyopathies;Cardiovascular Diseases;Cardiovascular system;Cell Separation;cell type;Cells;Cellular biology;Cessation of life;Clinical;Code;cohort;Communication;complex IV;critical limb Ischemia;cytochrome c oxidase;Data;demographics;density;design;Dilated Cardiomyopathy;Disease;Disease Outcome;Disparity;Endothelial Cells;Environment;Exertion;Gangrene;gene therapy;Genes;Genetic;Genetic Models;genetic variant;Glycolysis;Hindlimb;Histologic;Human;improved;In Vitro;in vivo;Inbred BALB C Mice;Incidence;Individual;Injury;innovation;Intermittent Claudication;Ischemia;Laboratories;Leg;limb ischemia;Limb structure;Link;Lower Extremity;Mediating;Medical;Metabolic;Mitochondria;mitochondrial dysfunction;Modeling;Molecular Chaperones;Morbidity - disease rate;mortality;mouse genetics;Mus;Muscle;Muscle Cells;Muscle Fibers;Muscle Mitochondria;muscle regeneration;Mutation;Myocardium;myogenesis;Myopathy;Natural regeneration;necrotic tissue;neovascularization;novel;Outcome;Outcome Measure;overexpression;Pain;paracrine;Pathology;patient population;Patient-Focused Outcomes;Patients;Perfusion;Peripheral;Peripheral arterial disease;Pharmaceutical Preparations;Phenotype;Physiological;pleiotropism;Pre-Clinical Model;preclinical study;Preclinical Testing;Prevention;Procedures;Process;Proliferating;Proteins;public health relevance;Quantitative Trait Loci;Race;racial disparity;Recovery;Research;Research Personnel;Rest;restoration;revascularization;Risk;Role;Scaffolding Protein;screening;skeletal;Skeletal Muscle;Striated Muscles;Surgeon;targeted treatment;Testing;Therapeutic;therapeutic candidate;therapeutic development;Therapeutic Effect;therapeutically effective;therapy design;Tissues;tool;Transgenic Organisms;translational scientist;Variant;Virus;Work,Variant Determinants of African American Limb Pathology in Peripheral Arterial Disease,157659,VCMB,Vascular Cell and Molecular Biology Study Section[VCMB],NA,NA,5,285186,101319,386505,NA
11215062,Y01,CA,NA,N,NA,NA,NA,NA,APC24004001,NA,NA,APC24004001-1-0-1,NCI:16000\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,"American;Censuses;Cessation of life;Data;data access;data registry;Data Set;Databases;Development;Evaluation;Funding;indexing;Link;Malignant Neoplasms;Morbidity - disease rate;mortality;National Cancer Institute;National Heart, Lung, and Blood Institute;neoplasm registry;Policies;population survey;Process;Research;Research Personnel;Tobacco;Tobacco use;United States National Center for Health Statistics;United States National Institutes of Health",Tobacco Longitudinal Mortality Study (TLMS),240040,NA,NA,NA,NA,NA,NA,NA,16000,NA
11215067,Y01,CA,NA,N,NA,NA,NA,NA,APC24007001,NA,NA,APC24007001-1-0-1,NCI:125000\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Agreement;Applied Research;Awareness;Benchmarking;Cancer Burden;Cancer Control;cancer genomics;cancer prevention;career;Clinical;Collaborations;Communication;Community Practice;Consultations;Data Set;Division of Cancer Control and Population Sciences;Division of Cancer Prevention;Evaluation;evidence base;Fellowship;Foundations;General Population;Genome;Genomics;Health;health application;Health Personnel;Healthcare;Hereditary Malignant Neoplasm;implementation science;implementation strategy;Knowledge;knowledge base;Malignant Neoplasms;online course;Pilot Projects;population health;Population Surveillance;Precision Health;programs;Provider;Public Health;public health research;Publishing;Research;Research Personnel;Research Training;Resources;Scanning;social media;symposium;Testing;tool;Training;Translating;Translations;United States;Update;web page;webinar,A Public Health Foundation for Translating Genomics and Precision Health Applications into Cancer Control and Prevention - 2024 TIDIRC Genomics,240070,NA,NA,NA,NA,NA,NA,NA,125000,NA
11215072,N02,HL,NA,N,NA,NA,NA,NA,92022A00592024F00001,NA,NA,92022A00592024F00001-0-0-1,NHLBI:8628759\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,RESEARCH TRIANGLE PARK,UNITED STATES,NA,04,004868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,NA,10498487 (contact),"SEVERYNSE-STEVENS, DIANA M (contact)",NA,2024-08-23,2025-08-22,"Agreement;Airway Disease;Analytical Chemistry;Animals;Blood;Canis familiaris;Cardiac;Catheters;Certification;clinical candidate;Contractor;Cyclic GMP;Cystic Fibrosis Transmembrane Conductance Regulator;Development;Devices;Documentation;Dose;drug candidate;Ensure;Formulation;Goals;hemoglobin polymer;Human;inhibitor;Integrins;Liver Microsomes;Lung;manufacture;manufacturing scale-up;Mediation;metabolic abnormality assessment;method development;Methods;Monkeys;National Heart, Lung, and Blood Institute;next generation;novel;Pharmaceutical Preparations;Phase;Plasma;Polychlorinated Biphenyls;Polymers;pre-clinical;Process;programs;prototype;Public Health;Rattus;Recovery;Regenerative Medicine;respiratory;Respiratory Mucosa;Robotics;Safety;safety study;Services;Sickle Cell Anemia;Site;Site Visit;small molecule;Source;Technology Transfer;Testing;Toxicology;Umbilical Cord Blood Transplantation;Update;Validation;Work",NHLBI CATALYZE PROGRAM - PRECLINICAL SERVICES COMPONENT - PROJECTS YEAR 3,0,NA,NA,NA,NA,NA,NA,NA,8628759,NA
11215073,N02,HL,NA,N,NA,NA,NA,NA,92023A04092024F00001,NA,NA,92023A04092024F00001-0-0-1,NHLBI:1934229\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,RESEARCH TRIANGLE PARK,UNITED STATES,NA,04,004868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,NA,10498487 (contact),"SEVERYNSE-STEVENS, DIANA M (contact)",NA,2024-09-13,2025-09-12,"Award;collaborative environment;commercialization;Contracts;Development;Development Plans;Future;Goals;National Heart, Lung, and Blood Institute;Play;preclinical development;product development;programs;Regulatory Affairs;Research;Research Personnel;Role;Services;Source",NHLBI CATALYZE COORDINATING CENTER - PRODUCT DEVELOPMENT SUPPORT SERVICES YEAR 2,0,NA,NA,NA,NA,NA,NA,NA,1934229,NA
11215076,Y01,CA,NA,N,NA,NA,NA,NA,APC24005001,NA,NA,APC24005001-1-0-1,NCI:15000\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Age Years;Area;base;Behavior;Behavioral Risk Factor Surveillance System;cancer risk;Censuses;County;Hispanic;Population;Race;Risk Factors;screening;sex;Sum,Estimates of Resident Population for Counties - Small Area Estimation for Cancer Risk Factors and Screening Behaviors by Combining NHIS and BRFSS for 2021 to 2022,240050,NA,NA,NA,NA,NA,NA,NA,15000,NA
11215088,N02,HD,NA,N,NA,NA,NA,NA,75N94024F00081,NA,NA,75N94024F00081-0-0-1,NIDDK:18711\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,FAIRFAX,UNITED STATES,NA,NA,NA,US,NA,NA,VA,220321237,NA,79874674 (contact),"ROBINSON, MINDY  (contact)",NA,2024-09-01,2025-08-31,Link;National Institute of Diabetes and Digestive and Kidney Diseases,NIDDK / HALO LINK 1-YEAR SMS  POP: 9/1/2024 THRU 8/31/2025,0,NA,NA,NA,NA,NA,NA,NA,18711,NA
11215094,N02,HD,NA,N,NA,NA,NA,NA,75N94024F00123,NA,NA,75N94024F00123-0-0-1,NIDDK:1031000\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,GAITHERSBURG,UNITED STATES,NA,NA,779951912,US,NA,SCIENTIFIC CONSULTING GRO,MD,208781409,NA,79963963 (contact),"NA, NA  (contact)",NA,2024-09-01,2025-08-31,Logistics;National Institute of Diabetes and Digestive and Kidney Diseases;symposium,NIDDK - ACQUISITION OF SCIENTIFIC CONFERENCE AND LOGISTICS SUPPORT FOR THE NIDDK,0,NA,NA,NA,NA,NA,NA,NA,1031000,NA
11215104,Y01,CA,NA,N,NA,NA,NA,NA,APC24006001,NA,NA,APC24006001-1-0-1,NCI:145700\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Agreement;cancer care;care delivery;care outcomes;care systems;Data;data exchange;Data Linkages;Data Protection;data registry;Data Set;Data Storage and Retrieval;Documentation;end of life;Enrollment;Health;health assessment;health care delivery;Health Personnel;Healthcare;Individual;insight;Institutional Review Boards;Link;Malignant Neoplasms;Medicaid;Medicare;Medicare/Medicaid;National Cancer Institute;neoplasm registry;Outcome;Persons;Policies;Population;Population Research;Process;Recording of previous events;Research;Role;screening;Screening for cancer;service programs;surveillance data;Surveys;System;trend;United States;United States Centers for Medicare and Medicaid Services;United States National Institutes of Health,Centers for Medicare & Medicaid Services (CMS) Data Linkages,240060,NA,NA,NA,NA,NA,NA,NA,145700,NA
11215109,N02,HD,NA,N,NA,NA,NA,NA,75N94024F00149,NA,NA,75N94024F00149-0-0-1,NIDDK:913129\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,BURLINGAME,UNITED STATES,NA,15,083778964,US,10001134,"ACUMEN, LLC",CA,940101936,NA,79979785 (contact),"YE, LEI SANDY  (contact)",NA,2024-09-29,2025-09-28,National Institute of Diabetes and Digestive and Kidney Diseases;Services;Urologic Diseases,NIDDK: SERVICES: UROLOGICAL DISEASES IN AMERICA (UDA) COMPENDIUM.,0,NA,NA,NA,NA,NA,NA,NA,913129,NA
11215110,N02,HD,NA,N,NA,NA,NA,NA,75N94024P00705,NA,NA,75N94024P00705-0-0-1,NIDDK:223870\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,LINCOLN,UNITED STATES,NA,01,010870587,US,4393501,"QUALITYMETRIC, INC.",RI,028653746,NA,80002001 (contact),"GREENING, TANYA  (contact)",NA,2024-09-27,2025-09-26,Data;Disease;Electronic Health Record;health care availability;Research Support;trend,THE PURPOSE OF THIS REQUIREMENT IS TO PROVIDE ACCESS TO HEALTHCARE CLAIMS DATA AND ELECTRONIC HEALTH RECORDS (EHR) TO SUPPORT THE RESEARCH AND ANALYSIS OF NATIONAL DISEASE AND CONDITION TRENDS THAT RE,0,NA,NA,NA,NA,NA,NA,NA,223870,NA
11215123,Y01,CA,NA,N,NA,NA,NA,NA,APC24009001,NA,NA,APC24009001-1-0-1,NCI:60000\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Acetaldehyde;Adult;aged;Agreement;Aromatic Polycyclic Hydrocarbons;behavioral study;Cancer Etiology;Cannabinoids;Cannabis;Carbon Monoxide;Carcinogen exposure;carcinogenicity;Carcinogens;Characteristics;Cigar;Cigarette;Data;Data Collection;Disease Outbreaks;District of Columbia;Dryness;epidemiology study;Etiology;experimental study;Filler;Flowers;Formaldehyde;Funding;Future;Health;Hemp;Individual;Investments;Journals;Laboratories;Legal;Length;Licensure;Long-Term Effects;Malignant Neoplasms;Manuscripts;marijuana smoke;Marijuana Smoking;marijuana use;Marketing;Medical Marijuana;Mercury;Metals;Methodology;Molecular;Nicotine;Peer Review;Pharmaceutical Preparations;Plants;Play;Publications;Publishing;Recording of previous events;Recreation;Reporting;Research;Role;Science;Smoke;Source;symposium;Tars;Testing;Tetrahydrocannabinol;Tobacco;tobacco products;Tobacco smoke;toxicant;United States;United States Substance Abuse and Mental Health Services Administration;volatile organic compound;Volatilization;Weight;Writing,CDC Examination of Cannabis Smoke for Carcinogens,240090,NA,NA,NA,NA,NA,NA,NA,60000,NA
11215140,Y01,CA,NA,N,NA,NA,NA,NA,APC24008001,NA,NA,APC24008001-1-0-1,NCI:1750000\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Agreement;authority;Cancer Control;Censuses;Chronic Disease;Collaborations;Computer Security;Consultations;cost;Data;data centers;Data Collection;data exchange;Data Files;data integrity;data quality;Data Security;data sharing;design;disorder prevention;Ensure;Funding;Grant;Health Promotion;Institutional Review Boards;instrument;Interviewer;Maintenance;Malignant Neoplasms;National Health Interview Survey;operation;Preparation;Publications;quality assurance;Questionnaire Designs;Research;Sampling;Security;Surveys;Testing;Training;Travel;United States National Center for Health Statistics;web site,Cancer Questions on the 2025 National Health Interview Survey,240080,NA,NA,NA,NA,NA,NA,NA,1750000,NA
11215201,N02,DA,NA,N,NA,NA,NA,NA,75N95020D00002,NA,NA,75N95020D00002-0-759502400001-1,NIMH:249995\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,HORSHAM,UNITED STATES,NA,04,064341449,US,3207801,"NATIONAL MEDICAL SERVICES, INC.",PA,190442208,NA,16429007 (contact),"BLUM, LEE  (contact)",NA,2020-01-01,2023-12-31,Autopsy;Blood;Brain;Databases;drug of abuse;Human;Pharmaceutical Preparations;Sampling;screening;Secure;Test Result;Testing;testing services;Therapeutic;Tissues;Toxic Environmental Substances;Toxicology;United States National Institutes of Health,UNSPECIFIED [24-000022],0,NA,NA,NA,NA,NA,NA,NA,249995,NA
11215273,Y01,AR,NA,N,NA,NA,NA,NA,AAR24001001,NA,NA,AAR24001001-1-0-1,NIAMS:350000\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES,NA,NA,NA,NA,(contact),NA,NA,NA,Dual-Energy X-Ray Absorptiometry;Hip region structure;National Health and Nutrition Examination Survey;Osteoporosis;United States National Center for Health Statistics;Vertebral column,FY2024 NHANES DXA Osteoporosis  Assessment Component/Study,240010,NA,NA,NA,NA,NA,NA,NA,350000,NA
11215669,N43,CA,NA,N,NA,NA,NA,NA,75N91024C00061,NA,NA,75N91024C00061-0-9999-1,NCI:388108\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,DURHAM,UNITED STATES,NA,04,NA,US,10071605,GRADIENT HEALTH INC,NC,277053040,NA,14655729 (contact),"HUANG, OUWEN  (contact)",NA,2024-09-16,2025-09-15,Algorithms;artificial intelligence algorithm;Breast Cancer Detection;breast density;Characteristics;Cone;Data;Data Set;Databases;demographics;diversity and equity;Ethnic Origin;Ethnic Population;Exhibits;Genotype;Goals;Health system;Impairment;indexing;Ingestion;Mammary Neoplasms;Mammography;Manufacturer;Medical Device;Medical Imaging;Metadata;Modeling;Multimodal Imaging;Pathology;Performance;Physiological;Race;racial population;Reporting;screening;software as a medical device;systems research;tool development;Training;training data;Tumor Markers;Variant;vector,ADVANCING EQUITY AND DIVERSITY IN BREAST CANCER SCREENING: CREATING A FOUNDATIONAL DATASET AND TOOLSET.,0,NA,NA,NA,NA,NA,NA,NA,388108,NA
11215799,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00021,NA,NA,75N95022D00021-0-759502400003-1,NINDS:91138\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,VIRAL GENE THERAPY FOR MENKES DISEASE,79403483 (contact),"BURNAUGH, AMANDA  (contact)",NA,2024-09-30,2027-09-29,animal safety;Disease;Funding;gene therapy;Menkes Kinky Hair Syndrome;National Institute of Neurological Disorders and Stroke;pre-clinical;Toxicology;U-Series Cooperative Agreements;Viral Genes,VIRAL GENE THERAPY FOR MENKES DISEASE,0,NA,NA,NA,NA,NA,NA,NA,91138,NA
11215804,R35,GM,7,N,2024-12-11,2024-09-01,2025-06-30,859,R35GM138321,SCHOOLS OF MEDICINE,PA-24-254,7R35GM138321-06,NIGMS:363789\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,CHICAGO,UNITED STATES,SOCIAL SCIENCES,05,005436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606114579,"PROJECT NARRATIVE Pannexin (PANX1-3) are important ATP-release channels playing critically physiological roles ranging from blood pressure regulation, glucose uptake, apoptotic cell clearance, tumor metastasis, ischemia-reperfusion, human oocyte development to skin/skeleton development. The proposed study focuses on untangling the oligomeric state, channel assembly, molecular structure, gating mechanism, and pharmacology of the PANX1-3, taking advantage of single-particle cryo-EM, electrophysiology, and other functional approaches. The proposed research is relevant to public health and NIH’s mission because this work will provide a deep understanding and broaden our knowledge of the relationships between atomic structures and the complex biological and pathological functions of PANXs, paving the way for the development of therapeutics to treat pannexin-related diseases.",15370491 (contact),"LU, WEI  (contact)","JUSTINOVA, ZUZANA",2020-07-02,2025-06-30,NA,Elucidating structures and molecular mechanisms of Pannexin channels,138321,ZRG1,Special Emphasis Panel[ZRG1-CB-P(55)R],NA,NA,6,227368,136421,363789,NA
11215874,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00069,NA,NA,75N93024C00069-0-9999-1,NIAID:1809220\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,MENANDS,UNITED STATES,NA,20,002436061,US,5966001,"NYSDOH/HEALTH RESEARCH, INC.",NY,122042893,NA,79983214 (contact),"MANTIS, NICHOLAS  (contact)",NA,2024-09-16,2025-09-15,Advanced Development;Antigens;B-Lymphocyte Epitopes;Borrelia burgdorferi;decorin binding protein B;Diagnostic;Epitope Mapping;Epitopes;Goals;Human;human monoclonal antibodies;Immunity;In Vitro;in vivo;Infection;innovation;Lipoproteins;Lyme Disease;Lyme Disease Vaccines;Modeling;novel;OspC protein;Patients;Resolution;Sampling;Serum;Surface;Surface Antigens;Techniques;Testing;Therapeutic;transmission process;United States;vector-borne infection,Innovations in Functional B Cell Epitope Discovery for Lyme Disease,0,NA,NA,NA,NA,NA,NA,NA,1809220,NA
11215899,N01,AI,NA,N,NA,NA,NA,NA,75N93024C00074,NA,NA,75N93024C00074-0-9999-1,NIAID:1614084\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,DURHAM,UNITED STATES,NA,04,044387793,US,2221101,DUKE UNIVERSITY,NC,277054673,NA,80000507 (contact),"KELSOE, GARNETT  (contact)",NA,2024-09-30,2025-09-29,Animals;Antibodies;B-Lymphocyte Epitopes;Binding;Clone Cells;Crystallography;Epidemic;Epitopes;Goals;Hemagglutinin;Human;Immunologic Memory;In Vitro;Influenza;Influenza A virus;Influenza B Virus;influenza infection;influenza virus strain;influenzavirus;innovation;Location;Memory B-Lymphocyte;Monoclonal Antibodies;Mus;Neuraminidase;novel;pandemic influenza;protective efficacy;Recombinant Antibody;Site;Structure;transmission process;Virus,Innovations in Functional B Cell Epitope Discovery for Influenza,0,NA,NA,NA,NA,NA,NA,NA,1614084,NA
11215968,N01,ES,NA,N,NA,NA,NA,NA,273201400015C,NA,NA,273201400015C-P00035-9999-32,NIEHS:1157546\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,COLUMBUS,UNITED STATES,NA,NA,926695685,US,NA,BATTELLE MEMORIAL INSTITU,OH,432012681,NA,79726079 (contact),"FALLACARA, DAWN  (contact)",NA,2014-04-15,2024-09-15,Address;Adverse effects;Alkanesulfonates;animal data;carboxylate;carcinogenicity;Chemicals;Complex Mixtures;Data;Dose;Environment;epidemiologic data;exposed human population;Exposure to;Female;Foundations;Future;in vivo;Individual;Joints;Liver;male;Modeling;Poly-fluoroalkyl substances;Rattus;Risk;Risk Assessment;System;Testing;Thyroid Gland;Thyroxine;Toxic effect;Toxicokinetics;Weight,In Vivo Assessment of an Equimolar or Environmentally Relevant Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) Mixture,0,NA,NA,NA,NA,NA,NA,NA,1157546,NA
11215972,N01,ES,NA,N,NA,NA,NA,NA,273201400015C,NA,NA,273201400015C-P00035-9999-33,NIEHS:313534\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,COLUMBUS,UNITED STATES,NA,NA,926695685,US,NA,BATTELLE MEMORIAL INSTITU,OH,432012681,NA,79726079 (contact),"FALLACARA, DAWN  (contact)",NA,2014-04-15,2024-09-15,Address;Benchmarking;Biological;Biological Assay;Chemicals;Collaborations;Communities;Data;Data Collection;Decision Making;Deodorants;developmental toxicity;Dose;Evaluation;genomic data;Genomics;hazard;high dimensionality;in vivo;Inhalation;Inhalation Exposure;Link;malignant mouth neoplasm;member;Methodology;Moths;Mus;National Toxicology Program;Oral;Property;Rattus;reproductive toxicity;Research;response;Risk;Risk Assessment;Testing;Toxic effect;Toxicology;transcriptomics;United States Environmental Protection Agency,"Short-term Transcriptomic Studies of 1,2-Dichlorobenzene and 1,4-Dichlorobenzene following Whole-body Inhalation Exposure in Rats and Mice",0,NA,NA,NA,NA,NA,NA,NA,313534,NA
11215993,N02,HL,NA,N,NA,NA,NA,NA,92023A03792024F00001,NA,NA,92023A03792024F00001-0-0-1,NHGRI:300000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,MIDDLETON,UNITED STATES,NA,06,136789562,US,10022210,"BIOTEAM, INC.",MA,019492494,NA,79820001 (contact),"JESSEL, CINDY  (contact)",NA,2024-06-07,2026-09-14,Address;Assessment tool;Characteristics;Collaborations;Communities;Computer software;Data;data ecosystem;data repository;Ecosystem;Educational workshop;Evaluation;Evaluation Reports;Extramural Activities;FAIR principles;Funding;genome resource;genomic data;Institution;Interview;National Human Genome Research Institute;Phase;public health relevance;Recommendation;Research;Research Personnel;Resources;Self Assessment;United States National Institutes of Health,DATA AND SOFTWARE RESOURCES ECOSYSTEM,0,NA,NA,NA,NA,NA,NA,NA,300000,NA
11216034,N01,ES,NA,N,NA,NA,NA,NA,75N96024C00005,NA,NA,75N96024C00005-0-9999-1,NIEHS:2456000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79983749 (contact),"FALLACARA, DAWN  (contact)",NA,2024-09-16,2025-09-15,Acquired Immunodeficiency Syndrome;Adult;Affect;Animal Model;antiretroviral therapy;Biochemical;cardiometabolism;Cardiomyopathies;Cardiovascular Diseases;Cardiovascular system;Chronic;Data;Diagnosis;Disease;Dose;Echocardiography;embryo/fetus;Exposure to;Fetus;Functional disorder;HIV;HIV Infections;HIV Seronegativity;HIV Seropositivity;Immunocompromised Host;Individual;Infection;Inflammation;Lactation;Lamivudine;Modeling;Mothers;Myocarditis;Oral;Persons;Pharmaceutical Preparations;Phenotype;Population;Pregnancy;Rattus;Risk;Therapeutic;Toxic effect;Virus;Virus Diseases,STUDIES TO EVALUATE THE CARDIOVASCULAR TOXICITY OF AN HIV TRICOMBO THERAPY (ABC/DTG/3TC) IN SPRAGUE DAWLEY (HSD: SPRAGUE DAWLEY® SD®) RATS (F0 DOSED BY ORAL GAVAGE,0,NA,NA,NA,NA,NA,NA,NA,2456000,NA
11216035,N01,ES,NA,N,NA,NA,NA,NA,75N96024C00005,NA,NA,75N96024C00005-0-9999-2,NIEHS:603660\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79983749 (contact),"FALLACARA, DAWN  (contact)",NA,2024-09-16,2025-09-15,Address;Benchmarking;Biological;Biological Assay;Chemicals;Collaborations;Communities;Data;Data Collection;Decision Making;Deodorants;developmental toxicity;Dose;Evaluation;genomic data;Genomics;hazard;high dimensionality;in vivo;Inhalation;Inhalation Exposure;Link;malignant mouth neoplasm;member;Methodology;Moths;Mus;National Toxicology Program;Oral;Property;Rattus;reproductive toxicity;Research;response;Risk;Risk Assessment;Testing;Toxic effect;Toxicology;transcriptomics;United States Environmental Protection Agency,"Short-term Transcriptomic Studies of 1,2-Dichlorobenzene and 1,4-Dichlorobenzene following Whole-body Inhalation Exposure in Rats and Mice",0,NA,NA,NA,NA,NA,NA,NA,603660,NA
11216053,N01,ES,NA,N,NA,NA,NA,NA,75N96024C00005,NA,NA,75N96024C00005-0-9999-3,NIEHS:2228674\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79983749 (contact),"FALLACARA, DAWN  (contact)",NA,2024-09-16,2025-09-15,Address;Adverse effects;Alkanesulfonates;animal data;carboxylate;carcinogenicity;Chemicals;Complex Mixtures;Data;Dose;Environment;epidemiologic data;exposed human population;Exposure to;Female;Foundations;Future;in vivo;Individual;Joints;Liver;male;Modeling;Poly-fluoroalkyl substances;Rattus;Risk;Risk Assessment;System;Testing;Thyroid Gland;Thyroxine;Toxic effect;Toxicokinetics;Weight,In Vivo Assessment of an Equimolar or Environmentally Relevant Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) Mixture,0,NA,NA,NA,NA,NA,NA,NA,2228674,NA
11216054,N01,HL,NA,N,NA,NA,NA,NA,75N92024D00013,NA,NA,75N92024D00013-0-759202400009-1,NHGRI:182700\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,BALTIMORE,UNITED STATES,NA,07,001910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212182680,NA,79998647 (contact),"DOHENY, KIM  (contact)",NA,2024-09-24,2027-09-08,Adult Children;Age;Benchmarking;biobank;Bioinformatics;bioinformatics tool;Biology;Blood;Blood specimen;Blood Tests;Cell Line;Child;Clinic;Communities;Consent;Data;database of Genotypes and Phenotypes;de novo mutation;Development;Disease;DNA;DNA Insertion Elements;DNA sequencing;empowerment;Enrollment;Event;Family;Family member;Generations;Genes;Genetic;Genetic Recombination;Genetic study;Genetic Variation;Genome;genome sequencing;Genomic DNA;genomic variation;Genomics;Genotype;Germ Lines;Germ-Line Mutation;grandparent;Health;Hereditary Disease;Human;Human Genome;Human Resources;Individual;Joints;kindred;Longevity;Lymphocyte Activation;Maps;Measurement;Medical Research;member;Menopause;method development;Methods;Morphologic artifacts;Mutation;National Human Genome Research Institute;neuronal cell body;Nucleotides;offspring;Parents;Participant;Personality Tests;Phenotype;phenotypic data;Platinum;Publications;Questionnaires;Research;Resources;Saliva;Sampling;segregation;Sensory;Short Tandem Repeat;Software Tools;Technology;Testing;tool;trait;transmission process;Universities;Utah;Variant;whole genome,HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE -WHOLE GENOME SEQUENCING (30X) FOR NHGRI (QUINLAN),0,NA,NA,NA,NA,NA,NA,NA,182700,NA
11216055,N01,ES,NA,N,NA,NA,NA,NA,75N96024C00005,NA,NA,75N96024C00005-0-9999-4,NIEHS:2137746\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79983749 (contact),"FALLACARA, DAWN  (contact)",NA,2024-09-16,2025-09-15,Adverse effects;Benzene;carcinogenicity;Chemicals;Data;design;Development;disorder prevention;Environmental Exposure;ethylbenzene;exposure route;Exposure to;Goals;Hazard Identification;Hazardous Chemicals;Health;Histopathology;Human;Inhalation;Laboratory Animals;Lung;Mission;Mus;public health research;Rattus;Reporting;Risk;Risk Assessment;sound;Toluene;Toxic effect;Toxicity Tests;Toxicology;Xylene,Conduct of studies to evaluate the toxic potential of mixed xylenes in laboratory animals,0,NA,NA,NA,NA,NA,NA,NA,2137746,NA
11216073,N01,ES,NA,N,NA,NA,NA,NA,75N96024C00005,NA,NA,75N96024C00005-0-9999-5,NIEHS:1675466\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79983749 (contact),"FALLACARA, DAWN  (contact)",NA,2024-09-16,2025-09-15,Adverse effects;Amphiboles;Asbestos;carcinogenicity;Chemicals;Chronic;Data;design;Development;disorder prevention;Environmental Exposure;Exposure to;Fiber;Goals;Hazard Identification;Hazardous Chemicals;Health;Histopathology;Human;Inhalation;Inhalation Exposure;Laboratory Animals;Lung;lung development;method development;Methods;Mineral Fibers;Mission;Nose;Phase;Preparation;public health research;Rattus;Reporting;Risk Assessment;Risk Factors;sound;Source;Tissues;Toxic effect;Toxicity Tests;Toxicology;Work,Conduct of studies to evaluate the toxic and carcinogenic potential of naturally occurring asbestos and related mineral fibers in laboratory animals,0,NA,NA,NA,NA,NA,NA,NA,1675466,NA
11216074,N01,ES,NA,N,NA,NA,NA,NA,75N96024C00005,NA,NA,75N96024C00005-0-9999-6,NIEHS:503295\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79983749 (contact),"FALLACARA, DAWN  (contact)",NA,2024-09-16,2025-09-15,Adverse effects;Chemicals;consumer product;Data;design;Development;developmental neurotoxicity;developmental toxicity;disorder prevention;Dose;Environment;Environmental Exposure;Evaluation;Exposure to;Flame Retardants;General Population;Goals;Hazard Identification;Hazardous Chemicals;Health;Human;inorganic phosphate;Lactation;Mission;Perinatal Exposure;Phenols;Pregnancy;public health research;Rattus;Risk Assessment;sound;Toxic effect;Toxicity Tests;Toxicology;Weaning,Conduct of studies to evaluate the subchronic and developmental neurotoxicity of isopropylated phenol phosphate (IPP) and triphenyl phosphate (TPHP)in rats (after perinatal exposure),0,NA,NA,NA,NA,NA,NA,NA,503295,NA
11216080,N02,HD,NA,N,NA,NA,NA,NA,75N94024P00101,NA,NA,75N94024P00101-0-0-1,NIAAA:14909\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,GAITHERSBURG,UNITED STATES,NA,NA,143526247,US,NA,FAST TRACK DRUGS AND BIOL,MD,208784276,NA,79579364 (contact),"RIGGS, KATRINA  (contact)",NA,2024-01-10,2025-01-09,alcohol abuse therapy;alcohol use disorder;Contractor;drug testing;Preparation;Protocols documentation,CONTRACTOR WILL ASSIST WITH PREPARATION OF FDA INFORMATION PACKAGE AND DISCUSSION OF THE PROTOCOL SYNOPSIS FOR DRUG TESTING FOR THE TREATMENT OF ALCOHOL USE DISORDER.,0,NA,NA,NA,NA,NA,NA,NA,14909,NA
11216081,N01,ES,NA,N,NA,NA,NA,NA,75N96024C00005,NA,NA,75N96024C00005-0-9999-7,NIEHS:1686984\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79983749 (contact),"FALLACARA, DAWN  (contact)",NA,2024-09-16,2025-09-15,Aerosols;Air;Air Pollutants;Animals;Cells;Complex Mixtures;Data;Data Correlations;design;Dryness;Evaluation;exposure route;Fiber;Goals;Government;Health Hazards;Human;In Vitro;in vitro testing;in vivo;Industrialization;Inhalation;Inhalation Exposure;Liquid substance;Lung;pilot test;Population;Powder dose form;programs;Rattus;System;Testing;Tissues;toxicant;Toxicity Tests;Toxicology;vapor,Establish and Characterize an Air Liquid Interface In Vitro Exposure System,0,NA,NA,NA,NA,NA,NA,NA,1686984,NA
11216082,N01,ES,NA,N,NA,NA,NA,NA,75N96024C00005,NA,NA,75N96024C00005-0-9999-8,NIEHS:2523707\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,COLUMBUS,UNITED STATES,NA,03,007901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012696,NA,79983749 (contact),"FALLACARA, DAWN  (contact)",NA,2024-09-16,2025-09-15,Animals;Apical;Blood Pressure;Case Study;Chemicals;design;Early Intervention;Euthanasia;Evaluation;Exposure to;Health;Heart Rate;heart rate variability;Histopathology;Human;Implant;Inhalation;Laboratory Animal Medicine;Outcome;Physiologic Monitoring;Telemetry;Testing;Toxic effect;Toxicology,Evaluation of Physiological Monitoring in Toxicology using 2-Ethyltoluene as a case study,0,NA,NA,NA,NA,NA,NA,NA,2523707,NA
11216122,N02,DA,NA,N,NA,NA,NA,NA,75N95024F00169,NA,NA,75N95024F00169-0-0-1,NCATS:2000141\NHGRI:100000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,COLUMBIA,UNITED STATES,NA,NA,NA,US,NA,NA,MD,210461554,NA,80002013 (contact),"MILSTEAD, KERRY  (contact)",NA,2024-09-29,2025-07-28,Advocacy;Clinical Research;Communities;Disease;experience;Family;genetic counselor;Genetic Diseases;Hand;Health Professional;Information Centers;Information Specialists;member;National Center for Advancing Translational Sciences;National Human Genome Research Institute;Nurses;Occupational Therapist;Patients;Persons;physical therapist;Physicians;programs;Rare Diseases;Research;Research Support;Resources;Scientist;Social Workers;Spanish/English;teacher;United States National Institutes of Health;virtual;Work;Writing,MANAGEMENT AND RESEARCH SUPPORT FOR THE GENETIC AND RARE DISEASES (GARD) INFORMATION CENTER AND RELATED PROGRAMS,0,NA,NA,NA,NA,NA,NA,NA,2100141,NA
11216255,N02,HD,NA,N,NA,NA,NA,NA,94022A00194022F00001,NA,NA,94022A00194022F00001-P00004-0-3,NIAAA:603867\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,NORTH BETHESDA,UNITED STATES,NA,08,020277339,US,10047839,"AXLE INFORMATICS, LLC",MD,208524931,NA,79559097 (contact),"MAYS, GARY  (contact)",NA,2021-12-13,2024-12-12,National Institute on Alcohol Abuse and Alcoholism;System,NIAAA PAY PLAN SOLUTION SYSTEM AND MICROSOFT AZURE CLOUD SUPPORT,0,NA,NA,NA,NA,NA,NA,NA,603867,NA
11216290,N01,HD,NA,N,NA,NA,NA,NA,75N94023C00002,NA,NA,75N94023C00002-P00003-9999-2,NIAAA:1562006\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,SILVER SPRING,UNITED STATES,NA,08,131331261,US,10005643,"SYNERGY ENTERPRISES, INC.",MD,209103737,NA,79558866 (contact),"SPARKS, ALICIA  (contact)",NA,2023-01-01,2024-12-31,alcohol policy information system;National Institute on Alcohol Abuse and Alcoholism,NIAAA ALCOHOL POLICY INFORMATION SYSTEM APIS,0,NA,NA,NA,NA,NA,NA,NA,1562006,NA
11216340,N01,CA,NA,N,NA,NA,NA,NA,75N91022D00006,NA,NA,75N91022D00006-P00001-759102400001-1,OD:313722\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,ROCKVILLE,UNITED STATES,NA,08,049508120,US,9611701,"WESTAT, INC.",MD,208503129,NA,79983193 (contact),"OLIVO, VANESSA  (contact)",NA,2024-09-20,2025-09-19,Clinical Research;Contractor;Contracts;Epidemiology;Equipment;Future;Government;Government Agencies;Human Resources;Immunologic Epidemiology;Infection;Performance;Progress Reports;Qualifying;Reporting;Services;study population;tumor;Work,INFECTIONS AND IMMUNOEPIDEMIOLOGY BRANCH (IIB) & INTEGRATIVE TUMOR EPIDEMIOLOGY BRANCH (ITEB) SUPPORT SERVICES,0,NA,NA,NA,NA,NA,NA,NA,313722,NA
11216361,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00361,NA,NA,75N91024P00361-0-0-1,NCI:119832\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,BETHESDA,UNITED STATES,NA,08,057052391,US,1603501,"TECHNICAL RESOURCES INTERNATIONAL, INC.",MD,208171197,NA,79795256 (contact),"KESSLAR, TIMOTHY  (contact)",NA,2024-06-03,2026-06-02,Archives;Caribbean region;Clinic;Clinical Trials;Clinical Trials Network;Collection;Data;Division of Cancer Prevention;HIV;Human Papillomavirus;improved;Information Technology;Language;Latin American;Maintenance;Persons;Portuguese;prevention clinical trial;programs;Reporting;Site;Spanish,CLINICAL TRIALS ACCRUAL QUALITY IMPROVEMENT PROGRAM (AQUIP) DATA AND INFORMATION TECHNOLOGY SUPPORT FOR THE US-LATIN AMERICAN-CARIBBEAN HIV/HPV PREVENTION CLINICAL TRIALS NETWORK (ULACNET),0,NA,NA,NA,NA,NA,NA,NA,119832,NA
11216480,N01,OD,NA,N,NA,NA,NA,NA,263201800029I,NA,NA,263201800029I-0-759802400001-1,NEI:50000\NIAAA:50000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,WASHINGTON,UNITED STATES,NA,98,041964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,204180007,NA,79558482 (contact),"DAY, ROBERT  (contact)",NA,2023-12-12,2024-12-11,Neurosciences,FY24 IC SUPPORT FOR THE NEUROSCIENCE FORUM,0,NA,NA,NA,NA,NA,NA,NA,100000,NA
11216483,N02,HD,NA,N,NA,NA,NA,NA,75N94020C00001,NA,NA,75N94020C00001-P00015-9999-3,NIAAA:979942\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,ROCKVILLE,UNITED STATES,NA,08,876875154,US,3122901,"IQ SOLUTIONS, INC.",MD,208523046,NA,79558845 (contact),"STEARMAN, KATHLEEN  (contact)",NA,2020-03-10,2024-03-09,alcohol research;Publications,"MANAGING, EDITING, AND PUBLICATION OF ALCOHOL RESEARCH: CURRENT REVIEWS",0,NA,NA,NA,NA,NA,NA,NA,979942,NA
11216485,N02,HD,NA,N,NA,NA,NA,NA,75N94022F00123,NA,NA,75N94022F00123-P00003-0-3,NIAAA:923166\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,ROCKVILLE,UNITED STATES,NA,08,876875154,US,3122901,"IQ SOLUTIONS, INC.",MD,208523046,NA,79558860 (contact),"BRACKETT, THOMAS  (contact)",NA,2023-08-05,2024-08-04,improved;web site,"TO SUPPORT AND IMPROVE THE INSTITUTE'S ABILITY TO PROVIDE ACCURATE, RELEVANT, AND UP-TO-DATE INFORMATION ON ITS PUBLIC WEBSITES.",0,NA,NA,NA,NA,NA,NA,NA,923166,NA
11216491,N01,HD,NA,N,NA,NA,NA,NA,75N94023C00001,NA,NA,75N94023C00001-P00004-9999-2,NIAAA:124329\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,PISCATAWAY,UNITED STATES,NA,06,001912864,US,1196203,"RUTGERS, THE STATE UNIV OF N.J.",NJ,088543925,NA,79558863 (contact),"TISCHFIELD, JAY  (contact)",NA,2022-12-01,2024-11-30,DNA,NESARC-III DNA STORAGE,0,NA,NA,NA,NA,NA,NA,NA,124329,NA
11216492,N01,HD,NA,N,NA,NA,NA,NA,75N94021D00006,NA,NA,75N94021D00006-P00004-759402100001-3,NIAAA:42799\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,BALTIMORE,UNITED STATES,NA,07,001910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212182680,NA,79671302 (contact),"STRAIN, ERIC  (contact)",NA,2021-05-14,2025-03-14,Advisory Services;Area;Award;Clinical;Clinical Research;Clinical Trials;Consultations;Contractor;Data;Data Security;meetings;operation;Performance;Preparation;Protocols documentation;Reporting;Services;Site,CORE FUNCTION ACTIVITIES TASK ORDER FOR ADVISORY SERVICES AND ADMINISTRATIVE REPORTING,0,NA,NA,NA,NA,NA,NA,NA,42799,NA
11216493,N01,HD,NA,N,NA,NA,NA,NA,75N94021D00016,NA,NA,75N94021D00016-P00005-759402100001-3,NIAAA:36253\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,Aurora,UNITED STATES,NA,06,041096314,US,1199905,UNIVERSITY OF COLORADO DENVER,CO,800452571,NA,79671317 (contact),"HUTCHISON, KENT  (contact)",NA,2021-03-15,2025-03-14,Advisory Services;Area;Award;Clinical;Clinical Research;Clinical Trials;Consultations;Contractor;Data;Data Security;meetings;operation;Performance;Preparation;Protocols documentation;Reporting;Services;Site,CORE FUNCTION ACTIVITIES TASK ORDER FOR ADVISORY SERVICES AND ADMINISTRATIVE REPORTING.  TASK ORDER NUMBER 75N94021D00016 75N94021F00001 ADMINISTRATIVELY REPLACES TASK ORDER NUMBER 75N94021D00009 75N9,0,NA,NA,NA,NA,NA,NA,NA,36253,NA
11216555,N01,OD,NA,N,NA,NA,NA,NA,263201800029I,NA,NA,263201800029I-0-759802400001-2,NIA:50000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,WASHINGTON,UNITED STATES,NA,98,041964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,204180007,NA,79558482 (contact),"DAY, ROBERT  (contact)",NA,2023-12-12,2024-12-11,Aging;Neurosciences,FY24 IC SUPPORT FOR THE NEUROSCIENCE FORUM - Aging,0,NA,NA,NA,NA,NA,NA,NA,50000,NA
11216565,N01,OD,NA,N,NA,NA,NA,NA,263201800029I,NA,NA,263201800029I-0-759802400002-1,NIA:50000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,WASHINGTON,UNITED STATES,NA,98,041964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,204180007,NA,79597304 (contact),"DAY, ROBERT  (contact)",NA,2024-01-19,2025-01-17,Aging;Regenerative Medicine,FORUM ON REGENERATIVE MEDICINE - Aging,0,NA,NA,NA,NA,NA,NA,NA,50000,NA
11216569,N01,OD,NA,N,NA,NA,NA,NA,263201800029I,NA,NA,263201800029I-0-759802400004-1,NIA:30000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,WASHINGTON,UNITED STATES,NA,98,041964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,204180007,NA,79666393 (contact),"DAY, ROBERT  (contact)",NA,2024-03-01,2025-02-28,Aging;disability,"IFG::OT::IFG: FORUM ON AGING, DISABILITY, AND INDEPENDENCE - Aging",0,NA,NA,NA,NA,NA,NA,NA,30000,NA
11216571,N01,OD,NA,N,NA,NA,NA,NA,263201800029I,NA,NA,263201800029I-0-759802400005-1,NIA:50000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,WASHINGTON,UNITED STATES,NA,98,041964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,204180007,NA,79772650 (contact),"DAY, ROBERT  (contact)",NA,2024-04-04,2025-04-03,Aging;Traumatic Brain Injury,FORUM ON TRAUMATIC BRAIN INJURY - Aging,0,NA,NA,NA,NA,NA,NA,NA,50000,NA
11216574,N02,HL,NA,N,NA,NA,NA,NA,263201800055I,NA,NA,263201800055I-0-759202400001-2,NIA:12500\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ROCKVILLE,UNITED STATES,NA,08,876875154,US,3122901,"IQ SOLUTIONS, INC.",MD,208523046,NA,79637883 (contact),"ROBINSON, NATE  (contact)",NA,2024-02-15,2025-02-14,Aging;Communication;outreach,PROFESSIONAL COMMUNICATIONS AND OUTREACH SUPPORT - Aging,0,NA,NA,NA,NA,NA,NA,NA,12500,NA
11216576,N01,DA,NA,N,NA,NA,NA,NA,271201600001I,NA,NA,271201600001I-0-759502400001-1,NIA:5316611\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,WILMINGTON,UNITED STATES,NA,06,019716729,US,1336801,"CHARLES RIVER LABORATORIES INTNTL, INC.",MA,018871096,NA,79678650 (contact),"URIAS, SERGIO  (contact)",NA,2024-03-14,2025-03-13,Aging;Development;Maintenance;old mice,DEVELOPMENT AND MAINTENANCE OF A MULTIGENOTYPIC AGED MOUSE COLONY - Aging,0,NA,NA,NA,NA,NA,NA,NA,5316611,NA
11216586,N01,DA,NA,N,NA,NA,NA,NA,271201700004I,NA,NA,271201700004I-0-759502400001-1,NIA:3233771\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,WILMINGTON,UNITED STATES,NA,06,019716729,US,1336801,"CHARLES RIVER LABORATORIES INTNTL, INC.",MA,018871096,NA,79586165 (contact),"URIAS, SERGIO  (contact)",NA,2024-01-20,2025-01-19,aged;Aging;Development;Maintenance;Rattus,DEVELOPMENT AND MAINTENANCE OF A MULTIGENOTYPIC AGED RAT COLONY,0,NA,NA,NA,NA,NA,NA,NA,3233771,NA
11216886,R01,GM,7,N,2024-12-17,2024-08-16,2026-02-28,859,R01GM141226,SCHOOLS OF PHARMACY,PA-24-254,7R01GM141226-05,NIGMS:324811\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,PITTSBURGH,UNITED STATES,PHARMACOLOGY,12,004514360,US,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PA,152133320,"Project Narrative Regulation of residue-specific protein ADP-ribosylations by ADP-ribosyl-acceptor hydrolases (ARHs) is important for cellular responses to DNA damage and the uncontrolled accumulation of ADP-ribosylations causes genomic instability, often leading to diseases. We aim to develop new quantitative tools that selectively monitor the reversal of different residue-specific ADP-ribosylations by ARHs and to elucidate the mechanisms of substrate selectivity and cleavage of ARHs. Our studies will overcome the existing technical hurdles in selective and quantitative measurement of site-specific ADP-ribosylations and will provide in-depth understanding of the roles of each enzymatic activity of ARHs in maintaining genomic integrity.",14263844 (contact),"KIM, IN-KWON  (contact)","BARSKI, OLEG",2021-05-01,2026-02-28,NA,Reversal of residue-specicific ADP-ribosylations by ADP-ribosyl-acceptor hydrolases,141226,MSFA,Macromolecular Structure and Function A Study Section[MSFA],NA,NA,5,217233,107578,324811,NA
11217319,N01,OD,NA,N,NA,NA,NA,NA,263201800029I,NA,NA,263201800029I-0-759802400002-2,NCATS:50000\NEI:50000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,WASHINGTON,UNITED STATES,NA,98,041964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,204180007,NA,14666275 (contact),"BEACHY, SARAH H (contact)",NA,2024-01-19,2025-01-17,"Development;Educational workshop;effective therapy;ethical, legal, and social implication;Fostering;information gathering;interest;Marketing;meetings;Patients;Policies;Regenerative Medicine;Science;Therapeutic;Translations;Work",FORUM ON REGENERATIVE MEDICINE,0,NA,NA,NA,NA,NA,NA,NA,100000,NA
11217375,Y01,DK,NA,N,NA,NA,NA,NA,ADK20001001,NA,NA,ADK20001001-1-0-1,NIDDK:5941\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,(contact),NA,NA,NA,NA,GINV: 75090421: CENTERS FOR DI,200010,NA,NA,NA,NA,NA,NA,NA,5941,NA
11217390,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-2,NIDDK:60000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,80003717 (contact),"DMITROVSKY, ETHAN  (contact)",NA,2024-09-28,2025-08-30,NA,NCI FY25 OPERATIONAL TASK ORDER,0,NA,NA,NA,NA,NA,NA,NA,60000,NA
11217394,N02,HD,NA,N,NA,NA,NA,NA,75N94023C00019,NA,NA,75N94023C00019-P00002-9999-2,NIDDK:118381\NIMHD:118381\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,FAIRFAX,UNITED STATES,NA,NA,078355846,US,NA,NA,VA,220333738,NA,79992365 (contact),"KHOSLA, MRINAL  (contact)",NA,2023-09-22,2025-09-21,Logistics;National Institute of Child Health and Human Development;Services,NICHD SERVICES: FIC LOGISTICS SUPPORT,0,NA,NA,NA,NA,NA,NA,NA,236762,NA
11217402,Y01,DK,NA,N,NA,NA,NA,NA,ADK15001002,NA,NA,ADK15001002-2-0-2,NIDDK:262500\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,(contact),NA,NA,NA,NA,GINV: 75090421: CENTERS FOR DI,150010,NA,NA,NA,NA,NA,NA,NA,262500,NA
11217403,Y01,DK,NA,N,NA,NA,NA,NA,ADK12004001,NA,NA,ADK12004001-1-0-2,NIDDK:140000\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,NA,NA,NA,NA,(contact),NA,NA,NA,Diabetes Mellitus;National Health and Nutrition Examination Survey,National Health and Nutrition Examination Survey 2019-2020 Diabetes Component,120040,NA,NA,NA,NA,NA,NA,NA,140000,NA
11217426,N02,DA,NA,N,NA,NA,NA,NA,316201200128W,NA,NA,316201200128W-P00007-759502000001-2,NIA:1014059\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,Rockville,UNITED STATES,NA,08,100350748,US,10007457,"DIGITAL INFUZION, INC.",MD,20852,NA,79738999 (contact),"GOLTZ, BRETT  (contact)",NA,2020-07-01,2025-06-30,Aging;aging process;Clinical Research;Data;design,"DESIGN/ADAPT, DEVELOP, MAINTAIN, AND OPERATE A UNIFIED CROMS THAT SUPPORTS THE UNIQUE DATA AND CLINICAL RESEARCH PROCESS - Aging",0,NA,NA,NA,NA,NA,NA,NA,1014059,NA
11217434,N02,DA,NA,N,NA,NA,NA,NA,316201200141W,NA,NA,316201200141W-P00002-759502300001-1,NIA:516282\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NA,NA,NA,NA,085476625,NA,NA,NA,NA,NA,NA,79558593 (contact),"ZHOU, YVONNE  (contact)",NA,2022-11-28,2024-11-27,Alzheimer&apos;s Disease;Data;Database Management Systems;Maintenance;Performance;Services;Systems Integration;website development,"PROVIDE SERVICES AND DELIVERABLES THROUGH PERFORMANCE OF TECHNICAL SERVICES SPECIFICALLY FOCUSED ON WEBSITE DEVELOPMENT, DATA/DATABASE MANAGEMENT, AND SYSTEM INTEGRATION AND MAINTENANCE",0,NA,NA,NA,NA,NA,NA,NA,516282,NA
11217435,N02,HD,NA,N,NA,NA,NA,NA,75N94022F00050,NA,NA,75N94022F00050-P00004-0-3,NIDDK:2866744\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,SILVER SPRING,UNITED STATES,NA,08,091340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,NA,79728573 (contact),"BYRD-CLARK, DANITA  (contact)",NA,2024-04-17,2025-04-16,base;Epidemiology;Performance;Services,"EPIDEMIOLOGY SUPPORT TASK ORDER  - BASE YEAR  PERIOD OF PERFORMANCE, APRIL 17, 2023 - APRIL 16, 2024 AND FOUR OPTIONAL PERIODS. PROFESSIONAL SERVICES",0,NA,NA,NA,NA,NA,NA,NA,2866744,NA
11217452,N01,AG,NA,N,NA,NA,NA,NA,7531009,NA,NA,7531009-0-0-1,NIA:665000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON AGING,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,(contact),NA,NA,NA,Aging,NIA START-UP CHALLENGE AND ACCELERATOR INITIAL OBLIGATION,0,NA,NA,NA,NA,NA,NA,NA,665000,NA
11217454,N01,DA,NA,N,NA,NA,NA,NA,75N95019D00012,NA,NA,75N95019D00012-P00001-759502300001-1,NCATS:192050\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ALBUQUERQUE,UNITED STATES,NA,01,075769000,US,10061906,LOVELACE BIOMEDICAL RESEARCH INSTITUTE,NM,871085129,NA,79558875 (contact),"ROBERTSON, MIKE  (contact)",NA,2023-08-07,2024-05-07,Animals;bone;Complex;Contractor;Defect;efficacy evaluation;Fracture;Government;healing;Health Care Costs;Hospitalization;Investigation;Lower Extremity;Medical;Modeling;Morbidity - disease rate;Operative Surgical Procedures;Orthopedics;Osteogenesis;Pain;Pharmacotherapy;pre-clinical;pre-clinical research;Quality of life;Research;Research Design;sheep model;Time;United States;Upper Extremity,CHARACTERIZATION OF SPONTANEOUS OSTEOGENESIS AFTER SURGICAL SEGMENTAL BONE DEFECT IN A LARGE ANIMAL,0,NA,NA,NA,NA,NA,NA,NA,192050,NA
11217456,N01,HD,NA,N,NA,NA,NA,NA,75N94021D00007,NA,NA,75N94021D00007-P00004-759402100001-3,NIAAA:43962\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,CHARLESTON,UNITED STATES,NA,06,183710748,US,7575301,MEDICAL UNIVERSITY OF SOUTH CAROLINA,SC,294074636,NA,79671305 (contact),"BOOK, SARAH  (contact)",NA,2021-03-15,2025-03-14,Advisory Services;Area;Award;Clinical;Clinical Research;Clinical Trials;Consultations;Contractor;Data;Data Security;meetings;operation;Performance;Preparation;Protocols documentation;Reporting;Services;Site,CORE FUNCTION ACTIVITIES TASK ORDER FOR ADVISORY SERVICES AND ADMINISTRATIVE REPORTING,0,NA,NA,NA,NA,NA,NA,NA,43962,NA
11217473,N02,HL,NA,N,NA,NA,NA,NA,75N92024P00357,NA,NA,75N92024P00357-0-0-1,NIA:25000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,WASHINGTON,UNITED STATES,NA,98,041964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,204180007,NA,79983690 (contact),"DAY, ROBERT  (contact)",NA,2024-09-14,2025-09-13,Aging;Genomics;Precision Health,ROUNDTABLE ON GENOMICS AND PRECISION HEALTH - Aging,0,NA,NA,NA,NA,NA,NA,NA,25000,NA
11217491,N01,HD,NA,N,NA,NA,NA,NA,75N94021D00008,NA,NA,75N94021D00008-P00004-759402100001-3,NIAAA:45493\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,LOS ANGELES,UNITED STATES,NA,36,092530369,US,577505,UNIVERSITY OF CALIFORNIA LOS ANGELES,CA,900952000,NA,79671308 (contact),"SHOPTAW, STEVEN  (contact)",NA,2021-03-25,2025-03-14,Advisory Services;Area;Award;Clinical;Clinical Research;Clinical Trials;Consultations;Contractor;Data;Data Security;meetings;operation;Performance;Preparation;Protocols documentation;Reporting;Services;Site,CORE FUNCTION ACTIVITIES TASK ORDER FOR ADVISORY SERVICES AND ADMINISTRATIVE REPORTING.,0,NA,NA,NA,NA,NA,NA,NA,45493,NA
11217518,N01,HD,NA,N,NA,NA,NA,NA,75N94021D00005,NA,NA,75N94021D00005-P00004-759402100001-3,NIAAA:37621\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,LEBANON,UNITED STATES,NA,02,150883460,US,10051750,DARTMOUTH-HITCHCOCK CLINIC,NH,037561000,NA,79671299 (contact),"BRUNETTE, MARY  (contact)",NA,2021-03-15,2025-03-14,Advisory Services;Area;Award;Clinical;Clinical Research;Clinical Trials;Consultations;Contractor;Data;Data Security;meetings;operation;Performance;Preparation;Protocols documentation;Reporting;Services;Site,CORE FUNCTION ACTIVITIES TASK ORDER FOR ADVISORY SERVICES AND ADMINISTRATIVE REPORTING,0,NA,NA,NA,NA,NA,NA,NA,37621,NA
11217548,N01,DA,NA,N,NA,NA,NA,NA,75N95020D00006,NA,NA,75N95020D00006-0-759502400001-1,NIA:192523\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,WESTBROOK,UNITED STATES,NA,NA,784226511,US,NA,NA,ME,040922040,NA,79660025 (contact),"COLE, JIM  (contact)",NA,2024-03-01,2025-02-28,aged;Aging;Monitor;Pathology;Rodent,PATHOLOGY MONITORING OF AGED RODENT COLONIES,0,NA,NA,NA,NA,NA,NA,NA,192523,NA
11217562,N01,HD,NA,N,NA,NA,NA,NA,75N94021D00010,NA,NA,75N94021D00010-P00004-759402100001-3,NIAAA:30352\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,CHARLOTTESVILLE,UNITED STATES,NA,05,065391526,US,1526402,UNIVERSITY OF VIRGINIA,VA,229044195,NA,79671311 (contact),"TIOURIRINE, NASSIMA  (contact)",NA,2021-03-15,2025-03-14,Advisory Services;Area;Award;Clinical;Clinical Research;Clinical Trials;Consultations;Contractor;Data;Data Security;meetings;operation;Performance;Preparation;Protocols documentation;Reporting;Services;Site,CORE FUNCTION ACTIVITY TASK ORDER FOR ADVISORY SERVICES AND ADMINISTRATIVE REPORTING.,0,NA,NA,NA,NA,NA,NA,NA,30352,NA
11217575,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00018,NA,NA,75N95022D00018-0-759502400001-1,NIA:6738555\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,WILMINGTON,UNITED STATES,NA,06,019716729,US,1336801,"CHARLES RIVER LABORATORIES INTNTL, INC.",MA,018871096,NA,79983732 (contact),"ESCOBAR URIAS, SERGIO  (contact)",NA,2024-09-30,2025-09-29,Aging;Development;Maintenance;old mice,DEVELOPMENT AND MAINTENANCE OF A MULTIGENOTYPIC AGED MOUSE COLONY,0,NA,NA,NA,NA,NA,NA,NA,6738555,NA
11217576,N01,HD,NA,N,NA,NA,NA,NA,75N94021D00003,NA,NA,75N94021D00003-P00004-759402100001-3,NIAAA:33986\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,BOSTON,UNITED STATES,NA,07,005492160,US,3617301,BOSTON MEDICAL CENTER,MA,021182908,NA,79671293 (contact),"DEVINE, ERIC  (contact)",NA,2021-03-15,2025-03-14,Advisory Services;Area;Award;Clinical;Clinical Research;Clinical Trials;Consultations;Contractor;Data;Data Security;meetings;operation;Performance;Preparation;Protocols documentation;Reporting;Services;Site,CORE FUNCTION ACTIVITIES TASK ORDER FOR ADVISORY SERVICES AND ADMINISTRATIVE REPORTING,0,NA,NA,NA,NA,NA,NA,NA,33986,NA
11217585,N01,HD,NA,N,NA,NA,NA,NA,75N94021D00011,NA,NA,75N94021D00011-P00006-759402100001-3,NIAAA:45216\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,DALLAS,UNITED STATES,NA,30,800771545,US,578404,UT SOUTHWESTERN MEDICAL CENTER,TX,753909105,NA,79671314 (contact),"BROWN, E. SHERWOOD  (contact)",NA,2021-03-15,2025-03-14,Advisory Services;Reporting,CORE FUNCTION ACTIVITIES TASK ORDER FOR ADVISORY SERVICES AND ADMINISTRATIVE REPORTING,0,NA,NA,NA,NA,NA,NA,NA,45216,NA
11217605,N02,DA,NA,N,NA,NA,NA,NA,75N95024D00006,NA,NA,75N95024D00006-0-759502400003-1,NCATS:1927422\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NORTH BETHESDA,UNITED STATES,NA,08,020277339,US,10047839,"AXLE INFORMATICS, LLC",MD,208524931,NA,79776825 (contact),"MAYS, GARY  (contact)",NA,2024-05-17,2024-10-16,Acceleration;Clinical and Translational Science Awards;Ethical Review;Ethics;flexibility;Goals;Institutional Review Boards;Modeling;Multi-site clinical study;National Center for Advancing Translational Sciences;Process;programs;Research Personnel;Resources;Site,SMARTIRB 2.0,0,NA,NA,NA,NA,NA,NA,NA,1927422,NA
11217606,N01,MH,NA,N,NA,NA,NA,NA,75N95023C00015,NA,NA,75N95023C00015-P00002-9999-3,NIA:1271052\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF MENTAL HEALTH,NA,NEW YORK,UNITED STATES,NA,13,078861598,US,3839801,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,NY,100296574,NA,79946584 (contact),"HADIJAH, VACTOR  (contact)",NA,2023-08-23,2025-08-22,Alzheimer&apos;s Disease;clinical research site;neuroAIDS;Tissues,NATIONAL NEUROHIV TISSUE CONSORTIUM (NNTC) - CLINICAL SITE - Alzheimer's disease,0,NA,NA,NA,NA,NA,NA,NA,1271052,NA
11217625,N01,DA,NA,N,NA,NA,NA,NA,75N95023C00016,NA,NA,75N95023C00016-P00002-9999-2,NIA:316467\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,GALVESTON,UNITED STATES,NA,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,NA,79946587 (contact),"GELMAN, BENJAMIN  (contact)",NA,2023-08-23,2025-08-22,Alzheimer&apos;s Disease;clinical research site;neuroAIDS;Tissues,NATIONAL NEUROHIV TISSUE CONSORTIUM (NNTC) - CLINICAL SITE - Alzheimer's disease,0,NA,NA,NA,NA,NA,NA,NA,316467,NA
11217654,N01,HD,NA,N,NA,NA,NA,NA,75N94019D00001,NA,NA,75N94019D00001-0-759402400001-1,NIAAA:37744\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,GAITHERSBURG,UNITED STATES,NA,NA,143526247,US,NA,FAST TRACK DRUGS AND BIOL,MD,208784276,NA,79743263 (contact),"RICKMAN, WILLIAM  (contact)",NA,2024-05-01,2025-01-31,Clinical Data;data management;Data Management Resources;Security;Update,IT SECURITY UPDATE TO CLINICAL DATA MANAGEMENT SYSTEM -- CRO STUDY AND DATA MANAGEMENT,0,NA,NA,NA,NA,NA,NA,NA,37744,NA
11217655,N43,DA,NA,N,NA,NA,NA,NA,75N95023C00024,NA,NA,75N95023C00024-P00004-9999-1,NIA:2549818\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,LOS ANGELES,UNITED STATES,NA,34,079582283,US,10049960,"HYPERTHESIS, LLC",CA,90012,NA,79983737 (contact),"POL, GRATIANA  (contact)",NA,2023-09-26,2026-09-25,Alzheimer&apos;s Disease;behavioral and social science;Small Business Innovation Research Grant;social science research;Visualization software,SBIR - TOPIC 009 - AI/ML TOOL FOR VISUALIZING BEHAVIORAL AND SOCIAL SCIENCE RESEARCH,0,NA,NA,NA,NA,NA,NA,NA,2549818,NA
11217662,N01,DA,NA,N,NA,NA,NA,NA,75N95023C00037,NA,NA,75N95023C00037-P00001-9999-1,NIA:140955\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,MADISON,UNITED STATES,NA,02,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,NA,79992064 (contact),"SIMMONS, HEATHER  (contact)",NA,2023-09-30,2025-09-29,Aging;Development;Maintenance;nonhuman primate;Tissue Banks,DEVELOPMENT AND MAINTENANCE OF A NON-HUMAN PRIMATE TISSUE BANK,0,NA,NA,NA,NA,NA,NA,NA,140955,NA
11217681,N01,DA,NA,N,NA,NA,NA,NA,75N95023D00024,NA,NA,75N95023D00024-0-759502400001-1,NIA:1327728\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,WILMINGTON,UNITED STATES,NA,06,019716729,US,1336801,"CHARLES RIVER LABORATORIES INTNTL, INC.",MA,018871096,NA,79973122 (contact),"URIAS, SERGIO  (contact)",NA,2024-09-30,2025-09-29,aged;Aging;Development;Maintenance;Rattus,DEVELOPMENT AND MAINTENANCE OF A MULTIGENOTYPIC AGED RAT COLONY,0,NA,NA,NA,NA,NA,NA,NA,1327728,NA
11217699,N43,DA,NA,N,NA,NA,NA,NA,75N95024C00001,NA,NA,75N95024C00001-P00001-9999-1,NIA:500000\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,MOUNTAIN VIEW,UNITED STATES,NA,16,080117469,US,10040976,"NEUCYTE, INC.",CA,94043,NA,79559016 (contact),"POON, WAYNE  (contact)",NA,2023-11-15,2024-11-14,Alzheimer&apos;s Disease;high-throughput drug screening;miniaturize,A MINIATURIZED AD MPS PLATFORM FOR HIGH-THROUGHPUT DRUG SCREENING,0,NA,NA,NA,NA,NA,NA,NA,500000,NA
11217742,N02,DA,NA,N,NA,NA,NA,NA,75N95024F00064,NA,NA,75N95024F00064-0-0-1,NCATS:3237500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,INDIANAPOLIS,UNITED STATES,NA,07,114135499,US,3311001,"REGENSTRIEF INSTITUTE, INC.",IN,462024800,NA,79660249 (contact),"GRANNIS, SHAUN  (contact)",NA,2024-03-01,2024-10-31,Characteristics;Clinical;Clinical Data;cohort;Computer software;COVID-19;Data;data enclave;Data Set;Disparate;Hospitals;Knowledge;member;Patients;Persons;privacy preservation;Process;Provider;Records;Research Personnel;response;Secure;Security;Series;Services;Vendor,LINKAGE HONEST BROKER SERVICES FOR THE N3C DATA ENCLAVE,0,NA,NA,NA,NA,NA,NA,NA,3237500,NA
11217756,N02,DA,NA,N,NA,NA,NA,NA,75N95023D00027,NA,NA,75N95023D00027-0-759502400001-1,NCATS:4180254\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,DENVER,UNITED STATES,NA,01,362130952,US,10065762,"PALANTIR TECHNOLOGIES, INC.",CO,802021866,NA,79561393 (contact),"ZAVERTNIK, BRIAN  (contact)",NA,2023-12-21,2024-03-20,Address;Clinical;cohort;COVID-19;COVID-19 pandemic;Data;data enclave;data harmonization;Data Set;Electronic Health Record;Health;Infrastructure;Institution;Medical Research;National Center for Advancing Translational Sciences;National Security;Outcome;patient privacy;Persons;Research;Research Personnel;Resources;response;Speed;Work,National Clinical Cohort Collaborative (N3C),0,NA,NA,NA,NA,NA,NA,NA,4180254,NA
11217763,R01,GM,7,N,2024-12-04,2024-07-01,2025-01-31,859,R01GM144489,SCHOOLS OF ARTS AND SCIENCES,PA-24-254,7R01GM144489-03,NIGMS:89920\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,HOUSTON,UNITED STATES,CHEMISTRY,09,050299031,US,9291001,RICE UNIVERSITY,TX,770051827,"PROJECT NARRATIVE  Natural products hold a crucial role in developing novel molecular tools, such as pharmaceutical agents and probes. Specifically, they provide a major driving force for discovering new chemotherapeutics and are the primary source of compounds for the effective treatment of cancer and infectious diseases. The proposed research aims to develop new strategies and methods to prepare and study promising small bioactive molecules based on complex natural products that are not readily accessible yet would be highly desirable if brought within the realm of medicinal chemistry.",12644041 (contact),"SARLAH, DAVID  (contact)","YANG, JIONG",2023-02-01,2027-01-31,NA,Synthesis of Biologically Active Terpenoids,144489,SBCA,Synthetic and Biological Chemistry A Study Section[SBCA],NA,NA,3,60028,29892,89920,NA
11217789,N02,HD,NA,N,NA,NA,NA,NA,75N94023F00044,NA,NA,75N94023F00044-P00005-0-2,NIAAA:1833570\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,FAIRFAX,UNITED STATES,NA,11,072648579,US,1644201,"ICF, INC., LLC",VA,220316050,NA,79688674 (contact),"MOYER, MELINDA MOYER  (contact)",NA,2023-03-21,2025-03-20,Exhibits;National Institute on Alcohol Abuse and Alcoholism;Publications,NIAAA PUBLICATIONS AND EXHIBITS SUPPORT,0,NA,NA,NA,NA,NA,NA,NA,1833570,NA
11217830,N01,HD,NA,N,NA,NA,NA,NA,275201300002C,NA,NA,275201300002C-P00016-9999-2,NIAAA:19329\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,BETHESDA,UNITED STATES,NA,08,177159456,US,3020801,"CDM GROUP, INC.",MD,208146133,NA,79704036 (contact),"HERRON, KATHERYN  (contact)",NA,2013-01-01,2017-12-31,alcohol policy information system;Data;Maintenance;National Institute on Alcohol Abuse and Alcoholism;Research;System;Update;web site,NIAAA ALCOHOL POLICY INFORMATION SYSTEM (APIS) SYSTEM/WEBSITE MAINTENANCE AND UPDATING OF RESEARCH DATA,0,NA,NA,NA,NA,NA,NA,NA,19329,NA
11217853,N02,DA,NA,N,NA,NA,NA,NA,316201200038W,NA,NA,316201200038W-0-759502400001-2,NIAAA:250000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NA,NA,NA,NA,802314120,NA,NA,NA,NA,NA,NA,79792043 (contact),"SCHULMAN, SAMARA  (contact)",NA,2012-06-01,2025-06-06,Acceleration;Affect;Archives;autism spectrum disorder;biomedical informatics;Brain Diseases;Communication;Data;data archive;Data Collection;data platform;Databases;Diagnosis;flexibility;Genetic;interest;National Institute of Mental Health;Persons;Prevention;repository;Research;Retrieval;Series;System;United States National Institutes of Health;Work,THE PURPOSE OF THIS TASK ORDER IS TO SUPPORT THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) DATA ARCHIVE (NDA) IN ACCORDANCE WITH THE INCORPORATED ATTACHMENT 1: STATEMENT OF WORK.,0,NA,NA,NA,NA,NA,NA,NA,250000,NA
11217854,N43,DA,NA,N,NA,NA,NA,NA,75N95024C00031,NA,NA,75N95024C00031-0-9999-1,NIA:498657\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,SEATTLE,UNITED STATES,NA,07,118440483,US,10067618,SEABRIGHT LLC,WA,981123425,NA,80000525 (contact),"THONGPANG, SANITTA  (contact)",NA,2024-09-25,2025-09-24,Alzheimer&apos;s Disease;Alzheimer&apos;s disease related dementia;Population;Resources;Small Business Innovation Research Grant;Technology,SBIR TOPIC 010 - TECHNOLOGY TO FACILITATE CHARACTERIZATION OF THE EXPOSOME IN UNDER-RESOURCED POPULATIONS FOR AD/ADRD STUDIES,0,NA,NA,NA,NA,NA,NA,NA,498657,NA
11217876,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00001,NA,NA,75N95024D00001-0-759502400001-1,NIA:4718200\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,Rockville,UNITED STATES,NA,08,100350748,US,10007457,"DIGITAL INFUZION, INC.",MD,20852,NA,79693922 (contact),"APPELMANS, ELINE  (contact)",NA,2024-03-25,2025-03-24,Alzheimer&apos;s Disease,"TASK ORDER 1 - OCR PROJECT MANAGEMENT, DSMB AND CROMS-RELATED SUPPORT",0,NA,NA,NA,NA,NA,NA,NA,4718200,NA
11217896,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00002,NA,NA,75N95024D00002-0-759502400001-1,NIA:962486\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,EXETER,UNITED KINGDOM,NA,NA,211320981,UK,2464801,UNIVERSITY OF EXETER,NA,EX4 4QJ,NA,79611665 (contact),"BALLARD, CLIVE  (contact)",NA,2024-02-01,2025-01-31,Alzheimer&apos;s Disease;controlled release;phenserine;research clinical testing;tablet formulation;Tartrates,CLINICAL EVALUATION OF PHENSERINE TARTRATE EXTENDED CONTROLLED RELEASE TABLET (ECRT) FORMULATION - Alzheimer's disease,0,NA,NA,NA,NA,NA,NA,NA,962486,NA
11217905,N02,DA,NA,N,NA,NA,NA,NA,75N95024D00024,NA,NA,75N95024D00024-0-759502400001-1,NIA:4299073\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,876875154,US,3122901,"IQ SOLUTIONS, INC.",MD,208523046,NA,79814147 (contact),"BRACKETT, THOMAS  (contact)",NA,2024-09-16,2025-09-15,Alzheimer&apos;s Disease;Information Resources;National Institute on Aging,TASK ORDER 1: NATIONAL INSTITUTE ON AGING (NIA) INFORMATION RESOURCE CENTER,0,NA,NA,NA,NA,NA,NA,NA,4299073,NA
11217906,F32,AA,7,N,2024-10-24,2024-10-01,2025-09-30,273,F32AA031898,SCHOOLS OF MEDICINE,PA-23-262,7F32AA031898-02,NIAAA:73408\,"TRAINING, INDIVIDUAL",2024,NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM,NA,SAN ANTONIO,UNITED STATES,PHARMACOLOGY,20,800772162,US,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,TX,782293901,"Project Narrative Astrocytes modulate neuronal function and current evidence indicates that alcohol dependence is associated with neuronal hyperexcitability. This project will examine how ethanol impacts astrocyte regulation of neuronal excitability using a novel cell culture model of in vitro, intermittent ethanol exposure with different molecular approaches. The goal of these experiments is to identify potential drug targets for the treatment of alcohol use disorder.",15570827 (contact),"EZERSKIY, LUBOV  (contact)","CUI, CHANGHAI",2024-10-01,2025-09-30,Abstinence;Acute;Agonist;alcohol abuse therapy;Alcohol consumption;Alcohol dependence;alcohol exposure;alcohol research;alcohol response;alcohol use disorder;Alcohol withdrawal syndrome;Alcohols;Amyotrophic Lateral Sclerosis;Astrocytes;Automobile Driving;Brain;Buffers;candidate identification;Cell Culture Techniques;Cells;central nervous system injury;Chronic;Clinical;Coculture Techniques;Communities;Dependence;Development;Diabetic Neuropathies;differential expression;Disease;drinking;Ethanol;excitotoxicity;experimental study;Exposure to;extracellular;FOLH1 gene;Gene Expression;gene network;Genes;glutamate carboxypeptidase;Glutamate Transporter;Glutamates;Goals;Homeostasis;in vitro Model;in vivo;Induced Neurons;innovation;interest;Mediating;Mediator;Medical;Messenger RNA;metabotropic glutamate receptor 2;Microelectrodes;Modeling;Molecular;Mus;N-acetylaspartate;N-acetylaspartylglutamate;negative affect;Neuroimmune system;neuronal excitability;Neurons;Neuropeptides;neuropsychiatry;neurotransmitter release;novel;pain model;Pathway Analysis;Pathway interactions;Patients;Persons;Pharmaceutical Preparations;pharmacologic;pinacolyl methylphosphonic acid;Play;presynaptic;Procedures;protein transport;Proteins;receptor;Regulation;Relapse;Research;Rodent;Role;Schizophrenia;Signal Transduction;social;Substance Withdrawal Syndrome;Synapses;Syndrome;targeted treatment;Testing;Therapeutic;Time;tool;Transcript;transcriptomics;treatment strategy;United States Food and Drug Administration;Withdrawal,Mechanisms by which alcohol disrupts astrocytic control of neuronal excitability,31898,ZAA1,ZAA1-GG(32)L,NA,NA,2,73408,0,73408,NA
11217913,N02,DA,NA,N,NA,NA,NA,NA,75N95024F00088,NA,NA,75N95024F00088-0-0-1,NIA:445387\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,MC LEAN,UNITED STATES,NA,11,040540304,US,324202,MITRE CORPORATION,VA,221027539,NA,79747549 (contact),"KUNZMAN, JON  (contact)",NA,2024-05-01,2024-07-10,Alzheimer&apos;s Disease;cloud based;data infrastructure;Research,CLOUD-BASED RESEARCH DATA INFRASTRUCTURE - Alzheimer's disease,0,NA,NA,NA,NA,NA,NA,NA,445387,NA
11217931,N02,DA,NA,N,NA,NA,NA,NA,75N95024F00088,NA,NA,75N95024F00088-0-0-2,NIA:170884\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,MC LEAN,UNITED STATES,NA,11,040540304,US,324202,MITRE CORPORATION,VA,221027539,NA,79747549 (contact),"KUNZMAN, JON  (contact)",NA,2024-05-01,2024-07-10,Aging;cloud based;data infrastructure;Research,CLOUD-BASED RESEARCH DATA INFRASTRUCTURE - Aging,0,NA,NA,NA,NA,NA,NA,NA,170884,NA
11217974,Y01,AG,NA,N,NA,NA,NA,NA,AAG22003001,NA,NA,AAG22003001-1-0-2,NIA:362500\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE ON AGING,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE ON AGING,NA,NA,NA,NA,(contact),NA,NA,NA,Alzheimer&apos;s Disease;Censuses,Census - Alzheimer's disease,220030,NA,NA,NA,NA,NA,NA,NA,362500,NA
11217983,Y01,AG,NA,N,NA,NA,NA,NA,AAG24001001,NA,NA,AAG24001001-1-0-1,NIA:2238116\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE ON AGING,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE ON AGING,NA,NA,NA,NA,(contact),NA,NA,NA,Alzheimer&apos;s Disease;Data,NIA-CMS IAA to Purchase CMS Data for NIA Grantees - Alzheimer's disease,240010,NA,NA,NA,NA,NA,NA,NA,2238116,NA
11217984,Y01,AG,NA,N,NA,NA,NA,NA,AAG24001001,NA,NA,AAG24001001-1-0-2,NIA:2088250\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE ON AGING,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE ON AGING,NA,NA,NA,NA,(contact),NA,NA,NA,Aging;Data,NIA-CMS IAA to Purchase CMS Data for NIA Grantees - Aging,240010,NA,NA,NA,NA,NA,NA,NA,2088250,NA
11217990,Y01,AG,NA,N,NA,NA,NA,NA,AAG24003001,NA,NA,AAG24003001-1-0-1,NIA:640000\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE ON AGING,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE ON AGING,NA,NA,NA,NA,(contact),NA,NA,NA,Alzheimer&apos;s Disease;statistics,Department of Labor - Bureau of Labor Statistics NLSY,240030,NA,NA,NA,NA,NA,NA,NA,640000,NA
11218000,Y01,AG,NA,N,NA,NA,NA,NA,AAG24006001,NA,NA,AAG24006001-1-0-1,NIA:20000\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE ON AGING,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE ON AGING,NA,NA,NA,NA,(contact),NA,NA,NA,Aging;aging related;statistics;United States National Center for Health Statistics,CDC/NCHS - Federal Interagency Forum on Aging-Related Statistics,240060,NA,NA,NA,NA,NA,NA,NA,20000,NA
11218008,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00010,NA,NA,75N92019D00010-P00007-759201900053-4,NIMHD:1000000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,CHAPEL HILL,UNITED STATES,NA,04,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275995023,NA,1974483 (contact),"CAI, JIANWEN  (contact)",NA,2018-11-30,2024-11-29,Accident and Emergency department;Acute myocardial infarction;Adult;aged;Ancillary Study;Asthma;asthma exacerbation;Back;Cardiovascular Diseases;Cardiovascular system;Central American;Certification;Cessation of life;Chicago;Chronic;Chronic Disease;Chronic Obstructive Pulmonary Disease;Cities;cohort;Community Participation;Contracts;Cross-Sectional Studies;Cuban;Diabetes Mellitus;Disease;Dominican;Echocardiography;Event;follow-up;Funding;Future;Goals;Health;health care service utilization;Health Status;hearing impairment;Heart Diseases;Heart failure;Hispanic;Hispanic Community Health Study/Study of Latinos;Hispanic Populations;Hospitalization;Human Resources;Hypertension;Interview;Journals;Latino;Latino Population;Longitudinal Studies;Lung;Lung Diseases;Medical History;meetings;Mexican;mortality;neurocognitive disorder;Newly Diagnosed Disease;Obesity;Observational Study;Participant;Performance;Periodontal Diseases;Pregnancy Histories;Prevalence;prospective;protective factors;Publishing;Puerto Rican;recruit;Reproductive History;Risk;Risk Factors;Sampling;Sleep Disorders;South American;Stroke;Time;Tooth Diseases;Training;United States;Update;Visit;Woman,HISPANIC COMMUNITY HEALTH STUDY-STUDY OF LATINOS (HCHS-SOL)- COORDINATING CENTER,0,NA,NA,NA,NA,NA,NA,NA,1000000,NA
11218015,N01,OD,NA,N,NA,NA,NA,NA,263201800029I,NA,NA,263201800029I-0-759802400001-3,NCCIH:25000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,WASHINGTON,UNITED STATES,NA,98,041964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,204180007,NA,NA,(contact),NA,2023-12-12,2024-12-11,NA,FY24 IC SUPPORT FOR THE NEUROSCIENCE FORUM,0,NA,NA,NA,NA,NA,NA,NA,25000,NA
11218032,N02,HD,NA,N,NA,NA,NA,NA,75N94022F00139,NA,NA,75N94022F00139-P00005-0-3,NIAAA:231525\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,WASHINGTON,UNITED STATES,NA,NA,116191875,US,NA,NA,DC,200363506,NA,79876919 (contact),"SLAUGHTER, SAMANTHA  (contact)",NA,2022-08-22,2025-08-21,Communication;Marketing;National Institute on Alcohol Abuse and Alcoholism;outreach;programs;Small Business Innovation Research Grant;Small Business Technology Transfer Research,TO PROVIDE MARKETING AND OUTREACH FOR THE NIAAA SBIR/STTR PROGRAM TO HELP COMMUNICATE THE OBJECTIVES OF THE PROGRAM.,0,NA,NA,NA,NA,NA,NA,NA,231525,NA
11218062,N01,DA,NA,N,NA,NA,NA,NA,75N95024C00003,NA,NA,75N95024C00003-P00002-9999-2,NIAAA:250000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,049508120,US,9611701,"WESTAT, INC.",MD,208503129,NA,79853241 (contact),"CARUSI, CHARLES  (contact)",NA,2024-02-01,2029-01-31,Country;Health;Longitudinal Studies;Performance;Persons;Population Assessment of Tobacco and Health;Research;Tobacco;Tobacco use;United States;United States Food and Drug Administration;United States National Institutes of Health,POPULATION ASSESSMENT OF TOBACCO AND HEALTH (PATH) STUDY PERIOD OF PERFORMANCE: 02/01/2024 - 01/31/2029,0,NA,NA,NA,NA,NA,NA,NA,250000,NA
11218198,N01,HD,NA,N,NA,NA,NA,NA,75N94019C00008,NA,NA,75N94019C00008-P00012-9999-3,NIAAA:102376\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,CHARLESTON,UNITED STATES,NA,06,183710748,US,7575301,MEDICAL UNIVERSITY OF SOUTH CAROLINA,SC,294074636,NA,79933124 (contact),"BECKER, PH.D., HOWARD C.  (contact)",NA,2019-08-16,2024-11-30,alcohol use disorder;Dependence;Modeling;Pharmaceutical Preparations;pre-clinical;screening,PRECLINICAL MEDICATIONS SCREENING IN DEPENDENCE MODELS OF ALCOHOL USE DISORDER,0,NA,NA,NA,NA,NA,NA,NA,102376,NA
11218227,N01,HD,NA,N,NA,NA,NA,NA,75N94021C00003,NA,NA,75N94021C00003-P00010-9999-3,NIAAA:185937\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,Oakland,UNITED STATES,NA,12,150829349,US,3497005,KAISER FOUNDATION RESEARCH INSTITUTE,CA,946123610,NA,79955958 (contact),"WEISNER, DR.PH., MSW, CONSTANCE  (contact)",NA,2021-09-22,2025-09-21,Affect;Alcohol consumption;alcohol use disorder;Alcohols;California;comorbidity;Data;demographics;Development;Health;Healthcare;Pharmacy facility;Primary Care;Recovery;Registries;screening;Substance abuse problem;success,KAISER PERMANENTE OF NORTHERN CALIFORNIA (KPNC) ALCOHOL REGISTRY,0,NA,NA,NA,NA,NA,NA,NA,185937,NA
11218300,N01,HD,NA,N,NA,NA,NA,NA,75N94019D00001,NA,NA,75N94019D00001-0-759402400002-1,NIAAA:5811442\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,GAITHERSBURG,UNITED STATES,NA,NA,143526247,US,NA,FAST TRACK DRUGS AND BIOL,MD,208784276,NA,79977823 (contact),"RANSOM, JANET  (contact)",NA,2024-09-16,2026-09-15,alcohol abuse therapy;alcohol use disorder;Clinical;Clinical Research;clinical research site;Clinical Trials;Contractor;Contracts;Data Analyses;data management;Development;electronic data;Extramural Activities;Good Clinical Practice;meetings;Monitor;National Institute on Alcohol Abuse and Alcoholism;Pharmaceutical Preparations;Preparation;Reporting;Research Contracts;Services;Shipping;Statistical Data Interpretation;treatment program;Work,APREMILAST FOR THE TREATMENT OF ALCOHOL USE DISORDER -- CONTRACT RESEARCH ORGANIZATION STUDY AND DATA MANAGEMENT,0,NA,NA,NA,NA,NA,NA,NA,5811442,NA
11218382,N02,HD,NA,N,NA,NA,NA,NA,75N94023F00148,NA,NA,75N94023F00148-P00003-0-2,NIAAA:1354006\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,FAIRFAX,UNITED STATES,NA,11,072648579,US,1644201,"ICF, INC., LLC",VA,220316050,NA,79942111 (contact),"MOYER, MELINDA  (contact)",NA,2023-09-01,2025-08-31,Communication;National Institute on Alcohol Abuse and Alcoholism;outreach,NIAAA OUTREACH AND COMMUNICATIONS SUPPORT,0,NA,NA,NA,NA,NA,NA,NA,1354006,NA
11218407,N01,HD,NA,N,NA,NA,NA,NA,75N94023C00014,NA,NA,75N94023C00014-P00001-9999-2,NIAAA:240999\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,NEW ORLEANS,UNITED STATES,NA,02,782627814,US,577902,LSU HEALTH SCIENCES CENTER,LA,701127021,NA,79983723 (contact),"EDWARDS, SCOTT  (contact)",NA,2023-09-27,2025-09-26,Affect;Alcoholism;Dependence;pain model;Pharmaceutical Preparations;pre-clinical;screening,"PRECLINICAL MEDICATIONS SCREENING IN DEPENDENCE, AFFECT AND PAIN MODELS OF ALCOHOLISM",0,NA,NA,NA,NA,NA,NA,NA,240999,NA
11218422,N01,HD,NA,N,NA,NA,NA,NA,75N94023C00015,NA,NA,75N94023C00015-P00003-9999-2,NIAAA:814097\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,ARLINGTON,UNITED STATES,NA,08,096356431,US,1379501,"CSR, INC.",VA,222013091,NA,79944286 (contact),"SLATER, MEGAN  (contact)",NA,2023-09-27,2025-09-26,alcohol epidemiology;Information Systems;National Institute on Alcohol Abuse and Alcoholism,NIAAA ALCOHOL EPIDEMIOLOGIC DATA SYSTEM (AEDS),0,NA,NA,NA,NA,NA,NA,NA,814097,NA
11218477,N02,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-P00023-759101900133-1,NCI:3437228\NIAID:297\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2019-08-31,2024-08-30,anti-cancer research;Funding;Industry;Laboratories;Medical center;National Cancer Institute;National Institute of Allergy and Infectious Disease;research and development,FFRDC TASK ORDER - LEASES,0,NA,NA,NA,NA,NA,NA,NA,3437525,NA
11218493,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400017-1,NCI:386616\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-05-20,2026-01-22,Animals;improved;Infrastructure;Procedures,FY24 FACILITIES TO A - 126615 CONVERSION OF ANIMAL ROOM,0,NA,NA,NA,NA,NA,NA,NA,386616,NA
11218498,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400019-1,NCI:905065\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-05-23,2026-11-24,Agreement;Chills;cost;Cost Savings;design;Drops;Equipment;Frequencies;heat exchanger;Maintenance;Temperature;Water,FY24 FACILITIES TO C - 126610 B555 CHILLER VFD INSTALL,0,NA,NA,NA,NA,NA,NA,NA,905065,NA
11218499,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400020-1,NCI:455377\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-05-23,2025-10-28,Ensure;Location;Vestibule,FY24 FACILITIES TO D - 126629 B322 INSTALL VESTIBULE AND COVERED WALKWAY,0,NA,NA,NA,NA,NA,NA,NA,455377,NA
11218578,ZIA,NS,1,N,NA,NA,NA,NA,ZIANS009457,NA,NA,1ZIANS009457-01,NINDS:170000\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,NA,NA,6980037 (contact),"KHALIQ, ZAYD M (contact)",NA,NA,NA,Automation;Basal Ganglia;Brain;Cell Nucleus;Cells;Computer software;connectome;Custom;data acquisition;dopamine system;dopaminergic neuron;Engineering;Equipment;experimental study;Future;Goals;Grant;Intramural Research Program;Laboratories;Midbrain structure;Morphology;National Institute of Neurological Disorders and Stroke;Neurons;neurophysiology;patch sequencing;Physiology;Population;Postdoctoral Fellow;Procedures;Property;Reagent;Site;Substantia nigra structure;Testing;tool;Training;transcriptome;transcriptomics;Ventral Tegmental Area,"BRAIN CONNECTS: PatchLink, scalable tools for integrating connectomes, projectomes, and transcriptomes",9457,NA,NA,NA,NA,1,NA,NA,170000,NA
11218771,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00027,NA,NA,75N92019D00027-0-759202400001-1,NHLBI:1332779\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,OKLAHOMA CITY,UNITED STATES,NA,05,878648294,US,1524003,UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,OK,731043609,NA,NA,(contact),NA,2023-11-01,2024-10-31,NA,STRONG HEART STUDY (SHS) - COORDINATING CENTER (CC) - TASK AREA B.2 - YEAR 2,0,NA,NA,NA,NA,NA,NA,NA,1332779,NA
11218773,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00030,NA,NA,75N92019D00030-0-759202400002-1,NHLBI:554134\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,HYATTSVILLE,UNITED STATES,NA,04,189030067,US,4046605,MEDSTAR HEALTH RESEARCH INSTITUTE,MD,207822031,NA,79701732 (contact),"UMANS, JASON  (contact)",NA,2024-04-01,2025-03-31,"Adverse event;American Indian community;Ancillary Study;Area;blind;Blood;Blood Volume;Cardiovascular Diseases;cardiovascular disorder epidemiology;Centrifugation;Certification;Clinic;Clinical;clinically relevant;clinically significant;cold temperature;community based research;Community Relations;Computers;Consent;Consultations;Contractor;Data;Data Analyses;data cleaning;Data Collection;data exchange;data management;Dry Ice;epidemiology study;Event;experience;follow-up;Funding;Health;Health Personnel;Heart;Human Resources;human subject;Informed Consent;Institutional Review Boards;Interview;Investigation;Laboratories;Laboratory Procedures;Lead;Measurement;Measures;Medical Staff;National Heart, Lung, and Blood Institute;operation;Participant;participant retention;Performance;Phase;Policies;Preparation;Principal Investigator;Procedures;protocol development;Protocols documentation;Qualifying;quality assurance;Quality Control;Recommendation;recruit;Refrigeration;Reporting;Research;Research Design;Research Institute;Research Personnel;Sampling;Schedule;Serious Adverse Event;Shipping;skills;Software Design;Specific qualifier value;Specimen;Training;transmission process;tribal community;Urine;Work","STRONG HEART STUDY (SHS)-MEDSTAR HEALTH RESEARCH INSTITUTE- FIELD CENTER (FC), TASK AREA B.2, YEAR 2",0,NA,NA,NA,NA,NA,NA,NA,554134,NA
11218774,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00029,NA,NA,75N92019D00029-0-759202400002-2,NHLBI:587606\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,EAGLE BUTTE,UNITED STATES,NA,00,180957714,US,3109602,"MISSOURI BREAKS RESEARCH, INC.",SD,576251824,NA,NA,(contact),NA,2024-04-01,2025-03-31,NA,"STRONG HEART STUDY (SHS)-MISSOURI BREAKS INDUSTRIES RESEARCH, INC.- FIELD CENTER (FC), TASK AREA B.2, YEAR 2",0,NA,NA,NA,NA,NA,NA,NA,587606,NA
11218776,N01,ES,NA,N,NA,NA,NA,NA,75N96022C00005,NA,NA,75N96022C00005-P00003-9999-2,NIEHS:400000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,RESEARCH TRIANGLE PARK,UNITED STATES,NA,04,962071515,US,10029058,"SCIOME, LLC",NC,277093169,NA,11060844 (contact),"SHAH, RUCHIR  (contact)",NA,2022-09-24,2024-03-23,Bioinformatics;Biometry;Contractor;Data;Data Analyses;Development;epigenomics;Experimental Designs;experimental study;Genomics;Image;In Vitro;in vivo;Informatics;Methods;National Institute of Environmental Health Sciences;Quality Control;Quantitative Structure-Activity Relationship;Review Literature;screening;Support Contracts;text searching;Toxicogenomics;transcriptomics,BIOINFORMATICS SUPPORT FOR DNTP & DIR,0,NA,NA,NA,NA,NA,NA,NA,400000,NA
11218778,N01,ES,NA,N,NA,NA,NA,NA,75N96022C00005,NA,NA,75N96022C00005-P00003-9999-3,NIEHS:475000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,RESEARCH TRIANGLE PARK,UNITED STATES,NA,04,962071515,US,10029058,"SCIOME, LLC",NC,277093169,NA,11060844 (contact),"SHAH, RUCHIR  (contact)",NA,2022-09-24,2024-03-23,Bioinformatics;Biometry;Chemicals;Contractor;Data;Development;epigenomics;Experimental Designs;Genomics;high throughput screening;Image;In Vitro;Informatics;Methods;model building;National Institute of Environmental Health Sciences;predictive modeling;Quantitative Structure-Activity Relationship;Review Literature;Support Contracts;Testing;text searching;tool;Toxicogenomics;Toxicology;transcriptomics;user-friendly;Validation,BIOINFORMATICS SUPPORT FOR DNTP & DIR,0,NA,NA,NA,NA,NA,NA,NA,475000,NA
11218779,N01,ES,NA,N,NA,NA,NA,NA,75N96022C00005,NA,NA,75N96022C00005-P00003-9999-4,NIEHS:400000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,RESEARCH TRIANGLE PARK,UNITED STATES,NA,04,962071515,US,10029058,"SCIOME, LLC",NC,277093169,NA,11060844 (contact),"SHAH, RUCHIR  (contact)",NA,2022-09-24,2024-03-23,Bioinformatics;Biometry;Cells;Classification;Collaborations;Contractor;Data;Development;epigenomics;Experimental Designs;Genomics;Hazard Assessment;Image;Image Analysis;Informatics;Machine Learning;Methods;Morphology;National Institute of Environmental Health Sciences;Quantitative Structure-Activity Relationship;Review Literature;Support Contracts;text searching;Toxic effect;Toxicogenomics;transcriptomics;Whole Organism;Zebrafish,BIOINFORMATICS SUPPORT FOR DNTP & DIR,0,NA,NA,NA,NA,NA,NA,NA,400000,NA
11218780,N01,ES,NA,N,NA,NA,NA,NA,273201600003I,NA,NA,273201600003I-0-759602400024-1,NIEHS:262146\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,SILVER SPRING,UNITED STATES,NA,08,091340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,NA,79795000 (contact),"JACKSON, BRAXTON  (contact)",NA,2016-06-30,2026-06-29,Age;Biological Markers;Chemical Exposure;Child;Childhood;cohort;Data;fetal;First Pregnancy Trimester;follow-up;Generations;Growth;Growth and Development function;Individual;Inflammation;insight;Longterm Follow-up;Measurement;Measures;metabolome;metabolomics;National Institute of Environmental Health Sciences;Outcome;Participant;Pathway interactions;Pattern;Physiological;Plasma;Pregnancy;prenatal;prospective;research and development;Sampling;Second Pregnancy Trimester;Time;Umbilical Cord Blood,TASK ORDER NO.: 75N96024F00024 RESEARCH DEVELOPMENT - GENR METABOLOMICS STUDY DATA SUPPORT,0,NA,NA,NA,NA,NA,NA,NA,262146,NA
11218781,N01,ES,NA,N,NA,NA,NA,NA,75N96022C00005,NA,NA,75N96022C00005-P00003-9999-5,NIEHS:89756\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,RESEARCH TRIANGLE PARK,UNITED STATES,NA,04,962071515,US,10029058,"SCIOME, LLC",NC,277093169,NA,11060844 (contact),"SHAH, RUCHIR  (contact)",NA,2022-09-24,2024-03-23,Bioinformatics;Biometry;Carcinogens;Data;Development;epigenomics;Experimental Designs;Genomics;Image;Informatics;Maps;Methods;National Institute of Environmental Health Sciences;Quantitative Structure-Activity Relationship;Reporting;Review Literature;Support Contracts;systematic review;text searching;tool;Toxicogenomics;transcriptomics,BIOINFORMATICS SUPPORT FOR DNTP & DIR,0,NA,NA,NA,NA,NA,NA,NA,89756,NA
11218782,N01,ES,NA,N,NA,NA,NA,NA,75N96022C00005,NA,NA,75N96022C00005-P00003-9999-6,NIEHS:300000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,RESEARCH TRIANGLE PARK,UNITED STATES,NA,04,962071515,US,10029058,"SCIOME, LLC",NC,277093169,NA,11060844 (contact),"SHAH, RUCHIR  (contact)",NA,2022-09-24,2024-03-23,Bioinformatics;Biometry;Contractor;Data;Databases;Development;epigenomics;Experimental Designs;Genomics;Image;Informatics;Methods;National Institute of Environmental Health Sciences;Quantitative Structure-Activity Relationship;Resources;Review Literature;Support Contracts;text searching;tool;Toxicogenomics;transcriptomics;Update,BIOINFORMATICS SUPPORT FOR DNTP & DIR,0,NA,NA,NA,NA,NA,NA,NA,300000,NA
11218825,N01,OD,NA,N,NA,NA,NA,NA,7387913,NA,NA,7387913-0-0-1,OD:5000000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,(contact),NA,NA,NA,Amendment;Animal Experiments;Authorization documentation;clinical translation;data submission;Development;Education;Engineering;experimental study;Future;Human;neuroregulation;novel;Peripheral;Phase;Prize;Rewards;Science;Scientist;Technology;United States National Institutes of Health,OD SPARC NEUROMOD CHALLENGE PRIZE PHASE 3 OBLIG,0,NA,NA,NA,NA,NA,NA,NA,5000000,NA
11218941,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00404,NA,NA,75N91024P00404-0-0-1,NCI:86402\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,HARTFORD,UNITED STATES,NA,01,807853791,US,1854401,CONNECTICUT STATE DEPT OF PUBLIC HEALTH,CT,061061367,NA,10656363 (contact),"GONSALVES, MARYLOU  (contact)",NA,2024-05-01,2025-04-30,20 year old;Adjuvant Therapy;Adopted;Affect;Age;American Cancer Society;Area;Beds;Biological Markers;cancer care;cancer diagnosis;Cancer Patient;cancer recurrence;cancer therapy;Characteristics;chemotherapy;clinical practice;Communities;comorbidity;Congresses;Consensus;COVID-19 pandemic;COVID-19 pandemic effects;Data;Diagnosis;Diagnostic tests;Division of Cancer Control and Population Sciences;Documentation;Educational process of instructing;Ethnic Origin;Geographic Locations;Guidelines;Healthcare Systems;hormone therapy;Hospitals;Immunotherapy;Incidence;Individual;Inpatients;Insurance Coverage;Knowledge;Laws;Malignant neoplasm of ovary;Malignant neoplasm of prostate;Malignant Neoplasms;Medical;Medical Records;National Cancer Institute;Neoplasm Metastasis;Newly Diagnosed;Operative Surgical Procedures;Outpatients;Palliative Care;pandemic potential;Patient Care;Patients;Pattern;Patterns of Care;Physicians;Physicians&apos; Offices;Race;Radiation therapy;Recommendation;Records;Reporting;Screening for cancer;sex;Systemic Therapy;targeted treatment;Testing;Time;treatment pattern;United States;Update;working group,NCI PATTERNS OF CARE STUDY- DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER),0,NA,NA,NA,NA,NA,NA,NA,86402,NA
11218976,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00413,NA,NA,75N91024P00413-0-0-1,NCI:99442\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,NEW ORLEANS,UNITED STATES,NA,02,782627814,US,577902,LSU HEALTH SCIENCES CENTER,LA,701127021,NA,79747543 (contact),"MANISCALCO, LAUREN  (contact)",NA,2024-05-01,2025-04-30,20 year old;Adjuvant Therapy;Adopted;Affect;Age;American Cancer Society;Area;Beds;Biological Markers;cancer care;cancer diagnosis;Cancer Patient;cancer recurrence;cancer therapy;Characteristics;chemotherapy;clinical practice;Communities;comorbidity;Congresses;Consensus;COVID-19 pandemic;COVID-19 pandemic effects;Data;Diagnosis;Diagnostic tests;Division of Cancer Control and Population Sciences;Documentation;Educational process of instructing;Ethnic Origin;Geographic Locations;Guidelines;Healthcare Systems;hormone therapy;Hospitals;Immunotherapy;Incidence;Individual;Inpatients;Insurance Coverage;Knowledge;Laws;Malignant neoplasm of ovary;Malignant neoplasm of prostate;Malignant Neoplasms;Medical;Medical Records;National Cancer Institute;Neoplasm Metastasis;Newly Diagnosed;Operative Surgical Procedures;Outpatients;Palliative Care;pandemic potential;Patient Care;Patients;Pattern;Patterns of Care;Physicians;Physicians&apos; Offices;Race;Radiation therapy;Recommendation;Records;Reporting;Screening for cancer;sex;Systemic Therapy;targeted treatment;Testing;Time;treatment pattern;United States;Update;working group,NCI PATTERNS OF CARE STUDY FY24 - DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER),0,NA,NA,NA,NA,NA,NA,NA,99442,NA
11218993,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00396,NA,NA,75N91024P00396-0-0-1,NCI:72901\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,SALT LAKE CITY,UNITED STATES,NA,01,009095365,US,514002,UNIVERSITY OF UTAH,UT,841129049,NA,9733280 (contact),"DOHERTY, JENNIFER A. (contact)",NA,2024-05-01,2025-04-30,20 year old;Adjuvant Therapy;Adopted;Affect;Age;American Cancer Society;Area;Beds;Biological Markers;cancer care;cancer diagnosis;Cancer Patient;cancer recurrence;cancer therapy;Characteristics;chemotherapy;clinical practice;Communities;comorbidity;Congresses;Consensus;COVID-19 pandemic;COVID-19 pandemic effects;Data;Diagnosis;Diagnostic tests;Division of Cancer Control and Population Sciences;Documentation;Educational process of instructing;Ethnic Origin;Geographic Locations;Guidelines;Healthcare Systems;hormone therapy;Hospitals;Immunotherapy;Incidence;Individual;Inpatients;Insurance Coverage;Knowledge;Laws;Malignant neoplasm of ovary;Malignant neoplasm of prostate;Malignant Neoplasms;Medical;Medical Records;National Cancer Institute;Neoplasm Metastasis;Newly Diagnosed;Operative Surgical Procedures;Outpatients;Palliative Care;pandemic potential;Patient Care;Patients;Pattern;Patterns of Care;Physicians;Physicians&apos; Offices;Race;Radiation therapy;Recommendation;Records;Reporting;Screening for cancer;sex;Systemic Therapy;targeted treatment;Testing;Time;treatment pattern;United States;Update;working group,NCI PATTERNS OF CARE STUDY FOR DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER),0,NA,NA,NA,NA,NA,NA,NA,72901,NA
11218998,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00395,NA,NA,75N91024P00395-0-0-1,NCI:91532\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,IOWA CITY,UNITED STATES,NA,01,062761671,US,3972901,UNIVERSITY OF IOWA,IA,522421320,NA,79743251 (contact),"WEST, MICHELE  (contact)",NA,2024-05-01,2025-04-30,20 year old;Adjuvant Therapy;Adopted;Affect;Age;American Cancer Society;Area;Beds;Biological Markers;cancer care;cancer diagnosis;Cancer Patient;cancer recurrence;cancer therapy;Characteristics;chemotherapy;clinical practice;Communities;comorbidity;Congresses;Consensus;COVID-19 pandemic;COVID-19 pandemic effects;Data;Diagnosis;Diagnostic tests;Division of Cancer Control and Population Sciences;Documentation;Educational process of instructing;Ethnic Origin;Geographic Locations;Guidelines;Healthcare Systems;hormone therapy;Hospitals;Immunotherapy;Incidence;Individual;Inpatients;Insurance Coverage;Knowledge;Laws;Malignant neoplasm of ovary;Malignant neoplasm of prostate;Malignant Neoplasms;Medical;Medical Records;National Cancer Institute;Neoplasm Metastasis;Newly Diagnosed;Operative Surgical Procedures;Outpatients;Palliative Care;pandemic potential;Patient Care;Patients;Pattern;Patterns of Care;Physicians;Physicians&apos; Offices;Race;Radiation therapy;Recommendation;Records;Reporting;Screening for cancer;sex;Systemic Therapy;targeted treatment;Testing;Time;treatment pattern;United States;Update;working group,NCI PATTERNS OF CARE STUDY - DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER),0,NA,NA,NA,NA,NA,NA,NA,91532,NA
11219004,N01,HD,NA,N,NA,NA,NA,NA,75N94021D00004,NA,NA,75N94021D00004-P00004-759402100001-3,NIAAA:39615\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,PROVIDENCE,UNITED STATES,NA,01,001785542,US,1003201,BROWN UNIVERSITY,RI,029034202,NA,79671296 (contact),"MIRANDA, ROBERT  (contact)",NA,2021-03-15,2025-03-14,Advisory Services;Area;Award;Clinical;Clinical Research;Clinical Trials;Consultations;Contractor;Data;Data Security;meetings;operation;Performance;Preparation;Protocols documentation;Reporting;Services;Site,CORE FUNCTION ACTIVITIES TASK ORDER FOR ADVISORY SERVICES AND ADMINISTRATIVE REPORTING,0,NA,NA,NA,NA,NA,NA,NA,39615,NA
11219005,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00397,NA,NA,75N91024P00397-0-0-1,NCI:244943\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,OAKLAND,UNITED STATES,NA,12,128663390,US,1618201,PUBLIC HEALTH INSTITUTE,CA,946074046,NA,79743257 (contact),"SHRESTHA, ANSHU  (contact)",NA,2024-05-01,2025-04-30,20 year old;Adjuvant Therapy;Adopted;Affect;Age;American Cancer Society;Area;Beds;Biological Markers;cancer care;cancer diagnosis;Cancer Patient;cancer recurrence;cancer therapy;Characteristics;chemotherapy;clinical practice;Communities;comorbidity;Congresses;Consensus;COVID-19 pandemic;COVID-19 pandemic effects;Data;Diagnosis;Diagnostic tests;Division of Cancer Control and Population Sciences;Documentation;Educational process of instructing;Ethnic Origin;Geographic Locations;Guidelines;Healthcare Systems;hormone therapy;Hospitals;Immunotherapy;Incidence;Individual;Inpatients;Insurance Coverage;Knowledge;Laws;Malignant neoplasm of ovary;Malignant neoplasm of prostate;Malignant Neoplasms;Medical;Medical Records;National Cancer Institute;Neoplasm Metastasis;Newly Diagnosed;Operative Surgical Procedures;Outpatients;Palliative Care;pandemic potential;Patient Care;Patients;Pattern;Patterns of Care;Physicians;Physicians&apos; Offices;Race;Radiation therapy;Recommendation;Records;Reporting;Screening for cancer;sex;Systemic Therapy;targeted treatment;Testing;Time;treatment pattern;United States;Update;working group,NCI PATTERNS OF CARE STUDY-DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER),0,NA,NA,NA,NA,NA,NA,NA,244943,NA
11219017,K23,HD,7,N,2025-01-22,2024-10-18,2025-07-31,865,K23HD115269,SCHOOLS OF MEDICINE,PA-24-254,7K23HD115269-02,NICHD:155589\,OTHER RESEARCH-RELATED,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,BIRMINGHAM,UNITED STATES,OBSTETRICS & GYNECOLOGY,07,063690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,"PROJECT NARRATIVE Latinas suffer more perioperative complications that their non-Hispanic peers when undergoing urogynecologic surgery, in part, because of lower surgical preparedness. Prior studies to increase surgical preparedness have been conducted mostly on White women, excluded non-English speakers, and not cost-effective nor practical. The proposed research will use human centered design and dissemination and implementation methods to center stakeholder input to develop a usable and sustainable intervention that considers the cultural and societal needs of Latina patients and their clinical environments, an approach not used thus far in the development and testing of other surgical preparedness interventions.",78585438 (contact),"HALDER, GABRIELA E. (contact)","AHN, HELENA HYESOOK",2024-10-18,2028-07-31,NA,A Telehealth Intervention to Increase Patient Preparedness for Surgery in Latinas,115269,CHHD,"Reproduction, Andrology, and Gynecology Study Section[CHHD-R]",NA,NA,2,144064,11525,155589,NA
11219032,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00410,NA,NA,75N91024P00410-0-0-1,NCI:104718\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,SEATTLE,UNITED STATES,NA,07,806433145,US,10068583,FRED HUTCHINSON CANCER CENTER,WA,981094433,NA,1859337 (contact),"SCHWARTZ, STEPHEN M (contact)",NA,2024-05-01,2025-04-30,20 year old;Adjuvant Therapy;Adopted;Affect;Age;American Cancer Society;Area;Beds;Biological Markers;cancer care;cancer diagnosis;Cancer Patient;cancer recurrence;cancer therapy;Characteristics;chemotherapy;clinical practice;Communities;comorbidity;Congresses;Consensus;COVID-19 pandemic;COVID-19 pandemic effects;Data;Diagnosis;Diagnostic tests;Division of Cancer Control and Population Sciences;Documentation;Educational process of instructing;Ethnic Origin;Geographic Locations;Guidelines;Healthcare Systems;hormone therapy;Hospitals;Immunotherapy;Incidence;Individual;Inpatients;Insurance Coverage;Knowledge;Laws;Malignant neoplasm of ovary;Malignant neoplasm of prostate;Malignant Neoplasms;Medical;Medical Records;National Cancer Institute;Neoplasm Metastasis;Newly Diagnosed;Operative Surgical Procedures;Outpatients;Palliative Care;pandemic potential;Patient Care;Patients;Pattern;Patterns of Care;Physicians;Physicians&apos; Offices;Race;Radiation therapy;Recommendation;Records;Reporting;Screening for cancer;sex;Systemic Therapy;targeted treatment;Testing;Time;treatment pattern;United States;Update;working group,NCI PATTERNS OF CARE STUDY - DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER),0,NA,NA,NA,NA,NA,NA,NA,104718,NA
11219054,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00411,NA,NA,75N91024P00411-0-0-1,NCI:193220\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,LEXINGTON,UNITED STATES,NA,06,939017877,US,2793601,UNIVERSITY OF KENTUCKY,KY,405260001,NA,79747540 (contact),"DURBIN, ERIC  (contact)",NA,2024-05-01,2025-04-30,20 year old;Adjuvant Therapy;Adopted;Affect;Age;American Cancer Society;Area;Beds;Biological Markers;cancer care;cancer diagnosis;Cancer Patient;cancer recurrence;cancer therapy;Characteristics;chemotherapy;clinical practice;Communities;comorbidity;Congresses;Consensus;COVID-19 pandemic;COVID-19 pandemic effects;Data;Diagnosis;Diagnostic tests;Division of Cancer Control and Population Sciences;Documentation;Educational process of instructing;Ethnic Origin;Geographic Locations;Guidelines;Healthcare Systems;hormone therapy;Hospitals;Immunotherapy;Incidence;Individual;Inpatients;Insurance Coverage;Knowledge;Laws;Malignant neoplasm of ovary;Malignant neoplasm of prostate;Malignant Neoplasms;Medical;Medical Records;National Cancer Institute;Neoplasm Metastasis;Newly Diagnosed;Operative Surgical Procedures;Outpatients;Palliative Care;pandemic potential;Patient Care;Patients;Pattern;Patterns of Care;Physicians;Physicians&apos; Offices;Race;Radiation therapy;Recommendation;Records;Reporting;Screening for cancer;sex;Systemic Therapy;targeted treatment;Testing;Time;treatment pattern;United States;Update;working group,NCI PATTERNS OF CARE STUDY FY24 - DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER),0,NA,NA,NA,NA,NA,NA,NA,193220,NA
11219058,N01,CA,NA,N,NA,NA,NA,NA,75N91024P00368,NA,NA,75N91024P00368-0-0-1,NCI:63204\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,ALBUQUERQUE,UNITED STATES,NA,01,829868723,US,10021612,UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR,NM,871310001,NA,79747534 (contact),"WIGGINS, CHARLES  (contact)",NA,2024-05-01,2025-04-30,20 year old;Adjuvant Therapy;Adopted;Affect;Age;American Cancer Society;Area;Beds;Biological Markers;cancer care;cancer diagnosis;Cancer Patient;cancer recurrence;cancer therapy;Characteristics;chemotherapy;clinical practice;Communities;comorbidity;Congresses;Consensus;COVID-19 pandemic;COVID-19 pandemic effects;Data;Diagnosis;Diagnostic tests;Division of Cancer Control and Population Sciences;Documentation;Educational process of instructing;Ethnic Origin;Geographic Locations;Guidelines;Healthcare Systems;hormone therapy;Hospitals;Immunotherapy;Incidence;Individual;Inpatients;Insurance Coverage;Knowledge;Laws;Malignant neoplasm of ovary;Malignant neoplasm of prostate;Malignant Neoplasms;Medical;Medical Records;National Cancer Institute;Neoplasm Metastasis;Newly Diagnosed;Operative Surgical Procedures;Outpatients;Palliative Care;pandemic potential;Patient Care;Patients;Pattern;Patterns of Care;Physicians;Physicians&apos; Offices;Race;Radiation therapy;Recommendation;Records;Reporting;Screening for cancer;sex;Systemic Therapy;targeted treatment;Testing;Time;treatment pattern;United States;Update;working group,NCI PATTERNS OF CARE (POC) STUDY: DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER),0,NA,NA,NA,NA,NA,NA,NA,63204,NA
11219071,N02,CA,NA,N,NA,NA,NA,NA,75N91023D00010,NA,NA,75N91023D00010-0-759102400001-1,NCI:1866116\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,KANSAS CITY,UNITED STATES,NA,05,007173453,US,5282001,MIDWEST RESEARCH INSTITUTE,MO,641102241,NA,79990367 (contact),"WHITE, JON  (contact)",NA,2024-09-18,2026-09-17,Atopobium vaginae;Bacterial Vaginosis;Biological Response Modifier Therapy;Cervical dysplasia;Clinical;Clinical Trials;dysbiosis;Lactobacillus;Malignant neoplasm of cervix uteri;microbiota;Pharmaceutical Preparations;Placebos;Production;Risk;Vagina;vaginal microbiota;Woman,"THE SCOPE OF THIS TASK ORDER IS (1). PRODUCTION OF A DRUG SUBSTANCE, (2) CONVERSION OF DRUG SUBSTANCE TO DRUG PRODUCT, (3) FILLING DRUG PRODUCT INTO APPLICATORS TO BE USED IN THE CLINICAL TRIALS, AND",0,NA,NA,NA,NA,NA,NA,NA,1866116,NA
11219072,N02,CA,NA,N,NA,NA,NA,NA,75N91023D00010,NA,NA,75N91023D00010-0-759102400002-1,NCI:1524929\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,KANSAS CITY,UNITED STATES,NA,05,007173453,US,5282001,MIDWEST RESEARCH INSTITUTE,MO,641102241,NA,80000483 (contact),"GINTHER, RACHEL  (contact)",NA,2024-09-25,2027-09-24,Antigens;Buffers;cell bank;Cells;Cyclic GMP;Development;DNA Vaccines;drug production;Elements;Engineering;Environment;Fermentation;follow-up;Guidelines;Human;manufacture;next generation sequencing;Pharmaceutical Preparations;plasmid DNA;Plasmids;Process;research and development;Running;screening;System;Vaccine Production;Work,MANUFACTURE OF PLASMID DNA DRUG SUBSTANCE AND DRUG PRODUCT,0,NA,NA,NA,NA,NA,NA,NA,1524929,NA
11219077,N02,CA,NA,N,NA,NA,NA,NA,75N91022D00010,NA,NA,75N91022D00010-0-759102400002-1,NCI:59313\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,WASHINGTON,UNITED STATES,NA,NA,NA,US,NA,NA,DC,200371542,NA,79992042 (contact),"KLEIN, AMANDA  (contact)",NA,2024-09-17,2026-03-16,Cancer health equity;design;Educational workshop;meetings;Persons;Series;service coordination;virtual,COORDINATION FOR THE CANCER HEALTH EQUITY DESIGN LAB WORKSHOP,0,NA,NA,NA,NA,NA,NA,NA,59313,NA
11219118,N01,CA,NA,N,NA,NA,NA,NA,261201800017I,NA,NA,261201800017I-0-759102400002-1,NCI:49168\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,MADISON,UNITED STATES,NA,02,036448835,US,9332801,WISCONSIN DEPARTMENT OF HEALTH SERVICES,WI,537033445,NA,8842448 (contact),"WERNER, MARK ALLAN (contact)",NA,2024-09-15,2028-04-30,Area;Data;data exchange;Data Linkages;data management;Malignant Childhood Neoplasm;Malignant Neoplasms;neoplasm registry;programs;Registries;Research;Research Activity;Research Support;SEER Program;surveillance data;trend;virtual;young adult,SEER RESEARCH SUPPORT REGISTRIES PROGRAM LINKAGES AND DATA MANAGEMENT SUPPORT,0,NA,NA,NA,NA,NA,NA,NA,49168,NA
11219122,N01,CA,NA,N,NA,NA,NA,NA,75N91021D00004,NA,NA,75N91021D00004-0-759102400002-1,NCI:49926\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,DENVER,UNITED STATES,NA,01,878208826,US,1719501,COLORADO STATE DEPT/PUB HLTH & ENVIRONMT,CO,802461523,NA,79951137 (contact),"AREND, JOHN  (contact)",NA,2024-09-15,2025-09-14,Area;Data;data exchange;Data Linkages;data management;Malignant Childhood Neoplasm;Malignant Neoplasms;neoplasm registry;programs;Registries;Research;Research Activity;Research Support;SEER Program;surveillance data;trend;virtual;young adult,SEER RESEARCH SUPPORT REGISTRIES PROGRAM LINKAGES AND DATA MANAGEMENT SUPPORT,0,NA,NA,NA,NA,NA,NA,NA,49926,NA
11219233,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400030-1,NA,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-08-31,2027-12-31,Area;Attention;Computers;Contractor;Data;Data Analyses;Data Collection;data exploration;Development;Disease;Goals;improved;Intuition;Malignant Neoplasms;Preparation;programs;Readability;Source;Textiles;tool;Work,ARPA-H BIOMEDICAL DATA FABRIC TOOLBOX PROGRAM,0,NA,NA,NA,NA,NA,NA,NA,11920234,NA
11219234,N01,CA,NA,N,NA,NA,NA,NA,75N91021D00010,NA,NA,75N91021D00010-0-759102400002-1,NCI:53988\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,NASHVILLE,UNITED STATES,NA,07,172636268,US,8246001,TENNESSEE STATE DEPARTMENT OF HEALTH,TN,372433400,NA,11998330 (contact),"WHITESIDE, MARTIN  (contact)",NA,2024-09-15,2025-09-14,Area;Data;data exchange;Data Linkages;data management;Malignant Childhood Neoplasm;Malignant Neoplasms;neoplasm registry;programs;Registries;Research;Research Activity;Research Support;SEER Program;surveillance data;trend;virtual;young adult,SEER RESEARCH SUPPORT REGISTRIES PROGRAM AND LINKAGES AND DATA MANAGEMENT SUPPORT,0,NA,NA,NA,NA,NA,NA,NA,53988,NA
11219235,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400027-1,NCI:16947915\NIAID:5963\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-08-31,2025-08-30,anti-cancer research;Funding;Industry;Laboratories;National Cancer Institute;National Institute of Allergy and Infectious Disease;research and development,FY24/FY25 FFRDC LEASES OPERATIONAL TASK ORDER,0,NA,NA,NA,NA,NA,NA,NA,16953878,NA
11219236,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-P00010-759101900140-1,NCATS:1363\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2019-09-16,2027-09-02,Biological Assay;Biological Products;cell bank;Chemistry;Clinical Research;Development;Engineering;Evaluation;GMP lots;Human;Logistics;manufacture;Pharmaceutical Preparations;Process;Qualifying;Records;Spinal cord injury;System;Vial device;Work,NEURESTA DRUG SUBSTANCE MANUFACTURING,0,NA,NA,NA,NA,NA,NA,NA,1363,NA
11219238,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400029-1,NCI:10719410\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-01,2029-08-31,Affinity;Antibodies;Antibody Formation;base;Biological Assay;cancer type;Clinical Trials;Communities;Complement;cost;Data;Deposition;Development;Ensure;Generations;Guidelines;Hybridomas;Individual;Length;Measurement;metabolomics;Methodology;Methods;Modification;Monoclonal Antibodies;Mus;Oryctolagus cuniculus;Peptides;pre-clinical research;Production;Proteins;Proteomics;Reagent;Reproducibility;Research;Sampling;Specific qualifier value;Standardization;Ubiquitin;United States National Institutes of Health;Work,PROTEOMIC AND ANTIBODY PRODUCTION AND CHARACTERIZATION,0,NA,NA,NA,NA,NA,NA,NA,10719410,NA
11219239,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400018-1,NCI:836990\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-06-06,2026-01-28,Age;Area;Chills;energy efficiency;System;Water,FY24 FACILITIES TO B - 126598 B560 DRAIN DOWN TANK REPLACEMENT,0,NA,NA,NA,NA,NA,NA,NA,836990,NA
11219241,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400026-1,NCI:461187\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-07-11,2026-02-25,Equipment;Immunocompromised Host;Work,WORK ORDER 126643 B539 EXPAND IC SUITE,0,NA,NA,NA,NA,NA,NA,NA,461187,NA
11219244,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400022-1,NCI:1117108\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-07-08,2026-02-27,CCR;Cells;Development;Laboratories;Research;Research Personnel;Signal Transduction;symposium;Update,FY24 FACILITIES TO E - W2F2 CCR AQUATICS FACILITY EXPANSION AND OFFICES ROOMS,0,NA,NA,NA,NA,NA,NA,NA,1117108,NA
11219245,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400025-1,NCI:1180316\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-07-08,2026-04-10,Biology;Chemicals;Laboratories,FY24 FACILITIES TASK ORDER G B376 RENOVATE ROOMS 204-207,0,NA,NA,NA,NA,NA,NA,NA,1180316,NA
11219248,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400023-1,NCI:708630\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-07-08,2026-03-06,Animals;Area;Chemicals;hazard;programs;Work,FACILITIES TASK ORDER F - BUILDING 539 ROOMS 49-51 RENOVATIONS.,0,NA,NA,NA,NA,NA,NA,NA,708630,NA
11219250,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400028-1,NCI:3088433\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-08-20,2026-08-06,Air;Floor,TO-I BUILDING 1021 2ND FLOOR AHU REPLACEMENT,0,NA,NA,NA,NA,NA,NA,NA,3088433,NA
11219255,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400035-1,NIAID:7499979\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-25,2027-09-24,Biological Assay;Clinical;clinical development;Clinical Trials;complex data;Data;data centers;Data Commons;data harmonization;data infrastructure;data ingestion;data integrity;data modeling;Data Set;data sharing;data tools;Development;diverse data;Ensure;Immunologic Monitoring;Immunologics;Immunooncology;improved;Maintenance;Malignant Neoplasms;Maps;operation;outreach;Preparation;Publishing;Research Personnel;Specimen;Standardization;Validation,CLINICAL AND TRANSLATIONAL DATA COMMONS (CTDC) AND IMMUNE ONCOLOGY DATA HARMONIZATION/MAPPING (IODH/M),0,NA,NA,NA,NA,NA,NA,NA,7499979,NA
11219260,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400031-1,NCI:390524\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-26,2026-05-11,Air;Cyclic GMP;experience;Future;improved;Nature;pressure;System;Wing,FY24 FACILITIES TO J  ATRF BDP FACILITY IMPROVEMENTS,0,NA,NA,NA,NA,NA,NA,NA,390524,NA
11219268,N01,CA,NA,N,NA,NA,NA,NA,261201800004I,NA,NA,261201800004I-0-759102400001-1,NCI:441908\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,SEATTLE,UNITED STATES,NA,07,806433145,US,10068583,FRED HUTCHINSON CANCER CENTER,WA,981094433,NA,79983189 (contact),"SCHWARTZ, STEPHEN  (contact)",NA,2024-09-17,2025-08-16,abstracting;Area;Award;base;Cancer Hospital;cancer registrars;Code;college;Contracts;Data Collection;Educational Curriculum;Exercise;Forms Controls;Guidelines;Hospital Registrar;improved;Logic;Maintenance;Mentors;Mentorship;National Cancer Program;neoplasm registry;programs;Registries;Reporting;Resources;response;SEER Program;Services;Students;Support Contracts;teacher;Testing;Training;Update,SEER*EDUCATE BASE AWARD,0,NA,NA,NA,NA,NA,NA,NA,441908,NA
11219284,N02,CA,NA,N,NA,NA,NA,NA,75N91024P00431,NA,NA,75N91024P00431-0-0-1,NCI:179000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,WASHINGTON,UNITED STATES,NA,NA,126551290,US,NA,WOODS & POOLE ECONOMICS I,DC,200092808,"These specifically-developed estimates will be used to produce cancer statistics and to monitor cancer trends over time by county and census tract characteristics such as age, gender, race, as well as by other population socioeconomic characteristics.  In addition to meeting crucial NCI data needs, these estimates will enable NCI scientists to better assess sociodemographic patterns and disparities in cancer rates.",79803723 (contact),"HOLDRICH, MARTIN  (contact)",NA,2024-05-23,2025-05-22,Age;age group;Age Years;Black race;Calendar;cancer health disparity;cancer statistics;Cancer Surveillance Research Program;Censuses;Characteristics;Contracts;County;Data;Gender;Geography;Hispanic;Malignant Neoplasms;meetings;Monitor;Pattern;Population;Race;Reporting;Scientist;Signal Recognition Particle;sociodemographics;socioeconomics;Time trend,ANNUAL POPULATION ESTIMATES FOR COUNTIES AND CENSUS TRACTS BASED ON THE COUNTS PRODUCED BY THE US CENSUS BUREAU.  THESE SPECIFI,0,NA,NA,NA,NA,NA,NA,NA,179000,NA
11219359,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-P00035-759102000003-62,NCI:215338\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2020-08-31,2024-08-30,Bacterial Artificial Chromosomes;Communities;data hub;data modeling;Development;Division of Cancer Control and Population Sciences;Future;Leadership;Maintenance;Population Sciences;Security;System;Update,DCCPS - BACS: Population Sciences,0,NA,NA,NA,NA,NA,NA,NA,215338,NA
11219378,N43,AI,NA,N,NA,NA,NA,NA,75N93024C00039,NA,NA,75N93024C00039-0-9999-1,NIAID:592751\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,SAN DIEGO,UNITED STATES,NA,51,186489899,US,10006668,"AVANTGEN, INC.",CA,921214329,NA,79951140 (contact),"FAN, XIAOMIN  (contact)",NA,2024-09-01,2026-08-31,Affinity;Antibodies;Antigen Targeting;Antigens;B-Lymphocytes;Biological Assay;Biological Markers;Cells;Chiroptera;cytokine;Cytokine Receptors;design;Development;Enzyme-Linked Immunosorbent Assay;Flow Cytometry;gene synthesis;Immune response;Immunize;Immunologic Markers;Libraries;Monoclonal Antibodies;National Institute of Allergy and Infectious Disease;novel;Oryctolagus cuniculus;Phase;Production;protein purification;Reagent;receptor;Research Personnel;Research Priority;Sampling;Specificity;Splenocyte;Tertiary Protein Structure;Testing;Virus Diseases;Yeasts,DEVELOPMENT OF RABBITMONOCLONAL ANTIBODIES FOR INDIANFLYING FOX (BAT) BIOMARKERS,0,NA,NA,NA,NA,NA,NA,NA,592751,NA
11219426,Y01,OD,NA,N,NA,NA,NA,NA,AOD24023001,NA,NA,AOD24023001-1-0-1,OD:4951\,INTERAGENCY AGREEMENTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,(contact),NA,NA,NA,Acquired Immunodeficiency Syndrome;Agreement;Area;authority;Categories;Childhood;Clinic;Collaborations;Communicable Diseases;Consent Forms;Data Collection;Data Management Resources;design;Development;Extramural Activities;feeding;Funding;Funding Opportunities;HIV;Infant;Institutional Review Boards;instrument;International;maternal outcome;meetings;Mission;Mothers;National Institute of Child Health and Human Development;NIH Office of AIDS Research;Outcome;Outcome Study;Parents;Peer Review;Persons;preference;prevent;Procedures;programs;Protocols documentation;Publishing;Research;Research Personnel;research study;Research Support;Site Visit;U-Series Cooperative Agreements;United States;United States National Institutes of Health;Writing,"UNDERSTANDING INFANT FEEDING PREFERENCES, PRACTICES, AND OUTCOMES FOR MOTHERS AND OTHER PARENTS WITH HIV IN THE UNITED STATES CDC RFA 24 040 AOD240230014951",240230,NA,NA,NA,NA,NA,NA,NA,4951,NA
11219428,N01,DA,NA,N,NA,NA,NA,NA,75N95021D00023,NA,NA,75N95021D00023-0-759502400001-1,NHLBI:575000\NIDA:4064112\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,MC LEAN,UNITED STATES,NA,11,006928857,US,682902,BOOZ ALLEN HAMILTON,VA,221023830,NA,79983229 (contact),"KELLER, MICHAEL  (contact)",NA,2024-09-17,2025-09-16,Award;biobank;Development;Helping to End Addiction Long-term;improved;National Institute of Drug Abuse;Opiate Addiction;Opioid;opioid epidemic;opioid misuse;Public Health;Research;Speed;Support Contracts;United States National Institutes of Health;Work,"FY24 AWARD. NIDA DEVELOPMENTAL STUDIES BIOREPOSITORY AND ANALYSIS CENTER. SEPTEMBER 17, 2024 - SEPTEMBER 16, 2025. N01DA-21-5588. TASK ORDER 75N95024F00001 (TO4).",0,NA,NA,NA,NA,NA,NA,NA,4639112,NA
11219434,N01,DA,NA,N,NA,NA,NA,NA,75N95024C00042,NA,NA,75N95024C00042-0-9999-1,NINDS:1520971\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,CAMDEN,UNITED STATES,NA,01,069894707,US,7603801,CORIELL INSTITUTE FOR MEDICAL RESEARCH,NJ,081031505,NA,9163359 (contact),"SCHEINFELDT, LAURA  (contact)",NA,2024-09-30,2025-09-29,Biological;Contracts;Data;genetic resource;Genotype;Human Genetics;human subject;National Institute of Neurological Disorders and Stroke;Phenotype;Process;Sampling,CORIELL - NINDS HUMAN GENETICS RESOURCE CENTER,0,NA,NA,NA,NA,NA,NA,NA,1520971,NA
11219439,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00658,NA,NA,75N95024P00658-0-0-1,NINDS:5366\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,CLIFTON,UNITED STATES,NA,NA,178149998,US,NA,NA,VA,201242550,NA,80002016 (contact),"MISHRA, SOMNATH  (contact)",NA,2024-09-26,2025-09-25,Biological Products;National Institute of Neurological Disorders and Stroke;Process;product development;Services,BIOLOGICS SME CONSULTING SERVICES,0,NA,NA,NA,NA,NA,NA,NA,5366,NA
11219441,N01,DA,NA,N,NA,NA,NA,NA,75N95020D00012,NA,NA,75N95020D00012-P00001-759502300004-2,NIDA:256829\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,NA,79937725 (contact),"JELSTROM, EVE  (contact)",NA,2023-08-28,2025-08-27,Buprenorphine;Dose;Helping to End Addiction Long-term;improved;Opiate Addiction;Opioid;opioid epidemic;opioid misuse;Public Health;Research;Speed;Support Contracts;United States National Institutes of Health;Work,CCC TO 11 - CTN-0145: STANDARD VERSUS HIGH DOSE ED-INITIATED BUPRENORPHINE INDUCTION. POP: 8/28/23 - 8/27/27.,0,NA,NA,NA,NA,NA,NA,NA,256829,NA
11219442,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00659,NA,NA,75N95024P00659-0-0-1,NINDS:6500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ALEXANDRIA,UNITED STATES,NA,NA,033068821,US,NA,NA,VA,22314,NA,80002019 (contact),"GRACE, MICHAEL  (contact)",NA,2024-09-26,2025-09-25,Biological Products;National Institute of Neurological Disorders and Stroke;Process;product development;Services,BIOLOGICS SME CONSULTING SERVICES,0,NA,NA,NA,NA,NA,NA,NA,6500,NA
11219443,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00660,NA,NA,75N95024P00660-0-0-1,NINDS:7900\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,WALNUT CREEK,UNITED STATES,NA,NA,NA,US,NA,NA,CA,94597,NA,80002022 (contact),"BALL, OLIVER  (contact)",NA,2024-09-26,2025-09-25,Biological Products;National Institute of Neurological Disorders and Stroke;Process;product development;Services,BIOLOGICS SME CONSULTING SERVICES,0,NA,NA,NA,NA,NA,NA,NA,7900,NA
11219541,N01,ES,NA,N,NA,NA,NA,NA,273201700005C,NA,NA,273201700005C-P00022-9999-22,NIEHS:544131\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,COLUMBUS,UNITED STATES,NA,NA,926695685,US,NA,BATTELLE MEMORIAL INSTITU,OH,432012681,NA,80000480 (contact),"SPARROW, BARNEY  (contact)",NA,2017-09-26,2025-09-25,Age;Animals;Biological Assay;carcinogenesis;carcinogenicity;Carcinogens;Chronic Disease;Clonal Expansion;Databases;Development;driver mutation;Environmental Exposure;Environmental Hazards;Future;Genes;hazard;Histologic;Human;In Vitro;Malignant Neoplasms;molecular diagnostics;Mutation;neoplastic;normal aging;novel;novel strategies;Pathogenicity;Process;programs;Rodent;Rodent Model;Sampling;screening panel;Screening procedure;Technology;Testing;Time;Tissues;Transcript;transcriptomics,Development of a cancer driver mutation screening panel to predict carcinogenesis using error corrected duplex sequencing technology,0,NA,NA,NA,NA,NA,NA,NA,544131,NA
11219590,N01,HD,NA,N,NA,NA,NA,NA,275201700002C,NA,NA,275201700002C-P00026-9999-2,NICHD:169423\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,NA,9335506 (contact),"ANAND, RAVINDER  (contact)",NA,2024-05-29,2025-05-28,Age;Amoxicillin;Anxiety;Azithromycin;Bacterial Infections;Best Pharmaceuticals for Children Act;Blood;Breast Feeding;Breastfed infant;Buprenorphine;Bupropion;Child;Childhood;chronic pain;Clindamycin;Clinical Research;clinical research site;Contracts;Data;Data Coordinating Center;data sharing;Data Storage and Retrieval;design;Diabetes Mellitus;Dose;Drug Kinetics;Drug usage;duloxetine;Enrollment;follow-up;Fright;Human Milk;Hydrocodone;Hypertension;Infant;Labetalol;Lactation;Levetiracetam;Medical;medication safety;Mental Depression;Metformin;Mothers;Nifedipine;off-patent;Ondansetron;Oxycodone;Paroxetine;participant enrollment;Pharmaceutical Preparations;preclinical study;Regulation;Research Personnel;Role;Safety;safety assessment;Sampling;Sertraline;Statistical Data Interpretation;Symptoms;Time;Tranexamic Acid;Woman,DATA COORDINATING CENTER FOR THE BEST PHARMACEUTICALS FOR CHILDREN ACT(BPCA) - PTN CUDDLE,0,NA,NA,NA,NA,NA,NA,NA,169423,NA
11219718,N01,HL,NA,N,NA,NA,NA,NA,75N92022D00004,NA,NA,75N92022D00004-0-759202400001-1,NHLBI:666139\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,JACKSON,UNITED STATES,NA,03,928824473,US,5390304,UNIVERSITY OF MISSISSIPPI MED CTR,MS,392164500,NA,79558719 (contact),"MOSLEY, THOMAS  (contact)",NA,2023-11-15,2024-11-14,"Adult;African American;aged;Amyloid deposition;Ancillary Study;Area;arterial stiffness;Atherosclerosis;Atherosclerosis Risk in Communities;Atrial Fibrillation;Biochemical;Biological Assay;Biological Specimen Banks;Blood specimen;Blood Vessels;Brain;Candidate Disease Gene;Cardiovascular Diseases;Case/Control Studies;caucasian American;Clinical;clinical development;clinical examination;Cognition;cohort;Cohort Studies;Communities;Consent Forms;Contractor;Contracts;coronary artery calcification;Coronary heart disease;County;Cryopreservation;Data;Death Rate;Dementia;Diabetes Mellitus;DNA;EFRAC;Electrocardiogram;Environmental Risk Factor;Event;follow-up;Funding;Funding Agency;Genetic;Genome Scan;Geographic Locations;Grant;Heart failure;Hospitalization;Injury;Investigation;Lymphocyte;member;middle age;Monitor;Myocardial Infarction;Natural History;novel;Participant;Preparation;preservation;Procedures;Prospective, cohort study;Publications;quality assurance;Quality Control;Recommendation;recruit;Research Personnel;residence;Risk Factors;rural setting;Standardization;suburb;Technology;trend;United States National Institutes of Health;Ventricular Dysfunction;Visit;Vital Status;Washington;Work",THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK AREA B,0,NA,NA,NA,NA,NA,NA,NA,666139,NA
11219719,N01,HL,NA,N,NA,NA,NA,NA,75N92022D00002,NA,NA,75N92022D00002-0-759202400001-1,NHLBI:501993\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,BALTIMORE,UNITED STATES,NA,07,001910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212182680,NA,79558707 (contact),"SELVIN, ELIZABETH  (contact)",NA,2023-11-15,2024-11-14,"Adult;African American;aged;Amyloid deposition;Ancillary Study;Area;arterial stiffness;Atherosclerosis;Atherosclerosis Risk in Communities;Atrial Fibrillation;Biochemical;Biological Assay;Biological Specimen Banks;Blood specimen;Blood Vessels;Brain;Candidate Disease Gene;Cardiovascular Diseases;Case/Control Studies;caucasian American;Clinical;clinical development;clinical examination;Cognition;cohort;Cohort Studies;Communities;Consent Forms;Contractor;Contracts;coronary artery calcification;Coronary heart disease;County;Cryopreservation;Data;Death Rate;Dementia;Diabetes Mellitus;DNA;EFRAC;Electrocardiogram;Environmental Risk Factor;Event;follow-up;Funding;Funding Agency;Genetic;Genome Scan;Geographic Locations;Grant;Heart failure;Hospitalization;Injury;Investigation;Lymphocyte;member;middle age;Monitor;Myocardial Infarction;Natural History;novel;Participant;Preparation;preservation;Procedures;Prospective, cohort study;Publications;quality assurance;Quality Control;Recommendation;recruit;Research Personnel;residence;Risk Factors;rural setting;Standardization;suburb;Technology;trend;United States National Institutes of Health;Ventricular Dysfunction;Visit;Vital Status;Washington;Work",THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK AREA B,0,NA,NA,NA,NA,NA,NA,NA,501993,NA
11219720,N01,HL,NA,N,NA,NA,NA,NA,75N92022D00003,NA,NA,75N92022D00003-0-759202400001-1,NHLBI:604301\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,MINNEAPOLIS,UNITED STATES,NA,05,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,NA,79558713 (contact),"LUTSEY, PAMELA  (contact)",NA,2023-11-15,2024-11-14,"Adult;African American;aged;Amyloid deposition;Ancillary Study;Area;arterial stiffness;Atherosclerosis;Atherosclerosis Risk in Communities;Atrial Fibrillation;Biochemical;Biological Assay;Biological Specimen Banks;Blood specimen;Blood Vessels;Brain;Candidate Disease Gene;Cardiovascular Diseases;Case/Control Studies;caucasian American;Clinical;clinical development;clinical examination;Cognition;cohort;Cohort Studies;Communities;Consent Forms;Contractor;Contracts;coronary artery calcification;Coronary heart disease;County;Cryopreservation;Data;Death Rate;Dementia;Diabetes Mellitus;DNA;EFRAC;Electrocardiogram;Environmental Risk Factor;Event;follow-up;Funding;Funding Agency;Genetic;Genome Scan;Geographic Locations;Grant;Heart failure;Hospitalization;Injury;Investigation;Lymphocyte;member;middle age;Monitor;Myocardial Infarction;Natural History;novel;Participant;Preparation;preservation;Procedures;Prospective, cohort study;Publications;quality assurance;Quality Control;Recommendation;recruit;Research Personnel;residence;Risk Factors;rural setting;Standardization;suburb;Technology;trend;United States National Institutes of Health;Ventricular Dysfunction;Visit;Vital Status;Washington;Work",THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY FIELD CENTER - TASK AREA B,0,NA,NA,NA,NA,NA,NA,NA,604301,NA
11219721,N01,HL,NA,N,NA,NA,NA,NA,75N92022D00005,NA,NA,75N92022D00005-0-759202400001-1,NHLBI:655937\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,WINSTON-SALEM,UNITED STATES,NA,05,937727907,US,9021205,WAKE FOREST UNIVERSITY HEALTH SCIENCES,NC,271570001,NA,79558725 (contact),"WAGENKNECHT, LYNNE  (contact)",NA,2023-11-15,2024-11-14,"Adult;African American;aged;Amyloid deposition;Ancillary Study;Area;arterial stiffness;Atherosclerosis;Atherosclerosis Risk in Communities;Atrial Fibrillation;Biochemical;Biological Assay;Biological Specimen Banks;Blood specimen;Blood Vessels;Brain;Candidate Disease Gene;Cardiovascular Diseases;Case/Control Studies;caucasian American;Clinical;clinical development;clinical examination;Cognition;cohort;Cohort Studies;Communities;Consent Forms;Contractor;Contracts;coronary artery calcification;Coronary heart disease;County;Cryopreservation;Data;Death Rate;Dementia;Diabetes Mellitus;DNA;EFRAC;Electrocardiogram;Environmental Risk Factor;Event;follow-up;Funding;Funding Agency;Genetic;Genome Scan;Geographic Locations;Grant;Heart failure;Hospitalization;Injury;Investigation;Lymphocyte;member;middle age;Monitor;Myocardial Infarction;Natural History;novel;Participant;Preparation;preservation;Procedures;Prospective, cohort study;Publications;quality assurance;Quality Control;Recommendation;recruit;Research Personnel;residence;Risk Factors;rural setting;Standardization;suburb;Technology;trend;United States National Institutes of Health;Ventricular Dysfunction;Visit;Vital Status;Washington;Work",THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY FIELD CENTER - TASK AREA B,0,NA,NA,NA,NA,NA,NA,NA,655937,NA
11219722,N01,HL,NA,N,NA,NA,NA,NA,75N92022D00001,NA,NA,75N92022D00001-0-759202400001-1,NHLBI:1452224\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,CHAPEL HILL,UNITED STATES,NA,04,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275995023,NA,79558701 (contact),"COUPER, DAVID  (contact)",NA,2023-11-15,2024-11-14,"Adult;African American;aged;Amyloid deposition;Ancillary Study;Area;arterial stiffness;Atherosclerosis;Atherosclerosis Risk in Communities;Atrial Fibrillation;Biochemical;Biological Assay;Biological Specimen Banks;Blood specimen;Blood Vessels;Brain;Candidate Disease Gene;Cardiovascular Diseases;Case/Control Studies;caucasian American;Clinical;clinical development;clinical examination;Cognition;cohort;Cohort Studies;Communities;Consent Forms;Contractor;Contracts;coronary artery calcification;Coronary heart disease;County;Cryopreservation;Data;Death Rate;Dementia;Diabetes Mellitus;DNA;EFRAC;Electrocardiogram;Environmental Risk Factor;Event;follow-up;Funding;Funding Agency;Genetic;Genome Scan;Geographic Locations;Grant;Heart failure;Hospitalization;Injury;Investigation;Lymphocyte;member;middle age;Monitor;Myocardial Infarction;Natural History;novel;Participant;Preparation;preservation;Procedures;Prospective, cohort study;Publications;quality assurance;Quality Control;Recommendation;recruit;Research Personnel;residence;Risk Factors;rural setting;Standardization;suburb;Technology;trend;United States National Institutes of Health;Ventricular Dysfunction;Visit;Vital Status;Washington;Work",THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - COORDINATING CENTER - TASK AREA B,0,NA,NA,NA,NA,NA,NA,NA,1452224,NA
11219739,N43,CA,NA,N,NA,NA,NA,NA,75N91024C00076,NA,NA,75N91024C00076-0-9999-1,NCI:399925\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,CHELMSFORD,UNITED STATES,NA,03,796010411,US,4327301,"TRITON SYSTEMS, INC.",MA,018244053,NA,79981707 (contact),"TAKEDA, TAKAKO  (contact)",NA,2024-09-16,2025-09-15,Age;Algorithms;Biological Assay;Biopsy;Blood specimen;Blood Tests;Classification;classification algorithm;cost;detection test;Development;Devices;Diagnostic Reagent Kits;Family;Fingers;Formulation;Geography;high risk population;Home;home test;Machine Learning;Malignant neoplasm of prostate;Malignant Neoplasms;Medical;Modeling;Monitor;mortality;Paper;Patients;Phase;point of care;point-of-care detection;Price;prostate cancer risk;Prostate specific antigen measurement;Prostate-Specific Antigen;prototype;PSA screening;Race;Reagent;Recording of previous events;Risk;Risk Factors;Screening for Prostate Cancer;Techniques;Technology;Triton,"TOPIC 455: A LOW COST, POINT-OF-CARE DETECTION DEVICE FOR PROSTATE SPECIFIC ANTIGEN USING A PAPER-BASED FLOW ASSAY",0,NA,NA,NA,NA,NA,NA,NA,399925,NA
11219740,N43,CA,NA,N,NA,NA,NA,NA,75N91024C00063,NA,NA,75N91024C00063-0-9999-1,NCI:382537\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,TORRANCE,UNITED STATES,NA,43,033449757,US,3841801,"INTELLIGENT OPTICAL SYSTEMS, INC.",CA,905031647,NA,79983199 (contact),"NGUYEN, TRONG  (contact)",NA,2024-09-16,2025-09-15,Address;Adopted;Biological Assay;Blood Tests;Clinical;combat;cost;cost effective;Counseling;Data;detection limit;Devices;Early Intervention;empowerment;FDA approved;Goals;Health;Home;innovation;lateral flow assay;male;Malignant neoplasm of prostate;Malignant Neoplasms;manufacture;men;Monitor;mortality;Phase;point of care;point-of-care detection;Prostate-Specific Antigen;prototype;PSA level;PSA screening;Reader;Regulatory Pathway;Sampling;self testing;Serum;smartphone application;Specificity;test strip;Testing;Validation;Whole Blood,TOPIC 455: FINGERSTICK BLOOD TEST FOR POINT-OF-CARE DETECTION OF PROSTATE SPECIFIC ANTIGEN,0,NA,NA,NA,NA,NA,NA,NA,382537,NA
11219741,N44,CA,NA,N,NA,NA,NA,NA,75N91024C00087,NA,NA,75N91024C00087-0-9999-1,NCI:1995119\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,BOSTON,UNITED STATES,NA,07,126775860,US,10001083,BOSTON CELL STANDARDS INC,MA,021111552,NA,79979767 (contact),"BOGEN, STEVE  (contact)",NA,2024-09-16,2026-09-15,accurate diagnosis;Address;Astronomy;Biopsy;Boston;Cancer Patient;Cells;Certification;Clinical;comparative;Computer software;Contracts;Data;Databases;Development;editorial;Image;Immunohistochemistry;improved;Instruction;Laboratories;Laboratory Research;Malignant Neoplasms;manufacture;Measures;Output;Performance;Phase;programs;Reference Standards;response;Small Business Innovation Research Grant;Stains;Testing;tissue biomarkers;Unit of Measure;whole slide imaging,"FY24 SBIR PHASE II RD CONTRACT - TOPIC 442 BOSTON CELL STANDARDS, INC.",0,NA,NA,NA,NA,NA,NA,NA,1995119,NA
11219742,N43,CA,NA,N,NA,NA,NA,NA,75N91024C00078,NA,NA,75N91024C00078-0-9999-1,NCI:399866\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,Seattle,UNITED STATES,NA,07,004006628,US,3966401,"INBIOS INTERNATIONAL, INC.",WA,98109,NA,79981710 (contact),"RATCHAUDHURI, SYAMAL  (contact)",NA,2024-09-16,2025-09-15,African American;antigen detection;Biological Assay;Blood;Blood specimen;Communicable Diseases;Death Rate;Detection;Development;Diagnostic Reagent Kits;Early Diagnosis;FDA approved;Fingers;Future;Goals;Home;home test;Immunoassay;Incidence;instrument;Lateral;Malignant neoplasm of prostate;Medical;men;Performance;Phase;Populations at Risk;Prospective Studies;prostate cancer risk;Prostate-Specific Antigen;prototype;PSA level;PSA screening;rapid test;reagent testing;research clinical testing;self testing;Small Business Innovation Research Grant;Technology;Testing,TOPIC 455: DEVELOPMENT OF A RAPID AT-HOME TEST TO DETECT PROSTATE-SPECIFIC ANTIGEN USING SELF-COLLECTED FINGER STICKBLOOD,0,NA,NA,NA,NA,NA,NA,NA,399866,NA
11219743,N43,CA,NA,N,NA,NA,NA,NA,75N91024C00077,NA,NA,75N91024C00077-0-9999-1,NCI:389535\,SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,SAN DIEGO,UNITED STATES,NA,51,129852864,US,10008060,"ELECTRONIC BIOSCIENCES, INC.",CA,921214206,NA,79972662 (contact),"ERVIN, ERIC  (contact)",NA,2024-09-16,2025-09-15,Blood;Body Regions;Calibration;cancer diagnosis;Cancer Etiology;Cessation of life;comparative;cost;design;Device or Instrument Development;Devices;Diagnosis;Diagnostic;Early Diagnosis;effective therapy;Evaluation;Healthcare;high risk men;Home;home test;improved;Laboratories;Malignant neoplasm of prostate;Malignant Neoplasms;Measures;men;Methodology;Patients;performance tests;Phase;Play;point of care;Price;Prognosis;programs;Prostate;Prostate-Specific Antigen;prototype;Provider;PSA level;PSA screening;Risk;screening;Small Business Innovation Research Grant;Structure of base of prostate;Surveys;Survival Rate;Technology;Testing;usability,TOPIC 455: IDEAL AT-HOME PROSTATE SPECIFIC ANTIGEN (PSA) TESTING,0,NA,NA,NA,NA,NA,NA,NA,389535,NA
11219745,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-3,NCI:2881737\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Affect;Biological;cancer genetics;Cancer Intervention;cancer risk;case control;Case/Control Studies;cohort;Collaborations;Complex;Data;data access;Data Set;deep sequencing;Diagnostic;Disease;disorder risk;Division of Cancer Epidemiology and Genetics;DNA;Ensure;epidemiology study;Extramural Activities;gene environment interaction;Genes;Genetic Markers;Genetic Predisposition to Disease;genetic variant;Genome Scan;genome wide association study;Genomics;Individual;Inherited;large datasets;Malignant Breast Neoplasm;Malignant neoplasm of prostate;Malignant Neoplasms;Maps;Persons;Phenotype;Pilot Projects;Population Study;Predisposition;Preventive;Private Sector;programs;Research;Research Personnel;Resources;Risk;Scanning;Scientist;Series;Techniques;Therapeutic Intervention;trait;United States National Institutes of Health;Variant,DCEG- GWAS Studies,0,NA,NA,NA,NA,NA,NA,NA,2881737,NA
11219746,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-4,NCI:17547387\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Affect;alpha Tocopherol;American Cancer Society;anti-cancer research;Area;Basic Science;Beta Carotene;bioinformatics pipeline;Biological Assay;Cancer Burden;cancer genomics;cancer prevention;Cervical Cancer Screening;clinically relevant;cohort;Colon;cost;Custom;Data;data access;Data Analyses;Data Storage and Retrieval;database of Genotypes and Phenotypes;design;Development;digital;digital pathology;Disease;Disease Outcome;Division of Cancer Epidemiology and Genetics;DNA;Electronics;Employment;Environmental Risk Factor;Epidemiologist;epidemiology study;exome;exome sequencing;Experimental Designs;Family;follow-up;Generations;Genes;Genetic;genetic epidemiology;Genetic Markers;genetic variant;Genetic Variation;Genome Scan;genome sequencing;genome wide association study;genome-wide;Genomics;Genotype;Heritability;Human Genome;human genomics;Human Papillomavirus;Image;Immunohistochemistry;Individual;Informatics;Information Management;interest;Intramural Research Program;Laboratories;Laboratory Research;Lung;Malignant Neoplasms;Meta-Analysis;Molecular Epidemiology;molecular pathology;Mutation;Normal tissue morphology;novel;Nucleic Acids;Outcome;Ovarian;Phenotype;Population;Population Group;Predisposition;Prostate;Publishing;rare variant;Research;Research Support;Resources;response;Sampling;Scanning;Scientist;screening;Specimen;Statistical Methods;Support Groups;Surveys;Techniques;Technology;tissue processing;Tissues;tumor;Work,DCEG- Genotyping for epidemiology studies,0,NA,NA,NA,NA,NA,NA,NA,17547387,NA
11219747,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-5,NCI:2349637\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Biological;cold temperature;Collection;computerized;Contracts;Development;Division of Cancer Epidemiology and Genetics;Epidemiology;epidemiology study;Equipment;Equipment and supply inventories;Human;Maintenance;Molecular Epidemiology;preservation;Procedures;programs;repository;Sampling;Services;Specimen;Transportation,DCEG- Repository Services for epidemiology studies,0,NA,NA,NA,NA,NA,NA,NA,2349637,NA
11219748,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-6,NCI:721598\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,anti-cancer research;biobank;Biological;Biological Assay;Biological Process;bioprocess;blood fractionation;Blood specimen;cancer epidemiology;cell immortalization;Cell Line;Cells;Cervical;CLIA certified;Clinical;cold temperature;Contracts;Cryopreservation;Cryopreserved Cell;Cytology;Detection;Diagnostics Research;Division of Cancer Epidemiology and Genetics;DNA;Electronics;Epidemiology;epidemiology study;Erythrocytes;established cell line;Feces;Fibroblasts;Flow Cytometry;Fluorescence-Activated Cell Sorting;Freeze Drying;Freezing;Hormones;Human;Human Herpesvirus 4;Immunologic Monitoring;Immunologic Tests;Immunologics;In Vitro;Infrastructure;instrumentation;Laboratories;Liquid substance;Malignant neoplasm of cervix uteri;Mass Spectrum Analysis;Measurement;Molecular;molecular diagnostics;Molecular Epidemiology;Mutation Detection;Nitrogen;Nucleic Acids;Paraffin Embedding;Pathogen detection;Pathogenesis;Peripheral Blood Mononuclear Cell;Phenotype;Plasma;Polymorphism Analysis;Preparation;Prevention;Process;programs;Proteins;quality assurance;Quality Control;Reporting;repository;Research Personnel;RNA;Scientist;Serum;Services;Single Nucleotide Polymorphism;small molecule;Specimen;Specimen Handling;Spectrophotometry;Structure;Techniques;Technology;Tissue Embedding;Tissues;transforming virus;tumor;Urine;Virus;Whole Blood,DCEG- Molecular Assays for epidemiology studies,0,NA,NA,NA,NA,NA,NA,NA,721598,NA
11219751,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-7,NCI:51708903\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Antineoplastic Agents;assay development;biobank;Biological;Biological Assay;Biological Markers;Biological Products;biopharmaceutical industry;Clinic;Clinical;clinical center;Clinical Trials;Collaborations;Contracts;Correlative Study;Cyclic GMP;Data Science;Development;Diagnostic;Diagnostic tests;Discipline of Nursing;Division of Cancer Treatment and Diagnosis;drug development;drug discovery;Drug Kinetics;drug production;Evaluation;Funding;Genomics;high throughput screening;Image;In Vitro;in vivo;Informatics;Information Systems;Laboratories;Libraries;Malignant Neoplasms;manufacture;Medical;Molecular;Nanotechnology;Natural Products;New Agents;novel diagnostics;novel therapeutic intervention;patient derived xenograft model;Patients;Performance;Pharmaceutical Preparations;pharmacodynamic biomarker;Pharmacology;Pre-Clinical Model;Precision medicine trial;Production;programs;Radiochemistry;Radiopharmaceuticals;repository;Research;Services;Technology;Testing;Therapeutic Intervention;Toxicology;Translational Research;tumor;United States National Institutes of Health;Work,Division of Cancer Treatment and Diagnosis- Operational Task Order,0,NA,NA,NA,NA,NA,NA,NA,51708903,NA
11219752,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-8,NCI:1106553\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Antibodies;Benign;Calibration;Capsid Proteins;Cells;Cervarix;Communities;Development;Dose;Evaluation;Gardasil;Genotype;Goals;high risk;Human;Human papilloma virus infection;Human Papilloma Virus Vaccine;Human Papillomavirus;Human papillomavirus 16;Human papillomavirus 18;Human papillomavirus HPV L1 protein;Insecta;Laboratories;Licensing;Malignant neoplasm of cervix uteri;Oncogenic;Qualifying;Reagent;Recombinants;Regimen;Resources;Serology;Serology test;Serum;Standardization;Testing;vaccine development;vaccine-induced immunity;Vaccines;virtual;Virus-like particle;Work;Yeasts,HPV Serology,0,NA,NA,NA,NA,NA,NA,NA,1106553,NA
11219753,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-9,NCI:872000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Acute Myelocytic Leukemia;Acute Promyelocytic Leukemia;Agonist;Anaphase;Aneuploidy;antagonist;Antineoplastic Agents;Biological Assay;Chimeric Proteins;combat;companion diagnostics;Differentiation Therapy;Etiology;FDA approved;Genetic;Immunotherapy;Laboratories;Malignant Neoplasms;Molecular;Normal Cell;Pathway interactions;Pharmacology;Play;Retinoic Acid Receptor;retinoic acid receptor alpha;Retinoids;RXR;Signal Transduction;targeted cancer therapy;tool;ubiquitin isopeptidase,Molecular Pharmacology Lab,0,NA,NA,NA,NA,NA,NA,NA,872000,NA
11219755,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-10,NCI:1264699\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Address;Area;Communities;Contractor;design;Employee;flexibility;Goals;Government;Incubators;Information Systems;Needs Assessment;Pilot Projects;programs;Recommendation;Research;Resources;Services,Strategic Scientific Pilot Support,0,NA,NA,NA,NA,NA,NA,NA,1264699,NA
11219758,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-11,NCI:3166810\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Address;anti-cancer research;Cryoelectron Microscopy;Data Collection;Goals;Image;interest;Laboratories;Macromolecular Complexes;Malignant Neoplasms;Microscope;National Cancer Institute;Resolution;Structural Biologist;United States National Institutes of Health,Cryo-EM,0,NA,NA,NA,NA,NA,NA,NA,3166810,NA
11219759,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-12,NCI:12689844\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,anti-cancer research;Capital;Core Facility;Development;Equipment;Expenditure;Funding;Gene Mutation;Institution;Intramural Research Program;Laboratories;Laboratory Research;Malignant Neoplasms;Modeling;programs;RAS genes;Research;research and development;Research Personnel;Signal Transduction;Technology;Therapeutic;United States Dept. of Health and Human Services,RAS Program at FNL,0,NA,NA,NA,NA,NA,NA,NA,12689844,NA
11219760,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-13,NCI:16206742\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,base;Clinical;clinical center;Computers;Contractor;Contracts;Development;Funding;improved;Libraries;Maryland;National Cancer Institute;Office of Administrative Management;operation;programs;repaired;research and development;Research Personnel;Services;statistical service;United States National Institutes of Health,NCI-F Operations and Technical Support II,0,NA,NA,NA,NA,NA,NA,NA,16206742,NA
11219761,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-14,NCI:26936471\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Back;Bioinformatics;Clinical;Databases;Funding;Informatics;Infrastructure;open source;Research;Resources;Software Tools;Speed;tool;Translational Research,Informatics Support at FNLCR,0,NA,NA,NA,NA,NA,NA,NA,26936471,NA
11219766,N01,HL,NA,N,NA,NA,NA,NA,75N92023D00004,NA,NA,75N92023D00004-0-759202400001-1,NHLBI:85453\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,Chicago,UNITED STATES,NA,05,160079455,US,6144601,NORTHWESTERN UNIVERSITY,IL,606114579,NA,79988563 (contact),"LYNCH, DAVID  (contact)",NA,2024-09-10,2025-09-09,Adult;Affect;African American;Age;Air;built environment;cardiovascular risk factor;Characteristics;Chicago;Coronary Artery Risk Development in Young Adults Study;Crime;Data;Discrimination;Drowsiness;Economics;Ensure;Environment;ethnic minority;Ethnic Origin;experience;Exposure to;Gender;Goals;Individual;Institutional Racism;Link;Mentors;Neighborhoods;Noise;parent grant;poor sleep;psychological distress;psychosocial;Race;racial minority;Racial Segregation;Reporting;residential segregation;Sleep;sleep behavior;sleep health;sleep quality;sociodemographic factors;Training;Trauma;United States,CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - CHICAGO FIELD CENTERDIVERSITY SUPPLEMENT FOR MORGANN WEST,0,NA,NA,NA,NA,NA,NA,NA,85453,NA
11219771,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-15,NCI:18486552\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,anti-cancer research;cancer genomics;Clinical Data;Collection;Communities;data repository;Data Set;data sharing;effective therapy;follow-up;Genomic approach;Genomic Data Commons;Malignant Childhood Neoplasm;Molecular;precision medicine;Research;Therapeutic;treatment program;Update,GDC Clinical Data Update,0,NA,NA,NA,NA,NA,NA,NA,18486552,NA
11219772,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-16,NCI:384950\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Blood;Breast Cancer Prevention Trial;Clinical Trials;cost;Leukocytes;Maintenance;National Surgical Adjuvant Breast and Bowel Project;Plasma;repository;Specimen;Study of Tamoxifen and Raloxifene;Woman;Women&apos;s study,DCP - COPTRG Support [National Surgical Adjuvant Breast and Bowel Project (NSABP),0,NA,NA,NA,NA,NA,NA,NA,384950,NA
11219773,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-17,NCI:641584\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,biomarker validation;Clinical;Clinical Research;Early Detection Research Network;Funding;Histologic;interest;Prevention;repository;Screening for cancer;Specimen;Tissues;Vial device,DCP - Early Detection Research Network (EDRN) Repository,0,NA,NA,NA,NA,NA,NA,NA,641584,NA
11219777,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-18,NCI:1514138\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Area;clinical development;Contractor;Development;Development Plans;human biological material;Knowledge;Laboratories;manufacturing capabilities;Marketing;Monitor;operation;Performance;Phase;pre-clinical;Procedures;Process;product development;programs;Protocols documentation;public-private partnership;quality assurance;Quality Control;research clinical testing;Site;skills;Specimen;Therapeutic;Vaccines,DCP - COPTRG - SELECT/PCPT,0,NA,NA,NA,NA,NA,NA,NA,1514138,NA
11219782,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-19,NCI:3163335\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Contractor;Dedications;Immunoprevention;Laboratories;Malignant Neoplasms;Methods;preclinical development;Standardization;Work,DCP- Cancer Immunoprevention Laboratory Support,0,NA,NA,NA,NA,NA,NA,NA,3163335,NA
11219788,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-20,NCI:25663\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,biobank;Biological Specimen Banks;cancer prevention;clinical research site;Contracts;Phase;prevention clinical trial;programs,DCP - Cancer Prevention Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia) BioRepository,0,NA,NA,NA,NA,NA,NA,NA,25663,NA
11219794,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-21,NCI:663302\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Clinical Trials;knowledge base;Maintenance;operation;System,DCP - Clin Trl Info Mgt -DCP Enterprise System Knowledge Base (DESK),0,NA,NA,NA,NA,NA,NA,NA,663302,NA
11219798,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-22,NCATS:3100000\NCI:112662150\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,base;Clinical;clinical center;Computers;Contract Services;Contractor;Contracts;data management;Development;Funding;improved;Information Services;International;Libraries;Maryland;National Cancer Institute;Office of Administrative Management;operation;programs;repaired;Research Personnel;Science;Services;statistical service;Support Contracts;United States National Institutes of Health,NCI-Frederick Operational Support,0,NA,NA,NA,NA,NA,NA,NA,115762150,NA
11219800,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-23,NCI:180000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,2019-nCoV;Antibody Response;Automobile Driving;COVID-19;COVID-19 pandemic;COVID-19 test;Diagnosis;Disease;Goals;Immune response;Laboratories;Light;Methods;Molecular;novel coronavirus;pathogen;Procedures;Public Health;Reagent;Research;response;Science;Serology;Serology test;Standardization;Testing,Serological Science for COVID-19 SeroNet,0,NA,NA,NA,NA,NA,NA,NA,180000,NA
11219801,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-24,NCI:965760\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Area;Biological Products;Cell Culture Techniques;Cell Therapy;Clinical;Clinical Trials;Contractor;Development;Good Manufacturing Process;Guidelines;Immunoconjugates;Industry;Investigational Drugs;manufacture;Mission;Monoclonal Antibodies;Peptides;Pharmacologic Substance;Phase;Phase I Clinical Trials;Phase III Clinical Trials;plasmid DNA;Program Development;Recombinant Proteins;Regulation;Research Personnel;Sterility;Testing;United States Food and Drug Administration;vector vaccine;Vial device;Virus;Work,DCP - Biopharmaceutical Development Program (BDP) Support,0,NA,NA,NA,NA,NA,NA,NA,965760,NA
11219802,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-25,NCI:500000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Area;Caribbean region;clinical development;Clinical Trials;Clinical Trials Design;Clinical Trials Network;Contractor;Contracts;Development;Development Plans;experience;HIV;human biological material;Human Papilloma Virus-Related Malignant Neoplasm;Knowledge;Laboratories;Latin American;manufacturing capabilities;Marketing;Monitor;Nursing Research;operation;Performance;Phase;pre-clinical;prevention clinical trial;Procedures;Process;product development;programs;Protocols documentation;public-private partnership;quality assurance;Quality Control;Regulatory Affairs;research clinical testing;Site;skills;Specialist;Specimen;Therapeutic;Vaccines,DCP - Clinical Trials Regulatory & Monitoring Support for US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network,0,NA,NA,NA,NA,NA,NA,NA,500000,NA
11219804,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-26,NCI:1200000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Advocate;American;anti-cancer research;Cancer Control;Congresses;Contractor;Country;Data;Data Analyses;Documentation;experience;global health;Grant;Individual;international partnership;Knowledge;Leadership;low and middle-income countries;meetings;Mission;Oncology;Play;Publications;Reporting;Research;Scientist;Site;technical writing;Training;Training Activity;Travel;web site;Work;Writing,"CGH - Center for Global Health Data Analysis, Technical Support and Dialogues",0,NA,NA,NA,NA,NA,NA,NA,1200000,NA
11219811,R01,AI,7,N,2024-12-23,2024-12-01,2025-04-30,855,R01AI153252,SCHOOLS OF MEDICINE,PA-24-254,7R01AI153252-05,NIAID:222535\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,GREENVILLE,UNITED STATES,MICROBIOLOGY/IMMUN/VIROLOGY,01,607579018,US,578209,EAST CAROLINA UNIVERSITY,NC,278581821,"Narrative Inhalation of the bacterium Yersinia pestis results in pneumonic plague, a highly lethal infection with mortality rates approaching 100%. The proposed work seeks to understand the interaction of Y. pestis with host cells in the lung by characterizing the function of a well-established mediator of pathogenesis in the early events that establish pneumonic plague.",12431408;9782662 (contact),"HUANG, LU ;PECHOUS, ROGER D (contact)","MUKHOPADHYAY, SUMAN",2021-05-01,2026-04-30,Adherence;Alveolar Macrophages;Attenuated;Bacteria;Bacterial Adhesins;bacterial resistance;cell type;Cells;Data;Death Rate;Disease;Epithelial Cells;Event;Feedback;Flow Cytometry;Fluorescence-Activated Cell Sorting;Growth;Human;Immune;Immune signaling;In Vitro;in vivo;Infection;Inflammation;Inflammatory;Inflammatory Response;Inhalation;innate immune mechanisms;Innate Immune Response;insight;Laboratories;Lung;Lung infections;Maps;Mediating;Mediator;Mus;mutant;neutrophil;Neutrophil Infiltration;novel;pathogen;Pathogenesis;Peptide Hydrolases;Phase;Phosphotransferases;Plague;Plasminogen Activator;Play;Pneumonic Plague;Population;Population Dynamics;prevent;Proteome;Proteomics;Reporter;Research;response;Role;sensor;Surface;Surveys;Symptoms;System;Testing;Time;Tissues;transcriptomics;Virulence Factors;Work;Yersinia;Yersinia pestis,Defining the Role of the Plasminogen Activator Protease in the Early Events that Establish Primary Pneumonic Plague,153252,HIBP,Host Interactions with Bacterial Pathogens Study Section[HIBP],NA,NA,5,176490,46045,222535,NA
11219816,P20,GM,5,N,2024-09-16,2024-09-01,2025-08-31,NA,P20GM121176,NA,PAR-19-312,5P20GM121176-08,NIGMS:231003\,RESEARCH CENTERS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,ALBUQUERQUE,UNITED STATES,NA,01,829868723,US,10021612,UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR,NM,871310001,NA,16181674 (contact),"BALNE, PRAVEEN K (contact)","CUPIT, PAULINE",2024-09-01,2027-08-31,Acute;Address;Adolescent;Adult;Affect;Age;age acceleration;age effect;aged;Aging;aging related;Autophagocytosis;Blindness;Blood Glucose;Cell Aging;Chronic;Confocal Microscopy;Cornea;corneal epithelial wound healing;corneal epithelium;Corneal Injury;Diabetes Mellitus;diabetic;diabetic patient;Disease;epithelial injury;Esthesia;experimental study;Exposure to;Eye;Flow Cytometry;FRAP1 gene;Gene Expression;Glucose;Health Expenditures;Human;Hyperglycemia;Immersion;Immunohistochemistry;Incidence;Infection;Inflammation;Injury;insight;Keratopathy;Length;Mass Spectrum Analysis;Metabolism;Methods;Modeling;Molecular;Morbidity - disease rate;mortality;novel;Organ;pandemic disease;Pharmaceutical Preparations;Phase;Physiological;Play;Predisposition;Prevalence;prevent;protein expression;Public Health;Quantitative Reverse Transcriptase PCR;Research Proposals;response;Role;Severities;Signal Transduction;Therapeutic;Time;transcriptome sequencing;Western Blotting;Zebrafish,Diabetic Keratopathy and Aging,121176,ZGM1,ZGM1-RCB-3(C2),5385,NA,8,151478,79525,NA,231003
11219820,P20,GM,5,N,2024-09-16,2024-10-21,2025-08-31,NA,P20GM121176,NA,PAR-19-312,5P20GM121176-08,NIGMS:283158\,RESEARCH CENTERS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,ALBUQUERQUE,UNITED STATES,NA,01,829868723,US,10021612,UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR,NM,871310001,NA,11553904 (contact),"ENDICOTT, SAMUEL JOSEPH  (contact)","CUPIT, PAULINE",2024-10-21,2027-08-31,"age-related disease;Alzheimer&apos;s Disease;Atherosclerosis;Autophagocytosis;Biological Assay;Biosensor;Cancer Center;Cell Culture Techniques;Cells;Clathrin;Clathrin Adaptors;Complex;Consensus;Cytoplasm;Data;Disease;Drug Side Effects;Dynamin;Endocytic Vesicle;Endocytosis;Endosomes;enhancer-binding protein AP-2;Equipment;Fatty Acids;fatty liver disease;Future;Glycolysis;Goals;Growth Factor;Growth Factor Receptors;Individual;Inflammation;inhibitor;insight;Insulin;Insulin Receptor;insulin receptor tyrosine kinase;insulin signaling;intervention refinement;Ligand Binding;Ligands;Lysosomes;Malignant Neoplasms;MAP4;Mediating;Membrane;Metabolism;Microscope;Microscopy;Microtubules;Molecular Chaperones;Mus;new therapeutic target;novel;Parkinson Disease;PDPK1 gene;Phase;phosphatidylinositol 3,4,5-triphosphate;phosphoinositide-3,4,5-triphosphate;Phosphorylation;PIK3CA gene;PIK3CG gene;Process;Production;Proteins;Proteolysis;Proteome;Proto-Oncogene Proteins c-akt;ratiometric;Receptor Inhibition;Receptor Protein-Tyrosine Kinases;recruit;Regulation;Reporter;Resistance;Ribosomes;Role;Serum;side effect;Signal Transduction;Small Interfering RNA;small molecule inhibitor;Starvation;System;Techniques;Therapeutic;trafficking;translational potential;Translations;tumorigenesis;uptake",Endocytosis and Endolysosomal Trafficking of Receptor Tyrosine Kinases in the Regulation of Chaperone-Mediated Autophagy,121176,ZGM1,ZGM1-RCB-3(C2),5386,NA,8,185677,97481,NA,283158
11219821,N01,HL,NA,N,NA,NA,NA,NA,75N92024C00008,NA,NA,75N92024C00008-0-9999-1,NHLBI:1712529\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,IOWA CITY,UNITED STATES,NA,01,062761671,US,3972901,UNIVERSITY OF IOWA,IA,522421320,NA,79992326 (contact),"BOYLE, JESSICA  (contact)",NA,2024-09-23,2025-09-22,"Advisory Committees;Age;Animal Model;Animals;Anti-Inflammatory Agents;Antibodies;Area;Biological;Biological Assay;Biology;Body Fluids;Breeding;Catalogs;Cell Separation;Cell Therapy;cell type;Cells;Communities;Complementary DNA;Contracts;Custom;Data;Databases;Deposition;Diet;Disease;disease model;Enzyme-Linked Immunosorbent Assay;experimental study;Farm;Ferrets;Fluorescence-Activated Cell Sorting;Funding;Gene Expression;Genes;Genetic;Genetic Engineering;Genetically Modified Animals;Genome;Goals;Grant;Health;Human;Human Resources;Immunoprecipitation;improved;In Situ Hybridization;Industrialization;Institution;Knock-in;Knock-out;Label;Left;Lung;Lung Diseases;Manuscripts;material transfer agreement;Messenger RNA;Methods;Mission;Modeling;Mus;National Heart, Lung, and Blood Institute;Outcome;pharmacologic;Phenotype;Physiological;Preparation;Procedures;Protocols documentation;Pulmonary function tests;Reagent;recombinant virus;Records;repository;Research;Research Personnel;Resources;RNA;sample collection;Sampling;single-cell RNA sequencing;Site;Source;Specimen;stem cell biology;stem cell therapy;Techniques;Technology;Testing;Therapeutic Agents;therapeutic evaluation;Tissue Model;Tissue Sample;Tissues;Training;Transgenic Organisms;United States Department of Agriculture;United States National Institutes of Health;web site;Western Blotting",NATIONAL FERRET RESOURCE AND RESEARCH CENTER ON LUNG DISEASE,0,NA,NA,NA,NA,NA,NA,NA,1712529,NA
11219823,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-27,NCI:105618\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Academia;anti-cancer research;biopharmaceutical industry;Cancer Center;cancer genomics;Cancer Model;Catalogs;Clinical;clinical diagnostics;Communities;Data;data modeling;Data Sources;Foundations;Genomic Data Commons;Genomics;Goals;Human;In Vitro;Institution;Intellectual Property;interest;International;Libraries;Malignant Neoplasms;member;Methods;model development;Modeling;Molecular;National Cancer Institute;next generation;novel;Office of Cancer Genomics;Online Systems;Organoids;query tools;Research Personnel;Resources;response;Source;System;Technology;Tissue Donors;Trust,HCMI Searchable Catalog,0,NA,NA,NA,NA,NA,NA,NA,105618,NA
11219825,N01,HL,NA,N,NA,NA,NA,NA,75N92023D00011,NA,NA,75N92023D00011-0-759202400001-1,NHLBI:9298220\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,DENVER,UNITED STATES,NA,01,076443019,US,5720901,NATIONAL JEWISH HEALTH,CO,802062761,NA,79907434 (contact),"CAPPO, JAMES  (contact)",NA,2024-08-10,2025-08-09,"Address;adjudication;Adverse event;Ancillary Study;Annual Reports;Applications Grants;Archives;Area;Award;biobank;Bioinformatics;Biological Markers;Biological Specimen Banks;Blood specimen;Bronchodilator Agents;catalyst;Cause of Death;Certification;Cessation of life;Characteristics;Chest;Chronic Obstructive Pulmonary Disease;Clinical;clinical center;Clinical Data;clinical phenotype;Clinical Research;clinical research site;Clinical/Radiologic;cohort;Collaborations;Collection;Communication;Communities;Compensation;Computer Security;Contractor;Contracts;cost;COVID-19;COVID-19 impact;Data;Data Analyses;Data Coordinating Center;data format;data management;data quality;data repository;data resource;Data Science;Data Security;Data Set;data sharing;data submission;database of Genotypes and Phenotypes;Databases;demographics;Development;Diagnostic;Diffusion;digital;Disease Progression;disorder subtype;DNA Methylation;Documentation;Educational workshop;Elderly;Electronics;Enrollment;Ensure;epidemiologic data;Epidemiology;Evaluation;Event;follow-up;follower of religion Jewish;former smoker;frailty;Funding;Funding Opportunities;Future;Genes;Genetic;genetic analysis;genetic epidemiology;genome sequencing;Genomics;Goals;Grant;Health;high risk;Hospitals;human subject protection;Image;image processing;imaging facilities;Impairment;Information Systems;Institutional Review Boards;International;Internet;Journals;Laboratories;Link;Longitudinal cohort study;Longterm Follow-up;Maintenance;Manuscripts;Measures;Medical History;meetings;member;metabolomics;Metadata;Methods;Molecular;Monitor;Names;National Heart, Lung, and Blood Institute;Natural History;new technology;non-smoking;Observational Study;Outcome;Oxygen;Parents;Participant;Peer Review;Persons;Phase;Physical Performance;Physiological;Physiology;Policies;preservation;Privatization;Procedures;prognostic;programs;Proteomics;Protocols documentation;Publications;Publishing;PubMed;Pulmonary Emphysema;Pulmonary function tests;quality assurance;Quality Control;Quality of life;Questionnaires;Recommendation;recruit;Reporting;repository;Research;Research Personnel;Resolution;Resources;Risk Factors;SARS-CoV-2 infection;Scanning;Schedule;Scientist;serial imaging;Site;smoking-related disease;socioeconomics;Specific qualifier value;Spirometry;Standardization;Subgroup;Support Contracts;System;Teleconferences;Telephone;Testing;Therapeutic;Time;Tobacco use;Training;Trans-Omics for Precision Medicine;transcriptome sequencing;Travel;U-Series Cooperative Agreements;United States National Institutes of Health;Update;Vaccination;Visit;Walking;web site;whole genome;Woman;Work;X-Ray Computed Tomography",GENETIC EPIDEMIOLOGY OF COPD (COPD GENE)  2024 - 2025 TASK ORDER FOR TASK AREA A: COLLECTION OF COPDGENE STUDY DATA AND BIOSPECIMENS AND OVERSIGHT OF THE COPDGENE STUDY.,0,NA,NA,NA,NA,NA,NA,NA,9298220,NA
11219828,N01,HL,NA,N,NA,NA,NA,NA,75N92024D00012,NA,NA,75N92024D00012-0-759202400001-1,NHLBI:6734645\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,SAN FRANCISCO,UNITED STATES,NA,NA,NA,US,NA,NA,CA,941432208,NA,79841366 (contact),"ANDERSON, ERICA  (contact)",NA,2024-06-18,2025-06-17,"Address;Adverse event;Airway Disease;Ancillary Study;Annual Reports;Archives;Area;Atmosphere;Award;biobank;Biochemical;Biological Specimen Banks;Blood;Bronchodilator Agents;catalyst;Certification;Characteristics;Chronic Obstructive Pulmonary Disease;Clinic Visits;Clinical;clinical center;Clinical Data;clinical research site;cohort;Cohort Studies;Collection;Communication;Communities;Companions;Compensation;Complete Blood Count;Computer Security;Contractor;Contracts;Data;Data Coordinating Center;data de-identification;data format;data integration;data quality;data repository;Data Science;Data Security;Data Set;data sharing;data submission;database of Genotypes and Phenotypes;demographics;Deposition;detector;Development;digital;Dimensions;Disease;Disease Progression;Documentation;Electronics;Enrollment;Ensure;Environmental Exposure;Environmental Monitoring;Environmental Risk Factor;Event;Exposure to;follow-up;Funding;genomic data;Genomics;Goals;Grant;Hand;Hand Strength;Heterogeneity;image processing;imaging facilities;imaging modality;Individual;Informatics;Information Dissemination;Information Systems;Institutional Review Boards;International;Internet;Intervention;Journals;Laboratories;Link;Longterm Follow-up;Lung Diseases;lung volume;Maintenance;Manuscripts;Measures;Medical History;meetings;member;Metadata;Methods;Molecular;Monitor;MUC5AC gene;MUC5B gene;Mucous body substance;multiple omics;Names;National Heart, Lung, and Blood Institute;Natural History;Nature;new technology;novel;Observational Study;Oscillometry;Outcome;Ownership;Participant;participant enrollment;Pathologic;Peer Review;Persons;Phenotype;Physical Performance;Policies;Population;preservation;Procedures;programs;Progress Reports;Proteins;Protocols documentation;Publications;PubMed;Pulmonary Emphysema;pulmonary function;Pulmonary function tests;quality assurance;Quality Control;Quality of life;Questionnaires;radiological imaging;Recommendation;Refractive Indices;Reporting;repository;Research;Research Personnel;Resources;respiratory;retention rate;Role;SARS-CoV-2 infection;Scanning;Schedule;Scientist;Smoker;Smoking;Smoking History;Social Environment;social health determinants;socioeconomics;Source;Specific qualifier value;Spirometry;Sputum;Standardization;Statistical Data Interpretation;Support Contracts;Symptoms;System;Telephone;Testing;Time;Tobacco use;Training;Trans-Omics for Precision Medicine;Travel;United States National Institutes of Health;Update;Urine;Vaccination;vascular abnormality;Visit;Walking;web site;Work;Writing;X-Ray Computed Tomography",SUBPOPULATIONS AND INTERMEDIATE OUTCOMES IN COPD (SPIROMICS) III - TASK AREA A,0,NA,NA,NA,NA,NA,NA,NA,6734645,NA
11219829,N01,HL,NA,N,NA,NA,NA,NA,75N92024D00012,NA,NA,75N92024D00012-0-759202400002-1,NHLBI:206351\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,SAN FRANCISCO,UNITED STATES,NA,NA,NA,US,NA,NA,CA,941432208,NA,79841369 (contact),"ANDERSON, ERICA  (contact)",NA,2024-06-18,2025-06-17,"Address;Adverse event;Airway Disease;Ancillary Study;Annual Reports;Archives;Area;Atmosphere;Award;biobank;Biochemical;Biological Specimen Banks;Blood;Bronchodilator Agents;catalyst;Certification;Characteristics;Chronic Obstructive Pulmonary Disease;Clinic Visits;Clinical;clinical center;Clinical Data;clinical research site;cohort;Cohort Studies;Collection;Communication;Communities;Companions;Compensation;Complete Blood Count;Computer Security;Contractor;Contracts;Data;Data Coordinating Center;data de-identification;data format;data integration;data quality;data repository;Data Science;Data Security;Data Set;data sharing;data submission;database of Genotypes and Phenotypes;demographics;Deposition;detector;Development;digital;Dimensions;Disease;Disease Progression;Documentation;Electronics;Enrollment;Ensure;Environmental Exposure;Environmental Monitoring;Environmental Risk Factor;Event;Exposure to;follow-up;Funding;genomic data;Genomics;Goals;Grant;Hand;Hand Strength;Heterogeneity;image processing;imaging facilities;imaging modality;Individual;Informatics;Information Dissemination;Information Systems;Institutional Review Boards;International;Internet;Intervention;Journals;Laboratories;Link;Longterm Follow-up;Lung Diseases;lung volume;Maintenance;Manuscripts;Measures;Medical History;meetings;member;Metadata;Methods;Molecular;Monitor;MUC5AC gene;MUC5B gene;Mucous body substance;multiple omics;Names;National Heart, Lung, and Blood Institute;Natural History;Nature;new technology;novel;Observational Study;Oscillometry;Outcome;Ownership;Participant;participant enrollment;Pathologic;Peer Review;Persons;Phenotype;Physical Performance;Policies;Population;preservation;Procedures;programs;Progress Reports;Proteins;Protocols documentation;Publications;PubMed;Pulmonary Emphysema;pulmonary function;Pulmonary function tests;quality assurance;Quality Control;Quality of life;Questionnaires;radiological imaging;Recommendation;Refractive Indices;Reporting;repository;Research;Research Personnel;Resources;respiratory;retention rate;Role;SARS-CoV-2 infection;Scanning;Schedule;Scientist;Smoker;Smoking;Smoking History;Social Environment;social health determinants;socioeconomics;Source;Specific qualifier value;Spirometry;Sputum;Standardization;Statistical Data Interpretation;Support Contracts;Symptoms;System;Telephone;Testing;Time;Tobacco use;Training;Trans-Omics for Precision Medicine;Travel;United States National Institutes of Health;Update;Urine;Vaccination;vascular abnormality;Visit;Walking;web site;Work;Writing;X-Ray Computed Tomography",SUBPOPULATIONS AND INTERMEDIATE OUTCOMES IN COPD (SPIROMICS) III - TASK AREA B,0,NA,NA,NA,NA,NA,NA,NA,206351,NA
11219841,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00023,NA,NA,75N95024D00023-0-759502400001-1,NCATS:1000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,WILMINGTON,UNITED STATES,NA,06,019716729,US,1336801,"CHARLES RIVER LABORATORIES INTNTL, INC.",MA,018871096,NA,79933139 (contact),"STUMP, DONALD  (contact)",NA,2024-08-12,2030-08-11,drug development;Evaluation;meetings;Safety;Services;Toxicology,KICK-OFF MEETING FOR SAFETY EVALUATION AND TOXICOLOGY STUDIES AND RELATED SERVICES FOR DRUG DEVELOPMENT,0,NA,NA,NA,NA,NA,NA,NA,1000,NA
11219842,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00010,NA,NA,75N95024D00010-0-759502400001-1,NCATS:1000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,MONROVIA,UNITED STATES,NA,NA,NA,US,NA,NA,MD,217708732,NA,NA,(contact),NA,2024-05-15,2031-05-14,meetings,CMC Kick Off meeting,0,NA,NA,NA,NA,NA,NA,NA,1000,NA
11219843,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00011,NA,NA,75N95024D00011-0-759502400001-1,NCATS:1000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,SAN DIEGO,UNITED STATES,NA,51,621516145,US,10027826,POLYPEPTIDE LABORATORIES SAN DIEGO,CA,921264310,NA,NA,(contact),NA,2024-05-15,2031-05-14,meetings;polypeptide,CMC-DS IDIQ Kick-Off Meeting for PolyPeptide Labs,0,NA,NA,NA,NA,NA,NA,NA,1000,NA
11219844,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00027,NA,NA,75N95024D00027-0-759502400001-1,NCATS:1000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ALBUQUERQUE,UNITED STATES,NA,01,075769000,US,10061906,LOVELACE BIOMEDICAL RESEARCH INSTITUTE,NM,871085129,NA,79918173 (contact),"BARRETT, EDWARD  (contact)",NA,2024-08-06,2024-09-30,animal model development;Contracts;drug development;meetings;Pharmacology Study;Services;Study models,KICK-OFF MEETING FOR THE PHARMACOLOGY STUDIES AND ANIMAL MODEL DEVELOPMENT AND RELATED SERVICES FOR DRUG DEVELOPMENT IDIQ CONTRACT.,0,NA,NA,NA,NA,NA,NA,NA,1000,NA
11219849,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00020,NA,NA,75N95024D00020-0-759502400002-1,NCATS:512266\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,CHICAGO,UNITED STATES,NA,01,005447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,NA,79988575 (contact),"HORN, THOMAS  (contact)",NA,2024-09-18,2025-02-10,Agonist;Canis familiaris;Immunologics;Malignant Neoplasms;Oral;Organ;Recovery;small molecule;Solid;Toxic effect;Toxicokinetics,FIRST-IN-CLASS SMALL MOLECULE CANDIDATE NCGC72 (CD206 AGONIST) FOR IMMUNOLOGICALLY COLD SOLID ORGAN CANCERS,0,NA,NA,NA,NA,NA,NA,NA,512266,NA
11219854,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00012,NA,NA,75N95024D00012-0-759502400002-1,NCATS:605287\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,KANSAS CITY,UNITED STATES,NA,05,007173453,US,5282001,MIDWEST RESEARCH INSTITUTE,MO,641102241,NA,80002007 (contact),"SLADE, DESMOND  (contact)",NA,2024-09-30,2026-09-29,Chemistry;Contractor;Development;manufacture;Process;Tuberculosis;tuberculosis treatment,PROCESS DEVELOPMENT OF TELACEBEC FOR TUBERCULOSIS,0,NA,NA,NA,NA,NA,NA,NA,605287,NA
11219859,N02,OD,NA,N,NA,NA,NA,NA,75N98020D00086,NA,NA,75N98020D00086-P00006-759802100046-1,NCATS:137368\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,MCLEAN,UNITED STATES,NA,NA,NA,US,NA,NA,VA,22102,NA,NA,(contact),NA,2021-06-28,2024-09-29,manufacture;National Center for Advancing Translational Sciences;Plasmids;therapeutic development;United States National Institutes of Health,"NATIONAL INSTITUTES OF HEALTH (NIH), NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS), THERAPEUTIC DEVELOPMENT BRANCH (TDB), GMP MANUFACTURE AND STABILITY STUDIES OF HBMP-6 PLASMID",0,NA,NA,NA,NA,NA,NA,NA,137368,NA
11219860,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00500,NA,NA,75N95024P00500-0-0-1,NCATS:24800\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,SACRAMENTO,UNITED STATES,NA,NA,NA,US,NA,NA,CA,95827,NA,NA,(contact),NA,2024-08-28,2024-12-28,Brain;induced pluripotent stem cell;Patients;single-cell RNA sequencing;transcriptomic profiling;X-Linked Mental Retardation,TRANSCRIPTOME PROFILING IN BAIN TYPE X-LINKED MENTAL RETARDATION SYNDROME (MRXSB) PATIENT'S IPSC-GENERATED BRAIN ORGANIODS BY USING SCRNA-SEQ,0,NA,NA,NA,NA,NA,NA,NA,24800,NA
11219861,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00487,NA,NA,75N95024P00487-0-0-1,NCATS:24000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,Rockville,UNITED STATES,NA,08,963268094,US,10026936,"CODEX BIOSOLUTIONS, INC.",MD,20852,NA,79956418 (contact),"NGUYEN, NAM  (contact)",NA,2024-09-04,2025-01-03,Brain;Generations;induced pluripotent stem cell;Organoids;X-Linked Mental Retardation,GENERATION AND CHARACTERIZATION IPSC DERIVED BRAIN ORGANOIDS FROM BAIN TYPE X-LINKED MENTAL RETARDATION SYNDROME (MRXSB),0,NA,NA,NA,NA,NA,NA,NA,24000,NA
11219862,N01,DA,NA,N,NA,NA,NA,NA,75N95019D00012,NA,NA,75N95019D00012-P00006-759502000004-1,NCATS:133039\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ALBUQUERQUE,UNITED STATES,NA,01,075769000,US,10061906,LOVELACE BIOMEDICAL RESEARCH INSTITUTE,NM,871085129,NA,79992506 (contact),"FARMER, JOHN  (contact)",NA,2020-09-24,2024-12-31,Fracture;therapeutic gene,CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES.,0,NA,NA,NA,NA,NA,NA,NA,133039,NA
11219863,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00036,NA,NA,75N95024D00036-0-759502400002-1,NCATS:322928\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,SAN DIEGO,UNITED STATES,NA,NA,NA,US,NA,NA,CA,921095754,NA,NA,(contact),NA,2024-09-27,2026-05-26,Chemistry;Dosage Forms;drug development;Injections;manufacture;Process;Services,"DOSAGE FORM REPROCESS AND STABILITY STUDIES OF FX-5A INJECTION UNDER IDIQ CHEMISTRY, MANUFACTURING AND CONTROLS AND RELATED SERVICES FOR DEVELOPMENT OF DRUG PRODUCTS",0,NA,NA,NA,NA,NA,NA,NA,322928,NA
11219917,N02,HL,NA,N,NA,NA,NA,NA,75N92022D00014,NA,NA,75N92022D00014-0-759202400002-1,NIBIB:198248\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,BOSTON,UNITED STATES,NA,08,073130411,US,4907701,MASSACHUSETTS GENERAL HOSPITAL,MA,021142621,NA,79872808 (contact),"SCHACHTER, STEVEN C.  (contact)",NA,2024-07-15,2026-03-14,Acceleration;Businesses;Clinical;commercialization;Communication;Complex;data management;Development;Diagnostic;diagnostic technologies;Electronics;endometriosis;Evaluation;Funding;Goals;innovation;point of care;Procedures;Process;Progress Reports;RADx;Resources;Schedule;Services;United States National Institutes of Health;web site,RADX INNOVATION FUNNEL FOR ENDOMETRIOSIS DIAGNOSTICS - COORDINATION CENTER,0,NA,NA,NA,NA,NA,NA,NA,198248,NA
11219925,N02,HL,NA,N,NA,NA,NA,NA,75N92022D00013,NA,NA,75N92022D00013-0-759202400002-1,NIBIB:801749\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,HADLEY,UNITED STATES,NA,02,110907578,US,10041458,VENTUREWELL,MA,010359462,NA,79872805 (contact),"MARINO, MARK  (contact)",NA,2024-07-15,2026-03-14,Acceleration;Clinical;commercialization;Development;Diagnostic;diagnostic technologies;endometriosis;Goals;innovation;parallelization;point of care;RADx;Resources;risk mitigation;Services;Speed;technology development;United States National Institutes of Health;Vendor,RADX INNOVATION FUNNEL FOR ENDOMETRIOSIS DIAGNOSTICS - COMMERCIALIZATION CENTER,0,NA,NA,NA,NA,NA,NA,NA,801749,NA
11219951,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00017,NA,NA,75N92019D00017-0-759202400001-1,NHLBI:10766\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ALBUQUERQUE,UNITED STATES,NA,01,075769000,US,10061906,LOVELACE BIOMEDICAL RESEARCH INSTITUTE,NM,871085129,NA,79560367 (contact),"WANG, GENSHENG  (contact)",NA,2023-12-19,2024-06-30,Animal Model;Animals;Area;Biodistribution;Biological Assay;Collaborations;Contractor;Emerging Technologies;Funding;gene therapy;Gene Transduction Agent;Gene Transfer;good laboratory practice;Laboratories;new technology;nonhuman primate;Pharmacology and Toxicology;pre-clinical;programs;Regulation;Research Personnel;Resources;Rodent;Technology;Testing;vector,GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY - TASK AREA A:  CORE ADMINISTRATIVE ACTIVITIES,0,NA,NA,NA,NA,NA,NA,NA,10766,NA
11219956,N01,HL,NA,N,NA,NA,NA,NA,75N92024D00013,NA,NA,75N92024D00013-0-759202400008-1,NEI:2400\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,BALTIMORE,UNITED STATES,NA,07,001910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212182680,NA,NA,(contact),NA,2024-09-24,2027-09-08,NA,"HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE -   WHOLE GENOME SEQUENCING, 30X COVERAGE FOR NEI (SHEN)",0,NA,NA,NA,NA,NA,NA,NA,2400,NA
11219967,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00023,NA,NA,75N91019D00023-0-759102400001-2,NCI:445206\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,ROCKVILLE,UNITED STATES,NA,08,049508120,US,9611701,"WESTAT, INC.",MD,208503129,NA,79660231 (contact),"MILLER, AMY  (contact)",NA,2024-03-15,2025-03-14,Contractor;Dietary Assessment;Hour;Self Administration;Services;System;Update,NCI SUPPORT FOR THE EXISTING AUTOMATED SELF-ADMINISTERED 24-HOUR DIETARY ASSESSMENT SYSTEM,0,NA,NA,NA,NA,NA,NA,NA,445206,NA
11219968,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00016,NA,NA,75N92019D00016-0-759202400001-1,NHLBI:213371\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,PHILADELPHIA,UNITED STATES,NA,03,042250712,US,6463801,UNIVERSITY OF PENNSYLVANIA,PA,191046205,NA,79560364 (contact),"JOHNSTON, JULIE  (contact)",NA,2023-12-19,2024-06-30,Animal Model;Animals;Area;Biodistribution;Biological Assay;Collaborations;Contractor;Emerging Technologies;Funding;gene therapy;Gene Transduction Agent;Gene Transfer;good laboratory practice;Laboratories;new technology;nonhuman primate;Pharmacology and Toxicology;pre-clinical;programs;Regulation;Research Personnel;Resources;Rodent;Technology;Testing;vector,"GENE THERAPY RESOURCE PROGRAM (GTRP),TASK AREA A: CORE ADMINISTRATIVE TASKS",0,NA,NA,NA,NA,NA,NA,NA,213371,NA
11219969,N01,HL,NA,N,NA,NA,NA,NA,75N92019D00015,NA,NA,75N92019D00015-0-759202400001-1,NHLBI:302586\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,SILVER SPRING,UNITED STATES,NA,08,091340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,NA,79561381 (contact),"PATTON, LISA  (contact)",NA,2023-12-19,2024-06-30,Animal Model;Animals;Area;Biodistribution;Biological Assay;Clinical;Collaborations;Contractor;Emerging Technologies;Funding;gene therapy;Gene Transduction Agent;Gene Transfer;good laboratory practice;Laboratories;new technology;nonhuman primate;Pharmacology and Toxicology;pre-clinical;programs;Regulation;Research Personnel;Resources;Rodent;Technology;Testing;vector,GENE THERAPY RESOURCE PROGRAM (GTRP) - CLINICAL COORDINATING CENTER: TASK AREA A: CORE ADMINISTRATIVE ACTIVITIES,0,NA,NA,NA,NA,NA,NA,NA,302586,NA
11219984,N02,CA,NA,N,NA,NA,NA,NA,75N98019D00057,NA,NA,75N98019D00057-0-759102400001-1,NCI:208675\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,ALACHUA,UNITED STATES,NA,03,012852344,US,10020711,ALCHEM LABORATORIES CORPORATION,FL,326156687,NA,79803735 (contact),"TALTON, JIM  (contact)",NA,2019-09-27,2024-09-30,Deoxycytidine;manufacture,DFMC- THE PURPOSE OF THIS TASK ORDER IS TO MANUFACTURE AND DELIVER 2200 CAPSULES OF 4MG AZA-TDC (5-AZA-4-THIO-2-DEOXYCYTIDINE),0,NA,NA,NA,NA,NA,NA,NA,208675,NA
11219995,N02,HL,NA,N,NA,NA,NA,NA,75N92024D00008,NA,NA,75N92024D00008-0-759202400001-1,NHLBI:5114949\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ANN ARBOR,UNITED STATES,NA,06,073133571,US,1506502,UNIVERSITY OF MICHIGAN AT ANN ARBOR,MI,481091276,NA,79772662 (contact),"STRAUGHN, JEREMY  (contact)",NA,2024-05-15,2025-05-14,"catalyst;Cells;Contractor;Data;database of Genotypes and Phenotypes;Databases;Development;Disease;functional genomics;Funding;genome sequencing;genomic data;Goals;Heart;Hematological Disease;Informatics;Lung;Multiomic Data;National Heart, Lung, and Blood Institute;Phase;precision medicine;Process;programs;Research;Research Personnel;Resolution;Resources;Sleep Disorders;Trans-Omics for Precision Medicine;whole genome",NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) INFORMATICS RESEARCH CENTER (IRC),0,NA,NA,NA,NA,NA,NA,NA,5114949,NA
11219997,N02,HL,NA,N,NA,NA,NA,NA,75N92023D00012,NA,NA,75N92023D00012-0-759202400001-1,NHLBI:6190172\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,HOUSTON,UNITED STATES,NA,09,051113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,NA,79992314 (contact),"RIVES, MICHELLE  (contact)",NA,2024-09-23,2025-09-22,"Area;catalyst;Cells;Contractor;Contracts;cost;Data;Data Analyses;data exchange;database of Genotypes and Phenotypes;Databases;Development;Disease;follow-up;functional genomics;Funding;genome sequencing;genome-wide;genomic data;Goals;Heart;Hematological Disease;Logistics;Lung;Manuals;metabolomics;Methods;Multiomic Data;National Heart, Lung, and Blood Institute;operation;Phase;precision medicine;Process;programs;protein profiling;Protocols documentation;Publications;Research Personnel;Resolution;Resources;Sampling;Secure;Services;Sleep Disorders;Standardization;timeline;Trans-Omics for Precision Medicine;transcriptome sequencing;Update;Vendor;whole genome;Work","NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) FOR THE CENTRALIZED OMICS RESOURCE (CORE) - TASK AREAS 2, 3, AND 4 - 2024 TASK ORDER",0,NA,NA,NA,NA,NA,NA,NA,6190172,NA
11220008,N01,DA,NA,N,NA,NA,NA,NA,75N95024C00003,NA,NA,75N95024C00003-P00002-9999-3,NCI:3000000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,049508120,US,9611701,"WESTAT, INC.",MD,208503129,NA,79853241 (contact),"CARUSI, CHARLES  (contact)",NA,2024-02-01,2029-01-31,Country;Health;Longitudinal Studies;Performance;Persons;Population Assessment of Tobacco and Health;Research;Tobacco;Tobacco use;United States;United States Food and Drug Administration;United States National Institutes of Health,POPULATION ASSESSMENT OF TOBACCO AND HEALTH (PATH) STUDY PERIOD OF PERFORMANCE: 02/01/2024 - 01/31/2029,0,NA,NA,NA,NA,NA,NA,NA,3000000,NA
11220009,N01,OD,NA,N,NA,NA,NA,NA,263201800029I,NA,NA,263201800029I-0-759802400006-1,NCI:25000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,WASHINGTON,UNITED STATES,NA,98,041964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,204180007,NA,79933407 (contact),"DAY, ROBERT  (contact)",NA,2024-08-15,2026-08-14,Engineering;frontier;Science;statistics,PARTIAL SUPPORT OF THE STUDY ON FRONTIERS OF STATISTICS FOR SCIENCE AND ENGINEERING: 2035 AND BEYOND,0,NA,NA,NA,NA,NA,NA,NA,25000,NA
11220029,N02,HL,NA,N,NA,NA,NA,NA,75N92022D00013,NA,NA,75N92022D00013-0-759202400003-1,NIBIB:478706\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,HADLEY,UNITED STATES,NA,02,110907578,US,10041458,VENTUREWELL,MA,010359462,NA,79884863 (contact),"MARINO, MARK  (contact)",NA,2024-07-17,2025-07-16,Acceleration;Clinical;cohort;commercialization;Device or Instrument Development;Diagnosis;Goals;Nervous System Disorder;RADx;Resources;risk mitigation;Services;technology development;United States National Institutes of Health,RADX BLUEPRINT MEDTECH TRANSLATOR COHORT 1 - COMMERCIALIZATION CENTER,0,NA,NA,NA,NA,NA,NA,NA,478706,NA
11220041,N02,HL,NA,N,NA,NA,NA,NA,92023A00892024F00001,NA,NA,92023A00892024F00001-0-0-1,NHLBI:1085450\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ROCKVILLE,UNITED STATES,NA,08,049508120,US,9611701,"WESTAT, INC.",MD,208503129,NA,79671102 (contact),"SAVAGE, TERRY  (contact)",NA,2024-03-06,2025-03-05,"Address;Awareness;Breathing;Communication;disorder prevention;Education;Education and Outreach;Goals;Health education;Health Promotion;Learning;Lung;Lung Diseases;lung health;National Heart, Lung, and Blood Institute;outreach program;Professional Education;programs;public education;Research;Resources;Science;Services;Translating","BPA ORDER TITLED ""LUNG HEALTH EDUCATION AND OUTREACH PROGRAMS"" AGAINST THE NHLBI COMMUNICATIONS, ENGAGEMENT, AND EDUCATION SUPPORT SERVICES BPA II.",0,NA,NA,NA,NA,NA,NA,NA,1085450,NA
11220042,N02,HL,NA,N,NA,NA,NA,NA,92023A00892024F00002,NA,NA,92023A00892024F00002-0-0-1,NHLBI:1117706\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ROCKVILLE,UNITED STATES,NA,08,049508120,US,9611701,"WESTAT, INC.",MD,208503129,NA,79680524 (contact),"SAVAGE, TERRY  (contact)",NA,2024-03-14,2025-03-13,"Awareness;Cardiac health;Cause of Death;Communication;Education;Education and Outreach;Health education;Heart;Heart Diseases;National Heart, Lung, and Blood Institute;outreach program;programs;Resources;Science;Services;Women&apos;s mortality","BPA ORDER TITLED ""HEART HEALTH EDUCATION AND OUTREACH PROGRAMS"" AGAINST THE NHLBI COMMUNICATIONS, ENGAGEMENT, AND EDUCATION SUPPORT SERVICES BPA II.",0,NA,NA,NA,NA,NA,NA,NA,1117706,NA
11220043,N01,HL,NA,N,NA,NA,NA,NA,75N92024D00013,NA,NA,75N92024D00013-0-759202400004-1,NCI:1263500\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,BALTIMORE,UNITED STATES,NA,07,001910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212182680,NA,79992332 (contact),"DOHENY, KIM  (contact)",NA,2024-09-19,2027-09-08,Communities;Contracts;Disease;DNA sequencing;Genes;Genetic;Genetic Services;Genetic study;Genotype;Goals;Health;Hereditary Disease;Human;Methylation;Modification;Parents;Research;Services,HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE -EPIC METHYLATION ARRAY FOR NCI,0,NA,NA,NA,NA,NA,NA,NA,1263500,NA
11220044,N02,HL,NA,N,NA,NA,NA,NA,92023A01192024F00001,NA,NA,92023A01192024F00001-0-0-1,NHLBI:1030800\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ARLINGTON,UNITED STATES,NA,08,129842667,US,10070411,FORS MARSH GROUP LLC,VA,22203,NA,79695938 (contact),"FOLEY, NICK  (contact)",NA,2024-03-26,2025-03-25,"Address;Awareness;Blood;Clinical Trials;Communication;Disease;Education;Health;Health education;Hematological Disease;National Heart, Lung, and Blood Institute;outreach program;programs;Research;Resources;Safety;Science;Services","BPA ORDER TITLED ""BLOOD HEALTH EDUCATION AND OUTREACH PROGRAMS"" AGAINST THE NHLBI COMMUNICATIONS, ENGAGEMENT, AND EDUCATION SUPPORT SERVICES BPA II.",0,NA,NA,NA,NA,NA,NA,NA,1030800,NA
11220048,N01,HL,NA,N,NA,NA,NA,NA,75N92024D00013,NA,NA,75N92024D00013-0-759202400003-1,NCI:2556500\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,BALTIMORE,UNITED STATES,NA,07,001910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212182680,NA,79992329 (contact),"DOHENY, KIM  (contact)",NA,2024-09-19,2027-09-01,Communities;Contracts;Disease;DNA sequencing;exome sequencing;Genes;Genetic;Genetic Services;Genetic study;genome sequencing;Genotype;Goals;Health;Hereditary Disease;Human;Modification;Parents;Research;Saliva;Services;whole genome,HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE -WHOLE EXOME SEQUENCING (SALIVA); WHOLE GENOME SEQUENCING UPGRADE FOR NCI,0,NA,NA,NA,NA,NA,NA,NA,2556500,NA
11220053,N01,HL,NA,N,NA,NA,NA,NA,75N92024D00013,NA,NA,75N92024D00013-0-759202400005-1,NCI:1018995\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,BALTIMORE,UNITED STATES,NA,07,001910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212182680,NA,79992335 (contact),"DOHENY, KIM  (contact)",NA,2024-09-19,2027-09-08,Communities;Contracts;Disease;DNA sequencing;Genes;Genetic;Genetic Services;Genetic study;Genotype;Goals;Health;Hereditary Disease;Human;Methylation;Modification;Parents;Research;Services,HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE - EPIC METHYLATION ARRAY & GDA ARRAY FOR NCI,0,NA,NA,NA,NA,NA,NA,NA,1018995,NA
11220055,N01,HL,NA,N,NA,NA,NA,NA,75N92024D00013,NA,NA,75N92024D00013-0-759202400006-1,NCI:416000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,BALTIMORE,UNITED STATES,NA,07,001910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212182680,NA,79992482 (contact),"DOHENY, KIM  (contact)",NA,2024-09-20,2027-09-08,Communities;Contracts;Disease;DNA sequencing;exome sequencing;Genes;Genetic;Genetic Services;Genetic study;Genotype;Goals;Health;Hereditary Disease;Human;Modification;Parents;Research;Services,HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE -  WHOLE EXOME SEQUENCING FOR NCI,0,NA,NA,NA,NA,NA,NA,NA,416000,NA
11220056,N01,HL,NA,N,NA,NA,NA,NA,75N92024D00013,NA,NA,75N92024D00013-0-759202400007-1,NCI:72335\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,BALTIMORE,UNITED STATES,NA,07,001910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212182680,NA,79992485 (contact),"DOHENY, KIM  (contact)",NA,2024-09-20,2027-09-08,Communities;Contracts;Disease;DNA sequencing;Genes;Genetic;Genetic Services;Genetic study;Genotype;Goals;Health;Hereditary Disease;Human;Modification;Parents;Research;Services,HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE -   ILLUMINA GLOBAL DIVERSITY ARRAY FOR NCI,0,NA,NA,NA,NA,NA,NA,NA,72335,NA
11220059,N01,OD,NA,N,NA,NA,NA,NA,7316481,NA,NA,7316481-0-0-1,OD:1000000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,(contact),NA,NA,NA,Animal Experimentation;Basic Science;Complement;crowdsourcing;Disease;Funding;Human Biology;human model;innovation;Investments;Knowledge;Methodology;Modeling;novel strategies;Prize;Process;programs;Research;Standardization;Strategic Planning;Translating;United States National Institutes of Health,Complement-ARIE OD (Complement-Animal Research In Experimentation) Challenge,0,NA,NA,NA,NA,NA,NA,NA,1000000,NA
11220060,N02,HL,NA,N,NA,NA,NA,NA,75N92022D00014,NA,NA,75N92022D00014-P00001-759202300004-1,NIBIB:710924\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,BOSTON,UNITED STATES,NA,08,073130411,US,4907701,MASSACHUSETTS GENERAL HOSPITAL,MA,021142621,NA,79953712 (contact),"SCHACHTER, STEVEN C.  (contact)",NA,2023-09-07,2025-09-06,Acceleration;Area;Clinical;Collaborations;commercialization;Development;diagnostic technologies;Goals;Government;Home;Industry;innovation;Institution;Knowledge;multidisciplinary;network models;new technology;point of care;Point of Care Technology;Readiness;Research;Resources;support network;Technology;technology development;technology research and development,POCTRN SUPPORT - COORDINATION CENTER,0,NA,NA,NA,NA,NA,NA,NA,710924,NA
11220084,N01,HL,NA,N,NA,NA,NA,NA,75N92020D00021,NA,NA,75N92020D00021-P00005-759202300001-1,NIBIB:1454000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,CHICAGO,UNITED STATES,NA,01,005421136,US,1413601,UNIVERSITY OF CHICAGO,IL,606372612,NA,79977807 (contact),"GIGER, MARYELLEN  (contact)",NA,2022-12-01,2024-11-30,Acceleration;Area;Clinical;Collaborations;commercialization;data resource;Development;diagnostic technologies;Goals;Government;Home;Industry;innovation;Institution;Knowledge;Medical Imaging;multidisciplinary;network models;new technology;point of care;Point of Care Technology;Readiness;Research;Resources;Technology;technology development;technology research and development,MEDICAL IMAGING AND DATA RESOURCE CENTER (MIDRC) YEAR 3,0,NA,NA,NA,NA,NA,NA,NA,1454000,NA
11220107,N02,HL,NA,N,NA,NA,NA,NA,75N92022C00021,NA,NA,75N92022C00021-P00007-9999-1,NIBIB:207592\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,Bethesda,UNITED STATES,NA,08,617077243,US,10013742,ASSOCIATION /PUBLIC HEALTH LABORATORIES,MD,20814,NA,79656197 (contact),"GARRETT, BRIAN  (contact)",NA,2023-02-28,2025-02-27,Acceleration;Area;Clinical;Collaborations;commercialization;Development;diagnostic technologies;Goals;Government;Home;Industry;innovation;Institution;Knowledge;multidisciplinary;network models;new technology;point of care;Point of Care Technology;Readiness;Reporting;Research;Resources;Technology;technology development;technology research and development;Testing,APHL OVER THE COUNTER (OTC) TEST MESSAGE REPORTING,0,NA,NA,NA,NA,NA,NA,NA,207592,NA
11220111,N02,HL,NA,N,NA,NA,NA,NA,75N92023P00086,NA,NA,75N92023P00086-P00001-0-1,NIBIB:225599\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,HADLEY,UNITED STATES,NA,02,110907578,US,10041458,VENTUREWELL,MA,010359462,NA,79656200 (contact),"NEAL, REBEKAH  (contact)",NA,2023-03-17,2025-03-16,Acceleration;Biomedical Engineering;biomedical imaging;Biomedical Technology;Clinical;Contracts;design;Development;experience;Goals;Health;Healthcare;improved;innovation;Mission;Modality;National Institute of Biomedical Imaging and Bioengineering;novel;open-ended problem;programs;Research Support;Technology;tool;Training;undergraduate student,DEBUT CHALLENGE MANAGEMENT CONTRACT,0,NA,NA,NA,NA,NA,NA,NA,225599,NA
11220120,N02,HL,NA,N,NA,NA,NA,NA,75N92022D00015,NA,NA,75N92022D00015-0-759202400003-3,NIBIB:2297307\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ATLANTA,UNITED STATES,NA,05,066469933,US,2384501,EMORY UNIVERSITY,GA,303221007,NA,80000486 (contact),"LAM, WILBUR  (contact)",NA,2024-09-30,2026-09-29,Acceleration;Address;Alzheimer&apos;s Disease;Chronic Disease;Clinical;commercialization;Communicable Diseases;Development;Diagnostic;Fetal health;Goals;Health;Health Technology;Hepatitis B;Home;innovation;Maternal Health;Monitor;National Institute of Biomedical Imaging and Bioengineering;Nervous System Disorder;neural stimulation;new technology;point of care;prototype;RADx;sensor;Speed;Technology;technology development;technology validation;United States National Institutes of Health;Validation;verification and validation,RADX INNOVATION FUNNEL FOR HEALTH TECHNOLOGIES - VALIDATION CENTER,0,NA,NA,NA,NA,NA,NA,NA,2297307,NA
11220138,N02,HL,NA,N,NA,NA,NA,NA,75N92022D00014,NA,NA,75N92022D00014-0-759202400003-2,NIBIB:403050\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,BOSTON,UNITED STATES,NA,08,073130411,US,4907701,MASSACHUSETTS GENERAL HOSPITAL,MA,021142621,NA,80001997 (contact),"SCHACHTER, STEVEN C.  (contact)",NA,2024-09-30,2026-09-29,Acceleration;Address;Alzheimer&apos;s Disease;Chronic Disease;Clinical;commercialization;Communicable Diseases;Development;Diagnostic;Fetal health;Goals;Health;Health Technology;Hepatitis B;Home;innovation;Maternal Health;Monitor;National Institute of Biomedical Imaging and Bioengineering;Nervous System Disorder;neural stimulation;new technology;point of care;prototype;RADx;sensor;Speed;Technology;technology development;United States National Institutes of Health;Validation;verification and validation,RADX INNOVATION FUNNEL FOR HEALTH TECHNOLOGIES - COORDINATION CENTER,0,NA,NA,NA,NA,NA,NA,NA,403050,NA
11220140,N02,HL,NA,N,NA,NA,NA,NA,92023A01192024F00002,NA,NA,92023A01192024F00002-0-0-1,NHLBI:992096\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,ARLINGTON,UNITED STATES,NA,08,129842667,US,10070411,FORS MARSH GROUP LLC,VA,22203,NA,79704057 (contact),"FOLEY, NICK  (contact)",NA,2024-04-01,2025-03-31,"Address;Awareness;Breathing;Communication;disorder prevention;Education;Goals;Health education;Health Promotion;Learning;Lung;Lung Diseases;lung health;Mission;National Heart, Lung, and Blood Institute;Professional Education;programs;public education;Research;Resources;Science;Services;Translating","BPA ORDER TITLED ""EXTERNAL ENGAGEMENTS AND PARTNERSHIPS IN SUPPORT OF THE NHLBI MISSION"" AGAINST THE NHLBI COMMUNICATIONS, ENGAGEMENT, AND EDUCATION SUPPORT SERVICES BPA II.",0,NA,NA,NA,NA,NA,NA,NA,992096,NA
11220152,N02,HL,NA,N,NA,NA,NA,NA,75N92022D00013,NA,NA,75N92022D00013-0-759202400004-2,NIBIB:5877947\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,HADLEY,UNITED STATES,NA,02,110907578,US,10041458,VENTUREWELL,MA,010359462,NA,80002102 (contact),"MARINO, MARK  (contact)",NA,2024-09-30,2026-09-29,Acceleration;Address;Alzheimer&apos;s Disease;Chronic Disease;Clinical;commercialization;Communicable Diseases;Development;Diagnostic;Fetal health;Goals;Health;Health Technology;Hepatitis B;Home;innovation;Maternal Health;Monitor;National Institute of Biomedical Imaging and Bioengineering;Nervous System Disorder;neural stimulation;new technology;point of care;RADx;Resources;sensor;Services;Speed;Technology;technology development;United States National Institutes of Health,RADX INNOVATION FUNNEL FOR HEALTH TECHNOLOGIES - COMMERCIALIZATION CENTER,0,NA,NA,NA,NA,NA,NA,NA,5877947,NA
11220153,R01,CA,7,N,2024-12-02,2024-07-01,2025-04-30,393,R01CA278818,SCHOOLS OF MEDICINE,PAR-20-131,7R01CA278818-02,NCI:481069\,NON-SBIR/STTR RPGS,2024,NATIONAL CANCER INSTITUTE,NA,EAST LANSING,UNITED STATES,BIOCHEMISTRY,07,NA,US,10071230,HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES,MI,488242600,"Narrative We aim to inhibit tumor growth and prevent disease recurrence by blocking the molecules that facilitate cancer development. We will find these molecules in genetically engineered mice that resemble humans in their cancer development to allow for mapping of cancer facilitating molecules. We will test if blocking LILRB4, the first candidate molecule we found and verified with human cancer data, will boost immune response and inhibit tumor growth.",7987579 (contact);11704729,"JACOB, JENNIFER B (contact);KIDDER, BENJAMIN L","GUNASEKHARAN, VIGNESH KUMAR",2024-03-01,2029-04-30,Acceleration;Active Immunization;Age of Onset;Algorithms;Antibodies;Antigen Presentation;Antigen-Presenting Cells;Atlas of Cancer Mortality in the United States;Binding;bioinformatics pipeline;Biological Assay;Biological Process;Breeding;Cancer Intervention;Cancer Patient;cancer risk;cancer survival;Cancer Vaccines;Candidate Disease Gene;candidate identification;carcinogenesis;Cell Line;Cells;Chromosomes;Clinical;Clinical Trials;Code;Data;Data Set;Development;disorder control;DNA;Enhancers;Equilibrium;ERBB2 gene;Fatty acid glycerol esters;Foundations;functional genomics;Gene Expression;Gene Expression Profile;Genes;Genetic;genetic linkage analysis;Genetic Polymorphism;Genetically Engineered Mouse;Genome;genome wide association study;Genotype;Goals;Growth;Haplotypes;Human;Immune;immune activation;Immune response;Individual;Intercistronic Region;Intervention;Knock-out;Laboratories;Length;Malignant Breast Neoplasm;Malignant neoplasm of lung;Malignant Neoplasms;mammary;Mammary Neoplasms;Measures;Modeling;Monoclonal Antibody Therapy;mosaic;Mus;Mutation;Myelogenous;Myeloid Cells;Natural Killer Cells;neoplastic cell;Normal Cell;Oncogenes;Open Reading Frames;Outcome;Pathway Analysis;Phenotype;prevent;Production;Proteins;Quantitative Trait Loci;Rattus;Reagent;Recurrent disease;Regulator Genes;risk variant;Role;Signal Transduction;single-cell RNA sequencing;T-Lymphocyte;Testing;Tissue-Specific Gene Expression;transcription factor;transcriptomics;Transgenic Mice;Translational Research;tumor;Tumor Antigens;Tumor Expansion;tumor growth;Tumor Immunity;tumor microenvironment;tumor progression;Tumor Suppressor Genes;vaccine response,Defining Cancer Intervention Targets by Functional Genomics Analysis of Outbred F1 Mice,278818,ZRG1,Special Emphasis Panel[ZRG1-CTH-E(55)R],NA,NA,2,436495,44574,481069,NA
11220169,R01,NS,7,N,2025-01-14,2024-10-25,2025-02-28,853,R01NS112363,SCHOOLS OF ARTS AND SCIENCES,PA-24-254,7R01NS112363-06,NINDS:200000\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,NA,Chicago,UNITED STATES,BIOCHEMISTRY,05,160079455,US,6144601,NORTHWESTERN UNIVERSITY,IL,606114579,"PROJECT NARRATIVE Calcium homeostasis modulators (CALHMs) constitute a family of nonselective ion channels that are permeable to the signaling molecules calcium and ATP; they are thus critically involved in calcium and purinergic signaling. The proposed study focuses on uncovering the oligomeric state, multichannel assembly, molecular structure, gating mechanism, and pharmacology of the CALHMs, taking advantage of single- particle cryo-EM, electrophysiology, and other functional approaches. The proposed research is relevant to public health and NIH's mission because this work will provide a deep understanding and broaden our knowledge of the relationships between atomic structures and the complex biological and pathological functions of CALHMs, paving the way for the development of therapeutics to treat neurological diseases including Alzheimer disease, ischemic brain damage, and depression.",15370491 (contact),"LU, WEI  (contact)","UMANAH, GEORGE KWABENA ESSIEN",2024-10-25,2025-02-28,NA,Structural and functional studies of CALHM channels,112363,BPNS,Biophysics of Neural Systems Study Section[BPNS],NA,NA,6,125000,75000,200000,NA
11220188,P20,GM,5,N,2024-07-17,2024-06-01,2025-05-31,NA,P20GM135007,NA,PAR-18-266,5P20GM135007-05,NIGMS:214500\,RESEARCH CENTERS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,BURLINGTON,UNITED STATES,NA,00,066811191,US,8738101,UNIVERSITY OF VERMONT & ST AGRIC COLLEGE,VT,054051704,NA,16411474 (contact);1862921,"ADRIANZEN HERRERA, DIEGO  (contact);NELSON, MARK T","BERNAL, FEDERICO",2024-06-01,2025-05-31,Address;Area;Biological;Biological Assay;Biological Markers;brain health;Cancer Etiology;Cardiovascular Diseases;cardiovascular disorder risk;cardiovascular health;Cardiovascular Models;Cardiovascular system;Cause of Death;Cells;Clinical;Clinical Data;clinical practice;Clinical Research;cohort;Dysmyelopoietic Syndromes;Enrollment;epidemiology study;Future;Goals;Hematologic Neoplasms;Hematopoietic;Hospitals;improved;Inflammation;Inflammatory;interest;Life;Link;Measures;Mediating;Medical center;Medicare;Modeling;Molecular Epidemiology;Morbidity - disease rate;mortality;mortality risk;Mutation;new technology;Observational Study;Patients;Persons;Pilot Projects;Population;predictive tools;Preventive;Procedures;Proteins;Proteome;Proteomics;recruit;Registries;Research;Research Design;Risk;Risk Assessment;Risk Factors;risk prediction;SEER Program;Source;Statistical Data Interpretation;Time;Translating;Translational Research;Universities;Variant;vascular inflammation;Vermont,Risk Prediction and Inflammatory Biomarkers of Cardiovascular Disease in Myelodysplastic Syndrome,135007,ZGM1,ZGM1-RCB-3(C1),5409,NA,5,137500,77000,NA,214500
11220233,N01,OD,NA,N,NA,NA,NA,NA,NHD23002001_24-2388,NA,NA,NHD23002001_24-2388-0-0-1,OD:95000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,(contact),NA,NA,NA,Adoptive Cell Transfers;Affinity;Agreement;antigen binding;antigen-specific T cells;Antigens;Autoimmunity;autoreactivity;Award;Back;bench to bedside;Binding;cancer therapy;CD3 Antigens;CD4 Positive T Lymphocytes;CD8-Positive T-Lymphocytes;Cell Physiology;Cell Surface Receptors;Clinical;Clinical Investigator;Clinical Research;Clinical Trials;clinically relevant;Collaborations;Community Health;Complex;Conserved Sequence;cross reactivity;Cytoplasmic Tail;Cytotoxic T-Lymphocytes;Data;Dependence;design;Discrimination;education research;engineered T cells;expectation;Experimental Models;Extramural Activities;Funding;Funding Opportunities;Gene Expression Profile;Growth;Human;Human Activities;humanized mouse;improved;in vivo;innovation;ITAM;Ligand Binding;Ligands;Love;Major Histocompatibility Complex;Malignant Neoplasms;Mediating;Methods;Modality;Modification;mouse model;Mus;mutant;National Institute of Child Health and Human Development;neoantigens;neoplasm immunotherapy;novel;novel strategies;outreach;Peptides;Phenotype;pre-clinical;Principal Investigator;programs;Proteins;receptor;receptor binding;Receptor Signaling;Reporter;Research Project Grants;Research Support;response;Role;Scientist;Services;Signal Transduction;Single Nucleotide Polymorphism;T cell response;T Chain;T-Cell Activation;T-Cell Receptor;T-Lymphocyte;Testing;Toxic effect;Translational Research;Treatment Efficacy;Treatment Protocols;tumor;Tumor Antigens;tumor infiltrating lymphocyte therapy;Tumor-Infiltrating Lymphocytes;Tyrosine;United States National Institutes of Health;Validation;Work,INTER-AGENCY SERVICE (NIH),0,NA,NA,NA,NA,NA,NA,NA,95000,NA
11220234,K01,HD,7,N,2025-01-24,2024-08-15,2025-03-31,865,K01HD112541,SCHOOLS OF PUBLIC HEALTH,PA-24-254,7K01HD112541-02,NICHD:92341\,OTHER RESEARCH-RELATED,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,NASHVILLE,UNITED STATES,NONE,07,041438185,US,5050201,MEHARRY MEDICAL COLLEGE,TN,372083501,"PROJECT NARRATIVE Annually, almost 8 million1 children are reported to child protective services for potential maltreatment; given the significant individual and societal costs of child maltreatment (CM), it is critical to develop programs to prevent and reduce its recurrence. The proposed project aims to adapt an online educational intervention to equip parents and primary caregivers with a better understanding of what qualifies as CM, strategies to reduce their child’s risk of CM from other adults, and skills to improve parent competency to manage their child’s difficult behavior, to thereby reduce children’s risk of CM. The intervention will adapt existing content and leverage innovative training methodologies from iLookOut, an evidence-based, online training2–4; the proposed intervention will incorporate input from end-users at all stages of development and implementation to ensure feasibility, usefulness, and implementation success.",78488919 (contact),"BARNETT, WHITNEY CHRISTINE (contact)","GILBERT, LEAH KAYE",2024-08-15,2029-03-31,NA,Adapting a web based parent training to reduce child maltreatment,112541,CHHD,"Health, Behavior, and Context Study Section[CHHD-M]",NA,NA,2,85501,6840,92341,NA
11220283,N02,DA,NA,N,NA,NA,NA,NA,75N95024D00006,NA,NA,75N95024D00006-0-759502400002-1,NCATS:350000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NORTH BETHESDA,UNITED STATES,NA,08,020277339,US,10047839,"AXLE INFORMATICS, LLC",MD,208524931,NA,79730423 (contact),"MAYS, GARY  (contact)",NA,2024-02-01,2024-05-31,Agreement;base;Clinical and Translational Science Awards;common rule;Communication;Communities;Contracts;Documentation;Funding;human subject;human subject protection;Institution;Institutional Review Boards;Mediation;National Center for Advancing Translational Sciences;prevent;Process;programs;Research;Services;Site;System;United States National Institutes of Health;Universities;user-friendly,BASE CONTRACT TITLE:  NCATS SCIENTIFIC AND TECHNICAL SUPPORT SERVICES (STSS) 2.5.TASK ORDER TITLE: SMART IRB ONLINE RELIANCE SYSTEM (ORS) AND JOINDER ENHANCEMENTS.,0,NA,NA,NA,NA,NA,NA,NA,350000,NA
11220287,N02,DA,NA,N,NA,NA,NA,NA,95023A00195024F00013,NA,NA,95023A00195024F00013-0-0-1,NCATS:12038222\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NORTH BETHESDA,UNITED STATES,NA,08,020277339,US,10047839,"AXLE INFORMATICS, LLC",MD,208524931,NA,80003720 (contact),"MAYS, GARY  (contact)",NA,2024-09-30,2025-09-29,analytical tool;Area;Clinical and Translational Science Awards;Clinical Data;Clinical Research;cloud based;cohort;Collaborations;Communities;Complex Analysis;Contracts;COVID-19;COVID-19 patient;Data;Data Analyses;Data Collection;data enclave;data harmonization;data platform;Data Science;Data Set;Electronic Health Record;Environment;genetic variant;Genomics;Health;Image;Informatics;Information Technology;Ingestion;meetings;multimodal data;National Center for Advancing Translational Sciences;open source;open source tool;Pathology;Privacy;Productivity;programs;protective factors;Pythons;Radiology Specialty;Research;Research Personnel;Risk Factors;Scientist;Secure;Security;Services;Statistical Data Interpretation;synthetic data;tool;United States;United States National Institutes of Health;Viral;virtual;Visualization;Work,NATIONAL CLINICAL DATA COLLABORATIVE COUNTS (NACDACC),0,NA,NA,NA,NA,NA,NA,NA,12038222,NA
11220289,N02,LM,NA,N,NA,NA,NA,NA,75N97023F00096,NA,NA,75N97023F00096-P00001-0-3,OD:750000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL LIBRARY OF MEDICINE,NA,MCLEAN,UNITED STATES,NA,11,838829794,US,10088013,"A-TEK, INC.",VA,221023022,NA,NA,(contact),NA,2024-09-28,2025-09-27,NA,SYSTEM ADMINISTRATION AND MANAGEMENT SUPPORT FOR BIOMEDICAL AND BIBLIOGRAPHIC INFORMATION RESOURCES,0,NA,NA,NA,NA,NA,NA,NA,750000,NA
11220304,N44,DA,NA,N,NA,NA,NA,NA,75N95024C00010,NA,NA,75N95024C00010-0-9999-1,NCATS:2000000\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,Newton,UNITED STATES,NA,04,802270988,US,10015346,"BIOSENSICS, LLC",MA,024581080,NA,79772873 (contact),"VAZIRI, ASHKAN  (contact)",NA,2024-05-20,2026-05-19,Activities of Daily Living;Clinical;Clinical Trials;cognitive function;Conduct Clinical Trials;Data;data platform;Decentralization;Development;Disease;Electronics;Enrollment;Exclusion;Home;improved;Individual;Measurement;mobile computing;Monitor;Motor;multimodality;Participant;Rare Diseases;Secure;sensor;Site;Source;Speech;study population;Study Subject;Technology;Testing;Translational Research;virtual,BIOSENSICS LLC:1186749 [24-003492],0,NA,NA,NA,NA,NA,NA,NA,2000000,NA
11220307,N43,DA,NA,N,NA,NA,NA,NA,75N95024C00023,NA,NA,75N95024C00023-0-9999-1,NCATS:325000\,SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,080171702,US,10064933,"ON DEMAND PHARMACEUTICALS, INC.",MD,20850,NA,79956415 (contact),"MCQUADE, TYLER  (contact)",NA,2024-09-24,2025-06-23,analog;Animals;Chemicals;Chemistry;Development;Devices;Engineering;innovation;manufacturing capabilities;manufacturing systems;Operations Research;Pharmacologic Substance;Phase;Preclinical Drug Development;Research;scale up;Small Business Innovation Research Grant;Speed;Time;tool,SMALL MANUFACTURING SYSTEMS TO PRODUCE RESEARCH GRADE PHARMACEUTICAL INTERMEDIATES-DIVERSITY ON DEMAND- SBIR PHASE 1 TOPIC 024,0,NA,NA,NA,NA,NA,NA,NA,325000,NA
11220311,N02,DA,NA,N,NA,NA,NA,NA,75N95024F00144,NA,NA,75N95024F00144-0-0-1,NCATS:1496698\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,LEAVENWORTH,UNITED STATES,NA,NA,828579644,US,NA,NA,KS,660482816,NA,79963969 (contact),"CROUSE, ANDY  (contact)",NA,2024-09-29,2025-09-28,Address;Adverse event;Biological;Biomedical Research;Cell Physiology;Clinical;Clinical Trials;Data;Data Sources;data translator;Development;Disease;Drug Design;Functional disorder;Health;health record;insight;interoperability;Location;Molecular;n-dimensional;National Center for Advancing Translational Sciences;Patients;Persons;Pharmaceutical Preparations;programs;Reporting;Scientific Advances and Accomplishments;Signs and Symptoms,BIOMEDICAL DATA TRANSLATOR USER INTERFACE DEVELOPMENT,0,NA,NA,NA,NA,NA,NA,NA,1496698,NA
11220317,N01,CA,NA,N,NA,NA,NA,NA,75N91019D00024,NA,NA,75N91019D00024-0-759102400011-28,NCATS:420000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,FREDERICK,UNITED STATES,NA,06,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,NA,79478801 (contact),"BRISCOE, LYNN  (contact)",NA,2024-09-28,2025-08-30,Address;Biodistribution;Biological Assay;Biomedical Computing;Biomedical Research;Canis familiaris;Cells;Clinical;Clinical Trials;comparative;Computational Science;coronavirus pandemic;COVID-19;Data Analyses;data integration;data resource;Development;Drug Kinetics;efficacy study;Electron Microscopy;Gene Expression;Image;Laboratory Animals;manufacture;Methods;novel coronavirus;Oncology;Pharmaceutical Preparations;pre-clinical;Proteomics;Public Health;Rare Diseases;screening;Serology test;Services;Standardization;therapeutic development;Translational Research;Validation,THE COVID 19 SERVICES CATALYZE TRANSLATIONAL RESEARCH FINDINGS INTO PUBLIC HEALTH CHANGES TO ADDRESS THE NOVEL CORONAVIRUS PANDEMIC THROUGH IMPLEMENTATION OF STANDARDIZED SEROLOGY TESTING FOR ITS INTE,0,NA,NA,NA,NA,NA,NA,NA,420000,NA
11220334,N02,DA,NA,N,NA,NA,NA,NA,95023A00195024F00015,NA,NA,95023A00195024F00015-0-0-1,NCATS:3152339\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NORTH BETHESDA,UNITED STATES,NA,08,020277339,US,10047839,"AXLE INFORMATICS, LLC",MD,208524931,NA,80003723 (contact),"MAYS, GARY  (contact)",NA,2024-09-30,2024-11-29,analytical tool;Area;Clinical and Translational Science Awards;Clinical Research;cloud based;cohort;Collaborations;Communities;Complex Analysis;Contracts;COVID-19;COVID-19 patient;Data;Data Analyses;Data Collection;data enclave;data harmonization;data platform;Data Science;Data Set;Electronic Health Record;Environment;genetic variant;Genomics;Health;Image;Informatics;Information Technology;Ingestion;meetings;multimodal data;National Center for Advancing Translational Sciences;open source;open source tool;Pathology;Privacy;Productivity;programs;protective factors;Pythons;Radiology Specialty;Research;Research Personnel;Risk Factors;Scientist;Secure;Security;Services;Statistical Data Interpretation;synthetic data;Technology;tool;United States;United States National Institutes of Health;Viral;virtual;Visualization;Work,NCATS SCIENTIFIC AND TECHNOLOGY SUPPORT SERVICES (STSS),0,NA,NA,NA,NA,NA,NA,NA,3152339,NA
11220337,N02,DA,NA,N,NA,NA,NA,NA,95023A00195024F00010,NA,NA,95023A00195024F00010-0-0-1,NCATS:1603808\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NORTH BETHESDA,UNITED STATES,NA,08,020277339,US,10047839,"AXLE INFORMATICS, LLC",MD,208524931,NA,79893885 (contact),"COLLINS, JACK  (contact)",NA,2024-07-18,2024-10-17,analytical tool;Area;Clinical and Translational Science Awards;Clinical Research;cloud based;cohort;Collaborations;Communities;Complex Analysis;Contracts;COVID-19;COVID-19 patient;Data;Data Analyses;Data Collection;data enclave;data harmonization;data platform;Data Science;Data Set;Electronic Health Record;Environment;genetic variant;Genomics;Health;Image;Informatics;Information Technology;Ingestion;meetings;multimodal data;National Center for Advancing Translational Sciences;open source;open source tool;operation;Pathology;Privacy;Productivity;programs;protective factors;Pythons;Radiology Specialty;Research;Research Personnel;Risk Factors;Scientist;Secure;Security;Services;Statistical Data Interpretation;synthetic data;tool;United States;United States National Institutes of Health;Viral;virtual;Visualization;Work,BO 011 - UNA OPERATIONS AND TECHNICAL SUPPORT SERVICES (OTSS),0,NA,NA,NA,NA,NA,NA,NA,1603808,NA
11220338,N02,DA,NA,N,NA,NA,NA,NA,75N95024D00006,NA,NA,75N95024D00006-P00001-759502400001-1,NCATS:10367151\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NORTH BETHESDA,UNITED STATES,NA,08,020277339,US,10047839,"AXLE INFORMATICS, LLC",MD,208524931,NA,79644847 (contact),"MAYS, GARY  (contact)",NA,2024-02-08,2024-05-31,analytical tool;Area;Clinical and Translational Science Awards;Clinical Research;cloud based;cohort;Collaborations;Communities;Complex Analysis;Contracts;COVID-19;COVID-19 patient;Data;Data Analyses;Data Collection;data enclave;data harmonization;data platform;Data Science;Data Set;Electronic Health Record;Environment;genetic variant;Genomics;Health;Image;Informatics;Information Technology;Ingestion;meetings;multimodal data;National Center for Advancing Translational Sciences;open source;open source tool;Pathology;Privacy;Productivity;programs;protective factors;Pythons;Radiology Specialty;Research;Research Personnel;Risk Factors;Scientist;Secure;Security;Services;Statistical Data Interpretation;synthetic data;tool;United States;United States National Institutes of Health;Viral;virtual;Visualization;Work,TO1 - STSS PROGRAM SUPPORT 1.0,0,NA,NA,NA,NA,NA,NA,NA,10367151,NA
11220340,N02,DA,NA,N,NA,NA,NA,NA,75N95024D00006,NA,NA,75N95024D00006-P00001-759502400001-2,NCATS:6500000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NORTH BETHESDA,UNITED STATES,NA,08,020277339,US,10047839,"AXLE INFORMATICS, LLC",MD,208524931,NA,79644847 (contact),"MAYS, GARY  (contact)",NA,2024-02-08,2024-05-31,analytical tool;cloud based;Environment;Information Systems;open source;Productivity;Rare Diseases;Services;tool,TO1 - STSS PROGRAM SUPPORT 1.0,0,NA,NA,NA,NA,NA,NA,NA,6500000,NA
11220343,N02,DA,NA,N,NA,NA,NA,NA,75N95023D00001,NA,NA,75N95023D00001-P00001-759502400001-1,NCATS:5000000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NORTH BETHESDA,UNITED STATES,NA,08,020277339,US,10047839,"AXLE INFORMATICS, LLC",MD,208524931,NA,79559013 (contact),"MAYS, GARY  (contact)",NA,2023-11-27,2024-02-29,analytical tool;Architecture;cloud based;Environment;Extramural Activities;National Center for Advancing Translational Sciences;open source;Productivity;programs;Security;Services;tool;Trust,STSS PROGRAM SUPPORT 5.0,0,NA,NA,NA,NA,NA,NA,NA,5000000,NA
11220344,N02,DA,NA,N,NA,NA,NA,NA,75N95024D00006,NA,NA,75N95024D00006-P00001-759502400001-3,NCATS:3000000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NORTH BETHESDA,UNITED STATES,NA,08,020277339,US,10047839,"AXLE INFORMATICS, LLC",MD,208524931,NA,79644847 (contact),"MAYS, GARY  (contact)",NA,2024-02-08,2024-05-31,analytical tool;Architecture;cloud based;Environment;Extramural Activities;National Center for Advancing Translational Sciences;open source;Productivity;programs;Security;Services;tool;Trust,TO1 - STSS PROGRAM SUPPORT 1.0,0,NA,NA,NA,NA,NA,NA,NA,3000000,NA
11220345,N02,DA,NA,N,NA,NA,NA,NA,95023A00195024F00015,NA,NA,95023A00195024F00015-0-0-2,NCATS:2339348\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NORTH BETHESDA,UNITED STATES,NA,08,020277339,US,10047839,"AXLE INFORMATICS, LLC",MD,208524931,NA,80003723 (contact),"MAYS, GARY  (contact)",NA,2024-09-30,2024-11-29,analytical tool;Architecture;cloud based;Environment;Extramural Activities;National Center for Advancing Translational Sciences;open source;Productivity;programs;Security;Services;Technology;tool;Trust,NCATS SCIENTIFIC AND TECHNOLOGY SUPPORT SERVICES (STSS),0,NA,NA,NA,NA,NA,NA,NA,2339348,NA
11220347,N01,DA,NA,N,NA,NA,NA,NA,75N95024C00012,NA,NA,75N95024C00012-0-9999-1,NCATS:645500\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,MILWAUKEE,UNITED STATES,NA,04,NA,US,10083870,EVERSANA LIFE SCIENCE SERVICES LLC,WI,532026013,NA,79761704 (contact),"RUSSO, PIERANTONIO  (contact)",NA,2024-05-03,2024-09-29,Healthcare Systems;Patients;programs;Rare Diseases;Research Support;Services,"CUSTOMER VALUE PARTNERS, INC.:1213137 [24-000129]",0,NA,NA,NA,NA,NA,NA,NA,645500,NA
11220348,N02,DA,NA,N,NA,NA,NA,NA,75N95024C00041,NA,NA,75N95024C00041-0-9999-1,NCATS:874750\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,MILWAUKEE,UNITED STATES,NA,04,NA,US,10083870,EVERSANA LIFE SCIENCE SERVICES LLC,WI,532026013,NA,79992073 (contact),"NATHAN, RAMAA  (contact)",NA,2024-09-30,2025-09-29,Biological Sciences;Healthcare Systems;Patients;programs;Rare Diseases;Research Support;Services,EVERSANA LIFE SCIENCE SERVICES LLC:1466808 [24-007681],0,NA,NA,NA,NA,NA,NA,NA,874750,NA
11220353,N01,DA,NA,N,NA,NA,NA,NA,271201800010I,NA,NA,271201800010I-0-759502400001-1,NCATS:105670\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,COLUMBIA,UNITED STATES,NA,03,963442723,US,4416001,"A AND G PHARMACEUTICAL, INC.",MD,210452006,NA,79680517 (contact),"KOSOWSKY, AKIVA  (contact)",NA,2024-03-18,2025-03-17,Cell Line;Congenital Myasthenic Syndromes;drug candidate;Drug Kinetics;gene therapy;Generations;Human;immunogenicity;method development;Monoclonal Antibodies;National Center for Advancing Translational Sciences;polyclonal antibody;Toxicokinetics,TASK ORDER 7 - DOK7,0,NA,NA,NA,NA,NA,NA,NA,105670,NA
11220354,N02,DA,NA,N,NA,NA,NA,NA,75N95024P00481,NA,NA,75N95024P00481-0-0-1,NCATS:183092\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,WESTBURY,UNITED STATES,NA,NA,013375885,US,NA,NA,NY,115905034,NA,79955973 (contact),"TAYLOR, ANDREW  (contact)",NA,2024-09-02,2025-02-28,Services;tumor,"TRANSPORTER SUBSTRATE ASSESSMENT STUDY, SERVICES",0,NA,NA,NA,NA,NA,NA,NA,183092,NA
11220359,ZIA,AI,1,N,NA,NA,NA,NA,ZIAAI001257,NA,NA,1ZIAAI001257-05,NIAID:910285\,INTRAMURAL RESEARCH,2024,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,NA,NA,NA,77880651 (contact),"SPARKS, RACHEL  (contact)",NA,NA,NA,accurate diagnosis;Affect;Cell Line;Cells;Clinical;Clinical Data;Clinical Management;clinically actionable;clinically significant;cytokine;Data;data integration;Defect;Diagnosis;Diagnostic;diagnostic strategy;diagnostic tool;Disease;disease classification;disease diagnosis;Etiology;Evaluation;experience;Frequencies;Future;Gene Expression;Generations;genetic disorder diagnosis;Genetic Predisposition to Disease;Goals;Guidelines;Immune;Immune system;Immune System Diseases;immunodeficiency;Immunologics;Immunology;improved;Individual;Knowledge;Malignant Neoplasms;Measures;Medical;Modeling;Molecular;Morbidity - disease rate;mortality;multiple data types;new technology;novel;Organism;Pathologic;Patients;personalized approach;Phenotype;Process;Proteins;Research;RNA;sample collection;System;Systems Biology;Techniques;technology development;therapeutic target;Transcript;transcriptome sequencing;Work,Sample collection for systems evaluation of patients with unknown or incompletely characterized immune defects,1257,NA,NA,NA,NA,5,NA,NA,910285,NA
11220386,Y01,ES,NA,N,NA,NA,NA,NA,AES24003001,NA,NA,AES24003001-1-0-1,NIEHS:659000\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,NA,NA,NA,(contact),NA,NA,NA,Agreement;Artificial Intelligence;Clinical Pathology;Data;Development;Environmental Health;Gene Expression;GENIE;health data;Histopathology;Informatics;Laboratories;Methods;Modeling;models and simulation;National Institute of Environmental Health Sciences;Organ;Public Health;research and development;Research Support;Resources;Software Tools;Tissues;Toxicology,Development of Artificial Intelligence to Support the Division of Translational Toxicology​,240030,NA,NA,NA,NA,NA,NA,NA,659000,NA
11220390,Y01,ES,NA,N,NA,NA,NA,NA,AES24001001,NA,NA,AES24001001-1-0-1,NIEHS:2379140\,INTERAGENCY AGREEMENTS,2024,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,NA,NA,NA,NA,(contact),NA,NA,NA,NA,INTERAGENCY AGREEMENT Between NATIONAL INSTITUTES OF HEALTH NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES and US FOOD AND DRUG ADMINISTRATION NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH,240010,NA,NA,NA,NA,NA,NA,NA,2379140,NA
11220480,R01,AG,7,N,2024-11-08,2024-11-01,2025-05-31,866,R01AG072753,NA,PA-20-185,7R01AG072753-05,NIA:953788\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE ON AGING,NA,NEW YORK,UNITED STATES,NA,13,621889815,US,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NY,100323725,"Project Narrative Alzheimer’s Disease (AD) poses an increasingly large public health burden. By providing new insights into the role of neuroinflammation in AD, this study will provide the foundation for future advances in prognostication and targeted anti-inflammatory therapies for this devastating disease.",11287075 (contact);8872567,"GUPTA, AJAY  (contact);RAJ, ASHISH","OPANASHUK, LISA A",2021-09-01,2026-05-31,"Address;Affinity;Age;Aging;Alzheimer&apos;s Disease;Alzheimer&apos;s disease model;Alzheimer&apos;s disease pathology;Alzheimer’s disease biomarker;Amyloid;animal data;Anti-Inflammatory Agents;Atrophic;Biological;Biological Markers;Biological Models;Brain;brain magnetic resonance imaging;Cerebrospinal Fluid;Clinical;clinical application;clinical heterogeneity;Cognition;Cognitive;Computer Models;Dementia;density;Diagnosis;Diagnostic;Diffusion;Disease;disease model;disease phenotype;Disease Progression;Education;Etiology;follow-up;Foundations;Functional disorder;Future;Generations;genetic risk factor;glial activation;Glucose;Goals;Human;Image;imaging study;in vivo;Inflammation;Inflammatory;inflammatory marker;insight;Investigation;Kinetics;Laboratories;Ligands;Linear Models;Longitudinal cohort;longitudinal, prospective study;Machine Learning;Magnetic Resonance Imaging;mathematical model;Measures;Mediating;Mediation;Microglia;model design;Modeling;Modernization;Nerve Degeneration;Neurofibrillary Tangles;neuroinflammation;neuron loss;neurotransmission;novel;older adult;Pathogenesis;Pathologic;Pathology;Patients;Pattern;Positron-Emission Tomography;predictive modeling;predictive test;prognostication;Property;Protocols documentation;Public Health;Race;Research;Role;Science;Senile Plaques;Series;Serum;sex;Signal Transduction;spatiotemporal;Specificity;Speed;Statistical Models;systemic inflammatory response;tau aggregation;tau interaction;tau mutation;tau Proteins;Testing;Time;tractography;transmission process;TREM2 gene;Visit",Understanding the dynamic interactions between tau pathology and microgliamediated inflammation in Alzheimer's Disease,72753,ZRG1,Special Emphasis Panel[ZRG1-ETTN-J(02)M],NA,NA,5,852674,101114,953788,NA
11220535,N02,CA,NA,N,NA,NA,NA,NA,261201800020I,NA,NA,261201800020I-0-759102400001-1,NCI:7553399\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,DETROIT,UNITED STATES,NA,13,073134603,US,218602,HENRY FORD HEALTH SYSTEM,MI,482023450,NA,80001796 (contact),"RYBICKI, BENJAMIN  (contact)",NA,2024-09-27,2025-09-19,Affect;Behavior;Cancer Etiology;cancer prevention;cancer risk;Collection;Consent;Contracts;Goals;Health;Healthcare;Institution;Participant;Patient Recruitments;Pattern;prevent;recruit;research study;Surveys,CONNECT TASK ORDER 8,0,NA,NA,NA,NA,NA,NA,NA,7553399,NA
11220536,N02,CA,NA,N,NA,NA,NA,NA,261201800021I,NA,NA,261201800021I-0-759102400001-1,NCI:4979276\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,Oakland,UNITED STATES,NA,12,150829349,US,3497005,KAISER FOUNDATION RESEARCH INSTITUTE,CA,946123610,NA,79992302 (contact),"FIEGLESON, HEATHER  (contact)",NA,2024-09-20,2025-09-19,Affect;Behavior;Cancer Etiology;cancer prevention;cancer risk;Collection;Consent;Contracts;Goals;Health;Healthcare;Institution;Participant;Patient Recruitments;Pattern;prevent;recruit;research study;Surveys,CONNECT TASK ORDER 8,0,NA,NA,NA,NA,NA,NA,NA,4979276,NA
11220548,N02,CA,NA,N,NA,NA,NA,NA,261201800022I,NA,NA,261201800022I-0-759102400001-1,OD:317650\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,SIOUX FALLS,UNITED STATES,NA,00,050113252,US,10014066,SANFORD RESEARCH/USD,SD,571040569,NA,80001799 (contact),"CHUN-HUNG, CHAN  (contact)",NA,2024-09-27,2025-09-19,Affect;Behavior;Cancer Etiology;cancer prevention;cancer risk;Collection;Consent;Contracts;Goals;Health;Healthcare;Institution;Participant;Patient Recruitments;Pattern;prevent;recruit;research study;Surveys,CONNECT TASK ORDER 8,0,NA,NA,NA,NA,NA,NA,NA,317650,NA
11220549,N02,CA,NA,N,NA,NA,NA,NA,261201800022I,NA,NA,261201800022I-0-759102400001-2,NCI:277290\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,SIOUX FALLS,UNITED STATES,NA,00,050113252,US,10014066,SANFORD RESEARCH/USD,SD,571040569,NA,80001799 (contact),"CHUN-HUNG, CHAN  (contact)",NA,2024-09-27,2025-09-19,Affect;Behavior;Cancer Etiology;cancer prevention;cancer risk;Collection;Consent;Contracts;Goals;Health;Healthcare;Institution;Participant;Patient Recruitments;Pattern;prevent;recruit;research study;Surveys,CONNECT TASK ORDER 8,0,NA,NA,NA,NA,NA,NA,NA,277290,NA
11220550,N02,CA,NA,N,NA,NA,NA,NA,261201800023I,NA,NA,261201800023I-P00001-759102400001-1,NCI:200000\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,CHICAGO,UNITED STATES,NA,01,005421136,US,1413601,UNIVERSITY OF CHICAGO,IL,606372612,NA,80001989 (contact),"AHSAN, HABIBUL  (contact)",NA,2024-09-20,2025-09-19,Affect;Behavior;Cancer Etiology;cancer prevention;cancer risk;Collection;Consent;Contracts;Goals;Health;Healthcare;Institution;Participant;Patient Recruitments;Pattern;prevent;recruit;research study;Surveys,CONNECT TASK ORDER 8,0,NA,NA,NA,NA,NA,NA,NA,200000,NA
11220592,N01,CA,NA,N,NA,NA,NA,NA,261201700012I,NA,NA,261201700012I-P00002-759102200002-1,NCI:608967\,NON SBIR/STTR CONTRACTS,2024,NATIONAL CANCER INSTITUTE,NA,SAN JOSE,COSTA RICA,NA,NA,853088008,CS,10011285,FUNDACION INCIENSA,NA,10108,NA,79983186 (contact),"PORRAS, CAROLINA  (contact)",NA,2024-09-26,2025-09-25,Adult women;Biological Assay;cancer genomics;Certification;cervical cancer prevention;Clinical Trials;Collaborations;Contractor;Contracts;Costa Rica;Dose;Evaluation;Genotype;Human papilloma virus infection;Human Papilloma Virus Vaccination;Human Papilloma Virus Vaccine;Human Papillomavirus;International;Laboratories;Laboratory Research;Measures;next generation sequencing;Participant;Prevention;primary endpoint;Procedures;quality assurance;Quality Control;Reporting;Sampling;Standardization;Testing;Training;vaccine trial;Validation;young adult,Laboratory testing of biospecimens collected from participants of the NCI’s HPV Vaccine studies.,0,NA,NA,NA,NA,NA,NA,NA,608967,NA
11220601,N02,HL,NA,N,NA,NA,NA,NA,75N92024P00357,NA,NA,75N92024P00357-0-0-2,NCI:15000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,WASHINGTON,UNITED STATES,NA,98,041964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,204180007,NA,79983690 (contact),"DAY, ROBERT  (contact)",NA,2024-09-14,2025-09-13,Genomics;Precision Health,ROUNDTABLE ON GENOMICS AND PRECISION HEALTH,0,NA,NA,NA,NA,NA,NA,NA,15000,NA
11220649,N01,DA,NA,N,NA,NA,NA,NA,75N95024C00003,NA,NA,75N95024C00003-P00002-9999-4,OD:24046\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,049508120,US,9611701,"WESTAT, INC.",MD,208503129,NA,NA,(contact),NA,2024-02-01,2029-01-31,NA,POPULATION ASSESSMENT OF TOBACCO AND HEALTH (PATH) STUDY PERIOD OF PERFORMANCE: 02/01/2024 - 01/31/2029,0,NA,NA,NA,NA,NA,NA,NA,24046,NA
11220668,P20,GM,1,N,2023-12-28,2024-01-01,2024-12-31,NA,P20GM152326,NA,PAR-22-250,1P20GM152326-01,NIGMS:307000\,RESEARCH CENTERS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,OMAHA,UNITED STATES,NA,02,168559177,US,578104,UNIVERSITY OF NEBRASKA MEDICAL CENTER,NE,681987835,"This research is important because it aims to better understand how heart cells (cardiomyocytes) mature, which is crucial for maintaining healthy heart function throughout life. Defects in this process can lead to severe cardiovascular diseases (CVDs), the leading cause of death globally. Advancing our knowledge in this area could improve treatments for congenital heart defects, adult heart diseases, and efforts to regenerate heart tissue.",15937387 (contact),"SHI, WEI  (contact)","CUPIT, PAULINE",2024-01-01,2028-12-31,Adult;Area;Binding;Blood Vessels;Calcium;Cardiac;Cardiac Myocytes;cardiogenesis;Cardiovascular Diseases;Catalytic Domain;Cause of Death;Cell Cycle Arrest;CHD4 gene;Chromatin;chromatin remodeling;Chromatin Remodeling Factor;clinical application;cohort;Complex;congenital heart abnormality;Congenital Heart Defects;Data;Deacetylase;Defect;DNA Binding;DNA-Binding Proteins;Embryo;Embryonic Heart;Ensure;Enzymes;Exhibits;fetal;Foundations;Gene Expression;gene regulatory network;Genes;Genetic Transcription;genomic locus;Glycolysis;Heart;heart cell;Heart Diseases;Heart failure;heart function;human pluripotent stem cell;improved;in vivo;Knowledge;Lead;Life;Metabolism;Missense Mutation;Molecular;mortality;mutant;Mutation;Natural regeneration;Nebraska;neonatal mice;NFIA gene;novel therapeutic intervention;Nucleosomes;Oxidative Phosphorylation;Phenotype;Pluripotent Stem Cells;postnatal;proband;Process;programs;Proteins;recruit;Regenerative Medicine;Research;Role;Time;Tissues;transcription factor;Transcriptional Regulation;Ventricular Septal Defects,Gene Regulatory Networks in Postnatal Cardiomyocyte Maturation,152326,ZGM1,Special Emphasis Panel[ZGM1 RCB-3 (C1)],5460,NA,1,200000,107000,NA,307000
11220737,N01,OD,NA,N,NA,NA,NA,NA,NCL23003001_24-2389,NA,NA,NCL23003001_24-2389-0-0-1,OD:42000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,(contact),NA,NA,NA,Allogenic;Award;Back;bench to bedside;Clinical;Clinical Investigator;Clinical Research;Collaborations;Community Health;education research;Extramural Activities;Funding Opportunities;Lung Diseases;outreach;programs;Research Project Grants;Scientist;Services;Stem cell transplant;Translational Research;United States National Institutes of Health;Work,INTER-AGENCY SERVICE (NIH),0,NA,NA,NA,NA,NA,NA,NA,42000,NA
11220754,N01,OD,NA,N,NA,NA,NA,NA,NAI22011001_24-2387,NA,NA,NAI22011001_24-2387-0-0-1,OD:345556\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,(contact),NA,NA,NA,Allogenic;Anus;Award;Back;bench to bedside;Clinical;Clinical Investigator;Clinical Research;Collaborations;Community Health;COVID-19;Dysplasia;education research;Eosinophilic Esophagitis;eosinophilic inflammation;Extramural Activities;Funding Opportunities;Hematopoiesis;HIV;Human Papillomavirus;Immunity;Lung Diseases;outreach;Population;programs;Research Project Grants;Resources;Scientist;screening;senescence;Services;Stem cell transplant;T-Lymphocyte;transgender women;Translational Research;United States National Institutes of Health;Work,INTER-AGENCY SERVICE (NIH),0,NA,NA,NA,NA,NA,NA,NA,345556,NA
11220755,N01,OD,NA,N,NA,NA,NA,NA,NHL24004001_24-2386,NA,NA,NHL24004001_24-2386-0-0-1,OD:348400\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,(contact),NA,NA,NA,Acute;Award;Back;bench to bedside;Clinical;Clinical Investigator;Clinical Research;Collaborations;Community Health;COVID-19;Degos disease;Development;education research;Endothelium;Extramural Activities;Funding Opportunities;gene therapy;Immune;in vivo;inhibitor;outreach;programs;Research Project Grants;Scientist;senescence;Services;Sickle Cell Anemia;Translational Research;United States National Institutes of Health;Vascular Diseases;Work,INTER-AGENCY SERVICE (NIH),0,NA,NA,NA,NA,NA,NA,NA,348400,NA
11220827,Y01,CA,NA,N,NA,NA,NA,NA,ACN24008001,NA,NA,ACN24008001-1-0-1,NCI:80000\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,Agreement;Animal Model;ChIP-on-chip;chromatin immunoprecipitation;Code;Development;dietary;Disease susceptibility;DNA Microarray Chip;Epigenetic Process;epigenomics;Etiology;Evaluation;Exhibits;Fatty Liver;fecal microbiota;Female;Fibrosis;Genetic Determinism;genome-wide;Genomics;Goals;Hepatic;High Fat Diet;Human;Individual;Leukocytes;Link;Liver;liver injury;male;Malignant neoplasm of liver;Methodology;MicroRNAs;Modeling;Molecular;molecular marker;Molecular Target;Mouse Strains;Mus;next generation sequencing;non-alcoholic fatty liver disease;nonalcoholic steatohepatitis;Pathogenesis;Pathway interactions;Phenotype;Plasma;Population;Population Heterogeneity;Predisposition;Process;protein expression;Quantitative Reverse Transcriptase PCR;Resistance;Role;Sampling;Severity of illness;Testing;Time;Untranslated RNA;western diet;whole genome,Genomic and genetic determinants of the susceptibility to non-alcoholic fatty liver disease (NAFLD) and NAFLD-related liver cancer,240080,NA,NA,NA,NA,NA,NA,NA,80000,NA
11220828,Y01,CA,NA,N,NA,NA,NA,NA,ACN24010001,NA,NA,ACN24010001-1-0-1,NCI:1655516\,INTERAGENCY AGREEMENTS,2024,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,NA,NA,NA,NA,NATIONAL CANCER INSTITUTE,NA,NA,NA,NA,(contact),NA,NA,NA,anti-cancer research;Apache;Bioinformatics;bioinformatics network;Biological Markers;biomarker validation;Biomedical Research;cancer biomarkers;Cancer Biomarkers Research Group;Cancer Detection;Collaborations;Communities;Complex;Computer software;Data;data archive;data management;data resource;Data Set;data sharing;Development;Discipline;Disease;distributed data;Early Detection Research Network;effective therapy;Environment;Foundations;Funding;Informatics;informatics tool;information model;Information Systems;Knowledge;knowledgebase;Laboratories;Laboratory Research;Machine Learning;Malignant Neoplasms;Metadata;Mission;Morphologic artifacts;network informatics;open source;Planet Earth;programs;Protocols documentation;Publications;Research;Research Personnel;Science;Semantics;System;Technology;United States National Aeronautics and Space Administration;Validation;validation studies;virtual;Visualization;Work,"NASA, JPL Bioinformatics for Cancer Detection",240100,NA,NA,NA,NA,NA,NA,NA,1655516,NA
11220919,P20,GM,5,N,2024-02-07,2024-02-01,2025-01-31,NA,P20GM139664,NA,PAR-19-313,5P20GM139664-03,NIGMS:261688\,RESEARCH CENTERS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,PROVIDENCE,UNITED STATES,NA,02,075710996,US,6959701,RHODE ISLAND HOSPITAL,RI,029034923,"Tracheal intubation (Tl) of critically ill children presenting to the emergency department after trauma, such as motor  vehicle collisions, falls, and penetrating injury, is a lifesaving but challenging procedure. Quality improvement efforts  using airway management checklists have improved outcomes for children undergoing Tl in pediatric and neonatal  intensive care units, but no such checklist has been implemented in the pediatric emergency department setting. This  study aims to pilot and refine a set of implementation strategies to implement a novel pre-intubation checklist at a  broad range of PEDs, which will be studied further in the future to evaluate its effect on clinical outcomes",79371313 (contact),"WING, ROBYN  (contact)","FRINCU, CRINA",2024-02-01,2027-01-31,"Accident and Emergency department;Address;Adherence;Adverse event;Caring;Centers of Research Excellence;Child;Childhood;Clinical;clinical care;cohort;Consensus;Critically ill children;Data;Data Coordinating Center;dissemination trial;Emergency Medicine;Emergency Situation;Event;evidence base;Exploration, Preparation, Implementation, and Sustainment;falls;feasibility trial;Feedback;Focus Groups;Future;Hospitals;implementation strategy;implementation trial;improved;improved outcome;Infrastructure;Injury;Intratracheal Intubation;Intubation;Life;Measures;Methods;multidisciplinary;Neonatal Intensive Care Units;novel;Outcome;Patients;pediatric emergency;pediatric trauma;Penetration;Procedures;Process;prospective;Provider;Recommendation;Registries;Reporting;Research;Rhode Island;Surveys;Time;Trauma;trauma centers;Vehicle crash",Feasibility Trial of an Implementation Bundle for the National Emergency Airway Registry for Pediatric Emergency Medicine (NEAR4PEM) Pre-Intubation Checklist,139664,ZGM1,ZGM1-RCB-2(C1),5511,NA,3,159566,102122,NA,261688
11220929,N02,HD,NA,N,NA,NA,NA,NA,75N94023F00170,NA,NA,75N94023F00170-P00002-0-1,OD:650000\,NON SBIR/STTR CONTRACTS,2024,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,NA,MIDDLETON,UNITED STATES,NA,06,136789562,US,10022210,"BIOTEAM, INC.",MA,019492494,NA,NA,(contact),NA,2024-09-29,2025-09-28,NA,NIMHD SCHARE RESEARCH PLATFORM:SCHARE-TERRA-GDE,0,NA,NA,NA,NA,NA,NA,NA,650000,NA
11220934,N02,DA,NA,N,NA,NA,NA,NA,75N95023D00027,NA,NA,75N95023D00027-P00001-759502300002-1,OD:209886\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,DENVER,UNITED STATES,NA,01,362130952,US,10065762,"PALANTIR TECHNOLOGIES, INC.",CO,802021866,NA,NA,(contact),NA,2023-09-28,2025-03-27,NA,AIM-AHEAD DATA SCIENCE TRAINING ENCLAVE,0,NA,NA,NA,NA,NA,NA,NA,209886,NA
11220935,N02,DA,NA,N,NA,NA,NA,NA,95023A00195024F00011,NA,NA,95023A00195024F00011-0-0-1,OD:1881832\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,NORTH BETHESDA,UNITED STATES,NA,08,020277339,US,10047839,"AXLE INFORMATICS, LLC",MD,208524931,NA,NA,(contact),NA,2024-09-27,2025-09-26,NA,AIM-AHEAD DATA SCIENCE TRAINING SERVICES: NCATS & AIM-AHEAD ADVANCED DATA ANALYSIS TRAINING PROGRAM (ADATP),0,NA,NA,NA,NA,NA,NA,NA,1881832,NA
11220938,N01,OD,NA,N,NA,NA,NA,NA,7483023,NA,NA,7483023-0-0-1,OD:50000\,NON SBIR/STTR CONTRACTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,(contact),NA,NA,NA,Address;anti-cancer research;Award;Data;Data Commons;experience;improved;Modeling;Participant;Prize;Process;Readiness;Recommendation;United States National Institutes of Health,NCI CANCER RESEARCH DATA COMMONS CRDC AI DATA READINESS CHALLENGE AWARD INITIAL OBLIG,0,NA,NA,NA,NA,NA,NA,NA,50000,NA
11220940,Y01,OD,NA,N,NA,NA,NA,NA,AOD24022001,NA,NA,AOD24022001-1-0-1,OD:2000000\,INTERAGENCY AGREEMENTS,2024,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,NA,NA,NA,NA,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",NA,NA,NA,NA,(contact),NA,NA,NA,Address;Affect;Algorithms;Biomedical Technology;Development;digital;digital twin;Engineering;Evaluation;Foundations;Goals;Healthcare;Human;in silico;Interdisciplinary Study;Mathematics;Medical Device;method development;Modeling;programs;Research Project Grants;synthetic data;technological innovation,Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation,240220,NA,NA,NA,NA,NA,NA,NA,2000000,NA
11220944,N02,HL,NA,N,NA,NA,NA,NA,75N92022D00013,NA,NA,75N92022D00013-P00002-759202300002-1,OD:6472783\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,HADLEY,UNITED STATES,NA,02,110907578,US,10041458,VENTUREWELL,MA,010359462,NA,NA,(contact),NA,2023-03-15,2026-03-14,NA,INNOVATION FUNNEL FOR COVID19 - COMMERCIALIZATION CENTER,0,NA,NA,NA,NA,NA,NA,NA,6472783,NA
11220945,R01,GM,7,N,2025-01-17,2024-08-01,2025-01-31,859,R01GM141230,SCHOOLS OF MEDICINE,PA-24-254,7R01GM141230-04,NIGMS:143600\,NON-SBIR/STTR RPGS,2024,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,NA,BIRMINGHAM,UNITED STATES,INTERNAL MEDICINE/MEDICINE,07,063690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,"Project Narrative This grant aims to understand the molecular and regulatory details of how a novel and conserved subfamily of heme-binding proteins responds to glyoxal-related toxicity. The data derived from this work is expected to shed light on the understudied area of glyoxal induced cellular stress, and how it regulates cellular metabolic changes and disease.",8629101 (contact),"ULIJASZ, ANDREW T (contact)","BARSKI, OLEG",2022-02-01,2026-01-31,NA,A novel family of conserved glyoxal toxicity response proteins.,141230,MSFB,Macromolecular Structure and Function B Study Section[MSFB],NA,NA,4,96700,46900,143600,NA
11220948,N02,HL,NA,N,NA,NA,NA,NA,75N92023D00001,NA,NA,75N92023D00001-P00002-759202300003-1,OD:2500000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,HADLEY,UNITED STATES,NA,02,110907578,US,10041458,VENTUREWELL,MA,010359462,NA,NA,(contact),NA,2023-06-01,2026-05-31,NA,RADX INNOVATION FUNNEL FOR COVID-19 - AWARD MANAGEMENT,0,NA,NA,NA,NA,NA,NA,NA,2500000,NA
11220951,N02,HL,NA,N,NA,NA,NA,NA,75N92024P00357,NA,NA,75N92024P00357-0-0-3,NCATS:25000\,NON SBIR/STTR CONTRACTS,2024,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",NA,WASHINGTON,UNITED STATES,NA,98,041964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,204180007,NA,79983690 (contact),"DAY, ROBERT  (contact)",NA,2024-09-14,2025-09-13,Genomics;National Center for Advancing Translational Sciences;Precision Health,ROUNDTABLE ON GENOMICS AND PRECISION HEALTH,0,NA,NA,NA,NA,NA,NA,NA,25000,NA
11220969,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00017,NA,NA,75N95022D00017-0-759502400007-1,NIDA:1510879\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,NA,79933133 (contact),"MCCORMACK, JENNIFER  (contact)",NA,2024-08-15,2028-03-31,Helping to End Addiction Long-term;improved;Opiate Addiction;Opioid;opioid misuse;opioid use disorder;Pharmacotherapy;Public Health;Research;Speed;Support Contracts;United States National Institutes of Health;Work,"OPTIMIZING RETENTION, DURATION AND DISCONTINUATION STRATEGIES FOR OPIOID USE DISORDER PHARMACOTHERAPY (CTN-0100). AUGUST 15, 2024 TO MARCH 31, 2028. N01DA-22-2253. TASK ORDER NO. 75N95024F00007 (TO23)",0,NA,NA,NA,NA,NA,NA,NA,1510879,NA
11220970,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00037,NA,NA,75N95024D00037-0-759502400003-1,NIDA:3419274\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,NA,79933148 (contact),"JELSTROM, EVE  (contact)",NA,2024-08-15,2028-04-02,Clinical;Contracts;Helping to End Addiction Long-term;improved;Opiate Addiction;Opioid;opioid misuse;opioid use disorder;Pharmacotherapy;Public Health;Research;Speed;Support Contracts;United States National Institutes of Health;Work,"CTN'S CLINICAL COORDINATING CENTER CONTRACT. CTN STUDY, OPTIMIZING RETENTION, DURATION AND DISCONTINUATION STRATEGIES FOR OPIOID USE DISORDER PHARMACOTHERAPY (CTN-0100). POP: 8/15/24 - 4/2/28",0,NA,NA,NA,NA,NA,NA,NA,3419274,NA
11220972,N01,DA,NA,N,NA,NA,NA,NA,75N95020D00012,NA,NA,75N95020D00012-0-759502400001-1,NIDA:2026076\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,NA,79656206 (contact),"JELSTROM, EVE  (contact)",NA,2024-02-26,2024-08-25,Behavioral Research;Biomedical Research;Clinical Research;Clinical Trials Network;Helping to End Addiction Long-term;improved;Longitudinal Studies;National Institute of Drug Abuse;Opiate Addiction;Opioid;opioid misuse;Public Health;Research;Resources;Services;Speed;Support Contracts;United States National Institutes of Health;Work,TO PROVIDE BIO-MEDICAL AND BEHAVIORAL RESEARCH RESOURCES AND CLINICAL RESEARCH COORDINATING SERVICES TO SUPPORT THE NIDA CLINICAL TRIALS NETWORK (CTN) HEAL STUDIES. POP 2/26/24 - 8/25/24,0,NA,NA,NA,NA,NA,NA,NA,2026076,NA
11220974,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00017,NA,NA,75N95022D00017-0-759502400003-1,NIDA:622266\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,NA,79814138 (contact),"MCCORMACK, JENNIFER  (contact)",NA,2024-06-10,2026-11-01,Helping to End Addiction Long-term;Hospitals;improved;Opiate Addiction;Opioid;opioid misuse;Public Health;Research;Speed;Support Contracts;United States National Institutes of Health;Work,"EXEMPLAR HOSPITAL INITIATION TRIAL TO ENHANCE TREATMENT ENGAGEMENT (CTN-0098). JUNE 10, 2024 TO NOVEMBER 1, 2026. N01DA-22-2253. TASK ORDER NO. 75N95024F00003 (TO19).",0,NA,NA,NA,NA,NA,NA,NA,622266,NA
11220980,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00017,NA,NA,75N95022D00017-0-759502400005-1,NIDA:1284879\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,NA,79912485 (contact),"MCCORMACK, JENNIFER  (contact)",NA,2024-08-02,2025-08-01,Contracts;Helping to End Addiction Long-term;improved;Opiate Addiction;Opioid;opioid epidemic;opioid misuse;Public Health;Research;Speed;United States National Institutes of Health,"HEAL MANAGEMENT AND SUPPORT. AUGUST 2, 2024 TO AUGUST 1, 2025. N01DA-22-2253. TASK ORDER NO. 75N95024F00005 (TO21).",0,NA,NA,NA,NA,NA,NA,NA,1284879,NA
11220981,N01,DA,NA,N,NA,NA,NA,NA,75N95022D00017,NA,NA,75N95022D00017-0-759502400008-1,NIDA:771451\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,NA,79907739 (contact),"MCCORMACK, JENNIFER  (contact)",NA,2024-08-01,2026-03-31,Helping to End Addiction Long-term;improved;Opiate Addiction;Opioid;opioid epidemic;opioid misuse;opioid use disorder;Pharmaceutical Preparations;Public Health;Research;Rural;Speed;Support Contracts;United States National Institutes of Health;Work,"RURAL EXPANSION OF MEDICATION TREATMENT FOR OPIOID USE DISORDER (CTN-0102). AUGUST 1, 2024 TO MARCH 31, 2026. N01DA-22-2253. TASK ORDER NO. 75N95024F00008 (TO24).",0,NA,NA,NA,NA,NA,NA,NA,771451,NA
11220982,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00037,NA,NA,75N95024D00037-0-759502400002-1,NIDA:2988430\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,NA,79933145 (contact),"JELSTROM, EVE  (contact)",NA,2024-08-15,2026-11-01,Clinical;Clinical Trials Network;Helping to End Addiction Long-term;improved;National Institute of Drug Abuse;Opiate Addiction;Opioid;opioid epidemic;opioid misuse;Public Health;Research;Speed;Support Contracts;United States National Institutes of Health;Work,CTN HEAL ENHANCEMENT. CLINICAL COORDINATING CENTER FOR NIDA'S CLINICAL TRIALS NETWORK. TO2. POP: 8/15/24 - 11/1/2026,0,NA,NA,NA,NA,NA,NA,NA,2988430,NA
11220985,N01,DA,NA,N,NA,NA,NA,NA,75N95024D00037,NA,NA,75N95024D00037-0-759502400001-1,NIDA:463233\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ROCKVILLE,UNITED STATES,NA,08,096360284,US,1381101,"THE EMMES COMPANY, LLC",MD,208501737,NA,79933142 (contact),"JELSTROM, EVE  (contact)",NA,2024-08-15,2025-08-14,Clinical;Clinical Trials Network;Helping to End Addiction Long-term;improved;National Institute of Drug Abuse;Opiate Addiction;Opioid;opioid epidemic;opioid misuse;Public Health;Research;Speed;Support Contracts;United States National Institutes of Health;Work,CLINICAL COORDINATING CENTER FOR NIDA'S CLINICAL TRIALS NETWORK.  CTN PORTFOLIO SUPPORT (NON-HEAL). 8/15/24 - 8/14/25,0,NA,NA,NA,NA,NA,NA,NA,463233,NA
11221078,N02,DA,NA,N,NA,NA,NA,NA,75N95024F00124,NA,NA,75N95024F00124-0-0-1,NCATS:522283\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,FAIRFAX,UNITED STATES,NA,11,072648579,US,1644201,"ICF, INC., LLC",VA,220316050,NA,79895837 (contact),"SAULS, KATE  (contact)",NA,2024-07-29,2024-09-28,Advocacy;Clinical Research;Communities;Disease;experience;Family;genetic counselor;Genetic Diseases;Hand;Health Professional;Information Centers;Information Specialists;member;National Center for Advancing Translational Sciences;National Human Genome Research Institute;Nurses;Occupational Therapist;Patients;Persons;physical therapist;Physicians;programs;Rare Diseases;Research;Research Support;Resources;Scientist;Social Workers;Spanish/English;teacher;United States National Institutes of Health;virtual;Work;Writing,MANAGEMENT AND RESEARCH SUPPORT FOR THE GENETIC AND RARE DISEASES (GARD) INFORMATION CENTER AND RELATED PROGRAMS,0,NA,NA,NA,NA,NA,NA,NA,522283,NA
11221079,N02,DA,NA,N,NA,NA,NA,NA,75N95023D00027,NA,NA,75N95023D00027-0-759502400007-1,NCATS:2612691\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,DENVER,UNITED STATES,NA,01,362130952,US,10065762,"PALANTIR TECHNOLOGIES, INC.",CO,802021866,NA,79859317 (contact),"MARIZAN-HO, JOHANNA  (contact)",NA,2024-07-01,2024-08-13,Advisory Committees;Award;Clinical;Clinical and Translational Science Awards;Clinical Data;Clinical Research;cloud based;cohort;Collaborations;COVID-19;Data;Data Aggregation;Data Analytics;data de-identification;data enclave;Data Set;Dedications;Development;Environment;Institution;member;National Center for Advancing Translational Sciences;National Institute of General Medical Sciences;Personally Identifiable Information;Persons;privacy protection;programs;Research;Secure;synthetic data;Translational Research;United States National Institutes of Health,"SECURE PLATFORMS SUPPORT FOR THE N3C, NIDAP, AND ASPIRE",0,NA,NA,NA,NA,NA,NA,NA,2612691,NA
11221080,N01,DA,NA,N,NA,NA,NA,NA,75N95019D00012,NA,NA,75N95019D00012-P00001-759502200001-1,NCATS:44201\,NON SBIR/STTR CONTRACTS,2024,NATIONAL INSTITUTE ON DRUG ABUSE,NA,ALBUQUERQUE,UNITED STATES,NA,01,075769000,US,10061906,LOVELACE BIOMEDICAL RESEARCH INSTITUTE,NM,871085129,NA,79837032 (contact),"ROBERTSON, MIKE  (contact)",NA,2022-06-17,2024-12-31,Biodistribution;Miniature Swine,BIOANALYTICAL SUPPORTS FOR A GLP TOX/BIODISTRIBUTION STUDY IN MINI-PIGS,0,NA,NA,NA,NA,NA,NA,NA,44201,NA
